<!DOCTYPE html>
<html lang="en">
  <head>
    <title>US20170210697A1 - Compounds and compositions for intracellular delivery of therapeutic agents 
      - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US20170210697A1/en">
    <meta name="description" content="
     The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Compounds and compositions for intracellular delivery of therapeutic agents 
     ">
    <meta name="DC.date" content="2017-03-31" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression. 
   
   ">
    <meta name="citation_patent_application_number" content="US:15/476,253">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/42/10/72/5bef6f3bbd8644/US20170210697A1.pdf">
    <meta name="citation_patent_publication_number" content="US:20170210697:A1">
    <meta name="DC.date" content="2017-07-27">
    <meta name="DC.contributor" content="Kerry E. Benenato" scheme="inventor">
    <meta name="DC.contributor" content="Ellalahewage Sathyajith Kumarasinghe" scheme="inventor">
    <meta name="DC.contributor" content="Mark Cornebise" scheme="inventor">
    <meta name="DC.contributor" content="ModernaTx Inc" scheme="assignee">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">US20170210697A1 - Compounds and compositions for intracellular delivery of therapeutic agents 
      - Google Patents</h1>
  <span itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
     </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/42/10/72/5bef6f3bbd8644/US20170210697A1.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">US20170210697A1</dd>
    <meta itemprop="numberWithoutCodes" content="20170210697">
    <meta itemprop="kindCode" content="A1">
    <meta itemprop="publicationDescription" content="Patent application publication">
    <span>US20170210697A1</span>
    <span>US15/476,253</span>
    <span>US201715476253A</span>
    <span>US2017210697A1</span>
    <span>US 20170210697 A1</span>
    <span>US20170210697 A1</span>
    <span>US 20170210697A1</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 201715476253 A</span>
    <span>US201715476253 A</span>
    <span>US 201715476253A</span>
    <span>US 2017210697 A1</span>
    <span>US2017210697 A1</span>
    <span>US 2017210697A1</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">US</dd>
    <dd itemprop="countryName">United States</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>nanoparticle composition</dd>
    <dd itemprop="priorArtKeywords" repeat>lipid</dd>
    <dd itemprop="priorArtKeywords" repeat>group</dd>
    <dd itemprop="priorArtKeywords" repeat>glycero</dd>
    <dd itemprop="priorArtKeywords" repeat>alkyl</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2015-09-17">2015-09-17</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Granted</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">US15/476,253</dd>

  

  <dt>Other versions</dt>
  <dd itemprop="directAssociations" itemscope repeat>
    <a href="/patent/US9868691B2/en">
      <span itemprop="publicationNumber">US9868691B2</span>
      (<span itemprop="primaryLanguage">en</span>
    </a>
  </dd>

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>Kerry E. Benenato</dd>
  <dd itemprop="inventor" repeat>Ellalahewage Sathyajith Kumarasinghe</dd>
  <dd itemprop="inventor" repeat>Mark Cornebise</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    ModernaTx Inc
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>ModernaTx Inc</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2015-09-17">2015-09-17</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2017-03-31">2017-03-31</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2017-07-27">2017-07-27</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-03-31">2017-03-31</time>
    <span itemprop="title">Priority to US15/476,253</span>
    <span itemprop="type">priority</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US9868691B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-03-31">2017-03-31</time>
    <span itemprop="title">Application filed by ModernaTx Inc</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">ModernaTx Inc</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-04-07">2017-04-07</time>
    <span itemprop="title">Assigned to MODERNATX, INC.</span>
    <span itemprop="type">reassignment</span>
    
    
    
    
    <span itemprop="assigneeSearch">MODERNATX, INC.</span>
    <span itemprop="description" repeat>ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</span>
    <span itemprop="description" repeat>Assignors: BENENATO, Kerry E., CORNEBISE, MARK, KUMARASINGHE, ELLALAHEWAGE SATHYAJITH</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-04-21">2017-04-21</time>
    <span itemprop="title">Priority to US15/493,281</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US9867888B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-04-27">2017-04-27</time>
    <span itemprop="title">Priority to US15/498,698</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US9868693B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-07-27">2017-07-27</time>
    <span itemprop="title">Publication of US20170210697A1</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US20170210697A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2017-12-18">2017-12-18</time>
    <span itemprop="title">Priority to US15/846,084</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US10442756B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-01-16">2018-01-16</time>
    <span itemprop="title">Publication of US9868691B2</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US9868691B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-01-16">2018-01-16</time>
    <span itemprop="title">Application granted</span>
    <span itemprop="type">granted</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-06-11">2018-06-11</time>
    <span itemprop="title">Priority to US16/005,286</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US10266485B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-10-01">2018-10-01</time>
    <span itemprop="title">Priority to US16/148,822</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US10392341B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2019-08-29">2019-08-29</time>
    <span itemprop="title">Priority to US16/555,045</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US11220476B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2021-11-30">2021-11-30</time>
    <span itemprop="title">Priority to US17/538,217</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US12404232B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2023-09-14">2023-09-14</time>
    <span itemprop="title">Priority to US18/467,190</span>
    <span itemprop="type">priority</span>
    
    
    
    <span itemprop="documentId">patent/US12151995B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Active</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2036-09-16">2036-09-16</time>
    <span itemprop="title">Anticipated expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoLink">
          <a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20170210697.PGNR." itemprop="url" target="_blank"><span itemprop="text">USPTO</span></a>
        </li>
        
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoPatentCenterLink">
          <a href="https://patentcenter.uspto.gov/applications/15476253" itemprop="url" target="_blank"><span itemprop="text">USPTO PatentCenter</span></a>
        </li>
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoAssignmentLink">
          <a href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=20170210697" itemprop="url" target="_blank"><span itemprop="text">USPTO Assignment</span></a>
        </li>

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=2017210697A1&amp;KC=A1&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/US/15476253/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/US20170210697" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
      
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">*C([2*])([3*])CC([5*])([6*])N([1*])[4*]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">*C([2*])([3*])CC([5*])([6*])N([1*])[4*]</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">20</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ABCVHPIKBGRCJA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">ABCVHPIKBGRCJA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">4</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HMINKGKWTZYEDR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">HMINKGKWTZYEDR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">3</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KTBHDRDAUZRLAK-SIBCGJTDSA-N</span>
      <span itemprop="name">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC</span>
      <span itemprop="inchi_key">KTBHDRDAUZRLAK-SIBCGJTDSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FADLIWCLOQPIHM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=CC=C(OC(=O)CCCCCCCBr)C=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=CC=C(OC(=O)CCCCCCCBr)C=C1</span>
      <span itemprop="inchi_key">FADLIWCLOQPIHM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BKIPRJNSOWMQFA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BKIPRJNSOWMQFA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NQYPGKXXADXOAK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)C(=O)N(C)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)C(=O)N(C)OC</span>
      <span itemprop="inchi_key">NQYPGKXXADXOAK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OYYXZGFIZTYYRB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)C(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)C(=O)O</span>
      <span itemprop="inchi_key">OYYXZGFIZTYYRB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LSIPUACQVOQISN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)CC(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)CC(C)C</span>
      <span itemprop="inchi_key">LSIPUACQVOQISN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RODWPGSFWOUCMW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">RODWPGSFWOUCMW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QJQPJSKGVRWYAN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(C)(O)CCCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(C)(O)CCCCCCCCBr</span>
      <span itemprop="inchi_key">QJQPJSKGVRWYAN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UWWZNRSISBWRJK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(C)(O)CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(C)(O)CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">UWWZNRSISBWRJK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SVCOJOYJSNUNBE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="inchi_key">SVCOJOYJSNUNBE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HZLMCBVJIXIHHQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC</span>
      <span itemprop="inchi_key">HZLMCBVJIXIHHQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YTEWVOJCOXWUEP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCBr</span>
      <span itemprop="inchi_key">YTEWVOJCOXWUEP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FDXZUBWPUOXVKI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CC</span>
      <span itemprop="inchi_key">FDXZUBWPUOXVKI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HZXHNSXPZMXSDW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/C#N)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/C#N)N(C)C</span>
      <span itemprop="inchi_key">HZXHNSXPZMXSDW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VLXSYZMRPOOYGH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=S)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=S)NC</span>
      <span itemprop="inchi_key">VLXSYZMRPOOYGH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XEMQGJMMVXHKRO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(N(C)C)C(=O)C1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(N(C)C)C(=O)C1=O</span>
      <span itemprop="inchi_key">XEMQGJMMVXHKRO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DWAWKCMHWHANEA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(NC)C(=O)C1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(NC)C(=O)C1=O</span>
      <span itemprop="inchi_key">DWAWKCMHWHANEA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CWZRTGDSYWPKAK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">CWZRTGDSYWPKAK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BDOMGVDXRXTXAM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1</span>
      <span itemprop="inchi_key">BDOMGVDXRXTXAM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GGILNPYWKAXMLJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">GGILNPYWKAXMLJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BJZNKPCTXRSZKS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="inchi_key">BJZNKPCTXRSZKS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NRWVIKNSONBNPT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(CCCCCCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCN)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(CCCCCCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCN)=O</span>
      <span itemprop="inchi_key">NRWVIKNSONBNPT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VRUKEZGVGPEZFE-UHFFFAOYSA-N</span>
      <span itemprop="name">C/N=C(/NCCCC(C)(C)C)N(C)C.C/N=C(\NC)NCCCC(C)(C)C.CC(C)(C)CCCN(O)S(C)(=O)=O.CC(C)(C)CCCNC1=NC=CS1.CC(C)C(=O)NCCCC(C)(C)C.CC(C)CCCNC(=O)CO.CCC(=O)N(O)CCCC(C)(C)C.CCC(=O)NCCCC(C)(C)C.CN(C)/C(=N\S(C)(=O)=O)NCCCC(C)(C)C.CN/C(=N\[N&#43;](=O)[O-])NCCCC(C)C.COC(=O)N(O)CCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C/N=C(/NCCCC(C)(C)C)N(C)C.C/N=C(\NC)NCCCC(C)(C)C.CC(C)(C)CCCN(O)S(C)(=O)=O.CC(C)(C)CCCNC1=NC=CS1.CC(C)C(=O)NCCCC(C)(C)C.CC(C)CCCNC(=O)CO.CCC(=O)N(O)CCCC(C)(C)C.CCC(=O)NCCCC(C)(C)C.CN(C)/C(=N\S(C)(=O)=O)NCCCC(C)(C)C.CN/C(=N\[N&#43;](=O)[O-])NCCCC(C)C.COC(=O)N(O)CCCC(C)(C)C</span>
      <span itemprop="inchi_key">VRUKEZGVGPEZFE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XFAOMRNGFVCAPI-JMGTVMBUSA-N</span>
      <span itemprop="name">C/N=C(/NCCCC(C)(C)C)N(C)C.CC(C)(C)CCCC(=O)CO.CC(C)(C)CCCC/C(N)=N/S(N)(=O)=O.CC(C)(C)CCCNC1=NC=CS1.CC(C)CCCNC(=O)CO.CCC(=O)CCCC(C)(C)C.CN(C)/C(=N\S(C)(=O)=O)NCCCC(C)(C)C.CN(C)/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.CN/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.COCC(=O)NCCCC(C)(C)C.CON(CCCC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C/N=C(/NCCCC(C)(C)C)N(C)C.CC(C)(C)CCCC(=O)CO.CC(C)(C)CCCC/C(N)=N/S(N)(=O)=O.CC(C)(C)CCCNC1=NC=CS1.CC(C)CCCNC(=O)CO.CCC(=O)CCCC(C)(C)C.CN(C)/C(=N\S(C)(=O)=O)NCCCC(C)(C)C.CN(C)/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.CN/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.COCC(=O)NCCCC(C)(C)C.CON(CCCC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">XFAOMRNGFVCAPI-JMGTVMBUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">TUGQDNJUDGZVSH-UHFFFAOYSA-N</span>
      <span itemprop="name">C/N=C(\NC)NCCCC(C)(C)C.CC(=O)N(O)CCCC(C)(C)C.CC(C)(C)CCCN1CCCC1=O.CC(C)C(=O)NCCCC(C)(C)C.CC(C)CCCN1C(=O)CNC1=O.CC(C)CCCN1CCNC1=O.CCC(=O)NCCCC(C)(C)C.CCCCN1CCOC1=O.CN/C(=N\[N&#43;](=O)[O-])NCCCC(C)C.COC(=O)N(O)CCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C/N=C(\NC)NCCCC(C)(C)C.CC(=O)N(O)CCCC(C)(C)C.CC(C)(C)CCCN1CCCC1=O.CC(C)C(=O)NCCCC(C)(C)C.CC(C)CCCN1C(=O)CNC1=O.CC(C)CCCN1CCNC1=O.CCC(=O)NCCCC(C)(C)C.CCCCN1CCOC1=O.CN/C(=N\[N&#43;](=O)[O-])NCCCC(C)C.COC(=O)N(O)CCCC(C)(C)C</span>
      <span itemprop="inchi_key">TUGQDNJUDGZVSH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LCAKDLWMNQDFBZ-UHFFFAOYSA-N</span>
      <span itemprop="name">C1CCOC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCNCCO.CCCCCCCCC(O)CCCCCCCC.CCCCCCCCC=O.CCCCCCCCCO.CCCCCCCCCOC(=O)CCCCCCCBr.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.O=C(O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C1CCOC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCNCCO.CCCCCCCCC(O)CCCCCCCC.CCCCCCCCC=O.CCCCCCCCCO.CCCCCCCCCOC(=O)CCCCCCCBr.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.O=C(O)CCCCCCCBr</span>
      <span itemprop="inchi_key">LCAKDLWMNQDFBZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZOPVCRZGFUSKEF-UHFFFAOYSA-N</span>
      <span itemprop="name">C=CCCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C=CCCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">ZOPVCRZGFUSKEF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JJQHMOFLDFXQDQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(=O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(=O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">JJQHMOFLDFXQDQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AMGNDAMPSOIHLB-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(=O)N(C)CCCC(C)C.CC(C)(C)CCCN(O)S(C)(=O)=O.CC(C)(C)CCCNC(=N)N.CC(C)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CC(C)CCCN1C(=O)CCC1=O.CC(C)CCCN1C(=O)CN(C)C1=O.CC(C)CCCN1C(=O)COCC1=O.CCC(=O)NCCCC(C)(C)C.CN/C(=N\S(C)(=O)=O)NCCCC(C)C.CNC(=O)OCCCC(C)(C)C.COC(=O)NCCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(=O)N(C)CCCC(C)C.CC(C)(C)CCCN(O)S(C)(=O)=O.CC(C)(C)CCCNC(=N)N.CC(C)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CC(C)CCCN1C(=O)CCC1=O.CC(C)CCCN1C(=O)CN(C)C1=O.CC(C)CCCN1C(=O)COCC1=O.CCC(=O)NCCCC(C)(C)C.CN/C(=N\S(C)(=O)=O)NCCCC(C)C.CNC(=O)OCCCC(C)(C)C.COC(=O)NCCCC(C)(C)C</span>
      <span itemprop="inchi_key">AMGNDAMPSOIHLB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FWPOEIVPWBIHTA-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(=O)OCCCCCC(C)C(C)C.CC(=O)OCCCCCCC(C)C.COC(=O)CCCCCC(C)C(C)C.COC(=O)CCCCCCC(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(=O)OCCCCCC(C)C(C)C.CC(=O)OCCCCCCC(C)C.COC(=O)CCCCCC(C)C(C)C.COC(=O)CCCCCCC(C)C</span>
      <span itemprop="inchi_key">FWPOEIVPWBIHTA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HTEACPIPUALJHJ-HECXYDNZSA-N</span>
      <span itemprop="name">CC(C)(C)CCCC(=O)CO.CC(C)(C)CCCC/C(N)=N/S(N)(=O)=O.CC(C)CCCN/C(=N/C#N)N(C)C.CC(C)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CCC(=O)CCCC(C)(C)C.CN(C)/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.CN(C)C1=C(NCCCC(C)(C)C)C(=O)C1=O.CN/C(=N\S(C)(=O)=O)NCCCC(C)C.CN/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.COCC(=O)CCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)CCCC(=O)CO.CC(C)(C)CCCC/C(N)=N/S(N)(=O)=O.CC(C)CCCN/C(=N/C#N)N(C)C.CC(C)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CCC(=O)CCCC(C)(C)C.CN(C)/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.CN(C)C1=C(NCCCC(C)(C)C)C(=O)C1=O.CN/C(=N\S(C)(=O)=O)NCCCC(C)C.CN/C(CCCCC(C)(C)C)=N\S(N)(=O)=O.COCC(=O)CCCC(C)(C)C</span>
      <span itemprop="inchi_key">HTEACPIPUALJHJ-HECXYDNZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CYCISGXWJDTOLO-QENNNEAQSA-N</span>
      <span itemprop="name">CC(C)(C)CCCC(N)=O.CC(C)CCCN(C)S(C)(=O)=O.CC(C)CCCN/C(=N/C#N)N(C)C.CC1=NN=C(CCC(C)C)O1.CC1=NOC(CCC(C)(C)C)=N1.CN(C)C(=O)CCCC(C)(C)C.CN(C)C1=C(NCCCC(C)(C)C)C(=O)C1=O.CN(O)C(=O)CCCC(C)(C)C.CN/C(=C\[N&#43;](=O)[O-])NCCCC(C)C.CO/N=C/CCCC(C)(C)C.COCC(=O)CCCC(C)(C)C.CON(C)C(=O)CCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)CCCC(N)=O.CC(C)CCCN(C)S(C)(=O)=O.CC(C)CCCN/C(=N/C#N)N(C)C.CC1=NN=C(CCC(C)C)O1.CC1=NOC(CCC(C)(C)C)=N1.CN(C)C(=O)CCCC(C)(C)C.CN(C)C1=C(NCCCC(C)(C)C)C(=O)C1=O.CN(O)C(=O)CCCC(C)(C)C.CN/C(=C\[N&#43;](=O)[O-])NCCCC(C)C.CO/N=C/CCCC(C)(C)C.COCC(=O)CCCC(C)(C)C.CON(C)C(=O)CCCC(C)(C)C</span>
      <span itemprop="inchi_key">CYCISGXWJDTOLO-QENNNEAQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MHYBSTAQYJFIFY-HVPWQDACSA-N</span>
      <span itemprop="name">CC(C)(C)CCCN1C=C(CO)N=N1.CC(C)(C)CCCN1C=C(COC(C)(C)C)N=N1.CC(C)(C)CCCN1C=CN=N1.CC(C)CCCN(C)S(C)(=O)=O.CN/C(=C\[N&#43;](=O)[O-])NCCCC(C)C.CNC(=O)OCCCC(C)(C)C.CNC1=C(NCCCC(C)(C)C)C(=O)C1=O.COC(=O)NCCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)CCCN1C=C(CO)N=N1.CC(C)(C)CCCN1C=C(COC(C)(C)C)N=N1.CC(C)(C)CCCN1C=CN=N1.CC(C)CCCN(C)S(C)(=O)=O.CN/C(=C\[N&#43;](=O)[O-])NCCCC(C)C.CNC(=O)OCCCC(C)(C)C.CNC1=C(NCCCC(C)(C)C)C(=O)C1=O.COC(=O)NCCCC(C)(C)C</span>
      <span itemprop="inchi_key">MHYBSTAQYJFIFY-HVPWQDACSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AJDNCFWGLIFRDK-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)CCCN1C=C(CO)N=N1.CC(C)(C)CCCN1C=C(COC(C)(C)C)N=N1.CC(C)(C)CCCN1C=CN=N1.CNC1=C(NCCCC(C)(C)C)C(=O)C1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)CCCN1C=C(CO)N=N1.CC(C)(C)CCCN1C=C(COC(C)(C)C)N=N1.CC(C)(C)CCCN1C=CN=N1.CNC1=C(NCCCC(C)(C)C)C(=O)C1=O</span>
      <span itemprop="inchi_key">AJDNCFWGLIFRDK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DGDQQRYGBLAXPE-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)NC1=NC=CS1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)NC1=NC=CS1</span>
      <span itemprop="inchi_key">DGDQQRYGBLAXPE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HGJYTBCLFXAZMO-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)OC(=O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)OC(=O)CCCCCCCBr</span>
      <span itemprop="inchi_key">HGJYTBCLFXAZMO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JJQWZLAHPYXLQA-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(CCCCCCO)C(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(CCCCCCO)C(=O)O</span>
      <span itemprop="inchi_key">JJQWZLAHPYXLQA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DATSUBGPINWSGJ-UHFFFAOYSA-O</span>
      <span itemprop="name">CC(CCCCCCO[SH&#43;](C(C)(C)C)(c1ccccc1)c1ccccc1)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(CCCCCCO[SH&#43;](C(C)(C)C)(c1ccccc1)c1ccccc1)O</span>
      <span itemprop="inchi_key">DATSUBGPINWSGJ-UHFFFAOYSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WXNHBXPKIVJCPL-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">WXNHBXPKIVJCPL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QUADBKCRXGFGAX-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(O)CCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(O)CCCCCCO</span>
      <span itemprop="inchi_key">QUADBKCRXGFGAX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DXDQYRDUSDQWAA-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(O)CCCCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(O)CCCCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="inchi_key">DXDQYRDUSDQWAA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MRJPCFMEQSWMNZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCC#CC1=CC=C(C)C=C1C=CCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC#CC1=CC=C(C)C=C1C=CCCC</span>
      <span itemprop="inchi_key">MRJPCFMEQSWMNZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VJXYGRSDAFJIFF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCC#CC1=CC=C(C)C=C1C=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC#CC1=CC=C(C)C=C1C=O</span>
      <span itemprop="inchi_key">VJXYGRSDAFJIFF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PFHWZJXOSLIGLK-YEBKCUGMSA-N</span>
      <span itemprop="name">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC.CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC.CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="inchi_key">PFHWZJXOSLIGLK-YEBKCUGMSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PIJOICFOUBBRDD-SGAFJUGLSA-N</span>
      <span itemprop="name">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCC(CC/C=C\CCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="inchi_key">PIJOICFOUBBRDD-SGAFJUGLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RGWZDBVOQSPDFG-HWAYABPNSA-N</span>
      <span itemprop="name">CCCC/C=C\CCC(O)CC/C=C\CCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCC(O)CC/C=C\CCCC</span>
      <span itemprop="inchi_key">RGWZDBVOQSPDFG-HWAYABPNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MPJIWIQOKGDQJE-LTXDKZCQSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">MPJIWIQOKGDQJE-LTXDKZCQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SOYXSTPNBHABIC-GQLNUIQRSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC.CCCCCCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC.CCCCCCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">SOYXSTPNBHABIC-GQLNUIQRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ODDKZGLUINEUOH-HDXUUTQWSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="inchi_key">ODDKZGLUINEUOH-HDXUUTQWSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XBGZBTQVKPJIQN-NNBSDLDLSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC.CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC.CCCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC.CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC.CCCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">XBGZBTQVKPJIQN-NNBSDLDLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WRUNGHDYAAYWAU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCC1CC1CCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC1CC1CCBr</span>
      <span itemprop="inchi_key">WRUNGHDYAAYWAU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JHZOZJFZBHWLAV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCC1CC1CCC(O)CCC1CC1CCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC1CC1CCC(O)CCC1CC1CCCC</span>
      <span itemprop="inchi_key">JHZOZJFZBHWLAV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PNLBFKFFXCKXKE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCC1CC1CCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC1CC1CCO</span>
      <span itemprop="inchi_key">PNLBFKFFXCKXKE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KLOJLONWZXHJQQ-MKCFTUBBSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">KLOJLONWZXHJQQ-MKCFTUBBSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NNJWXNWBEZUWMO-BZZDLMLGSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C1CCCCC1O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.[C-]#[N&#43;]CCN(CCCCCCCC(=O)OCCCCCCCCC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C1CCCCC1O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.[C-]#[N&#43;]CCN(CCCCCCCC(=O)OCCCCCCCCC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">NNJWXNWBEZUWMO-BZZDLMLGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HLRZIPPKHPBDEV-DQIQZUARSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC/C=C\CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC/C=C\CCCCCC</span>
      <span itemprop="inchi_key">HLRZIPPKHPBDEV-DQIQZUARSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QJRLYSQAKLLLSB-AIHUGWNBSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC/C=C\CCCCCC.CCCCCCCC/C=C\COC(=O)CCCCCN(CCO)CCCCCC(=O)OC/C=C\CCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC/C=C\CCCCCC.CCCCCCCC/C=C\COC(=O)CCCCCN(CCO)CCCCCC(=O)OC/C=C\CCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OCCCCCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCCCC</span>
      <span itemprop="inchi_key">QJRLYSQAKLLLSB-AIHUGWNBSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PKRXCMGHHJRZGM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=C(CCCCC)C=C(OC(=O)CCCCCCCBr)C=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=C(CCCCC)C=C(OC(=O)CCCCCCCBr)C=C1</span>
      <span itemprop="inchi_key">PKRXCMGHHJRZGM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OOMWFBIWMCOELW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=CC=C(C)C=C1CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=CC=C(C)C=C1CCCCC</span>
      <span itemprop="inchi_key">OOMWFBIWMCOELW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UXFHUZKAUYEYAB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=CC=C(O)C=C1CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=CC=C(O)C=C1CCCCC</span>
      <span itemprop="inchi_key">UXFHUZKAUYEYAB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LWZQGUMHXPGQAF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=CC=CC(O)=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=CC=CC(O)=C1</span>
      <span itemprop="inchi_key">LWZQGUMHXPGQAF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VBYINDWOIITNST-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1=CC=CC(OC(=O)CCCCCCCBr)=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1=CC=CC(OC(=O)CCCCCCCBr)=C1</span>
      <span itemprop="inchi_key">VBYINDWOIITNST-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NJDBYPOLUVLNGL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCC1CC1CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCC1CC1CO</span>
      <span itemprop="inchi_key">NJDBYPOLUVLNGL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OYSQCYWMQQNMAU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCC(=O)OCCCCCCCCC(C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC(=O)OCCCCCCCCC(C)O</span>
      <span itemprop="inchi_key">OYSQCYWMQQNMAU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BEWLZRQXFVSUPD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCC(C)COC(=O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC(C)COC(=O)CCCCCCCBr</span>
      <span itemprop="inchi_key">BEWLZRQXFVSUPD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CACZMYPDQAYUHD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCC(COC(=O)CCCCCCCBr)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC(COC(=O)CCCCCCCBr)OC</span>
      <span itemprop="inchi_key">CACZMYPDQAYUHD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HWZLFTGFRCPJFU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCC(O)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC(O)CO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="inchi_key">HWZLFTGFRCPJFU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HDXVQUXVZWOEPI-VXPUYCOJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">HDXVQUXVZWOEPI-VXPUYCOJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BDZUYYAZWUFVJU-IQPBZJLXSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC1CC1CCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC1CC1CCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BDZUYYAZWUFVJU-IQPBZJLXSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QWEHNEJDGNULTE-MFYXSQMNSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\COC(=O)CCCCCN(CCO)CCCCCC(=O)OC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\COC(=O)CCCCCN(CCO)CCCCCC(=O)OC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">QWEHNEJDGNULTE-MFYXSQMNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">STUWHEMXKNCQPC-GFMRDNFCSA-N</span>
      <span itemprop="name">CCCCCCCCC(/C=C\CCCCCCCBr)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(/C=C\CCCCCCCBr)CCCCCCCC</span>
      <span itemprop="inchi_key">STUWHEMXKNCQPC-GFMRDNFCSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KZOOYEQEKKYCBH-GFMRDNFCSA-N</span>
      <span itemprop="name">CCCCCCCCC(/C=C\CCCCCCCO)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(/C=C\CCCCCCCO)CCCCCCCC</span>
      <span itemprop="inchi_key">KZOOYEQEKKYCBH-GFMRDNFCSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VWFIGBKDWXQICF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">VWFIGBKDWXQICF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JHUYTHGFLPKHHU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)C1CC1.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCC.CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)C1CC1.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCC.CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="inchi_key">JHUYTHGFLPKHHU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BPRGRMGYJPIPFS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BPRGRMGYJPIPFS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LRGQPIYDVYKDPY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCC</span>
      <span itemprop="inchi_key">LRGQPIYDVYKDPY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PRLIIKWUHXOBCB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">PRLIIKWUHXOBCB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YKDMNXMPMKJHSX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CC1CCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=C(C)C=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CC1CCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=C(C)C=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=CC=C1</span>
      <span itemprop="inchi_key">YKDMNXMPMKJHSX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JBFVYCLQXGDUQY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">JBFVYCLQXGDUQY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNEDOBSDJWCWDU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(=O)O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOP(=O)(OCCCCCCCCC)OCCCCCCCCC.CCCCCCCCCOC(=O)CCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(=O)O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOP(=O)(OCCCCCCCCC)OCCCCCCCCC.CCCCCCCCCOC(=O)CCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">XNEDOBSDJWCWDU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JKDZNDDWKBXOIM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">JKDZNDDWKBXOIM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GLSITKCOTSUYPE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(C)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C1CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(C)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C1CC1.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CO</span>
      <span itemprop="inchi_key">GLSITKCOTSUYPE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OFKZNNZLTIRWMC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">OFKZNNZLTIRWMC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OKXFJMHCWXHUIC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">OKXFJMHCWXHUIC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FVKJRBUHOVYDBR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCC)OC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">FVKJRBUHOVYDBR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UXMNAUTXKRMWDP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">UXMNAUTXKRMWDP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LCGUQJHPZKWKMM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCC)OC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">LCGUQJHPZKWKMM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KFXBJDQSSXBOIZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCC)C(=O)OCCCCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">KFXBJDQSSXBOIZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CHXDPQPXBMDUNG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCBr</span>
      <span itemprop="inchi_key">CHXDPQPXBMDUNG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YRXKTLBYCZVCEL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC</span>
      <span itemprop="inchi_key">YRXKTLBYCZVCEL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PEVBQKOKYPNODO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)C(=O)OCCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">PEVBQKOKYPNODO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WIVUPZGXTKGEMN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)CCCCCCCCCC(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)CCCCCCCCCC(C)C</span>
      <span itemprop="inchi_key">WIVUPZGXTKGEMN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QTMANNCVNAREBM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)COC(=O)CCCCCCBr</span>
      <span itemprop="inchi_key">QTMANNCVNAREBM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">REEXUBUHTVAARJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCC(=O)OC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCC(C)N(CCO)CCCCCCCC(=O)OCCCCCCC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CC.CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OCCCCCCC(=O)OC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCC(C)N(CCO)CCCCCCCC(=O)OCCCCCCC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CC.CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCC)CC1</span>
      <span itemprop="inchi_key">REEXUBUHTVAARJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KHEPAYMMEKWSAW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr</span>
      <span itemprop="inchi_key">KHEPAYMMEKWSAW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DQEOFBNIKFQWOF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCO.CCCCCCCCC(O)CCCCCCCC.CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.O=C(O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCBr.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCO.CCCCCCCCC(O)CCCCCCCC.CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.O=C(O)CCCCCCCBr</span>
      <span itemprop="inchi_key">DQEOFBNIKFQWOF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LLRRNNJUBAULBL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">LLRRNNJUBAULBL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IIFPLDIGYRLCEQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCCCCO</span>
      <span itemprop="inchi_key">IIFPLDIGYRLCEQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OECBDUZKBHEDBB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">OECBDUZKBHEDBB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QJZIRHMXURWVQP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCC(=O)OCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCC(=O)OCCCCCCC</span>
      <span itemprop="inchi_key">QJZIRHMXURWVQP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OSRZIQFQXCZPAW-IZIUWEPXSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCC(=O)OCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCCCC(=O)OCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(CCCCCCC)OC.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC/C=C\C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCC(=O)OCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCCCC(=O)OCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(CCCCCCC)OC.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC/C=C\C(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">OSRZIQFQXCZPAW-IZIUWEPXSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">TWUMZDVCMBUSIE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCCCC(=O)OCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(C)CCCCCCCCCCCC(=O)OCCCCC</span>
      <span itemprop="inchi_key">TWUMZDVCMBUSIE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JDRFXQRBTSGKPV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)C(C)CCCCCCCCOC(=O)CCCCCCC</span>
      <span itemprop="inchi_key">JDRFXQRBTSGKPV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">STZFRWHMRXQJCQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">STZFRWHMRXQJCQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BHYOWVOPIAZYDA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC(CCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BHYOWVOPIAZYDA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DQWFCHQRJOARPA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">DQWFCHQRJOARPA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VRJALQFKMNIYHD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCC1CC1CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCC1CC1CCCCCC</span>
      <span itemprop="inchi_key">VRJALQFKMNIYHD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KSPIGACSDYCJIP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCC1CC1CCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCC)CCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCC1CC1CCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCC)CCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">KSPIGACSDYCJIP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QCZARIFIPVDLDF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCC</span>
      <span itemprop="inchi_key">QCZARIFIPVDLDF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RTIVVLYFLGCJGH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCC</span>
      <span itemprop="inchi_key">RTIVVLYFLGCJGH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZASYBSZHBWXDIG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCC</span>
      <span itemprop="inchi_key">ZASYBSZHBWXDIG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AWKZXBWMVGHCNT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCC(=O)OCCCCCCC</span>
      <span itemprop="inchi_key">AWKZXBWMVGHCNT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HDWOXAKOSZZDKH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC</span>
      <span itemprop="inchi_key">HDWOXAKOSZZDKH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UXUFNDMFMCCMRQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)N(C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)N(C)CCCCCCCC</span>
      <span itemprop="inchi_key">UXUFNDMFMCCMRQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VMEVEIYPYREJSN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)N(C)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(C)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.COC(=O)CCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)N(C)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(C)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC.COC(=O)CCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="inchi_key">VMEVEIYPYREJSN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MARSDTAHPRZKCH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)C1CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCC)C1CC1</span>
      <span itemprop="inchi_key">MARSDTAHPRZKCH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GREIDTLHMPLUTK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">GREIDTLHMPLUTK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VMJQKYXENBGQDY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCC.CCCCCCCCCN(C)C(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(F)(F)F.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(N)C(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCC(=O)OCCCCC.CCCCCCCCCN(C)C(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(F)(F)F.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(N)C(=O)O</span>
      <span itemprop="inchi_key">VMJQKYXENBGQDY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZVXMGZQMZIZJTI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC</span>
      <span itemprop="inchi_key">ZVXMGZQMZIZJTI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HPULGVRDRUYPHX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)N(C)CCCCCCCC</span>
      <span itemprop="inchi_key">HPULGVRDRUYPHX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MOPBGGUFHRETCA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="inchi_key">MOPBGGUFHRETCA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HSFUMJNETZAFOO-XLTIVWPESA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=C/[N&#43;](=O)[O-])NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/C#N)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(N(C)C)C(=O)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=C/[N&#43;](=O)[O-])NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/C#N)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(N(C)C)C(=O)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="inchi_key">HSFUMJNETZAFOO-XLTIVWPESA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IEFIHJPKKUMELA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C</span>
      <span itemprop="inchi_key">IEFIHJPKKUMELA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CRSJXICTKDWMBK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(CO)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCO.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(CO)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCO.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">CRSJXICTKDWMBK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FFTJROYARDCIJM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CC1CCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CCC)CCCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CC1CCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">FFTJROYARDCIJM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AYIZRNTVFSQCPJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCC(=O)OC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCCCC)CCCCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCC)CC1.CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCC(=O)OC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OCCCCCCC.CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCCCC)CCCCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(CCCC)CC1.CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">AYIZRNTVFSQCPJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZOUZDDGOXMJISE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCOC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/OC)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/S(C)(=O)=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/S(C)(=O)=O)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCOC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/OC)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/S(C)(=O)=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/S(C)(=O)=O)NC</span>
      <span itemprop="inchi_key">ZOUZDDGOXMJISE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VODKVQOZLGYNAZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C1CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)C1CC1</span>
      <span itemprop="inchi_key">VODKVQOZLGYNAZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GBJHIVHVWKHKDG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">GBJHIVHVWKHKDG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HPJSKZOEVIJTDY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(C)CCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(C)CCCCCCC</span>
      <span itemprop="inchi_key">HPJSKZOEVIJTDY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PMZTURQZYPORFC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(C)CCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCNCCO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(NC)C(=O)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(COCCCCCC)COCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(C)CCCCCCC.CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCNCCO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=C(NC)C(=O)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(COCCCCCC)COCCCCCC</span>
      <span itemprop="inchi_key">PMZTURQZYPORFC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PBWQBMCZUJHBTH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(CCCCCCC)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC(CCCCCCC)OC</span>
      <span itemprop="inchi_key">PBWQBMCZUJHBTH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WSWKKSLDBCQIFR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC1CC1CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OCC1CC1CCCCCC</span>
      <span itemprop="inchi_key">WSWKKSLDBCQIFR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BPRGRMGYJPIPFS-HUESYALOSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O[C@H](C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O[C@H](C)CCCCCCCC</span>
      <span itemprop="inchi_key">BPRGRMGYJPIPFS-HUESYALOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PVHFVWRXCSOAPZ-ZWHLOMAUSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O[C@H](C)CCCCCCCC.CCCCCCCCCC(C)(O)CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)S(C)(=O)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CNC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC(=O)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O[C@H](C)CCCCCCCC.CCCCCCCCCC(C)(O)CCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)S(C)(=O)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CNC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC(=O)NC</span>
      <span itemprop="inchi_key">PVHFVWRXCSOAPZ-ZWHLOMAUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WPCQQCDDSYTARY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCC1CC1CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCC1CC1CCCCCCCC</span>
      <span itemprop="inchi_key">WPCQQCDDSYTARY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JWQPOBNFKVIGEW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCC1CC1CCCCCCCC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=C(N)CC2=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCC1CC1CCCCCCCC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=C(N)CC2=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="inchi_key">JWQPOBNFKVIGEW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WMMLUZSSEGDBKE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CCCCCCCC)OC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OCCCCCCC</span>
      <span itemprop="inchi_key">WMMLUZSSEGDBKE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JYZLSYFPFQTNNO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCC(CO)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCC(CO)CCCCCCCC</span>
      <span itemprop="inchi_key">JYZLSYFPFQTNNO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SDIAJCVZGWTVOE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">SDIAJCVZGWTVOE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GKLATNGDYWRGOE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCC(=O)OC(C)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCC(=O)OCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCC(=O)OC(C)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCCCCCC(=O)OCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">GKLATNGDYWRGOE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WEVHETVMKOJNNI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">WEVHETVMKOJNNI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MIADSYNITYONNC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(C)CCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(C)CCCCCCO</span>
      <span itemprop="inchi_key">MIADSYNITYONNC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XJVLKYHMYSTVJS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(C)CCCCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(C)CCCCCCO[Si](C1=CC=CC=C1)(C1=CC=CC=C1)C(C)(C)C</span>
      <span itemprop="inchi_key">XJVLKYHMYSTVJS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VDEODXUUXZARQC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">VDEODXUUXZARQC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WXWGWXLLNUBBRB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">WXWGWXLLNUBBRB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BFRHBYWYJXIDAU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(=O)OCCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BFRHBYWYJXIDAU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DDYMCBYRRIVTNN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(C)(O)CCCCCCCCC(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(C)(O)CCCCCCCCC(C)C</span>
      <span itemprop="inchi_key">DDYMCBYRRIVTNN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZAKGPCUXSQLWAK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(C)(O)CCCCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(C)(O)CCCCCCCCO</span>
      <span itemprop="inchi_key">ZAKGPCUXSQLWAK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">APSPKAVIMNBIDY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCC(C)(O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCC(C)(O)CCCCCCCCOCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">APSPKAVIMNBIDY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YRBBPTAONRHLSB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">YRBBPTAONRHLSB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZMSOOHFVQWGODU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">ZMSOOHFVQWGODU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YDXPMICNZYCJHE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCCCC)CCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCC(=O)OC(CCCCCCCCCC)CCCCCCCCCC</span>
      <span itemprop="inchi_key">YDXPMICNZYCJHE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DPLNVQCIBIWEPE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)N(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">DPLNVQCIBIWEPE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BGNVBNJYBVCBJH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCOC(=O)CCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">BGNVBNJYBVCBJH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MBPSDYYZYLRDCS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=C1</span>
      <span itemprop="inchi_key">MBPSDYYZYLRDCS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HGOLDTCMZWRMAB-OTVIMDRISA-N</span>
      <span itemprop="name">CCCCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=C1.CCCCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(C)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@@H](C)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@H](C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=C1.CCCCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(C)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@@H](C)O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@H](C)O</span>
      <span itemprop="inchi_key">HGOLDTCMZWRMAB-OTVIMDRISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DLMTWRVBWNMZAW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCN(CCCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCN(CCCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">DLMTWRVBWNMZAW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GZUWFRJHCUMYRM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">GZUWFRJHCUMYRM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">INBRBABYYNMEAP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">INBRBABYYNMEAP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZTTRBYMTFHPNOU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">ZTTRBYMTFHPNOU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HVXOFEFMVZKXBV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)C(C)CCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">HVXOFEFMVZKXBV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WEAVVSQYEXFDGN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)C(C)CCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)C(C)CCCCCCO</span>
      <span itemprop="inchi_key">WEAVVSQYEXFDGN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JQGRGGGSILHZKR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCCCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCCCCO</span>
      <span itemprop="inchi_key">JQGRGGGSILHZKR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ALYWXPAJTUPRSJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">ALYWXPAJTUPRSJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OIORMPQEONULQQ-DPYNXENVSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCC/C=N/OC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC1=NC(C)=NO1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC1=NN=C(C)O1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCC/C=N/OC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC1=NC(C)=NO1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC1=NN=C(C)O1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">OIORMPQEONULQQ-DPYNXENVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OMKHXTYQZGIAOI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(C)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(C)CO</span>
      <span itemprop="inchi_key">OMKHXTYQZGIAOI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VKMJBFYCIZCISL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(C)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC1CC1CCCC)CCC1CC1CCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(C)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC1CC1CCCC)CCC1CC1CCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">VKMJBFYCIZCISL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ALNVFMJLVHSFDB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(CO)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C(CO)CO</span>
      <span itemprop="inchi_key">ALNVFMJLVHSFDB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IEMKOJCZSAWWKM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C1CCCCC1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C1CCCCC1O</span>
      <span itemprop="inchi_key">IEMKOJCZSAWWKM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WQDBTPDJHJPVCW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(C)O</span>
      <span itemprop="inchi_key">WQDBTPDJHJPVCW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OLRTWZZSCGUJHI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC(O)CO</span>
      <span itemprop="inchi_key">OLRTWZZSCGUJHI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BXDYZQGGISULTF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CC1=CC=CC=C1</span>
      <span itemprop="inchi_key">BXDYZQGGISULTF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HQZKEUDQXUBLNJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(=O)O</span>
      <span itemprop="inchi_key">HQZKEUDQXUBLNJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MUFFFTMYQJFCPU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCC(C)=O</span>
      <span itemprop="inchi_key">MUFFFTMYQJFCPU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DYLIRWSOIMQIKX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(N)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(=N/S(N)(=O)=O)NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(N)=N/S(N)(=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(N)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(=N/S(N)(=O)=O)NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(N)=N/S(N)(=O)=O</span>
      <span itemprop="inchi_key">DYLIRWSOIMQIKX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNNGAUJBOCBJKC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)COC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)COC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC(=O)N(C)O</span>
      <span itemprop="inchi_key">XNNGAUJBOCBJKC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UBTKXNZHZOXMGF-CXCVGUITSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(=N/S(N)(=O)=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(CO)N=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)C(C)CCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(C)C(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCSSCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCC/C(=N/S(N)(=O)=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(CO)N=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)C(C)CCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(C)C(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCSSCCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">UBTKXNZHZOXMGF-CXCVGUITSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZDERZLBQWQPYAM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCS(C)(=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCS(C)(=O)=O</span>
      <span itemprop="inchi_key">ZDERZLBQWQPYAM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNFVGIAAFZVTLE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=C(N)CC2=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)CC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=C(N)CC2=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="inchi_key">XNFVGIAAFZVTLE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KFCZEWMXGGJQLD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)C(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1CCCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)C(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)C(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1CCCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)C(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CO.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">KFCZEWMXGGJQLD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WNXJGLTXBQETSR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)S(C)(=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(C)S(C)(=O)=O</span>
      <span itemprop="inchi_key">WNXJGLTXBQETSR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">TWUGIBJWNUIDHP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)C(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)C(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)S(C)(=O)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(OC)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)C(=O)OC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)C(C)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(O)S(C)(=O)=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN(OC)C(C)=O</span>
      <span itemprop="inchi_key">TWUGIBJWNUIDHP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MJSZVXRFQREXJJ-AGWFHUCLSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=C/[N&#43;](=O)[O-])NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=C/[N&#43;](=O)[O-])NC</span>
      <span itemprop="inchi_key">MJSZVXRFQREXJJ-AGWFHUCLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NRRJJWPEKFHMMZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/OC)NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=N)N.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=NC=CS1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/OC)NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])N(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=N)N.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC1=NC=CS1</span>
      <span itemprop="inchi_key">NRRJJWPEKFHMMZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KWAAFWAKOSBTRP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])NC</span>
      <span itemprop="inchi_key">KWAAFWAKOSBTRP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CRMGZJSXUIMKLL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CN(C)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)COCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1CCOC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN/C(=N/[N&#43;](=O)[O-])NC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CN(C)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)COCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1CCOC1=O</span>
      <span itemprop="inchi_key">CRMGZJSXUIMKLL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FLRZHCSYVQUACU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CCC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CCC1=O</span>
      <span itemprop="inchi_key">FLRZHCSYVQUACU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZLKZYTVCAQFBCK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(COC(C)(C)C)N=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CCC1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(COC(C)(C)C)N=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=N1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COC</span>
      <span itemprop="inchi_key">ZLKZYTVCAQFBCK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KWJZAZALNWECRC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CNC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C(=O)CNC1=O</span>
      <span itemprop="inchi_key">KWJZAZALNWECRC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HEJRDKUAKAZIFO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(CO)N=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(CO)N=N1</span>
      <span itemprop="inchi_key">HEJRDKUAKAZIFO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNIZJQSXDZLSEG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(COC(C)(C)C)N=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C(COC(C)(C)C)N=N1</span>
      <span itemprop="inchi_key">XNIZJQSXDZLSEG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MQHWDOURUNLTGC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C([Si](C)(C)C)N=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=C([Si](C)(C)C)N=N1</span>
      <span itemprop="inchi_key">MQHWDOURUNLTGC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WXKXTEWZRXEOMX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O</span>
      <span itemprop="inchi_key">WXKXTEWZRXEOMX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CBAQIKQQTZQFNS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(N)=NC1=O</span>
      <span itemprop="inchi_key">CBAQIKQQTZQFNS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QQDJLOHYTUDRGS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=N1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CN=N1</span>
      <span itemprop="inchi_key">QQDJLOHYTUDRGS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OZRLDJDPUDQNSZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=NC2=C1N=CN=C2N</span>
      <span itemprop="inchi_key">OZRLDJDPUDQNSZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZXZOTGSEHAFBQY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN=C(NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN=C(NC(=O)OC(C)(C)C)NC(=O)OC(C)(C)C</span>
      <span itemprop="inchi_key">ZXZOTGSEHAFBQY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BHARBXWVQFPGEA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN=[N&#43;]=[N-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN=[N&#43;]=[N-]</span>
      <span itemprop="inchi_key">BHARBXWVQFPGEA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WXKQGFNPJIDLIG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=N)N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=N)N</span>
      <span itemprop="inchi_key">WXKQGFNPJIDLIG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KPFNNYPGQDYUES-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)C(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)C(C)C</span>
      <span itemprop="inchi_key">KPFNNYPGQDYUES-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VEWDTBPRZPDDEX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)CO</span>
      <span itemprop="inchi_key">VEWDTBPRZPDDEX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VIXOUEKDHRLEIK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COC</span>
      <span itemprop="inchi_key">VIXOUEKDHRLEIK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RPZGDUBSMAEKNU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)COCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">RPZGDUBSMAEKNU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNDACGLIOZKFLH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)N(C)C</span>
      <span itemprop="inchi_key">XNDACGLIOZKFLH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JOSRDMCGLCOJGI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)NC</span>
      <span itemprop="inchi_key">JOSRDMCGLCOJGI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BHQASMQYDQSNNI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=O)OC</span>
      <span itemprop="inchi_key">BHQASMQYDQSNNI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FIFTXQNMOIGPKY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=S)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(=S)N(C)C</span>
      <span itemprop="inchi_key">FIFTXQNMOIGPKY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FSNMAKXAJPMNTG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNC(C)=O</span>
      <span itemprop="inchi_key">FSNMAKXAJPMNTG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BITPGHWCOMNCEE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNS(C)(=O)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCNS(C)(=O)=O</span>
      <span itemprop="inchi_key">BITPGHWCOMNCEE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QMDWBMJAXQXUGH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC</span>
      <span itemprop="inchi_key">QMDWBMJAXQXUGH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WENXIWXIHOERQI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC(=O)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC(=O)NC</span>
      <span itemprop="inchi_key">WENXIWXIHOERQI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JPTWHYQUEXMXFR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCN(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCOC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCN(C)C.CCCCCCCCCOC(=O)CCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">JPTWHYQUEXMXFR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WIWRPGNHBSINBB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN(C)C</span>
      <span itemprop="inchi_key">WIWRPGNHBSINBB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZOOPSQVJGIQISR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1C(=O)C2=C(C=CC=C2)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(C)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(CC2=CC=C(C)C=C2)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCOCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1C(=O)C2=C(C=CC=C2)C1=O.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(C)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(CC2=CC=C(C)C=C2)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCOCC1</span>
      <span itemprop="inchi_key">ZOOPSQVJGIQISR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OEIORIHUPBWCQV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(C)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCN(C)CC1</span>
      <span itemprop="inchi_key">OEIORIHUPBWCQV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XTWAFDRVBKPPLP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCOCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCN1CCOCC1</span>
      <span itemprop="inchi_key">XTWAFDRVBKPPLP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MVQANIZCCCUNOI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC</span>
      <span itemprop="inchi_key">MVQANIZCCCUNOI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CDLJTVGOULEJFP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOC(C)=O</span>
      <span itemprop="inchi_key">CDLJTVGOULEJFP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DLCYBUOAQTYVIL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCN(C)C</span>
      <span itemprop="inchi_key">DLCYBUOAQTYVIL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QUSVSSKXXKJBLM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCOCCO</span>
      <span itemprop="inchi_key">QUSVSSKXXKJBLM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WQDBTPDJHJPVCW-HUESYALOSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@@H](C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@@H](C)O</span>
      <span itemprop="inchi_key">WQDBTPDJHJPVCW-HUESYALOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WQDBTPDJHJPVCW-WBCKFURZSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@H](C)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)C[C@H](C)O</span>
      <span itemprop="inchi_key">WQDBTPDJHJPVCW-WBCKFURZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SSPBGIBDTCULGG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">SSPBGIBDTCULGG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MBJGKYOENXHILR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCCl)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">MBJGKYOENXHILR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IOKATCMEJQGHFT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCN)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C(CCCCC)=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=CC(CCCCC)=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCN)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C(CCCCC)=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=CC(CCCCC)=C1</span>
      <span itemprop="inchi_key">IOKATCMEJQGHFT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DSNJXBBGALIZJN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">DSNJXBBGALIZJN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KPKSDSMESZBZNA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCC(=O)OC1CCC(CCCCC)CC1</span>
      <span itemprop="inchi_key">KPKSDSMESZBZNA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WZAMAOJDLIIHIQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">WZAMAOJDLIIHIQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CLHNMSWPOAEMPJ-ONQIKCEGSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC/C=C\C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCC/C=C\C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">CLHNMSWPOAEMPJ-ONQIKCEGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UEDWDABYRNGIDC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)O</span>
      <span itemprop="inchi_key">UEDWDABYRNGIDC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WRDNHADSFDWJFH-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(C)C</span>
      <span itemprop="inchi_key">WRDNHADSFDWJFH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IJVPGNBDBZSQQB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(C2CCCCC2)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCCCCCCCCCCCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)(CCCCCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(C2CCCCC2)CC1.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCCCCCCCCCCCCC1</span>
      <span itemprop="inchi_key">IJVPGNBDBZSQQB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PARZEKJBNRBSHD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="inchi_key">PARZEKJBNRBSHD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UYZXANGGKQCHLU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCCCC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCC)CCCCCCCC.CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCCCC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(C)=O</span>
      <span itemprop="inchi_key">UYZXANGGKQCHLU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QVLDUKBXFITRAD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CC</span>
      <span itemprop="inchi_key">QVLDUKBXFITRAD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IQAXLMVLOHNOSA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CC)CCCCCCCC</span>
      <span itemprop="inchi_key">IQAXLMVLOHNOSA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DYJHDZJSTSIOHW-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCC</span>
      <span itemprop="inchi_key">DYJHDZJSTSIOHW-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ITEBMSZNAWSLHT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC)CCCCCCCC</span>
      <span itemprop="inchi_key">ITEBMSZNAWSLHT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GUBYCVOHWNMTKA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC1CC1CCCC)CCC1CC1CCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCC1CC1CCCC)CCC1CC1CCCC</span>
      <span itemprop="inchi_key">GUBYCVOHWNMTKA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LXWJGJXKOIOSPD-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCC)CCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCC)CCCC</span>
      <span itemprop="inchi_key">LXWJGJXKOIOSPD-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XYAWDLIWTKSURR-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">XYAWDLIWTKSURR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NXNJIQWBBBSZDY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">NXNJIQWBBBSZDY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HYVYTRBFWRKXOX-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(CCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">HYVYTRBFWRKXOX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VRCDRERJQCWHKI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(COCCCCCC)COCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC(COCCCCCC)COCCCCCC</span>
      <span itemprop="inchi_key">VRCDRERJQCWHKI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JSKJKSYZGMXAGJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=C(CCCCC)C=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=C(CCCCC)C=C1</span>
      <span itemprop="inchi_key">JSKJKSYZGMXAGJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PJMGWCILPPIPOU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=CC=C1</span>
      <span itemprop="inchi_key">PJMGWCILPPIPOU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NBEOFPSSSHXAPS-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(C2CCCCC2)CC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCC(C2CCCCC2)CC1</span>
      <span itemprop="inchi_key">NBEOFPSSSHXAPS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DPHSGLCDGYEMPI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCCCCCCCCCCCCC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1CCCCCCCCCCCCCC1</span>
      <span itemprop="inchi_key">DPHSGLCDGYEMPI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PCPLHOKFQVVDNP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">PCPLHOKFQVVDNP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FVWVRGKYSOKQCV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">FVWVRGKYSOKQCV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CGULDMLPKUIKFI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOC(=O)C(CCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">CGULDMLPKUIKFI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AVKJNSMRYXJCOV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOP(=O)(OCCCCCCCCC)OCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCCCOP(=O)(OCCCCCCCCC)OCCCCCCCCC</span>
      <span itemprop="inchi_key">AVKJNSMRYXJCOV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QNTJORIUGGAOBT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOC(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">QNTJORIUGGAOBT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZXXDNQJFJPFKIU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCC</span>
      <span itemprop="inchi_key">ZXXDNQJFJPFKIU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XZHXGCBHPOIKBU-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCN(CCO)CCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">XZHXGCBHPOIKBU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UREMWPUBMCQBNL-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCNCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCNCCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">UREMWPUBMCQBNL-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WVLFWTWZTYIFBA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCCCCCNCCO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCCCCCNCCO</span>
      <span itemprop="inchi_key">WVLFWTWZTYIFBA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GAIFUPKQTQRQOG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCN(C)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">GAIFUPKQTQRQOG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FYYWODKUCHPELM-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCOC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCOC(=O)CCCN(CCO)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">FYYWODKUCHPELM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JRJCMDVYNJMXGG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCN(CCCCCCCC)C(=O)CCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCN(CCCCCCCC)C(=O)CCCCCCCBr</span>
      <span itemprop="inchi_key">JRJCMDVYNJMXGG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MITJBICHSPMEOF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)CC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)N(C)C.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)CC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)N(C)C.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCS(C)(=O)=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)CC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=O)N(C)C.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)CC.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCC(=S)N(C)C.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCCS(C)(=O)=O.CCCCCCCCOC(=O)CCCCCCCN(CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC)CCCN1C=CC(=O)NC1=O</span>
      <span itemprop="inchi_key">MITJBICHSPMEOF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XMYVRBIYQSIGRI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=C(CCCCC)C=C1.CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=CC=C1.CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=C(CCCCC)C=C1.CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC(CCCCC)=CC=C1.CCCCCCCCOC(=O)CCCCCCCN(CCO)CCCCCCCC(=O)OC1=CC=C(CCCCC)C=C1</span>
      <span itemprop="inchi_key">XMYVRBIYQSIGRI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KOVSHFIKURLHLZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCBr</span>
      <span itemprop="inchi_key">KOVSHFIKURLHLZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XZTAMFDOAQMWCO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCOP(=O)(OCCCCCCCC)OCCCCCCCN(CCO)CCCCCCCC(=O)OC(C)CCCCCCCC</span>
      <span itemprop="inchi_key">XZTAMFDOAQMWCO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JXOBCKZTPPWHSB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCOC(=O)CCCCCCCCCN(CCO)CCCCCCCCCC(=O)OC(CCCCCC)CCCCCC</span>
      <span itemprop="inchi_key">JXOBCKZTPPWHSB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WZVFCJBIYMXEDE-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCOCC(COCCCCCC)OCC1=CC=CC=C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCOCC(COCCCCCC)OCC1=CC=CC=C1</span>
      <span itemprop="inchi_key">WZVFCJBIYMXEDE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DIBKSEAWEAXXPQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCOCC(O)COCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCOCC(O)COCCCCCC</span>
      <span itemprop="inchi_key">DIBKSEAWEAXXPQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CFEWTLRXMFAHGQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CN/C(=N\OON)SC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CN/C(=N\OON)SC</span>
      <span itemprop="inchi_key">CFEWTLRXMFAHGQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FCFIXIAXNVTUTF-UHFFFAOYSA-N</span>
      <span itemprop="name">CNC1=C(OC)C(=O)C1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CNC1=C(OC)C(=O)C1=O</span>
      <span itemprop="inchi_key">FCFIXIAXNVTUTF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QNXOHINFQALBQN-UHFFFAOYSA-N</span>
      <span itemprop="name">COC(=O)CCCCCCCCCCCBr</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COC(=O)CCCCCCCCCCCBr</span>
      <span itemprop="inchi_key">QNXOHINFQALBQN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WRUQLKXQKANATA-UHFFFAOYSA-N</span>
      <span itemprop="name">COC(=O)CCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COC(=O)CCCCCCCCCCCN(CCO)CCCCCCCCCCCC(=O)OC</span>
      <span itemprop="inchi_key">WRUQLKXQKANATA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DPHIXPMOZQIUPM-UHFFFAOYSA-N</span>
      <span itemprop="name">COC1=C(N(C)C)C(=O)C1=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COC1=C(N(C)C)C(=O)C1=O</span>
      <span itemprop="inchi_key">DPHIXPMOZQIUPM-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MGMIAAOKLRHCES-UHFFFAOYSA-N</span>
      <span itemprop="name">COCCCCCCC(C)C(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COCCCCCCC(C)C(=O)O</span>
      <span itemprop="inchi_key">MGMIAAOKLRHCES-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SFUHMTFLLZZXJO-UHFFFAOYSA-N</span>
      <span itemprop="name">COCCCCCCCC(=O)O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COCCCCCCCC(=O)O</span>
      <span itemprop="inchi_key">SFUHMTFLLZZXJO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DQQNEXPEVZEYNS-UHFFFAOYSA-N</span>
      <span itemprop="name">[C-]#[N&#43;]CCN(CCCCCCCC(=O)OCCCCCCCCC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[C-]#[N&#43;]CCN(CCCCCCCC(=O)OCCCCCCCCC)CCCCCCCC(=O)OC(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">DQQNEXPEVZEYNS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OYGRVQCXQURSER-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]C(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]C(=O)C(CCCCCCCC)CCCCCCCC</span>
      <span itemprop="inchi_key">OYGRVQCXQURSER-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
  </ul>

  <section>
    <h2>Images</h2>
    <ul>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/6a/df/39/ef3cceea06ea8a/US20170210697A1-20170727-D00001.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/93/d9/ec/01b9079bb081ed/US20170210697A1-20170727-D00001.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1856">
              <meta itemprop="top" content="2049">
              <meta itemprop="right" content="1908">
              <meta itemprop="bottom" content="2072">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="15">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1850">
              <meta itemprop="top" content="836">
              <meta itemprop="right" content="1902">
              <meta itemprop="bottom" content="886">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="22">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1844">
              <meta itemprop="top" content="256">
              <meta itemprop="right" content="1896">
              <meta itemprop="bottom" content="314">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/8e/09/03/33b3be6b19f6e0/US20170210697A1-20170727-D00002.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/2a/fc/59/4958b8efb09faf/US20170210697A1-20170727-D00002.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1659">
              <meta itemprop="top" content="1656">
              <meta itemprop="right" content="1717">
              <meta itemprop="bottom" content="1697">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/f5/aa/5d/53d893b8087673/US20170210697A1-20170727-D00003.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/b3/f6/f9/588a629679cfb9/US20170210697A1-20170727-D00003.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1501">
              <meta itemprop="top" content="909">
              <meta itemprop="right" content="1545">
              <meta itemprop="bottom" content="964">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="26">
            <meta itemprop="label" content="compositions including Compounds">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="314">
              <meta itemprop="top" content="554">
              <meta itemprop="right" content="380">
              <meta itemprop="bottom" content="614">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="26">
            <meta itemprop="label" content="compositions including Compounds">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="391">
              <meta itemprop="top" content="554">
              <meta itemprop="right" content="452">
              <meta itemprop="bottom" content="615">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="26">
            <meta itemprop="label" content="compositions including Compounds">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="780">
              <meta itemprop="top" content="551">
              <meta itemprop="right" content="839">
              <meta itemprop="bottom" content="613">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="2">
            <meta itemprop="id" content="26">
            <meta itemprop="label" content="compositions including Compounds">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="857">
              <meta itemprop="top" content="551">
              <meta itemprop="right" content="915">
              <meta itemprop="bottom" content="612">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/a6/fb/e8/26b07173876bf9/US20170210697A1-20170727-D00004.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/34/c6/ba/34454721bb13a9/US20170210697A1-20170727-D00004.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="348">
              <meta itemprop="top" content="705">
              <meta itemprop="right" content="413">
              <meta itemprop="bottom" content="751">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="441">
              <meta itemprop="top" content="705">
              <meta itemprop="right" content="503">
              <meta itemprop="bottom" content="748">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="542">
              <meta itemprop="top" content="702">
              <meta itemprop="right" content="602">
              <meta itemprop="bottom" content="748">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="3">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1517">
              <meta itemprop="top" content="1064">
              <meta itemprop="right" content="1565">
              <meta itemprop="bottom" content="1128">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/c7/16/59/ef05e1915a34e0/US20170210697A1-20170727-D00005.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/ad/8f/e1/c42a54eedd63c2/US20170210697A1-20170727-D00005.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="4">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1477">
              <meta itemprop="top" content="1035">
              <meta itemprop="right" content="1520">
              <meta itemprop="bottom" content="1088">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="4">
            <meta itemprop="id" content="25">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="316">
              <meta itemprop="top" content="632">
              <meta itemprop="right" content="373">
              <meta itemprop="bottom" content="685">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/15/cc/a7/42809ab69fea8a/US20170210697A1-20170727-D00006.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/44/b3/ca/798751c6d906fb/US20170210697A1-20170727-D00006.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="5">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1432">
              <meta itemprop="top" content="1757">
              <meta itemprop="right" content="1474">
              <meta itemprop="bottom" content="1789">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="5">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1489">
              <meta itemprop="top" content="1703">
              <meta itemprop="right" content="1533">
              <meta itemprop="bottom" content="1733">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="5">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1486">
              <meta itemprop="top" content="1054">
              <meta itemprop="right" content="1530">
              <meta itemprop="bottom" content="1107">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/ae/b0/1e/05ed84b563a31c/US20170210697A1-20170727-D00007.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/d2/18/7c/c0df329c9cae35/US20170210697A1-20170727-D00007.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1827">
              <meta itemprop="top" content="1684">
              <meta itemprop="right" content="1873">
              <meta itemprop="bottom" content="1730">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1865">
              <meta itemprop="top" content="323">
              <meta itemprop="right" content="1915">
              <meta itemprop="bottom" content="358">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="588">
              <meta itemprop="top" content="1125">
              <meta itemprop="right" content="647">
              <meta itemprop="bottom" content="1181">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1865">
              <meta itemprop="top" content="145">
              <meta itemprop="right" content="1915">
              <meta itemprop="bottom" content="180">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="25">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="524">
              <meta itemprop="top" content="1120">
              <meta itemprop="right" content="583">
              <meta itemprop="bottom" content="1186">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="26">
            <meta itemprop="label" content="compositions including Compounds">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="650">
              <meta itemprop="top" content="1126">
              <meta itemprop="right" content="710">
              <meta itemprop="bottom" content="1185">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="6">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="466">
              <meta itemprop="top" content="1336">
              <meta itemprop="right" content="514">
              <meta itemprop="bottom" content="1369">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/03/96/6b/10c5d6cc034f4d/US20170210697A1-20170727-D00008.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/c3/37/98/494819e4de097e/US20170210697A1-20170727-D00008.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1485">
              <meta itemprop="top" content="1931">
              <meta itemprop="right" content="1529">
              <meta itemprop="bottom" content="1962">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1524">
              <meta itemprop="top" content="848">
              <meta itemprop="right" content="1571">
              <meta itemprop="bottom" content="883">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1529">
              <meta itemprop="top" content="1356">
              <meta itemprop="right" content="1576">
              <meta itemprop="bottom" content="1388">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1523">
              <meta itemprop="top" content="756">
              <meta itemprop="right" content="1570">
              <meta itemprop="bottom" content="791">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1528">
              <meta itemprop="top" content="1270">
              <meta itemprop="right" content="1575">
              <meta itemprop="bottom" content="1303">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1533">
              <meta itemprop="top" content="1775">
              <meta itemprop="right" content="1580">
              <meta itemprop="bottom" content="1809">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="24">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="651">
              <meta itemprop="top" content="317">
              <meta itemprop="right" content="705">
              <meta itemprop="bottom" content="365">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1527">
              <meta itemprop="top" content="1184">
              <meta itemprop="right" content="1574">
              <meta itemprop="bottom" content="1217">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1522">
              <meta itemprop="top" content="673">
              <meta itemprop="right" content="1569">
              <meta itemprop="bottom" content="709">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="463">
              <meta itemprop="top" content="341">
              <meta itemprop="right" content="518">
              <meta itemprop="bottom" content="371">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1532">
              <meta itemprop="top" content="1689">
              <meta itemprop="right" content="1579">
              <meta itemprop="bottom" content="1726">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1522">
              <meta itemprop="top" content="602">
              <meta itemprop="right" content="1569">
              <meta itemprop="bottom" content="643">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1531">
              <meta itemprop="top" content="1621">
              <meta itemprop="right" content="1578">
              <meta itemprop="bottom" content="1658">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1526">
              <meta itemprop="top" content="1110">
              <meta itemprop="right" content="1573">
              <meta itemprop="bottom" content="1149">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1521">
              <meta itemprop="top" content="536">
              <meta itemprop="right" content="1568">
              <meta itemprop="bottom" content="572">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1526">
              <meta itemprop="top" content="1044">
              <meta itemprop="right" content="1573">
              <meta itemprop="bottom" content="1079">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1530">
              <meta itemprop="top" content="1554">
              <meta itemprop="right" content="1577">
              <meta itemprop="bottom" content="1589">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="558">
              <meta itemprop="top" content="344">
              <meta itemprop="right" content="612">
              <meta itemprop="bottom" content="368">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1521">
              <meta itemprop="top" content="473">
              <meta itemprop="right" content="1568">
              <meta itemprop="bottom" content="504">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1525">
              <meta itemprop="top" content="980">
              <meta itemprop="right" content="1572">
              <meta itemprop="bottom" content="1012">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1530">
              <meta itemprop="top" content="1491">
              <meta itemprop="right" content="1577">
              <meta itemprop="bottom" content="1523">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="7">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1529">
              <meta itemprop="top" content="1419">
              <meta itemprop="right" content="1576">
              <meta itemprop="bottom" content="1454">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="7">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1525">
              <meta itemprop="top" content="910">
              <meta itemprop="right" content="1572">
              <meta itemprop="bottom" content="944">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="7">
            <meta itemprop="id" content="7">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1520">
              <meta itemprop="top" content="406">
              <meta itemprop="right" content="1567">
              <meta itemprop="bottom" content="437">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/f9/88/01/d38ea9319057c7/US20170210697A1-20170727-D00009.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/d9/50/cd/9ce493a6daf23e/US20170210697A1-20170727-D00009.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="8">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1460">
              <meta itemprop="top" content="2253">
              <meta itemprop="right" content="1505">
              <meta itemprop="bottom" content="2282">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/df/8c/6f/315f423ee0f4fa/US20170210697A1-20170727-D00010.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/15/34/ce/951c9e944d5a43/US20170210697A1-20170727-D00010.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="0">
            <meta itemprop="label" content="Hexanes">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1202">
              <meta itemprop="top" content="1737">
              <meta itemprop="right" content="1248">
              <meta itemprop="bottom" content="1770">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Representative Procedure">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1541">
              <meta itemprop="top" content="1649">
              <meta itemprop="right" content="1587">
              <meta itemprop="bottom" content="1675">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="10">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1535">
              <meta itemprop="top" content="915">
              <meta itemprop="right" content="1581">
              <meta itemprop="bottom" content="975">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="11">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1534">
              <meta itemprop="top" content="844">
              <meta itemprop="right" content="1580">
              <meta itemprop="bottom" content="896">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="12">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1533">
              <meta itemprop="top" content="762">
              <meta itemprop="right" content="1580">
              <meta itemprop="bottom" content="818">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="13">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1533">
              <meta itemprop="top" content="683">
              <meta itemprop="right" content="1579">
              <meta itemprop="bottom" content="739">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="14">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1532">
              <meta itemprop="top" content="604">
              <meta itemprop="right" content="1578">
              <meta itemprop="bottom" content="662">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="15">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1531">
              <meta itemprop="top" content="526">
              <meta itemprop="right" content="1578">
              <meta itemprop="bottom" content="586">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="16">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1531">
              <meta itemprop="top" content="436">
              <meta itemprop="right" content="1577">
              <meta itemprop="bottom" content="496">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="17">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1530">
              <meta itemprop="top" content="341">
              <meta itemprop="right" content="1576">
              <meta itemprop="bottom" content="401">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1529">
              <meta itemprop="top" content="265">
              <meta itemprop="right" content="1576">
              <meta itemprop="bottom" content="325">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="19">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1528">
              <meta itemprop="top" content="185">
              <meta itemprop="right" content="1575">
              <meta itemprop="bottom" content="249">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1540">
              <meta itemprop="top" content="1583">
              <meta itemprop="right" content="1586">
              <meta itemprop="bottom" content="1619">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1528">
              <meta itemprop="top" content="109">
              <meta itemprop="right" content="1574">
              <meta itemprop="bottom" content="171">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="dideoxynucleoside">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1539">
              <meta itemprop="top" content="1508">
              <meta itemprop="right" content="1585">
              <meta itemprop="bottom" content="1545">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="4">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1539">
              <meta itemprop="top" content="1414">
              <meta itemprop="right" content="1585">
              <meta itemprop="bottom" content="1454">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="5">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1538">
              <meta itemprop="top" content="1342">
              <meta itemprop="right" content="1584">
              <meta itemprop="bottom" content="1378">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="6">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1537">
              <meta itemprop="top" content="1257">
              <meta itemprop="right" content="1583">
              <meta itemprop="bottom" content="1288">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="9">
            <meta itemprop="id" content="7">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1537">
              <meta itemprop="top" content="1181">
              <meta itemprop="right" content="1583">
              <meta itemprop="bottom" content="1218">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/78/53/eb/1f847c9e3dfc73/US20170210697A1-20170727-D00011.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/71/44/4d/a6e706bc072e63/US20170210697A1-20170727-D00011.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="10">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="317">
              <meta itemprop="top" content="1553">
              <meta itemprop="right" content="372">
              <meta itemprop="bottom" content="1600">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="10">
            <meta itemprop="id" content="18">
            <meta itemprop="label" content="Compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="263">
              <meta itemprop="top" content="251">
              <meta itemprop="right" content="325">
              <meta itemprop="bottom" content="300">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="10">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="699">
              <meta itemprop="top" content="1181">
              <meta itemprop="right" content="741">
              <meta itemprop="bottom" content="1209">
            </span>
          </li>
        </ul>
      </li>
    </ul>
  </section>

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/06</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/10</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/12</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7105</span>&mdash;<span itemprop="Description">Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3&#39;-5&#39; phosphodiester links</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing peptides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/16</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/17</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/1703</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/1709</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/1725</span>&mdash;<span itemprop="Description">Complement proteins, e.g. anaphylatoxin, C3a or C5a</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing peptides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/16</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/17</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/18</span>&mdash;<span itemprop="Description">Growth factors; Growth regulators</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K38/1816</span>&mdash;<span itemprop="Description">Erythropoietin [EPO]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/51</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/54</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/543</span>&mdash;<span itemprop="Description">Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/50</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/69</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6905</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K47/6911</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0008</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0025</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/0033</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;non-active&#39; part of the composition delivered, e.g. wherein such &#39;non-active&#39; part is not delivered simultaneously with the &#39;active&#39; part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/005</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the &#39;active&#39; part of the composition delivered, i.e. the nucleic acid delivered</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0012</span>&mdash;<span itemprop="Description">Galenical forms characterised by the site of application</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0019</span>&mdash;<span itemprop="Description">Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0012</span>&mdash;<span itemprop="Description">Galenical forms characterised by the site of application</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0043</span>&mdash;<span itemprop="Description">Nose</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0012</span>&mdash;<span itemprop="Description">Galenical forms characterised by the site of application</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/007</span>&mdash;<span itemprop="Description">Pulmonary tract; Aromatherapy</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/0073</span>&mdash;<span itemprop="Description">Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1271</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1272</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/14</span>&mdash;<span itemprop="Description">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/16</span>&mdash;<span itemprop="Description">Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1605</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1617</span>&mdash;<span itemprop="Description">Organic compounds, e.g. phospholipids, fats</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/14</span>&mdash;<span itemprop="Description">Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/16</span>&mdash;<span itemprop="Description">Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1605</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1629</span>&mdash;<span itemprop="Description">Organic macromolecular compounds</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1641</span>&mdash;<span itemprop="Description">Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5123</span>&mdash;<span itemprop="Description">Organic compounds, e.g. fats, sugars</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/513</span>&mdash;<span itemprop="Description">Organic macromolecular compounds; Dendrimers</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5146</span>&mdash;<span itemprop="Description">Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P25/00</span>&mdash;<span itemprop="Description">Drugs for disorders of the nervous system</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P3/00</span>&mdash;<span itemprop="Description">Drugs for disorders of the metabolism</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P3/00</span>&mdash;<span itemprop="Description">Drugs for disorders of the metabolism</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P3/08</span>&mdash;<span itemprop="Description">Drugs for disorders of the metabolism for glucose homeostasis</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P3/10</span>&mdash;<span itemprop="Description">Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P31/00</span>&mdash;<span itemprop="Description">Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P35/00</span>&mdash;<span itemprop="Description">Antineoplastic agents</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/00</span>&mdash;<span itemprop="Description">Drugs for immunological or allergic disorders</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/02</span>&mdash;<span itemprop="Description">Immunomodulators</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/04</span>&mdash;<span itemprop="Description">Immunostimulants</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/00</span>&mdash;<span itemprop="Description">Drugs for immunological or allergic disorders</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/02</span>&mdash;<span itemprop="Description">Immunomodulators</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P37/06</span>&mdash;<span itemprop="Description">Immunosuppressants, e.g. drugs for graft rejection</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P43/00</span>&mdash;<span itemprop="Description">Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P9/00</span>&mdash;<span itemprop="Description">Drugs for disorders of the cardiovascular system</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/00</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/14</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/16</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/00</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/14</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C227/18</span>&mdash;<span itemprop="Description">Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/00</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/02</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/04</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/06</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/10</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C229/16</span>&mdash;<span itemprop="Description">Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/00</span>&mdash;<span itemprop="Description">Carboxylic acid amides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/01</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/34</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/35</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/36</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/00</span>&mdash;<span itemprop="Description">Carboxylic acid amides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/64</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/67</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/68</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C233/72</span>&mdash;<span itemprop="Description">Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C235/00</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C235/02</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C235/04</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C235/10</span>&mdash;<span itemprop="Description">Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C255/00</span>&mdash;<span itemprop="Description">Carboxylic acid nitriles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C255/01</span>&mdash;<span itemprop="Description">Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C255/24</span>&mdash;<span itemprop="Description">Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C263/00</span>&mdash;<span itemprop="Description">Preparation of derivatives of isocyanic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C263/18</span>&mdash;<span itemprop="Description">Separation; Purification; Stabilisation; Use of additives</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C263/20</span>&mdash;<span itemprop="Description">Separation; Purification</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/00</span>&mdash;<span itemprop="Description">Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/06</span>&mdash;<span itemprop="Description">Esters of carbamic acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/08</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/10</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C271/20</span>&mdash;<span itemprop="Description">Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C275/00</span>&mdash;<span itemprop="Description">Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C275/04</span>&mdash;<span itemprop="Description">Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C275/06</span>&mdash;<span itemprop="Description">Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C275/14</span>&mdash;<span itemprop="Description">Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/00</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/04</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/12</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/00</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/20</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/24</span>&mdash;<span itemprop="Description">Y being a hetero atom</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/00</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/28</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/00</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/30</span>&mdash;<span itemprop="Description">Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C279/32</span>&mdash;<span itemprop="Description">N-nitroguanidines</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C311/00</span>&mdash;<span itemprop="Description">Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C311/01</span>&mdash;<span itemprop="Description">Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C311/02</span>&mdash;<span itemprop="Description">Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C311/03</span>&mdash;<span itemprop="Description">Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C311/05</span>&mdash;<span itemprop="Description">Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C335/00</span>&mdash;<span itemprop="Description">Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C335/04</span>&mdash;<span itemprop="Description">Derivatives of thiourea</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C335/06</span>&mdash;<span itemprop="Description">Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C335/08</span>&mdash;<span itemprop="Description">Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of a saturated carbon skeleton</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/18</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/22</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/24</span>&mdash;<span itemprop="Description">Oxygen or sulfur atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/26</span>&mdash;<span itemprop="Description">2-Pyrrolidones</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/263</span>&mdash;<span itemprop="Description">2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/27</span>&mdash;<span itemprop="Description">2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/54</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/66</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D233/72</span>&mdash;<span itemprop="Description">Two oxygen atoms, e.g. hydantoin</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D249/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D249/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D249/04</span>&mdash;<span itemprop="Description">1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/16</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/18</span>&mdash;<span itemprop="Description">Oxygen atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D263/20</span>&mdash;<span itemprop="Description">Oxygen atoms attached in position 2</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D265/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D265/28</span>&mdash;<span itemprop="Description">1,4-Oxazines; Hydrogenated 1,4-oxazines</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D265/30</span>&mdash;<span itemprop="Description">1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D265/32</span>&mdash;<span itemprop="Description">1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D265/33</span>&mdash;<span itemprop="Description">Two oxygen atoms, in positions 3 and 5</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/06</span>&mdash;<span itemprop="Description">1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D271/10</span>&mdash;<span itemprop="Description">1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D277/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D277/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D277/20</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D277/32</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D277/38</span>&mdash;<span itemprop="Description">Nitrogen atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F</span>&mdash;<span itemprop="Description">ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/00</span>&mdash;<span itemprop="Description">Compounds containing elements of Groups 5 or 15 of the Periodic Table</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/02</span>&mdash;<span itemprop="Description">Phosphorus compounds</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/06</span>&mdash;<span itemprop="Description">Phosphorus compounds without PC bonds</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/08</span>&mdash;<span itemprop="Description">Esters of oxyacids of phosphorus</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/09</span>&mdash;<span itemprop="Description">Esters of phosphoric acids</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07F9/091</span>&mdash;<span itemprop="Description">Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07K</span>&mdash;<span itemprop="Description">PEPTIDES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07K14/00</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07K14/435</span>&mdash;<span itemprop="Description">Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07K14/475</span>&mdash;<span itemprop="Description">Growth factors; Growth regulators</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07K14/505</span>&mdash;<span itemprop="Description">Erythropoietin [EPO]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K48/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1271</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/00</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/02</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings with a three-membered ring</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/00</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/04</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings with a four-membered ring</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/00</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/12</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings with a six-membered ring</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/14</span>&mdash;<span itemprop="Description">The ring being saturated</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/00</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C2601/18</span>&mdash;<span itemprop="Description">Systems containing only non-condensed rings with a ring being at least seven-membered</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid nanoparticle compositions of the disclosure</span>
        <span itemprop="definition">may include one or more cationic and/or ionizable amino lipids, phospholipids including polyunsaturated lipids, PEG lipids, structural lipids, and/or therapeutic and/or prophylactics in specific fractions.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">The effective targeted delivery of biologically active substances such as small molecule drugs, proteins, and nucleic acids represents a continuing medical challenge.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">the delivery of nucleic acids to cells is made difficult by the relative instability and low cell permeability of such species.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid-containing nanoparticle compositions, liposomes, and lipoplexes</span>
        <span itemprop="definition">have proven effective as transport vehicles into cells and/or intracellular compartments for biologically active substances such as small molecule drugs, proteins, and nucleic acids.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such compositions</span>
        <span itemprop="definition">generally include one or more cationic and/or amino (ionizable) lipids, phospholipids including polyunsaturated lipids, structural lipids (e.g., sterols), and/or lipids containing polyethylene glycol (PEG lipids).</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cationic and/or ionizable lipids</span>
        <span itemprop="definition">include, for example, amine-containing lipids that can be readily protonated. Though a variety of such lipid-containing nanoparticle compositions have been demonstrated, improvements in safety, efficacy, and specificity are still lacking.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">provides novel compounds and compositions and methods involving the same.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a first aspect of the disclosure</span>
        <span itemprop="definition">relates to compounds of Formula (I):</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0010">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 1-6 alkyl, where Q is selected from a carbocycle, heterocycle, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, N(R) 2 , C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , N(R)R 8 , O(CH 2 ) n OR,</span>
        <meta itemprop="num_attr" content="0011">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0012">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0013">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0014">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0015">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is selected from the group consisting of C 3-6 carbocycle and heterocycle</span>
        <meta itemprop="num_attr" content="0016">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, OR, S(O) 2 R, S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;</span>
        <meta itemprop="num_attr" content="0017">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 2-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0021">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0022">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0023">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.</span>
        <meta itemprop="num_attr" content="0024">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which when R 4 is (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, or CQ(R) 2 , then (i) Q is not N(R) 2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">another subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0028">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 1-6 alkyl, where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , CRN</span>
        <meta itemprop="num_attr" content="0029">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is selected from the group consisting of C 3-6 carbocycle and heterocycle</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, OR, S(O) 2 R, S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;</span>
        <meta itemprop="num_attr" content="0035">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0036">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0037">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 2-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0039">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">another subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which</span>
        <meta itemprop="num_attr" content="0044">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0045">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 1-6 alkyl, where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , CRN(</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0048">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0049">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0050">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is selected from the group consisting of C 3-6 carbocycle and heterocycle</span>
        <meta itemprop="num_attr" content="0052">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, OR, S(O) 2 R, S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;</span>
        <meta itemprop="num_attr" content="0053">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0056">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 2-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0058">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0059">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0064">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 1-6 alkyl, where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , CRN</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0068">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0069">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is selected from the group consisting of C 3-6 carbocycle and heterocycle</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, OR, S(O) 2 R, S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 2-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">another subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 2-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is (CH 2 ) n Q or (CH 2 ) n CHQR, where Q is N(R) 2 , and n is selected from 3, 4, and 5;</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0088">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 1-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0091">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those in which</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and CQ(R) 2 , where Q is N(R) 2 , and n is selected from 1, 2, 3, 4, and 5;</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0105">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0106">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 1-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0107">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (IA):</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is a bond or M;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (II):</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is a bond or M</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (IIa), (IIb), (IIc), or (IIe):</span>
        <meta itemprop="num_attr" content="0114">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is as described herein.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (IId):</span>
        <meta itemprop="num_attr" content="0115">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 2 and R 3</span>
        <span itemprop="definition">may be independently selected from the group consisting of C 5-14 alkyl and C 5-14 alkenyl.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">features a nanoparticle composition including a lipid component comprising a compound as described herein (e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)).</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound as described herein</span>
        <span itemprop="definition">e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)).</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">features a pharmaceutical composition</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">comprising a nanoparticle composition according to the preceding aspects and a pharmaceutically acceptable carrier.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition</span>
        <span itemprop="definition">is refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4 C. or lower, such as a temperature between about   150 C. and about 0 C. or between about   80 C. and about   20 C.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition</span>
        <span itemprop="definition">is a solution that is refrigerated for storage and/or shipment at, for example, about   20 C.,   30 C.,   40 C.,   50 C.,   60 C.,   70 C.,   80 C.,   90 C.,   130 C. or   150 C.).</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition</span>
        <span itemprop="definition">is a solution that is refrigerated for storage and/or shipment at, for example, about   20 C.,   30 C.,   40 C.,   50 C.,   60 C.,   70 C., or   80 C.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a method of delivering a therapeutic and/or prophylactic (e.g., an mRNA) to a cell (e.g., a mammalian cell).</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This method</span>
        <span itemprop="definition">includes the step of administering to a subject (e.g., a mammal, such as a human) a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic, in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the cell.</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid component</span>
        <span itemprop="definition">including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a method of producing a polypeptide of interest in a cell (e.g., a mammalian cell).</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">includes the step of contacting the cell with a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) an mRNA encoding the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide.</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (I</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a method of delivering (e.g., specifically delivering) a therapeutic and/or prophylactic to a mammalian organ (e.g., a liver, spleen, lung, or femur).</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This method</span>
        <span itemprop="definition">includes the step of administering to a subject (e.g., a mammal) a nanoparticle composition including (i) a lipid component including a phospholipid, a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA), in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target organ (e.g., a liver, spleen, lung, or femur).</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mammalian organ</span>
        <span itemprop="definition">e</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">features a method for the enhanced delivery of a therapeutic and/or prophylactic (e.g., an mRNA) to a target tissue (e.g., a liver, spleen, lung, or femur).</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">e.g., an mRNA</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a target tissue</span>
        <span itemprop="definition">e.g., a liver, spleen, lung, or femur.</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This method</span>
        <span itemprop="definition">includes administering to a subject (e.g., a mammal) a nanoparticle composition, the composition including (i) a lipid component including a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a structural lipid, and a PEG lipid; and (ii) a therapeutic and/or prophylactic, the administering including contacting the target tissue with the nanoparticle composition, whereby the therapeutic and/or prophylactic</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">features a method of lowering immunogenicity comprising introducing the nanoparticle composition of the disclosure into cells, wherein the nanoparticle composition reduces the induction of the cellular immune response of the cells to the nanoparticle composition, as compared to the induction of the cellular immune response in cells induced by a reference composition which comprises a reference lipid instead of a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cellular immune response</span>
        <span itemprop="definition">is an innate immune response, an adaptive immune response, or both.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">also includes methods of synthesizing a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and methods of making a nanoparticle composition including a lipid component comprising the compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 1</span>
        <span itemprop="definition">shows the results of pretreating non-human primates with methotrexate or dexamethasone prior to administration of a nanoparticle composition including MC3.</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 2</span>
        <span itemprop="definition">shows the hEPO mRNA expression measured after intravenous administration of various nanoparticle compositions at a 0.01 mpk dose with 60 minutes infusion to naive cynomolgus monkeys.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIGS. 3-6</span>
        <span itemprop="definition">respectively shows the results of hEPO expression measured upon intravenous administration of various nanoparticle compositions including Compounds 26, 18, 25, and MC3 to rat at various doses.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 7</span>
        <span itemprop="definition">shows the area under the curve (AUC) for nanoparticle compositions including Compounds 18, 25, and 26 and MC3 at various doses between 0.005 mpk and 2 mpk.</span>
        <meta itemprop="num_attr" content="0128">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 8</span>
        <span itemprop="definition">shows the results of luciferase expression measured upon intramuscular administration of various nanoparticle compositions including MC3, Compounds 168-170, and 173-175 to mice at 0.01 mpk at various time points: 3 hr (left block), 6 hr (middle block) and 24 hr (right block).</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the numbers 1-7 in this figure</span>
        <span itemprop="definition">correspond to MC3, Compounds 168-170, and 173-175 respectively.</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 9</span>
        <span itemprop="definition">shows the results of hEPO expression measured upon intramuscular administration of various nanoparticle compositions including MC3, Compounds 18, 25, 30, 108-112, 60, and 122 to mice at 0.01 mpk at various time points: 3 hr (left block), 6 hr (middle block) and 24 hr (right block).</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the numbers 1-11 in this figure</span>
        <span itemprop="definition">correspond to MC3, Compounds 18, 25, 30, 108-112, 60, and 122 respectively.</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 10</span>
        <span itemprop="definition">shows the results of luciferase expression (total flux) measured upon intravenous administration of various nanoparticle compositions including MC3 or various compounds disclosed herein.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the numbers 1-12 in this figure</span>
        <span itemprop="definition">correspond to Compound 18, MC3, Compounds 48-50, 54, 111, 60, 75, 68, 66, 128, 65, 130, 133-135, 147, 96, and 151 respectively.</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIGS. 11A and 11B</span>
        <span itemprop="definition">show the results of anti-HA (anti-hemagglutinin) antibody expression measured after intravenous administration of various nanoparticle compositions including MC3 and Compound 18 at a 0.1 mpk ( FIG. 11A ) or 0.3 mpk ( FIG. 11B ) dose with 60 minutes infusion to naive cynomolgus monkeys.</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">relates to novel lipids and lipid nanoparticle compositions including a novel lipid.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">also provides methods of delivering a therapeutic and/or prophylactic to a mammalian cell, specifically delivering a therapeutic and/or prophylactic to a mammalian organ, producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method of producing a polypeptide of interest in a cell</span>
        <span itemprop="definition">involves contacting a nanoparticle composition comprising an mRNA with a mammalian cell, whereby the mRNA may be translated to produce the polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method of delivering a therapeutic and/or prophylactic to a mammalian cell or organ</span>
        <span itemprop="definition">may involve administration of a nanoparticle composition including the therapeutic and/or prophylactic to a subject, in which the administration involves contacting the cell or organ with the composition, whereby the therapeutic and/or prophylactic is delivered to the cell or organ.</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">provides lipids including a central amine moiety and at least one biodegradable group.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids described herein</span>
        <span itemprop="definition">may be advantageously used in lipid nanoparticle compositions for the delivery of therapeutic and/or prophylactics to mammalian cells or organs.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids described herein</span>
        <span itemprop="definition">have little or no immunogenicity.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid compound of any of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)</span>
        <span itemprop="definition">has a lower immunogenicity as compared to a reference lipid (e.g., MC3, KC2, or DLinDMA).</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a formulation comprising a lipid disclosed herein and a therapeutic or prophylactic agent</span>
        <span itemprop="definition">has an increased therapeutic index as compared to a corresponding formulation which comprise a reference lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or prophylactic agent.</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a reference lipid</span>
        <span itemprop="definition">e.g., MC3, KC2, or DLinDMA</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-30 alkyl, C 5-20 alkenyl, R*YR, YR, and RMR;</span>
        <meta itemprop="num_attr" content="0137">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of H, C 1-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle;</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, CQ(R) 2 , and unsubstituted C 1-6 alkyl, where Q is selected from a carbocycle, heterocycle, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, N(R) 2 , C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , N(R)R 8 , O(CH 2 ) n OR,</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 6</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , SS, an aryl group, and a heteroaryl group;</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0143">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is selected from the group consisting of C 3-6 carbocycle and heterocycle</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is selected from the group consisting of H, CN, NO 2 , C 1-6 alkyl, OR, S(O) 2 R, S(O) 2 N(R) 2 , C 2-6 alkenyl, C 3-6 carbocycle and heterocycle;</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-3 alkyl, C 2-3 alkenyl, and H;</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-18 alkyl, C 2-18 alkenyl, R*YR, YR, and H;</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R</span>
        <span itemprop="definition">is independently selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R*</span>
        <span itemprop="definition">is independently selected from the group consisting of C 1-12 alkyl and C 2-12 alkenyl;</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y</span>
        <span itemprop="definition">is independently a C 3-6 carbocycle</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X</span>
        <span itemprop="definition">is independently selected from the group consisting of F, Cl, Br, and I;</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and wherein when R 4 is (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, or CQ(R) 2 , then (i) Q is not N(R) 2 when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (IA):</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is a bond or M;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 5, 7, or 9.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is OH, NHC(S)N(R) 2 , or NHC(O)N(R) 2 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)C(O)R, or N(R)S(O) 2 R.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subset of compounds of Formula (I)</span>
        <span itemprop="definition">includes those of Formula (II):</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is a bond or M</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of any one of formula (I) or (IA)</span>
        <span itemprop="definition">include one or more of the following features when applicable.</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is M.</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently C(O)O or OC(O).</span>
        <meta itemprop="num_attr" content="0157">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">At least one of M and M</span>
        <span itemprop="definition">is C(O)O or OC(O).</span>
        <meta itemprop="num_attr" content="0158">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">are independently SS.</span>
        <meta itemprop="num_attr" content="0159">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">At least one of M and M</span>
        <span itemprop="definition">is SS.</span>
        <meta itemprop="num_attr" content="0160">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one of M and M</span>
        <span itemprop="definition">is C(O)O or OC(O) and the other is SS.</span>
        <meta itemprop="num_attr" content="0161">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is C(O)O or OC(O) and M is SS or M is C(O)O or OC(O) and M is SS.</span>
        <meta itemprop="num_attr" content="0161">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">1</span>
        <span itemprop="definition">is 1, 3, or 5.</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is unsubstituted methyl or (CH 2 ) n Q, in which Q is OH, NHC(S)N(R) 2 , NHC(O)N(R) 2 , N(R)C(O)R, or N(R)S(O) 2 R.</span>
        <meta itemprop="num_attr" content="0163">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is OH</span>
        <meta itemprop="num_attr" content="0164">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(S)N(R) 2 .</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(O)N(R) 2 .</span>
        <meta itemprop="num_attr" content="0166">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)C(O)R.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)S(O) 2 R.</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is O(CH 2 ) n N(R) 2 .</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is O(CH 2 ) n OR.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)R 8 .</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  NR 9 )N(R) 2 .</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  CHR 9 )N(R) 2 .</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is OC(O)N(R) 2 .</span>
        <meta itemprop="num_attr" content="0174">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)C(O)OR.</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is 2.</span>
        <meta itemprop="num_attr" content="0176">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">3.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">4.</span>
        <meta itemprop="num_attr" content="0178">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1</span>
        <span itemprop="definition">is absent.</span>
        <meta itemprop="num_attr" content="0179">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is C 1-18 alkyl, C 2-18 alkenyl, R*YR, or YR.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently C 3-14 alkyl or C 3-14 alkenyl.</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of Formula (I)</span>
        <span itemprop="definition">are of Formula (IIa),</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of Formula (I)</span>
        <span itemprop="definition">are of Formula (IIb),</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of Formula (I)</span>
        <span itemprop="definition">are of Formula (IIc) or (IIe):</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of Formula (I)</span>
        <span itemprop="definition">are of Formula (IId),</span>
        <meta itemprop="num_attr" content="0185">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 2 and R 3</span>
        <span itemprop="definition">may be independently selected from the group consisting of C 5-14 alkyl and C 5-14 alkenyl.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compounds of any one of formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe)</span>
        <span itemprop="definition">include one or more of the following features when applicable.</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, 5- to 14-membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, N(R) 2 , C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , </span>
        <meta itemprop="num_attr" content="0187">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , C(R)N(R) 2 C(O</span>
        <meta itemprop="num_attr" content="0188">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , C(R)N(R) 2 C(O)</span>
        <meta itemprop="num_attr" content="0189">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from the group consisting of a C 3-6 carbocycle, (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and -CQ(R) 2 , where Q is selected from a C 3-6 carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH 2 ) n N(R) 2 , C(O)OR, OC(O)R, CX 3 , CX 2 H, CXH 2 , CN, C(O)N(R) 2 , N(R)C(O)R, N(R)S(O) 2 R, N(R)C(O)N(R) 2 , N(R)C(S)N(R) 2 , C(R)N(R) 2 C(O</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is unsubstituted C 1-4 alkyl, e.g., unsubstituted methyl.</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a compound having the Formula (I), wherein R 4 is (CH 2 ) n Q or (CH 2 ) n CHQR, where Q is N(R) 2 , and n is selected from 3, 4, and 5.</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a compound having the Formula (I), wherein R 4 is selected from the group consisting of (CH 2 ) n Q, (CH 2 ) n CHQR, CHQR, and -CQ(R) 2 , where Q is N(R) 2 , and n is selected from 1, 2, 3, 4, and 5.</span>
        <meta itemprop="num_attr" content="0193">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">provides a compound having the Formula (I), wherein R 2 and R 3 are independently selected from the group consisting of C 2-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle, and R 4 is (CH 2 ) n Q or (CH 2 ) n CHQR, where Q is N(R) 2 , and n is selected from 3, 4, and 5.</span>
        <meta itemprop="num_attr" content="0194">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently selected from the group consisting of C 2-14 alkyl, C 2-14 alkenyl, R*YR, YR, and R*OR, or R 2 and R 3 , together with the atom to which they are attached, form a heterocycle or carbocycle.</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of C 5-20 alkyl and C 5-20 alkenyl.</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from the group consisting of R*YR, YR, and RMR.</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is selected from R*YR and YR.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is a cyclopropyl group.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R*</span>
        <span itemprop="definition">is C 8 alkyl or C 8 alkenyl.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is C 3-12 alkyl.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">may be C 3 alkyl.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">may be C 4-8 alkyl (e.g., C 4 , C 5 , C 6 , C 7 , or C 8 alkyl).</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is C 5-20 alkyl. In some embodiments, R 1 is C 6 alkyl. In some embodiments, R 1 is C 8 alkyl. In other embodiments, R 1 is C 9 alkyl. In certain embodiments, R 1 is C 14 alkyl. In other embodiments, R 1 is C 18 alkyl.</span>
        <meta itemprop="num_attr" content="0199">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is C 21-30 alkyl. In some embodiments, R 1 is C 26 alkyl. In some embodiments, R 1 is C 28 alkyl. In certain embodiments, R 1 is</span>
        <meta itemprop="num_attr" content="0200">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is C 5-20 alkenyl. In certain embodiments, R 1 is C 18 alkenyl. In some embodiments, R 1 is linoleyl.</span>
        <meta itemprop="num_attr" content="0201">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl).</span>
        <meta itemprop="num_attr" content="0202">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl).</span>
        <meta itemprop="num_attr" content="0202">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl,</span>
        <meta itemprop="num_attr" content="0202">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is unsubstituted C 5-20 alkyl or C 5-20 alkenyl.</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is substituted C 5-20 alkyl or C 5-20 alkenyl (e.g., substituted with a C 3-6 carbocycle such as 1-cyclopropylnonyl or substituted with OH or alkoxy).</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1</span>
        <span itemprop="definition">is RMR.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from R*YR and YR.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is C 3-8 cycloalkyl.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is C 6-10 aryl.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is a cyclopropyl group.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y</span>
        <span itemprop="definition">is a cyclohexyl group.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R*</span>
        <span itemprop="definition">is C 1 alkyl.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from the group consisting of C 3-12 alkyl and C 3-12 alkenyl.</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R adjacent to Y</span>
        <span itemprop="definition">is C 1 alkyl.</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R adjacent to Y</span>
        <span itemprop="definition">is C 4-9 alkyl (e.g., C 4 , C 5 , C 6 , C 7 or C 8 or C 9 alkyl).</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from C 4 alkyl and C 4 alkenyl. In certain embodiments, R is selected from C 5 alkyl and C 5 alkenyl. In some embodiments, R is selected from C 6 alkyl and C 6 alkenyl. In some embodiments, R is selected from C 7 alkyl and C 7 alkenyl. In some embodiments, R is selected from C 9 alkyl and C 9 alkenyl.</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from C 11 alkyl and C 11 alkenyl. In other embodiments, R is selected from C 12 alkyl, C 12 alkenyl, C 13 alkyl, C 13 alkenyl, C 14 alkyl, C 14 alkenyl, C 15 alkyl, C 15 alkenyl, C 16 alkyl, C 16 alkenyl, C 17 alkyl, C 17 alkenyl, C 18 alkyl, and C 18 alkenyl.</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or heptadeca-9-yl).</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or heptadeca-9-yl).</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, t</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is unsubstituted C 1-18 alkyl.</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is substituted C 1-18 alkyl (e.g., C 1-15 alkyl substituted with, e.g., an alkoxy such as methoxy, or a C 3-6 carbocycle such as 1-cyclopropylnonyl, or C(O)O-alkyl or OC(O)-alkyl such as C(O)OCH 3 or OC(O)CH 3 ).</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is selected from the group consisting of C 3-14 alkyl and C 3-14 alkenyl. In some embodiments, R is C 3 alkyl, C 4 alkyl, C 5 alkyl, C 6 alkyl, C 7 alkyl, or C 8 alkyl. In some embodiments, R is C 9 alkyl, C 10 alkyl, C 11 alkyl, C 12 alkyl, C 13 alkyl, or C 14 alkyl.</span>
        <meta itemprop="num_attr" content="0210">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is C(O)O. In some embodiments, M is OC(O).</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is an aryl group or heteroaryl group.</span>
        <meta itemprop="num_attr" content="0212">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">may be selected from the group consisting of phenyl, oxazole, and thiazole.</span>
        <meta itemprop="num_attr" content="0212">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is C(O)O. In some embodiments, M is OC(O). In some embodiments, M is C(O)N(R). In some embodiments, M is P(O)(OR)O.</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is an aryl group or heteroaryl group.</span>
        <meta itemprop="num_attr" content="0214">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">may be selected from the group consisting of phenyl, oxazole, and thiazole.</span>
        <meta itemprop="num_attr" content="0214">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is the same as M. In other embodiments, M is different from M.</span>
        <meta itemprop="num_attr" content="0215">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each R 5</span>
        <span itemprop="definition">is H. In certain such embodiments, each R 6 is also H.</span>
        <meta itemprop="num_attr" content="0216">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is H. In other embodiments, R 7 is C 1-3 alkyl (e.g., methyl, ethyl, propyl, or i-propyl).</span>
        <meta itemprop="num_attr" content="0217">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are independently C 5-14 alkyl or C 5-14 alkenyl.</span>
        <meta itemprop="num_attr" content="0218">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are the same. In some embodiments, R 2 and R 3 are C 8 alkyl. In certain embodiments, R 2 and R 3 are C 2 alkyl. In other embodiments, R 2 and R 3 are C 3 alkyl. In some embodiments, R 2 and R 3 are C 4 alkyl. In certain embodiments, R 2 and R 3 are C 5 alkyl. In other embodiments, R 2 and R 3 are C 6 alkyl. In some embodiments, R 2 and R 3 are C 7 alkyl.</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">are different.</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is C 8 alkyl.</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is C 1-7 (e.g., C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , or C 7 alkyl) or C 9 alkyl.</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7 and R 3</span>
        <span itemprop="definition">are H.</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2</span>
        <span itemprop="definition">is H.</span>
        <meta itemprop="num_attr" content="0222">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 5, 7, or 9.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from (CH 2 ) n Q and (CH 2 ) n CHQR.</span>
        <meta itemprop="num_attr" content="0224">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is selected from the group consisting of OR, OH, O(CH 2 ) n N(R) 2 , OC(O)R, CX 3 , CN, N(R)C(O)R, N(H)C(O)R, N(R)S(O) 2 R, N(H)S(O) 2 R, N(R)C(O)N(R) 2 , N(H)C(O)N(R) 2 , N(H)C(O)N(H)(R), N(R)C(S)N(R) 2 , N(H)C(S)N(R) 2 , N(H)C(S)N(H)(R), C(R)N(R) 2 C(O)OR, a carbocycle, and a heterocycle.</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(R)R 8 , O(CH 2 ) n OR, N(R)C(  NR 9 )N(R) 2 , N(R)C(  CHR 9 )N(R) 2 , OC(O)N(R) 2 , or N(R)C(O)OR.</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is N(OR)C(O)R, N(OR)S(O) 2 R, N(OR)C(O)OR, N(OR)C(O)N(R) 2 , N(OR)C(S)N(R) 2 , N(OR)C(  NR 9 )N(R) 2 , or N(OR)C(  CHR 9 )N(R) 2 .</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is thiourea or an isostere thereof, e.g.,</span>
        <meta itemprop="num_attr" content="0228">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is C(  NR 9 )N(R) 2 .</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is 4 or 5.</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is S(O) 2 N(R) 2 .</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is C(  NR 9 )R or C(O)N(R)OR, e.g., CH(  NOCH 3 ), C(O)NHOH, C(O)NHOCH 3 , C(O)N(CH 3 )OH, or C(O)N(CH 3 )OCH 3 .</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is OH</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is a substituted or unsubstituted 5- to 10-membered heteroaryl, e.g., Q is a triazole, an imidazole, a pyrimidine, a purine, 2-amino-1,9-dihydro-6H-purin-6-one-9-yl (or guanin-9-yl), adenin-9-yl, cytosin-1-yl, or uracil-1-yl, each of which is optionally substituted with one or more substituents selected from alkyl, OH, alkoxy, -alkyl-OH, -alkyl-O-alkyl, and the substituent can be further substituted.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is a triazole, an imidazole, a pyrimidine, a purine, 2-amino-1,9-dihydro-6H-purin-6-one-9-yl (or guanin-9-yl), adenin-9-yl, cytosin-1-</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is a substituted 5- to 14-membered heterocycloalkyl, e.g., substituted with one or more substituents selected from oxo (  O), OH, amino, mono- or di-alkylamino, and C 1-3 alkyl.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is 4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, isoindolin-2-yl-1,3-dione, pyrrolidin-1-yl-2,5-dione, or imidazolidin-3-yl-2,4-dione.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHR 8 , in which R 8 is a C 3-6 cycloalkyl optionally substituted with one or more substituents selected from oxo (  O), amino (NH 2 ), mono- or di-alkylamino, C 1-3 alkyl and halo.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is cyclobutenyl, e.g., 3-(dimethylamino)-cyclobut-3-ene-4-yl-1,2-dione.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHR 8 , in which R 8 is a heteroaryl optionally substituted with one or more substituents selected from amino (NH 2 ), mono- or di-alkylamino, C 1-3 alkyl and halo.</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8</span>
        <span itemprop="definition">is thiazole or imidazole.</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  NR 9 )N(R) 2 in which R 9 is CN, C 1-6 alkyl, NO 2 , S(O) 2 N(R) 2 , OR, S(O) 2 R, or H.</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is CN, C 1-6 alkyl, NO 2 , S(O) 2 N(R) 2 , OR, S(O) 2 R, or H.</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  NR 9 )N(CH 3 ) 2 , NHC(  NR 9 )NHCH 3 , NHC(  NR 9 )NH 2 .</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  CHR 9 )N(R) 2 , in which R 9 is NO 2 , CN, C 1-6 alkyl, S(O) 2 N(R) 2 , OR, S(O) 2 R, or H.</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 9</span>
        <span itemprop="definition">is NO 2 , CN, C 1-6 alkyl, S(O) 2 N(R) 2 , OR, S(O) 2 R, or H.</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is NHC(  CHR 9 )N(CH 3 ) 2 , NHC(  CHR 9 )NHCH 3 , or NHC(  CHR 9 )NH 2 .</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is OC(O)N(R) 2 , N(R)C(O)OR, N(OR)C(O)OR, such as OC(O)NHCH 3 , N(OH)C(O)OCH 3 , N(OH)C(O)CH 3 , N(OCH 3 )C(O)OCH 3 , N(OCH 3 )C(O)CH 3 , N(OH)S(O) 2 CH 3 , or NHC(O)OCH 3 .</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is an unsubstituted or substituted C 6-10 aryl (such as phenyl) or C 3-6 cycloalkyl.</span>
        <meta itemprop="num_attr" content="0238">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is 1. In other embodiments, n is 2. In further embodiments, n is 3. In certain other embodiments, n is 4.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be (CH 2 ) 2 OH.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be (CH 2 ) 30 H.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be (CH 2 ) 40 H.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be benzyl.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be 4-methoxybenzyl.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is a C 3-6 carbocycle. In some embodiments, R 4 is a C 3-6 cycloalkyl.</span>
        <meta itemprop="num_attr" content="0240">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be cyclohexyl optionally substituted with e.g., OH, halo, C 1-6 alkyl, etc.</span>
        <meta itemprop="num_attr" content="0240">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be 2-hydroxycyclohexyl.</span>
        <meta itemprop="num_attr" content="0240">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is H.</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is unsubstituted C 1-3 alkyl or unsubstituted C 2-3 alkenyl.</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be CH 2 CH(OH)CH 3 , CH(CH 3 )CH 2 OH, or CH 2 CH(OH)CH 2 CH 3 .</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is substituted C 1-3 alkyl, e.g., CH 2 OH.</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">may be CH 2 CH(OH)CH 2 OH, (CH 2 ) 3 NHC(O)CH 2 OH, (CH 2 ) 3 NHC(O)CH 2 OBn, (CH 2 ) 2 O(CH 2 ) 2 OH, or CH(CH 2 OH) 2 .</span>
        <meta itemprop="num_attr" content="0243">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from any of the following groups:</span>
        <meta itemprop="num_attr" content="0244">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from any of the following groups:</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of any of the formulae described herein</span>
        <span itemprop="definition">is suitable for making a nanoparticle composition for intramuscular administration.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a heterocycle or carbocycle. In some embodiments, R 2 and R 3 , together with the atom to which they are attached, form a 5- to 14-membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P. In some embodiments, R 2 and R 3 , together with the atom to which they are attached, form an optionally substituted C 3-20 carbocycle (e.g., C 3-18 carbocycle, C 3-15 carbocycle, C 3-12 carbocycle, or C 3-10 carbocycle), either aromatic or non-aromatic.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 3-20 carbocycle</span>
        <span itemprop="definition">e.g., C 3-18 carbocycle, C 3-15 carbocycle, C 3-12 carbocycle, or C 3-10 carbocycle</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a C 3-6 carbocycle.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a C 6 carbocycle, such as a cyclohexyl or phenyl group.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocycle or C 3-6 carbocycle</span>
        <span itemprop="definition">is substituted with one or more alkyl groups (e.g., at the same ring atom or at adjacent or non-adjacent ring atoms).</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, may form a cyclohexyl or phenyl group bearing one or more C 8 alkyl substitutions.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocycle or C 3-6 carbocycle formed by R 2 and R 3</span>
        <span itemprop="definition">is substituted with a carbocycle groups.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, may form a cyclohexyl or phenyl group that is substituted with cyclohexyl.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a C 7-15 carbocycle, such as a cycloheptyl, cyclopentadecanyl, or naphthyl group.</span>
        <meta itemprop="num_attr" content="0246">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is selected from (CH 2 ) n Q and (CH 2 ) n CHQR.</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Q</span>
        <span itemprop="definition">is selected from the group consisting of OR, OH, O(CH 2 ) n N(R) 2 , OC(O)R, CX 3 , CN, N(R)C(O)R, N(H)C(O)R, N(R)S(O) 2 R, N(H)S(O) 2 R, N(H)S(O) 2 R, N(R)C(O)N(R) 2 , N(H)C(O) N(R) 2 , N(H)C(O)N(H)(R), N(R)C(S)N(R) 2 , N(H)C(S)N(R) 2 , N(H)C(S)N(H)(R), and a heterocycle</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a heterocycle or carbocycle.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, form a C 3-6 carbocycle, such as a phenyl group.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the heterocycle or C 3-6 carbocycle</span>
        <span itemprop="definition">is substituted with one or more alkyl groups (e.g., at the same ring atom or at adjacent or non-adjacent ring atoms).</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 2 and R 3</span>
        <span itemprop="definition">together with the atom to which they are attached, may form a phenyl group bearing one or more C 5 alkyl substitutions.</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of Formula (I)</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of Formula (I)</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of Formula (I)</span>
        <span itemprop="definition">is selected from the group consisting of:</span>
        <meta itemprop="num_attr" content="0251">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid</span>
        <span itemprop="definition">may have a positive or partial positive charge at physiological pH.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such lipids</span>
        <span itemprop="definition">may be referred to as cationic or ionizable (amino)lipids.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipids</span>
        <span itemprop="definition">may also be zwitterionic, i.e., neutral molecules having both a positive and a negative charge.</span>
        <meta itemprop="num_attr" content="0252">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl</span>
        <span itemprop="definition">or alkyl group means a linear or branched, saturated hydrocarbon including one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms), which is optionally substituted.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 1-14 alkyl</span>
        <span itemprop="definition">means an optionally substituted linear or branched, saturated hydrocarbon including 1-14 carbon atoms.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alkyl group described herein</span>
        <span itemprop="definition">refers to both unsubstituted and substituted alkyl groups.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkenyl</span>
        <span itemprop="definition">or alkenyl group means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one double bond, which is optionally substituted.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the notation C 2-14 alkenyl</span>
        <span itemprop="definition">means an optionally substituted linear or branched hydrocarbon including 2-14 carbon atoms and at least one carbon-carbon double bond.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An alkenyl group</span>
        <span itemprop="definition">may include one, two, three, four, or more carbon-carbon double bonds.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 18 alkenyl</span>
        <span itemprop="definition">may include one or more double bonds.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a C 18 alkenyl group including two double bonds</span>
        <span itemprop="definition">may be a linoleyl group.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alkenyl group described herein</span>
        <span itemprop="definition">refers to both unsubstituted and substituted alkenyl groups.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl</span>
        <span itemprop="definition">or alkynyl group means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one carbon-carbon triple bond, which is optionally substituted.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the notation C 2-14 alkynyl</span>
        <span itemprop="definition">means an optionally substituted linear or branched hydrocarbon including 2-14 carbon atoms and at least one carbon-carbon triple bond.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An alkynyl group</span>
        <span itemprop="definition">may include one, two, three, four, or more carbon-carbon triple bonds.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">C 18 alkynyl</span>
        <span itemprop="definition">may include one or more carbon-carbon triple bonds.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alkynyl group described herein</span>
        <span itemprop="definition">refers to both unsubstituted and substituted alkynyl groups.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term carbocycle or carbocyclic group</span>
        <span itemprop="definition">means an optionally substituted mono- or multi-cyclic system including one or more rings of carbon atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty membered rings.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the notation C 3-6 carbocycle</span>
        <span itemprop="definition">means a carbocycle including a single ring having 3-6 carbon atoms. Carbocycles may include one or more carbon-carbon double or triple bonds and may be non-aromatic or aromatic (e.g., cycloalkyl or aryl groups).</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carbocycles</span>
        <span itemprop="definition">include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cycloalkyl</span>
        <span itemprop="definition">as used herein means a non-aromatic carbocycle and may or may not include any double or triple bond.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carbocycles described herein</span>
        <span itemprop="definition">refers to both unsubstituted and substituted carbocycle groups, i.e., optionally substituted carbocycles.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocycle</span>
        <span itemprop="definition">or heterocyclic group means an optionally substituted mono- or multi-cyclic system including one or more rings, where at least one ring includes at least one heteroatom.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Heteroatoms</span>
        <span itemprop="definition">may be, for example, nitrogen, oxygen, or sulfur atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen membered rings.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Heterocycles</span>
        <span itemprop="definition">may include one or more double or triple bonds and may be non-aromatic or aromatic (e.g., heterocycloalkyl or heteroaryl groups).</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocycles</span>
        <span itemprop="definition">include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl groups.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heterocycloalkyl</span>
        <span itemprop="definition">as used herein means a non-aromatic heterocycle and may or may not include any double or triple bond. Unless otherwise specified, heterocycles described herein refers to both unsubstituted and substituted heterocycle groups, i.e., optionally substituted heterocycles.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a biodegradable group</span>
        <span itemprop="definition">is a group that may facilitate faster metabolism of a lipid in a mammalian entity.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a biodegradable group</span>
        <span itemprop="definition">may be selected from the group consisting of, but is not limited to, C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O) 2 , an aryl group, and a heteroaryl group.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an aryl group</span>
        <span itemprop="definition">is an optionally substituted carbocyclic group including one or more aromatic rings.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aryl groups</span>
        <span itemprop="definition">include phenyl and naphthyl groups.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a heteroaryl group</span>
        <span itemprop="definition">is an optionally substituted heterocyclic group including one or more aromatic rings.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heteroaryl groups</span>
        <span itemprop="definition">include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups may be optionally substituted.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">can be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole, and thiazole.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M and M</span>
        <span itemprop="definition">can be independently selected from the list of biodegradable groups above.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aryl or heteroaryl groups described herein</span>
        <span itemprop="definition">refers to both unsubstituted and substituted groups, i.e., optionally substituted aryl or heteroaryl groups.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and heterocyclyl) groups</span>
        <span itemprop="definition">may be optionally substituted unless otherwise specified.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Optional substituents</span>
        <span itemprop="definition">may be selected from the group consisting of, but are not limited to, a halogen atom (e.g., a chloride, bromide, fluoride, or iodide group), a carboxylic acid (e.g., C(O)OH), an alcohol (e.g., a hydroxyl, OH), an ester (e.g., C(O)OR or OC(O)R), an aldehyde (e.g., C(O)H), a carbonyl (e.g., C(O)R, alternatively represented by C  O), an acyl halide (e.g., C(O)X, in which X is a halide selected from bromide, fluoride, chloride,</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is an alkyl or alkenyl group, as defined herein.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the substituent groups</span>
        <span itemprop="definition">themselves may be further substituted with, for example, one, two, three, four, five, or six substituents as defined herein.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a C 1-6 alkyl group</span>
        <span itemprop="definition">may be further substituted with one, two, three, four, five, or six substituents as described herein.</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term approximately or about</span>
        <span itemprop="definition">refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value).</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition including a lipid component having about 40% of a given compound</span>
        <span itemprop="definition">may include 30-50% of the compound.</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">contacting</span>
        <span itemprop="definition">means establishing a physical connection between two or more entities.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">contacting a mammalian cell with a nanoparticle composition</span>
        <span itemprop="definition">means that the mammalian cell and a nanoparticle are made to share a physical connection.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods of contacting cells with external entities both in vivo and ex vivo</span>
        <span itemprop="definition">are well known in the biological arts.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">contacting a nanoparticle composition and a mammalian cell disposed within a mammal</span>
        <span itemprop="definition">may be performed by varied routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve varied amounts of nanoparticle compositions.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">routes of administration</span>
        <span itemprop="definition">e.g., intravenous, intramuscular, intradermal, and subcutaneous</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">more than one mammalian cell</span>
        <span itemprop="definition">may be contacted by a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">delivering</span>
        <span itemprop="definition">means providing an entity to a destination.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">delivering a therapeutic and/or prophylactic to a subject</span>
        <span itemprop="definition">may involve administering a nanoparticle composition including the therapeutic and/or prophylactic to the subject (e.g., by an intravenous, intramuscular, intradermal, or subcutaneous route).</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Administration of a nanoparticle composition to a mammal or mammalian cell</span>
        <span itemprop="definition">may involve contacting one or more cells with the nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0263">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term enhanced delivery</span>
        <span itemprop="definition">means delivery of more (e.g., at least 1.5 fold more, at least 2-fold more, at least 3-fold more, at least 4-fold more, at least 5-fold more, at least 6-fold more, at least 7-fold more, at least 8-fold more, at least 9-fold more, at least 10-fold more) of a therapeutic and/or prophylactic by a nanoparticle to a target tissue of interest (e.g., mammalian liver) compared to the level of delivery of a therapeutic and/or prophylactic by a control nanoparticle to a target tissue of interest (e.g., MC3, KC2, or DLinDMA).</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a target tissue of interest</span>
        <span itemprop="definition">e.g., mammalian liver</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a control nanoparticle to a target tissue of interest</span>
        <span itemprop="definition">e.g., MC3, KC2, or DLinDMA</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the level of delivery of a nanoparticle to a particular tissue</span>
        <span itemprop="definition">may be measured by comparing the amount of protein produced in a tissue to the weight of said tissue, comparing the amount of therapeutic and/or prophylactic in a tissue to the weight of said tissue, comparing the amount of protein produced in a tissue to the amount of total protein in said tissue, or comparing the amount of therapeutic and/or prophylactic in a tissue to the amount of total therapeutic and/or prophylactic in said tissue.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a surrogate</span>
        <span itemprop="definition">such as an animal model (e.g., a rat model).</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)</span>
        <span itemprop="definition">has substantively the same level of delivery enhancement regardless of administration routes.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain compounds disclosed herein</span>
        <span itemprop="definition">exhibit similar delivery enhancement when they are used for delivering a therapeutic and/or prophylactic either intravenously or intramuscularly.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">certain compounds disclosed herein</span>
        <span itemprop="definition">e.g., a compound of Formula (IA) or (II), such as Compound 18, 25, 30, 60, 108-112, or 122) exhibit a higher level of delivery enhancement when they are used for delivering a therapeutic and/or prophylactic intramuscularly than intravenously.</span>
        <meta itemprop="num_attr" content="0264">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term specific delivery, specifically deliver, or specifically delivering</span>
        <span itemprop="definition">means delivery of more (e.g., at least 1.5 fold more, at least 2-fold more, at least 3-fold more, at least 4-fold more, at least 5-fold more, at least 6-fold more, at least 7-fold more, at least 8-fold more, at least 9-fold more, at least 10-fold more) of a therapeutic and/or prophylactic by a nanoparticle to a target tissue of interest (e.g., mammalian liver) compared to an off-target tissue (e.g., mammalian spleen).</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a target tissue of interest</span>
        <span itemprop="definition">e.g., mammalian liver</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an off-target tissue</span>
        <span itemprop="definition">e.g., mammalian spleen</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the level of delivery of a nanoparticle to a particular tissue</span>
        <span itemprop="definition">may be measured by comparing the amount of protein produced in a tissue to the weight of said tissue, comparing the amount of therapeutic and/or prophylactic in a tissue to the weight of said tissue, comparing the amount of protein produced in a tissue to the amount of total protein in said tissue, or comparing the amount of therapeutic and/or prophylactic in a tissue to the amount of total therapeutic and/or prophylactic in said tissue.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is specifically provided to a mammalian kidney as compared to the liver and spleen if 1.5, 2-fold, 3-fold, 5-fold, 10-fold, 15 fold, or 20 fold more therapeutic and/or prophylactic per 1 g of tissue is delivered to a kidney compared to that delivered to the liver or spleen following systemic administration of the therapeutic and/or prophylactic.</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a surrogate</span>
        <span itemprop="definition">such as an animal model (e.g., a rat model).</span>
        <meta itemprop="num_attr" content="0265">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">encapsulation efficiency</span>
        <span itemprop="definition">refers to the amount of a therapeutic and/or prophylactic that becomes part of a nanoparticle composition, relative to the initial total amount of therapeutic and/or prophylactic used in the preparation of a nanoparticle composition. For example, if 97 mg of therapeutic and/or prophylactic are encapsulated in a nanoparticle composition out of a total 100 mg of therapeutic and/or prophylactic initially provided to the composition, the encapsulation efficiency may be given as 97%. As used herein, encapsulation may refer to complete, substantial, or partial enclosure, confinement, surrounding, or encasement.</span>
        <meta itemprop="num_attr" content="0266">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">expression of a nucleic acid sequence</span>
        <span itemprop="definition">refers to translation of an mRNA into a polypeptide or protein and/or post-translational modification of a polypeptide or protein.</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">in vitro</span>
        <span itemprop="definition">refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">in vivo</span>
        <span itemprop="definition">refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ex vivo</span>
        <span itemprop="definition">refers to events that occur outside of an organism (e.g., animal, plant, or microbe or cell or tissue thereof). Ex vivo events may take place in an environment minimally altered from a natural (e.g., in vivo) environment.</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term isomer</span>
        <span itemprop="definition">means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds</span>
        <span itemprop="definition">may include one or more chiral centers and/or double bonds and may thus exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (&#43;) or (  )) or cis/trans isomers).</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">encompasses any and all isomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereomeric mixtures of compounds and means of resolving them into their component enantiomers or stereoisomers are well-known.</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid component</span>
        <span itemprop="definition">is that component of a nanoparticle composition that includes one or more lipids.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component</span>
        <span itemprop="definition">may include one or more cationic/ionizable, PEGylated, structural, or other lipids, such as phospholipids.</span>
        <meta itemprop="num_attr" content="0272">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a linker</span>
        <span itemprop="definition">is a moiety connecting two moieties, for example, the connection between two nucleosides of a cap species.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a linker</span>
        <span itemprop="definition">may include one or more groups including but not limited to phosphate groups (e.g., phosphates, boranophosphates, thiophosphates, selenophosphates, and phosphonates), alkyl groups, amidates, or glycerols.</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phosphate groups</span>
        <span itemprop="definition">e.g., phosphates, boranophosphates, thiophosphates, selenophosphates, and phosphonates</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl groups</span>
        <span itemprop="definition">e.g., phosphates, boranophosphates, thiophosphates, selenophosphates, and phosphonates</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl groups</span>
        <span itemprop="definition">e.g., phosphates, boranophosphates, thiophosphates, selenophosphates, and phosphonates</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl groups</span>
        <span itemprop="definition">e.g.,</span>
        <meta itemprop="num_attr" content="0273">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methods of administration</span>
        <span itemprop="definition">may include intravenous, intramuscular, intradermal, subcutaneous, or other methods of delivering a composition to a subject.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method of administration</span>
        <span itemprop="definition">may be selected to target delivery (e.g., to specifically deliver) to a specific region or system of a body.</span>
        <meta itemprop="num_attr" content="0274">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">may be a modified RNA. That is, an RNA may include one or more nucleobases, nucleosides, nucleotides, or linkers that are non-naturally occurring.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a modified species</span>
        <span itemprop="definition">may also be referred to herein as an altered species. Species may be modified or altered chemically, structurally, or functionally. For example, a modified nucleobase species may include one or more substitutions that are not naturally occurring.</span>
        <meta itemprop="num_attr" content="0275">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the N:P ratio</span>
        <span itemprop="definition">is the molar ratio of ionizable (in the physiological pH range) nitrogen atoms in a lipid to phosphate groups in an RNA, e.g., in a nanoparticle composition including a lipid component and an RNA.</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle composition</span>
        <span itemprop="definition">is a composition comprising one or more lipids. Nanoparticle compositions are typically sized on the order of micrometers or smaller and may include a lipid bilayer. Nanoparticle compositions encompass lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, a nanoparticle composition may be a liposome having a lipid bilayer with a diameter of 500 nm or less.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LNPs</span>
        <span itemprop="definition">lipid nanoparticles</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">liposomes</span>
        <span itemprop="definition">e.g., lipid vesicles</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipoplexes</span>
        <span itemprop="definition">e.g., lipoplexes.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be a liposome having a lipid bilayer with a diameter of 500 nm or less.</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">naturally occurring</span>
        <span itemprop="definition">means existing in nature without artificial aid.</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">patient</span>
        <span itemprop="definition">refers to a subject who may seek or be in need of treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under care by a trained professional for a particular disease or condition.</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a PEG lipid or PEGylated lipid</span>
        <span itemprop="definition">refers to a lipid comprising a polyethylene glycol component.</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phrases pharmaceutically acceptable</span>
        <span itemprop="definition">is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phrases pharmaceutically acceptable excipient, as used herein,</span>
        <span itemprop="definition">refers to any ingredient other than the compounds described herein (for example, a vehicle capable of suspending, complexing, or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Excipients</span>
        <span itemprop="definition">may include, for example: anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">anti-adherents</span>
        <span itemprop="definition">antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration.</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">excipients</span>
        <span itemprop="definition">include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E (alpha-</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the structural formula of the compound</span>
        <span itemprop="definition">represents a certain isomer for convenience in some cases, but the present disclosure includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like, it being understood that not all isomers may have the same level of activity.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a crystal polymorphism</span>
        <span itemprop="definition">may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present disclosure.</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">crystal polymorphs</span>
        <span itemprop="definition">means crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">may also include salts of one or more compounds.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Salts</span>
        <span itemprop="definition">may be pharmaceutically acceptable salts.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutically acceptable salts</span>
        <span itemprop="definition">refers to derivatives of the disclosed compounds wherein the parent compound is altered by converting an existing acid or base moiety to its salt form (e.g., by reacting a free base group with a suitable organic acid).</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of pharmaceutically acceptable salts</span>
        <span itemprop="definition">include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Representative acid addition salts</span>
        <span itemprop="definition">include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pe</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkali or alkaline earth metal salts</span>
        <span itemprop="definition">include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutically acceptable salts of the present disclosure</span>
        <span itemprop="definition">include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutically acceptable salts of the present disclosure</span>
        <span itemprop="definition">can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">such salts</span>
        <span itemprop="definition">can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nonaqueous media</span>
        <span itemprop="definition">like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lists of suitable salts</span>
        <span itemprop="definition">are found in Remington&#39;s Pharmaceutical Sciences, 17 th ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P. H. Stahl and C. G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">is a lipid that includes a phosphate moiety and one or more carbon chains, such as unsaturated fatty acid chains.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">may include one or more multiple (e.g., double or triple) bonds (e.g., one or more unsaturations).</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Particular phospholipids</span>
        <span itemprop="definition">may facilitate fusion to a membrane.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cationic phospholipid</span>
        <span itemprop="definition">may interact with one or more negatively charged phospholipids of a membrane (e.g., a cellular or intracellular membrane). Fusion of a phospholipid to a membrane may allow one or more elements of a lipid-containing composition to pass through the membrane permitting, e.g., delivery of the one or more elements to a cell.</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polydispersity index</span>
        <span itemprop="definition">is a ratio that describes the homogeneity of the particle size distribution of a system. A small value, e.g., less than 0.3, indicates a narrow particle size distribution.</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polypeptide</span>
        <span itemprop="definition">or polypeptide of interest refers to a polymer of amino acid residues typically joined by peptide bonds that can be produced naturally (e.g., isolated or purified) or synthetically.</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an RNA</span>
        <span itemprop="definition">refers to a ribonucleic acid that may be naturally or non-naturally occurring.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an RNA</span>
        <span itemprop="definition">may include modified and/or non-naturally occurring components such as one or more nucleobases, nucleosides, nucleotides, or linkers.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An RNA</span>
        <span itemprop="definition">may include a cap structure, a chain terminating nucleoside, a stem loop, a polyA sequence, and/or a polyadenylation signal.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An RNA</span>
        <span itemprop="definition">may have a nucleotide sequence encoding a polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an RNA</span>
        <span itemprop="definition">may be a messenger RNA (mRNA).</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNAs</span>
        <span itemprop="definition">may be selected from the non-liming group consisting of small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">small interfering RNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aiRNA</span>
        <span itemprop="definition">asymmetrical interfering RNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miRNA</span>
        <span itemprop="definition">microRNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dsRNA</span>
        <span itemprop="definition">Dicer-substrate RNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">shRNA</span>
        <span itemprop="definition">small hairpin RNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">small hairpin RNA</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a single unit dose</span>
        <span itemprop="definition">is a dose of any therapeutic administered in one dose/at one time/single route/single point of contact, i.e., single administration event.</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a split dose</span>
        <span itemprop="definition">is the division of single unit dose or total daily dose into two or more doses.</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">total daily dose</span>
        <span itemprop="definition">is an amount given or prescribed in 24 hour period. It may be administered as a single unit dose.</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">size</span>
        <span itemprop="definition">or mean size in the context of nanoparticle compositions refers to the mean diameter of a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term subject or patient</span>
        <span itemprop="definition">refers to any organism to which a composition in accordance with the disclosure may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Typical subjects</span>
        <span itemprop="definition">include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">targeted cells</span>
        <span itemprop="definition">refers to any one or more cells of interest.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cells</span>
        <span itemprop="definition">may be found in vitro, in vivo, in situ, or in the tissue or organ of an organism.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the organism</span>
        <span itemprop="definition">may be an animal, preferably a mammal, more preferably a human and most preferably a patient.</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">target tissue</span>
        <span itemprop="definition">refers to any one or more tissue types of interest in which the delivery of a therapeutic and/or prophylactic would result in a desired biological and/or pharmacological effect.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">target tissues of interest</span>
        <span itemprop="definition">include specific tissues, organs, and systems or groups thereof.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a target tissue</span>
        <span itemprop="definition">may be a kidney, a lung, a spleen, vascular endothelium in vessels (e.g., intra-coronary or intra-femoral), or tumor tissue (e.g., via intratumoral injection).</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An off-target tissue</span>
        <span itemprop="definition">refers to any one or more tissue types in which the expression of the encoded protein does not result in a desired biological and/or pharmacological effect.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">off-target tissues</span>
        <span itemprop="definition">may include the liver and the spleen.</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">therapeutic agent</span>
        <span itemprop="definition">refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Therapeutic agents</span>
        <span itemprop="definition">are also referred to as actives or active agents. Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the term therapeutically effective amount</span>
        <span itemprop="definition">means an amount of an agent to be delivered (e.g., nucleic acid, drug, composition, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an agent to be delivered</span>
        <span itemprop="definition">e.g., nucleic acid, drug, composition, therapeutic agent, diagnostic agent, prophylactic agent, etc.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">transfection</span>
        <span itemprop="definition">refers to the introduction of a species (e.g., an RNA) into a cell. Transfection may occur, for example, in vitro, ex vivo, or in vivo.</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a species</span>
        <span itemprop="definition">e.g., an RNA</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">treating</span>
        <span itemprop="definition">refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a particular infection, disease, disorder, and/or condition.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">treating cancer</span>
        <span itemprop="definition">may refer to inhibiting survival, growth, and/or spread of a tumor. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the zeta potential</span>
        <span itemprop="definition">is the electrokinetic potential of a lipid, e.g., in a particle composition.</span>
        <meta itemprop="num_attr" content="0301">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">also features nanoparticle compositions comprising a lipid component comprising a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) as described herein.</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the largest dimension of a nanoparticle composition</span>
        <span itemprop="definition">is 1 m or shorter (e.g., 1   m, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, or shorter), e.g., when measured by dynamic light scattering (DLS), transmission electron microscopy, scanning electron microscopy, or another method.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">include, for example, lipid nanoparticles (LNPs), liposomes, lipid vesicles, and lipoplexes.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nanoparticle compositions</span>
        <span itemprop="definition">are vesicles including one or more lipid bilayers.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">includes two or more concentric bilayers separated by aqueous compartments.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid bilayers</span>
        <span itemprop="definition">may be functionalized and/or crosslinked to one another.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid bilayers</span>
        <span itemprop="definition">may include one or more ligands, proteins, or channels.</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">comprise a lipid component including at least one compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include one or more of Compounds 1-147.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may also include a variety of other components.</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include one or more other lipids in addition to a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may include one or more cationic and/or ionizable lipids (e.g., lipids that may have a positive or partial positive charge at physiological pH) in addition to a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipids</span>
        <span itemprop="definition">e.g., lipids that may have a positive or partial positive charge at physiological pH</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cationic and/or ionizable lipids</span>
        <span itemprop="definition">may be selected from the non-limiting group consisting of 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include one or more PEG or PEG-modified lipids. Such species may be alternately referred to as PEGylated lipids.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a PEG lipid</span>
        <span itemprop="definition">is a lipid modified with polyethylene glycol.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a PEG lipid</span>
        <span itemprop="definition">may be selected from the non-limiting group consisting of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a PEG lipid</span>
        <span itemprop="definition">may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid.</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include one or more structural lipids.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Structural lipids</span>
        <span itemprop="definition">can be selected from the group consisting of, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the structural lipid</span>
        <span itemprop="definition">is cholesterol.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the structural lipid</span>
        <span itemprop="definition">includes cholesterol and a corticosteroid (such as prednisolone, dexamethasone, prednisone, and hydrocortisone), or a combination thereof.</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include one or more phospholipids, such as one or more (poly)unsaturated lipids.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phospholipids</span>
        <span itemprop="definition">may assemble into one or more lipid bilayers.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phospholipids</span>
        <span itemprop="definition">may include a phospholipid moiety and one or more fatty acid moieties.</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">may be a lipid according to Formula (III):</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R p</span>
        <span itemprop="definition">represents a phospholipid moiety and R 1 and R 2 represent fatty acid moieties with or without unsaturation that may be the same or different.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid moiety</span>
        <span itemprop="definition">may be selected from the non-limiting group consisting of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and a sphingomyelin.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a fatty acid moiety</span>
        <span itemprop="definition">may be selected from the non-limiting group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-natural species</span>
        <span itemprop="definition">including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes are also contemplated.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">may be functionalized with or cross-linked to one or more alkynes (e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynes</span>
        <span itemprop="definition">e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alkyne group</span>
        <span itemprop="definition">may undergo a copper-catalyzed cycloaddition upon exposure to an azide.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such reactions</span>
        <span itemprop="definition">may be useful in functionalizing a lipid bilayer of a nanoparticle composition to facilitate membrane permeation or cellular recognition or in conjugating a nanoparticle composition to a useful component such as a targeting or imaging moiety (e.g., a dye).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phospholipids useful in the compositions and methods</span>
        <span itemprop="definition">may be selected from the non-limiting group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-g</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition that includes one or more lipids described herein</span>
        <span itemprop="definition">may further include one or more adjuvants, e.g., Glucopyranosyl Lipid Adjuvant (GLA), CpG oligodeoxynucleotides (e.g., Class A or B), poly(I:C), aluminum hydroxide, and Pam3CSK4.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GLA</span>
        <span itemprop="definition">Glucopyranosyl Lipid Adjuvant</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CpG oligodeoxynucleotides</span>
        <span itemprop="definition">e.g., Class A or B</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">poly(I:C)</span>
        <span itemprop="definition">poly(I:C)</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">aluminum hydroxide</span>
        <span itemprop="definition">e.g., aluminum hydroxide, and Pam3CSK4.</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may include one or more therapeutic and/or prophylactics.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">features methods of delivering a therapeutic and/or prophylactic to a mammalian cell or organ, producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof comprising administering to a mammal and/or contacting a mammalian cell with a nanoparticle composition including a therapeutic and/or prophylactic.</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Therapeutic and/or prophylactics</span>
        <span itemprop="definition">include biologically active substances and are alternately referred to as active agents.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">may be a substance that, once delivered to a cell or organ, brings about a desirable change in the cell, organ, or other bodily tissue or system. Such species may be useful in the treatment of one or more diseases, disorders, or conditions.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is a small molecule drug useful in the treatment of a particular disease, disorder, or condition.</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">drugs useful in the nanoparticle compositions</span>
        <span itemprop="definition">include, but are not limited to, antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antitumor agents (e.g., actinomycin D, vincristine, vinblastine, cystine arabinoside, anthracyclines, alkylative agents, platinum compounds, antimetabolites, and nucleoside analogs, such as methotrexate and purine and pyrimidine analogs), anti-infective agents, local anesthetics (e.g., dibucaine and chlorpromazine), beta-adrenergic blockers (e.g., propranolol, timolol, and labetolol), antihypertensive agents (e.g., clonidine and hydral</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is a cytotoxin, a radioactive ion, a chemotherapeutic, a vaccine, a compound that elicits an immune response, and/or another therapeutic and/or prophylactic.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cytotoxin or cytotoxic agent</span>
        <span itemprop="definition">includes any agent that may be detrimental to cells.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples</span>
        <span itemprop="definition">include, but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracinedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g., maytansinol, rachelmycin (CC-1065), and analogs or homologs thereof.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">taxol</span>
        <span itemprop="definition">cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine,</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Radioactive ions</span>
        <span itemprop="definition">include, but are not limited to iodine (e.g., iodine 125 or iodine 131), strontium 89, phosphorous, palladium, cesium, iridium, phosphate, cobalt, yttrium 90, samarium 153, and praseodymium.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">iodine</span>
        <span itemprop="definition">e.g., iodine 125 or iodine 131</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">strontium 89</span>
        <span itemprop="definition">phosphorous</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">palladium</span>
        <span itemprop="definition">cesium</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">iridium</span>
        <span itemprop="definition">phosphate</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cobalt</span>
        <span itemprop="definition">yttrium 90</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">samarium 153</span>
        <span itemprop="definition">samarium 153</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">praseodymium</span>
        <span itemprop="definition">praseodymium</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Vaccines</span>
        <span itemprop="definition">include compounds and preparations that are capable of providing immunity against one or more conditions related to infectious diseases such as influenza, measles, human papillomavirus (HPV), rabies, meningitis, whooping cough, tetanus, plague, hepatitis, and tuberculosis and can include mRNAs encoding infectious disease derived antigens and/or epitopes.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Vaccines</span>
        <span itemprop="definition">also include compounds and preparations that direct an immune response against cancer cells and can include mRNAs encoding tumor cell derived antigens, epitopes, and/or neoepitopes.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds eliciting immune responses</span>
        <span itemprop="definition">may include vaccines, corticosteroids (e.g., dexamethasone), and other species.</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a vaccine and/or a compound capable of eliciting an immune response</span>
        <span itemprop="definition">is administered intramuscularly via a composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) (e.g., Compound 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122).</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other therapeutic and/or prophylactics</span>
        <span itemprop="definition">include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, rachelmycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthra</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is a protein.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Therapeutic proteins useful in the nanoparticles in the disclosure</span>
        <span itemprop="definition">include, but are not limited to, gentamycin, amikacin, insulin, erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), Factor VIR, luteinizing hormone-releasing hormone (LHRH) analogs, interferons, heparin, Hepatitis B surface antigen, typhoid vaccine, and cholera vaccine.</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EPO</span>
        <span itemprop="definition">erythropoietin</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">G-CSF</span>
        <span itemprop="definition">granulocyte-colony stimulating factor</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GM-CSF</span>
        <span itemprop="definition">granulocyte-macrophage colony stimulating factor</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LHRH</span>
        <span itemprop="definition">luteinizing hormone-releasing hormone</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic agent</span>
        <span itemprop="definition">is a polynucleotide or nucleic acid (e.g., ribonucleic acid or deoxyribonucleic acid).</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid</span>
        <span itemprop="definition">e.g., ribonucleic acid or deoxyribonucleic acid.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polynucleotide</span>
        <span itemprop="definition">in its broadest sense, includes any compound and/or substance that is or can be incorporated into an oligonucleotide chain.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary polynucleotides for use in accordance with the present disclosure</span>
        <span itemprop="definition">include, but are not limited to, one or more of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) including messenger mRNA (mRNA), hybrids thereof, RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, RNAs that induce triple helix formation, aptamers, vectors, etc.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is an RNA.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNAs useful in the compositions and methods described herein</span>
        <span itemprop="definition">can be selected from the group consisting of, but are not limited to, shortmers, antagomirs, antisense, ribozymes, small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the RNA</span>
        <span itemprop="definition">is an mRNA.</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is an mRNA.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An mRNA</span>
        <span itemprop="definition">may encode any polypeptide of interest, including any naturally or non-naturally occurring or otherwise modified polypeptide.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polypeptide encoded by an mRNA</span>
        <span itemprop="definition">may be of any size and may have any secondary structure or activity.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polypeptide encoded by an mRNA</span>
        <span itemprop="definition">may have a therapeutic effect when expressed in a cell.</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is an siRNA.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An siRNA</span>
        <span itemprop="definition">may be capable of selectively knocking down or down regulating expression of a gene of interest.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an siRNA</span>
        <span itemprop="definition">could be selected to silence a gene associated with a particular disease, disorder, or condition upon administration to a subject in need thereof of a nanoparticle composition including the siRNA.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An siRNA</span>
        <span itemprop="definition">may comprise a sequence that is complementary to an mRNA sequence that encodes a gene or protein of interest.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the siRNA</span>
        <span itemprop="definition">may be an immunomodulatory siRNA.</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">is an shRNA or a vector or plasmid encoding the same.</span>
        <meta itemprop="num_attr" content="0318">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An shRNA</span>
        <span itemprop="definition">may be produced inside a target cell upon delivery of an appropriate construct to the nucleus. Constructs and mechanisms relating to shRNA are well known in the relevant arts.</span>
        <meta itemprop="num_attr" content="0318">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids and polynucleotides useful in the disclosure</span>
        <span itemprop="definition">typically include a first region of linked nucleosides encoding a polypeptide of interest (e.g., a coding region), a first flanking region located at the 5-terminus of the first region (e.g., a 5-UTR), a second flanking region located at the 3-terminus of the first region (e.g., a 3-UTR), at least one 5-cap region, and a 3-stabilizing region.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid or polynucleotide</span>
        <span itemprop="definition">further includes a poly-A region or a Kozak sequence (e.g., in the 5-UTR).</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polynucleotides</span>
        <span itemprop="definition">may contain one or more intronic nucleotide sequences capable of being excised from the polynucleotide.</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide or nucleic acid</span>
        <span itemprop="definition">e.g., an mRNA</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide or nucleic acid</span>
        <span itemprop="definition">may include a 5 cap structure, a chain terminating nucleotide, a stem loop, a polyA sequence, and/or a polyadenylation signal. Any one of the regions of a nucleic acid may include one or more alternative components (e.g., an alternative nucleoside).</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-stabilizing region</span>
        <span itemprop="definition">may contain an alternative nucleoside such as an L-nucleoside, an inverted thymidine, or a 2-O-methyl nucleoside and/or the coding region, 5-UTR, 3-UTR, or cap region may include an alternative nucleoside such as a 5-substituted uridine (e.g., 5-methoxyuridine), a 1-substituted pseudouridine (e.g., 1-methyl-pseudouridine or 1-ethyl-pseudouridine), and/or a 5-substituted cytidine (e.g., 5-methyl-cytidine).</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5-substituted uridine</span>
        <span itemprop="definition">e.g., 5-methoxyuridine</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 1-substituted pseudouridine</span>
        <span itemprop="definition">e.g., 1-methyl-pseudouridine or 1-ethyl-pseudouridine</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytidine</span>
        <span itemprop="definition">e</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the shortest length of a polynucleotide</span>
        <span itemprop="definition">can be the length of the polynucleotide sequence that is sufficient to encode for a dipeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a tripeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a tetrapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a pentapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a hexapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a heptapeptide.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length of the polynucleotide sequence</span>
        <span itemprop="definition">is sufficient to encode for an octapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a nonapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a decapeptide.</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dipeptides that the alternative polynucleotide sequences can encode for</span>
        <span itemprop="definition">include, but are not limited to, carnosine and anserine.</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">is greater than 30 nucleotides in length. In another embodiment, the polynucleotide molecule is greater than 35 nucleotides in length. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 50 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides. In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 1800 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides. In another embodiment, the length is at least 4000 nucleotides. In another embodiment, the length is at least 5000 nucleotides, or greater than 5000 nucleotides.</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids and polynucleotides</span>
        <span itemprop="definition">may include one or more naturally occurring components, including any of the canonical nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine).</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">all or substantially all of the nucleotides comprising</span>
        <span itemprop="definition">(a) the 5-UTR, (b) the open reading frame (ORF), (c) the 3-UTR, (d) the poly A tail, and any combination of (a, b, c, or d above) comprise naturally occurring canonical nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine).</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleic acids and polynucleotides</span>
        <span itemprop="definition">may include one or more alternative components, as described herein, which impart useful properties including increased stability and/or the lack of a substantial induction of the innate immune response of a cell into which the polynucleotide is introduced.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an alternative polynucleotide or nucleic acid</span>
        <span itemprop="definition">exhibits reduced degradation in a cell into which the polynucleotide or nucleic acid is introduced, relative to a corresponding unaltered polynucleotide or nucleic acid.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These alternative species</span>
        <span itemprop="definition">may enhance the efficiency of protein production, intracellular retention of the polynucleotides, and/or viability of contacted cells, as well as possess reduced immunogenicity.</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides and nucleic acids</span>
        <span itemprop="definition">may be naturally or non-naturally occurring.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides and nucleic acids</span>
        <span itemprop="definition">may include one or more modified (e.g., altered or alternative) nucleobases, nucleosides, nucleotides, or combinations thereof.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids and polynucleotides useful in a nanoparticle composition</span>
        <span itemprop="definition">can include any useful modification or alteration, such as to the nucleobase, the sugar, or the internucleoside linkage (e.g., to a linking phosphate/to a phosphodiester linkage/to the phosphodiester backbone).</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alterations</span>
        <span itemprop="definition">are present in each of the nucleobase, the sugar, and the internucleoside linkage.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alterations according to the present disclosure</span>
        <span itemprop="definition">may be alterations of ribonucleic acids (RNAs) to deoxyribonucleic acids (DNAs), e.g., the substitution of the 2-OH of the ribofuranosyl ring to 2-H, threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs), or hybrids thereof. Additional alterations are described herein.</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides and nucleic acids</span>
        <span itemprop="definition">may or may not be uniformly altered along the entire length of the molecule.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more or all types of nucleotide</span>
        <span itemprop="definition">e.g., purine or pyrimidine, or any one or more or all of A, G, U, C</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotide</span>
        <span itemprop="definition">may or may not be uniformly altered in a polynucleotide or nucleic acid, or in a given predetermined sequence region thereof.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotides X in a polynucleotide</span>
        <span itemprop="definition">are altered, wherein X may any one of nucleotides A, G, U, C, or any one of the combinations A&#43;G, A&#43;U, A&#43;C, G&#43;U, G&#43;C, U&#43;C, A&#43;G&#43;U, A&#43;G&#43;C, G&#43;U&#43;C or A&#43;G&#43;C.</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotide analogs or other alteration(s)</span>
        <span itemprop="definition">may be located at any position(s) of a polynucleotide such that the function of the polynucleotide is not substantially decreased.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An alteration</span>
        <span itemprop="definition">may also be a 5- or 3-terminal alteration.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide</span>
        <span itemprop="definition">includes an alteration at the 3-terminus.</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide</span>
        <span itemprop="definition">may contain from about 1% to about 100% alternative nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from</span>
        <meta itemprop="num_attr" content="0327">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides</span>
        <span itemprop="definition">may contain at a minimum zero and at maximum 100% alternative nucleotides, or any intervening percentage, such as at least 5% alternative nucleotides, at least 10% alternative nucleotides, at least 25% alternative nucleotides, at least 50% alternative nucleotides, at least 80% alternative nucleotides, or at least 90% alternative nucleotides.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polynucleotides</span>
        <span itemprop="definition">may contain an alternative pyrimidine such as an alternative uracil or cytosine.</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">At least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in a polynucleotide</span>
        <span itemprop="definition">is replaced with an alternative uracil (e.g., a 5-substituted uracil).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative uracil</span>
        <span itemprop="definition">can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cytosine in the polynucleotide</span>
        <span itemprop="definition">is replaced with an alternative cytosine (e.g., a 5-substituted cytosine).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative cytosine</span>
        <span itemprop="definition">can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">do not substantially induce an innate immune response of a cell into which the polynucleotide (e.g., mRNA) is introduced.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cell into which the polynucleotide</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">features of an induced innate immune response</span>
        <span itemprop="definition">include 1) increased expression of pro-inflammatory cytokines, 2) activation of intracellular PRRs (RIG-I, MDA5, etc., and/or 3) termination or reduction in protein translation.</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids</span>
        <span itemprop="definition">can optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, tRNA, RNAs that induce triple helix formation, aptamers, vectors).</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acids</span>
        <span itemprop="definition">may include one or more messenger RNAs (mRNAs) having one or more alternative nucleoside or nucleotides (i.e., alternative mRNA molecules).</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid (e.g. mRNA) molecule, formula, composition or method associated therewith</span>
        <span itemprop="definition">comprises one or more polynucleotides comprising features as described in WO2002/098443, WO2003/051401, WO2008/052770, WO2009127230, WO2006122828, WO2008/083949, WO2010088927, WO2010/037539, WO2004/004743, WO2005/016376, WO2006/024518, WO2007/095976, WO2008/014979, WO2008/077592, WO2009/030481, WO2009/095226, WO2011069586, WO2011026641, WO2011/144358, WO2012019780, WO2012013326, WO2012089338, WO2012113513, WO2012116811, WO2012116810, WO2013113502, WO2013113501, WO2013113736, WO20131436</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative nucleosides and nucleotides</span>
        <span itemprop="definition">can include an alternative nucleobase.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleobase of a nucleic acid</span>
        <span itemprop="definition">is an organic base such as a purine or pyrimidine or a derivative thereof.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleobase</span>
        <span itemprop="definition">may be a canonical base (e.g., adenine, guanine, uracil, thymine, and cytosine). These nucleobases can be altered or wholly replaced to provide polynucleotide molecules having enhanced properties, e.g., increased stability such as resistance to nucleases.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-canonical or modified bases</span>
        <span itemprop="definition">may include, for example, one or more substitutions or modifications including but not limited to alkyl, aryl, halo, oxo, hydroxyl, alkyloxy, and/or thio substitutions; one or more fused or open rings; oxidation; and/or reduction.</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alternative nucleotide base pairing</span>
        <span itemprop="definition">encompasses not only the standard adenine-thymine, adenine-uracil, or guanine-cytosine base pairs, but also base pairs formed between nucleotides and/or alternative nucleotides including non-standard or alternative bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">non-standard base pairing</span>
        <span itemprop="definition">is the base pairing between the alternative nucleotide inosine and adenine, cytosine, or uracil.</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">is an alternative uracil.</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary nucleobases and nucleosides having an alternative uracil</span>
        <span itemprop="definition">include pseudouridine (  ), pyridin-4-one ribonucleoside, 5-aza-uracil, 6-aza-uracil, 2-thio-5-aza-uracil, 2-thio-uracil (s 2 U), 4-thio-uracil (s 4 U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uracil (ho 5 U), 5-aminoallyl-uracil, 5-halo-uracil (e.g., 5-iodo-uracil or 5-bromo-uracil), 3-methyl-uracil (m 3 U), 5-methoxy-uracil (mo 5 U), uracil 5-oxyacetic acid (cmo 5 U), uracil 5-oxyacetic acid methyl ester (mcmo 5 U), 5-carboxymethyl</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">is an alternative cytosine.</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary nucleobases and nucleosides having an alternative cytosine</span>
        <span itemprop="definition">include 5-aza-cytosine, 6-aza-cytosine, pseudoisocytidine, 3-methyl-cytosine (m3C), N4-acetyl-cytosine (ac4C), 5-formyl-cytosine (f5C), N4-methyl-cytosine (m4C), 5-methyl-cytosine (m5C), 5-halo-cytosine (e.g., 5-iodo-cytosine), 5-hydroxymethyl-cytosine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytosine, pyrrolo-pseudoisocytidine, 2-thio-cytosine (s2C), 2-thio-5-methyl-cytosine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudois</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">is an alternative adenine.</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary nucleobases and nucleosides having an alternative adenine</span>
        <span itemprop="definition">include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), 2-methylthio-</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">is an alternative guanine.</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary nucleobases and nucleosides having an alternative guanine</span>
        <span itemprop="definition">include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW), hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW*), 7-deaza-guanine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanine (preQ0), 7-aminomethyl-7-deaza-guanine (preQ1), archae</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative nucleobase of a nucleotide</span>
        <span itemprop="definition">can be independently a purine, a pyrimidine, a purine or pyrimidine analog.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">can be an alternative to adenine, cytosine, guanine, uracil, or hypoxanthine.</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleobase</span>
        <span itemprop="definition">can also include, for example, naturally-occurring and synthetic derivatives of a base, including pyrazolo[3,4-d]pyrimidines, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each letter</span>
        <span itemprop="definition">refers to the representative base and/or derivatives thereof, e.g., A includes adenine or adenine analogs, e.g., 7-deaza adenine).</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nucleosides</span>
        <span itemprop="definition">include a sugar molecule (e.g., a 5-carbon or 6-carbon sugar, such as pentose, ribose, arabinose, xylose, glucose, galactose, or a deoxy derivative thereof) in combination with a nucleobase, while nucleotides are nucleosides containing a nucleoside and a phosphate group or alternative group (e.g., boranophosphate, thiophosphate, selenophosphate, phosphonate, alkyl group, amidate, and glycerol).</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a sugar molecule</span>
        <span itemprop="definition">e.g., a 5-carbon or 6-carbon sugar, such as pentose, ribose, arabinose, xylose, glucose, galactose, or a deoxy derivative thereof</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotides</span>
        <span itemprop="definition">are nucleosides containing a nucleoside and a phosphate group or alternative group (e.g., boranophosphate, thio</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleoside or nucleotide</span>
        <span itemprop="definition">may be a canonical species, e.g., a nucleoside or nucleotide including a canonical nucleobase, sugar, and, in the case of nucleotides, a phosphate group, or may be an alternative nucleoside or nucleotide including one or more alternative components.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alternative nucleosides and nucleotides</span>
        <span itemprop="definition">can be altered on the sugar of the nucleoside or nucleotide.</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative nucleosides or nucleotides</span>
        <span itemprop="definition">include the structure:</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of m and n</span>
        <span itemprop="definition">is independently, an integer from 0 to 5,</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of U and U</span>
        <span itemprop="definition">independently, is O, S, N(R U ) nu , or C(R U ) nu , wherein nu is an integer from 0 to 2 and each R U is, independently, H, halo, or optionally substituted alkyl;</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 1 , R 2 , R 1 , R 2 , R 1 , R 2 , R 3 , R 4 , and R 5</span>
        <span itemprop="definition">is, independently, if present, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; wherein the combination of R 3 with one or more of R 1 , R 1 , R 2 , R 2 , or R 5 (e.g., the combination of R 1 and R 3 , the combination of R 1 and R 3 , the combination of R 2 and R 3</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of Y 1 , Y 2 , and Y 3</span>
        <span itemprop="definition">is, independently, O, S, Se, NR N1 , optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R N1 is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; each Y 4 is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each Y 5</span>
        <span itemprop="definition">is, independently, O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; and</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B</span>
        <span itemprop="definition">is a nucleobase, either modified or unmodified.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 2-hydroxy group (OH)</span>
        <span itemprop="definition">can be modified or replaced with a number of different substituents.</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Exemplary substitutions at the 2-position</span>
        <span itemprop="definition">include, but are not limited to, H, azido, halo (e.g., fluoro), optionally substituted C 1-6 alkyl (e.g., methyl); optionally substituted C 1-6 alkoxy (e.g., methoxy or ethoxy); optionally substituted C 6-10 aryloxy; optionally substituted C 3-8 cycloalkyl; optionally substituted C 6-10 aryl-C 1-6 alkoxy, optionally substituted C 1-12 (heterocyclyl)oxy; a sugar (e.g., ribose, pentose, or any described herein); a polyethyleneglycol (PEG), O(CH 2 CH 2 O) n CH 2 CH 2 OR, where R is H or optionally substituted alkyl,</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">includes the sugar group ribose, which is a 5-membered ring having an oxygen.</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">exemplary, non-limiting alternative nucleotides</span>
        <span itemprop="definition">include replacement of the oxygen in ribose (e.g., with S, Se, or alkylene, such as methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino (that also has a phosphoramidate backbone)); multicyclic forms (</span>
        <meta itemprop="num_attr" content="0346">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sugar group</span>
        <span itemprop="definition">contains one or more carbons that possess the opposite stereochemical configuration of the corresponding carbon in ribose.</span>
        <meta itemprop="num_attr" content="0347">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide molecule</span>
        <span itemprop="definition">can include nucleotides containing, e.g., arabinose or L-ribose, as the sugar.</span>
        <meta itemprop="num_attr" content="0347">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide</span>
        <span itemprop="definition">includes at least one nucleoside wherein the sugar is L-ribose, 2-O-methyl-ribose, 2-fluoro-ribose, arabinose, hexitol, an LNA, or a PNA.</span>
        <meta itemprop="num_attr" content="0348">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleotides</span>
        <span itemprop="definition">can be altered on the internucleoside linkage (e.g., phosphate backbone).</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">phosphate backbone</span>
        <span itemprop="definition">in the context of the polynucleotide backbone, the phrases phosphate and phosphodiester are used interchangeably.</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Backbone phosphate groups</span>
        <span itemprop="definition">can be altered by replacing one or more of the oxygen atoms with a different substituent.</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative nucleotides</span>
        <span itemprop="definition">can include the wholesale replacement of an unaltered phosphate moiety with another internucleoside linkage as described herein.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alternative phosphate groups</span>
        <span itemprop="definition">include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphorodithioates</span>
        <span itemprop="definition">have both non-linking oxygens replaced by sulfur.</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phosphate linker</span>
        <span itemprop="definition">can also be altered by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative nucleosides and nucleotides</span>
        <span itemprop="definition">can include the replacement of one or more of the non-bridging oxygens with a borane moiety (BH 3 ), sulfur (thio), methyl, ethyl, and/or methoxy.</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a borane moiety</span>
        <span itemprop="definition">BH 3</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">sulfur (thio)</span>
        <span itemprop="definition">thio</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methyl</span>
        <span itemprop="definition">ethyl</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methoxy</span>
        <span itemprop="definition">e.g., methoxy of two non-bridging oxygens at the same position</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">two non-bridging oxygens at the same position</span>
        <span itemprop="definition">e.g., the alpha (  ), beta (  ) or gamma (  ) position</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the replacement of one or more of the oxygen atoms at the a position of the phosphate moiety</span>
        <span itemprop="definition">is provided to confer stability (such as against exonucleases and endonucleases) to RNA and DNA through the unnatural phosphorothioate backbone linkages.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Phosphorothioate DNA and RNA</span>
        <span itemprop="definition">have increased nuclease resistance and subsequently a longer half-life in a cellular environment.</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">internucleoside linkages</span>
        <span itemprop="definition">that may be employed according to the present disclosure, including internucleoside linkages which do not contain a phosphorous atom, are described herein.</span>
        <meta itemprop="num_attr" content="0353">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides</span>
        <span itemprop="definition">may contain an internal ribosome entry site (IRES).</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IRES</span>
        <span itemprop="definition">may act as the sole ribosome binding site, or may serve as one of multiple ribosome binding sites of an mRNA.</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide containing more than one functional ribosome binding site</span>
        <span itemprop="definition">may encode several peptides or polypeptides that are translated independently by the ribosomes (e.g., multicistronic mRNA).</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a second translatable region</span>
        <span itemprop="definition">is optionally provided.</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">IRES sequences</span>
        <span itemprop="definition">that can be used according to the present disclosure include without limitation, those from picornaviruses (e.g., FMDV), pest viruses (CFFV), polio viruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukemia virus (MLV), simian immune deficiency viruses (SIV) or cricket paralysis viruses (CrPV).</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">picornaviruses</span>
        <span itemprop="definition">e.g., FMDV</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CFFV</span>
        <span itemprop="definition">pest viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PV</span>
        <span itemprop="definition">polio viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ECMV</span>
        <span itemprop="definition">encephalomyocarditis viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FMDV</span>
        <span itemprop="definition">foot-and-mouth disease viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HCV</span>
        <span itemprop="definition">hepatitis C viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CSFV</span>
        <span itemprop="definition">classical swine fever viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MLV</span>
        <span itemprop="definition">murine leukemia virus</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">SIV</span>
        <span itemprop="definition">simian immune deficiency viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CrPV</span>
        <span itemprop="definition">cricket paralysis viruses</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include a 5-cap structure.</span>
        <meta itemprop="num_attr" content="0355">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-cap structure of a polynucleotide</span>
        <span itemprop="definition">is involved in nuclear export and increasing polynucleotide stability and binds the mRNA Cap Binding Protein (CBP), which is responsible for polynucleotide stability in the cell and translation competency through the association of CBP with poly-A binding protein to form the mature cyclic mRNA species.</span>
        <meta itemprop="num_attr" content="0355">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CBP</span>
        <span itemprop="definition">mRNA Cap Binding Protein</span>
        <meta itemprop="num_attr" content="0355">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cap</span>
        <span itemprop="definition">further assists the removal of 5-proximal introns removal during mRNA splicing.</span>
        <meta itemprop="num_attr" content="0355">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Endogenous polynucleotide molecules</span>
        <span itemprop="definition">may be 5-end capped generating a 5-ppp-5-triphosphate linkage between a terminal guanosine cap residue and the 5-terminal transcribed sense nucleotide of the polynucleotide.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">This 5-guanylate cap</span>
        <span itemprop="definition">may then be methylated to generate an N7-methyl-guanylate residue.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5 end of the polynucleotide</span>
        <span itemprop="definition">may optionally also be 2-O-methylated.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5-decapping through hydrolysis and cleavage of the guanylate cap structure</span>
        <span itemprop="definition">may target a polynucleotide molecule, such as an mRNA molecule, for degradation.</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alterations to polynucleotides</span>
        <span itemprop="definition">may generate a non-hydrolyzable cap structure preventing decapping and thus increasing polynucleotide half-life. Because cap structure hydrolysis requires cleavage of 5-ppp-5 phosphorodiester linkages, alternative nucleotides may be used during the capping reaction. For example, a Vaccinia Capping Enzyme from New England Biolabs (Ipswich, Mass.) may be used with   -thio-guanosine nucleotides according to the manufacturer&#39;s instructions to create a phosphorothioate linkage in the 5-ppp-5 cap. Additional alternative guanosine nucleotides may be used such as   -methyl-phosphonate and seleno-phosphate nucleotides.</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Additional alterations</span>
        <span itemprop="definition">include, but are not limited to, 2-O-methylation of the ribose sugars of 5-terminal and/or 5-anteterminal nucleotides of the polynucleotide (as mentioned above) on the 2-hydroxy group of the sugar.</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Multiple distinct 5-cap structures</span>
        <span itemprop="definition">can be used to generate the 5-cap of a polynucleotide, such as an mRNA molecule.</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5-Cap structures</span>
        <span itemprop="definition">include those described in International Patent Publication Nos. WO2008127688, WO 2008016473, and WO 2011015347, the cap structures of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cap analogs</span>
        <span itemprop="definition">which herein are also referred to as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ from natural (i.e., endogenous, wild-type, or physiological) 5-caps in their chemical structure, while retaining cap function. Cap analogs may be chemically (i.e., non-enzymatically) or enzymatically synthesized and/linked to a polynucleotide.</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the Anti-Reverse Cap Analog (ARCA) cap</span>
        <span itemprop="definition">contains two guanosines linked by a 5-5-triphosphate group, wherein one guanosine contains an N7-methyl group as well as a 3-O-methyl group (i.e., N7,3-O-dimethyl-guanosine-5-triphosphate-5-guanosine, m 7 G-3mppp-G, which may equivalently be designated 3 O-Me-m7G(5)ppp(5)G).</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N7,3-O-dimethyl-guanosine-5-triphosphate-5-guanosine, m 7 G-3mppp-G</span>
        <span itemprop="definition">which may equivalently be designated 3 O-Me-m7G(5)ppp(5)G).</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-O atom of the other, unaltered, guanosine</span>
        <span itemprop="definition">becomes linked to the 5-terminal nucleotide of the capped polynucleotide (e.g., an mRNA).</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the N7- and 3-O-methlyated guanosine</span>
        <span itemprop="definition">provides the terminal moiety of the capped polynucleotide (e.g., mRNA).</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mCAP</span>
        <span itemprop="definition">is similar to ARCA but has a 2-O-methyl group on guanosine (i.e., N7,2-O-dimethyl-guanosine-5-triphosphate-5-guanosine, m 7 Gm-ppp-G).</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cap</span>
        <span itemprop="definition">may be a dinucleotide cap analog.</span>
        <meta itemprop="num_attr" content="0363">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the dinucleotide cap analog</span>
        <span itemprop="definition">may be modified at different phosphate positions with a boranophosphate group or a phophoroselenoate group such as the dinucleotide cap analogs described in U.S. Pat. No. 8,519,110, the cap structures of which are herein incorporated by reference.</span>
        <meta itemprop="num_attr" content="0363">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cap analog</span>
        <span itemprop="definition">may be a N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analog known in the art and/or described herein.</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analogs</span>
        <span itemprop="definition">include a N7-(4-chlorophenoxyethyl)-G(5)ppp(5)G and a N7-(4-chlorophenoxyethyl)-m3-OG(5)ppp(5)G cap analog (see, e.g., the various cap analogs and the methods of synthesizing cap analogs described in Kore et al.</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cap analog useful in the polynucleotides of the present disclosure</span>
        <span itemprop="definition">is a 4-chloro/bromophenoxyethyl analog.</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cap analogs</span>
        <span itemprop="definition">allow for the concomitant capping of a polynucleotide in an in vitro transcription reaction, up to 20% of transcripts remain uncapped. This, as well as the structural differences of a cap analog from endogenous 5-cap structures of polynucleotides produced by the endogenous, cellular transcription machinery, may lead to reduced translational competency and reduced cellular stability.</span>
        <meta itemprop="num_attr" content="0365">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alternative polynucleotides</span>
        <span itemprop="definition">may also be capped post-transcriptionally, using enzymes, in order to generate more authentic 5-cap structures.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phrase more authentic</span>
        <span itemprop="definition">refers to a feature that closely mirrors or mimics, either structurally or functionally, an endogenous or wild type feature. That is, a more authentic feature is better representative of an endogenous, wild-type, natural or physiological cellular function, and/or structure as compared to synthetic features or analogs of the prior art, or which outperforms the corresponding endogenous, wild-type, natural, or physiological feature in one or more respects.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of more authentic 5-cap structures useful in the polynucleotides of the present disclosure</span>
        <span itemprop="definition">are those which, among other things, have enhanced binding of cap binding proteins, increased half life, reduced susceptibility to 5-endonucleases, and/or reduced 5-decapping, as compared to synthetic 5-cap structures known in the art (or to a wild-type, natural or physiological 5-cap structure).</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">recombinant Vaccinia Virus Capping Enzyme and recombinant 2-O-methyltransferase enzyme</span>
        <span itemprop="definition">can create a canonical 5-5-triphosphate linkage between the 5-terminal nucleotide of a polynucleotide and a guanosine cap nucleotide wherein the cap guanosine contains an N7-methylation and the 5-terminal nucleotide of the polynucleotide contains a 2-O-methyl.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Cap1 structure</span>
        <span itemprop="definition">Such a structure is termed the Cap1 structure.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cap</span>
        <span itemprop="definition">results in a higher translational-competency, cellular stability, and a reduced activation of cellular pro-inflammatory cytokines, as compared, e.g., to other 5cap analog structures known in the art.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other exemplary cap structures</span>
        <span itemprop="definition">include 7mG(5)ppp(5)N,pN2p (Cap 0), 7mG(5)ppp(5)NlmpNp (Cap 1), 7mG(5)-ppp(5)NlmpN2mp (Cap 2), and m(7)Gpppm(3)(6,6,2)Apm(2)Apm(2)Cpm(2)(3,2)Up (Cap 4).</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alternative polynucleotides</span>
        <span itemprop="definition">may be capped post-transcriptionally, and because this process is more efficient, nearly 100% of the alternative polynucleotides may be capped. This is in contrast to   80% when a cap analog is linked to an polynucleotide in the course of an in vitro transcription reaction.</span>
        <meta itemprop="num_attr" content="0367">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5-terminal caps</span>
        <span itemprop="definition">may include endogenous caps or cap analogs.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5-terminal cap</span>
        <span itemprop="definition">may include a guanosine analog.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Useful guanosine analogs</span>
        <span itemprop="definition">include inosine, N1-methyl-guanosine, 2-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">contains a modified 5-cap.</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a modification on the 5-cap</span>
        <span itemprop="definition">may increase the stability of polynucleotide, increase the half-life of the polynucleotide, and could increase the polynucleotide translational efficiency.</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the modified 5-cap</span>
        <span itemprop="definition">may include, but is not limited to, one or more of the following modifications: modification at the 2- and/or 3-position of a capped guanosine triphosphate (GTP), a replacement of the sugar ring oxygen (that produced the carbocyclic ring) with a methylene moiety (CH 2 ), a modification at the triphosphate bridge moiety of the cap structure, or a modification at the nucleobase (G) moiety.</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">GTP</span>
        <span itemprop="definition">capped guanosine triphosphate</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">CH 2</span>
        <span itemprop="definition">methylene moiety</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">G</span>
        <span itemprop="definition">nucleobase</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5-UTR</span>
        <span itemprop="definition">may be provided as a flanking region to polynucleotides (e.g., mRNAs).</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5-UTR</span>
        <span itemprop="definition">may be homologous or heterologous to the coding region found in a polynucleotide.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Multiple 5-UTRs</span>
        <span itemprop="definition">may be included in the flanking region and may be the same or of different sequences. Any portion of the flanking regions, including none, may be codon optimized and any may independently contain one or more different structural or chemical alterations, before and/or after codon optimization.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each 5-UTR</span>
        <span itemprop="definition">(5-UTR-005 to 5-UTR 68511) is identified by its start and stop site relative to its native or wild type (homologous) transcript (ENST; the identifier used in the ENSEMBL database).</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5-UTRs</span>
        <span itemprop="definition">which are heterologous to the coding region of an alternative polynucleotide (e.g., mRNA) may be engineered.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides</span>
        <span itemprop="definition">may then be administered to cells, tissue or organisms and outcomes such as protein level, localization, and/or half-life may be measured to evaluate the beneficial effects the heterologous 5-UTR may have on the alternative polynucleotides (mRNA).</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Variants of the 5-UTRs</span>
        <span itemprop="definition">may be utilized wherein one or more nucleotides are added or removed to the termini, including A, T, C or G.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">5-UTRs</span>
        <span itemprop="definition">may also be codon-optimized, or altered in any manner described herein.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-UTR of a polynucleotides</span>
        <span itemprop="definition">may include at least one translation enhancer element.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">translation enhancer element</span>
        <span itemprop="definition">refers to sequences that increase the amount of polypeptide or protein produced from a polynucleotide.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE</span>
        <span itemprop="definition">may be located between the transcription promoter and the start codon.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides (e.g., mRNA) with at least one TEE in the 5-UTR</span>
        <span itemprop="definition">may include a cap at the 5-UTR. Further, at least one TEE may be located in the 5-UTR of polynucleotides (e.g., mRNA) undergoing cap-dependent or cap-independent translation.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TEEs</span>
        <span itemprop="definition">are conserved elements in the UTR which can promote translational activity of a polynucleotide such as, but not limited to, cap-dependent or cap-independent translation.</span>
        <meta itemprop="num_attr" content="0374">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">such as, but not limited to, cap-dependent or cap-independent translation.</span>
        <meta itemprop="num_attr" content="0374">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Panek et al.</span>
        <span itemprop="definition">Nucleic Acids Research, 2013, 1-10) across 14 species including humans.</span>
        <meta itemprop="num_attr" content="0374">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs known</span>
        <span itemprop="definition">may be in the 5-leader of the Gtx homeodomain protein (Chappell et al., Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004, the TEEs of which are incorporated herein by reference).</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TEEs</span>
        <span itemprop="definition">are disclosed as SEQ ID NOs: 1-35 in US Patent Publication No. 2009/0226470, SEQ ID NOs: 1-35 in US Patent Publication No. 2013/0177581, SEQ ID NOs: 1-35 in International Patent Publication No. WO2009/075886, SEQ ID NOs: 1-5, and 7-645 in International Patent Publication No. WO2012/009644, SEQ ID NO: 1 in International Patent Publication No. WO1999/024595, SEQ ID NO: 1 in U.S. Pat. No. 6,310,197, and SEQ ID NO: 1 in U.S. Pat. No. 6,849,405, the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0376">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE</span>
        <span itemprop="definition">may be an internal ribosome entry site (IRES), HCV-IRES or an IRES element such as, but not limited to, those described in U.S. Pat. No. 7,468,275, US Patent Publication Nos. 2007/0048776 and 2011/0124100 and International Patent Publication Nos. WO2007/025008 and WO2001/055369, the IRES sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0377">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the IRES elements</span>
        <span itemprop="definition">may include, but are not limited to, the Gtx sequences (e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt) described by Chappell et al. (Proc. Natl. Acad. Sci.</span>
        <meta itemprop="num_attr" content="0377">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Translational enhancer polynucleotides</span>
        <span itemprop="definition">are polynucleotides which include one or more of the specific TEE exemplified herein and/or disclosed in the art (see e.g., U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, U.S. Patent Publication Nos. 20090/226470, 2007/0048776, 2011/0124100, 2009/0093049, 2013/0177581, International Patent Publication Nos. WO2009/075886, WO2007/025008, WO2012/009644, WO2001/055371 WO1999/024595, and European Patent Nos.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">TEE sequences of each of which are incorporated herein by reference</span>
        <span itemprop="definition">or their variants, homologs or functional derivatives.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One or multiple copies of a specific TEE</span>
        <span itemprop="definition">can be present in a polynucleotide (e.g., mRNA).</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs in the translational enhancer polynucleotides</span>
        <span itemprop="definition">can be organized in one or more sequence segments.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a sequence segment</span>
        <span itemprop="definition">can harbor one or more of the specific TEEs exemplified herein, with each TEE being present in one or more copies.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">multiple sequence segments</span>
        <span itemprop="definition">are present in a translational enhancer polynucleotide, they can be homogenous or heterogeneous.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the multiple sequence segments in a translational enhancer polynucleotide</span>
        <span itemprop="definition">can harbor identical or different types of the specific TEEs exemplified herein, identical or different number of copies of each of the specific TEEs, and/or identical or different organization of the TEEs within each sequence segment.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include at least one TEE that is described in International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886, WO2007/025008, WO1999/024595, European Patent Publication Nos. 2610341 and 2610340, U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, and US Patent Publication Nos. 2009/0226470, 2011/0124100, 2007/0048776, 2009/0093049, and 2013/0177581 the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE</span>
        <span itemprop="definition">may be located in the 5-UTR of the polynucleotides (e.g., mRNA).</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include at least one TEE that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identity with the TEEs described in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886 and WO2007/025008, European Patent Publication Nos. 2610341 and 2610340, U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55 or more than 60 TEE sequences.</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE sequences in the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">may be the same or different TEE sequences.</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE sequences</span>
        <span itemprop="definition">may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variants thereof, repeated once, twice, or more than three times.</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each letter, A, B, or C</span>
        <span itemprop="definition">represent a different TEE sequence at the nucleotide level.</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-UTR</span>
        <span itemprop="definition">may include a spacer to separate two TEE sequences.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the spacer</span>
        <span itemprop="definition">may be a 15 nucleotide spacer and/or other spacers known in the art.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-UTR</span>
        <span itemprop="definition">may include a TEE sequence-spacer module repeated at least once, at least twice, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or more than 9 times in the 5-UTR.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the spacer separating two TEE sequences</span>
        <span itemprop="definition">may include other sequences known in the art which may regulate the translation of the polynucleotides (e.g., mRNA) of the present disclosure such as, but not limited to, miR sequences (e.g., miR binding sites and miR seeds).</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miR sequences</span>
        <span itemprop="definition">e.g., miR binding sites and miR seeds.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each spacer used to separate two TEE sequences</span>
        <span itemprop="definition">may include a different miR sequence or component of a miR sequence (e.g., miR seed sequence).</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE in the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">may include at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more than 99% of the TEE sequences disclosed in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure</span>
        <span itemprop="definition">may include a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, a 5-10 nucleotide fragment of the TEE sequences disclosed in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886 and WO2007/025008, European Patent Publication Nos. 2610341 and 2610340, and U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395; the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure</span>
        <span itemprop="definition">may include at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more than 99% of the TEE sequences disclosed in Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al.</span>
        <meta itemprop="num_attr" content="0385">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure</span>
        <span itemprop="definition">may include a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, a 5-10 nucleotide fragment of the TEE sequences disclosed in Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al.</span>
        <meta itemprop="num_attr" content="0385">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE used in the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">is an IRES sequence such as, but not limited to, those described in U.S. Pat. No. 7,468,275 and International Patent Publication No. WO2001/055369, the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0386">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs used in the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">may be identified by the methods described in US Patent Publication Nos. 2007/0048776 and 2011/0124100 and International Patent Publication Nos. WO2007/025008 and WO2012/009644, the methods of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs used in the 5-UTR of a polynucleotide (e.g., mRNA) of the present disclosure</span>
        <span itemprop="definition">may be a transcription regulatory element described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the TEE sequences of each of which is incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the transcription regulatory elements</span>
        <span itemprop="definition">may be identified by methods known in the art, such as, but not limited to, the methods described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the methods of each of which is incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE used in the 5-UTR of a polynucleotide</span>
        <span itemprop="definition">is a polynucleotide or portion thereof as described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-UTR including at least one TEE described herein</span>
        <span itemprop="definition">may be incorporated in a monocistronic sequence such as, but not limited to, a vector system or a polynucleotide vector.</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a monocistronic sequence</span>
        <span itemprop="definition">such as, but not limited to, a vector system or a polynucleotide vector.</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the vector systems and polynucleotide vectors</span>
        <span itemprop="definition">may include those described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication Nos. 2007/0048776, 2009/0093049 and 2011/0124100, and International Patent Publication Nos. WO2007/025008 and WO2001/055371, the TEE sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs described herein</span>
        <span itemprop="definition">may be located in the 5-UTR and/or the 3-UTR of the polynucleotides (e.g., mRNA).</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEEs located in the 3-UTR</span>
        <span itemprop="definition">may be the same and/or different than the TEEs located in and/or described for incorporation in the 5-UTR.</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-UTR of a polynucleotide</span>
        <span itemprop="definition">may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55 or more than 60 TEE sequences.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE sequences in the 3-UTR of the polynucleotides (e.g., mRNA) of the present disclosure</span>
        <span itemprop="definition">may be the same or different TEE sequences.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the TEE sequences</span>
        <span itemprop="definition">may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variants thereof, repeated once, twice, or more than three times.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each letter, A, B, or C</span>
        <span itemprop="definition">represent a different TEE sequence at the nucleotide level.</span>
        <meta itemprop="num_attr" content="0392">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-UTR</span>
        <span itemprop="definition">may include a spacer to separate two TEE sequences.</span>
        <meta itemprop="num_attr" content="0393">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the spacer</span>
        <span itemprop="definition">may be a 15 nucleotide spacer and/or other spacers known in the art.</span>
        <meta itemprop="num_attr" content="0393">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-UTR</span>
        <span itemprop="definition">may include a TEE sequence-spacer module repeated at least once, at least twice, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or more than 9 times in the 3-UTR.</span>
        <meta itemprop="num_attr" content="0393">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the spacer separating two TEE sequences</span>
        <span itemprop="definition">may include other sequences known in the art which may regulate the translation of the polynucleotides (e.g., mRNA) of the present disclosure such as, but not limited to, miR sequences described herein (e.g., miR binding sites and miR seeds).</span>
        <meta itemprop="num_attr" content="0394">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">miR sequences described herein</span>
        <span itemprop="definition">e.g., miR binding sites and miR seeds.</span>
        <meta itemprop="num_attr" content="0394">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each spacer used to separate two TEE sequences</span>
        <span itemprop="definition">may include a different miR sequence or component of a miR sequence (e.g., miR seed sequence).</span>
        <meta itemprop="num_attr" content="0394">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the incorporation of a miR sequence and/or a TEE sequence</span>
        <span itemprop="definition">changes the shape of the stem loop region which may increase and/or decrease translation.</span>
        <meta itemprop="num_attr" content="0395">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a miR sequence and/or a TEE sequence</span>
        <span itemprop="definition">changes the shape of the stem loop region which may increase and/or decrease translation.</span>
        <meta itemprop="num_attr" content="0395">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides</span>
        <span itemprop="definition">may include a stem loop such as, but not limited to, a histone stem loop.</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the stem loop</span>
        <span itemprop="definition">may be a nucleotide sequence that is about 25 or about 26 nucleotides in length such as, but not limited to, SEQ ID NOs: 7-17 as described in International Patent Publication No. WO2013/103659, of which SEQ ID NOs: 7-17 are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the histone stem loop</span>
        <span itemprop="definition">may be located 3-relative to the coding region (e.g., at the 3-terminus of the coding region). As a non-limiting example, the stem loop may be located at the 3-end of a polynucleotide described herein.</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">e.g., an mRNA</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">includes more than one stem loop</span>
        <span itemprop="definition">e.g., two stem loops.</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">stem loop sequences</span>
        <span itemprop="definition">are described in International Patent Publication Nos. WO2012/019780 and WO201502667, the stem loop sequences of which are herein incorporated by reference.</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">includes the stem loop sequence CAAAGGCTCTTTTCAGAGCCACCA (SEQ ID NO: 5).</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">includes the stem loop sequence CAAAGGCUCUUUUCAGAGCCACCA (SEQ ID NO: 6).</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a stem loop</span>
        <span itemprop="definition">may be located in a second terminal region of a polynucleotide.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the stem loop</span>
        <span itemprop="definition">may be located within an untranslated region (e.g., 3-UTR) in a second terminal region.</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop</span>
        <span itemprop="definition">may be stabilized by the addition of a 3-stabilizing region (e.g., a 3-stabilizing region including at least one chain terminating nucleoside).</span>
        <meta itemprop="num_attr" content="0398">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 3-stabilizing region</span>
        <span itemprop="definition">e.g., a 3-stabilizing region including at least one chain terminating nucleoside.</span>
        <meta itemprop="num_attr" content="0398">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the addition of at least one chain terminating nucleoside</span>
        <span itemprop="definition">may slow the degradation of a polynucleotide and thus can increase the half-life of the polynucleotide.</span>
        <meta itemprop="num_attr" content="0398">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop</span>
        <span itemprop="definition">may be stabilized by an alteration to the 3-region of the polynucleotide that can prevent and/or inhibit the addition of oligio(U) (see e.g., International Patent Publication No. WO2013/103659).</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop</span>
        <span itemprop="definition">may be stabilized by the addition of an oligonucleotide that terminates in a 3-deoxynucleoside, 2,3-dideoxynucleoside 3-O-methylnucleosides, 3-O-ethylnucleosides, 3-arabinosides, and other alternative nucleosides known in the art and/or described herein.</span>
        <meta itemprop="num_attr" content="0400">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides of the present disclosure</span>
        <span itemprop="definition">may include a histone stem loop, a poly-A region, and/or a 5-cap structure.</span>
        <meta itemprop="num_attr" content="0401">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the histone stem loop</span>
        <span itemprop="definition">may be before and/or after the poly-A region.</span>
        <meta itemprop="num_attr" content="0401">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides including the histone stem loop and a poly-A region sequence</span>
        <span itemprop="definition">may include a chain terminating nucleoside described herein.</span>
        <meta itemprop="num_attr" content="0401">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides of the present disclosure</span>
        <span itemprop="definition">may include a histone stem loop and a 5-cap structure.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 5-cap structure</span>
        <span itemprop="definition">may include, but is not limited to, those described herein and/or known in the art.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conserved stem loop region</span>
        <span itemprop="definition">may include a miR sequence described herein.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the stem loop region</span>
        <span itemprop="definition">may include the seed sequence of a miR sequence described herein.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the stem loop region</span>
        <span itemprop="definition">may include a miR-122 seed sequence.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the conserved stem loop region</span>
        <span itemprop="definition">may include a miR sequence described herein and may also include a TEE sequence.</span>
        <meta itemprop="num_attr" content="0404">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the incorporation of a miR sequence and/or a TEE sequence</span>
        <span itemprop="definition">changes the shape of the stem loop region which may increase and/or decrease translation.</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a miR sequence and/or a TEE sequence</span>
        <span itemprop="definition">changes the shape of the stem loop region which may increase and/or decrease translation.</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Polynucleotides</span>
        <span itemprop="definition">may include at least one histone stem-loop and a poly-A region or polyadenylation signal.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non-limiting examples of polynucleotide sequences encoding for at least one histone stem-loop and a poly-A region or a polyadenylation signal</span>
        <span itemprop="definition">are described in International Patent Publication No. WO2013/120497, WO2013/120629, WO2013/120500, WO2013/120627, WO2013/120498, WO2013/120626, WO2013/120499 and WO2013/120628, the sequences of each of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal</span>
        <span itemprop="definition">may code for a pathogen antigen or fragment thereof such as the polynucleotide sequences described in International Patent Publication No WO2013/120499 and WO2013/120628, the sequences of both of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal</span>
        <span itemprop="definition">may code for a therapeutic protein such as the polynucleotide sequences described in International Patent Publication No WO2013/120497 and WO2013/120629, the sequences of both of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal</span>
        <span itemprop="definition">may code for a tumor antigen or fragment thereof such as the polynucleotide sequences described in International Patent Publication No WO2013/120500 and WO2013/120627, the sequences of both of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal</span>
        <span itemprop="definition">may code for a allergenic antigen or an autoimmune self-antigen such as the polynucleotide sequences described in International Patent Publication No WO2013/120498 and WO2013/120626, the sequences of both of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide or nucleic acid</span>
        <span itemprop="definition">may include a polyA sequence and/or polyadenylation signal.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polyA sequence</span>
        <span itemprop="definition">may be comprised entirely or mostly of adenine nucleotides or analogs or derivatives thereof.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polyA sequence</span>
        <span itemprop="definition">may be a tail located adjacent to a 3 untranslated region of a nucleic acid.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">poly-A region</span>
        <span itemprop="definition">a long chain of adenosine nucleotides (poly-A region) is normally added to messenger RNA (mRNA) molecules to increase the stability of the molecule.</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNA</span>
        <span itemprop="definition">messenger RNA</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">poly-A polymerase</span>
        <span itemprop="definition">adds a chain of adenosine nucleotides to the RNA.</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the process</span>
        <span itemprop="definition">called polyadenylation, adds a poly-A region that is between 100 and 250 residues long.</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Unique poly-A region lengths</span>
        <span itemprop="definition">may provide certain advantages to the alternative polynucleotides of the present disclosure.</span>
        <meta itemprop="num_attr" content="0409">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length of a poly-A region of the present disclosure</span>
        <span itemprop="definition">is at least 30 nucleotides in length. In another embodiment, the poly-A region is at least 35 nucleotides in length. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 70 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides.</span>
        <meta itemprop="num_attr" content="0410">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides.</span>
        <meta itemprop="num_attr" content="0410">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides. In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides.</span>
        <meta itemprop="num_attr" content="0410">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the length</span>
        <span itemprop="definition">is at least 1700 nucleotides. In another embodiment, the length is at least 1800 nucleotides. In another embodiment, the length is at least 1900 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides.</span>
        <meta itemprop="num_attr" content="0410">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">may be 80 nucleotides, 120 nucleotides, 160 nucleotides in length on an alternative polynucleotide molecule described herein.</span>
        <meta itemprop="num_attr" content="0411">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">may be 20, 40, 80, 100, 120, 140 or 160 nucleotides in length on an alternative polynucleotide molecule described herein.</span>
        <meta itemprop="num_attr" content="0412">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">is designed relative to the length of the overall alternative polynucleotide. This design may be based on the length of the coding region of the alternative polynucleotide, the length of a particular feature or region of the alternative polynucleotide (such as mRNA), or based on the length of the ultimate product expressed from the alternative polynucleotide.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">may be 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% greater in length than the additional feature.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">may also be designed as a fraction of the alternative polynucleotide to which it belongs.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the poly-A region</span>
        <span itemprop="definition">may be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct or the total length of the construct minus the poly-A region.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">engineered binding sites and/or the conjugation of polynucleotides (e.g., mRNA) for poly-A binding protein</span>
        <span itemprop="definition">may be used to enhance expression.</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the engineered binding sites</span>
        <span itemprop="definition">may be sensor sequences which can operate as binding sites for ligands of the local microenvironment of the polynucleotides (e.g., mRNA).</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides (e.g., mRNA)</span>
        <span itemprop="definition">may include at least one engineered binding site to alter the binding affinity of poly-A binding protein (PABP) and analogs thereof. The incorporation of at least one engineered binding site may increase the binding affinity of the PABP and analogs thereof.</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PABP</span>
        <span itemprop="definition">poly-A binding protein</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">multiple distinct polynucleotides</span>
        <span itemprop="definition">may be linked together to the PABP (poly-A binding protein) through the 3-end using alternative nucleotides at the 3-terminus of the poly-A region.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Transfection experiments</span>
        <span itemprop="definition">can be conducted in relevant cell lines at and protein production can be assayed by ELISA at 12 hours, 24 hours, 48 hours, 72 hours, and day 7 post-transfection. As a non-limiting example, the transfection experiments may be used to evaluate the effect on PABP or analogs thereof binding affinity as a result of the addition of at least one engineered binding site.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a poly-A region</span>
        <span itemprop="definition">may be used to modulate translation initiation. While not wishing to be bound by theory, the poly-A region recruits PABP which in turn can interact with translation initiation complex and thus may be essential for protein synthesis.</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a poly-A region</span>
        <span itemprop="definition">may also be used in the present disclosure to protect against 3-5-exonuclease digestion.</span>
        <meta itemprop="num_attr" content="0417">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include a polyA-G quartet.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the G-quartet</span>
        <span itemprop="definition">is a cyclic hydrogen bonded array of four guanosine nucleotides that can be formed by G-rich sequences in both DNA and RNA.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the G-quartet</span>
        <span itemprop="definition">is incorporated at the end of the poly-A region.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the resultant polynucleotides</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polyA-G quartet</span>
        <span itemprop="definition">results in protein production equivalent to at least 75% of that seen using a poly-A region of 120 nucleotides alone.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include a poly-A region and may be stabilized by the addition of a 3-stabilizing region.</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides (e.g., mRNA) with a poly-A region</span>
        <span itemprop="definition">may further include a 5-cap structure.</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">may include a poly-A-G quartet.</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polynucleotides (e.g., mRNA) with a poly-A-G quartet</span>
        <span itemprop="definition">may further include a 5-cap structure.</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-stabilizing region which may be used to stabilize a polynucleotide (e.g., mRNA) including a poly-A region or poly-A-G quartet</span>
        <span itemprop="definition">may be, but is not limited to, those described in International Patent Publication No. WO2013/103659, the poly-A regions and poly-A-G quartets of which are incorporated herein by reference.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the 3-stabilizing region which may be used with the present disclosure</span>
        <span itemprop="definition">include a chain termination nucleoside such as 3-deoxyadenosine (cordycepin), 3-deoxyuridine, 3-deoxycytosine, 3-deoxyguanosine, 3-deoxythymine, 2,3-dideoxynucleosides, such as 2,3-dideoxyadenosine, 2,3-dideoxyuridine, 2,3-dideoxycytosine, 2,3-dideoxyguanosine, 2,3-dideoxythymine, a 2-deoxynucleoside, or an O-methylnucleoside.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a chain termination nucleoside</span>
        <span itemprop="definition">such as 3-deoxyadenosine (cordycepin), 3-deoxyuridine, 3-deoxycytosine, 3-deoxyguanosine, 3-deoxythymine, 2,</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">such as, but not limited to mRNA, which includes a polyA region or a poly-A-G quartet may be stabilized by an alteration to the 3-region of the polynucleotide that can prevent and/or inhibit the addition of oligio(U) (see e.g., International Patent Publication No. WO2013/103659).</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polynucleotide</span>
        <span itemprop="definition">such as, but not limited to mRNA, which includes a poly-A region or a poly-A-G quartet may be stabilized by the addition of an oligonucleotide that terminates in a 3-deoxynucleoside, 2,3-dideoxynucleoside 3-O-methylnucleosides, 3-O-ethylnucleosides, 3-arabinosides, and other alternative nucleosides known in the art and/or described herein.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid</span>
        <span itemprop="definition">may include a chain terminating nucleoside.</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a chain terminating nucleoside</span>
        <span itemprop="definition">may include those nucleosides deoxygenated at the 2 and/or 3 positions of their sugar group.</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such species</span>
        <span itemprop="definition">may include 3-deoxyadenosine (cordycepin), 3-deoxyuridine, 3-deoxycytosine, 3-deoxyguanosine, 3-deoxythymine, and 2,3-dideoxynucleosides, such as 2,3-dideoxyadenosine, 2,3-dideoxyuridine, 2,3-dideoxycytosine, 2,3-dideoxyguanosine, and 2,3-dideoxythymine.</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may include one or more components in addition to those described in the preceding sections.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may include one or more small hydrophobic molecules such as a vitamin (e.g., vitamin A or vitamin E) or a sterol.</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may also include one or more permeability enhancer molecules, carbohydrates, polymers, surface altering agents, or other components.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a permeability enhancer molecule</span>
        <span itemprop="definition">may be a molecule described by U.S. patent application publication No. 2005/0222064, for example.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Carbohydrates</span>
        <span itemprop="definition">may include simple sugars (e.g., glucose) and polysaccharides (e.g., glycogen and derivatives and analogs thereof).</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polymer</span>
        <span itemprop="definition">may be included in and/or used to encapsulate or partially encapsulate a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polymer</span>
        <span itemprop="definition">may be biodegradable and/or biocompatible.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polymer</span>
        <span itemprop="definition">may be selected from, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polymer</span>
        <span itemprop="definition">may include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA)</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Surface altering agents</span>
        <span itemprop="definition">may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytic agents (e.g., acetylcysteine, mugwort, bromelain, papain, clerodendrum, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin   4, dornase alfa, neltenexine, and erdosteine), and DNases (e.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may also comprise one or more functionalized lipids.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid</span>
        <span itemprop="definition">may be functionalized with an alkyne group that, when exposed to an azide under appropriate reaction conditions, may undergo a cycloaddition reaction.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid bilayer</span>
        <span itemprop="definition">may be functionalized in this fashion with one or more groups useful in facilitating membrane permeation, cellular recognition, or imaging.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the surface of a nanoparticle composition</span>
        <span itemprop="definition">may also be conjugated with one or more useful antibodies. Functional groups and conjugates useful in targeted cell delivery, imaging, and membrane permeation are well known in the art.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nanoparticle compositions</span>
        <span itemprop="definition">may include any substance useful in pharmaceutical compositions.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle composition</span>
        <span itemprop="definition">may include one or more pharmaceutically acceptable excipients or accessory ingredients such as, but not limited to, one or more solvents, dispersion media, diluents, dispersion aids, suspension aids, granulating aids, disintegrants, fillers, glidants, liquid vehicles, binders, surface active agents, isotonic agents, thickening or emulsifying agents, buffering agents, lubricating agents, oils, preservatives, and other species. Excipients such as waxes, butters, coloring agents, coating agents, flavorings, and perfuming agents may also be included. Pharmaceutically acceptable excipients are well known in the art (see for example Remington&#39;s The Science and Practice of Pharmacy, 21 st Edition, A. R. Gennaro; Lippincott, Williams &amp; Wilkins, Baltimore, Md., 2006).</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diluents</span>
        <span itemprop="definition">may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and/or combinations thereof.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Granulating and dispersing agents</span>
        <span itemprop="definition">may be selected from the non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM), sodium lauryl sulfate, quaternary ammonium compounds, and/or combinations thereof.</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">crospovidone</span>
        <span itemprop="definition">cross-linked poly(vinyl-pyrrolidone)</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">crospovidone</span>
        <span itemprop="definition">cross-</span>
        <meta itemprop="num_attr" content="0431">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Surface active agents and/or emulsifiers</span>
        <span itemprop="definition">may include, but are not limited to, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and VEEGUM [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">natural emulsifiers</span>
        <span itemprop="definition">e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">colloidal clays</span>
        <span itemprop="definition">e.g. bentonite [aluminum silicate]</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">stearyl alcohol</span>
        <span itemprop="definition">cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polyoxyethylene monostearate</span>
        <span itemprop="definition">[MYRJ 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. CREMOPHOR), polyoxyethylene ethers, (e.g.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">polyoxyethylene lauryl ether</span>
        <span itemprop="definition">[BRIJ 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONICF 68, POLOXAMER 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or combinations thereof.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a binding agent</span>
        <span itemprop="definition">may be starch (e.g. cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (VEEGUM), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; and combinations thereof, or any other suitable binding agent.</span>
        <meta itemprop="num_attr" content="0433">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">preservatives</span>
        <span itemprop="definition">may include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antioxidants</span>
        <span itemprop="definition">include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and/or sodium sulfite.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">chelating agents</span>
        <span itemprop="definition">include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and/or trisodium edetate.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">EDTA</span>
        <span itemprop="definition">ethylenediaminetetraacetic acid</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">citric acid monohydrate</span>
        <span itemprop="definition">disodium edetate</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dipotassium edetate</span>
        <span itemprop="definition">dipotassium edetate</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">edetic acid</span>
        <span itemprop="definition">fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and/or trisodium edetate.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antimicrobial preservatives</span>
        <span itemprop="definition">include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">antifungal preservatives</span>
        <span itemprop="definition">include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alcohol preservatives</span>
        <span itemprop="definition">include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and/or phenylethyl alcohol.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acidic preservatives</span>
        <span itemprop="definition">include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid, and/or phytic acid.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">preservatives</span>
        <span itemprop="definition">include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS, PHENONIP, methylparaben, GERMALL 115, GERMABENII, NEOLONETM, KATHONTM, and/or EUXYL.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">buffering agents</span>
        <span itemprop="definition">include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, amino-sulfonate buffers (e.g., HEPES), magnesium</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lubricating agents</span>
        <span itemprop="definition">may selected from the non-limiting group consisting of magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oils</span>
        <span itemprop="definition">include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, eucalyptus , evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, litsea cubeba , macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, s</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may include a lipid component and one or more additional components, such as a therapeutic and/or prophylactic.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be designed for one or more specific applications or targets.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the elements of a nanoparticle composition</span>
        <span itemprop="definition">may be selected based on a particular application or target, and/or based on the efficacy, toxicity, expense, ease of use, availability, or other feature of one or more elements.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particular formulation of a nanoparticle composition</span>
        <span itemprop="definition">may be selected for a particular application or target according to, for example, the efficacy and toxicity of particular combinations of elements.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may include, for example, a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid (such as an unsaturated lipid, e.g., DOPE or DSPC), a PEG lipid, and a structural lipid.</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid</span>
        <span itemprop="definition">such as an unsaturated lipid, e.g., DOPE or DSPC</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PEG lipid</span>
        <span itemprop="definition">poly(ethylene glycol)</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">includes a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a PEG lipid, and a structural lipid.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of the nanoparticle composition</span>
        <span itemprop="definition">includes about 30 mol % to about 60 mol % compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % of PEG lipid, provided that the total mol % does not exceed 100%.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component of the nanoparticle composition</span>
        <span itemprop="definition">includes about 35 mol % to about 55 mol % compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % of PEG lipid.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component</span>
        <span itemprop="definition">includes about 50 mol % said compound, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % of PEG lipid.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid component</span>
        <span itemprop="definition">includes about 40 mol % said compound, about 20 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % of PEG lipid.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phospholipid</span>
        <span itemprop="definition">may be DOPE or DSPC.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the PEG lipid</span>
        <span itemprop="definition">may be PEG-DMG and/or the structural lipid may be cholesterol.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may be designed for one or more specific applications or targets.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be designed to deliver a therapeutic and/or prophylactic such as an RNA to a particular cell, tissue, organ, or system or group thereof in a mammal&#39;s body.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Physiochemical properties of nanoparticle compositions</span>
        <span itemprop="definition">may be altered in order to increase selectivity for particular bodily targets. For instance, particle sizes may be adjusted based on the fenestration sizes of different organs.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the therapeutic and/or prophylactic included in a nanoparticle composition</span>
        <span itemprop="definition">may also be selected based on the desired delivery target or targets.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">may be selected for a particular indication, condition, disease, or disorder and/or for delivery to a particular cell, tissue, organ, or system or group thereof (e.g., localized or specific delivery).</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may include an mRNA encoding a polypeptide of interest capable of being translated within a cell to produce the polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such a composition</span>
        <span itemprop="definition">may be designed to be specifically delivered to a particular organ.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a composition</span>
        <span itemprop="definition">may be designed to be specifically delivered to a mammalian liver.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of a therapeutic and/or prophylactic in a nanoparticle composition</span>
        <span itemprop="definition">may depend on the size, composition, desired target and/or application, or other properties of the nanoparticle composition as well as on the properties of the therapeutic and/or prophylactic.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of an RNA useful in a nanoparticle composition</span>
        <span itemprop="definition">may depend on the size, sequence, and other characteristics of the RNA.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the relative amounts of a therapeutic and/or prophylactic and other elements (e.g., lipids) in a nanoparticle composition</span>
        <span itemprop="definition">may also vary.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the wt/wt ratio of the lipid component to a therapeutic and/or prophylactic in a nanoparticle composition</span>
        <span itemprop="definition">may be from about 5:1 to about 60:1, such as 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, and 60:1.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the wt/wt ratio of the lipid component to a therapeutic and/or prophylactic</span>
        <span itemprop="definition">may be from about 10:1 to about 40:1. In certain embodiments, the wt/wt ratio is about 20:1.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of a therapeutic and/or prophylactic in a nanoparticle composition</span>
        <span itemprop="definition">may, for example, be measured using absorption spectroscopy (e.g., ultraviolet-visible spectroscopy).</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">includes one or more RNAs, and the one or more RNAs, lipids, and amounts thereof may be selected to provide a specific N:P ratio.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the N:P ratio of the composition</span>
        <span itemprop="definition">refers to the molar ratio of nitrogen atoms in one or more lipids to the number of phosphate groups in an RNA. In general, a lower N:P ratio is preferred.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the one or more RNA, lipids, and amounts thereof</span>
        <span itemprop="definition">may be selected to provide an N:P ratio from about 2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the N:P ratio</span>
        <span itemprop="definition">may be from about 2:1 to about 8:1. In other embodiments, the N:P ratio is from about 5:1 to about 8:1. For example, the N:P ratio may be about 5.0:1, about 5.5:1, about 5.67:1, about 6.0:1, about 6.5:1, or about 7.0:1. For example, the N:P ratio may be about 5.67:1.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the characteristics of a nanoparticle composition</span>
        <span itemprop="definition">may depend on the components thereof. For example, a nanoparticle composition including cholesterol as a structural lipid may have different characteristics than a nanoparticle composition that includes a different structural lipid. Similarly, the characteristics of a nanoparticle composition may depend on the absolute or relative amounts of its components. For instance, a nanoparticle composition including a higher molar fraction of a phospholipid may have different characteristics than a nanoparticle composition including a lower molar fraction of a phospholipid. Characteristics may also vary depending on the method and conditions of preparation of the nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) may be used to examine the morphology and size distribution of a nanoparticle composition. Dynamic light scattering or potentiometry (e.g., potentiometric titrations) may be used to measure zeta potentials. Dynamic light scattering may also be utilized to determine particle sizes. Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) may also be used to measure multiple characteristics of a nanoparticle composition, such as particle size, polydispersity index, and zeta potential.</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">microscopy</span>
        <span itemprop="definition">e.g., transmission electron microscopy or scanning electron microscopy</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dynamic light scattering or potentiometry</span>
        <span itemprop="definition">e.g., potentiometric titrations</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dynamic light scattering</span>
        <span itemprop="definition">may also be utilized to determine particle sizes.</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Instruments</span>
        <span itemprop="definition">such as the Ze</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mean size of a nanoparticle composition</span>
        <span itemprop="definition">may be from about 50 nm to about 100 nm, from about 50 nm to about 90 nm, from about 50 nm to about 80 nm, from about 50 nm to about 70 nm, from about 50 nm to about 60 nm, from about 60 nm to about 100 nm, from about 60 nm to about 90 nm, from about 60 nm to about 80 nm, from about 60 nm to about 70 nm, from about 70 nm to about 100 nm, from about 70 nm to about 90 nm, from about 70 nm to about 80 nm, from about 80 nm to about 100 nm, from about 80 nm to about 90 nm, or from about 90 nm to about 100 nm.</span>
        <meta itemprop="num_attr" content="0445">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mean size of a nanoparticle composition</span>
        <span itemprop="definition">may be from about 70 nm to about 100 nm. In a particular embodiment, the mean size may be about</span>
        <meta itemprop="num_attr" content="0445">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be relatively homogenous.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a polydispersity index</span>
        <span itemprop="definition">may be used to indicate the homogeneity of a nanoparticle composition, e.g., the particle size distribution of the nanoparticle compositions.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a small (e.g., less than 0.3) polydispersity index</span>
        <span itemprop="definition">generally indicates a narrow particle size distribution.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may have a polydispersity index from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the polydispersity index of a nanoparticle composition</span>
        <span itemprop="definition">may be from about 0.10 to about 0.20.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the zeta potential of a nanoparticle composition</span>
        <span itemprop="definition">may be used to indicate the electrokinetic potential of the composition.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the zeta potential</span>
        <span itemprop="definition">may describe the surface charge of a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions with relatively low charges, positive or negative,</span>
        <span itemprop="definition">are generally desirable, as more highly charged species may interact undesirably with cells, tissues, and other elements in the body.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the zeta potential of a nanoparticle composition</span>
        <span itemprop="definition">may be from about   10 mV to about &#43;20 mV, from about   10 mV to about &#43;15 mV, from about   10 mV to about &#43;10 mV, from about   10 mV to about &#43;5 mV, from about   10 mV to about 0 mV, from about   10 mV to about   5 mV, from about   5 mV to about &#43;20 mV, from about   5 mV to about &#43;15 mV, from about   5 mV to about &#43;10 mV, from about   5 mV to about &#43;5 mV, from about   5 mV to about 0 mV, from about 0 mV to about &#43;20 mV, from about 0 mV to about &#43;15 mV, from about 0 mV to about &#43;10 mV, from about 0 mV to about &#43;10 mV, from about</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the efficiency of encapsulation of a therapeutic and/or prophylactic</span>
        <span itemprop="definition">describes the amount of therapeutic and/or prophylactic that is encapsulated or otherwise associated with a nanoparticle composition after preparation, relative to the initial amount provided.</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the encapsulation efficiency</span>
        <span itemprop="definition">is desirably high (e.g., close to 100%).</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the encapsulation efficiency</span>
        <span itemprop="definition">may be measured, for example, by comparing the amount of therapeutic and/or prophylactic in a solution containing the nanoparticle composition before and after breaking up the nanoparticle composition with one or more organic solvents or detergents. Fluorescence may be used to measure the amount of free therapeutic and/or prophylactic (e.g., RNA) in a solution.</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the encapsulation efficiency of a therapeutic and/or prophylactic</span>
        <span itemprop="definition">may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency may be at least 80%. In certain embodiments, the encapsulation efficiency may be at least 90%.</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may optionally comprise one or more coatings.</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be formulated in a capsule, film, or tablet having a coating.</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a capsule, film, or tablet including a composition described herein</span>
        <span itemprop="definition">may have any useful size, tensile strength, hardness, or density.</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may be formulated in whole or in part as pharmaceutical compositions.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Pharmaceutical compositions</span>
        <span itemprop="definition">may include one or more nanoparticle compositions.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may include one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Pharmaceutical compositions</span>
        <span itemprop="definition">may further include one or more pharmaceutically acceptable excipients or accessory ingredients such as those described herein.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">General guidelines for the formulation and manufacture of pharmaceutical compositions and agents</span>
        <span itemprop="definition">are available, for example, in Remington&#39;s The Science and Practice of Pharmacy, 21 st Edition, A. R. Gennaro; Lippincott, Williams &amp; Wilkins, Baltimore, Md., 2006.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">excipients and accessory ingredients</span>
        <span itemprop="definition">may be used in any pharmaceutical composition, except insofar as any conventional excipient or accessory ingredient may be incompatible with one or more components of a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An excipient or accessory ingredient</span>
        <span itemprop="definition">may be incompatible with a component of a nanoparticle composition if its combination with the component may result in any undesirable biological effect or otherwise deleterious effect.</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more excipients or accessory ingredients</span>
        <span itemprop="definition">may make up greater than 50% of the total mass or volume of a pharmaceutical composition including a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the one or more excipients or accessory ingredients</span>
        <span itemprop="definition">may make up 50%, 60%, 70%, 80%, 90%, or more of a pharmaceutical convention.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutically acceptable excipient</span>
        <span itemprop="definition">is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an excipient</span>
        <span itemprop="definition">is approved for use in humans and for veterinary use.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an excipient</span>
        <span itemprop="definition">is approved by United States Food and Drug Administration.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an excipient</span>
        <span itemprop="definition">is pharmaceutical grade.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an excipient</span>
        <span itemprop="definition">meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may comprise between 0.1% and 100% (wt/wt) of one or more nanoparticle compositions.</span>
        <meta itemprop="num_attr" content="0452">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle compositions and/or pharmaceutical compositions of the disclosure</span>
        <span itemprop="definition">are refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4 C. or lower, such as a temperature between about   150 C. and about 0 C. or between about   80 C. and about   20 C. (e.g., about   5 C.,   10 C.,   15 C.,   20 C.,   25 C.,   30 C.,   40 C.,   50 C.,   60 C.,   70 C.,   80 C.,   90 C.,   130 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a temperature of 4 C. or lower</span>
        <span itemprop="definition">such as a temperature between about   150 C. and about 0 C. or between about   80 C. and about   20 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject"> 5 C.</span>
        <span itemprop="definition">e.g., about   5 C.,</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition</span>
        <span itemprop="definition">comprising a compound of any of Formulae (I), (IA), (II), and (IIa)-(IIe) is a solution that is refrigerated for storage and/or shipment at, for example, about   20 C.,   30 C.,   40 C.,   50 C.,   60 C.,   70 C., or   80 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">also relates to a method of increasing stability of the nanoparticle compositions and/or pharmaceutical compositions comprising a compound of any of Formulae (I), (IA), (II), and (IIa)-(IIe) by storing the nanoparticle compositions and/or pharmaceutical compositions at a temperature of 4 C. or lower, such as a temperature between about   150 C. and about 0 C. or between about   80 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject"> 20 C.</span>
        <span itemprop="definition">e.g., about   5 C.,   10 C.,   15 C.,   20 C.,   25 C.,   30 C.,   40 C.,   50 C.,   60 C.,   70 C.,   80 C.,   90 C.,   130 C. or   150 C.).</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle compositions and/or pharmaceutical compositions disclosed herein</span>
        <span itemprop="definition">are stable for about at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, or at least 24 months, e.g., at a temperature of 4 C. or lower (e.g., between about 4 C. and   20 C.).</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the formulation</span>
        <span itemprop="definition">is stabilized for at least 4 weeks at about 4 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition of the disclosure</span>
        <span itemprop="definition">comprises a nanoparticle composition disclosed herein and a pharmaceutically acceptable carrier selected from one or more of Tris, an acetate (e.g., sodium acetate), an citrate (e.g., sodium citrate), saline, PBS, and sucrose.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutically acceptable carrier</span>
        <span itemprop="definition">selected from one or more of Tris, an acetate (e.g., sodium acetate), an citrate (e.g., sodium citrate), saline, PBS, and sucrose.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the pharmaceutical composition of the disclosure</span>
        <span itemprop="definition">has a pH value between about 7 and 8 (e.g., 6.8 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 or 8.0, or between 7.5 and 8 or between 7 and 7.8).</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition of the disclosure</span>
        <span itemprop="definition">comprises a nanoparticle composition disclosed herein, Tris, saline and sucrose, and has a pH of about 7.5-8, which is suitable for storage and/or shipment at, for example, about   20 C.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition of the disclosure</span>
        <span itemprop="definition">comprises a nanoparticle composition disclosed herein and PBS and has a pH of about 7-7.8, suitable for storage and/or shipment at, for example, about 4 C. or lower.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Stability, stabilized, and stable in the context of the present disclosure</span>
        <span itemprop="definition">refers to the resistance of nanoparticle compositions and/or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given manufacturing, preparation, transportation, storage and/or in-use conditions, e.g., when stress is applied such as shear force, freeze/thaw stress, etc.</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions and/or pharmaceutical compositions including one or more nanoparticle compositions</span>
        <span itemprop="definition">may be administered to any patient or subject, including those patients or subjects that may benefit from a therapeutic effect provided by the delivery of a therapeutic and/or prophylactic to one or more particular cells, tissues, organs, or systems or groups thereof, such as the renal system.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic effect provided by the delivery of a therapeutic and/or prophylactic to one or more particular cells, tissues, organs, or systems or groups thereof, such as the renal system</span>
        <span itemprop="definition">such as the renal system.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions suitable for administration to humans</span>
        <span itemprop="definition">in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Subjects to which administration of the compositions is contemplated</span>
        <span itemprop="definition">include, but are not limited to, humans, other primates, and other mammals, including commercially relevant mammals such as cattle, pigs, hoses, sheep, cats, dogs, mice, and/or rats.</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition including one or more nanoparticle compositions</span>
        <span itemprop="definition">may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if desirable or necessary, dividing, shaping, and/or packaging the product into a desired single- or multi-dose unit.</span>
        <meta itemprop="num_attr" content="0455">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition in accordance with the present disclosure</span>
        <span itemprop="definition">may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses.</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a unit dose</span>
        <span itemprop="definition">is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient (e.g., nanoparticle composition).</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of the active ingredient</span>
        <span itemprop="definition">is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">may be prepared in a variety of forms suitable for a variety of routes and methods of administration.</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pharmaceutical compositions</span>
        <span itemprop="definition">may be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and/or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">liquid dosage forms</span>
        <span itemprop="definition">e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">injectable forms</span>
        <span itemprop="definition">e.g., solid dosage forms (e.g., capsules, tablets, pills, powders, and granules)</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Liquid dosage forms for oral and parenteral administration</span>
        <span itemprop="definition">include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and/or elixirs.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">liquid dosage forms</span>
        <span itemprop="definition">may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">inert diluents</span>
        <span itemprop="definition">commonly used in the art</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oral compositions</span>
        <span itemprop="definition">can include additional therapeutic and/or prophylactics, additional agents such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">additional agents</span>
        <span itemprop="definition">such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solubilizing agents</span>
        <span itemprop="definition">such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Injectable preparations</span>
        <span itemprop="definition">for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Sterile injectable preparations</span>
        <span itemprop="definition">may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the acceptable vehicles and solvents</span>
        <span itemprop="definition">that may be employed are water, Ringer&#39;s solution, U.S.P., and isotonic sodium chloride solution.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Sterile, fixed oils</span>
        <span itemprop="definition">are conventionally employed as a solvent or suspending medium.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">any bland fixed oil</span>
        <span itemprop="definition">can be employed including synthetic mono- or diglycerides.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Fatty acids</span>
        <span itemprop="definition">such as oleic acid can be used in the preparation of injectables.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Injectable formulations</span>
        <span itemprop="definition">can be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.</span>
        <meta itemprop="num_attr" content="0460">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the rate of drug release</span>
        <span itemprop="definition">can be controlled.</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">biodegradable polymers</span>
        <span itemprop="definition">include poly(orthoesters) and poly(anhydrides).</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Depot injectable formulations</span>
        <span itemprop="definition">are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions for rectal or vaginal administration</span>
        <span itemprop="definition">are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.</span>
        <meta itemprop="num_attr" content="0462">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">suitable non-irritating excipients</span>
        <span itemprop="definition">such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.</span>
        <meta itemprop="num_attr" content="0462">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Solid dosage forms for oral administration</span>
        <span itemprop="definition">include capsules, tablets, pills, films, powders, and granules.</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an active ingredient</span>
        <span itemprop="definition">is mixed with at least one inert, pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and/or fillers or extenders (e.g.</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">starches</span>
        <span itemprop="definition">lactose, sucrose, glucose, mannitol, and silicic acid</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">binders</span>
        <span itemprop="definition">e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">humectants</span>
        <span itemprop="definition">e.g., glycerol</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">disintegrating agents</span>
        <span itemprop="definition">e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solution retarding agents</span>
        <span itemprop="definition">e.g., paraffin</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">absorption accelerators</span>
        <span itemprop="definition">e.g., quaternary ammonium compounds</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">wetting agents</span>
        <span itemprop="definition">e.g., cetyl alcohol and glycerol monostearate</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">absorbents</span>
        <span itemprop="definition">e.g., kaolin and bentonite clay, silicates</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lubricants</span>
        <span itemprop="definition">e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Solid compositions of a similar type</span>
        <span itemprop="definition">may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.</span>
        <meta itemprop="num_attr" content="0464">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Solid dosage forms of tablets, dragees, capsules, pills, and granules</span>
        <span itemprop="definition">can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes.</span>
        <meta itemprop="num_attr" content="0464">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Solid compositions of a similar type</span>
        <span itemprop="definition">may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.</span>
        <meta itemprop="num_attr" content="0464">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dosage forms for topical and/or transdermal administration of a composition</span>
        <span itemprop="definition">may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an active ingredient</span>
        <span itemprop="definition">is admixed under sterile conditions with a pharmaceutically acceptable excipient and/or any needed preservatives and/or buffers as may be required.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">dosage forms</span>
        <span itemprop="definition">may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">rate</span>
        <span itemprop="definition">may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix and/or gel.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Suitable devices for use in delivering intradermal pharmaceutical compositions described herein</span>
        <span itemprop="definition">include short needle devices such as those described in U.S. Pat. Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Intradermal compositions</span>
        <span itemprop="definition">may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Jet injection devices</span>
        <span itemprop="definition">which deliver liquid compositions to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Jet injection devices</span>
        <span itemprop="definition">are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ballistic powder/particle delivery devices</span>
        <span itemprop="definition">which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">conventional syringes</span>
        <span itemprop="definition">may be used in the classical mantoux method of intradermal administration.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for topical administration</span>
        <span itemprop="definition">include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions.</span>
        <meta itemprop="num_attr" content="0467">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Topically-administrable formulations</span>
        <span itemprop="definition">may, for example, comprise from about 1% to about 10% (wt/wt) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent.</span>
        <meta itemprop="num_attr" content="0467">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations for topical administration</span>
        <span itemprop="definition">may further comprise one or more of the additional ingredients described herein.</span>
        <meta itemprop="num_attr" content="0467">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity.</span>
        <meta itemprop="num_attr" content="0468">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a formulation</span>
        <span itemprop="definition">may comprise dry particles which comprise the active ingredient.</span>
        <meta itemprop="num_attr" content="0468">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such compositions</span>
        <span itemprop="definition">are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container.</span>
        <meta itemprop="num_attr" content="0468">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Dry powder compositions</span>
        <span itemprop="definition">may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.</span>
        <meta itemprop="num_attr" content="0468">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Low boiling propellants</span>
        <span itemprop="definition">generally include liquid propellants having a boiling point of below 65 F. at atmospheric pressure. Generally the propellant may constitute 50% to 99.9% (wt/wt) of the composition, and active ingredient may constitute 0.1% to 20% (wt/wt) of the composition.</span>
        <meta itemprop="num_attr" content="0469">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a propellant</span>
        <span itemprop="definition">may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).</span>
        <meta itemprop="num_attr" content="0469">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions formulated for pulmonary delivery</span>
        <span itemprop="definition">may provide an active ingredient in the form of droplets of a solution and/or suspension.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such formulations</span>
        <span itemprop="definition">may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising active ingredient, and may conveniently be administered using any nebulization and/or atomization device.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such formulations</span>
        <span itemprop="definition">may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Droplets provided by this route of administration</span>
        <span itemprop="definition">may have an average diameter in the range from about 1 nm to about 200 nm.</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations described herein as being useful for pulmonary delivery</span>
        <span itemprop="definition">are useful for intranasal delivery of a pharmaceutical composition.</span>
        <meta itemprop="num_attr" content="0471">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Another formulation suitable for intranasal administration</span>
        <span itemprop="definition">is a coarse powder comprising the active ingredient and having an average particle from about 0.2   m to 500   m. Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose.</span>
        <meta itemprop="num_attr" content="0471">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formulations suitable for nasal administration</span>
        <span itemprop="definition">may, for example, comprise from about as little as 0.1% (wt/wt) and as much as 100% (wt/wt) of active ingredient, and may comprise one or more of the additional ingredients described herein.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (wt/wt) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">formulations suitable for buccal administration</span>
        <span itemprop="definition">may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising active ingredient.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such powdered, aerosolized, and/or aerosolized formulations</span>
        <span itemprop="definition">when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a pharmaceutical composition</span>
        <span itemprop="definition">may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such formulations</span>
        <span itemprop="definition">may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (wt/wt) solution and/or suspension of the active ingredient in an aqueous or oily liquid excipient.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Such drops</span>
        <span itemprop="definition">may further comprise buffering agents, salts, and/or one or more other of any additional ingredients described herein.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Other ophthalmically-administrable formulations which are useful</span>
        <span itemprop="definition">include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this present disclosure.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">provides methods of producing a polypeptide of interest in a mammalian cell.</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods of producing polypeptides</span>
        <span itemprop="definition">involve contacting a cell with a nanoparticle composition including an mRNA encoding the polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the mRNA</span>
        <span itemprop="definition">may be taken up and translated in the cell to produce the polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the step of contacting a mammalian cell with a nanoparticle composition including an mRNA encoding a polypeptide of interest</span>
        <span itemprop="definition">may be performed in vivo, ex vivo, in culture, or in vitro.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the amount of nanoparticle composition contacted with a cell, and/or the amount of mRNA therein,</span>
        <span itemprop="definition">may depend on the type of cell or tissue being contacted, the means of administration, the physiochemical characteristics of the nanoparticle composition and the mRNA (e.g., size, charge, and chemical composition) therein, and other factors.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an effective amount of the nanoparticle composition</span>
        <span itemprop="definition">will allow for efficient polypeptide production in the cell. Metrics for efficiency may include polypeptide translation (indicated by polypeptide expression), level of mRNA degradation, and immune response indicators.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the step of contacting a nanoparticle composition including an mRNA with a cell</span>
        <span itemprop="definition">may involve or cause transfection.</span>
        <meta itemprop="num_attr" content="0476">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a phospholipid including in the lipid component of a nanoparticle composition</span>
        <span itemprop="definition">may facilitate transfection and/or increase transfection efficiency, for example, by interacting and/or fusing with a cellular or intracellular membrane. Transfection may allow for the translation of the mRNA within the cell.</span>
        <meta itemprop="num_attr" content="0476">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nanoparticle compositions described herein</span>
        <span itemprop="definition">may be used therapeutically.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an mRNA included in a nanoparticle composition</span>
        <span itemprop="definition">may encode a therapeutic polypeptide (e.g., in a translatable region) and produce the therapeutic polypeptide upon contacting and/or entry (e.g., transfection) into a cell.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an mRNA included in a nanoparticle composition</span>
        <span itemprop="definition">may encode a polypeptide that may improve or increase the immunity of a subject.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an mRNA</span>
        <span itemprop="definition">may encode a granulocyte-colony stimulating factor or trastuzumab.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an mRNA included in a nanoparticle composition</span>
        <span itemprop="definition">may encode a recombinant polypeptide that may replace one or more polypeptides that may be substantially absent in a cell contacted with the nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the one or more substantially absent polypeptides</span>
        <span itemprop="definition">may be lacking due to a genetic mutation of the encoding gene or a regulatory pathway thereof.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a recombinant polypeptide produced by translation of the mRNA</span>
        <span itemprop="definition">may antagonize the activity of an endogenous protein present in, on the surface of, or secreted from the cell.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An antagonistic recombinant polypeptide</span>
        <span itemprop="definition">may be desirable to combat deleterious effects caused by activities of the endogenous protein, such as altered activities or localization caused by mutation.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a recombinant polypeptide produced by translation of the mRNA</span>
        <span itemprop="definition">may indirectly or directly antagonize the activity of a biological moiety present in, on the surface of, or secreted from the cell.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Antagonized biological moieties</span>
        <span itemprop="definition">may include, but are not limited to, lipids (e.g., cholesterol), lipoproteins (e.g., low density lipoprotein), nucleic acids, carbohydrates, and small molecule toxins.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Recombinant polypeptides produced by translation of the mRNA</span>
        <span itemprop="definition">may be engineered for localization within the cell, such as within a specific compartment such as the nucleus, or may be engineered for secretion from the cell or for translocation to the plasma membrane of the cell.</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">contacting a cell with a nanoparticle composition including an mRNA</span>
        <span itemprop="definition">may reduce the innate immune response of a cell to an exogenous nucleic acid.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cell</span>
        <span itemprop="definition">may be contacted with a first nanoparticle composition including a first amount of a first exogenous mRNA including a translatable region and the level of the innate immune response of the cell to the first exogenous mRNA may be determined.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cell</span>
        <span itemprop="definition">may be contacted with a second composition including a second amount of the first exogenous mRNA, the second amount being a lesser amount of the first exogenous mRNA compared to the first amount.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the second composition</span>
        <span itemprop="definition">may include a first amount of a second exogenous mRNA that is different from the first exogenous mRNA.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the steps of contacting the cell with the first and second compositions</span>
        <span itemprop="definition">may be repeated one or more times. Additionally, efficiency of polypeptide production (e.g., translation) in the cell may be optionally determined, and the cell may be re-contacted with the first and/or second composition repeatedly until a target protein production efficiency is achieved.</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">provides methods of delivering a therapeutic and/or prophylactic to a mammalian cell or organ.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Delivery of a therapeutic and/or prophylactic to a cell</span>
        <span itemprop="definition">involves administering a nanoparticle composition including the therapeutic and/or prophylactic to a subject, where administration of the composition involves contacting the cell with the composition.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a protein, cytotoxic agent, radioactive ion, chemotherapeutic agent, or nucleic acid</span>
        <span itemprop="definition">such as an RNA, e.g., mRNA</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNA</span>
        <span itemprop="definition">e.g., mRNA</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a translatable mRNA</span>
        <span itemprop="definition">upon contacting a cell with the nanoparticle composition, a translatable mRNA may be translated in the cell to produce a polypeptide of interest.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">mRNAs that are substantially not translatable</span>
        <span itemprop="definition">may also be delivered to cells.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Substantially non-translatable mRNAs</span>
        <span itemprop="definition">may be useful as vaccines and/or may sequester translational components of a cell to reduce expression of other species in the cell.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may target a particular type or class of cells (e.g., cells of a particular organ or system thereof).</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition including a therapeutic and/or prophylactic of interest</span>
        <span itemprop="definition">may be specifically delivered to a mammalian liver, kidney, spleen, femur, or lung.</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Specific delivery to a particular class of cells, an organ, or a system or group thereof</span>
        <span itemprop="definition">implies that a higher proportion of nanoparticle compositions including a therapeutic and/or prophylactic are delivered to the destination (e.g., tissue) of interest relative to other destinations, e.g., upon administration of a nanoparticle composition to a mammal.</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">specific delivery</span>
        <span itemprop="definition">may result in a greater than 2 fold, 5 fold, 10 fold, 15 fold, or 20 fold increase in the amount of therapeutic and/or prophylactic per 1 g of tissue of the targeted destination (e.g., tissue of interest, such as a liver) as compared to another destination (e.g., the spleen).</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">tissue of interest</span>
        <span itemprop="definition">e.g., tissue of interest, such as a liver</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">another destination</span>
        <span itemprop="definition">e.g., the spleen</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the tissue of interest</span>
        <span itemprop="definition">is selected from the group consisting of a liver, kidney, a lung, a spleen, a femur, an ocular tissue (e.g., via intraocular, subretinal, or intravitreal injection), vascular endothelium in vessels (e.g., intra-coronary or intra-femoral) or kidney, and tumor tissue (e.g., via intratumoral injection).</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an mRNA that encodes a protein-binding partner (e.g., an antibody or functional fragment thereof, a scaffold protein, or a peptide) or a receptor on a cell surface</span>
        <span itemprop="definition">may be included in a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An mRNA</span>
        <span itemprop="definition">may additionally or instead be used to direct the synthesis and extracellular localization of lipids, carbohydrates, or other biological moieties.</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">other therapeutic and/or prophylactics or elements (e.g., lipids or ligands) of a nanoparticle composition</span>
        <span itemprop="definition">may be selected based on their affinity for particular receptors (e.g., low density lipoprotein receptors) such that a nanoparticle composition may more readily interact with a target cell population including the receptors.</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ligands</span>
        <span itemprop="definition">may include, but are not limited to, members of a specific binding pair, antibodies, monoclonal antibodies, Fv fragments, single chain Fv (scFv) fragments, Fab fragments, F(ab)2 fragments, single domain antibodies, camelized antibodies and fragments thereof, humanized antibodies and fragments thereof, and multivalent versions thereof; multivalent binding reagents including mono- or bi-specific antibodies such as disulfide stabilized Fv fragments, scFv tandems, diabodies, tribodies, or tetrabodies; and aptamers, receptors, and fusion proteins.</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a ligand</span>
        <span itemprop="definition">may be a surface-bound antibody, which can permit tuning of cell targeting specificity. This is especially useful since highly specific antibodies can be raised against an epitope of interest for the desired targeting site.</span>
        <meta itemprop="num_attr" content="0483">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">multiple antibodies</span>
        <span itemprop="definition">are expressed on the surface of a cell, and each antibody can have a different specificity for a desired target. Such approaches can increase the avidity and specificity of targeting interactions.</span>
        <meta itemprop="num_attr" content="0483">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a ligand</span>
        <span itemprop="definition">can be selected, e.g., by a person skilled in the biological arts, based on the desired localization or function of the cell.</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an estrogen receptor ligand</span>
        <span itemprop="definition">such as tamoxifen, can target cells to estrogen-dependent breast cancer cells that have an increased number of estrogen receptors on the cell surface.</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ligand/receptor interactions</span>
        <span itemprop="definition">include CCR1 (e.g., for treatment of inflamed joint tissues or brain in rheumatoid arthritis, and/or multiple sclerosis), CCR7, CCR8 (e.g., targeting to lymph node tissue), CCR6, CCR9,CCR10 (e.g., to target to intestinal tissue), CCR4, CCR10 (e.g., for targeting to skin), CXCR4 (e.g., for general enhanced transmigration), HCELL (e.g., for treatment of inflammation and inflammatory disorders, bone marrow), Alpha4beta7 (e.g., for intestinal mucosa targeting), and VLA-4NCAM-1 (e.g., targeting to endothelium).</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">any receptor involved in targeting</span>
        <span itemprop="definition">e.g., cancer metastasis</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">any receptor involved in targeting</span>
        <span itemprop="definition">can be harnessed for use in the methods and compositions described herein.</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Targeted cells</span>
        <span itemprop="definition">may include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, and tumor cells.</span>
        <meta itemprop="num_attr" content="0485">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may target hepatocytes.</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Apolipoprotiens</span>
        <span itemprop="definition">such as apolipoprotein E (apoE) have been shown to associate with neutral or near neutral lipid-containing nanoparticle compositions in the body, and are known to associate with receptors such as low-density lipoprotein receptors (LDLRs) found on the surface of hepatocytes.</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LDLRs</span>
        <span itemprop="definition">low-density lipoprotein receptors</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition including a lipid component with a neutral or near neutral charge that is administered to a subject</span>
        <span itemprop="definition">may acquire apoE in a subject&#39;s body and may subsequently deliver a therapeutic and/or prophylactic (e.g., an RNA) to hepatocytes including LDLRs in a targeted manner.</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic</span>
        <span itemprop="definition">e.g., an RNA</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions</span>
        <span itemprop="definition">may be useful for treating a disease, disorder, or condition.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">such compositions</span>
        <span itemprop="definition">may be useful in treating a disease, disorder, or condition characterized by missing or aberrant protein or polypeptide activity.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">comprising an mRNA encoding a missing or aberrant polypeptide may be administered or delivered to a cell. Subsequent translation of the mRNA may produce the polypeptide, thereby reducing or eliminating an issue caused by the absence of or aberrant activity caused by the polypeptide. Because translation may occur rapidly, the methods and compositions may be useful in the treatment of acute diseases, disorders, or conditions such as sepsis, stroke, and myocardial infarction.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic and/or prophylactic included in a nanoparticle composition</span>
        <span itemprop="definition">may also be capable of altering the rate of transcription of a given species, thereby affecting gene expression.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Diseases, disorders, and/or conditions characterized by dysfunctional or aberrant protein or polypeptide activity for which a composition may be administered</span>
        <span itemprop="definition">include, but are not limited to, rare diseases, infectious diseases (as both vaccines and therapeutics), cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and reno-vascular diseases, and metabolic diseases. Multiple diseases, disorders, and/or conditions may be characterized by missing (or substantially diminished such that proper protein function does not occur) protein activity. Such proteins may not be present, or they may be essentially non-functional.</span>
        <meta itemprop="num_attr" content="0488">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a specific example of a dysfunctional protein</span>
        <span itemprop="definition">is the missense mutation variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which produce a dysfunctional protein variant of CFTR protein, which causes cystic fibrosis.</span>
        <meta itemprop="num_attr" content="0488">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">provides a method for treating such diseases, disorders, and/or conditions in a subject by administering a nanoparticle composition including an RNA and a lipid component including a lipid according to Formula (I), a phospholipid (optionally unsaturated), a PEG lipid, and a structural lipid, wherein the RNA may be an mRNA encoding a polypeptide that antagonizes or otherwise overcomes an aberrant protein activity present in the cell of the subject.</span>
        <meta itemprop="num_attr" content="0488">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">including an RNA and a lipid component including a lipid according to Formula (I), a phospholipid (optionally unsaturated), a PEG lipid, and a structural lipid, wherein the RNA may be an mRNA encoding a</span>
        <meta itemprop="num_attr" content="0488">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions, or imaging, diagnostic, or prophylactic compositions thereof</span>
        <span itemprop="definition">may be administered to a subject using any reasonable amount and any route of administration effective for preventing, treating, diagnosing, or imaging a disease, disorder, and/or condition and/or any other purpose.</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the specific amount administered to a given subject</span>
        <span itemprop="definition">may vary depending on the species, age, and general condition of the subject; the purpose of the administration; the particular composition; the mode of administration; and the like.</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions in accordance with the present disclosure</span>
        <span itemprop="definition">may be formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of a composition of the present disclosure will be decided by an attending physician within the scope of sound medical judgment.</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the specific therapeutically effective, prophylactically effective, or otherwise appropriate dose level (e.g., for imaging) for any particular patient</span>
        <span itemprop="definition">will depend upon a variety of factors including the severity and identify of a disorder being treated, if any; the one or more therapeutic and/or prophylactics employed; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific pharmaceutical composition employed; the duration of the treatment; drugs used in combination or coincidental with the specific pharmaceutical composition employed; and like factors well known in the medical arts.</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions, including prophylactic, diagnostic, or imaging compositions including one or more nanoparticle compositions described herein</span>
        <span itemprop="definition">are administered by one or more of a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, trans- or intra-dermal, interdermal, rectal, intravaginal, intraperitoneal, intraocular, subretinal, intravitreal, topical (e.g.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a composition</span>
        <span itemprop="definition">may be administered intravenously, intramuscularly, intradermally, intra-arterially, intratumorally, subcutaneously, intraocularly, subretinally, intravitreally, or by inhalation.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">encompasses the delivery or administration of compositions described herein by any appropriate route taking into consideration likely advances in the sciences of drug delivery.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the most appropriate route of administration</span>
        <span itemprop="definition">will depend upon a variety of factors including the nature of the nanoparticle composition including one or more therapeutic and/or prophylactics (e.g., its stability in various bodily environments such as the bloodstream and gastrointestinal tract), the condition of the patient (e.g., whether the patient is able to tolerate particular routes of administration), etc.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions in accordance with the present disclosure</span>
        <span itemprop="definition">may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 10 mg/kg, from about 0.001 mg/kg to about 10 mg/kg, from about 0.005 mg/kg to about 10 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.05 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 10 mg/kg, from about 2 mg/kg to about 10 mg/kg, from about 5 mg/kg to about 10 mg/kg, from about 0.0001 mg/kg to about 5 mg/kg, from about 0.001 mg/kg to about 5 mg/kg, from about 0.005 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to about 5 mg/kg, from about 0.05 mg/kg to about 5 mg/kg, from about 0.1 mg/kg to about 5 mg/kg, from about 1 mg/kg to about 5 mg/kg, from about 2 mg/kg</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dose of about 0.001 mg/kg to about 10 mg/kg of a therapeutic and/or prophylactic (e.g., mRNA) of a nanoparticle composition</span>
        <span itemprop="definition">may be administered.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dose of about 0.005 mg/kg to about 2.5 mg/kg of a therapeutic and/or prophylactic</span>
        <span itemprop="definition">may be administered.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dose of about 0.1 mg/kg to about 1 mg/kg</span>
        <span itemprop="definition">may be administered.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dose of about 0.05 mg/kg to about 0.25 mg/kg</span>
        <span itemprop="definition">may be administered.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a dose</span>
        <span itemprop="definition">may be administered one or more times per day, in the same or a different amount, to obtain a desired level of mRNA expression and/or therapeutic, diagnostic, prophylactic, or imaging effect.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the desired dosage</span>
        <span itemprop="definition">may be delivered, for example, three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the desired dosage</span>
        <span itemprop="definition">may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations).</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a single dose</span>
        <span itemprop="definition">may be administered, for example, prior to or after a surgical procedure or in the instance of an acute disease, disorder, or condition.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticle compositions including one or more therapeutic and/or prophylactics</span>
        <span itemprop="definition">may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents.</span>
        <meta itemprop="num_attr" content="0492">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">combination with</span>
        <span itemprop="definition">it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the present disclosure.</span>
        <meta itemprop="num_attr" content="0492">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics</span>
        <span itemprop="definition">may be administered in combination.</span>
        <meta itemprop="num_attr" content="0492">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compositions</span>
        <span itemprop="definition">can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent.</span>
        <meta itemprop="num_attr" content="0492">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present disclosure</span>
        <span itemprop="definition">encompasses the delivery of compositions, or imaging, diagnostic, or prophylactic compositions thereof in combination with agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.</span>
        <meta itemprop="num_attr" content="0492">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">therapeutically, prophylactically, diagnostically, or imaging active agents utilized in combination</span>
        <span itemprop="definition">may be administered together in a single composition or administered separately in different compositions.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">agents utilized in combination</span>
        <span itemprop="definition">will be utilized at levels that do not exceed the levels at which they are utilized individually.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the levels utilized in combination</span>
        <span itemprop="definition">may be lower than those utilized individually.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen</span>
        <span itemprop="definition">will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, a composition useful for treating cancer may be administered concurrently with a chemotherapeutic agent), or they may achieve different effects (e.g., control of any adverse effects, such as infusion related reactions).</span>
        <meta itemprop="num_attr" content="0494">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be used in combination with an agent to increase the effectiveness and/or therapeutic window of the composition.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an agent</span>
        <span itemprop="definition">may be, for example, an anti-inflammatory compound, a steroid (e.g., a corticosteroid), a statin, an estradiol, a BTK inhibitor, an S1P1 agonist, a glucocorticoid receptor modulator (GRM), or an anti-histamine.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nanoparticle composition</span>
        <span itemprop="definition">may be used in combination with dexamethasone, methotrexate, acetaminophen, an H1 receptor blocker, or an H2 receptor blocker.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method of treating a subject in need thereof or of delivering a therapeutic and/or prophylactic to a subject</span>
        <span itemprop="definition">may involve pre-treating the subject with one or more agents prior to administering a nanoparticle composition.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a subject</span>
        <span itemprop="definition">may be pre-treated with a useful amount (e.g., 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any other useful amount) of dexamethasone, methotrexate, acetaminophen, an H1 receptor blocker, or an H2 receptor blocker.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Pre-treatment</span>
        <span itemprop="definition">may occur 24 or fewer hours (e.g., 24 hours, 20 hours, 16 hours, 12 hours, 8 hours, 4 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or 10 minutes) before administration of the nanoparticle composition and may occur one, two, or more times in, for example, increasing dosage amounts.</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">articles such as a, an, and the</span>
        <span itemprop="definition">may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include or between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">includes embodiments in which more than one, or all, of the group members are present in, employed in, or otherwise relevant to a given product or process.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compositions</span>
        <span itemprop="definition">are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">methods or processes</span>
        <span itemprop="definition">are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">order of steps or order for performing certain actions</span>
        <span itemprop="definition">is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the synthetic processes of the disclosure</span>
        <span itemprop="definition">can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used.</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the processes</span>
        <span itemprop="definition">generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt thereof.</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">protecting groups</span>
        <span itemprop="definition">may require protection from the reaction conditions via the use of protecting groups.</span>
        <meta itemprop="num_attr" content="0503">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Protecting groups</span>
        <span itemprop="definition">may also be used to differentiate similar functional groups in molecules.</span>
        <meta itemprop="num_attr" content="0503">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a list of protecting groups and how to introduce and remove these groups</span>
        <span itemprop="definition">can be found in Greene, T. W., Wuts, P. G. M., Protective Groups in Organic Synthesis, 3 rd edition, John Wiley &amp; Sons: New York, 1999.</span>
        <meta itemprop="num_attr" content="0503">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Preferred protecting groups</span>
        <span itemprop="definition">include, but are not limited to:</span>
        <meta itemprop="num_attr" content="0504">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">di-alkyl acetals</span>
        <span itemprop="definition">such as dimethoxy acetal or diethyl acetyl.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 1</span>
        <span itemprop="definition">8-bromooctanoic acid reacts with an alcohol a1 (e.g., heptadecan-9-ol) to afford an ester b1 (e.g., heptadecan-9-yl 8-bromooctanoate).</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 1</span>
        <span itemprop="definition">can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP.</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 1</span>
        <span itemprop="definition">can take place at room temperature for 18 h.</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ester b1</span>
        <span itemprop="definition">reacts with 2-aminoethan-1-ol to afford amine c1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate).</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 2</span>
        <span itemprop="definition">can take place in ethanol at, e.g., a temperature of about 60 C.</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">amine c1</span>
        <span itemprop="definition">reacts with an bromoalkyl R 1 Br (e.g., 1-bromotetradecane) to afford compound d1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate).</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 3</span>
        <span itemprop="definition">can take place in ethanol in the presence of N,N-diisopropylethylamine.</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an acid a2</span>
        <span itemprop="definition">(t is an integer between 1 and 7; e.g., 8-bromooctanoic acid) reacts with an alcohol b2 (e.g., nonan-1-ol) to afford an ester c2 (e.g., nonyl-8-bromooctanoate).</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 1</span>
        <span itemprop="definition">can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Alcohol e2</span>
        <span itemprop="definition">(e.g., heptadecan-9-ol) can be obtained from reacting aldehyde d2 (e.g., nonanal) with a Grignard reagent R 3 MgX (e.g., n-C 8 H 17 MgBr) via Step 2.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">Grignard reagent</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">8-bromooctanoic acid</span>
        <span itemprop="definition">reacts with an alcohol e2 (e.g., heptadecan-9-ol) to afford an ester f2 (e.g., heptadecan-9-yl 8-bromooctanoate).</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 3</span>
        <span itemprop="definition">can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ester f2</span>
        <span itemprop="definition">reacts with 2-aminoethan-1-ol to afford amine g2 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate).</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 4</span>
        <span itemprop="definition">can take place in ethanol in the presence of i-Pr 2 EtN.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ester c2</span>
        <span itemprop="definition">e.g., nonyl-8-bromooctanoate</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ester c2</span>
        <span itemprop="definition">e.g., nonyl-8-bromooctanoate</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">h2</span>
        <span itemprop="definition">e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 5</span>
        <span itemprop="definition">can take place in an organic solvent (e.g., a mixture of CPME and MeCN), in the presence of a base (such as an inorganic base (e.g., K2CO 3 ) or non-nucleophilic organic base (e.g., i-Pr2EtN)) and a catalyst (e.g., an iodide such as KI or NaI) at, e.g., an elevated temperature (such as at about 70-90 C., e.g., about 80 C.).</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">such as an inorganic base (e.g., K2CO 3 ) or non-nucleophilic organic base (e.g., i-Pr2EtN)</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a catalyst</span>
        <span itemprop="definition">e.g., an iodide such as KI or NaI</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the disclosure</span>
        <span itemprop="definition">also includes methods of synthesizing a compound of any of Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and intermediate(s) for synthesizing the compound.</span>
        <meta itemprop="num_attr" content="0516">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method of synthesizing a compound of Formula (I)</span>
        <span itemprop="definition">includes reacting a compound of Formula (X2):</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 Br</span>
        <span itemprop="definition">to afford the compound of Formula (I), wherein each variables are as defined herein.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">m</span>
        <span itemprop="definition">is 5, 6, 7, 8, or 9, preferably 5, 7, or 9.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 5 , R 6 , and R 7</span>
        <span itemprop="definition">is H.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M</span>
        <span itemprop="definition">is C(O)O or OC(O).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4</span>
        <span itemprop="definition">is unsubstituted C 1-3 alkyl, or (CH 2 ) n Q, in which n is 2, 3, or 4 and Q is OH, NHC(S)N(R) 2 , NHC(O)N(R) 2 , N(R)C(O)R, or N(R)S(O) 2 R.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction of the compound of Formula (X2) with R 1 Br</span>
        <span itemprop="definition">takes place in the presence of a base (such as an inorganic base (e.g., K 2 CO 3 ) or non-nucleophilic organic base (e.g., i-Pr 2 EtN)).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">such as an inorganic base (e.g., K 2 CO 3 ) or non-nucleophilic organic base (e.g., i-Pr 2 EtN)</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction</span>
        <span itemprop="definition">takes place in the presence of an inorganic base (e.g., K 2 CO 3 ) and a catalyst (e.g., an iodide such as KI or NaI).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction</span>
        <span itemprop="definition">takes place at an elevated temperature, e.g., about 50-100 C., 70-90 C., or about 80 C.).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the method</span>
        <span itemprop="definition">may also include reacting a compound of Formula (X1):</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the intermediate(s)</span>
        <span itemprop="definition">include those having any of Formulae (X1) and (X2):</span>
        <meta itemprop="num_attr" content="0519">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the intermediate</span>
        <span itemprop="definition">includes heptadecan-9-yl 8-bromooctanoate, and heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate, and morphic forms thereof (e.g., a crystalline form).</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Example 1</span>
        <span itemprop="definition">Synthesis of Compounds According to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)</span>
        <meta itemprop="num_attr" content="">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">heptadecan-9-yl 8-((3-chloropropyl)(nonyl)amino)octanoate</span>
        <span itemprop="definition">50 mg, 0.083 mmol</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">imidazole</span>
        <span itemprop="definition">17 mg, 0.25 mmol</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">K2CO 3</span>
        <span itemprop="definition">35 mg, 0.25 mmol</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">MeCN</span>
        <span itemprop="definition">MeCN</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the flask</span>
        <span itemprop="definition">was fitted with a condenser and placed in an 82 C. heating mantle and was allowed to stir for 24 h. After this time, the reaction was allowed to cool to rt, was filtered and the filtrate was concentrated in vacuo.</span>
        <meta itemprop="num_attr" content="0583">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical Kinetics &amp; Catalysis</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Immunology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nuclear Medicine, Radiotherapy &amp; Molecular Imaging</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Proteomics, Peptides &amp; Aminoacids</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Gastroenterology &amp; Hepatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dispersion Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Otolaryngology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Diabetes</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Optics &amp; Photonics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nanotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dermatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Marine Sciences &amp; Fisheries</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pulmonology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Obesity</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Hematology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Toxicology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Endocrinology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Heart &amp; Thoracic Surgery</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA201262814" lang="EN" load-source="patent-office">
    <div id="p-0001" num="0000" class="abstract">The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><ul mxw-id="PDES118414152" lang="EN" load-source="patent-office" class="description">
    
    <heading id="h-0001">RELATED APPLICATIONS</heading>
    <li> <para-num num="[0001]"> </para-num> <div id="p-0002" num="0001" class="description-line">This application is a continuation application of International Application PCT/US2016/052352, having an international filing date of Sep. 16, 2016, which claims priority to, and the benefit of, U.S. Provisional Application Nos. 62/220,085, filed Sep. 17, 2015; 62/220,091, filed Sep. 17, 2015; 62/252,316, filed Nov. 6, 2015; 62/253,433, filed Nov. 10, 2015; 62/266,460, filed Dec. 11, 2015; 62/333,557, filed May 9, 2016; 62/382,740, filed Sep. 1, 2016; and 62/393,940, filed Sep. 13, 2016; the entire contents of each of which are incorporated herein by reference in their entireties.</div>
    
    
    </li> <heading id="h-0002">INCORPORATION-BY-REFERENCE OF SEQUENCE LISTING</heading>
    <li> <para-num num="[0002]"> </para-num> <div id="p-0003" num="0002" class="description-line">The contents of the text file named MRNA014001WOST25.txt, which was created on Dec. 2, 2016 and is 1 KB in size, are hereby incorporated by reference in their entireties.</div>
    </li> <heading id="h-0003">FIELD OF DISCLOSURE</heading>
    <li> <para-num num="[0003]"> </para-num> <div id="p-0004" num="0003" class="description-line">The present disclosure provides novel compounds, compositions comprising such compounds, and methods involving lipid nanoparticle compositions to deliver one or more therapeutic and/or prophylactics to and/or produce polypeptides in mammalian cells or organs. In addition to a novel lipid, lipid nanoparticle compositions of the disclosure may include one or more cationic and/or ionizable amino lipids, phospholipids including polyunsaturated lipids, PEG lipids, structural lipids, and/or therapeutic and/or prophylactics in specific fractions.</div>
    </li> <heading id="h-0004">BACKGROUND OF THE DISCLOSURE</heading>
    <li> <para-num num="[0004]"> </para-num> <div id="p-0005" num="0004" class="description-line">The effective targeted delivery of biologically active substances such as small molecule drugs, proteins, and nucleic acids represents a continuing medical challenge. In particular, the delivery of nucleic acids to cells is made difficult by the relative instability and low cell permeability of such species. Thus, there exists a need to develop methods and compositions to facilitate the delivery of therapeutic and/or prophylactics such as nucleic acids to cells.</div>
    </li> <li> <para-num num="[0005]"> </para-num> <div id="p-0006" num="0005" class="description-line">Lipid-containing nanoparticle compositions, liposomes, and lipoplexes have proven effective as transport vehicles into cells and/or intracellular compartments for biologically active substances such as small molecule drugs, proteins, and nucleic acids. Such compositions generally include one or more cationic and/or amino (ionizable) lipids, phospholipids including polyunsaturated lipids, structural lipids (e.g., sterols), and/or lipids containing polyethylene glycol (PEG lipids). Cationic and/or ionizable lipids include, for example, amine-containing lipids that can be readily protonated. Though a variety of such lipid-containing nanoparticle compositions have been demonstrated, improvements in safety, efficacy, and specificity are still lacking.</div>
    </li> <heading id="h-0005">SUMMARY OF THE DISCLOSURE</heading>
    <li> <para-num num="[0006]"> </para-num> <div id="p-0007" num="0006" class="description-line">The present disclosure provides novel compounds and compositions and methods involving the same.</div>
    </li> <li> <para-num num="[0007]"> </para-num> <div id="p-0008" num="0007" class="description-line">A first aspect of the disclosure relates to compounds of Formula (I):</div>
    </li> <li> <div id="p-0009" num="0000" class="description-line">
      <chemistry id="CHEM-US-00001" num="00001">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/09/9a/b9/cda5ce0f6cfe81/US20170210697A1-20170727-C00001.png"><img id="EMI-C00001" he="19.81mm" wi="52.66mm" file="US20170210697A1-20170727-C00001.TIF" alt="Figure US20170210697A1-20170727-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="211" height="79" alt="Figure US20170210697A1-20170727-C00001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/09/9a/b9/cda5ce0f6cfe81/US20170210697A1-20170727-C00001.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US20170210697A1-20170727-C00001.CDX"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US20170210697A1-20170727-C00001.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0008]"> </para-num> <div id="p-0010" num="0008" class="description-line">or a salt or isomer thereof, wherein:</div>
    </li> <li> <para-num num="[0009]"> </para-num> <div id="p-0011" num="0009" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0010]"> </para-num> <div id="p-0012" num="0010" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0011]"> </para-num> <div id="p-0013" num="0011" class="description-line">R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, CQ(R)<sub>2</sub>, and unsubstituted C<sub>1-6 </sub>alkyl, where Q is selected from a carbocycle, heterocycle, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, N(R)<sub>2</sub>, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)R, C(O)N(R)OR, and C(R)N(R)<sub>2</sub>C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;</div>
    </li> <li> <para-num num="[0012]"> </para-num> <div id="p-0014" num="0012" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0013]"> </para-num> <div id="p-0015" num="0013" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0014]"> </para-num> <div id="p-0016" num="0014" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0015]"> </para-num> <div id="p-0017" num="0015" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0016]"> </para-num> <div id="p-0018" num="0016" class="description-line">R<sub>8 </sub>is selected from the group consisting of C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0017]"> </para-num> <div id="p-0019" num="0017" class="description-line">R<sub>9 </sub>is selected from the group consisting of H, CN, NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, OR, S(O)<sub>2</sub>R, S(O)<sub>2</sub>N(R)<sub>2</sub>, C<sub>2-6 </sub>alkenyl, C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0018]"> </para-num> <div id="p-0020" num="0018" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0019]"> </para-num> <div id="p-0021" num="0019" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0020]"> </para-num> <div id="p-0022" num="0020" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0021]"> </para-num> <div id="p-0023" num="0021" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>2-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0022]"> </para-num> <div id="p-0024" num="0022" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0023]"> </para-num> <div id="p-0025" num="0023" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0024]"> </para-num> <div id="p-0026" num="0024" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.</div>
    </li> <li> <para-num num="[0025]"> </para-num> <div id="p-0027" num="0025" class="description-line">In some embodiments, a subset of compounds of Formula (I) includes those in which when R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, or CQ(R)<sub>2</sub>, then (i) Q is not N(R)<sub>2 </sub>when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.</div>
    </li> <li> <para-num num="[0026]"> </para-num> <div id="p-0028" num="0026" class="description-line">In another embodiments, another subset of compounds of Formula (I) includes those in which</div>
    </li> <li> <para-num num="[0027]"> </para-num> <div id="p-0029" num="0027" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0028]"> </para-num> <div id="p-0030" num="0028" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0029]"> </para-num> <div id="p-0031" num="0029" class="description-line">R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, CQ(R)<sub>2</sub>, and unsubstituted C<sub>1-6 </sub>alkyl, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, CRN(R)<sub>2</sub>C(O)OR, N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)R, C(O)N(R)OR, and a 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S which is substituted with one or more substituents selected from oxo (O), OH, amino, mono- or di-alkylamino, and C<sub>1-3 </sub>alkyl, and each n is independently selected from 1, 2, 3, 4, and 5;</div>
    </li> <li> <para-num num="[0030]"> </para-num> <div id="p-0032" num="0030" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0031]"> </para-num> <div id="p-0033" num="0031" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0032]"> </para-num> <div id="p-0034" num="0032" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0033]"> </para-num> <div id="p-0035" num="0033" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0034]"> </para-num> <div id="p-0036" num="0034" class="description-line">R<sub>8 </sub>is selected from the group consisting of C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0035]"> </para-num> <div id="p-0037" num="0035" class="description-line">R<sub>9 </sub>is selected from the group consisting of H, CN, NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, OR, S(O)<sub>2</sub>R, S(O)<sub>2</sub>N(R)<sub>2</sub>, C<sub>2-6 </sub>alkenyl, C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0036]"> </para-num> <div id="p-0038" num="0036" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0037]"> </para-num> <div id="p-0039" num="0037" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0038]"> </para-num> <div id="p-0040" num="0038" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0039]"> </para-num> <div id="p-0041" num="0039" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>2-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0040]"> </para-num> <div id="p-0042" num="0040" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0041]"> </para-num> <div id="p-0043" num="0041" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0042]"> </para-num> <div id="p-0044" num="0042" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</div>
    </li> <li> <para-num num="[0043]"> </para-num> <div id="p-0045" num="0043" class="description-line">or salts or isomers thereof.</div>
    </li> <li> <para-num num="[0044]"> </para-num> <div id="p-0046" num="0044" class="description-line">In yet another embodiments, another subset of compounds of Formula (I) includes those in which</div>
    </li> <li> <para-num num="[0045]"> </para-num> <div id="p-0047" num="0045" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0046]"> </para-num> <div id="p-0048" num="0046" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0047]"> </para-num> <div id="p-0049" num="0047" class="description-line">R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, CQ(R)<sub>2</sub>, and unsubstituted C<sub>1-6 </sub>alkyl, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, CRN(R)<sub>2</sub>C(O)OR, N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)R, C(O)N(R)OR, and C(NR<sub>9</sub>)N(R)<sub>2</sub>, and each n is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycle and (i) R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q in which n is 1 or 2, or (ii) R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>CHQR in which n is 1, or (iii) R<sub>4 </sub>is CHQR, and -CQ(R)<sub>2</sub>, then Q is either a 5- to 14-membered heteroaryl or 8- to 14-membered heterocycloalkyl;</div>
    </li> <li> <para-num num="[0048]"> </para-num> <div id="p-0050" num="0048" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0049]"> </para-num> <div id="p-0051" num="0049" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0050]"> </para-num> <div id="p-0052" num="0050" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0051]"> </para-num> <div id="p-0053" num="0051" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0052]"> </para-num> <div id="p-0054" num="0052" class="description-line">R<sub>8 </sub>is selected from the group consisting of C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0053]"> </para-num> <div id="p-0055" num="0053" class="description-line">R<sub>9 </sub>is selected from the group consisting of H, CN, NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, OR, S(O)<sub>2</sub>R, S(O)<sub>2</sub>N(R)<sub>2</sub>, C<sub>2-6 </sub>alkenyl, C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0054]"> </para-num> <div id="p-0056" num="0054" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0055]"> </para-num> <div id="p-0057" num="0055" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0056]"> </para-num> <div id="p-0058" num="0056" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0057]"> </para-num> <div id="p-0059" num="0057" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>2-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0058]"> </para-num> <div id="p-0060" num="0058" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0059]"> </para-num> <div id="p-0061" num="0059" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0060]"> </para-num> <div id="p-0062" num="0060" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</div>
    </li> <li> <para-num num="[0061]"> </para-num> <div id="p-0063" num="0061" class="description-line">or salts or isomers thereof.</div>
    </li> <li> <para-num num="[0062]"> </para-num> <div id="p-0064" num="0062" class="description-line">In still another embodiments, another subset of compounds of Formula (I) includes those in which</div>
    </li> <li> <para-num num="[0063]"> </para-num> <div id="p-0065" num="0063" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0064]"> </para-num> <div id="p-0066" num="0064" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0065]"> </para-num> <div id="p-0067" num="0065" class="description-line">R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, CQ(R)<sub>2</sub>, and unsubstituted C<sub>1-6 </sub>alkyl, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, CRN(R)<sub>2</sub>C(O)OR, N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)R, C(O)N(R)OR, and C(NR<sub>9</sub>)N(R)<sub>2</sub>, and each n is independently selected from 1, 2, 3, 4, and 5;</div>
    </li> <li> <para-num num="[0066]"> </para-num> <div id="p-0068" num="0066" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0067]"> </para-num> <div id="p-0069" num="0067" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0068]"> </para-num> <div id="p-0070" num="0068" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0069]"> </para-num> <div id="p-0071" num="0069" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0070]"> </para-num> <div id="p-0072" num="0070" class="description-line">R<sub>8 </sub>is selected from the group consisting of C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0071]"> </para-num> <div id="p-0073" num="0071" class="description-line">R<sub>9 </sub>is selected from the group consisting of H, CN, NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, OR, S(O)<sub>2</sub>R, S(O)<sub>2</sub>N(R)<sub>2</sub>, C<sub>2-6 </sub>alkenyl, C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0072]"> </para-num> <div id="p-0074" num="0072" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0073]"> </para-num> <div id="p-0075" num="0073" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0074]"> </para-num> <div id="p-0076" num="0074" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0075]"> </para-num> <div id="p-0077" num="0075" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>2-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0076]"> </para-num> <div id="p-0078" num="0076" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0077]"> </para-num> <div id="p-0079" num="0077" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0078]"> </para-num> <div id="p-0080" num="0078" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</div>
    </li> <li> <para-num num="[0079]"> </para-num> <div id="p-0081" num="0079" class="description-line">or salts or isomers thereof.</div>
    </li> <li> <para-num num="[0080]"> </para-num> <div id="p-0082" num="0080" class="description-line">In yet another embodiments, another subset of compounds of Formula (I) includes those in which</div>
    </li> <li> <para-num num="[0081]"> </para-num> <div id="p-0083" num="0081" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0082]"> </para-num> <div id="p-0084" num="0082" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>2-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0083]"> </para-num> <div id="p-0085" num="0083" class="description-line">R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q or (CH<sub>2</sub>)<sub>n</sub>CHQR, where Q is N(R)<sub>2</sub>, and n is selected from 3, 4, and 5;</div>
    </li> <li> <para-num num="[0084]"> </para-num> <div id="p-0086" num="0084" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0085]"> </para-num> <div id="p-0087" num="0085" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0086]"> </para-num> <div id="p-0088" num="0086" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0087]"> </para-num> <div id="p-0089" num="0087" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0088]"> </para-num> <div id="p-0090" num="0088" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0089]"> </para-num> <div id="p-0091" num="0089" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0090]"> </para-num> <div id="p-0092" num="0090" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0091]"> </para-num> <div id="p-0093" num="0091" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>1-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0092]"> </para-num> <div id="p-0094" num="0092" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0093]"> </para-num> <div id="p-0095" num="0093" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0094]"> </para-num> <div id="p-0096" num="0094" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</div>
    </li> <li> <para-num num="[0095]"> </para-num> <div id="p-0097" num="0095" class="description-line">or salts or isomers thereof.</div>
    </li> <li> <para-num num="[0096]"> </para-num> <div id="p-0098" num="0096" class="description-line">In still another embodiments, another subset of compounds of Formula (I) includes those in which</div>
    </li> <li> <para-num num="[0097]"> </para-num> <div id="p-0099" num="0097" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0098]"> </para-num> <div id="p-0100" num="0098" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0099]"> </para-num> <div id="p-0101" num="0099" class="description-line">R<sub>4 </sub>is selected from the group consisting of (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and CQ(R)<sub>2</sub>, where Q is N(R)<sub>2</sub>, and n is selected from 1, 2, 3, 4, and 5;</div>
    </li> <li> <para-num num="[0100]"> </para-num> <div id="p-0102" num="0100" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0101]"> </para-num> <div id="p-0103" num="0101" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0102]"> </para-num> <div id="p-0104" num="0102" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0103]"> </para-num> <div id="p-0105" num="0103" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0104]"> </para-num> <div id="p-0106" num="0104" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0105]"> </para-num> <div id="p-0107" num="0105" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0106]"> </para-num> <div id="p-0108" num="0106" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0107]"> </para-num> <div id="p-0109" num="0107" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>1-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0108]"> </para-num> <div id="p-0110" num="0108" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0109]"> </para-num> <div id="p-0111" num="0109" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0110]"> </para-num> <div id="p-0112" num="0110" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,</div>
    </li> <li> <para-num num="[0111]"> </para-num> <div id="p-0113" num="0111" class="description-line">or salts or isomers thereof.</div>
    </li> <li> <para-num num="[0112]"> </para-num> <div id="p-0114" num="0112" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (IA):</div>
    </li> <li> <div id="p-0115" num="0000" class="description-line">
      <chemistry id="CHEM-US-00002" num="00002">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/71/63/d5/7c16417646e57e/US20170210697A1-20170727-C00002.png"><img id="EMI-C00002" he="21.42mm" wi="54.19mm" file="US20170210697A1-20170727-C00002.TIF" alt="Figure US20170210697A1-20170727-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="217" height="86" alt="Figure US20170210697A1-20170727-C00002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/71/63/d5/7c16417646e57e/US20170210697A1-20170727-C00002.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US20170210697A1-20170727-C00002.CDX"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US20170210697A1-20170727-C00002.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0116" num="0000" class="description-line">or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M<sub>1 </sub>is a bond or M; R<sub>4 </sub>is unsubstituted C<sub>1-3 </sub>alkyl, or (CH<sub>2</sub>)<sub>n</sub>Q, in which Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)R<sub>8</sub>,
<br/>
NHC(NR<sub>9</sub>)N(R)<sub>2</sub>, NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M are independently selected
<br/>
from C(O)O, OC(O), C(O)N(R), P(O)(OR)O, SS, an aryl group, and a heteroaryl group; and R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, and C<sub>2-14 </sub>alkenyl.
</div>
    </li> <li> <para-num num="[0113]"> </para-num> <div id="p-0117" num="0113" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (II):</div>
    </li> <li> <div id="p-0118" num="0000" class="description-line">
      <chemistry id="CHEM-US-00003" num="00003">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d6/59/37/f0dcccf3048786/US20170210697A1-20170727-C00003.png"><img id="EMI-C00003" he="27.09mm" wi="64.85mm" file="US20170210697A1-20170727-C00003.TIF" alt="Figure US20170210697A1-20170727-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="259" height="108" alt="Figure US20170210697A1-20170727-C00003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d6/59/37/f0dcccf3048786/US20170210697A1-20170727-C00003.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US20170210697A1-20170727-C00003.CDX"> </attachment>
          <attachment idref="CHEM-US-00003" attachment-type="mol" file="US20170210697A1-20170727-C00003.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0119" num="0000" class="description-line">or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; M<sub>1 </sub>is a bond or M; R<sub>4 </sub>is unsubstituted C<sub>1-3 </sub>alkyl, or (CH<sub>2</sub>)<sub>n</sub>Q, in which n is 2, 3, or 4, and Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)R<sub>8</sub>, NHC(NR<sub>9</sub>)N(R)<sub>2</sub>, NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M are independently selected
<br/>
from C(O)O, OC(O), C(O)N(R), P(O)(OR)O, SS, an aryl group, and a heteroaryl group; and R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, and C<sub>2-14 </sub>alkenyl.
</div>
    </li> <li> <para-num num="[0114]"> </para-num> <div id="p-0120" num="0114" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (IIa), (IIb), (IIc), or (IIe):</div>
    </li> <li> <div id="p-0121" num="0000" class="description-line">
      <chemistry id="CHEM-US-00004" num="00004">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/71/30/aa/327e4992291b09/US20170210697A1-20170727-C00004.png"><img id="EMI-C00004" he="160.78mm" wi="75.61mm" file="US20170210697A1-20170727-C00004.TIF" alt="Figure US20170210697A1-20170727-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="643" alt="Figure US20170210697A1-20170727-C00004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/71/30/aa/327e4992291b09/US20170210697A1-20170727-C00004.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US20170210697A1-20170727-C00004.CDX"> </attachment>
          <attachment idref="CHEM-US-00004" attachment-type="mol" file="US20170210697A1-20170727-C00004.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0122" num="0000" class="description-line">or a salt or isomer thereof, wherein R<sub>4 </sub>is as described herein.</div>
    </li> <li> <para-num num="[0115]"> </para-num> <div id="p-0123" num="0115" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (IId):</div>
    </li> <li> <div id="p-0124" num="0000" class="description-line">
      <chemistry id="CHEM-US-00005" num="00005">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/02/d4/11/cd8ca4b4c98174/US20170210697A1-20170727-C00005.png"><img id="EMI-C00005" he="29.29mm" wi="57.83mm" file="US20170210697A1-20170727-C00005.TIF" alt="Figure US20170210697A1-20170727-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="231" height="117" alt="Figure US20170210697A1-20170727-C00005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/02/d4/11/cd8ca4b4c98174/US20170210697A1-20170727-C00005.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US20170210697A1-20170727-C00005.CDX"> </attachment>
          <attachment idref="CHEM-US-00005" attachment-type="mol" file="US20170210697A1-20170727-C00005.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0125" num="0000" class="description-line">or a salt or isomer thereof, wherein n is 2, 3, or 4; and m, R, R, and R<sub>2 </sub>through R<sub>6 </sub>are as described herein. For example, each of R<sub>2 </sub>and R<sub>3 </sub>may be independently selected from the group consisting of C<sub>5-14 </sub>alkyl and C<sub>5-14 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0116]"> </para-num> <div id="p-0126" num="0116" class="description-line">In another aspect, the disclosure features a nanoparticle composition including a lipid component comprising a compound as described herein (e.g., a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)).</div>
    </li> <li> <para-num num="[0117]"> </para-num> <div id="p-0127" num="0117" class="description-line">In yet another aspect, the disclosure features a pharmaceutical composition comprising a nanoparticle composition according to the preceding aspects and a pharmaceutically acceptable carrier. For example, the pharmaceutical composition is refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4 C. or lower, such as a temperature between about 150 C. and about 0 C. or between about 80 C. and about 20 C. (e.g., about 5 C., 10 C., 15 C., 20 C., 25 C., 30 C., 40 C., 50 C., 60 C., 70 C., 80 C., 90 C., 130 C. or 150 C.). For example, the pharmaceutical composition is a solution that is refrigerated for storage and/or shipment at, for example, about 20 C., 30 C., 40 C., 50 C., 60 C., 70 C., or 80 C.</div>
    </li> <li> <para-num num="[0118]"> </para-num> <div id="p-0128" num="0118" class="description-line">In another aspect, the disclosure provides a method of delivering a therapeutic and/or prophylactic (e.g., an mRNA) to a cell (e.g., a mammalian cell). This method includes the step of administering to a subject (e.g., a mammal, such as a human) a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic, in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the cell.</div>
    </li> <li> <para-num num="[0119]"> </para-num> <div id="p-0129" num="0119" class="description-line">In another aspect, the disclosure provides a method of producing a polypeptide of interest in a cell (e.g., a mammalian cell). The method includes the step of contacting the cell with a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) an mRNA encoding the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide.</div>
    </li> <li> <para-num num="[0120]"> </para-num> <div id="p-0130" num="0120" class="description-line">In another aspect, the disclosure provides a method of treating a disease or disorder in a mammal (e.g., a human) in need thereof. The method includes the step of administering to the mammal a therapeutically effective amount of a nanoparticle composition including (i) a lipid component including a phospholipid (such as a polyunsaturated lipid), a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA). In some embodiments, the disease or disorder is characterized by dysfunctional or aberrant protein or polypeptide activity. For example, the disease or disorder is selected from the group consisting of rare diseases, infectious diseases, cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and reno-vascular diseases, and metabolic diseases.</div>
    </li> <li> <para-num num="[0121]"> </para-num> <div id="p-0131" num="0121" class="description-line">In another aspect, the disclosure provides a method of delivering (e.g., specifically delivering) a therapeutic and/or prophylactic to a mammalian organ (e.g., a liver, spleen, lung, or femur). This method includes the step of administering to a subject (e.g., a mammal) a nanoparticle composition including (i) a lipid component including a phospholipid, a PEG lipid, a structural lipid, and a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and (ii) a therapeutic and/or prophylactic (e.g., an mRNA), in which administering involves contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target organ (e.g., a liver, spleen, lung, or femur).</div>
    </li> <li> <para-num num="[0122]"> </para-num> <div id="p-0132" num="0122" class="description-line">In another aspect, the disclosure features a method for the enhanced delivery of a therapeutic and/or prophylactic (e.g., an mRNA) to a target tissue (e.g., a liver, spleen, lung, or femur). This method includes administering to a subject (e.g., a mammal) a nanoparticle composition, the composition including (i) a lipid component including a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a structural lipid, and a PEG lipid; and (ii) a therapeutic and/or prophylactic, the administering including contacting the target tissue with the nanoparticle composition, whereby the therapeutic and/or prophylactic is delivered to the target tissue.</div>
    </li> <li> <para-num num="[0123]"> </para-num> <div id="p-0133" num="0123" class="description-line">In yet another aspect, the disclosure features a method of lowering immunogenicity comprising introducing the nanoparticle composition of the disclosure into cells, wherein the nanoparticle composition reduces the induction of the cellular immune response of the cells to the nanoparticle composition, as compared to the induction of the cellular immune response in cells induced by a reference composition which comprises a reference lipid instead of a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). For example, the cellular immune response is an innate immune response, an adaptive immune response, or both.</div>
    </li> <li> <para-num num="[0124]"> </para-num> <div id="p-0134" num="0124" class="description-line">The disclosure also includes methods of synthesizing a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and methods of making a nanoparticle composition including a lipid component comprising the compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</div>
    
    
    </li> <description-of-drawings>
      <heading id="h-0006">BRIEF DESCRIPTION OF THE DRAWINGS</heading>
      <li> <para-num num="[0125]"> </para-num> <div id="p-0135" num="0125" class="description-line"> <figref idrefs="DRAWINGS">FIG. 1</figref> shows the results of pretreating non-human primates with methotrexate or dexamethasone prior to administration of a nanoparticle composition including MC3.</div>
      </li> <li> <para-num num="[0126]"> </para-num> <div id="p-0136" num="0126" class="description-line"> <figref idrefs="DRAWINGS">FIG. 2</figref> shows the hEPO mRNA expression measured after intravenous administration of various nanoparticle compositions at a 0.01 mpk dose with 60 minutes infusion to naive cynomolgus monkeys.</div>
      </li> <li> <para-num num="[0127]"> </para-num> <div id="p-0137" num="0127" class="description-line"> <figref idrefs="DRAWINGS">FIGS. 3-6</figref> respectively shows the results of hEPO expression measured upon intravenous administration of various nanoparticle <figure-callout id="26" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="18" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00004.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="25" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00005.png,US20170210697A1-20170727-D00007.png" state="{{state}}">compositions including Compounds</figure-callout> </figure-callout> </figure-callout> 26, 18, 25, and MC3 to rat at various doses.</div>
      </li> <li> <para-num num="[0128]"> </para-num> <div id="p-0138" num="0128" class="description-line"> <figref idrefs="DRAWINGS">FIG. 7</figref> shows the area under the curve (AUC) for nanoparticle <figure-callout id="18" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00004.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="25" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00005.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="26" label="compositions including Compounds" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00007.png" state="{{state}}">compositions including Compounds</figure-callout> </figure-callout> </figure-callout> 18, 25, and 26 and MC3 at various doses between 0.005 mpk and 2 mpk.</div>
      </li> <li> <para-num num="[0129]"> </para-num> <div id="p-0139" num="0129" class="description-line"> <figref idrefs="DRAWINGS">FIG. 8</figref> shows the results of luciferase expression measured upon intramuscular administration of various nanoparticle compositions including MC3, Compounds 168-170, and 173-175 to mice at 0.01 mpk at various time points: 3 hr (left block), 6 hr (middle block) and 24 hr (right block). The numbers 1-7 in this figure correspond to MC3, Compounds 168-170, and 173-175 respectively.</div>
      </li> <li> <para-num num="[0130]"> </para-num> <div id="p-0140" num="0130" class="description-line"> <figref idrefs="DRAWINGS">FIG. 9</figref> shows the results of hEPO expression measured upon intramuscular administration of various nanoparticle compositions including MC3, Compounds 18, 25, 30, 108-112, 60, and 122 to mice at 0.01 mpk at various time points: 3 hr (left block), 6 hr (middle block) and 24 hr (right block). The numbers 1-11 in this figure correspond to MC3, Compounds 18, 25, 30, 108-112, 60, and 122 respectively.</div>
      </li> <li> <para-num num="[0131]"> </para-num> <div id="p-0141" num="0131" class="description-line"> <figref idrefs="DRAWINGS">FIG. 10</figref> shows the results of luciferase expression (total flux) measured upon intravenous administration of various nanoparticle compositions including MC3 or various compounds disclosed herein. The numbers 1-12 in this figure correspond to Compound 18, MC3, Compounds 48-50, 54, 111, 60, 75, 68, 66, 128, 65, 130, 133-135, 147, 96, and 151 respectively.</div>
      </li> <li> <para-num num="[0132]"> </para-num> <div id="p-0142" num="0132" class="description-line"> <figref idrefs="DRAWINGS">FIGS. 11A and 11B</figref> show the results of anti-HA (anti-hemagglutinin) antibody expression measured after intravenous administration of various nanoparticle compositions including MC3 and <figure-callout id="18" label="Compound" filenames="US20170210697A1-20170727-D00004.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Compound</figure-callout> 18 at a 0.1 mpk (<figref idrefs="DRAWINGS">FIG. 11A</figref>) or 0.3 mpk (<figref idrefs="DRAWINGS">FIG. 11B</figref>) dose with 60 minutes infusion to naive cynomolgus monkeys.</div>
    </li> </description-of-drawings>
    
    
    <heading id="h-0007">DETAILED DESCRIPTION</heading>
    <li> <para-num num="[0133]"> </para-num> <div id="p-0143" num="0133" class="description-line">The disclosure relates to novel lipids and lipid nanoparticle compositions including a novel lipid. The disclosure also provides methods of delivering a therapeutic and/or prophylactic to a mammalian cell, specifically delivering a therapeutic and/or prophylactic to a mammalian organ, producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof. For example, a method of producing a polypeptide of interest in a cell involves contacting a nanoparticle composition comprising an mRNA with a mammalian cell, whereby the mRNA may be translated to produce the polypeptide of interest. A method of delivering a therapeutic and/or prophylactic to a mammalian cell or organ may involve administration of a nanoparticle composition including the therapeutic and/or prophylactic to a subject, in which the administration involves contacting the cell or organ with the composition, whereby the therapeutic and/or prophylactic is delivered to the cell or organ.</div>
    </li> <heading id="h-0008">Lipids</heading>
    <li> <para-num num="[0134]"> </para-num> <div id="p-0144" num="0134" class="description-line">The present disclosure provides lipids including a central amine moiety and at least one biodegradable group. The lipids described herein may be advantageously used in lipid nanoparticle compositions for the delivery of therapeutic and/or prophylactics to mammalian cells or organs. For example, the lipids described herein have little or no immunogenicity. For example, the lipid compound of any of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) has a lower immunogenicity as compared to a reference lipid (e.g., MC3, KC2, or DLinDMA). For example, a formulation comprising a lipid disclosed herein and a therapeutic or prophylactic agent has an increased therapeutic index as compared to a corresponding formulation which comprise a reference lipid (e.g., MC3, KC2, or DLinDMA) and the same therapeutic or prophylactic agent.</div>
    </li> <li> <para-num num="[0135]"> </para-num> <div id="p-0145" num="0135" class="description-line">In a first aspect of the invention, the compounds described herein are of Formula (I):</div>
    </li> <li> <div id="p-0146" num="0000" class="description-line">
      <chemistry id="CHEM-US-00006" num="00006">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/d3/d1/9c4dd0f0bc7daa/US20170210697A1-20170727-C00006.png"><img id="EMI-C00006" he="21.25mm" wi="52.15mm" file="US20170210697A1-20170727-C00006.TIF" alt="Figure US20170210697A1-20170727-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="85" alt="Figure US20170210697A1-20170727-C00006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/d3/d1/9c4dd0f0bc7daa/US20170210697A1-20170727-C00006.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US20170210697A1-20170727-C00006.CDX"> </attachment>
          <attachment idref="CHEM-US-00006" attachment-type="mol" file="US20170210697A1-20170727-C00006.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0136]"> </para-num> <div id="p-0147" num="0136" class="description-line">or salts or isomers thereof, wherein:</div>
    </li> <li> <para-num num="[0137]"> </para-num> <div id="p-0148" num="0137" class="description-line">R<sub>1 </sub>is selected from the group consisting of C<sub>5-30 </sub>alkyl, C<sub>5-20 </sub>alkenyl, R*YR, YR, and RMR;</div>
    </li> <li> <para-num num="[0138]"> </para-num> <div id="p-0149" num="0138" class="description-line">R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle;</div>
    </li> <li> <para-num num="[0139]"> </para-num> <div id="p-0150" num="0139" class="description-line">R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, CQ(R)<sub>2</sub>, and unsubstituted C<sub>1-6 </sub>alkyl, where Q is selected from a carbocycle, heterocycle, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, N(R)<sub>2</sub>, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)N(R)<sub>2</sub>, C(NR<sub>9</sub>)R, C(O)N(R)OR, and C(R)N(R)<sub>2</sub>C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5;</div>
    </li> <li> <para-num num="[0140]"> </para-num> <div id="p-0151" num="0140" class="description-line">each R<sub>5 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0141]"> </para-num> <div id="p-0152" num="0141" class="description-line">each R<sub>6 </sub>is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0142]"> </para-num> <div id="p-0153" num="0142" class="description-line">M and M are independently selected from C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, SS, an aryl group, and a heteroaryl group;</div>
    </li> <li> <para-num num="[0143]"> </para-num> <div id="p-0154" num="0143" class="description-line">R<sub>7 </sub>is selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0144]"> </para-num> <div id="p-0155" num="0144" class="description-line">R<sub>8 </sub>is selected from the group consisting of C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0145]"> </para-num> <div id="p-0156" num="0145" class="description-line">R<sub>9 </sub>is selected from the group consisting of H, CN, NO<sub>2</sub>, C<sub>1-6 </sub>alkyl, OR, S(O)<sub>2</sub>R, S(O)<sub>2</sub>N(R)<sub>2</sub>, C<sub>2-6 </sub>alkenyl, C<sub>3-6 </sub>carbocycle and heterocycle;</div>
    </li> <li> <para-num num="[0146]"> </para-num> <div id="p-0157" num="0146" class="description-line">each R is independently selected from the group consisting of C<sub>1-3 </sub>alkyl, C<sub>2-3 </sub>alkenyl, and H;</div>
    </li> <li> <para-num num="[0147]"> </para-num> <div id="p-0158" num="0147" class="description-line">each R is independently selected from the group consisting of C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, YR, and H;</div>
    </li> <li> <para-num num="[0148]"> </para-num> <div id="p-0159" num="0148" class="description-line">each R is independently selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0149]"> </para-num> <div id="p-0160" num="0149" class="description-line">each R* is independently selected from the group consisting of C<sub>1-12 </sub>alkyl and C<sub>2-12 </sub>alkenyl;</div>
    </li> <li> <para-num num="[0150]"> </para-num> <div id="p-0161" num="0150" class="description-line">each Y is independently a C<sub>3-6 </sub>carbocycle;</div>
    </li> <li> <para-num num="[0151]"> </para-num> <div id="p-0162" num="0151" class="description-line">each X is independently selected from the group consisting of F, Cl, Br, and I; and</div>
    </li> <li> <para-num num="[0152]"> </para-num> <div id="p-0163" num="0152" class="description-line">m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13; and wherein when R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, or CQ(R)<sub>2</sub>, then (i) Q is not N(R)<sub>2 </sub>when n is 1, 2, 3, 4 or 5, or (ii) Q is not 5, 6, or 7-membered heterocycloalkyl when n is 1 or 2.</div>
    </li> <li> <para-num num="[0153]"> </para-num> <div id="p-0164" num="0153" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (IA):</div>
    </li> <li> <div id="p-0165" num="0000" class="description-line">
      <chemistry id="CHEM-US-00007" num="00007">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/b6/81/4794a669027404/US20170210697A1-20170727-C00007.png"><img id="EMI-C00007" he="21.42mm" wi="54.86mm" file="US20170210697A1-20170727-C00007.TIF" alt="Figure US20170210697A1-20170727-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="86" alt="Figure US20170210697A1-20170727-C00007" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/b6/81/4794a669027404/US20170210697A1-20170727-C00007.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US20170210697A1-20170727-C00007.CDX"> </attachment>
          <attachment idref="CHEM-US-00007" attachment-type="mol" file="US20170210697A1-20170727-C00007.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0166" num="0000" class="description-line">or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; m is selected from 5, 6, 7, 8, and 9; M<sub>1 </sub>is a bond or M; R<sub>4 </sub>is unsubstituted C<sub>1-3 </sub>alkyl, or (CH<sub>2</sub>)<sub>n</sub>Q, in which Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)R<sub>8</sub>, NHC(NR<sub>9</sub>)N(R)<sub>2</sub>, NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M are independently selected
<br/>
from C(O)O, OC(O), C(O)N(R), P(O)(OR)O, SS, an aryl group, and a heteroaryl group; and R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, and C<sub>2-14 </sub>alkenyl. For example, m is 5, 7, or 9. For example, Q is OH, NHC(S)N(R)<sub>2</sub>, or NHC(O)N(R)<sub>2</sub>. For example, Q is N(R)C(O)R, or N(R)S(O)<sub>2</sub>R.
</div>
    </li> <li> <para-num num="[0154]"> </para-num> <div id="p-0167" num="0154" class="description-line">In certain embodiments, a subset of compounds of Formula (I) includes those of Formula (II):</div>
    </li> <li> <div id="p-0168" num="0000" class="description-line">
      <chemistry id="CHEM-US-00008" num="00008">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/45/1c/42/c8ab58b0c7286d/US20170210697A1-20170727-C00008.png"><img id="EMI-C00008" he="29.72mm" wi="65.36mm" file="US20170210697A1-20170727-C00008.TIF" alt="Figure US20170210697A1-20170727-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="261" height="119" alt="Figure US20170210697A1-20170727-C00008" class="patent-full-image" src="https://patentimages.storage.googleapis.com/45/1c/42/c8ab58b0c7286d/US20170210697A1-20170727-C00008.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US20170210697A1-20170727-C00008.CDX"> </attachment>
          <attachment idref="CHEM-US-00008" attachment-type="mol" file="US20170210697A1-20170727-C00008.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0169" num="0000" class="description-line">or a salt or isomer thereof, wherein 1 is selected from 1, 2, 3, 4, and 5; M<sub>1 </sub>is a bond or M; R<sub>4 </sub>is unsubstituted C<sub>1-3 </sub>alkyl, or (CH<sub>2</sub>)<sub>n</sub>Q, in which n is 2, 3, or 4, and Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)R<sub>8</sub>, NHC(NR<sub>9</sub>)N(R)<sub>2</sub>, NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, heteroaryl or heterocycloalkyl; M and M are independently selected
<br/>
from C(O)O, OC(O), C(O)N(R), P(O)(OR)O, SS, an aryl group, and a heteroaryl group; and R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of H, C<sub>1-14 </sub>alkyl, and C<sub>2-14 </sub>alkenyl.
</div>
    </li> <li> <para-num num="[0155]"> </para-num> <div id="p-0170" num="0155" class="description-line">The compounds of any one of formula (I) or (IA) include one or more of the following features when applicable.</div>
    </li> <li> <para-num num="[0156]"> </para-num> <div id="p-0171" num="0156" class="description-line">In some embodiments, M<sub>1 </sub>is M.</div>
    </li> <li> <para-num num="[0157]"> </para-num> <div id="p-0172" num="0157" class="description-line">In some embodiments, M and M are independently C(O)O or OC(O).</div>
    </li> <li> <para-num num="[0158]"> </para-num> <div id="p-0173" num="0158" class="description-line">In some embodiments, at least one of M and M is C(O)O or OC(O).</div>
    </li> <li> <para-num num="[0159]"> </para-num> <div id="p-0174" num="0159" class="description-line">In some embodiments, M and M are independently SS.</div>
    </li> <li> <para-num num="[0160]"> </para-num> <div id="p-0175" num="0160" class="description-line">In some embodiments, at least one of M and M is SS.</div>
    </li> <li> <para-num num="[0161]"> </para-num> <div id="p-0176" num="0161" class="description-line">In some embodiments, one of M and M is C(O)O or OC(O) and the other is SS. For example, M is C(O)O or OC(O) and M is SS or M is C(O)O or OC(O) and M is SS.</div>
    </li> <li> <para-num num="[0162]"> </para-num> <div id="p-0177" num="0162" class="description-line">In some embodiments, 1 is 1, 3, or 5.</div>
    </li> <li> <para-num num="[0163]"> </para-num> <div id="p-0178" num="0163" class="description-line">In some embodiments, R<sub>4 </sub>is unsubstituted methyl or (CH<sub>2</sub>)<sub>n</sub>Q, in which Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, or N(R)S(O)<sub>2</sub>R.</div>
    </li> <li> <para-num num="[0164]"> </para-num> <div id="p-0179" num="0164" class="description-line">In some embodiments, Q is OH.</div>
    </li> <li> <para-num num="[0165]"> </para-num> <div id="p-0180" num="0165" class="description-line">In some embodiments, Q is NHC(S)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0166]"> </para-num> <div id="p-0181" num="0166" class="description-line">In some embodiments, Q is NHC(O)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0167]"> </para-num> <div id="p-0182" num="0167" class="description-line">In some embodiments, Q is N(R)C(O)R.</div>
    </li> <li> <para-num num="[0168]"> </para-num> <div id="p-0183" num="0168" class="description-line">In some embodiments, Q is N(R)S(O)<sub>2</sub>R.</div>
    </li> <li> <para-num num="[0169]"> </para-num> <div id="p-0184" num="0169" class="description-line">In some embodiments, Q is O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0170]"> </para-num> <div id="p-0185" num="0170" class="description-line">In some embodiments, Q is O(CH<sub>2</sub>)<sub>n</sub>OR.</div>
    </li> <li> <para-num num="[0171]"> </para-num> <div id="p-0186" num="0171" class="description-line">In some embodiments, Q is N(R)R<sub>8</sub>.</div>
    </li> <li> <para-num num="[0172]"> </para-num> <div id="p-0187" num="0172" class="description-line">In some embodiments, Q is NHC(NR<sub>9</sub>)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0173]"> </para-num> <div id="p-0188" num="0173" class="description-line">In some embodiments, Q is NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0174]"> </para-num> <div id="p-0189" num="0174" class="description-line">In some embodiments, Q is OC(O)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0175]"> </para-num> <div id="p-0190" num="0175" class="description-line">In some embodiments, Q is N(R)C(O)OR.</div>
    </li> <li> <para-num num="[0176]"> </para-num> <div id="p-0191" num="0176" class="description-line">In some embodiments, n is 2.</div>
    </li> <li> <para-num num="[0177]"> </para-num> <div id="p-0192" num="0177" class="description-line">In some embodiments, n is 3.</div>
    </li> <li> <para-num num="[0178]"> </para-num> <div id="p-0193" num="0178" class="description-line">In some embodiments, n is 4.</div>
    </li> <li> <para-num num="[0179]"> </para-num> <div id="p-0194" num="0179" class="description-line">In some embodiments, M<sub>1 </sub>is absent.</div>
    </li> <li> <para-num num="[0180]"> </para-num> <div id="p-0195" num="0180" class="description-line">In some embodiments, R is C<sub>1-18 </sub>alkyl, C<sub>2-18 </sub>alkenyl, R*YR, or YR.</div>
    </li> <li> <para-num num="[0181]"> </para-num> <div id="p-0196" num="0181" class="description-line">In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are independently C<sub>3-14 </sub>alkyl or C<sub>3-14 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0182]"> </para-num> <div id="p-0197" num="0182" class="description-line">In one embodiment, the compounds of Formula (I) are of Formula (IIa),</div>
    </li> <li> <div id="p-0198" num="0000" class="description-line">
      <chemistry id="CHEM-US-00009" num="00009">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/97/36/30ef8af31be4c4/US20170210697A1-20170727-C00009.png"><img id="EMI-C00009" he="28.11mm" wi="76.12mm" file="US20170210697A1-20170727-C00009.TIF" alt="Figure US20170210697A1-20170727-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="112" alt="Figure US20170210697A1-20170727-C00009" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/97/36/30ef8af31be4c4/US20170210697A1-20170727-C00009.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US20170210697A1-20170727-C00009.CDX"> </attachment>
          <attachment idref="CHEM-US-00009" attachment-type="mol" file="US20170210697A1-20170727-C00009.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0199" num="0000" class="description-line">or salts or isomers thereof, wherein R<sub>4 </sub>is as described herein.</div>
    </li> <li> <para-num num="[0183]"> </para-num> <div id="p-0200" num="0183" class="description-line">In another embodiment, the compounds of Formula (I) are of Formula (IIb),</div>
    </li> <li> <div id="p-0201" num="0000" class="description-line">
      <chemistry id="CHEM-US-00010" num="00010">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c2/d5/a8/cb8db7aa2761be/US20170210697A1-20170727-C00010.png"><img id="EMI-C00010" he="28.11mm" wi="76.12mm" file="US20170210697A1-20170727-C00010.TIF" alt="Figure US20170210697A1-20170727-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="112" alt="Figure US20170210697A1-20170727-C00010" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c2/d5/a8/cb8db7aa2761be/US20170210697A1-20170727-C00010.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US20170210697A1-20170727-C00010.CDX"> </attachment>
          <attachment idref="CHEM-US-00010" attachment-type="mol" file="US20170210697A1-20170727-C00010.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0202" num="0000" class="description-line">or salts or isomers thereof, wherein R<sub>4 </sub>is as described herein.</div>
    </li> <li> <para-num num="[0184]"> </para-num> <div id="p-0203" num="0184" class="description-line">In another embodiment, the compounds of Formula (I) are of Formula (IIc) or (IIe):</div>
    </li> <li> <div id="p-0204" num="0000" class="description-line">
      <chemistry id="CHEM-US-00011" num="00011">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/33/2d/24c76480e29ea2/US20170210697A1-20170727-C00011.png"><img id="EMI-C00011" he="62.40mm" wi="76.20mm" file="US20170210697A1-20170727-C00011.TIF" alt="Figure US20170210697A1-20170727-C00011" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="305" height="250" alt="Figure US20170210697A1-20170727-C00011" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/33/2d/24c76480e29ea2/US20170210697A1-20170727-C00011.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00011" attachment-type="cdx" file="US20170210697A1-20170727-C00011.CDX"> </attachment>
          <attachment idref="CHEM-US-00011" attachment-type="mol" file="US20170210697A1-20170727-C00011.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0205" num="0000" class="description-line">or salts or isomers thereof, wherein R<sub>4 </sub>is as described herein.</div>
    </li> <li> <para-num num="[0185]"> </para-num> <div id="p-0206" num="0185" class="description-line">In a further embodiment, the compounds of Formula (I) are of Formula (IId),</div>
    </li> <li> <div id="p-0207" num="0000" class="description-line">
      <chemistry id="CHEM-US-00012" num="00012">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a6/88/0f/34c3485d174268/US20170210697A1-20170727-C00012.png"><img id="EMI-C00012" he="34.29mm" wi="58.34mm" file="US20170210697A1-20170727-C00012.TIF" alt="Figure US20170210697A1-20170727-C00012" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="233" height="137" alt="Figure US20170210697A1-20170727-C00012" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a6/88/0f/34c3485d174268/US20170210697A1-20170727-C00012.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00012" attachment-type="cdx" file="US20170210697A1-20170727-C00012.CDX"> </attachment>
          <attachment idref="CHEM-US-00012" attachment-type="mol" file="US20170210697A1-20170727-C00012.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0208" num="0000" class="description-line">or salts or isomers thereof, wherein n is 2, 3, or 4; and m, R, R, and R<sub>2 </sub>through R<sub>6 </sub>are as described herein. For example, each of R<sub>2 </sub>and R<sub>3 </sub>may be independently selected from the group consisting of C<sub>5-14 </sub>alkyl and C<sub>5-14 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0186]"> </para-num> <div id="p-0209" num="0186" class="description-line">The compounds of any one of formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId), and (IIe) include one or more of the following features when applicable.</div>
    </li> <li> <para-num num="[0187]"> </para-num> <div id="p-0210" num="0187" class="description-line">In some embodiments, R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and -CQ(R)<sub>2</sub>, where Q is selected from a C<sub>3-6 </sub>carbocycle, 5- to 14-membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, N(R)<sub>2</sub>, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, and C(R)N(R)<sub>2</sub>C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5.</div>
    </li> <li> <para-num num="[0188]"> </para-num> <div id="p-0211" num="0188" class="description-line">In another embodiment, R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and -CQ(R)<sub>2</sub>, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, C(R)N(R)<sub>2</sub>C(O)OR, and a 5- to 14-membered heterocycloalkyl having one or more heteroatoms selected from N, O, and S which is substituted with one or more substituents selected from oxo (O), OH, amino, and C<sub>1-3 </sub>alkyl, and each n is independently selected from 1, 2, 3, 4, and 5.</div>
    </li> <li> <para-num num="[0189]"> </para-num> <div id="p-0212" num="0189" class="description-line">In another embodiment, R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and -CQ(R)<sub>2</sub>, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heterocycle having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, C(R)N(R)<sub>2</sub>C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5; and when Q is a 5- to 14-membered heterocycle and (i) R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q in which n is 1 or 2, or (ii) R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>CHQR in which n is 1, or (iii) R<sub>4 </sub>is CHQR, and -CQ(R)<sub>2</sub>, then Q is either a 5- to 14-membered heteroaryl or 8- to 14-membered heterocycloalkyl.</div>
    </li> <li> <para-num num="[0190]"> </para-num> <div id="p-0213" num="0190" class="description-line">In another embodiment, R<sub>4 </sub>is selected from the group consisting of a C<sub>3-6 </sub>carbocycle, (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and -CQ(R)<sub>2</sub>, where Q is selected from a C<sub>3-6 </sub>carbocycle, a 5- to 14-membered heteroaryl having one or more heteroatoms selected from N, O, and S, OR, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, C(O)OR, OC(O)R, CX<sub>3</sub>, CX<sub>2</sub>H, CXH<sub>2</sub>, CN, C(O)N(R)<sub>2</sub>, N(R)C(O)R, N(R)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(R)C(S)N(R)<sub>2</sub>, C(R)N(R)<sub>2</sub>C(O)OR, and each n is independently selected from 1, 2, 3, 4, and 5.</div>
    </li> <li> <para-num num="[0191]"> </para-num> <div id="p-0214" num="0191" class="description-line">In another embodiment, R<sub>4 </sub>is unsubstituted C<sub>1-4 </sub>alkyl, e.g., unsubstituted methyl.</div>
    </li> <li> <para-num num="[0192]"> </para-num> <div id="p-0215" num="0192" class="description-line">In certain embodiments, the disclosure provides a compound having the Formula (I), wherein R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q or (CH<sub>2</sub>)<sub>n</sub>CHQR, where Q is N(R)<sub>2</sub>, and n is selected from 3, 4, and 5.</div>
    </li> <li> <para-num num="[0193]"> </para-num> <div id="p-0216" num="0193" class="description-line">In certain embodiments, the disclosure provides a compound having the Formula (I), wherein R<sub>4 </sub>is selected from the group consisting of (CH<sub>2</sub>)<sub>n</sub>Q, (CH<sub>2</sub>)<sub>n</sub>CHQR, CHQR, and -CQ(R)<sub>2</sub>, where Q is N(R)<sub>2</sub>, and n is selected from 1, 2, 3, 4, and 5.</div>
    </li> <li> <para-num num="[0194]"> </para-num> <div id="p-0217" num="0194" class="description-line">In certain embodiments, the disclosure provides a compound having the Formula (I), wherein R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of C<sub>2-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle, and R<sub>4 </sub>is (CH<sub>2</sub>)<sub>n</sub>Q or (CH<sub>2</sub>)<sub>n</sub>CHQR, where Q is N(R)<sub>2</sub>, and n is selected from 3, 4, and 5.</div>
    </li> <li> <para-num num="[0195]"> </para-num> <div id="p-0218" num="0195" class="description-line">In certain embodiments, R<sub>2 </sub>and R<sub>3 </sub>are independently selected from the group consisting of C<sub>2-14 </sub>alkyl, C<sub>2-14 </sub>alkenyl, R*YR, YR, and R*OR, or R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle.</div>
    </li> <li> <para-num num="[0196]"> </para-num> <div id="p-0219" num="0196" class="description-line">In some embodiments, R<sub>1 </sub>is selected from the group consisting of C<sub>5-20 </sub>alkyl and C<sub>5-20 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0197]"> </para-num> <div id="p-0220" num="0197" class="description-line">In other embodiments, R<sub>1 </sub>is selected from the group consisting of R*YR, YR, and RMR.</div>
    </li> <li> <para-num num="[0198]"> </para-num> <div id="p-0221" num="0198" class="description-line">In certain embodiments, R<sub>1 </sub>is selected from R*YR and YR. In some embodiments, Y is a cyclopropyl group. In some embodiments, R* is C<sub>8 </sub>alkyl or C<sub>8 </sub>alkenyl. In certain embodiments, R is C<sub>3-12 </sub>alkyl. For example, R may be C<sub>3 </sub>alkyl. For example, R may be C<sub>4-8 </sub>alkyl (e.g., C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7</sub>, or C<sub>8 </sub>alkyl).</div>
    </li> <li> <para-num num="[0199]"> </para-num> <div id="p-0222" num="0199" class="description-line">In some embodiments, R<sub>1 </sub>is C<sub>5-20 </sub>alkyl. In some embodiments, R<sub>1 </sub>is C<sub>6 </sub>alkyl. In some embodiments, R<sub>1 </sub>is C<sub>8 </sub>alkyl. In other embodiments, R<sub>1 </sub>is C<sub>9 </sub>alkyl. In certain embodiments, R<sub>1 </sub>is C<sub>14 </sub>alkyl. In other embodiments, R<sub>1 </sub>is C<sub>18 </sub>alkyl.</div>
    </li> <li> <para-num num="[0200]"> </para-num> <div id="p-0223" num="0200" class="description-line">In some embodiments, R<sub>1 </sub>is C<sub>21-30 </sub>alkyl. In some embodiments, R<sub>1 </sub>is C<sub>26 </sub>alkyl. In some embodiments, R<sub>1 </sub>is C<sub>28 </sub>alkyl. In certain embodiments, R<sub>1 </sub>is</div>
    </li> <li> <div id="p-0224" num="0000" class="description-line">
      <chemistry id="CHEM-US-00013" num="00013">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ce/81/1c/e2cf69c5c44de5/US20170210697A1-20170727-C00013.png"><img id="EMI-C00013" he="23.37mm" wi="75.18mm" file="US20170210697A1-20170727-C00013.TIF" alt="Figure US20170210697A1-20170727-C00013" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="93" alt="Figure US20170210697A1-20170727-C00013" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ce/81/1c/e2cf69c5c44de5/US20170210697A1-20170727-C00013.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00013" attachment-type="cdx" file="US20170210697A1-20170727-C00013.CDX"> </attachment>
          <attachment idref="CHEM-US-00013" attachment-type="mol" file="US20170210697A1-20170727-C00013.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0201]"> </para-num> <div id="p-0225" num="0201" class="description-line">In some embodiments, R<sub>1 </sub>is C<sub>5-20 </sub>alkenyl. In certain embodiments, R<sub>1 </sub>is C<sub>18 </sub>alkenyl. In some embodiments, R<sub>1 </sub>is linoleyl.</div>
    </li> <li> <para-num num="[0202]"> </para-num> <div id="p-0226" num="0202" class="description-line">In certain embodiments, R<sub>1 </sub>is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl, or heptadeca-9-yl). In certain embodiments, R<sub>1 </sub>is</div>
    </li> <li> <div id="p-0227" num="0000" class="description-line">
      <chemistry id="CHEM-US-00014" num="00014">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/84/6b/017299b83af4d1/US20170210697A1-20170727-C00014.png"><img id="EMI-C00014" he="13.72mm" wi="53.51mm" file="US20170210697A1-20170727-C00014.TIF" alt="Figure US20170210697A1-20170727-C00014" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="214" height="55" alt="Figure US20170210697A1-20170727-C00014" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/84/6b/017299b83af4d1/US20170210697A1-20170727-C00014.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00014" attachment-type="cdx" file="US20170210697A1-20170727-C00014.CDX"> </attachment>
          <attachment idref="CHEM-US-00014" attachment-type="mol" file="US20170210697A1-20170727-C00014.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0203]"> </para-num> <div id="p-0228" num="0203" class="description-line">In certain embodiments, R<sub>1 </sub>is unsubstituted C<sub>5-20 </sub>alkyl or C<sub>5-20 </sub>alkenyl. In certain embodiments, R is substituted C<sub>5-20 </sub>alkyl or C<sub>5-20 </sub>alkenyl (e.g., substituted with a C<sub>3-6 </sub>carbocycle such as 1-cyclopropylnonyl or substituted with OH or alkoxy). For example, R<sub>1 </sub>is</div>
    </li> <li> <div id="p-0229" num="0000" class="description-line">
      <chemistry id="CHEM-US-00015" num="00015">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/c3/cf/a0b8962d43ec36/US20170210697A1-20170727-C00015.png"><img id="EMI-C00015" he="11.94mm" wi="75.18mm" file="US20170210697A1-20170727-C00015.TIF" alt="Figure US20170210697A1-20170727-C00015" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="48" alt="Figure US20170210697A1-20170727-C00015" class="patent-full-image" src="https://patentimages.storage.googleapis.com/31/c3/cf/a0b8962d43ec36/US20170210697A1-20170727-C00015.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00015" attachment-type="cdx" file="US20170210697A1-20170727-C00015.CDX"> </attachment>
          <attachment idref="CHEM-US-00015" attachment-type="mol" file="US20170210697A1-20170727-C00015.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0204]"> </para-num> <div id="p-0230" num="0204" class="description-line">In other embodiments, R<sub>1 </sub>is RMR.</div>
    </li> <li> <para-num num="[0205]"> </para-num> <div id="p-0231" num="0205" class="description-line">In some embodiments, R is selected from R*YR and YR. In some embodiments, Y is C<sub>3-8 </sub>cycloalkyl. In some embodiments, Y is C<sub>6-10 </sub>aryl. In some embodiments, Y is a cyclopropyl group. In some embodiments, Y is a cyclohexyl group. In certain embodiments, R* is C<sub>1 </sub>alkyl.</div>
    </li> <li> <para-num num="[0206]"> </para-num> <div id="p-0232" num="0206" class="description-line">In some embodiments, R is selected from the group consisting of C<sub>3-12 </sub>alkyl and C<sub>3-12 </sub>alkenyl. In some embodiments, R adjacent to Y is C<sub>1 </sub>alkyl. In some embodiments, R adjacent to Y is C<sub>4-9 </sub>alkyl (e.g., C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, C<sub>7 </sub>or C<sub>8 </sub>or C<sub>9 </sub>alkyl).</div>
    </li> <li> <para-num num="[0207]"> </para-num> <div id="p-0233" num="0207" class="description-line">In some embodiments, R is selected from C<sub>4 </sub>alkyl and C<sub>4 </sub>alkenyl. In certain embodiments, R is selected from C<sub>5 </sub>alkyl and C<sub>5 </sub>alkenyl. In some embodiments, R is selected from C<sub>6 </sub>alkyl and C<sub>6 </sub>alkenyl. In some embodiments, R is selected from C<sub>7 </sub>alkyl and C<sub>7 </sub>alkenyl. In some embodiments, R is selected from C<sub>9 </sub>alkyl and C<sub>9 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0208]"> </para-num> <div id="p-0234" num="0208" class="description-line">In other embodiments, R is selected from C<sub>11 </sub>alkyl and C<sub>11 </sub>alkenyl. In other embodiments, R is selected from C<sub>12 </sub>alkyl, C<sub>12 </sub>alkenyl, C<sub>13 </sub>alkyl, C<sub>13 </sub>alkenyl, C<sub>14 </sub>alkyl, C<sub>14 </sub>alkenyl, C<sub>15 </sub>alkyl, C<sub>15 </sub>alkenyl, C<sub>16 </sub>alkyl, C<sub>16 </sub>alkenyl, C<sub>17 </sub>alkyl, C<sub>17 </sub>alkenyl, C<sub>18 </sub>alkyl, and C<sub>18 </sub>alkenyl. In certain embodiments, R is branched (e.g., decan-2-yl, undecan-3-yl, dodecan-4-yl, tridecan-5-yl, tetradecan-6-yl, 2-methylundecan-3-yl, 2-methyldecan-2-yl, 3-methylundecan-3-yl, 4-methyldodecan-4-yl or heptadeca-9-yl). In certain embodiments, R is</div>
    </li> <li> <div id="p-0235" num="0000" class="description-line">
      <chemistry id="CHEM-US-00016" num="00016">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/41/64/9b/0b5b5ae324862a/US20170210697A1-20170727-C00016.png"><img id="EMI-C00016" he="13.72mm" wi="53.42mm" file="US20170210697A1-20170727-C00016.TIF" alt="Figure US20170210697A1-20170727-C00016" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="214" height="55" alt="Figure US20170210697A1-20170727-C00016" class="patent-full-image" src="https://patentimages.storage.googleapis.com/41/64/9b/0b5b5ae324862a/US20170210697A1-20170727-C00016.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00016" attachment-type="cdx" file="US20170210697A1-20170727-C00016.CDX"> </attachment>
          <attachment idref="CHEM-US-00016" attachment-type="mol" file="US20170210697A1-20170727-C00016.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0209]"> </para-num> <div id="p-0236" num="0209" class="description-line">In certain embodiments, R is unsubstituted C<sub>1-18 </sub>alkyl. In certain embodiments, R is substituted C<sub>1-18 </sub>alkyl (e.g., C<sub>1-15 </sub>alkyl substituted with, e.g., an alkoxy such as methoxy, or a C<sub>3-6 </sub>carbocycle such as 1-cyclopropylnonyl, or C(O)O-alkyl or OC(O)-alkyl such as C(O)OCH<sub>3 </sub>or OC(O)CH<sub>3</sub>). For example, R is</div>
    </li> <li> <div id="p-0237" num="0000" class="description-line">
      <chemistry id="CHEM-US-00017" num="00017">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/e2/a7/6089030a7f67fd/US20170210697A1-20170727-C00017.png"><img id="EMI-C00017" he="81.36mm" wi="52.32mm" file="US20170210697A1-20170727-C00017.TIF" alt="Figure US20170210697A1-20170727-C00017" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="325" alt="Figure US20170210697A1-20170727-C00017" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/e2/a7/6089030a7f67fd/US20170210697A1-20170727-C00017.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00017" attachment-type="cdx" file="US20170210697A1-20170727-C00017.CDX"> </attachment>
          <attachment idref="CHEM-US-00017" attachment-type="mol" file="US20170210697A1-20170727-C00017.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0210]"> </para-num> <div id="p-0238" num="0210" class="description-line">In some embodiments, R is selected from the group consisting of C<sub>3-14 </sub>alkyl and C<sub>3-14 </sub>alkenyl. In some embodiments, R is C<sub>3 </sub>alkyl, C<sub>4 </sub>alkyl, C<sub>5 </sub>alkyl, C<sub>6 </sub>alkyl, C<sub>7 </sub>alkyl, or C<sub>8 </sub>alkyl. In some embodiments, R is C<sub>9 </sub>alkyl, C<sub>10 </sub>alkyl, C<sub>11 </sub>alkyl, C<sub>12 </sub>alkyl, C<sub>13 </sub>alkyl, or C<sub>14 </sub>alkyl.</div>
    </li> <li> <para-num num="[0211]"> </para-num> <div id="p-0239" num="0211" class="description-line">In some embodiments, M is C(O)O. In some embodiments, M is OC(O).</div>
    </li> <li> <para-num num="[0212]"> </para-num> <div id="p-0240" num="0212" class="description-line">In other embodiments, M is an aryl group or heteroaryl group. For example, M may be selected from the group consisting of phenyl, oxazole, and thiazole.</div>
    </li> <li> <para-num num="[0213]"> </para-num> <div id="p-0241" num="0213" class="description-line">In some embodiments, M is C(O)O. In some embodiments, M is OC(O). In some embodiments, M is C(O)N(R). In some embodiments, M is P(O)(OR)O.</div>
    </li> <li> <para-num num="[0214]"> </para-num> <div id="p-0242" num="0214" class="description-line">In other embodiments, M is an aryl group or heteroaryl group. For example, M may be selected from the group consisting of phenyl, oxazole, and thiazole.</div>
    </li> <li> <para-num num="[0215]"> </para-num> <div id="p-0243" num="0215" class="description-line">In some embodiments, M is the same as M. In other embodiments, M is different from M.</div>
    </li> <li> <para-num num="[0216]"> </para-num> <div id="p-0244" num="0216" class="description-line">In some embodiments, each R<sub>5 </sub>is H. In certain such embodiments, each R<sub>6 </sub>is also H.</div>
    </li> <li> <para-num num="[0217]"> </para-num> <div id="p-0245" num="0217" class="description-line">In some embodiments, R<sub>7 </sub>is H. In other embodiments, R<sub>7 </sub>is C<sub>1-3 </sub>alkyl (e.g., methyl, ethyl, propyl, or i-propyl).</div>
    </li> <li> <para-num num="[0218]"> </para-num> <div id="p-0246" num="0218" class="description-line">In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are independently C<sub>5-14 </sub>alkyl or C<sub>5-14 </sub>alkenyl.</div>
    </li> <li> <para-num num="[0219]"> </para-num> <div id="p-0247" num="0219" class="description-line">In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are the same. In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>8 </sub>alkyl. In certain embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>2 </sub>alkyl. In other embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>3 </sub>alkyl. In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>4 </sub>alkyl. In certain embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>5 </sub>alkyl. In other embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>6 </sub>alkyl. In some embodiments, R<sub>2 </sub>and R<sub>3 </sub>are C<sub>7 </sub>alkyl.</div>
    </li> <li> <para-num num="[0220]"> </para-num> <div id="p-0248" num="0220" class="description-line">In other embodiments, R<sub>2 </sub>and R<sub>3 </sub>are different. In certain embodiments, R<sub>2 </sub>is C<sub>8 </sub>alkyl. In some embodiments, R<sub>3 </sub>is C<sub>1-7 </sub>(e.g., C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub>, C<sub>6</sub>, or C<sub>7 </sub>alkyl) or C<sub>9 </sub>alkyl.</div>
    </li> <li> <para-num num="[0221]"> </para-num> <div id="p-0249" num="0221" class="description-line">In some embodiments, R<sub>7 </sub>and R<sub>3 </sub>are H.</div>
    </li> <li> <para-num num="[0222]"> </para-num> <div id="p-0250" num="0222" class="description-line">In certain embodiments, R<sub>2 </sub>is H.</div>
    </li> <li> <para-num num="[0223]"> </para-num> <div id="p-0251" num="0223" class="description-line">In some embodiments, m is 5, 7, or 9.</div>
    </li> <li> <para-num num="[0224]"> </para-num> <div id="p-0252" num="0224" class="description-line">In some embodiments, R<sub>4 </sub>is selected from (CH<sub>2</sub>)<sub>n</sub>Q and (CH<sub>2</sub>)<sub>n</sub>CHQR.</div>
    </li> <li> <para-num num="[0225]"> </para-num> <div id="p-0253" num="0225" class="description-line">In some embodiments, Q is selected from the group consisting of OR, OH, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, OC(O)R, CX<sub>3</sub>, CN, N(R)C(O)R, N(H)C(O)R, N(R)S(O)<sub>2</sub>R, N(H)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(H)C(O)N(R)<sub>2</sub>, N(H)C(O)N(H)(R), N(R)C(S)N(R)<sub>2</sub>, N(H)C(S)N(R)<sub>2</sub>, N(H)C(S)N(H)(R), C(R)N(R)<sub>2</sub>C(O)OR, a carbocycle, and a heterocycle.</div>
    </li> <li> <para-num num="[0226]"> </para-num> <div id="p-0254" num="0226" class="description-line">In certain embodiments, Q is N(R)R<sub>8</sub>, O(CH<sub>2</sub>)<sub>n</sub>OR, N(R)C(NR<sub>9</sub>)N(R)<sub>2</sub>, N(R)C(CHR<sub>9</sub>)N(R)<sub>2</sub>, OC(O)N(R)<sub>2</sub>, or N(R)C(O)OR.</div>
    </li> <li> <para-num num="[0227]"> </para-num> <div id="p-0255" num="0227" class="description-line">In certain embodiments, Q is N(OR)C(O)R, N(OR)S(O)<sub>2</sub>R, N(OR)C(O)OR, N(OR)C(O)N(R)<sub>2</sub>, N(OR)C(S)N(R)<sub>2</sub>, N(OR)C(NR<sub>9</sub>)N(R)<sub>2</sub>, or N(OR)C(CHR<sub>9</sub>)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0228]"> </para-num> <div id="p-0256" num="0228" class="description-line">In certain embodiments, Q is thiourea or an isostere thereof, e.g.,</div>
    </li> <li> <div id="p-0257" num="0000" class="description-line">
      <chemistry id="CHEM-US-00018" num="00018">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/76/b9/b3/274e9a9731f2b4/US20170210697A1-20170727-C00018.png"><img id="EMI-C00018" he="13.12mm" wi="23.54mm" file="US20170210697A1-20170727-C00018.TIF" alt="Figure US20170210697A1-20170727-C00018" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="94" height="52" alt="Figure US20170210697A1-20170727-C00018" class="patent-full-image" src="https://patentimages.storage.googleapis.com/76/b9/b3/274e9a9731f2b4/US20170210697A1-20170727-C00018.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00018" attachment-type="cdx" file="US20170210697A1-20170727-C00018.CDX"> </attachment>
          <attachment idref="CHEM-US-00018" attachment-type="mol" file="US20170210697A1-20170727-C00018.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0258" num="0000" class="description-line">or NHC(NR<sub>9</sub>)N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0229]"> </para-num> <div id="p-0259" num="0229" class="description-line">In certain embodiments, Q is C(NR<sub>9</sub>)N(R)<sub>2</sub>. For example, when Q is C(NR<sub>9</sub>)N(R)<sub>2</sub>, n is 4 or 5. For example, R<sub>9 </sub>is S(O)<sub>2</sub>N(R)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0230]"> </para-num> <div id="p-0260" num="0230" class="description-line">In certain embodiments, Q is C(NR<sub>9</sub>)R or C(O)N(R)OR, e.g., CH(NOCH<sub>3</sub>), C(O)NHOH, C(O)NHOCH<sub>3</sub>, C(O)N(CH<sub>3</sub>)OH, or C(O)N(CH<sub>3</sub>)OCH<sub>3</sub>.</div>
    </li> <li> <para-num num="[0231]"> </para-num> <div id="p-0261" num="0231" class="description-line">In certain embodiments, Q is OH.</div>
    </li> <li> <para-num num="[0232]"> </para-num> <div id="p-0262" num="0232" class="description-line">In certain embodiments, Q is a substituted or unsubstituted 5- to 10-membered heteroaryl, e.g., Q is a triazole, an imidazole, a pyrimidine, a purine, 2-amino-1,9-dihydro-6H-purin-6-one-9-yl (or guanin-9-yl), adenin-9-yl, cytosin-1-yl, or uracil-1-yl, each of which is optionally substituted with one or more substituents selected from alkyl, OH, alkoxy, -alkyl-OH, -alkyl-O-alkyl, and the substituent can be further substituted. In certain embodiments, Q is a substituted 5- to 14-membered heterocycloalkyl, e.g., substituted with one or more substituents selected from oxo (O), OH, amino, mono- or di-alkylamino, and C<sub>1-3 </sub>alkyl. For example, Q is 4-methylpiperazinyl, 4-(4-methoxybenzyl)piperazinyl, isoindolin-2-yl-1,3-dione, pyrrolidin-1-yl-2,5-dione, or imidazolidin-3-yl-2,4-dione.</div>
    </li> <li> <para-num num="[0233]"> </para-num> <div id="p-0263" num="0233" class="description-line">In certain embodiments, Q is NHR<sub>8</sub>, in which R<sub>8 </sub>is a C<sub>3-6 </sub>cycloalkyl optionally substituted with one or more substituents selected from oxo (O), amino (NH<sub>2</sub>), mono- or di-alkylamino, C<sub>1-3 </sub>alkyl and halo. For example, R<sub>8 </sub>is cyclobutenyl, e.g., 3-(dimethylamino)-cyclobut-3-ene-4-yl-1,2-dione.</div>
    </li> <li> <para-num num="[0234]"> </para-num> <div id="p-0264" num="0234" class="description-line">In certain embodiments, Q is NHR<sub>8</sub>, in which R<sub>8 </sub>is a heteroaryl optionally substituted with one or more substituents selected from amino (NH<sub>2</sub>), mono- or di-alkylamino, C<sub>1-3 </sub>alkyl and halo. For example, R<sub>8 </sub>is thiazole or imidazole.</div>
    </li> <li> <para-num num="[0235]"> </para-num> <div id="p-0265" num="0235" class="description-line">In certain embodiments, Q is NHC(NR<sub>9</sub>)N(R)<sub>2 </sub>in which R<sub>9 </sub>is CN, C<sub>1-6 </sub>alkyl, NO<sub>2</sub>, S(O)<sub>2</sub>N(R)<sub>2</sub>, OR, S(O)<sub>2</sub>R, or H. For example, Q is NHC(NR<sub>9</sub>)N(CH<sub>3</sub>)<sub>2</sub>, NHC(NR<sub>9</sub>)NHCH<sub>3</sub>, NHC(NR<sub>9</sub>)NH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0236]"> </para-num> <div id="p-0266" num="0236" class="description-line">In certain embodiments, Q is NHC(CHR<sub>9</sub>)N(R)<sub>2</sub>, in which R<sub>9 </sub>is NO<sub>2</sub>, CN, C<sub>1-6 </sub>alkyl, S(O)<sub>2</sub>N(R)<sub>2</sub>, OR, S(O)<sub>2</sub>R, or H. For example, Q is NHC(CHR<sub>9</sub>)N(CH<sub>3</sub>)<sub>2</sub>, NHC(CHR<sub>9</sub>)NHCH<sub>3</sub>, or NHC(CHR<sub>9</sub>)NH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0237]"> </para-num> <div id="p-0267" num="0237" class="description-line">In certain embodiments, Q is OC(O)N(R)<sub>2</sub>, N(R)C(O)OR, N(OR)C(O)OR, such as OC(O)NHCH<sub>3</sub>, N(OH)C(O)OCH<sub>3</sub>, N(OH)C(O)CH<sub>3</sub>, N(OCH<sub>3</sub>)C(O)OCH<sub>3</sub>, N(OCH<sub>3</sub>)C(O)CH<sub>3</sub>, N(OH)S(O)<sub>2</sub>CH<sub>3</sub>, or NHC(O)OCH<sub>3</sub>.</div>
    </li> <li> <para-num num="[0238]"> </para-num> <div id="p-0268" num="0238" class="description-line">In certain embodiments, Q is an unsubstituted or substituted C<sub>6-10 </sub>aryl (such as phenyl) or C<sub>3-6 </sub>cycloalkyl.</div>
    </li> <li> <para-num num="[0239]"> </para-num> <div id="p-0269" num="0239" class="description-line">In some embodiments, n is 1. In other embodiments, n is 2. In further embodiments, n is 3. In certain other embodiments, n is 4. For example, R<sub>4 </sub>may be (CH<sub>2</sub>)<sub>2</sub>OH. For example, R<sub>4 </sub>may be (CH<sub>2</sub>)<sub>30</sub>H. For example, R<sub>4 </sub>may be (CH<sub>2</sub>)<sub>40</sub>H. For example, R<sub>4 </sub>may be benzyl. For example, R<sub>4 </sub>may be 4-methoxybenzyl.</div>
    </li> <li> <para-num num="[0240]"> </para-num> <div id="p-0270" num="0240" class="description-line">In some embodiments, R<sub>4 </sub>is a C<sub>3-6 </sub>carbocycle. In some embodiments, R<sub>4 </sub>is a C<sub>3-6 </sub>cycloalkyl. For example, R<sub>4 </sub>may be cyclohexyl optionally substituted with e.g., OH, halo, C<sub>1-6 </sub>alkyl, etc. For example, R<sub>4 </sub>may be 2-hydroxycyclohexyl.</div>
    </li> <li> <para-num num="[0241]"> </para-num> <div id="p-0271" num="0241" class="description-line">In some embodiments, R is H.</div>
    </li> <li> <para-num num="[0242]"> </para-num> <div id="p-0272" num="0242" class="description-line">In some embodiments, R is unsubstituted C<sub>1-3 </sub>alkyl or unsubstituted C<sub>2-3 </sub>alkenyl. For example, R<sub>4 </sub>may be CH<sub>2</sub>CH(OH)CH<sub>3</sub>, CH(CH<sub>3</sub>)CH<sub>2</sub>OH, or CH<sub>2</sub>CH(OH)CH<sub>2</sub>CH<sub>3</sub>.</div>
    </li> <li> <para-num num="[0243]"> </para-num> <div id="p-0273" num="0243" class="description-line">In some embodiments, R is substituted C<sub>1-3 </sub>alkyl, e.g., CH<sub>2</sub>OH. For example, R<sub>4 </sub>may be CH<sub>2</sub>CH(OH)CH<sub>2</sub>OH, (CH<sub>2</sub>)<sub>3</sub>NHC(O)CH<sub>2</sub>OH, (CH<sub>2</sub>)<sub>3</sub>NHC(O)CH<sub>2</sub>OBn, (CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>OH, or CH(CH<sub>2</sub>OH)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0244]"> </para-num> <div id="p-0274" num="0244" class="description-line">In some embodiments, R<sub>4 </sub>is selected from any of the following groups:</div>
    </li> <li> <div id="p-0275" num="0000" class="description-line">
      <chemistry id="CHEM-US-00019" num="00019">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1c/88/29/7321bebae1b33b/US20170210697A1-20170727-C00019.png"><img id="EMI-C00019" he="218.78mm" wi="39.29mm" file="US20170210697A1-20170727-C00019.TIF" alt="Figure US20170210697A1-20170727-C00019" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="157" height="875" alt="Figure US20170210697A1-20170727-C00019" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1c/88/29/7321bebae1b33b/US20170210697A1-20170727-C00019.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00019" attachment-type="cdx" file="US20170210697A1-20170727-C00019.CDX"> </attachment>
          <attachment idref="CHEM-US-00019" attachment-type="mol" file="US20170210697A1-20170727-C00019.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00020" num="00020">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/cc/59/082cef0cc2e60d/US20170210697A1-20170727-C00020.png"><img id="EMI-C00020" he="229.53mm" wi="43.01mm" file="US20170210697A1-20170727-C00020.TIF" alt="Figure US20170210697A1-20170727-C00020" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="172" height="918" alt="Figure US20170210697A1-20170727-C00020" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/cc/59/082cef0cc2e60d/US20170210697A1-20170727-C00020.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00020" attachment-type="cdx" file="US20170210697A1-20170727-C00020.CDX"> </attachment>
          <attachment idref="CHEM-US-00020" attachment-type="mol" file="US20170210697A1-20170727-C00020.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00021" num="00021">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b6/3d/a9/4c7fc8b5b59b8b/US20170210697A1-20170727-C00021.png"><img id="EMI-C00021" he="238.08mm" wi="44.20mm" file="US20170210697A1-20170727-C00021.TIF" alt="Figure US20170210697A1-20170727-C00021" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="177" height="952" alt="Figure US20170210697A1-20170727-C00021" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b6/3d/a9/4c7fc8b5b59b8b/US20170210697A1-20170727-C00021.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00021" attachment-type="cdx" file="US20170210697A1-20170727-C00021.CDX"> </attachment>
          <attachment idref="CHEM-US-00021" attachment-type="mol" file="US20170210697A1-20170727-C00021.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00022" num="00022">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/11/23/72d466e3593393/US20170210697A1-20170727-C00022.png"><img id="EMI-C00022" he="236.05mm" wi="43.35mm" file="US20170210697A1-20170727-C00022.TIF" alt="Figure US20170210697A1-20170727-C00022" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="173" height="944" alt="Figure US20170210697A1-20170727-C00022" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/11/23/72d466e3593393/US20170210697A1-20170727-C00022.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00022" attachment-type="cdx" file="US20170210697A1-20170727-C00022.CDX"> </attachment>
          <attachment idref="CHEM-US-00022" attachment-type="mol" file="US20170210697A1-20170727-C00022.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00023" num="00023">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/09/07/3870abb59751e8/US20170210697A1-20170727-C00023.png"><img id="EMI-C00023" he="81.28mm" wi="52.24mm" file="US20170210697A1-20170727-C00023.TIF" alt="Figure US20170210697A1-20170727-C00023" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="325" alt="Figure US20170210697A1-20170727-C00023" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/09/07/3870abb59751e8/US20170210697A1-20170727-C00023.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00023" attachment-type="cdx" file="US20170210697A1-20170727-C00023.CDX"> </attachment>
          <attachment idref="CHEM-US-00023" attachment-type="mol" file="US20170210697A1-20170727-C00023.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0245]"> </para-num> <div id="p-0276" num="0245" class="description-line">In some embodiments, R<sub>4 </sub>is selected from any of the following groups:</div>
    </li> <li> <div id="p-0277" num="0000" class="description-line">
      <chemistry id="CHEM-US-00024" num="00024">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/e5/37/5faf77bc13582c/US20170210697A1-20170727-C00024.png"><img id="EMI-C00024" he="235.12mm" wi="41.15mm" file="US20170210697A1-20170727-C00024.TIF" alt="Figure US20170210697A1-20170727-C00024" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="165" height="940" alt="Figure US20170210697A1-20170727-C00024" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/e5/37/5faf77bc13582c/US20170210697A1-20170727-C00024.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00024" attachment-type="cdx" file="US20170210697A1-20170727-C00024.CDX"> </attachment>
          <attachment idref="CHEM-US-00024" attachment-type="mol" file="US20170210697A1-20170727-C00024.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00025" num="00025">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/d9/ef/02e086515f4853/US20170210697A1-20170727-C00025.png"><img id="EMI-C00025" he="235.03mm" wi="43.35mm" file="US20170210697A1-20170727-C00025.TIF" alt="Figure US20170210697A1-20170727-C00025" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="173" height="940" alt="Figure US20170210697A1-20170727-C00025" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/d9/ef/02e086515f4853/US20170210697A1-20170727-C00025.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00025" attachment-type="cdx" file="US20170210697A1-20170727-C00025.CDX"> </attachment>
          <attachment idref="CHEM-US-00025" attachment-type="mol" file="US20170210697A1-20170727-C00025.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00026" num="00026">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/33/32/0c/e7bfe9ee454bae/US20170210697A1-20170727-C00026.png"><img id="EMI-C00026" he="162.64mm" wi="52.15mm" file="US20170210697A1-20170727-C00026.TIF" alt="Figure US20170210697A1-20170727-C00026" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="651" alt="Figure US20170210697A1-20170727-C00026" class="patent-full-image" src="https://patentimages.storage.googleapis.com/33/32/0c/e7bfe9ee454bae/US20170210697A1-20170727-C00026.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00026" attachment-type="cdx" file="US20170210697A1-20170727-C00026.CDX"> </attachment>
          <attachment idref="CHEM-US-00026" attachment-type="mol" file="US20170210697A1-20170727-C00026.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0278" num="0000" class="description-line">In some embodiments the compound of any of the formulae described herein is suitable for making a nanoparticle composition for intramuscular administration.</div>
    </li> <li> <para-num num="[0246]"> </para-num> <div id="p-0279" num="0246" class="description-line">In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle. In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a 5- to 14-membered aromatic or non-aromatic heterocycle having one or more heteroatoms selected from N, O, S, and P. In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form an optionally substituted C<sub>3-20 </sub>carbocycle (e.g., C<sub>3-18 </sub>carbocycle, C<sub>3-15 </sub>carbocycle, C<sub>3-12 </sub>carbocycle, or C<sub>3-10 </sub>carbocycle), either aromatic or non-aromatic. In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a C<sub>3-6 </sub>carbocycle. In other embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a C<sub>6 </sub>carbocycle, such as a cyclohexyl or phenyl group. In certain embodiments, the heterocycle or C<sub>3-6 </sub>carbocycle is substituted with one or more alkyl groups (e.g., at the same ring atom or at adjacent or non-adjacent ring atoms). For example, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, may form a cyclohexyl or phenyl group bearing one or more C<sub>8 </sub>alkyl substitutions. In certain embodiments, the heterocycle or C<sub>3-6 </sub>carbocycle formed by R<sub>2 </sub>and R<sub>3</sub>, is substituted with a carbocycle groups. For example, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, may form a cyclohexyl or phenyl group that is substituted with cyclohexyl. In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a C<sub>7-15 </sub>carbocycle, such as a cycloheptyl, cyclopentadecanyl, or naphthyl group.</div>
    </li> <li> <para-num num="[0247]"> </para-num> <div id="p-0280" num="0247" class="description-line">In some embodiments, R<sub>4 </sub>is selected from (CH<sub>2</sub>)<sub>n</sub>Q and (CH<sub>2</sub>)<sub>n</sub>CHQR. In some embodiments, Q is selected from the group consisting of OR, OH, O(CH<sub>2</sub>)<sub>n</sub>N(R)<sub>2</sub>, OC(O)R, CX<sub>3</sub>, CN, N(R)C(O)R, N(H)C(O)R, N(R)S(O)<sub>2</sub>R, N(H)S(O)<sub>2</sub>R, N(R)C(O)N(R)<sub>2</sub>, N(H)C(O) N(R)<sub>2</sub>, N(H)C(O)N(H)(R), N(R)C(S)N(R)<sub>2</sub>, N(H)C(S)N(R)<sub>2</sub>, N(H)C(S)N(H)(R), and a heterocycle. In other embodiments, Q is selected from the group consisting of an imidazole, a pyrimidine, and a purine.</div>
    </li> <li> <para-num num="[0248]"> </para-num> <div id="p-0281" num="0248" class="description-line">In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a heterocycle or carbocycle. In some embodiments, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, form a C<sub>3-6 </sub>carbocycle, such as a phenyl group. In certain embodiments, the heterocycle or C<sub>3-6 </sub>carbocycle is substituted with one or more alkyl groups (e.g., at the same ring atom or at adjacent or non-adjacent ring atoms). For example, R<sub>2 </sub>and R<sub>3</sub>, together with the atom to which they are attached, may form a phenyl group bearing one or more C<sub>5 </sub>alkyl substitutions.</div>
    </li> <li> <para-num num="[0249]"> </para-num> <div id="p-0282" num="0249" class="description-line">In some embodiments, the compound of Formula (I) is selected from the group consisting of:</div>
    </li> <li> <div id="p-0283" num="0000" class="description-line">
      <chemistry id="CHEM-US-00027" num="00027">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/d1/b0/eabd5c6a499b2a/US20170210697A1-20170727-C00027.png"><img id="EMI-C00027" he="225.38mm" wi="158.75mm" file="US20170210697A1-20170727-C00027.TIF" alt="Figure US20170210697A1-20170727-C00027" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="902" alt="Figure US20170210697A1-20170727-C00027" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/d1/b0/eabd5c6a499b2a/US20170210697A1-20170727-C00027.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00027" attachment-type="cdx" file="US20170210697A1-20170727-C00027.CDX"> </attachment>
          <attachment idref="CHEM-US-00027" attachment-type="mol" file="US20170210697A1-20170727-C00027.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00028" num="00028">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/9f/94/d2e5cdf94987b0/US20170210697A1-20170727-C00028.png"><img id="EMI-C00028" he="234.87mm" wi="158.75mm" file="US20170210697A1-20170727-C00028.TIF" alt="Figure US20170210697A1-20170727-C00028" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="939" alt="Figure US20170210697A1-20170727-C00028" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/9f/94/d2e5cdf94987b0/US20170210697A1-20170727-C00028.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00028" attachment-type="cdx" file="US20170210697A1-20170727-C00028.CDX"> </attachment>
          <attachment idref="CHEM-US-00028" attachment-type="mol" file="US20170210697A1-20170727-C00028.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00029" num="00029">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/b0/65/5f65bddc879a6c/US20170210697A1-20170727-C00029.png"><img id="EMI-C00029" he="236.47mm" wi="158.75mm" file="US20170210697A1-20170727-C00029.TIF" alt="Figure US20170210697A1-20170727-C00029" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="946" alt="Figure US20170210697A1-20170727-C00029" class="patent-full-image" src="https://patentimages.storage.googleapis.com/06/b0/65/5f65bddc879a6c/US20170210697A1-20170727-C00029.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00029" attachment-type="cdx" file="US20170210697A1-20170727-C00029.CDX"> </attachment>
          <attachment idref="CHEM-US-00029" attachment-type="mol" file="US20170210697A1-20170727-C00029.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00030" num="00030">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/03/a9/8851284d8a953f/US20170210697A1-20170727-C00030.png"><img id="EMI-C00030" he="233.68mm" wi="158.75mm" file="US20170210697A1-20170727-C00030.TIF" alt="Figure US20170210697A1-20170727-C00030" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="935" alt="Figure US20170210697A1-20170727-C00030" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/03/a9/8851284d8a953f/US20170210697A1-20170727-C00030.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00030" attachment-type="cdx" file="US20170210697A1-20170727-C00030.CDX"> </attachment>
          <attachment idref="CHEM-US-00030" attachment-type="mol" file="US20170210697A1-20170727-C00030.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00031" num="00031">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dc/25/a0/48195b2ede0b5e/US20170210697A1-20170727-C00031.png"><img id="EMI-C00031" he="241.47mm" wi="158.75mm" file="US20170210697A1-20170727-C00031.TIF" alt="Figure US20170210697A1-20170727-C00031" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="966" alt="Figure US20170210697A1-20170727-C00031" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dc/25/a0/48195b2ede0b5e/US20170210697A1-20170727-C00031.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00031" attachment-type="cdx" file="US20170210697A1-20170727-C00031.CDX"> </attachment>
          <attachment idref="CHEM-US-00031" attachment-type="mol" file="US20170210697A1-20170727-C00031.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00032" num="00032">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b0/cb/7c/fab5eec0a0f3a9/US20170210697A1-20170727-C00032.png"><img id="EMI-C00032" he="226.06mm" wi="158.75mm" file="US20170210697A1-20170727-C00032.TIF" alt="Figure US20170210697A1-20170727-C00032" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="904" alt="Figure US20170210697A1-20170727-C00032" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b0/cb/7c/fab5eec0a0f3a9/US20170210697A1-20170727-C00032.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00032" attachment-type="cdx" file="US20170210697A1-20170727-C00032.CDX"> </attachment>
          <attachment idref="CHEM-US-00032" attachment-type="mol" file="US20170210697A1-20170727-C00032.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00033" num="00033">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/90/7f/c9d61c7751fea4/US20170210697A1-20170727-C00033.png"><img id="EMI-C00033" he="223.52mm" wi="158.75mm" file="US20170210697A1-20170727-C00033.TIF" alt="Figure US20170210697A1-20170727-C00033" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="894" alt="Figure US20170210697A1-20170727-C00033" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/90/7f/c9d61c7751fea4/US20170210697A1-20170727-C00033.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00033" attachment-type="cdx" file="US20170210697A1-20170727-C00033.CDX"> </attachment>
          <attachment idref="CHEM-US-00033" attachment-type="mol" file="US20170210697A1-20170727-C00033.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00034" num="00034">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a7/41/b1/f7e5ce9a7164e0/US20170210697A1-20170727-C00034.png"><img id="EMI-C00034" he="189.23mm" wi="158.75mm" file="US20170210697A1-20170727-C00034.TIF" alt="Figure US20170210697A1-20170727-C00034" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="757" alt="Figure US20170210697A1-20170727-C00034" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a7/41/b1/f7e5ce9a7164e0/US20170210697A1-20170727-C00034.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00034" attachment-type="cdx" file="US20170210697A1-20170727-C00034.CDX"> </attachment>
          <attachment idref="CHEM-US-00034" attachment-type="mol" file="US20170210697A1-20170727-C00034.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00035" num="00035">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/82/9a/44/c27ca2ba183216/US20170210697A1-20170727-C00035.png"><img id="EMI-C00035" he="231.06mm" wi="158.75mm" file="US20170210697A1-20170727-C00035.TIF" alt="Figure US20170210697A1-20170727-C00035" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="924" alt="Figure US20170210697A1-20170727-C00035" class="patent-full-image" src="https://patentimages.storage.googleapis.com/82/9a/44/c27ca2ba183216/US20170210697A1-20170727-C00035.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00035" attachment-type="cdx" file="US20170210697A1-20170727-C00035.CDX"> </attachment>
          <attachment idref="CHEM-US-00035" attachment-type="mol" file="US20170210697A1-20170727-C00035.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00036" num="00036">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/69/46/1fb86a76eb183d/US20170210697A1-20170727-C00036.png"><img id="EMI-C00036" he="232.92mm" wi="158.75mm" file="US20170210697A1-20170727-C00036.TIF" alt="Figure US20170210697A1-20170727-C00036" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="932" alt="Figure US20170210697A1-20170727-C00036" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/69/46/1fb86a76eb183d/US20170210697A1-20170727-C00036.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00036" attachment-type="cdx" file="US20170210697A1-20170727-C00036.CDX"> </attachment>
          <attachment idref="CHEM-US-00036" attachment-type="mol" file="US20170210697A1-20170727-C00036.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00037" num="00037">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/cd/e9/18294837ceb4ad/US20170210697A1-20170727-C00037.png"><img id="EMI-C00037" he="74.34mm" wi="158.75mm" file="US20170210697A1-20170727-C00037.TIF" alt="Figure US20170210697A1-20170727-C00037" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="297" alt="Figure US20170210697A1-20170727-C00037" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/cd/e9/18294837ceb4ad/US20170210697A1-20170727-C00037.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00037" attachment-type="cdx" file="US20170210697A1-20170727-C00037.CDX"> </attachment>
          <attachment idref="CHEM-US-00037" attachment-type="mol" file="US20170210697A1-20170727-C00037.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0250]"> </para-num> <div id="p-0284" num="0250" class="description-line">In further embodiments, the compound of Formula (I) is selected from the group consisting of:</div>
    </li> <li> <div id="p-0285" num="0000" class="description-line">
      <chemistry id="CHEM-US-00038" num="00038">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/c7/43/e0a36562e86225/US20170210697A1-20170727-C00038.png"><img id="EMI-C00038" he="110.24mm" wi="158.75mm" file="US20170210697A1-20170727-C00038.TIF" alt="Figure US20170210697A1-20170727-C00038" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="441" alt="Figure US20170210697A1-20170727-C00038" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/c7/43/e0a36562e86225/US20170210697A1-20170727-C00038.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00038" attachment-type="cdx" file="US20170210697A1-20170727-C00038.CDX"> </attachment>
          <attachment idref="CHEM-US-00038" attachment-type="mol" file="US20170210697A1-20170727-C00038.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0251]"> </para-num> <div id="p-0286" num="0251" class="description-line">In some embodiments, the compound of Formula (I) is selected from the group consisting of:</div>
    </li> <li> <div id="p-0287" num="0000" class="description-line">
      <chemistry id="CHEM-US-00039" num="00039">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a0/51/c8/efc1a2c00f211d/US20170210697A1-20170727-C00039.png"><img id="EMI-C00039" he="201.68mm" wi="158.75mm" file="US20170210697A1-20170727-C00039.TIF" alt="Figure US20170210697A1-20170727-C00039" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="807" alt="Figure US20170210697A1-20170727-C00039" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a0/51/c8/efc1a2c00f211d/US20170210697A1-20170727-C00039.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00039" attachment-type="cdx" file="US20170210697A1-20170727-C00039.CDX"> </attachment>
          <attachment idref="CHEM-US-00039" attachment-type="mol" file="US20170210697A1-20170727-C00039.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00040" num="00040">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/91/e8/b74ee98b62573f/US20170210697A1-20170727-C00040.png"><img id="EMI-C00040" he="227.67mm" wi="158.75mm" file="US20170210697A1-20170727-C00040.TIF" alt="Figure US20170210697A1-20170727-C00040" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="911" alt="Figure US20170210697A1-20170727-C00040" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/91/e8/b74ee98b62573f/US20170210697A1-20170727-C00040.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00040" attachment-type="cdx" file="US20170210697A1-20170727-C00040.CDX"> </attachment>
          <attachment idref="CHEM-US-00040" attachment-type="mol" file="US20170210697A1-20170727-C00040.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00041" num="00041">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/cd/c5/ae53eaaff858b0/US20170210697A1-20170727-C00041.png"><img id="EMI-C00041" he="203.45mm" wi="158.75mm" file="US20170210697A1-20170727-C00041.TIF" alt="Figure US20170210697A1-20170727-C00041" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="814" alt="Figure US20170210697A1-20170727-C00041" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7b/cd/c5/ae53eaaff858b0/US20170210697A1-20170727-C00041.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00041" attachment-type="cdx" file="US20170210697A1-20170727-C00041.CDX"> </attachment>
          <attachment idref="CHEM-US-00041" attachment-type="mol" file="US20170210697A1-20170727-C00041.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00042" num="00042">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/49/29/a3/c9cf8c8d8f9caa/US20170210697A1-20170727-C00042.png"><img id="EMI-C00042" he="215.65mm" wi="158.75mm" file="US20170210697A1-20170727-C00042.TIF" alt="Figure US20170210697A1-20170727-C00042" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="863" alt="Figure US20170210697A1-20170727-C00042" class="patent-full-image" src="https://patentimages.storage.googleapis.com/49/29/a3/c9cf8c8d8f9caa/US20170210697A1-20170727-C00042.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00042" attachment-type="cdx" file="US20170210697A1-20170727-C00042.CDX"> </attachment>
          <attachment idref="CHEM-US-00042" attachment-type="mol" file="US20170210697A1-20170727-C00042.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00043" num="00043">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/d8/27/a376361f4da7bf/US20170210697A1-20170727-C00043.png"><img id="EMI-C00043" he="232.49mm" wi="158.75mm" file="US20170210697A1-20170727-C00043.TIF" alt="Figure US20170210697A1-20170727-C00043" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="930" alt="Figure US20170210697A1-20170727-C00043" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/d8/27/a376361f4da7bf/US20170210697A1-20170727-C00043.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00043" attachment-type="cdx" file="US20170210697A1-20170727-C00043.CDX"> </attachment>
          <attachment idref="CHEM-US-00043" attachment-type="mol" file="US20170210697A1-20170727-C00043.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00044" num="00044">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b1/4d/93/c6b5142b1bfc0c/US20170210697A1-20170727-C00044.png"><img id="EMI-C00044" he="198.29mm" wi="158.75mm" file="US20170210697A1-20170727-C00044.TIF" alt="Figure US20170210697A1-20170727-C00044" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="793" alt="Figure US20170210697A1-20170727-C00044" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b1/4d/93/c6b5142b1bfc0c/US20170210697A1-20170727-C00044.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00044" attachment-type="cdx" file="US20170210697A1-20170727-C00044.CDX"> </attachment>
          <attachment idref="CHEM-US-00044" attachment-type="mol" file="US20170210697A1-20170727-C00044.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00045" num="00045">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e2/2c/0d/2a7223a1432ca2/US20170210697A1-20170727-C00045.png"><img id="EMI-C00045" he="208.03mm" wi="158.75mm" file="US20170210697A1-20170727-C00045.TIF" alt="Figure US20170210697A1-20170727-C00045" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="832" alt="Figure US20170210697A1-20170727-C00045" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e2/2c/0d/2a7223a1432ca2/US20170210697A1-20170727-C00045.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00045" attachment-type="cdx" file="US20170210697A1-20170727-C00045.CDX"> </attachment>
          <attachment idref="CHEM-US-00045" attachment-type="mol" file="US20170210697A1-20170727-C00045.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00046" num="00046">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5e/da/8d/5f72e2cea2c179/US20170210697A1-20170727-C00046.png"><img id="EMI-C00046" he="226.40mm" wi="158.75mm" file="US20170210697A1-20170727-C00046.TIF" alt="Figure US20170210697A1-20170727-C00046" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="906" alt="Figure US20170210697A1-20170727-C00046" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5e/da/8d/5f72e2cea2c179/US20170210697A1-20170727-C00046.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00046" attachment-type="cdx" file="US20170210697A1-20170727-C00046.CDX"> </attachment>
          <attachment idref="CHEM-US-00046" attachment-type="mol" file="US20170210697A1-20170727-C00046.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00047" num="00047">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/66/29/89e70cfe0410b0/US20170210697A1-20170727-C00047.png"><img id="EMI-C00047" he="191.18mm" wi="158.75mm" file="US20170210697A1-20170727-C00047.TIF" alt="Figure US20170210697A1-20170727-C00047" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="765" alt="Figure US20170210697A1-20170727-C00047" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/66/29/89e70cfe0410b0/US20170210697A1-20170727-C00047.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00047" attachment-type="cdx" file="US20170210697A1-20170727-C00047.CDX"> </attachment>
          <attachment idref="CHEM-US-00047" attachment-type="mol" file="US20170210697A1-20170727-C00047.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00048" num="00048">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e7/82/ff/ef03e2691f96b4/US20170210697A1-20170727-C00048.png"><img id="EMI-C00048" he="219.54mm" wi="158.75mm" file="US20170210697A1-20170727-C00048.TIF" alt="Figure US20170210697A1-20170727-C00048" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="878" alt="Figure US20170210697A1-20170727-C00048" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e7/82/ff/ef03e2691f96b4/US20170210697A1-20170727-C00048.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00048" attachment-type="cdx" file="US20170210697A1-20170727-C00048.CDX"> </attachment>
          <attachment idref="CHEM-US-00048" attachment-type="mol" file="US20170210697A1-20170727-C00048.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00049" num="00049">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/aa/77/6813d615eb4e3d/US20170210697A1-20170727-C00049.png"><img id="EMI-C00049" he="174.92mm" wi="158.75mm" file="US20170210697A1-20170727-C00049.TIF" alt="Figure US20170210697A1-20170727-C00049" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="700" alt="Figure US20170210697A1-20170727-C00049" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/aa/77/6813d615eb4e3d/US20170210697A1-20170727-C00049.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00049" attachment-type="cdx" file="US20170210697A1-20170727-C00049.CDX"> </attachment>
          <attachment idref="CHEM-US-00049" attachment-type="mol" file="US20170210697A1-20170727-C00049.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00050" num="00050">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e2/e3/8e/0eddfa2ab3ac32/US20170210697A1-20170727-C00050.png"><img id="EMI-C00050" he="210.74mm" wi="158.75mm" file="US20170210697A1-20170727-C00050.TIF" alt="Figure US20170210697A1-20170727-C00050" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="843" alt="Figure US20170210697A1-20170727-C00050" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e2/e3/8e/0eddfa2ab3ac32/US20170210697A1-20170727-C00050.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00050" attachment-type="cdx" file="US20170210697A1-20170727-C00050.CDX"> </attachment>
          <attachment idref="CHEM-US-00050" attachment-type="mol" file="US20170210697A1-20170727-C00050.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00051" num="00051">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/de/ce/e201a80ce19405/US20170210697A1-20170727-C00051.png"><img id="EMI-C00051" he="235.54mm" wi="158.75mm" file="US20170210697A1-20170727-C00051.TIF" alt="Figure US20170210697A1-20170727-C00051" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="942" alt="Figure US20170210697A1-20170727-C00051" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/de/ce/e201a80ce19405/US20170210697A1-20170727-C00051.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00051" attachment-type="cdx" file="US20170210697A1-20170727-C00051.CDX"> </attachment>
          <attachment idref="CHEM-US-00051" attachment-type="mol" file="US20170210697A1-20170727-C00051.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00052" num="00052">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/51/31/7b01a3173680d9/US20170210697A1-20170727-C00052.png"><img id="EMI-C00052" he="203.62mm" wi="158.75mm" file="US20170210697A1-20170727-C00052.TIF" alt="Figure US20170210697A1-20170727-C00052" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="814" alt="Figure US20170210697A1-20170727-C00052" class="patent-full-image" src="https://patentimages.storage.googleapis.com/eb/51/31/7b01a3173680d9/US20170210697A1-20170727-C00052.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00052" attachment-type="cdx" file="US20170210697A1-20170727-C00052.CDX"> </attachment>
          <attachment idref="CHEM-US-00052" attachment-type="mol" file="US20170210697A1-20170727-C00052.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00053" num="00053">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f2/64/5f/f27787220bba98/US20170210697A1-20170727-C00053.png"><img id="EMI-C00053" he="166.54mm" wi="158.75mm" file="US20170210697A1-20170727-C00053.TIF" alt="Figure US20170210697A1-20170727-C00053" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="666" alt="Figure US20170210697A1-20170727-C00053" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f2/64/5f/f27787220bba98/US20170210697A1-20170727-C00053.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00053" attachment-type="cdx" file="US20170210697A1-20170727-C00053.CDX"> </attachment>
          <attachment idref="CHEM-US-00053" attachment-type="mol" file="US20170210697A1-20170727-C00053.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00054" num="00054">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/38/83/760ce49196ec6c/US20170210697A1-20170727-C00054.png"><img id="EMI-C00054" he="221.74mm" wi="158.75mm" file="US20170210697A1-20170727-C00054.TIF" alt="Figure US20170210697A1-20170727-C00054" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="887" alt="Figure US20170210697A1-20170727-C00054" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/38/83/760ce49196ec6c/US20170210697A1-20170727-C00054.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00054" attachment-type="cdx" file="US20170210697A1-20170727-C00054.CDX"> </attachment>
          <attachment idref="CHEM-US-00054" attachment-type="mol" file="US20170210697A1-20170727-C00054.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00055" num="00055">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/3e/1e/c56250b1d9a28c/US20170210697A1-20170727-C00055.png"><img id="EMI-C00055" he="210.99mm" wi="158.75mm" file="US20170210697A1-20170727-C00055.TIF" alt="Figure US20170210697A1-20170727-C00055" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="844" alt="Figure US20170210697A1-20170727-C00055" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8d/3e/1e/c56250b1d9a28c/US20170210697A1-20170727-C00055.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00055" attachment-type="cdx" file="US20170210697A1-20170727-C00055.CDX"> </attachment>
          <attachment idref="CHEM-US-00055" attachment-type="mol" file="US20170210697A1-20170727-C00055.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00056" num="00056">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/7b/eb/d3a0eaeaee2707/US20170210697A1-20170727-C00056.png"><img id="EMI-C00056" he="192.28mm" wi="158.75mm" file="US20170210697A1-20170727-C00056.TIF" alt="Figure US20170210697A1-20170727-C00056" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="769" alt="Figure US20170210697A1-20170727-C00056" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/7b/eb/d3a0eaeaee2707/US20170210697A1-20170727-C00056.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00056" attachment-type="cdx" file="US20170210697A1-20170727-C00056.CDX"> </attachment>
          <attachment idref="CHEM-US-00056" attachment-type="mol" file="US20170210697A1-20170727-C00056.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00057" num="00057">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/28/55/4ee2fde53d864c/US20170210697A1-20170727-C00057.png"><img id="EMI-C00057" he="233.85mm" wi="158.75mm" file="US20170210697A1-20170727-C00057.TIF" alt="Figure US20170210697A1-20170727-C00057" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="935" alt="Figure US20170210697A1-20170727-C00057" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/28/55/4ee2fde53d864c/US20170210697A1-20170727-C00057.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00057" attachment-type="cdx" file="US20170210697A1-20170727-C00057.CDX"> </attachment>
          <attachment idref="CHEM-US-00057" attachment-type="mol" file="US20170210697A1-20170727-C00057.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00058" num="00058">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/e3/0f/5e0c71bc74f2b9/US20170210697A1-20170727-C00058.png"><img id="EMI-C00058" he="234.10mm" wi="158.75mm" file="US20170210697A1-20170727-C00058.TIF" alt="Figure US20170210697A1-20170727-C00058" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="936" alt="Figure US20170210697A1-20170727-C00058" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/e3/0f/5e0c71bc74f2b9/US20170210697A1-20170727-C00058.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00058" attachment-type="cdx" file="US20170210697A1-20170727-C00058.CDX"> </attachment>
          <attachment idref="CHEM-US-00058" attachment-type="mol" file="US20170210697A1-20170727-C00058.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00059" num="00059">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/57/88/b023e20e42eb61/US20170210697A1-20170727-C00059.png"><img id="EMI-C00059" he="230.63mm" wi="158.75mm" file="US20170210697A1-20170727-C00059.TIF" alt="Figure US20170210697A1-20170727-C00059" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="923" alt="Figure US20170210697A1-20170727-C00059" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/57/88/b023e20e42eb61/US20170210697A1-20170727-C00059.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00059" attachment-type="cdx" file="US20170210697A1-20170727-C00059.CDX"> </attachment>
          <attachment idref="CHEM-US-00059" attachment-type="mol" file="US20170210697A1-20170727-C00059.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00060" num="00060">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/fb/6e/1dd42727358538/US20170210697A1-20170727-C00060.png"><img id="EMI-C00060" he="236.90mm" wi="158.75mm" file="US20170210697A1-20170727-C00060.TIF" alt="Figure US20170210697A1-20170727-C00060" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="948" alt="Figure US20170210697A1-20170727-C00060" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/fb/6e/1dd42727358538/US20170210697A1-20170727-C00060.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00060" attachment-type="cdx" file="US20170210697A1-20170727-C00060.CDX"> </attachment>
          <attachment idref="CHEM-US-00060" attachment-type="mol" file="US20170210697A1-20170727-C00060.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00061" num="00061">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/4f/47/0ea63565c8adff/US20170210697A1-20170727-C00061.png"><img id="EMI-C00061" he="195.66mm" wi="158.75mm" file="US20170210697A1-20170727-C00061.TIF" alt="Figure US20170210697A1-20170727-C00061" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="783" alt="Figure US20170210697A1-20170727-C00061" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/4f/47/0ea63565c8adff/US20170210697A1-20170727-C00061.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00061" attachment-type="cdx" file="US20170210697A1-20170727-C00061.CDX"> </attachment>
          <attachment idref="CHEM-US-00061" attachment-type="mol" file="US20170210697A1-20170727-C00061.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00062" num="00062">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/82/50/82d2c8eb3655d6/US20170210697A1-20170727-C00062.png"><img id="EMI-C00062" he="206.84mm" wi="158.75mm" file="US20170210697A1-20170727-C00062.TIF" alt="Figure US20170210697A1-20170727-C00062" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="827" alt="Figure US20170210697A1-20170727-C00062" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/82/50/82d2c8eb3655d6/US20170210697A1-20170727-C00062.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00062" attachment-type="cdx" file="US20170210697A1-20170727-C00062.CDX"> </attachment>
          <attachment idref="CHEM-US-00062" attachment-type="mol" file="US20170210697A1-20170727-C00062.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00063" num="00063">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/be/14/58/88dac1fcf9e8f5/US20170210697A1-20170727-C00063.png"><img id="EMI-C00063" he="234.19mm" wi="158.75mm" file="US20170210697A1-20170727-C00063.TIF" alt="Figure US20170210697A1-20170727-C00063" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="937" alt="Figure US20170210697A1-20170727-C00063" class="patent-full-image" src="https://patentimages.storage.googleapis.com/be/14/58/88dac1fcf9e8f5/US20170210697A1-20170727-C00063.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00063" attachment-type="cdx" file="US20170210697A1-20170727-C00063.CDX"> </attachment>
          <attachment idref="CHEM-US-00063" attachment-type="mol" file="US20170210697A1-20170727-C00063.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00064" num="00064">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/46/35/e9e95b10a40af1/US20170210697A1-20170727-C00064.png"><img id="EMI-C00064" he="182.88mm" wi="158.75mm" file="US20170210697A1-20170727-C00064.TIF" alt="Figure US20170210697A1-20170727-C00064" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="732" alt="Figure US20170210697A1-20170727-C00064" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/46/35/e9e95b10a40af1/US20170210697A1-20170727-C00064.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00064" attachment-type="cdx" file="US20170210697A1-20170727-C00064.CDX"> </attachment>
          <attachment idref="CHEM-US-00064" attachment-type="mol" file="US20170210697A1-20170727-C00064.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00065" num="00065">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/16/f5/5fd4ed15602e97/US20170210697A1-20170727-C00065.png"><img id="EMI-C00065" he="222.25mm" wi="158.75mm" file="US20170210697A1-20170727-C00065.TIF" alt="Figure US20170210697A1-20170727-C00065" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="889" alt="Figure US20170210697A1-20170727-C00065" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/16/f5/5fd4ed15602e97/US20170210697A1-20170727-C00065.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00065" attachment-type="cdx" file="US20170210697A1-20170727-C00065.CDX"> </attachment>
          <attachment idref="CHEM-US-00065" attachment-type="mol" file="US20170210697A1-20170727-C00065.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00066" num="00066">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/67/4f/74/83262de37ae54b/US20170210697A1-20170727-C00066.png"><img id="EMI-C00066" he="202.10mm" wi="158.75mm" file="US20170210697A1-20170727-C00066.TIF" alt="Figure US20170210697A1-20170727-C00066" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="808" alt="Figure US20170210697A1-20170727-C00066" class="patent-full-image" src="https://patentimages.storage.googleapis.com/67/4f/74/83262de37ae54b/US20170210697A1-20170727-C00066.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00066" attachment-type="cdx" file="US20170210697A1-20170727-C00066.CDX"> </attachment>
          <attachment idref="CHEM-US-00066" attachment-type="mol" file="US20170210697A1-20170727-C00066.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00067" num="00067">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/24/5d/ce/b94ea5dfbd1484/US20170210697A1-20170727-C00067.png"><img id="EMI-C00067" he="183.81mm" wi="158.75mm" file="US20170210697A1-20170727-C00067.TIF" alt="Figure US20170210697A1-20170727-C00067" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="735" alt="Figure US20170210697A1-20170727-C00067" class="patent-full-image" src="https://patentimages.storage.googleapis.com/24/5d/ce/b94ea5dfbd1484/US20170210697A1-20170727-C00067.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00067" attachment-type="cdx" file="US20170210697A1-20170727-C00067.CDX"> </attachment>
          <attachment idref="CHEM-US-00067" attachment-type="mol" file="US20170210697A1-20170727-C00067.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00068" num="00068">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/a0/79/17bd36f51656df/US20170210697A1-20170727-C00068.png"><img id="EMI-C00068" he="208.28mm" wi="158.75mm" file="US20170210697A1-20170727-C00068.TIF" alt="Figure US20170210697A1-20170727-C00068" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="833" alt="Figure US20170210697A1-20170727-C00068" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/a0/79/17bd36f51656df/US20170210697A1-20170727-C00068.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00068" attachment-type="cdx" file="US20170210697A1-20170727-C00068.CDX"> </attachment>
          <attachment idref="CHEM-US-00068" attachment-type="mol" file="US20170210697A1-20170727-C00068.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00069" num="00069">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/58/84/b3/447f6c84be7a09/US20170210697A1-20170727-C00069.png"><img id="EMI-C00069" he="203.28mm" wi="158.75mm" file="US20170210697A1-20170727-C00069.TIF" alt="Figure US20170210697A1-20170727-C00069" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="813" alt="Figure US20170210697A1-20170727-C00069" class="patent-full-image" src="https://patentimages.storage.googleapis.com/58/84/b3/447f6c84be7a09/US20170210697A1-20170727-C00069.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00069" attachment-type="cdx" file="US20170210697A1-20170727-C00069.CDX"> </attachment>
          <attachment idref="CHEM-US-00069" attachment-type="mol" file="US20170210697A1-20170727-C00069.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00070" num="00070">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cd/ec/ce/e8fcc9f4aefed4/US20170210697A1-20170727-C00070.png"><img id="EMI-C00070" he="215.14mm" wi="158.75mm" file="US20170210697A1-20170727-C00070.TIF" alt="Figure US20170210697A1-20170727-C00070" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="861" alt="Figure US20170210697A1-20170727-C00070" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cd/ec/ce/e8fcc9f4aefed4/US20170210697A1-20170727-C00070.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00070" attachment-type="cdx" file="US20170210697A1-20170727-C00070.CDX"> </attachment>
          <attachment idref="CHEM-US-00070" attachment-type="mol" file="US20170210697A1-20170727-C00070.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00071" num="00071">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/6f/85/59121fc17d6a80/US20170210697A1-20170727-C00071.png"><img id="EMI-C00071" he="186.69mm" wi="158.75mm" file="US20170210697A1-20170727-C00071.TIF" alt="Figure US20170210697A1-20170727-C00071" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="747" alt="Figure US20170210697A1-20170727-C00071" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/6f/85/59121fc17d6a80/US20170210697A1-20170727-C00071.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00071" attachment-type="cdx" file="US20170210697A1-20170727-C00071.CDX"> </attachment>
          <attachment idref="CHEM-US-00071" attachment-type="mol" file="US20170210697A1-20170727-C00071.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00072" num="00072">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/59/35/78/bec0631e1e8989/US20170210697A1-20170727-C00072.png"><img id="EMI-C00072" he="180.42mm" wi="158.75mm" file="US20170210697A1-20170727-C00072.TIF" alt="Figure US20170210697A1-20170727-C00072" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="722" alt="Figure US20170210697A1-20170727-C00072" class="patent-full-image" src="https://patentimages.storage.googleapis.com/59/35/78/bec0631e1e8989/US20170210697A1-20170727-C00072.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00072" attachment-type="cdx" file="US20170210697A1-20170727-C00072.CDX"> </attachment>
          <attachment idref="CHEM-US-00072" attachment-type="mol" file="US20170210697A1-20170727-C00072.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00073" num="00073">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/0d/ee/69ea09214ed9cf/US20170210697A1-20170727-C00073.png"><img id="EMI-C00073" he="232.07mm" wi="158.75mm" file="US20170210697A1-20170727-C00073.TIF" alt="Figure US20170210697A1-20170727-C00073" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="635" height="928" alt="Figure US20170210697A1-20170727-C00073" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/0d/ee/69ea09214ed9cf/US20170210697A1-20170727-C00073.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00073" attachment-type="cdx" file="US20170210697A1-20170727-C00073.CDX"> </attachment>
          <attachment idref="CHEM-US-00073" attachment-type="mol" file="US20170210697A1-20170727-C00073.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0288" num="0000" class="description-line">and salts and isomers thereof.</div>
    </li> <li> <para-num num="[0252]"> </para-num> <div id="p-0289" num="0252" class="description-line">The central amine moiety of a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) may be protonated at a physiological pH. Thus, a lipid may have a positive or partial positive charge at physiological pH. Such lipids may be referred to as cationic or ionizable (amino)lipids. Lipids may also be zwitterionic, i.e., neutral molecules having both a positive and a negative charge.</div>
    </li> <li> <para-num num="[0253]"> </para-num> <div id="p-0290" num="0253" class="description-line">As used herein, the term alkyl or alkyl group means a linear or branched, saturated hydrocarbon including one or more carbon atoms (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms), which is optionally substituted. The notation C<sub>1-14 </sub>alkyl means an optionally substituted linear or branched, saturated hydrocarbon including 1-14 carbon atoms. Unless otherwise specified, an alkyl group described herein refers to both unsubstituted and substituted alkyl groups.</div>
    </li> <li> <para-num num="[0254]"> </para-num> <div id="p-0291" num="0254" class="description-line">As used herein, the term alkenyl or alkenyl group means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one double bond, which is optionally substituted. The notation C<sub>2-14 </sub>alkenyl means an optionally substituted linear or branched hydrocarbon including 2-14 carbon atoms and at least one carbon-carbon double bond. An alkenyl group may include one, two, three, four, or more carbon-carbon double bonds. For example, C<sub>18 </sub>alkenyl may include one or more double bonds. A C<sub>18 </sub>alkenyl group including two double bonds may be a linoleyl group. Unless otherwise specified, an alkenyl group described herein refers to both unsubstituted and substituted alkenyl groups.</div>
    </li> <li> <para-num num="[0255]"> </para-num> <div id="p-0292" num="0255" class="description-line">As used herein, the term alkynyl or alkynyl group means a linear or branched hydrocarbon including two or more carbon atoms (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or more carbon atoms) and at least one carbon-carbon triple bond, which is optionally substituted. The notation C<sub>2-14 </sub>alkynyl means an optionally substituted linear or branched hydrocarbon including 2-14 carbon atoms and at least one carbon-carbon triple bond. An alkynyl group may include one, two, three, four, or more carbon-carbon triple bonds. For example, C<sub>18 </sub>alkynyl may include one or more carbon-carbon triple bonds. Unless otherwise specified, an alkynyl group described herein refers to both unsubstituted and substituted alkynyl groups.</div>
    </li> <li> <para-num num="[0256]"> </para-num> <div id="p-0293" num="0256" class="description-line">As used herein, the term carbocycle or carbocyclic group means an optionally substituted mono- or multi-cyclic system including one or more rings of carbon atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty membered rings. The notation C<sub>3-6 </sub>carbocycle means a carbocycle including a single ring having 3-6 carbon atoms. Carbocycles may include one or more carbon-carbon double or triple bonds and may be non-aromatic or aromatic (e.g., cycloalkyl or aryl groups). Examples of carbocycles include cyclopropyl, cyclopentyl, cyclohexyl, phenyl, naphthyl, and 1,2-dihydronaphthyl groups. The term cycloalkyl as used herein means a non-aromatic carbocycle and may or may not include any double or triple bond. Unless otherwise specified, carbocycles described herein refers to both unsubstituted and substituted carbocycle groups, i.e., optionally substituted carbocycles.</div>
    </li> <li> <para-num num="[0257]"> </para-num> <div id="p-0294" num="0257" class="description-line">As used herein, the term heterocycle or heterocyclic group means an optionally substituted mono- or multi-cyclic system including one or more rings, where at least one ring includes at least one heteroatom. Heteroatoms may be, for example, nitrogen, oxygen, or sulfur atoms. Rings may be three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen membered rings. Heterocycles may include one or more double or triple bonds and may be non-aromatic or aromatic (e.g., heterocycloalkyl or heteroaryl groups). Examples of heterocycles include imidazolyl, imidazolidinyl, oxazolyl, oxazolidinyl, thiazolyl, thiazolidinyl, pyrazolidinyl, pyrazolyl, isoxazolidinyl, isoxazolyl, isothiazolidinyl, isothiazolyl, morpholinyl, pyrrolyl, pyrrolidinyl, furyl, tetrahydrofuryl, thiophenyl, pyridinyl, piperidinyl, quinolyl, and isoquinolyl groups. The term heterocycloalkyl as used herein means a non-aromatic heterocycle and may or may not include any double or triple bond. Unless otherwise specified, heterocycles described herein refers to both unsubstituted and substituted heterocycle groups, i.e., optionally substituted heterocycles.</div>
    </li> <li> <para-num num="[0258]"> </para-num> <div id="p-0295" num="0258" class="description-line">As used herein, a biodegradable group is a group that may facilitate faster metabolism of a lipid in a mammalian entity. A biodegradable group may be selected from the group consisting of, but is not limited to, C(O)O, OC(O), C(O)N(R), N(R)C(O), C(O), C(S), C(S)S, SC(S), CH(OH), P(O)(OR)O, S(O)<sub>2</sub>, an aryl group, and a heteroaryl group. As used herein, an aryl group is an optionally substituted carbocyclic group including one or more aromatic rings. Examples of aryl groups include phenyl and naphthyl groups. As used herein, a heteroaryl group is an optionally substituted heterocyclic group including one or more aromatic rings. Examples of heteroaryl groups include pyrrolyl, furyl, thiophenyl, imidazolyl, oxazolyl, and thiazolyl. Both aryl and heteroaryl groups may be optionally substituted. For example, M and M can be selected from the non-limiting group consisting of optionally substituted phenyl, oxazole, and thiazole. In the formulas herein, M and M can be independently selected from the list of biodegradable groups above. Unless otherwise specified, aryl or heteroaryl groups described herein refers to both unsubstituted and substituted groups, i.e., optionally substituted aryl or heteroaryl groups.</div>
    </li> <li> <para-num num="[0259]"> </para-num> <div id="p-0296" num="0259" class="description-line">Alkyl, alkenyl, and cyclyl (e.g., carbocyclyl and heterocyclyl) groups may be optionally substituted unless otherwise specified. Optional substituents may be selected from the group consisting of, but are not limited to, a halogen atom (e.g., a chloride, bromide, fluoride, or iodide group), a carboxylic acid (e.g., C(O)OH), an alcohol (e.g., a hydroxyl, OH), an ester (e.g., C(O)OR or OC(O)R), an aldehyde (e.g., C(O)H), a carbonyl (e.g., C(O)R, alternatively represented by CO), an acyl halide (e.g., C(O)X, in which X is a halide selected from bromide, fluoride, chloride, and iodide), a carbonate (e.g., OC(O)OR), an alkoxy (e.g., OR), an acetal (e.g., C(OR)<sub>2</sub>R, in which each OR are alkoxy groups that can be the same or different and R is an alkyl or alkenyl group), a phosphate (e.g., P(O)<sub>4</sub> <sup>3</sup>), a thiol (e.g., SH), a sulfoxide (e.g., S(O)R), a sulfinic acid (e.g., S(O)OH), a sulfonic acid (e.g., S(O)<sub>20</sub>H), a thial (e.g., C(S)H), a sulfate (e.g., S(O)<sub>4</sub> <sup>2</sup>), a sulfonyl (e.g., S(O)<sub>2</sub>), an amide (e.g., C(O)NR<sub>2</sub>, or N(R)C(O)R), an azido (e.g., N<sub>3</sub>), a nitro (e.g., NO<sub>2</sub>), a cyano (e.g., CN), an isocyano (e.g., NC), an acyloxy (e.g., OC(O)R), an amino (e.g., NR<sub>2</sub>, NRH, or NH<sub>2</sub>), a carbamoyl (e.g., OC(O)NR<sub>2</sub>, OC(O)NRH, or OC(O)NH<sub>2</sub>), a sulfonamide (e.g., S(O)<sub>2</sub>NR<sub>2</sub>, S(O)<sub>2</sub>NRH, S(O)<sub>2</sub>NH<sub>2</sub>, N(R)S(O)<sub>2</sub>R, N(H)S(O)<sub>2</sub>R, N(R)S(O)<sub>2</sub>H, or N(H)S(O)<sub>2</sub>H), an alkyl group, an alkenyl group, and a cyclyl (e.g., carbocyclyl or heterocyclyl) group. In any of the preceding, R is an alkyl or alkenyl group, as defined herein. In some embodiments, the substituent groups themselves may be further substituted with, for example, one, two, three, four, five, or six substituents as defined herein. For example, a C<sub>1-6 </sub>alkyl group may be further substituted with one, two, three, four, five, or six substituents as described herein.</div>
    </li> <li> <para-num num="[0260]"> </para-num> <div id="p-0297" num="0260" class="description-line">About, Approximately: As used herein, the terms approximately and about, as applied to one or more values of interest, refer to a value that is similar to a stated reference value. In certain embodiments, the term approximately or about refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater than or less than) of the stated reference value unless otherwise stated or otherwise evident from the context (except where such number would exceed 100% of a possible value). For example, when used in the context of an amount of a given compound in a lipid component of a nanoparticle composition, about may mean+/10% of the recited value. For instance, a nanoparticle composition including a lipid component having about 40% of a given compound may include 30-50% of the compound.</div>
    </li> <li> <para-num num="[0261]"> </para-num> <div id="p-0298" num="0261" class="description-line">As used herein, the term compound, is meant to include all isomers and isotopes of the structure depicted. Isotopes refers to atoms having the same atomic number but different mass numbers resulting from a different number of neutrons in the nuclei. For example, isotopes of hydrogen include tritium and deuterium. Further, a compound, salt, or complex of the present disclosure can be prepared in combination with solvent or water molecules to form solvates and hydrates by routine methods.</div>
    </li> <li> <para-num num="[0262]"> </para-num> <div id="p-0299" num="0262" class="description-line">As used herein, the term contacting means establishing a physical connection between two or more entities. For example, contacting a mammalian cell with a nanoparticle composition means that the mammalian cell and a nanoparticle are made to share a physical connection. Methods of contacting cells with external entities both in vivo and ex vivo are well known in the biological arts. For example, contacting a nanoparticle composition and a mammalian cell disposed within a mammal may be performed by varied routes of administration (e.g., intravenous, intramuscular, intradermal, and subcutaneous) and may involve varied amounts of nanoparticle compositions. Moreover, more than one mammalian cell may be contacted by a nanoparticle composition.</div>
    </li> <li> <para-num num="[0263]"> </para-num> <div id="p-0300" num="0263" class="description-line">As used herein, the term delivering means providing an entity to a destination. For example, delivering a therapeutic and/or prophylactic to a subject may involve administering a nanoparticle composition including the therapeutic and/or prophylactic to the subject (e.g., by an intravenous, intramuscular, intradermal, or subcutaneous route). Administration of a nanoparticle composition to a mammal or mammalian cell may involve contacting one or more cells with the nanoparticle composition.</div>
    </li> <li> <para-num num="[0264]"> </para-num> <div id="p-0301" num="0264" class="description-line">As used herein, the term enhanced delivery means delivery of more (e.g., at least 1.5 fold more, at least 2-fold more, at least 3-fold more, at least 4-fold more, at least 5-fold more, at least 6-fold more, at least 7-fold more, at least 8-fold more, at least 9-fold more, at least 10-fold more) of a therapeutic and/or prophylactic by a nanoparticle to a target tissue of interest (e.g., mammalian liver) compared to the level of delivery of a therapeutic and/or prophylactic by a control nanoparticle to a target tissue of interest (e.g., MC3, KC2, or DLinDMA). The level of delivery of a nanoparticle to a particular tissue may be measured by comparing the amount of protein produced in a tissue to the weight of said tissue, comparing the amount of therapeutic and/or prophylactic in a tissue to the weight of said tissue, comparing the amount of protein produced in a tissue to the amount of total protein in said tissue, or comparing the amount of therapeutic and/or prophylactic in a tissue to the amount of total therapeutic and/or prophylactic in said tissue. It will be understood that the enhanced delivery of a nanoparticle to a target tissue need not be determined in a subject being treated, it may be determined in a surrogate such as an animal model (e.g., a rat model). In certain embodiments, a nanoparticle composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) has substantively the same level of delivery enhancement regardless of administration routes. For example, certain compounds disclosed herein exhibit similar delivery enhancement when they are used for delivering a therapeutic and/or prophylactic either intravenously or intramuscularly. In other embodiments, certain compounds disclosed herein (e.g., a compound of Formula (IA) or (II), such as <figure-callout id="18" label="Compound" filenames="US20170210697A1-20170727-D00004.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="25" label="Compound" filenames="US20170210697A1-20170727-D00005.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Compound</figure-callout> </figure-callout> 18, 25, 30, 60, 108-112, or 122) exhibit a higher level of delivery enhancement when they are used for delivering a therapeutic and/or prophylactic intramuscularly than intravenously.</div>
    </li> <li> <para-num num="[0265]"> </para-num> <div id="p-0302" num="0265" class="description-line">As used herein, the term specific delivery, specifically deliver, or specifically delivering means delivery of more (e.g., at least 1.5 fold more, at least 2-fold more, at least 3-fold more, at least 4-fold more, at least 5-fold more, at least 6-fold more, at least 7-fold more, at least 8-fold more, at least 9-fold more, at least 10-fold more) of a therapeutic and/or prophylactic by a nanoparticle to a target tissue of interest (e.g., mammalian liver) compared to an off-target tissue (e.g., mammalian spleen). The level of delivery of a nanoparticle to a particular tissue may be measured by comparing the amount of protein produced in a tissue to the weight of said tissue, comparing the amount of therapeutic and/or prophylactic in a tissue to the weight of said tissue, comparing the amount of protein produced in a tissue to the amount of total protein in said tissue, or comparing the amount of therapeutic and/or prophylactic in a tissue to the amount of total therapeutic and/or prophylactic in said tissue. For example, for renovascular targeting, a therapeutic and/or prophylactic is specifically provided to a mammalian kidney as compared to the liver and spleen if 1.5, 2-fold, 3-fold, 5-fold, 10-fold, 15 fold, or 20 fold more therapeutic and/or prophylactic per 1 g of tissue is delivered to a kidney compared to that delivered to the liver or spleen following systemic administration of the therapeutic and/or prophylactic. It will be understood that the ability of a nanoparticle to specifically deliver to a target tissue need not be determined in a subject being treated, it may be determined in a surrogate such as an animal model (e.g., a rat model).</div>
    </li> <li> <para-num num="[0266]"> </para-num> <div id="p-0303" num="0266" class="description-line">As used herein, encapsulation efficiency refers to the amount of a therapeutic and/or prophylactic that becomes part of a nanoparticle composition, relative to the initial total amount of therapeutic and/or prophylactic used in the preparation of a nanoparticle composition. For example, if 97 mg of therapeutic and/or prophylactic are encapsulated in a nanoparticle composition out of a total 100 mg of therapeutic and/or prophylactic initially provided to the composition, the encapsulation efficiency may be given as 97%. As used herein, encapsulation may refer to complete, substantial, or partial enclosure, confinement, surrounding, or encasement.</div>
    </li> <li> <para-num num="[0267]"> </para-num> <div id="p-0304" num="0267" class="description-line">As used herein, expression of a nucleic acid sequence refers to translation of an mRNA into a polypeptide or protein and/or post-translational modification of a polypeptide or protein.</div>
    </li> <li> <para-num num="[0268]"> </para-num> <div id="p-0305" num="0268" class="description-line">As used herein, the term in vitro refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, in a Petri dish, etc., rather than within an organism (e.g., animal, plant, or microbe).</div>
    </li> <li> <para-num num="[0269]"> </para-num> <div id="p-0306" num="0269" class="description-line">As used herein, the term in vivo refers to events that occur within an organism (e.g., animal, plant, or microbe or cell or tissue thereof).</div>
    </li> <li> <para-num num="[0270]"> </para-num> <div id="p-0307" num="0270" class="description-line">As used herein, the term ex vivo refers to events that occur outside of an organism (e.g., animal, plant, or microbe or cell or tissue thereof). Ex vivo events may take place in an environment minimally altered from a natural (e.g., in vivo) environment.</div>
    </li> <li> <para-num num="[0271]"> </para-num> <div id="p-0308" num="0271" class="description-line">As used herein, the term isomer means any geometric isomer, tautomer, zwitterion, stereoisomer, enantiomer, or diastereomer of a compound. Compounds may include one or more chiral centers and/or double bonds and may thus exist as stereoisomers, such as double-bond isomers (i.e., geometric E/Z isomers) or diastereomers (e.g., enantiomers (i.e., (+) or ()) or cis/trans isomers). The present disclosure encompasses any and all isomers of the compounds described herein, including stereomerically pure forms (e.g., geometrically pure, enantiomerically pure, or diastereomerically pure) and enantiomeric and stereoisomeric mixtures, e.g., racemates. Enantiomeric and stereomeric mixtures of compounds and means of resolving them into their component enantiomers or stereoisomers are well-known.</div>
    </li> <li> <para-num num="[0272]"> </para-num> <div id="p-0309" num="0272" class="description-line">As used herein, a lipid component is that component of a nanoparticle composition that includes one or more lipids. For example, the lipid component may include one or more cationic/ionizable, PEGylated, structural, or other lipids, such as phospholipids.</div>
    </li> <li> <para-num num="[0273]"> </para-num> <div id="p-0310" num="0273" class="description-line">As used herein, a linker is a moiety connecting two moieties, for example, the connection between two nucleosides of a cap species. A linker may include one or more groups including but not limited to phosphate groups (e.g., phosphates, boranophosphates, thiophosphates, selenophosphates, and phosphonates), alkyl groups, amidates, or glycerols. For example, two nucleosides of a cap analog may be linked at their 5 positions by a triphosphate group or by a chain including two phosphate moieties and a boranophosphate moiety.</div>
    </li> <li> <para-num num="[0274]"> </para-num> <div id="p-0311" num="0274" class="description-line">As used herein, methods of administration may include intravenous, intramuscular, intradermal, subcutaneous, or other methods of delivering a composition to a subject. A method of administration may be selected to target delivery (e.g., to specifically deliver) to a specific region or system of a body.</div>
    </li> <li> <para-num num="[0275]"> </para-num> <div id="p-0312" num="0275" class="description-line">As used herein, modified means non-natural. For example, an RNA may be a modified RNA. That is, an RNA may include one or more nucleobases, nucleosides, nucleotides, or linkers that are non-naturally occurring. A modified species may also be referred to herein as an altered species. Species may be modified or altered chemically, structurally, or functionally. For example, a modified nucleobase species may include one or more substitutions that are not naturally occurring.</div>
    </li> <li> <para-num num="[0276]"> </para-num> <div id="p-0313" num="0276" class="description-line">As used herein, the N:P ratio is the molar ratio of ionizable (in the physiological pH range) nitrogen atoms in a lipid to phosphate groups in an RNA, e.g., in a nanoparticle composition including a lipid component and an RNA.</div>
    </li> <li> <para-num num="[0277]"> </para-num> <div id="p-0314" num="0277" class="description-line">As used herein, a nanoparticle composition is a composition comprising one or more lipids. Nanoparticle compositions are typically sized on the order of micrometers or smaller and may include a lipid bilayer. Nanoparticle compositions encompass lipid nanoparticles (LNPs), liposomes (e.g., lipid vesicles), and lipoplexes. For example, a nanoparticle composition may be a liposome having a lipid bilayer with a diameter of 500 nm or less.</div>
    </li> <li> <para-num num="[0278]"> </para-num> <div id="p-0315" num="0278" class="description-line">As used herein, naturally occurring means existing in nature without artificial aid.</div>
    </li> <li> <para-num num="[0279]"> </para-num> <div id="p-0316" num="0279" class="description-line">As used herein, patient refers to a subject who may seek or be in need of treatment, requires treatment, is receiving treatment, will receive treatment, or a subject who is under care by a trained professional for a particular disease or condition.</div>
    </li> <li> <para-num num="[0280]"> </para-num> <div id="p-0317" num="0280" class="description-line">As used herein, a PEG lipid or PEGylated lipid refers to a lipid comprising a polyethylene glycol component.</div>
    </li> <li> <para-num num="[0281]"> </para-num> <div id="p-0318" num="0281" class="description-line">The phrase pharmaceutically acceptable is used herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.</div>
    </li> <li> <para-num num="[0282]"> </para-num> <div id="p-0319" num="0282" class="description-line">The phrase pharmaceutically acceptable excipient, as used herein, refers to any ingredient other than the compounds described herein (for example, a vehicle capable of suspending, complexing, or dissolving the active compound) and having the properties of being substantially nontoxic and non-inflammatory in a patient. Excipients may include, for example: anti-adherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (colors), emollients, emulsifiers, fillers (diluents), film formers or coatings, flavors, fragrances, glidants (flow enhancers), lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, and waters of hydration. Exemplary excipients include, but are not limited to: butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (dibasic), calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E (alpha-tocopherol), vitamin C, xylitol, and other species disclosed herein.</div>
    </li> <li> <para-num num="[0283]"> </para-num> <div id="p-0320" num="0283" class="description-line">In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present disclosure includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like, it being understood that not all isomers may have the same level of activity. In addition, a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present disclosure.</div>
    </li> <li> <para-num num="[0284]"> </para-num> <div id="p-0321" num="0284" class="description-line">The term crystal polymorphs, polymorphs or crystal forms means crystal structures in which a compound (or a salt or solvate thereof) can crystallize in different crystal packing arrangements, all of which have the same elemental composition. Different crystal forms usually have different X-ray diffraction patterns, infrared spectral, melting points, density hardness, crystal shape, optical and electrical properties, stability and solubility. Recrystallization solvent, rate of crystallization, storage temperature, and other factors may cause one crystal form to dominate. Crystal polymorphs of the compounds can be prepared by crystallization under different conditions.</div>
    </li> <li> <para-num num="[0285]"> </para-num> <div id="p-0322" num="0285" class="description-line">Compositions may also include salts of one or more compounds. Salts may be pharmaceutically acceptable salts. As used herein, pharmaceutically acceptable salts refers to derivatives of the disclosed compounds wherein the parent compound is altered by converting an existing acid or base moiety to its salt form (e.g., by reacting a free base group with a suitable organic acid). Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Representative acid addition salts include acetate, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptonate, hexanoate, hydrobromide, hydrochloride, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like, as well as nontoxic ammonium, quaternary ammonium, and amine cations, including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. The pharmaceutically acceptable salts of the present disclosure include the conventional non-toxic salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. The pharmaceutically acceptable salts of the present disclosure can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington&#39;s Pharmaceutical Sciences, 17<sup>th </sup>ed., Mack Publishing Company, Easton, Pa., 1985, p. 1418, Pharmaceutical Salts: Properties, Selection, and Use, P. H. Stahl and C. G. Wermuth (eds.), Wiley-VCH, 2008, and Berge et al., Journal of Pharmaceutical Science, 66, 1-19 (1977), each of which is incorporated herein by reference in its entirety.</div>
    </li> <li> <para-num num="[0286]"> </para-num> <div id="p-0323" num="0286" class="description-line">As used herein, a phospholipid is a lipid that includes a phosphate moiety and one or more carbon chains, such as unsaturated fatty acid chains. A phospholipid may include one or more multiple (e.g., double or triple) bonds (e.g., one or more unsaturations). Particular phospholipids may facilitate fusion to a membrane. For example, a cationic phospholipid may interact with one or more negatively charged phospholipids of a membrane (e.g., a cellular or intracellular membrane). Fusion of a phospholipid to a membrane may allow one or more elements of a lipid-containing composition to pass through the membrane permitting, e.g., delivery of the one or more elements to a cell.</div>
    </li> <li> <para-num num="[0287]"> </para-num> <div id="p-0324" num="0287" class="description-line">As used herein, the polydispersity index is a ratio that describes the homogeneity of the particle size distribution of a system. A small value, e.g., less than 0.3, indicates a narrow particle size distribution.</div>
    </li> <li> <para-num num="[0288]"> </para-num> <div id="p-0325" num="0288" class="description-line">As used herein, the term polypeptide or polypeptide of interest refers to a polymer of amino acid residues typically joined by peptide bonds that can be produced naturally (e.g., isolated or purified) or synthetically.</div>
    </li> <li> <para-num num="[0289]"> </para-num> <div id="p-0326" num="0289" class="description-line">As used herein, an RNA refers to a ribonucleic acid that may be naturally or non-naturally occurring. For example, an RNA may include modified and/or non-naturally occurring components such as one or more nucleobases, nucleosides, nucleotides, or linkers. An RNA may include a cap structure, a chain terminating nucleoside, a stem loop, a polyA sequence, and/or a polyadenylation signal. An RNA may have a nucleotide sequence encoding a polypeptide of interest. For example, an RNA may be a messenger RNA (mRNA). Translation of an mRNA encoding a particular polypeptide, for example, in vivo translation of an mRNA inside a mammalian cell, may produce the encoded polypeptide. RNAs may be selected from the non-liming group consisting of small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), mRNA, and mixtures thereof.</div>
    </li> <li> <para-num num="[0290]"> </para-num> <div id="p-0327" num="0290" class="description-line">As used herein, a single unit dose is a dose of any therapeutic administered in one dose/at one time/single route/single point of contact, i.e., single administration event.</div>
    </li> <li> <para-num num="[0291]"> </para-num> <div id="p-0328" num="0291" class="description-line">As used herein, a split dose is the division of single unit dose or total daily dose into two or more doses.</div>
    </li> <li> <para-num num="[0292]"> </para-num> <div id="p-0329" num="0292" class="description-line">As used herein, a total daily dose is an amount given or prescribed in 24 hour period. It may be administered as a single unit dose.</div>
    </li> <li> <para-num num="[0293]"> </para-num> <div id="p-0330" num="0293" class="description-line">As used herein, size or mean size in the context of nanoparticle compositions refers to the mean diameter of a nanoparticle composition.</div>
    </li> <li> <para-num num="[0294]"> </para-num> <div id="p-0331" num="0294" class="description-line">As used herein, the term subject or patient refers to any organism to which a composition in accordance with the disclosure may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans) and/or plants.</div>
    </li> <li> <para-num num="[0295]"> </para-num> <div id="p-0332" num="0295" class="description-line">As used herein, targeted cells refers to any one or more cells of interest. The cells may be found in vitro, in vivo, in situ, or in the tissue or organ of an organism. The organism may be an animal, preferably a mammal, more preferably a human and most preferably a patient.</div>
    </li> <li> <para-num num="[0296]"> </para-num> <div id="p-0333" num="0296" class="description-line">As used herein target tissue refers to any one or more tissue types of interest in which the delivery of a therapeutic and/or prophylactic would result in a desired biological and/or pharmacological effect. Examples of target tissues of interest include specific tissues, organs, and systems or groups thereof. In particular applications, a target tissue may be a kidney, a lung, a spleen, vascular endothelium in vessels (e.g., intra-coronary or intra-femoral), or tumor tissue (e.g., via intratumoral injection). An off-target tissue refers to any one or more tissue types in which the expression of the encoded protein does not result in a desired biological and/or pharmacological effect. In particular applications, off-target tissues may include the liver and the spleen.</div>
    </li> <li> <para-num num="[0297]"> </para-num> <div id="p-0334" num="0297" class="description-line">The term therapeutic agent or prophylactic agent refers to any agent that, when administered to a subject, has a therapeutic, diagnostic, and/or prophylactic effect and/or elicits a desired biological and/or pharmacological effect. Therapeutic agents are also referred to as actives or active agents. Such agents include, but are not limited to, cytotoxins, radioactive ions, chemotherapeutic agents, small molecule drugs, proteins, and nucleic acids.</div>
    </li> <li> <para-num num="[0298]"> </para-num> <div id="p-0335" num="0298" class="description-line">As used herein, the term therapeutically effective amount means an amount of an agent to be delivered (e.g., nucleic acid, drug, composition, therapeutic agent, diagnostic agent, prophylactic agent, etc.) that is sufficient, when administered to a subject suffering from or susceptible to an infection, disease, disorder, and/or condition, to treat, improve symptoms of, diagnose, prevent, and/or delay the onset of the infection, disease, disorder, and/or condition.</div>
    </li> <li> <para-num num="[0299]"> </para-num> <div id="p-0336" num="0299" class="description-line">As used herein, transfection refers to the introduction of a species (e.g., an RNA) into a cell. Transfection may occur, for example, in vitro, ex vivo, or in vivo.</div>
    </li> <li> <para-num num="[0300]"> </para-num> <div id="p-0337" num="0300" class="description-line">As used herein, the term treating refers to partially or completely alleviating, ameliorating, improving, relieving, delaying onset of, inhibiting progression of, reducing severity of, and/or reducing incidence of one or more symptoms or features of a particular infection, disease, disorder, and/or condition. For example, treating cancer may refer to inhibiting survival, growth, and/or spread of a tumor. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and/or condition and/or to a subject who exhibits only early signs of a disease, disorder, and/or condition for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and/or condition.</div>
    </li> <li> <para-num num="[0301]"> </para-num> <div id="p-0338" num="0301" class="description-line">As used herein, the zeta potential is the electrokinetic potential of a lipid, e.g., in a particle composition.</div>
    </li> <heading id="h-0009">Nanoparticle Compositions</heading>
    <li> <para-num num="[0302]"> </para-num> <div id="p-0339" num="0302" class="description-line">The disclosure also features nanoparticle compositions comprising a lipid component comprising a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) as described herein.</div>
    </li> <li> <para-num num="[0303]"> </para-num> <div id="p-0340" num="0303" class="description-line">In some embodiments, the largest dimension of a nanoparticle composition is 1 m or shorter (e.g., 1 m, 900 nm, 800 nm, 700 nm, 600 nm, 500 nm, 400 nm, 300 nm, 200 nm, 175 nm, 150 nm, 125 nm, 100 nm, 75 nm, 50 nm, or shorter), e.g., when measured by dynamic light scattering (DLS), transmission electron microscopy, scanning electron microscopy, or another method. Nanoparticle compositions include, for example, lipid nanoparticles (LNPs), liposomes, lipid vesicles, and lipoplexes. In some embodiments, nanoparticle compositions are vesicles including one or more lipid bilayers. In certain embodiments, a nanoparticle composition includes two or more concentric bilayers separated by aqueous compartments. Lipid bilayers may be functionalized and/or crosslinked to one another. Lipid bilayers may include one or more ligands, proteins, or channels.</div>
    </li> <li> <para-num num="[0304]"> </para-num> <div id="p-0341" num="0304" class="description-line">Nanoparticle compositions comprise a lipid component including at least one compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). For example, the lipid component of a nanoparticle composition may include one or more of Compounds 1-147. Nanoparticle compositions may also include a variety of other components. For example, the lipid component of a nanoparticle composition may include one or more other lipids in addition to a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</div>
    </li> <heading id="h-0010">Cationic/Ionizable Lipids</heading>
    <li> <para-num num="[0305]"> </para-num> <div id="p-0342" num="0305" class="description-line">A nanoparticle composition may include one or more cationic and/or ionizable lipids (e.g., lipids that may have a positive or partial positive charge at physiological pH) in addition to a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). Cationic and/or ionizable lipids may be selected from the non-limiting group consisting of 3-(didodecylamino)-N1,N1,4-tridodecyl-1-piperazineethanamine (KL10), N1-[2-(didodecylamino)ethyl]-N1,N4,N4-tridodecyl-1,4-piperazinediethanamine (KL22), 14,25-ditridecyl-15,18,21,24-tetraaza-octatriacontane (KL25), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane (DLin-K-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (DLin-MC3-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), 1,2-dioleyloxy-N,N-dimethylaminopropane (DODMA), 2-({8-[(3)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA), (2R)-2-({8-[(3)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA (2R)), and (2S)-2-({8-[(313)-cholest-5-en-3-yloxy]octyl}oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (Octyl-CLinDMA (2S)). In addition to these, a cationic lipid may also be a lipid including a cyclic amine group.</div>
    </li> <heading id="h-0011">PEG Lipids</heading>
    <li> <para-num num="[0306]"> </para-num> <div id="p-0343" num="0306" class="description-line">The lipid component of a nanoparticle composition may include one or more PEG or PEG-modified lipids. Such species may be alternately referred to as PEGylated lipids. A PEG lipid is a lipid modified with polyethylene glycol. A PEG lipid may be selected from the non-limiting group consisting of PEG-modified phosphatidylethanolamines, PEG-modified phosphatidic acids, PEG-modified ceramides, PEG-modified dialkylamines, PEG-modified diacylglycerols, PEG-modified dialkylglycerols, and mixtures thereof. For example, a PEG lipid may be PEG-c-DOMG, PEG-DMG, PEG-DLPE, PEG-DMPE, PEG-DPPC, or a PEG-DSPE lipid.</div>
    </li> <heading id="h-0012">Structural Lipids</heading>
    <li> <para-num num="[0307]"> </para-num> <div id="p-0344" num="0307" class="description-line">The lipid component of a nanoparticle composition may include one or more structural lipids. Structural lipids can be selected from the group consisting of, but are not limited to, cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, tomatine, ursolic acid, alpha-tocopherol, and mixtures thereof. In some embodiments, the structural lipid is cholesterol. In some embodiments, the structural lipid includes cholesterol and a corticosteroid (such as prednisolone, dexamethasone, prednisone, and hydrocortisone), or a combination thereof.</div>
    </li> <heading id="h-0013">Phospholipids</heading>
    <li> <para-num num="[0308]"> </para-num> <div id="p-0345" num="0308" class="description-line">The lipid component of a nanoparticle composition may include one or more phospholipids, such as one or more (poly)unsaturated lipids. Phospholipids may assemble into one or more lipid bilayers. In general, phospholipids may include a phospholipid moiety and one or more fatty acid moieties. For example, a phospholipid may be a lipid according to Formula (III):</div>
    </li> <li> <div id="p-0346" num="0000" class="description-line">
      <chemistry id="CHEM-US-00074" num="00074">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/b6/09/8dd2970f55cad8/US20170210697A1-20170727-C00074.png"><img id="EMI-C00074" he="27.35mm" wi="62.74mm" file="US20170210697A1-20170727-C00074.TIF" alt="Figure US20170210697A1-20170727-C00074" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="251" height="109" alt="Figure US20170210697A1-20170727-C00074" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/b6/09/8dd2970f55cad8/US20170210697A1-20170727-C00074.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00074" attachment-type="cdx" file="US20170210697A1-20170727-C00074.CDX"> </attachment>
          <attachment idref="CHEM-US-00074" attachment-type="mol" file="US20170210697A1-20170727-C00074.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0347" num="0000" class="description-line">in which R<sub>p </sub>represents a phospholipid moiety and R<sub>1 </sub>and R<sub>2 </sub>represent fatty acid moieties with or without unsaturation that may be the same or different. A phospholipid moiety may be selected from the non-limiting group consisting of phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl glycerol, phosphatidyl serine, phosphatidic acid, 2-lysophosphatidyl choline, and a sphingomyelin. A fatty acid moiety may be selected from the non-limiting group consisting of lauric acid, myristic acid, myristoleic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, linoleic acid, alpha-linolenic acid, erucic acid, phytanoic acid, arachidic acid, arachidonic acid, eicosapentaenoic acid, behenic acid, docosapentaenoic acid, and docosahexaenoic acid. Non-natural species including natural species with modifications and substitutions including branching, oxidation, cyclization, and alkynes are also contemplated. For example, a phospholipid may be functionalized with or cross-linked to one or more alkynes (e.g., an alkenyl group in which one or more double bonds is replaced with a triple bond). Under appropriate reaction conditions, an alkyne group may undergo a copper-catalyzed cycloaddition upon exposure to an azide. Such reactions may be useful in functionalizing a lipid bilayer of a nanoparticle composition to facilitate membrane permeation or cellular recognition or in conjugating a nanoparticle composition to a useful component such as a targeting or imaging moiety (e.g., a dye).</div>
    </li> <li> <para-num num="[0309]"> </para-num> <div id="p-0348" num="0309" class="description-line">Phospholipids useful in the compositions and methods may be selected from the non-limiting group consisting of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC), 1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC), 1-hexadecyl-sn-glycero-3-phosphocholine (C16 Lyso PC), 1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine, 1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine, 1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine, 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, 1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), and sphingomyelin. In some embodiments, a nanoparticle composition includes DSPC. In certain embodiments, a nanoparticle composition includes DOPE. In some embodiments, a nanoparticle composition includes both DSPC and DOPE.</div>
    </li> <heading id="h-0014">Adjuvants</heading>
    <li> <para-num num="[0310]"> </para-num> <div id="p-0349" num="0310" class="description-line">In some embodiments, a nanoparticle composition that includes one or more lipids described herein may further include one or more adjuvants, e.g., Glucopyranosyl Lipid Adjuvant (GLA), CpG oligodeoxynucleotides (e.g., Class A or B), poly(I:C), aluminum hydroxide, and Pam3CSK4.</div>
    </li> <heading id="h-0015">Therapeutic Agents</heading>
    <li> <para-num num="[0311]"> </para-num> <div id="p-0350" num="0311" class="description-line">Nanoparticle compositions may include one or more therapeutic and/or prophylactics. The disclosure features methods of delivering a therapeutic and/or prophylactic to a mammalian cell or organ, producing a polypeptide of interest in a mammalian cell, and treating a disease or disorder in a mammal in need thereof comprising administering to a mammal and/or contacting a mammalian cell with a nanoparticle composition including a therapeutic and/or prophylactic.</div>
    </li> <li> <para-num num="[0312]"> </para-num> <div id="p-0351" num="0312" class="description-line">Therapeutic and/or prophylactics include biologically active substances and are alternately referred to as active agents. A therapeutic and/or prophylactic may be a substance that, once delivered to a cell or organ, brings about a desirable change in the cell, organ, or other bodily tissue or system. Such species may be useful in the treatment of one or more diseases, disorders, or conditions. In some embodiments, a therapeutic and/or prophylactic is a small molecule drug useful in the treatment of a particular disease, disorder, or condition. Examples of drugs useful in the nanoparticle compositions include, but are not limited to, antineoplastic agents (e.g., vincristine, doxorubicin, mitoxantrone, camptothecin, cisplatin, bleomycin, cyclophosphamide, methotrexate, and streptozotocin), antitumor agents (e.g., actinomycin D, vincristine, vinblastine, cystine arabinoside, anthracyclines, alkylative agents, platinum compounds, antimetabolites, and nucleoside analogs, such as methotrexate and purine and pyrimidine analogs), anti-infective agents, local anesthetics (e.g., dibucaine and chlorpromazine), beta-adrenergic blockers (e.g., propranolol, timolol, and labetolol), antihypertensive agents (e.g., clonidine and hydralazine), anti-depressants (e.g., imipramine, amitriptyline, and doxepim), anti-conversants (e.g., phenytoin), antihistamines (e.g., diphenhydramine, chlorphenirimine, and promethazine), antibiotic/antibacterial agents (e.g., gentamycin, ciprofloxacin, and cefoxitin), antifungal agents (e.g., miconazole, terconazole, econazole, isoconazole, butaconazole, clotrimazole, itraconazole, nystatin, naftifine, and amphotericin B), antiparasitic agents, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, antiglaucoma agents, vitamins, narcotics, and imaging agents.</div>
    </li> <li> <para-num num="[0313]"> </para-num> <div id="p-0352" num="0313" class="description-line">In some embodiments, a therapeutic and/or prophylactic is a cytotoxin, a radioactive ion, a chemotherapeutic, a vaccine, a compound that elicits an immune response, and/or another therapeutic and/or prophylactic. A cytotoxin or cytotoxic agent includes any agent that may be detrimental to cells. Examples include, but are not limited to, taxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracinedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, maytansinoids, e.g., maytansinol, rachelmycin (CC-1065), and analogs or homologs thereof. Radioactive ions include, but are not limited to iodine (e.g., iodine 125 or iodine 131), strontium 89, phosphorous, palladium, cesium, iridium, phosphate, cobalt, yttrium 90, samarium 153, and praseodymium. Vaccines include compounds and preparations that are capable of providing immunity against one or more conditions related to infectious diseases such as influenza, measles, human papillomavirus (HPV), rabies, meningitis, whooping cough, tetanus, plague, hepatitis, and tuberculosis and can include mRNAs encoding infectious disease derived antigens and/or epitopes. Vaccines also include compounds and preparations that direct an immune response against cancer cells and can include mRNAs encoding tumor cell derived antigens, epitopes, and/or neoepitopes. Compounds eliciting immune responses may include vaccines, corticosteroids (e.g., dexamethasone), and other species. In some embodiments, a vaccine and/or a compound capable of eliciting an immune response is administered intramuscularly via a composition including a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) (e.g., <figure-callout id="3" label="Compound" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}"> <figure-callout id="18" label="Compound" filenames="US20170210697A1-20170727-D00004.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="20" label="Compound" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00004.png" state="{{state}}"> <figure-callout id="25" label="Compound" filenames="US20170210697A1-20170727-D00005.png,US20170210697A1-20170727-D00007.png" state="{{state}}"> <figure-callout id="26" label="Compound" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Compound</figure-callout> </figure-callout> </figure-callout> </figure-callout> </figure-callout> 3, 18, 20, 25, 26, 29, 30, 60, 108-112, or 122). Other therapeutic and/or prophylactics include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thiotepa chlorambucil, rachelmycin (CC-1065), melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine, vinblastine, taxol and maytansinoids).</div>
    </li> <li> <para-num num="[0314]"> </para-num> <div id="p-0353" num="0314" class="description-line">In other embodiments, a therapeutic and/or prophylactic is a protein. Therapeutic proteins useful in the nanoparticles in the disclosure include, but are not limited to, gentamycin, amikacin, insulin, erythropoietin (EPO), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), Factor VIR, luteinizing hormone-releasing hormone (LHRH) analogs, interferons, heparin, Hepatitis B surface antigen, typhoid vaccine, and cholera vaccine.</div>
    </li> <heading id="h-0016">Polynucleotides and Nucleic Acids</heading>
    <li> <para-num num="[0315]"> </para-num> <div id="p-0354" num="0315" class="description-line">In some embodiments, a therapeutic agent is a polynucleotide or nucleic acid (e.g., ribonucleic acid or deoxyribonucleic acid). The term polynucleotide, in its broadest sense, includes any compound and/or substance that is or can be incorporated into an oligonucleotide chain. Exemplary polynucleotides for use in accordance with the present disclosure include, but are not limited to, one or more of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) including messenger mRNA (mRNA), hybrids thereof, RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, RNAs that induce triple helix formation, aptamers, vectors, etc. In some embodiments, a therapeutic and/or prophylactic is an RNA. RNAs useful in the compositions and methods described herein can be selected from the group consisting of, but are not limited to, shortmers, antagomirs, antisense, ribozymes, small interfering RNA (siRNA), asymmetrical interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), and mixtures thereof. In certain embodiments, the RNA is an mRNA.</div>
    </li> <li> <para-num num="[0316]"> </para-num> <div id="p-0355" num="0316" class="description-line">In certain embodiments, a therapeutic and/or prophylactic is an mRNA. An mRNA may encode any polypeptide of interest, including any naturally or non-naturally occurring or otherwise modified polypeptide. A polypeptide encoded by an mRNA may be of any size and may have any secondary structure or activity. In some embodiments, a polypeptide encoded by an mRNA may have a therapeutic effect when expressed in a cell.</div>
    </li> <li> <para-num num="[0317]"> </para-num> <div id="p-0356" num="0317" class="description-line">In other embodiments, a therapeutic and/or prophylactic is an siRNA. An siRNA may be capable of selectively knocking down or down regulating expression of a gene of interest. For example, an siRNA could be selected to silence a gene associated with a particular disease, disorder, or condition upon administration to a subject in need thereof of a nanoparticle composition including the siRNA. An siRNA may comprise a sequence that is complementary to an mRNA sequence that encodes a gene or protein of interest. In some embodiments, the siRNA may be an immunomodulatory siRNA.</div>
    </li> <li> <para-num num="[0318]"> </para-num> <div id="p-0357" num="0318" class="description-line">In some embodiments, a therapeutic and/or prophylactic is an shRNA or a vector or plasmid encoding the same. An shRNA may be produced inside a target cell upon delivery of an appropriate construct to the nucleus. Constructs and mechanisms relating to shRNA are well known in the relevant arts.</div>
    </li> <li> <para-num num="[0319]"> </para-num> <div id="p-0358" num="0319" class="description-line">Nucleic acids and polynucleotides useful in the disclosure typically include a first region of linked nucleosides encoding a polypeptide of interest (e.g., a coding region), a first flanking region located at the 5-terminus of the first region (e.g., a 5-UTR), a second flanking region located at the 3-terminus of the first region (e.g., a 3-UTR), at least one 5-cap region, and a 3-stabilizing region. In some embodiments, a nucleic acid or polynucleotide further includes a poly-A region or a Kozak sequence (e.g., in the 5-UTR). In some cases, polynucleotides may contain one or more intronic nucleotide sequences capable of being excised from the polynucleotide. In some embodiments, a polynucleotide or nucleic acid (e.g., an mRNA) may include a 5 cap structure, a chain terminating nucleotide, a stem loop, a polyA sequence, and/or a polyadenylation signal. Any one of the regions of a nucleic acid may include one or more alternative components (e.g., an alternative nucleoside). For example, the 3-stabilizing region may contain an alternative nucleoside such as an L-nucleoside, an inverted thymidine, or a 2-O-methyl nucleoside and/or the coding region, 5-UTR, 3-UTR, or cap region may include an alternative nucleoside such as a 5-substituted uridine (e.g., 5-methoxyuridine), a 1-substituted pseudouridine (e.g., 1-methyl-pseudouridine or 1-ethyl-pseudouridine), and/or a 5-substituted cytidine (e.g., 5-methyl-cytidine).</div>
    </li> <li> <para-num num="[0320]"> </para-num> <div id="p-0359" num="0320" class="description-line">Generally, the shortest length of a polynucleotide can be the length of the polynucleotide sequence that is sufficient to encode for a dipeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a tripeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a tetrapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a pentapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a hexapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a heptapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for an octapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a nonapeptide. In another embodiment, the length of the polynucleotide sequence is sufficient to encode for a decapeptide.</div>
    </li> <li> <para-num num="[0321]"> </para-num> <div id="p-0360" num="0321" class="description-line">Examples of dipeptides that the alternative polynucleotide sequences can encode for include, but are not limited to, carnosine and anserine.</div>
    </li> <li> <para-num num="[0322]"> </para-num> <div id="p-0361" num="0322" class="description-line">In some cases, a polynucleotide is greater than 30 nucleotides in length. In another embodiment, the polynucleotide molecule is greater than 35 nucleotides in length. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 50 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides. In another embodiment, the length is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides. In another embodiment, the length is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides. In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides. In another embodiment, the length is at least 1800 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides. In another embodiment, the length is at least 4000 nucleotides. In another embodiment, the length is at least 5000 nucleotides, or greater than 5000 nucleotides.</div>
    </li> <li> <para-num num="[0323]"> </para-num> <div id="p-0362" num="0323" class="description-line">Nucleic acids and polynucleotides may include one or more naturally occurring components, including any of the canonical nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine). In one embodiment, all or substantially all of the nucleotides comprising (a) the 5-UTR, (b) the open reading frame (ORF), (c) the 3-UTR, (d) the poly A tail, and any combination of (a, b, c, or d above) comprise naturally occurring canonical nucleotides A (adenosine), G (guanosine), C (cytosine), U (uridine), or T (thymidine).</div>
    </li> <li> <para-num num="[0324]"> </para-num> <div id="p-0363" num="0324" class="description-line">Nucleic acids and polynucleotides may include one or more alternative components, as described herein, which impart useful properties including increased stability and/or the lack of a substantial induction of the innate immune response of a cell into which the polynucleotide is introduced. For example, an alternative polynucleotide or nucleic acid exhibits reduced degradation in a cell into which the polynucleotide or nucleic acid is introduced, relative to a corresponding unaltered polynucleotide or nucleic acid. These alternative species may enhance the efficiency of protein production, intracellular retention of the polynucleotides, and/or viability of contacted cells, as well as possess reduced immunogenicity.</div>
    </li> <li> <para-num num="[0325]"> </para-num> <div id="p-0364" num="0325" class="description-line">Polynucleotides and nucleic acids may be naturally or non-naturally occurring. Polynucleotides and nucleic acids may include one or more modified (e.g., altered or alternative) nucleobases, nucleosides, nucleotides, or combinations thereof. The nucleic acids and polynucleotides useful in a nanoparticle composition can include any useful modification or alteration, such as to the nucleobase, the sugar, or the internucleoside linkage (e.g., to a linking phosphate/to a phosphodiester linkage/to the phosphodiester backbone). In certain embodiments, alterations (e.g., one or more alterations) are present in each of the nucleobase, the sugar, and the internucleoside linkage. Alterations according to the present disclosure may be alterations of ribonucleic acids (RNAs) to deoxyribonucleic acids (DNAs), e.g., the substitution of the 2-OH of the ribofuranosyl ring to 2-H, threose nucleic acids (TNAs), glycol nucleic acids (GNAs), peptide nucleic acids (PNAs), locked nucleic acids (LNAs), or hybrids thereof. Additional alterations are described herein.</div>
    </li> <li> <para-num num="[0326]"> </para-num> <div id="p-0365" num="0326" class="description-line">Polynucleotides and nucleic acids may or may not be uniformly altered along the entire length of the molecule. For example, one or more or all types of nucleotide (e.g., purine or pyrimidine, or any one or more or all of A, G, U, C) may or may not be uniformly altered in a polynucleotide or nucleic acid, or in a given predetermined sequence region thereof. In some instances, all nucleotides X in a polynucleotide (or in a given sequence region thereof) are altered, wherein X may any one of nucleotides A, G, U, C, or any one of the combinations A+G, A+U, A+C, G+U, G+C, U+C, A+G+U, A+G+C, G+U+C or A+G+C.</div>
    </li> <li> <para-num num="[0327]"> </para-num> <div id="p-0366" num="0327" class="description-line">Different sugar alterations and/or internucleoside linkages (e.g., backbone structures) may exist at various positions in a polynucleotide. One of ordinary skill in the art will appreciate that the nucleotide analogs or other alteration(s) may be located at any position(s) of a polynucleotide such that the function of the polynucleotide is not substantially decreased. An alteration may also be a 5- or 3-terminal alteration. In some embodiments, the polynucleotide includes an alteration at the 3-terminus. The polynucleotide may contain from about 1% to about 100% alternative nucleotides (either in relation to overall nucleotide content, or in relation to one or more types of nucleotide, i.e., any one or more of A, G, U or C) or any intervening percentage (e.g., from 1% to 20%, from 1% to 25%, from 1% to 50%, from 1% to 60%, from 1% to 70%, from 1% to 80%, from 1% to 90%, from 1% to 95%, from 10% to 20%, from 10% to 25%, from 10% to 50%, from 10% to 60%, from 10% to 70%, from 10% to 80%, from 10% to 90%, from 10% to 95%, from 10% to 100%, from 20% to 25%, from 20% to 50%, from 20% to 60%, from 20% to 70%, from 20% to 80%, from 20% to 90%, from 20% to 95%, from 20% to 100%, from 50% to 60%, from 50% to 70%, from 50% to 80%, from 50% to 90%, from 50% to 95%, from 50% to 100%, from 70% to 80%, from 70% to 90%, from 70% to 95%, from 70% to 100%, from 80% to 90%, from 80% to 95%, from 80% to 100%, from 90% to 95%, from 90% to 100%, and from 95% to 100%). It will be understood that any remaining percentage is accounted for by the presence of a canonical nucleotide (e.g., A, G, U, or C).</div>
    </li> <li> <para-num num="[0328]"> </para-num> <div id="p-0367" num="0328" class="description-line">Polynucleotides may contain at a minimum zero and at maximum 100% alternative nucleotides, or any intervening percentage, such as at least 5% alternative nucleotides, at least 10% alternative nucleotides, at least 25% alternative nucleotides, at least 50% alternative nucleotides, at least 80% alternative nucleotides, or at least 90% alternative nucleotides. For example, polynucleotides may contain an alternative pyrimidine such as an alternative uracil or cytosine. In some embodiments, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the uracil in a polynucleotide is replaced with an alternative uracil (e.g., a 5-substituted uracil). The alternative uracil can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures). In some instances, at least 5%, at least 10%, at least 25%, at least 50%, at least 80%, at least 90% or 100% of the cytosine in the polynucleotide is replaced with an alternative cytosine (e.g., a 5-substituted cytosine). The alternative cytosine can be replaced by a compound having a single unique structure, or can be replaced by a plurality of compounds having different structures (e.g., 2, 3, 4 or more unique structures).</div>
    </li> <li> <para-num num="[0329]"> </para-num> <div id="p-0368" num="0329" class="description-line">In some instances, nucleic acids do not substantially induce an innate immune response of a cell into which the polynucleotide (e.g., mRNA) is introduced. Features of an induced innate immune response include 1) increased expression of pro-inflammatory cytokines, 2) activation of intracellular PRRs (RIG-I, MDA5, etc., and/or 3) termination or reduction in protein translation.</div>
    </li> <li> <para-num num="[0330]"> </para-num> <div id="p-0369" num="0330" class="description-line">The nucleic acids can optionally include other agents (e.g., RNAi-inducing agents, RNAi agents, siRNAs, shRNAs, miRNAs, antisense RNAs, ribozymes, catalytic DNA, tRNA, RNAs that induce triple helix formation, aptamers, vectors). In some embodiments, the nucleic acids may include one or more messenger RNAs (mRNAs) having one or more alternative nucleoside or nucleotides (i.e., alternative mRNA molecules).</div>
    </li> <li> <para-num num="[0331]"> </para-num> <div id="p-0370" num="0331" class="description-line">In some embodiments, a nucleic acid (e.g. mRNA) molecule, formula, composition or method associated therewith comprises one or more polynucleotides comprising features as described in WO2002/098443, WO2003/051401, WO2008/052770, WO2009127230, WO2006122828, WO2008/083949, WO2010088927, WO2010/037539, WO2004/004743, WO2005/016376, WO2006/024518, WO2007/095976, WO2008/014979, WO2008/077592, WO2009/030481, WO2009/095226, WO2011069586, WO2011026641, WO2011/144358, WO2012019780, WO2012013326, WO2012089338, WO2012113513, WO2012116811, WO2012116810, WO2013113502, WO2013113501, WO2013113736, WO2013143698, WO2013143699, WO2013143700, WO2013/120626, WO2013120627, WO2013120628, WO2013120629, WO2013174409, WO2014127917, WO2015/024669, WO2015/024668, WO2015/024667, WO2015/024665, WO2015/024666, WO2015/024664, WO2015101415, WO2015101414, WO2015024667, WO2015062738, WO2015101416, all of which are incorporated by reference herein.</div>
    </li> <heading id="h-0017">Nucleobase Alternatives</heading>
    <li> <para-num num="[0332]"> </para-num> <div id="p-0371" num="0332" class="description-line">The alternative nucleosides and nucleotides can include an alternative nucleobase. A nucleobase of a nucleic acid is an organic base such as a purine or pyrimidine or a derivative thereof. A nucleobase may be a canonical base (e.g., adenine, guanine, uracil, thymine, and cytosine). These nucleobases can be altered or wholly replaced to provide polynucleotide molecules having enhanced properties, e.g., increased stability such as resistance to nucleases. Non-canonical or modified bases may include, for example, one or more substitutions or modifications including but not limited to alkyl, aryl, halo, oxo, hydroxyl, alkyloxy, and/or thio substitutions; one or more fused or open rings; oxidation; and/or reduction.</div>
    </li> <li> <para-num num="[0333]"> </para-num> <div id="p-0372" num="0333" class="description-line">Alternative nucleotide base pairing encompasses not only the standard adenine-thymine, adenine-uracil, or guanine-cytosine base pairs, but also base pairs formed between nucleotides and/or alternative nucleotides including non-standard or alternative bases, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits hydrogen bonding between a non-standard base and a standard base or between two complementary non-standard base structures. One example of such non-standard base pairing is the base pairing between the alternative nucleotide inosine and adenine, cytosine, or uracil.</div>
    </li> <li> <para-num num="[0334]"> </para-num> <div id="p-0373" num="0334" class="description-line">In some embodiments, the nucleobase is an alternative uracil. Exemplary nucleobases and nucleosides having an alternative uracil include pseudouridine (), pyridin-4-one ribonucleoside, 5-aza-uracil, 6-aza-uracil, 2-thio-5-aza-uracil, 2-thio-uracil (s<sup>2</sup>U), 4-thio-uracil (s<sup>4</sup>U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uracil (ho<sup>5</sup>U), 5-aminoallyl-uracil, 5-halo-uracil (e.g., 5-iodo-uracil or 5-bromo-uracil), 3-methyl-uracil (m<sup>3</sup>U), 5-methoxy-uracil (mo<sup>5</sup>U), uracil 5-oxyacetic acid (cmo<sup>5</sup>U), uracil 5-oxyacetic acid methyl ester (mcmo<sup>5</sup>U), 5-carboxymethyl-uracil (cm<sup>5</sup>U), 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uracil (chm<sup>5</sup>U), 5-carboxyhydroxymethyl-uracil methyl ester (mchm<sup>5</sup>U), 5-methoxycarbonylmethyl-uracil (mcm<sup>5</sup>U), 5-methoxycarbonylmethyl-2-thio-uracil (mcm<sup>5</sup>s<sup>2</sup>U), 5-aminomethyl-2-thio-uracil (nm<sup>5</sup>s<sup>2</sup>U), 5-methylaminomethyl-uracil (mnm<sup>5</sup>U), 5-methylaminomethyl-2-thio-uracil (mnm<sup>5</sup>s<sup>2</sup>U), 5-methylaminomethyl-2-seleno-uracil (mnm<sup>5</sup>se<sup>2</sup>U), 5-carbamoylmethyl-uracil (ncm<sup>5</sup>U), 5-carboxymethylaminomethyl-uracil (cmnm<sup>5</sup>U), 5-carboxymethylaminomethyl-2-thio-uracil (cmnm<sup>5</sup>s<sup>2</sup>U), 5-propynyl-uracil, 1-propynyl-pseudouracil, 5-taurinomethyl-uracil (m<sup>5</sup>U), 1-taurinomethyl-pseudouridine, 5-taurinomethyl-2-thio-uracil(m<sup>5</sup>s<sup>2</sup>U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uracil (m<sup>5</sup>U, i.e., having the nucleobase deoxythymine), 1-methyl-pseudouridine (m<sup>1</sup>), 1-ethyl-pseudouridine (Et<sup>1</sup>), 5-methyl-2-thio-uracil (m<sup>5</sup>s<sup>2</sup>U), 1-methyl-4-thio-pseudouridine (m<sup>1</sup>), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m<sup>3</sup>), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouracil (D), dihydropseudouridine, 5,6-dihydrouracil, 5-methyl-dihydrouracil (m<sup>5</sup>D), 2-thio-dihydrouracil, 2-thio-dihydropseudouridine, 2-methoxy-uracil, 2-methoxy-4-thio-uracil, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 3-(3-amino-3-carboxypropyl)uracil (acp<sup>3</sup>U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp<sup>3 </sup>), 5-(isopentenylaminomethyl)uracil (inm<sup>5</sup>U), 5-(isopentenylaminomethyl)-2-thio-uracil (inm<sup>5</sup>s<sup>2</sup>U), 5,2-O-dimethyl-uridine (m<sup>5</sup>Um), 2-thio-2-O_methyl-uridine (s<sup>2</sup>Um), 5-methoxycarbonylmethyl-2-O-methyl-uridine (mcm<sup>5</sup>Um), 5-carbamoylmethyl-2-O-methyl-uridine (ncm<sup>5</sup>Um), 5-carboxymethylaminomethyl-2-O-methyl-uridine (cmnm<sup>5</sup>Um), 3,2-O-dimethyl-uridine (m<sup>3</sup>Um), and 5-(isopentenylaminomethyl)-2-O-methyl-uridine (inm<sup>5</sup>Um), 1-thio-uracil, deoxythymidine, 5-(2-carbomethoxyvinyl)-uracil, 5-(carbamoylhydroxymethyl)-uracil, 5-carbamoylmethyl-2-thio-uracil, 5-carboxymethyl-2-thio-uracil, 5-cyanomethyl-uracil, 5-methoxy-2-thio-uracil, and 5-[3-(1-E-propenylamino)]uracil.</div>
    </li> <li> <para-num num="[0335]"> </para-num> <div id="p-0374" num="0335" class="description-line">In some embodiments, the nucleobase is an alternative cytosine. Exemplary nucleobases and nucleosides having an alternative cytosine include 5-aza-cytosine, 6-aza-cytosine, pseudoisocytidine, 3-methyl-cytosine (m3C), N4-acetyl-cytosine (ac4C), 5-formyl-cytosine (f5C), N4-methyl-cytosine (m4C), 5-methyl-cytosine (m5C), 5-halo-cytosine (e.g., 5-iodo-cytosine), 5-hydroxymethyl-cytosine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytosine, pyrrolo-pseudoisocytidine, 2-thio-cytosine (s2C), 2-thio-5-methyl-cytosine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine, 2-methoxy-cytosine, 2-methoxy-5-methyl-cytosine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k2C), 5,2-O-dimethyl-cytidine (m5Cm), N4-acetyl-2-O-methyl-cytidine (ac4Cm), N4,2-O-dimethyl-cytidine (m4Cm), 5-formyl-2-O-methyl-cytidine (f5Cm), N4,N4,2-O-trimethyl-cytidine (m42Cm), 1-thio-cytosine, 5-hydroxy-cytosine, 5-(3-azidopropyl)-cytosine, and 5-(2-azidoethyl)-cytosine.</div>
    </li> <li> <para-num num="[0336]"> </para-num> <div id="p-0375" num="0336" class="description-line">In some embodiments, the nucleobase is an alternative adenine. Exemplary nucleobases and nucleosides having an alternative adenine include 2-amino-purine, 2,6-diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6-chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenine, 7-deaza-adenine, 7-deaza-8-aza-adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine, 1-methyl-adenine (m1A), 2-methyl-adenine (m2A), N6-methyl-adenine (m6A), 2-methylthio-N6-methyl-adenine (ms2m6A), N6-isopentenyl-adenine (i6A), 2-methylthio-N6-isopentenyl-adenine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenine (ms2io6A), N6-glycinylcarbamoyl-adenine (g6A), N6-threonylcarbamoyl-adenine (t6A), N6-methyl-N6-threonylcarbamoyl-adenine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenine (ms2g6A), N6,N6-dimethyl-adenine (m62A), N6-hydroxynorvalylcarbamoyl-adenine (hn6A), 2-methylthio-N6-hydroxynorvalylcarbamoyl-adenine (ms2hn6A), N6-acetyl-adenine (ac6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, N6,2-O-dimethyl-adenosine (m6Am), N6,N6,2-O-trimethyl-adenosine (m62Am), 1,2-O-dimethyl-adenosine (m1Am), 2-amino-N6-methyl-purine, 1-thio-adenine, 8-azido-adenine, N6-(19-amino-pentaoxanonadecyl)-adenine, 2,8-dimethyl-adenine, N6-formyl-adenine, and N6-hydroxymethyl-adenine.</div>
    </li> <li> <para-num num="[0337]"> </para-num> <div id="p-0376" num="0337" class="description-line">In some embodiments, the nucleobase is an alternative guanine. Exemplary nucleobases and nucleosides having an alternative guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW), hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW*), 7-deaza-guanine, queuosine (Q), epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7-deaza-guanine (preQ0), 7-aminomethyl-7-deaza-guanine (preQ1), archaeosine (G+), 7-deaza-8-aza-guanine, 6-thio-guanine, 6-thio-7-deaza-guanine, 6-thio-7-deaza-8-aza-guanine, 7-methyl-guanine (m7G), 6-thio-7-methyl-guanine, 7-methyl-inosine, 6-methoxy-guanine, 1-methyl-guanine (m1G), N2-methyl-guanine (m2G), N2,N2-dimethyl-guanine (m22G), N2,7-dimethyl-guanine (m2,7G), N2, N2,7-dimethyl-guanine (m2,2,7G), 8-oxo-guanine, 7-methyl-8-oxo-guanine, 1-methyl-6-thio-guanine, N2-methyl-6-thio-guanine, N2,N2-dimethyl-6-thio-guanine, N2-methyl-2-O-methyl-guanosine (m2Gm), N2,N2-dimethyl-2-O-methyl-guanosine (m22Gm), 1-methyl-2-O-methyl-guanosine (m1Gm), N2,7-dimethyl-2-O-methyl-guanosine (m2,7Gm), 2-O-methyl-inosine (Im), 1,2-O-dimethyl-inosine (m1Im), 1-thio-guanine, and O-6-methyl-guanine.</div>
    </li> <li> <para-num num="[0338]"> </para-num> <div id="p-0377" num="0338" class="description-line">The alternative nucleobase of a nucleotide can be independently a purine, a pyrimidine, a purine or pyrimidine analog. For example, the nucleobase can be an alternative to adenine, cytosine, guanine, uracil, or hypoxanthine. In another embodiment, the nucleobase can also include, for example, naturally-occurring and synthetic derivatives of a base, including pyrazolo[3,4-d]pyrimidines, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxy and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3-deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5 triazinones, 9-deazapurines, imidazo[4,5-d]pyrazines, thiazolo[4,5-d]pyrimidines, pyrazin-2-ones, 1,2,4-triazine, pyridazine; or 1,3,5 triazine. When the nucleotides are depicted using the shorthand A, G, C, T or U, each letter refers to the representative base and/or derivatives thereof, e.g., A includes adenine or adenine analogs, e.g., 7-deaza adenine).</div>
    </li> <heading id="h-0018">Alterations on the Sugar</heading>
    <li> <para-num num="[0339]"> </para-num> <div id="p-0378" num="0339" class="description-line">Nucleosides include a sugar molecule (e.g., a 5-carbon or 6-carbon sugar, such as pentose, ribose, arabinose, xylose, glucose, galactose, or a deoxy derivative thereof) in combination with a nucleobase, while nucleotides are nucleosides containing a nucleoside and a phosphate group or alternative group (e.g., boranophosphate, thiophosphate, selenophosphate, phosphonate, alkyl group, amidate, and glycerol). A nucleoside or nucleotide may be a canonical species, e.g., a nucleoside or nucleotide including a canonical nucleobase, sugar, and, in the case of nucleotides, a phosphate group, or may be an alternative nucleoside or nucleotide including one or more alternative components. For example, alternative nucleosides and nucleotides can be altered on the sugar of the nucleoside or nucleotide. In some embodiments, the alternative nucleosides or nucleotides include the structure:</div>
    </li> <li> <div id="p-0379" num="0000" class="description-line">
      <chemistry id="CHEM-US-00075" num="00075">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e0/07/a2/6bbead560783f8/US20170210697A1-20170727-C00075.png"><img id="EMI-C00075" he="199.47mm" wi="70.19mm" file="US20170210697A1-20170727-C00075.TIF" alt="Figure US20170210697A1-20170727-C00075" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="281" height="798" alt="Figure US20170210697A1-20170727-C00075" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e0/07/a2/6bbead560783f8/US20170210697A1-20170727-C00075.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00075" attachment-type="cdx" file="US20170210697A1-20170727-C00075.CDX"> </attachment>
          <attachment idref="CHEM-US-00075" attachment-type="mol" file="US20170210697A1-20170727-C00075.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0380" num="0000" class="description-line">In each of the Formulae IV, V, VI and VII,</div>
    </li> <li> <para-num num="[0340]"> </para-num> <div id="p-0381" num="0340" class="description-line">each of m and n is independently, an integer from 0 to 5,</div>
    </li> <li> <para-num num="[0341]"> </para-num> <div id="p-0382" num="0341" class="description-line">each of U and U independently, is O, S, N(R<sup>U</sup>)<sub>nu</sub>, or C(R<sup>U</sup>)<sub>nu</sub>, wherein nu is an integer from 0 to 2 and each R<sup>U </sup>is, independently, H, halo, or optionally substituted alkyl;</div>
    </li> <li> <para-num num="[0342]"> </para-num> <div id="p-0383" num="0342" class="description-line">each of R<sup>1</sup>, R<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, and R<sup>5 </sup>is, independently, if present, H, halo, hydroxy, thiol, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted aminoalkoxy, optionally substituted alkoxyalkoxy, optionally substituted hydroxyalkoxy, optionally substituted amino, azido, optionally substituted aryl, optionally substituted aminoalkyl, optionally substituted aminoalkenyl, optionally substituted aminoalkynyl, or absent; wherein the combination of R<sup>3 </sup>with one or more of R<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>2</sup>, or R<sup>5 </sup>(e.g., the combination of R<sup>1</sup> and R<sup>3</sup>, the combination of R<sup>1</sup> and R<sup>3</sup>, the combination of R<sup>2</sup> and R<sup>3</sup>, the combination of R<sup>2</sup> and R<sup>3</sup>, or the combination of R<sup>5 </sup>and R<sup>3</sup>) can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); wherein the combination of R<sup>5 </sup>with one or more of R<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, or R<sup>2</sup> (e.g., the combination of R<sup>1</sup> and R<sup>5</sup>, the combination of R<sup>1</sup> and R<sup>5</sup>, the combination of R<sup>2</sup> and R<sup>5</sup>, or the combination of R<sup>2</sup> and R<sup>5</sup>) can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); and wherein the combination of R<sup>4 </sup>and one or more of R<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>2</sup>, R<sup>3</sup>, or R<sup>5 </sup>can join together to form optionally substituted alkylene or optionally substituted heteroalkylene and, taken together with the carbons to which they are attached, provide an optionally substituted heterocyclyl (e.g., a bicyclic, tricyclic, or tetracyclic heterocyclyl); each of m and m is, independently, an integer from 0 to 3 (e.g., from 0 to 2, from 0 to 1, from 1 to 3, or from 1 to 2);</div>
    </li> <li> <para-num num="[0343]"> </para-num> <div id="p-0384" num="0343" class="description-line">each of Y<sup>1</sup>, Y<sup>2</sup>, and Y<sup>3</sup>, is, independently, O, S, Se, NR<sup>N1</sup>, optionally substituted alkylene, or optionally substituted heteroalkylene, wherein R<sup>N1 </sup>is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, or absent; each Y<sup>4 </sup>is, independently, H, hydroxy, thiol, boranyl, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, optionally substituted alkenyloxy, optionally substituted alkynyloxy, optionally substituted thioalkoxy, optionally substituted alkoxyalkoxy, or optionally substituted amino;</div>
    </li> <li> <para-num num="[0344]"> </para-num> <div id="p-0385" num="0344" class="description-line">each Y<sup>5 </sup>is, independently, O, S, Se, optionally substituted alkylene (e.g., methylene), or optionally substituted heteroalkylene; and</div>
    </li> <li> <para-num num="[0345]"> </para-num> <div id="p-0386" num="0345" class="description-line">B is a nucleobase, either modified or unmodified. In some embodiments, the 2-hydroxy group (OH) can be modified or replaced with a number of different substituents. Exemplary substitutions at the 2-position include, but are not limited to, H, azido, halo (e.g., fluoro), optionally substituted C<sub>1-6 </sub>alkyl (e.g., methyl); optionally substituted C<sub>1-6 </sub>alkoxy (e.g., methoxy or ethoxy); optionally substituted C<sub>6-10 </sub>aryloxy; optionally substituted C<sub>3-8 </sub>cycloalkyl; optionally substituted C<sub>6-10 </sub>aryl-C<sub>1-6 </sub>alkoxy, optionally substituted C<sub>1-12 </sub>(heterocyclyl)oxy; a sugar (e.g., ribose, pentose, or any described herein); a polyethyleneglycol (PEG), O(CH<sub>2</sub>CH<sub>2</sub>O)<sub>n</sub>CH<sub>2</sub>CH<sub>2</sub>OR, where R is H or optionally substituted alkyl, and n is an integer from 0 to 20 (e.g., from 0 to 4, from 0 to 8, from 0 to 10, from 0 to 16, from 1 to 4, from 1 to 8, from 1 to 10, from 1 to 16, from 1 to 20, from 2 to 4, from 2 to 8, from 2 to 10, from 2 to 16, from 2 to 20, from 4 to 8, from 4 to 10, from 4 to 16, and from 4 to 20); locked nucleic acids (LNA) in which the 2-hydroxy is connected by a C<sub>1-6 </sub>alkylene or C<sub>1-6 </sub>heteroalkylene bridge to the 4-carbon of the same ribose sugar, where exemplary bridges included methylene, propylene, ether, or amino bridges; aminoalkyl, as defined herein; aminoalkoxy, as defined herein; amino as defined herein; and amino acid, as defined herein.</div>
    </li> <li> <para-num num="[0346]"> </para-num> <div id="p-0387" num="0346" class="description-line">Generally, RNA includes the sugar group ribose, which is a 5-membered ring having an oxygen. Exemplary, non-limiting alternative nucleotides include replacement of the oxygen in ribose (e.g., with S, Se, or alkylene, such as methylene or ethylene); addition of a double bond (e.g., to replace ribose with cyclopentenyl or cyclohexenyl); ring contraction of ribose (e.g., to form a 4-membered ring of cyclobutane or oxetane); ring expansion of ribose (e.g., to form a 6- or 7-membered ring having an additional carbon or heteroatom, such as for anhydrohexitol, altritol, mannitol, cyclohexanyl, cyclohexenyl, and morpholino (that also has a phosphoramidate backbone)); multicyclic forms (e.g., tricyclo and unlocked forms, such as glycol nucleic acid (GNA) (e.g., R-GNA or S-GNA, where ribose is replaced by glycol units attached to phosphodiester bonds), threose nucleic acid (TNA, where ribose is replace with -L-threofuranosyl-(32)), and peptide nucleic acid (PNA, where 2-amino-ethyl-glycine linkages replace the ribose and phosphodiester backbone).</div>
    </li> <li> <para-num num="[0347]"> </para-num> <div id="p-0388" num="0347" class="description-line">In some embodiments, the sugar group contains one or more carbons that possess the opposite stereochemical configuration of the corresponding carbon in ribose. Thus, a polynucleotide molecule can include nucleotides containing, e.g., arabinose or L-ribose, as the sugar.</div>
    </li> <li> <para-num num="[0348]"> </para-num> <div id="p-0389" num="0348" class="description-line">In some embodiments, the polynucleotide includes at least one nucleoside wherein the sugar is L-ribose, 2-O-methyl-ribose, 2-fluoro-ribose, arabinose, hexitol, an LNA, or a PNA.</div>
    </li> <heading id="h-0019">Alterations on the Internucleoside Linkage</heading>
    <li> <para-num num="[0349]"> </para-num> <div id="p-0390" num="0349" class="description-line">Alternative nucleotides can be altered on the internucleoside linkage (e.g., phosphate backbone). Herein, in the context of the polynucleotide backbone, the phrases phosphate and phosphodiester are used interchangeably. Backbone phosphate groups can be altered by replacing one or more of the oxygen atoms with a different substituent.</div>
    </li> <li> <para-num num="[0350]"> </para-num> <div id="p-0391" num="0350" class="description-line">The alternative nucleotides can include the wholesale replacement of an unaltered phosphate moiety with another internucleoside linkage as described herein. Examples of alternative phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be altered by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).</div>
    </li> <li> <para-num num="[0351]"> </para-num> <div id="p-0392" num="0351" class="description-line">The alternative nucleosides and nucleotides can include the replacement of one or more of the non-bridging oxygens with a borane moiety (BH<sub>3</sub>), sulfur (thio), methyl, ethyl, and/or methoxy. As a non-limiting example, two non-bridging oxygens at the same position (e.g., the alpha (), beta () or gamma () position) can be replaced with a sulfur (thio) and a methoxy.</div>
    </li> <li> <para-num num="[0352]"> </para-num> <div id="p-0393" num="0352" class="description-line">The replacement of one or more of the oxygen atoms at the a position of the phosphate moiety (e.g., -thio phosphate) is provided to confer stability (such as against exonucleases and endonucleases) to RNA and DNA through the unnatural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment.</div>
    </li> <li> <para-num num="[0353]"> </para-num> <div id="p-0394" num="0353" class="description-line">Other internucleoside linkages that may be employed according to the present disclosure, including internucleoside linkages which do not contain a phosphorous atom, are described herein.</div>
    </li> <heading id="h-0020">Internal Ribosome Entry Sites</heading>
    <li> <para-num num="[0354]"> </para-num> <div id="p-0395" num="0354" class="description-line">Polynucleotides may contain an internal ribosome entry site (IRES). An IRES may act as the sole ribosome binding site, or may serve as one of multiple ribosome binding sites of an mRNA. A polynucleotide containing more than one functional ribosome binding site may encode several peptides or polypeptides that are translated independently by the ribosomes (e.g., multicistronic mRNA). When polynucleotides are provided with an IRES, further optionally provided is a second translatable region. Examples of IRES sequences that can be used according to the present disclosure include without limitation, those from picornaviruses (e.g., FMDV), pest viruses (CFFV), polio viruses (PV), encephalomyocarditis viruses (ECMV), foot-and-mouth disease viruses (FMDV), hepatitis C viruses (HCV), classical swine fever viruses (CSFV), murine leukemia virus (MLV), simian immune deficiency viruses (SIV) or cricket paralysis viruses (CrPV).</div>
    </li> <heading id="h-0021">5-Cap Structure</heading>
    <li> <para-num num="[0355]"> </para-num> <div id="p-0396" num="0355" class="description-line">A polynucleotide (e.g., an mRNA) may include a 5-cap structure. The 5-cap structure of a polynucleotide is involved in nuclear export and increasing polynucleotide stability and binds the mRNA Cap Binding Protein (CBP), which is responsible for polynucleotide stability in the cell and translation competency through the association of CBP with poly-A binding protein to form the mature cyclic mRNA species. The cap further assists the removal of 5-proximal introns removal during mRNA splicing.</div>
    </li> <li> <para-num num="[0356]"> </para-num> <div id="p-0397" num="0356" class="description-line">Endogenous polynucleotide molecules may be 5-end capped generating a 5-ppp-5-triphosphate linkage between a terminal guanosine cap residue and the 5-terminal transcribed sense nucleotide of the polynucleotide. This 5-guanylate cap may then be methylated to generate an N7-methyl-guanylate residue. The ribose sugars of the terminal and/or anteterminal transcribed nucleotides of the 5 end of the polynucleotide may optionally also be 2-O-methylated. 5-decapping through hydrolysis and cleavage of the guanylate cap structure may target a polynucleotide molecule, such as an mRNA molecule, for degradation.</div>
    </li> <li> <para-num num="[0357]"> </para-num> <div id="p-0398" num="0357" class="description-line">Alterations to polynucleotides may generate a non-hydrolyzable cap structure preventing decapping and thus increasing polynucleotide half-life. Because cap structure hydrolysis requires cleavage of 5-ppp-5 phosphorodiester linkages, alternative nucleotides may be used during the capping reaction. For example, a Vaccinia Capping Enzyme from New England Biolabs (Ipswich, Mass.) may be used with -thio-guanosine nucleotides according to the manufacturer&#39;s instructions to create a phosphorothioate linkage in the 5-ppp-5 cap. Additional alternative guanosine nucleotides may be used such as -methyl-phosphonate and seleno-phosphate nucleotides.</div>
    </li> <li> <para-num num="[0358]"> </para-num> <div id="p-0399" num="0358" class="description-line">Additional alterations include, but are not limited to, 2-O-methylation of the ribose sugars of 5-terminal and/or 5-anteterminal nucleotides of the polynucleotide (as mentioned above) on the 2-hydroxy group of the sugar. Multiple distinct 5-cap structures can be used to generate the 5-cap of a polynucleotide, such as an mRNA molecule.</div>
    </li> <li> <para-num num="[0359]"> </para-num> <div id="p-0400" num="0359" class="description-line">5-Cap structures include those described in International Patent Publication Nos. WO2008127688, WO 2008016473, and WO 2011015347, the cap structures of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0360]"> </para-num> <div id="p-0401" num="0360" class="description-line">Cap analogs, which herein are also referred to as synthetic cap analogs, chemical caps, chemical cap analogs, or structural or functional cap analogs, differ from natural (i.e., endogenous, wild-type, or physiological) 5-caps in their chemical structure, while retaining cap function. Cap analogs may be chemically (i.e., non-enzymatically) or enzymatically synthesized and/linked to a polynucleotide.</div>
    </li> <li> <para-num num="[0361]"> </para-num> <div id="p-0402" num="0361" class="description-line">For example, the Anti-Reverse Cap Analog (ARCA) cap contains two guanosines linked by a 5-5-triphosphate group, wherein one guanosine contains an N7-methyl group as well as a 3-O-methyl group (i.e., N7,3-O-dimethyl-guanosine-5-triphosphate-5-guanosine, m<sup>7</sup>G-3mppp-G, which may equivalently be designated 3 O-Me-m7G(5)ppp(5)G). The 3-O atom of the other, unaltered, guanosine becomes linked to the 5-terminal nucleotide of the capped polynucleotide (e.g., an mRNA). The N7- and 3-O-methlyated guanosine provides the terminal moiety of the capped polynucleotide (e.g., mRNA).</div>
    </li> <li> <para-num num="[0362]"> </para-num> <div id="p-0403" num="0362" class="description-line">Another exemplary cap is mCAP, which is similar to ARCA but has a 2-O-methyl group on guanosine (i.e., N7,2-O-dimethyl-guanosine-5-triphosphate-5-guanosine, m<sup>7</sup>Gm-ppp-G).</div>
    </li> <li> <para-num num="[0363]"> </para-num> <div id="p-0404" num="0363" class="description-line">A cap may be a dinucleotide cap analog. As a non-limiting example, the dinucleotide cap analog may be modified at different phosphate positions with a boranophosphate group or a phophoroselenoate group such as the dinucleotide cap analogs described in U.S. Pat. No. 8,519,110, the cap structures of which are herein incorporated by reference.</div>
    </li> <li> <para-num num="[0364]"> </para-num> <div id="p-0405" num="0364" class="description-line">Alternatively, a cap analog may be a N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analog known in the art and/or described herein. Non-limiting examples of N7-(4-chlorophenoxyethyl) substituted dinucleotide cap analogs include a N7-(4-chlorophenoxyethyl)-G(5)ppp(5)G and a N7-(4-chlorophenoxyethyl)-m3-OG(5)ppp(5)G cap analog (see, e.g., the various cap analogs and the methods of synthesizing cap analogs described in Kore et al. Bioorganic &amp; Medicinal Chemistry 2013 21:4570-4574; the cap structures of which are herein incorporated by reference). In other instances, a cap analog useful in the polynucleotides of the present disclosure is a 4-chloro/bromophenoxyethyl analog.</div>
    </li> <li> <para-num num="[0365]"> </para-num> <div id="p-0406" num="0365" class="description-line">While cap analogs allow for the concomitant capping of a polynucleotide in an in vitro transcription reaction, up to 20% of transcripts remain uncapped. This, as well as the structural differences of a cap analog from endogenous 5-cap structures of polynucleotides produced by the endogenous, cellular transcription machinery, may lead to reduced translational competency and reduced cellular stability.</div>
    </li> <li> <para-num num="[0366]"> </para-num> <div id="p-0407" num="0366" class="description-line">Alternative polynucleotides may also be capped post-transcriptionally, using enzymes, in order to generate more authentic 5-cap structures. As used herein, the phrase more authentic refers to a feature that closely mirrors or mimics, either structurally or functionally, an endogenous or wild type feature. That is, a more authentic feature is better representative of an endogenous, wild-type, natural or physiological cellular function, and/or structure as compared to synthetic features or analogs of the prior art, or which outperforms the corresponding endogenous, wild-type, natural, or physiological feature in one or more respects. Non-limiting examples of more authentic 5-cap structures useful in the polynucleotides of the present disclosure are those which, among other things, have enhanced binding of cap binding proteins, increased half life, reduced susceptibility to 5-endonucleases, and/or reduced 5-decapping, as compared to synthetic 5-cap structures known in the art (or to a wild-type, natural or physiological 5-cap structure). For example, recombinant Vaccinia Virus Capping Enzyme and recombinant 2-O-methyltransferase enzyme can create a canonical 5-5-triphosphate linkage between the 5-terminal nucleotide of a polynucleotide and a guanosine cap nucleotide wherein the cap guanosine contains an N7-methylation and the 5-terminal nucleotide of the polynucleotide contains a 2-O-methyl. Such a structure is termed the Cap1 structure. This cap results in a higher translational-competency, cellular stability, and a reduced activation of cellular pro-inflammatory cytokines, as compared, e.g., to other 5cap analog structures known in the art. Other exemplary cap structures include 7mG(5)ppp(5)N,pN2p (Cap 0), 7mG(5)ppp(5)NlmpNp (Cap 1), 7mG(5)-ppp(5)NlmpN2mp (Cap 2), and m(7)Gpppm(3)(6,6,2)Apm(2)Apm(2)Cpm(2)(3,2)Up (Cap 4).</div>
    </li> <li> <para-num num="[0367]"> </para-num> <div id="p-0408" num="0367" class="description-line">Because the alternative polynucleotides may be capped post-transcriptionally, and because this process is more efficient, nearly 100% of the alternative polynucleotides may be capped. This is in contrast to 80% when a cap analog is linked to an polynucleotide in the course of an in vitro transcription reaction.</div>
    </li> <li> <para-num num="[0368]"> </para-num> <div id="p-0409" num="0368" class="description-line">5-terminal caps may include endogenous caps or cap analogs. A 5-terminal cap may include a guanosine analog. Useful guanosine analogs include inosine, N1-methyl-guanosine, 2-fluoro-guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2-azido-guanosine.</div>
    </li> <li> <para-num num="[0369]"> </para-num> <div id="p-0410" num="0369" class="description-line">In some cases, a polynucleotide contains a modified 5-cap. A modification on the 5-cap may increase the stability of polynucleotide, increase the half-life of the polynucleotide, and could increase the polynucleotide translational efficiency. The modified 5-cap may include, but is not limited to, one or more of the following modifications: modification at the 2- and/or 3-position of a capped guanosine triphosphate (GTP), a replacement of the sugar ring oxygen (that produced the carbocyclic ring) with a methylene moiety (CH<sub>2</sub>), a modification at the triphosphate bridge moiety of the cap structure, or a modification at the nucleobase (G) moiety.</div>
    </li> <heading id="h-0022">5-UTRs</heading>
    <li> <para-num num="[0370]"> </para-num> <div id="p-0411" num="0370" class="description-line">A 5-UTR may be provided as a flanking region to polynucleotides (e.g., mRNAs). A 5-UTR may be homologous or heterologous to the coding region found in a polynucleotide. Multiple 5-UTRs may be included in the flanking region and may be the same or of different sequences. Any portion of the flanking regions, including none, may be codon optimized and any may independently contain one or more different structural or chemical alterations, before and/or after codon optimization.</div>
    </li> <li> <para-num num="[0371]"> </para-num> <div id="p-0412" num="0371" class="description-line">Shown in Table 21 in U.S. Provisional Application No. 61/775,509, and in Table 21 and in Table 22 in U.S. Provisional Application No. 61/829,372, of which are incorporated herein by reference, is a listing of the start and stop site of alternative polynucleotides (e.g., mRNA). In Table 21 each 5-UTR (5-UTR-005 to 5-UTR 68511) is identified by its start and stop site relative to its native or wild type (homologous) transcript (ENST; the identifier used in the ENSEMBL database).</div>
    </li> <li> <para-num num="[0372]"> </para-num> <div id="p-0413" num="0372" class="description-line">To alter one or more properties of a polynucleotide (e.g., mRNA), 5-UTRs which are heterologous to the coding region of an alternative polynucleotide (e.g., mRNA) may be engineered. The polynucleotides (e.g., mRNA) may then be administered to cells, tissue or organisms and outcomes such as protein level, localization, and/or half-life may be measured to evaluate the beneficial effects the heterologous 5-UTR may have on the alternative polynucleotides (mRNA). Variants of the 5-UTRs may be utilized wherein one or more nucleotides are added or removed to the termini, including A, T, C or G. 5-UTRs may also be codon-optimized, or altered in any manner described herein.</div>
    </li> <heading id="h-0023">5-UTRs, 3-UTRs, and Translation Enhancer Elements (TEEs)</heading>
    <li> <para-num num="[0373]"> </para-num> <div id="p-0414" num="0373" class="description-line">The 5-UTR of a polynucleotides (e.g., mRNA) may include at least one translation enhancer element. The term translational enhancer element refers to sequences that increase the amount of polypeptide or protein produced from a polynucleotide. As a non-limiting example, the TEE may be located between the transcription promoter and the start codon. The polynucleotides (e.g., mRNA) with at least one TEE in the 5-UTR may include a cap at the 5-UTR. Further, at least one TEE may be located in the 5-UTR of polynucleotides (e.g., mRNA) undergoing cap-dependent or cap-independent translation.</div>
    </li> <li> <para-num num="[0374]"> </para-num> <div id="p-0415" num="0374" class="description-line">In one aspect, TEEs are conserved elements in the UTR which can promote translational activity of a polynucleotide such as, but not limited to, cap-dependent or cap-independent translation. The conservation of these sequences has been previously shown by Panek et al. (Nucleic Acids Research, 2013, 1-10) across 14 species including humans.</div>
    </li> <li> <para-num num="[0375]"> </para-num> <div id="p-0416" num="0375" class="description-line">In one non-limiting example, the TEEs known may be in the 5-leader of the Gtx homeodomain protein (Chappell et al., Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004, the TEEs of which are incorporated herein by reference).</div>
    </li> <li> <para-num num="[0376]"> </para-num> <div id="p-0417" num="0376" class="description-line">In another non-limiting example, TEEs are disclosed as SEQ ID NOs: 1-35 in US Patent Publication No. 2009/0226470, SEQ ID NOs: 1-35 in US Patent Publication No. 2013/0177581, SEQ ID NOs: 1-35 in International Patent Publication No. WO2009/075886, SEQ ID NOs: 1-5, and 7-645 in International Patent Publication No. WO2012/009644, SEQ ID NO: 1 in International Patent Publication No. WO1999/024595, SEQ ID NO: 1 in U.S. Pat. No. 6,310,197, and SEQ ID NO: 1 in U.S. Pat. No. 6,849,405, the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0377]"> </para-num> <div id="p-0418" num="0377" class="description-line">In yet another non-limiting example, the TEE may be an internal ribosome entry site (IRES), HCV-IRES or an IRES element such as, but not limited to, those described in U.S. Pat. No. 7,468,275, US Patent Publication Nos. 2007/0048776 and 2011/0124100 and International Patent Publication Nos. WO2007/025008 and WO2001/055369, the IRES sequences of each of which are incorporated herein by reference. The IRES elements may include, but are not limited to, the Gtx sequences (e.g., Gtx9-nt, Gtx8-nt, Gtx7-nt) described by Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005) and in US Patent Publication Nos. 2007/0048776 and 2011/0124100 and International Patent Publication No. WO2007/025008, the IRES sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0378]"> </para-num> <div id="p-0419" num="0378" class="description-line">Translational enhancer polynucleotides are polynucleotides which include one or more of the specific TEE exemplified herein and/or disclosed in the art (see e.g., U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, U.S. Patent Publication Nos. 20090/226470, 2007/0048776, 2011/0124100, 2009/0093049, 2013/0177581, International Patent Publication Nos. WO2009/075886, WO2007/025008, WO2012/009644, WO2001/055371 WO1999/024595, and European Patent Nos. 2610341 and 2610340; the TEE sequences of each of which are incorporated herein by reference) or their variants, homologs or functional derivatives. One or multiple copies of a specific TEE can be present in a polynucleotide (e.g., mRNA). The TEEs in the translational enhancer polynucleotides can be organized in one or more sequence segments. A sequence segment can harbor one or more of the specific TEEs exemplified herein, with each TEE being present in one or more copies. When multiple sequence segments are present in a translational enhancer polynucleotide, they can be homogenous or heterogeneous. Thus, the multiple sequence segments in a translational enhancer polynucleotide can harbor identical or different types of the specific TEEs exemplified herein, identical or different number of copies of each of the specific TEEs, and/or identical or different organization of the TEEs within each sequence segment.</div>
    </li> <li> <para-num num="[0379]"> </para-num> <div id="p-0420" num="0379" class="description-line">A polynucleotide (e.g., mRNA) may include at least one TEE that is described in International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886, WO2007/025008, WO1999/024595, European Patent Publication Nos. 2610341 and 2610340, U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, and US Patent Publication Nos. 2009/0226470, 2011/0124100, 2007/0048776, 2009/0093049, and 2013/0177581 the TEE sequences of each of which are incorporated herein by reference. The TEE may be located in the 5-UTR of the polynucleotides (e.g., mRNA).</div>
    </li> <li> <para-num num="[0380]"> </para-num> <div id="p-0421" num="0380" class="description-line">A polynucleotide (e.g., mRNA) may include at least one TEE that has at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 99% identity with the TEEs described in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886 and WO2007/025008, European Patent Publication Nos. 2610341 and 2610340, U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, 7,183,395, the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0381]"> </para-num> <div id="p-0422" num="0381" class="description-line">The 5-UTR of a polynucleotide (e.g., mRNA) may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55 or more than 60 TEE sequences. The TEE sequences in the 5-UTR of a polynucleotide (e.g., mRNA) may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variants thereof, repeated once, twice, or more than three times. In these patterns, each letter, A, B, or C represent a different TEE sequence at the nucleotide level.</div>
    </li> <li> <para-num num="[0382]"> </para-num> <div id="p-0423" num="0382" class="description-line">In some cases, the 5-UTR may include a spacer to separate two TEE sequences. As a non-limiting example, the spacer may be a 15 nucleotide spacer and/or other spacers known in the art. As another non-limiting example, the 5-UTR may include a TEE sequence-spacer module repeated at least once, at least twice, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or more than 9 times in the 5-UTR.</div>
    </li> <li> <para-num num="[0383]"> </para-num> <div id="p-0424" num="0383" class="description-line">In other instances, the spacer separating two TEE sequences may include other sequences known in the art which may regulate the translation of the polynucleotides (e.g., mRNA) of the present disclosure such as, but not limited to, miR sequences (e.g., miR binding sites and miR seeds). As a non-limiting example, each spacer used to separate two TEE sequences may include a different miR sequence or component of a miR sequence (e.g., miR seed sequence).</div>
    </li> <li> <para-num num="[0384]"> </para-num> <div id="p-0425" num="0384" class="description-line">In some instances, the TEE in the 5-UTR of a polynucleotide (e.g., mRNA) may include at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more than 99% of the TEE sequences disclosed in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos. WO 1999/024595, WO2012/009644, WO2009/075886 and WO2007/025008, European Patent Publication Nos. 2610341 and 2610340, and U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395 the TEE sequences of each of which are incorporated herein by reference. In another embodiment, the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure may include a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, a 5-10 nucleotide fragment of the TEE sequences disclosed in US Patent Publication Nos. 2009/0226470, 2007/0048776, 2013/0177581 and 2011/0124100, International Patent Publication Nos. WO1999/024595, WO2012/009644, WO2009/075886 and WO2007/025008, European Patent Publication Nos. 2610341 and 2610340, and U.S. Pat. Nos. 6,310,197, 6,849,405, 7,456,273, and 7,183,395; the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0385]"> </para-num> <div id="p-0426" num="0385" class="description-line">In certain cases, the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure may include at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or more than 99% of the TEE sequences disclosed in Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), in Supplemental Table 1 and in Supplemental Table 2 disclosed by Wellensiek et al (Genome-wide profiling of human cap-independent translation-enhancing elements, Nature Methods, 2013; DOI: 10.1038/NMETH.2522); the TEE sequences of each of which are herein incorporated by reference. In another embodiment, the TEE in the 5-UTR of the polynucleotides (e.g., mRNA) of the present disclosure may include a 5-30 nucleotide fragment, a 5-25 nucleotide fragment, a 5-20 nucleotide fragment, a 5-15 nucleotide fragment, a 5-10 nucleotide fragment of the TEE sequences disclosed in Chappell et al. (Proc. Natl. Acad. Sci. USA 101:9590-9594, 2004) and Zhou et al. (PNAS 102:6273-6278, 2005), in Supplemental Table 1 and in Supplemental Table 2 disclosed by Wellensiek et al (Genome-wide profiling of human cap-independent translation-enhancing elements, Nature Methods, 2013; DOI:10.1038/NMETH.2522); the TEE sequences of each of which is incorporated herein by reference.</div>
    </li> <li> <para-num num="[0386]"> </para-num> <div id="p-0427" num="0386" class="description-line">In some cases, the TEE used in the 5-UTR of a polynucleotide (e.g., mRNA) is an IRES sequence such as, but not limited to, those described in U.S. Pat. No. 7,468,275 and International Patent Publication No. WO2001/055369, the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0387]"> </para-num> <div id="p-0428" num="0387" class="description-line">In some instances, the TEEs used in the 5-UTR of a polynucleotide (e.g., mRNA) may be identified by the methods described in US Patent Publication Nos. 2007/0048776 and 2011/0124100 and International Patent Publication Nos. WO2007/025008 and WO2012/009644, the methods of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0388]"> </para-num> <div id="p-0429" num="0388" class="description-line">In some cases, the TEEs used in the 5-UTR of a polynucleotide (e.g., mRNA) of the present disclosure may be a transcription regulatory element described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the TEE sequences of each of which is incorporated herein by reference. The transcription regulatory elements may be identified by methods known in the art, such as, but not limited to, the methods described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the methods of each of which is incorporated herein by reference.</div>
    </li> <li> <para-num num="[0389]"> </para-num> <div id="p-0430" num="0389" class="description-line">In yet other instances, the TEE used in the 5-UTR of a polynucleotide (e.g., mRNA) is a polynucleotide or portion thereof as described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication No. 2009/0093049, and International Publication No. WO2001/055371, the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0390]"> </para-num> <div id="p-0431" num="0390" class="description-line">The 5-UTR including at least one TEE described herein may be incorporated in a monocistronic sequence such as, but not limited to, a vector system or a polynucleotide vector. As a non-limiting example, the vector systems and polynucleotide vectors may include those described in U.S. Pat. Nos. 7,456,273 and 7,183,395, US Patent Publication Nos. 2007/0048776, 2009/0093049 and 2011/0124100, and International Patent Publication Nos. WO2007/025008 and WO2001/055371, the TEE sequences of each of which are incorporated herein by reference.</div>
    </li> <li> <para-num num="[0391]"> </para-num> <div id="p-0432" num="0391" class="description-line">The TEEs described herein may be located in the 5-UTR and/or the 3-UTR of the polynucleotides (e.g., mRNA). The TEEs located in the 3-UTR may be the same and/or different than the TEEs located in and/or described for incorporation in the 5-UTR.</div>
    </li> <li> <para-num num="[0392]"> </para-num> <div id="p-0433" num="0392" class="description-line">In some cases, the 3-UTR of a polynucleotide (e.g., mRNA) may include at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18 at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55 or more than 60 TEE sequences. The TEE sequences in the 3-UTR of the polynucleotides (e.g., mRNA) of the present disclosure may be the same or different TEE sequences. The TEE sequences may be in a pattern such as ABABAB, AABBAABBAABB, or ABCABCABC, or variants thereof, repeated once, twice, or more than three times. In these patterns, each letter, A, B, or C represent a different TEE sequence at the nucleotide level.</div>
    </li> <li> <para-num num="[0393]"> </para-num> <div id="p-0434" num="0393" class="description-line">In one instance, the 3-UTR may include a spacer to separate two TEE sequences. As a non-limiting example, the spacer may be a 15 nucleotide spacer and/or other spacers known in the art. As another non-limiting example, the 3-UTR may include a TEE sequence-spacer module repeated at least once, at least twice, at least 3 times, at least 4 times, at least 5 times, at least 6 times, at least 7 times, at least 8 times, at least 9 times, or more than 9 times in the 3-UTR.</div>
    </li> <li> <para-num num="[0394]"> </para-num> <div id="p-0435" num="0394" class="description-line">In other cases, the spacer separating two TEE sequences may include other sequences known in the art which may regulate the translation of the polynucleotides (e.g., mRNA) of the present disclosure such as, but not limited to, miR sequences described herein (e.g., miR binding sites and miR seeds). As a non-limiting example, each spacer used to separate two TEE sequences may include a different miR sequence or component of a miR sequence (e.g., miR seed sequence).</div>
    </li> <li> <para-num num="[0395]"> </para-num> <div id="p-0436" num="0395" class="description-line">In yet other cases, the incorporation of a miR sequence and/or a TEE sequence changes the shape of the stem loop region which may increase and/or decrease translation. (see e.g., Kedde et al. A Pumilio-induced RNA structure switch in p27-3UTR controls miR-221 and miR-22 accessibility. Nature Cell Biology. 2010).</div>
    </li> <heading id="h-0024">Stem Loops</heading>
    <li> <para-num num="[0396]"> </para-num> <div id="p-0437" num="0396" class="description-line">Polynucleotides (e.g., mRNAs) may include a stem loop such as, but not limited to, a histone stem loop. The stem loop may be a nucleotide sequence that is about 25 or about 26 nucleotides in length such as, but not limited to, SEQ ID NOs: 7-17 as described in International Patent Publication No. WO2013/103659, of which SEQ ID NOs: 7-17 are incorporated herein by reference. The histone stem loop may be located 3-relative to the coding region (e.g., at the 3-terminus of the coding region). As a non-limiting example, the stem loop may be located at the 3-end of a polynucleotide described herein. In some cases, a polynucleotide (e.g., an mRNA) includes more than one stem loop (e.g., two stem loops). Examples of stem loop sequences are described in International Patent Publication Nos. WO2012/019780 and WO201502667, the stem loop sequences of which are herein incorporated by reference. In some instances, a polynucleotide includes the stem loop sequence CAAAGGCTCTTTTCAGAGCCACCA (SEQ ID NO: 5). In others, a polynucleotide includes the stem loop sequence CAAAGGCUCUUUUCAGAGCCACCA (SEQ ID NO: 6).</div>
    </li> <li> <para-num num="[0397]"> </para-num> <div id="p-0438" num="0397" class="description-line">A stem loop may be located in a second terminal region of a polynucleotide. As a non-limiting example, the stem loop may be located within an untranslated region (e.g., 3-UTR) in a second terminal region.</div>
    </li> <li> <para-num num="[0398]"> </para-num> <div id="p-0439" num="0398" class="description-line">In some cases, a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop may be stabilized by the addition of a 3-stabilizing region (e.g., a 3-stabilizing region including at least one chain terminating nucleoside). Not wishing to be bound by theory, the addition of at least one chain terminating nucleoside may slow the degradation of a polynucleotide and thus can increase the half-life of the polynucleotide.</div>
    </li> <li> <para-num num="[0399]"> </para-num> <div id="p-0440" num="0399" class="description-line">In other cases, a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop may be stabilized by an alteration to the 3-region of the polynucleotide that can prevent and/or inhibit the addition of oligio(U) (see e.g., International Patent Publication No. WO2013/103659).</div>
    </li> <li> <para-num num="[0400]"> </para-num> <div id="p-0441" num="0400" class="description-line">In yet other cases, a polynucleotide such as, but not limited to mRNA, which includes the histone stem loop may be stabilized by the addition of an oligonucleotide that terminates in a 3-deoxynucleoside, 2,3-<figure-callout id="3" label="dideoxynucleoside" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">dideoxynucleoside</figure-callout> 3-O-methylnucleosides, 3-O-ethylnucleosides, 3-arabinosides, and other alternative nucleosides known in the art and/or described herein.</div>
    </li> <li> <para-num num="[0401]"> </para-num> <div id="p-0442" num="0401" class="description-line">In some instances, the polynucleotides of the present disclosure may include a histone stem loop, a poly-A region, and/or a 5-cap structure. The histone stem loop may be before and/or after the poly-A region. The polynucleotides including the histone stem loop and a poly-A region sequence may include a chain terminating nucleoside described herein.</div>
    </li> <li> <para-num num="[0402]"> </para-num> <div id="p-0443" num="0402" class="description-line">In other instances, the polynucleotides of the present disclosure may include a histone stem loop and a 5-cap structure. The 5-cap structure may include, but is not limited to, those described herein and/or known in the art.</div>
    </li> <li> <para-num num="[0403]"> </para-num> <div id="p-0444" num="0403" class="description-line">In some cases, the conserved stem loop region may include a miR sequence described herein. As a non-limiting example, the stem loop region may include the seed sequence of a miR sequence described herein. In another non-limiting example, the stem loop region may include a miR-122 seed sequence.</div>
    </li> <li> <para-num num="[0404]"> </para-num> <div id="p-0445" num="0404" class="description-line">In certain instances, the conserved stem loop region may include a miR sequence described herein and may also include a TEE sequence.</div>
    </li> <li> <para-num num="[0405]"> </para-num> <div id="p-0446" num="0405" class="description-line">In some cases, the incorporation of a miR sequence and/or a TEE sequence changes the shape of the stem loop region which may increase and/or decrease translation. (See, e.g., Kedde et al. A Pumilio-induced RNA structure switch in p27-3UTR controls miR-221 and miR-22 accessibility. Nature Cell Biology. 2010, herein incorporated by reference in its entirety).</div>
    </li> <li> <para-num num="[0406]"> </para-num> <div id="p-0447" num="0406" class="description-line">Polynucleotides may include at least one histone stem-loop and a poly-A region or polyadenylation signal. Non-limiting examples of polynucleotide sequences encoding for at least one histone stem-loop and a poly-A region or a polyadenylation signal are described in International Patent Publication No. WO2013/120497, WO2013/120629, WO2013/120500, WO2013/120627, WO2013/120498, WO2013/120626, WO2013/120499 and WO2013/120628, the sequences of each of which are incorporated herein by reference. In certain cases, the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal may code for a pathogen antigen or fragment thereof such as the polynucleotide sequences described in International Patent Publication No WO2013/120499 and WO2013/120628, the sequences of both of which are incorporated herein by reference. In other cases, the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal may code for a therapeutic protein such as the polynucleotide sequences described in International Patent Publication No WO2013/120497 and WO2013/120629, the sequences of both of which are incorporated herein by reference. In some cases, the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal may code for a tumor antigen or fragment thereof such as the polynucleotide sequences described in International Patent Publication No WO2013/120500 and WO2013/120627, the sequences of both of which are incorporated herein by reference. In other cases, the polynucleotide encoding for a histone stem loop and a poly-A region or a polyadenylation signal may code for a allergenic antigen or an autoimmune self-antigen such as the polynucleotide sequences described in International Patent Publication No WO2013/120498 and WO2013/120626, the sequences of both of which are incorporated herein by reference.</div>
    </li> <heading id="h-0025">Poly-A Regions</heading>
    <li> <para-num num="[0407]"> </para-num> <div id="p-0448" num="0407" class="description-line">A polynucleotide or nucleic acid (e.g., an mRNA) may include a polyA sequence and/or polyadenylation signal. A polyA sequence may be comprised entirely or mostly of adenine nucleotides or analogs or derivatives thereof. A polyA sequence may be a tail located adjacent to a 3 untranslated region of a nucleic acid.</div>
    </li> <li> <para-num num="[0408]"> </para-num> <div id="p-0449" num="0408" class="description-line">During RNA processing, a long chain of adenosine nucleotides (poly-A region) is normally added to messenger RNA (mRNA) molecules to increase the stability of the molecule. Immediately after transcription, the 3-end of the transcript is cleaved to free a 3-hydroxy. Then poly-A polymerase adds a chain of adenosine nucleotides to the RNA. The process, called polyadenylation, adds a poly-A region that is between 100 and 250 residues long.</div>
    </li> <li> <para-num num="[0409]"> </para-num> <div id="p-0450" num="0409" class="description-line">Unique poly-A region lengths may provide certain advantages to the alternative polynucleotides of the present disclosure.</div>
    </li> <li> <para-num num="[0410]"> </para-num> <div id="p-0451" num="0410" class="description-line">Generally, the length of a poly-A region of the present disclosure is at least 30 nucleotides in length. In another embodiment, the poly-A region is at least 35 nucleotides in length. In another embodiment, the length is at least 40 nucleotides. In another embodiment, the length is at least 45 nucleotides. In another embodiment, the length is at least 55 nucleotides. In another embodiment, the length is at least 60 nucleotides. In another embodiment, the length is at least 70 nucleotides. In another embodiment, the length is at least 80 nucleotides. In another embodiment, the length is at least 90 nucleotides. In another embodiment, the length is at least 100 nucleotides. In another embodiment, the length is at least 120 nucleotides. In another embodiment, the length is at least 140 nucleotides. In another embodiment, the length is at least 160 nucleotides. In another embodiment, the length is at least 180 nucleotides. In another embodiment, the length is at least 200 nucleotides. In another embodiment, the length is at least 250 nucleotides. In another embodiment, the length is at least 300 nucleotides. In another embodiment, the length is at least 350 nucleotides. In another embodiment, the length is at least 400 nucleotides. In another embodiment, the length is at least 450 nucleotides. In another embodiment, the length is at least 500 nucleotides. In another embodiment, the length is at least 600 nucleotides. In another embodiment, the length is at least 700 nucleotides. In another embodiment, the length is at least 800 nucleotides. In another embodiment, the length is at least 900 nucleotides. In another embodiment, the length is at least 1000 nucleotides. In another embodiment, the length is at least 1100 nucleotides. In another embodiment, the length is at least 1200 nucleotides. In another embodiment, the length is at least 1300 nucleotides. In another embodiment, the length is at least 1400 nucleotides. In another embodiment, the length is at least 1500 nucleotides. In another embodiment, the length is at least 1600 nucleotides. In another embodiment, the length is at least 1700 nucleotides. In another embodiment, the length is at least 1800 nucleotides. In another embodiment, the length is at least 1900 nucleotides. In another embodiment, the length is at least 2000 nucleotides. In another embodiment, the length is at least 2500 nucleotides. In another embodiment, the length is at least 3000 nucleotides.</div>
    </li> <li> <para-num num="[0411]"> </para-num> <div id="p-0452" num="0411" class="description-line">In some instances, the poly-A region may be 80 nucleotides, 120 nucleotides, 160 nucleotides in length on an alternative polynucleotide molecule described herein.</div>
    </li> <li> <para-num num="[0412]"> </para-num> <div id="p-0453" num="0412" class="description-line">In other instances, the poly-A region may be 20, 40, 80, 100, 120, 140 or 160 nucleotides in length on an alternative polynucleotide molecule described herein.</div>
    </li> <li> <para-num num="[0413]"> </para-num> <div id="p-0454" num="0413" class="description-line">In some cases, the poly-A region is designed relative to the length of the overall alternative polynucleotide. This design may be based on the length of the coding region of the alternative polynucleotide, the length of a particular feature or region of the alternative polynucleotide (such as mRNA), or based on the length of the ultimate product expressed from the alternative polynucleotide. When relative to any feature of the alternative polynucleotide (e.g., other than the mRNA portion which includes the poly-A region) the poly-A region may be 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100% greater in length than the additional feature. The poly-A region may also be designed as a fraction of the alternative polynucleotide to which it belongs. In this context, the poly-A region may be 10, 20, 30, 40, 50, 60, 70, 80, or 90% or more of the total length of the construct or the total length of the construct minus the poly-A region.</div>
    </li> <li> <para-num num="[0414]"> </para-num> <div id="p-0455" num="0414" class="description-line">In certain cases, engineered binding sites and/or the conjugation of polynucleotides (e.g., mRNA) for poly-A binding protein may be used to enhance expression. The engineered binding sites may be sensor sequences which can operate as binding sites for ligands of the local microenvironment of the polynucleotides (e.g., mRNA). As a non-limiting example, the polynucleotides (e.g., mRNA) may include at least one engineered binding site to alter the binding affinity of poly-A binding protein (PABP) and analogs thereof. The incorporation of at least one engineered binding site may increase the binding affinity of the PABP and analogs thereof.</div>
    </li> <li> <para-num num="[0415]"> </para-num> <div id="p-0456" num="0415" class="description-line">Additionally, multiple distinct polynucleotides (e.g., mRNA) may be linked together to the PABP (poly-A binding protein) through the 3-end using alternative nucleotides at the 3-terminus of the poly-A region. Transfection experiments can be conducted in relevant cell lines at and protein production can be assayed by ELISA at 12 hours, 24 hours, 48 hours, 72 hours, and <figure-callout id="7" label="day" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">day</figure-callout> 7 post-transfection. As a non-limiting example, the transfection experiments may be used to evaluate the effect on PABP or analogs thereof binding affinity as a result of the addition of at least one engineered binding site.</div>
    </li> <li> <para-num num="[0416]"> </para-num> <div id="p-0457" num="0416" class="description-line">In certain cases, a poly-A region may be used to modulate translation initiation. While not wishing to be bound by theory, the poly-A region recruits PABP which in turn can interact with translation initiation complex and thus may be essential for protein synthesis.</div>
    </li> <li> <para-num num="[0417]"> </para-num> <div id="p-0458" num="0417" class="description-line">In some cases, a poly-A region may also be used in the present disclosure to protect against 3-5-exonuclease digestion.</div>
    </li> <li> <para-num num="[0418]"> </para-num> <div id="p-0459" num="0418" class="description-line">In some instances, a polynucleotide (e.g., mRNA) may include a polyA-G Quartet. The G-quartet is a cyclic hydrogen bonded array of four guanosine nucleotides that can be formed by G-rich sequences in both DNA and RNA. In this embodiment, the G-quartet is incorporated at the end of the poly-A region. The resultant polynucleotides (e.g., mRNA) may be assayed for stability, protein production and other parameters including half-life at various time points. It has been discovered that the polyA-G quartet results in protein production equivalent to at least 75% of that seen using a poly-A region of 120 nucleotides alone.</div>
    </li> <li> <para-num num="[0419]"> </para-num> <div id="p-0460" num="0419" class="description-line">In some cases, a polynucleotide (e.g., mRNA) may include a poly-A region and may be stabilized by the addition of a 3-stabilizing region. The polynucleotides (e.g., mRNA) with a poly-A region may further include a 5-cap structure.</div>
    </li> <li> <para-num num="[0420]"> </para-num> <div id="p-0461" num="0420" class="description-line">In other cases, a polynucleotide (e.g., mRNA) may include a poly-A-G Quartet. The polynucleotides (e.g., mRNA) with a poly-A-G Quartet may further include a 5-cap structure.</div>
    </li> <li> <para-num num="[0421]"> </para-num> <div id="p-0462" num="0421" class="description-line">In some cases, the 3-stabilizing region which may be used to stabilize a polynucleotide (e.g., mRNA) including a poly-A region or poly-A-G Quartet may be, but is not limited to, those described in International Patent Publication No. WO2013/103659, the poly-A regions and poly-A-G Quartets of which are incorporated herein by reference. In other cases, the 3-stabilizing region which may be used with the present disclosure include a chain termination nucleoside such as 3-deoxyadenosine (cordycepin), 3-deoxyuridine, 3-deoxycytosine, 3-deoxyguanosine, 3-deoxythymine, 2,3-dideoxynucleosides, such as 2,3-dideoxyadenosine, 2,3-dideoxyuridine, 2,3-dideoxycytosine, 2,3-dideoxyguanosine, 2,3-dideoxythymine, a 2-deoxynucleoside, or an O-methylnucleoside.</div>
    </li> <li> <para-num num="[0422]"> </para-num> <div id="p-0463" num="0422" class="description-line">In other cases, a polynucleotide such as, but not limited to mRNA, which includes a polyA region or a poly-A-G Quartet may be stabilized by an alteration to the 3-region of the polynucleotide that can prevent and/or inhibit the addition of oligio(U) (see e.g., International Patent Publication No. WO2013/103659).</div>
    </li> <li> <para-num num="[0423]"> </para-num> <div id="p-0464" num="0423" class="description-line">In yet other instances, a polynucleotide such as, but not limited to mRNA, which includes a poly-A region or a poly-A-G Quartet may be stabilized by the addition of an oligonucleotide that terminates in a 3-deoxynucleoside, 2,3-<figure-callout id="3" label="dideoxynucleoside" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">dideoxynucleoside</figure-callout> 3-O-methylnucleosides, 3-O-ethylnucleosides, 3-arabinosides, and other alternative nucleosides known in the art and/or described herein.</div>
    </li> <heading id="h-0026">Chain Terminating Nucleosides</heading>
    <li> <para-num num="[0424]"> </para-num> <div id="p-0465" num="0424" class="description-line">A nucleic acid may include a chain terminating nucleoside. For example, a chain terminating nucleoside may include those nucleosides deoxygenated at the 2 and/or 3 positions of their sugar group. Such species may include 3-deoxyadenosine (cordycepin), 3-deoxyuridine, 3-deoxycytosine, 3-deoxyguanosine, 3-deoxythymine, and 2,3-dideoxynucleosides, such as 2,3-dideoxyadenosine, 2,3-dideoxyuridine, 2,3-dideoxycytosine, 2,3-dideoxyguanosine, and 2,3-dideoxythymine.</div>
    </li> <heading id="h-0027">Other Components</heading>
    <li> <para-num num="[0425]"> </para-num> <div id="p-0466" num="0425" class="description-line">A nanoparticle composition may include one or more components in addition to those described in the preceding sections. For example, a nanoparticle composition may include one or more small hydrophobic molecules such as a vitamin (e.g., vitamin A or vitamin E) or a sterol.</div>
    </li> <li> <para-num num="[0426]"> </para-num> <div id="p-0467" num="0426" class="description-line">Nanoparticle compositions may also include one or more permeability enhancer molecules, carbohydrates, polymers, surface altering agents, or other components. A permeability enhancer molecule may be a molecule described by U.S. patent application publication No. 2005/0222064, for example. Carbohydrates may include simple sugars (e.g., glucose) and polysaccharides (e.g., glycogen and derivatives and analogs thereof).</div>
    </li> <li> <para-num num="[0427]"> </para-num> <div id="p-0468" num="0427" class="description-line">A polymer may be included in and/or used to encapsulate or partially encapsulate a nanoparticle composition. A polymer may be biodegradable and/or biocompatible. A polymer may be selected from, but is not limited to, polyamines, polyethers, polyamides, polyesters, polycarbamates, polyureas, polycarbonates, polystyrenes, polyimides, polysulfones, polyurethanes, polyacetylenes, polyethylenes, polyethyleneimines, polyisocyanates, polyacrylates, polymethacrylates, polyacrylonitriles, and polyarylates. For example, a polymer may include poly(caprolactone) (PCL), ethylene vinyl acetate polymer (EVA), poly(lactic acid) (PLA), poly(L-lactic acid) (PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid) (PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide) (PDLA), poly(L-lactide) (PLLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide), poly(D,L-lactide-co-PPO-co-D,L-lactide), polyalkyl cyanoacrylate, polyurethane, poly-L-lysine (PLL), hydroxypropyl methacrylate (HPMA), polyethyleneglycol, poly-L-glutamic acid, poly(hydroxy acids), polyanhydrides, polyorthoesters, poly(ester amides), polyamides, poly(ester ethers), polycarbonates, polyalkylenes such as polyethylene and polypropylene, polyalkylene glycols such as poly(ethylene glycol) (PEG), polyalkylene oxides (PEO), polyalkylene terephthalates such as poly(ethylene terephthalate), polyvinyl alcohols (PVA), polyvinyl ethers, polyvinyl esters such as poly(vinyl acetate), polyvinyl halides such as poly(vinyl chloride) (PVC), polyvinylpyrrolidone (PVP), polysiloxanes, polystyrene (PS), polyurethanes, derivatized celluloses such as alkyl celluloses, hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses, hydroxypropylcellulose, carboxymethylcellulose, polymers of acrylic acids, such as poly(methyl(meth)acrylate) (PMMA), poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate), poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate), poly(isodecyl(meth)acrylate), poly(lauryl(meth)acrylate), poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), poly(octadecyl acrylate) and copolymers and mixtures thereof, polydioxanone and its copolymers, polyhydroxyalkanoates, polypropylene fumarate, polyoxymethylene, poloxamers, polyoxamines, poly(ortho)esters, poly(butyric acid), poly(valeric acid), poly(lactide-co-caprolactone), trimethylene carbonate, poly(N-acryloylmorpholine) (PAcM), poly(2-methyl-2-oxazoline) (PMOX), poly(2-ethyl-2-oxazoline) (PEOZ), and polyglycerol.</div>
    </li> <li> <para-num num="[0428]"> </para-num> <div id="p-0469" num="0428" class="description-line">Surface altering agents may include, but are not limited to, anionic proteins (e.g., bovine serum albumin), surfactants (e.g., cationic surfactants such as dimethyldioctadecyl-ammonium bromide), sugars or sugar derivatives (e.g., cyclodextrin), nucleic acids, polymers (e.g., heparin, polyethylene glycol, and poloxamer), mucolytic agents (e.g., acetylcysteine, mugwort, bromelain, papain, clerodendrum, bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol, domiodol, letosteine, stepronin, tiopronin, gelsolin, thymosin 4, dornase alfa, neltenexine, and erdosteine), and DNases (e.g., rhDNase). A surface altering agent may be disposed within a nanoparticle and/or on the surface of a nanoparticle composition (e.g., by coating, adsorption, covalent linkage, or other process).</div>
    </li> <li> <para-num num="[0429]"> </para-num> <div id="p-0470" num="0429" class="description-line">A nanoparticle composition may also comprise one or more functionalized lipids. For example, a lipid may be functionalized with an alkyne group that, when exposed to an azide under appropriate reaction conditions, may undergo a cycloaddition reaction. In particular, a lipid bilayer may be functionalized in this fashion with one or more groups useful in facilitating membrane permeation, cellular recognition, or imaging. The surface of a nanoparticle composition may also be conjugated with one or more useful antibodies. Functional groups and conjugates useful in targeted cell delivery, imaging, and membrane permeation are well known in the art.</div>
    </li> <li> <para-num num="[0430]"> </para-num> <div id="p-0471" num="0430" class="description-line">In addition to these components, nanoparticle compositions may include any substance useful in pharmaceutical compositions. For example, the nanoparticle composition may include one or more pharmaceutically acceptable excipients or accessory ingredients such as, but not limited to, one or more solvents, dispersion media, diluents, dispersion aids, suspension aids, granulating aids, disintegrants, fillers, glidants, liquid vehicles, binders, surface active agents, isotonic agents, thickening or emulsifying agents, buffering agents, lubricating agents, oils, preservatives, and other species. Excipients such as waxes, butters, coloring agents, coating agents, flavorings, and perfuming agents may also be included. Pharmaceutically acceptable excipients are well known in the art (see for example Remington&#39;s <i>The Science and Practice of Pharmacy, </i>21<sup>st </sup>Edition, A. R. Gennaro; Lippincott, Williams &amp; Wilkins, Baltimore, Md., 2006).</div>
    </li> <li> <para-num num="[0431]"> </para-num> <div id="p-0472" num="0431" class="description-line">Examples of diluents may include, but are not limited to, calcium carbonate, sodium carbonate, calcium phosphate, dicalcium phosphate, calcium sulfate, calcium hydrogen phosphate, sodium phosphate lactose, sucrose, cellulose, microcrystalline cellulose, kaolin, mannitol, sorbitol, inositol, sodium chloride, dry starch, cornstarch, powdered sugar, and/or combinations thereof. Granulating and dispersing agents may be selected from the non-limiting list consisting of potato starch, corn starch, tapioca starch, sodium starch glycolate, clays, alginic acid, guar gum, citrus pulp, agar, bentonite, cellulose and wood products, natural sponge, cation-exchange resins, calcium carbonate, silicates, sodium carbonate, cross-linked poly(vinyl-pyrrolidone) (crospovidone), sodium carboxymethyl starch (sodium starch glycolate), carboxymethyl cellulose, cross-linked sodium carboxymethyl cellulose (croscarmellose), methylcellulose, pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, calcium carboxymethyl cellulose, magnesium aluminum silicate (VEEGUM), sodium lauryl sulfate, quaternary ammonium compounds, and/or combinations thereof.</div>
    </li> <li> <para-num num="[0432]"> </para-num> <div id="p-0473" num="0432" class="description-line">Surface active agents and/or emulsifiers may include, but are not limited to, natural emulsifiers (e.g. acacia, agar, alginic acid, sodium alginate, tragacanth, chondrux, cholesterol, xanthan, pectin, gelatin, egg yolk, casein, wool fat, cholesterol, wax, and lecithin), colloidal clays (e.g. bentonite [aluminum silicate] and VEEGUM [magnesium aluminum silicate]), long chain amino acid derivatives, high molecular weight alcohols (e.g. stearyl alcohol, cetyl alcohol, oleyl alcohol, triacetin monostearate, ethylene glycol distearate, glyceryl monostearate, and propylene glycol monostearate, polyvinyl alcohol), carbomers (e.g. carboxy polymethylene, polyacrylic acid, acrylic acid polymer, and carboxyvinyl polymer), carrageenan, cellulosic derivatives (e.g. carboxymethylcellulose sodium, powdered cellulose, hydroxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methylcellulose), sorbitan fatty acid esters (e.g. polyoxyethylene sorbitan monolaurate [TWEEN20], polyoxyethylene sorbitan [TWEEN 60], polyoxyethylene sorbitan monooleate [TWEEN80], sorbitan monopalmitate [SPAN40], sorbitan monostearate [SPAN60], sorbitan tristearate [SPAN65], glyceryl monooleate, sorbitan monooleate [SPAN80]), polyoxyethylene esters (e.g. polyoxyethylene monostearate [MYRJ 45], polyoxyethylene hydrogenated castor oil, polyethoxylated castor oil, polyoxymethylene stearate, and SOLUTOL), sucrose fatty acid esters, polyethylene glycol fatty acid esters (e.g. CREMOPHOR), polyoxyethylene ethers, (e.g. polyoxyethylene lauryl ether [BRIJ 30]), poly(vinyl-pyrrolidone), diethylene glycol monolaurate, triethanolamine oleate, sodium oleate, potassium oleate, ethyl oleate, oleic acid, ethyl laurate, sodium lauryl sulfate, PLURONICF 68, POLOXAMER 188, cetrimonium bromide, cetylpyridinium chloride, benzalkonium chloride, docusate sodium, and/or combinations thereof.</div>
    </li> <li> <para-num num="[0433]"> </para-num> <div id="p-0474" num="0433" class="description-line">A binding agent may be starch (e.g. cornstarch and starch paste); gelatin; sugars (e.g. sucrose, glucose, dextrose, dextrin, molasses, lactose, lactitol, mannitol); natural and synthetic gums (e.g., acacia, sodium alginate, extract of Irish moss, panwar gum, ghatti gum, mucilage of isapol husks, carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, microcrystalline cellulose, cellulose acetate, poly(vinyl-pyrrolidone), magnesium aluminum silicate (VEEGUM), and larch arabogalactan); alginates; polyethylene oxide; polyethylene glycol; inorganic calcium salts; silicic acid; polymethacrylates; waxes; water; alcohol; and combinations thereof, or any other suitable binding agent.</div>
    </li> <li> <para-num num="[0434]"> </para-num> <div id="p-0475" num="0434" class="description-line">Examples of preservatives may include, but are not limited to, antioxidants, chelating agents, antimicrobial preservatives, antifungal preservatives, alcohol preservatives, acidic preservatives, and/or other preservatives. Examples of antioxidants include, but are not limited to, alpha tocopherol, ascorbic acid, acorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, monothioglycerol, potassium metabisulfite, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, and/or sodium sulfite. Examples of chelating agents include ethylenediaminetetraacetic acid (EDTA), citric acid monohydrate, disodium edetate, dipotassium edetate, edetic acid, fumaric acid, malic acid, phosphoric acid, sodium edetate, tartaric acid, and/or trisodium edetate. Examples of antimicrobial preservatives include, but are not limited to, benzalkonium chloride, benzethonium chloride, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, cresol, ethyl alcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol, phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, and/or thimerosal. Examples of antifungal preservatives include, but are not limited to, butyl paraben, methyl paraben, ethyl paraben, propyl paraben, benzoic acid, hydroxybenzoic acid, potassium benzoate, potassium sorbate, sodium benzoate, sodium propionate, and/or sorbic acid. Examples of alcohol preservatives include, but are not limited to, ethanol, polyethylene glycol, benzyl alcohol, phenol, phenolic compounds, bisphenol, chlorobutanol, hydroxybenzoate, and/or phenylethyl alcohol. Examples of acidic preservatives include, but are not limited to, vitamin A, vitamin C, vitamin E, beta-carotene, citric acid, acetic acid, dehydroascorbic acid, ascorbic acid, sorbic acid, and/or phytic acid. Other preservatives include, but are not limited to, tocopherol, tocopherol acetate, deteroxime mesylate, cetrimide, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ethylenediamine, sodium lauryl sulfate (SLS), sodium lauryl ether sulfate (SLES), sodium bisulfite, sodium metabisulfite, potassium sulfite, potassium metabisulfite, GLYDANT PLUS, PHENONIP, methylparaben, GERMALL 115, GERMABENII, NEOLONE, KATHON, and/or EUXYL.</div>
    </li> <li> <para-num num="[0435]"> </para-num> <div id="p-0476" num="0435" class="description-line">Examples of buffering agents include, but are not limited to, citrate buffer solutions, acetate buffer solutions, phosphate buffer solutions, ammonium chloride, calcium carbonate, calcium chloride, calcium citrate, calcium glubionate, calcium gluceptate, calcium gluconate, d-gluconic acid, calcium glycerophosphate, calcium lactate, calcium lactobionate, propanoic acid, calcium levulinate, pentanoic acid, dibasic calcium phosphate, phosphoric acid, tribasic calcium phosphate, calcium hydroxide phosphate, potassium acetate, potassium chloride, potassium gluconate, potassium mixtures, dibasic potassium phosphate, monobasic potassium phosphate, potassium phosphate mixtures, sodium acetate, sodium bicarbonate, sodium chloride, sodium citrate, sodium lactate, dibasic sodium phosphate, monobasic sodium phosphate, sodium phosphate mixtures, tromethamine, amino-sulfonate buffers (e.g., HEPES), magnesium hydroxide, aluminum hydroxide, alginic acid, pyrogen-free water, isotonic saline, Ringer&#39;s solution, ethyl alcohol, and/or combinations thereof. Lubricating agents may selected from the non-limiting group consisting of magnesium stearate, calcium stearate, stearic acid, silica, talc, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, sodium lauryl sulfate, and combinations thereof.</div>
    </li> <li> <para-num num="[0436]"> </para-num> <div id="p-0477" num="0436" class="description-line">Examples of oils include, but are not limited to, almond, apricot kernel, avocado, babassu, bergamot, black current seed, borage, cade, camomile, canola, caraway, carnauba, castor, cinnamon, cocoa butter, coconut, cod liver, coffee, corn, cotton seed, emu, <i>eucalyptus</i>, evening primrose, fish, flaxseed, geraniol, gourd, grape seed, hazel nut, hyssop, isopropyl myristate, jojoba, kukui nut, lavandin, lavender, lemon, <i>litsea cubeba</i>, macademia nut, mallow, mango seed, meadowfoam seed, mink, nutmeg, olive, orange, orange roughy, palm, palm kernel, peach kernel, peanut, poppy seed, pumpkin seed, rapeseed, rice bran, rosemary, safflower, sandalwood, sasquana, savoury, sea buckthorn, sesame, shea butter, silicone, soybean, sunflower, tea tree, thistle, tsubaki, vetiver, walnut, and wheat germ oils as well as butyl stearate, caprylic triglyceride, capric triglyceride, cyclomethicone, diethyl sebacate, dimethicone 360, simethicone, isopropyl myristate, mineral oil, octyldodecanol, oleyl alcohol, silicone oil, and/or combinations thereof.</div>
    </li> <heading id="h-0028">Formulations</heading>
    <li> <para-num num="[0437]"> </para-num> <div id="p-0478" num="0437" class="description-line">Nanoparticle compositions may include a lipid component and one or more additional components, such as a therapeutic and/or prophylactic. A nanoparticle composition may be designed for one or more specific applications or targets. The elements of a nanoparticle composition may be selected based on a particular application or target, and/or based on the efficacy, toxicity, expense, ease of use, availability, or other feature of one or more elements. Similarly, the particular formulation of a nanoparticle composition may be selected for a particular application or target according to, for example, the efficacy and toxicity of particular combinations of elements.</div>
    </li> <li> <para-num num="[0438]"> </para-num> <div id="p-0479" num="0438" class="description-line">The lipid component of a nanoparticle composition may include, for example, a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid (such as an unsaturated lipid, e.g., DOPE or DSPC), a PEG lipid, and a structural lipid. The elements of the lipid component may be provided in specific fractions.</div>
    </li> <li> <para-num num="[0439]"> </para-num> <div id="p-0480" num="0439" class="description-line">In some embodiments, the lipid component of a nanoparticle composition includes a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid, a PEG lipid, and a structural lipid. In certain embodiments, the lipid component of the nanoparticle composition includes about 30 mol % to about 60 mol % compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % of PEG lipid, provided that the total mol % does not exceed 100%. In some embodiments, the lipid component of the nanoparticle composition includes about 35 mol % to about 55 mol % compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % of PEG lipid. In a particular embodiment, the lipid component includes about 50 mol % said compound, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % of PEG lipid. In another particular embodiment, the lipid component includes about 40 mol % said compound, about 20 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % of PEG lipid. In some embodiments, the phospholipid may be DOPE or DSPC. In other embodiments, the PEG lipid may be PEG-DMG and/or the structural lipid may be cholesterol.</div>
    </li> <li> <para-num num="[0440]"> </para-num> <div id="p-0481" num="0440" class="description-line">Nanoparticle compositions may be designed for one or more specific applications or targets. For example, a nanoparticle composition may be designed to deliver a therapeutic and/or prophylactic such as an RNA to a particular cell, tissue, organ, or system or group thereof in a mammal&#39;s body. Physiochemical properties of nanoparticle compositions may be altered in order to increase selectivity for particular bodily targets. For instance, particle sizes may be adjusted based on the fenestration sizes of different organs. The therapeutic and/or prophylactic included in a nanoparticle composition may also be selected based on the desired delivery target or targets. For example, a therapeutic and/or prophylactic may be selected for a particular indication, condition, disease, or disorder and/or for delivery to a particular cell, tissue, organ, or system or group thereof (e.g., localized or specific delivery). In certain embodiments, a nanoparticle composition may include an mRNA encoding a polypeptide of interest capable of being translated within a cell to produce the polypeptide of interest. Such a composition may be designed to be specifically delivered to a particular organ. In some embodiments, a composition may be designed to be specifically delivered to a mammalian liver.</div>
    </li> <li> <para-num num="[0441]"> </para-num> <div id="p-0482" num="0441" class="description-line">The amount of a therapeutic and/or prophylactic in a nanoparticle composition may depend on the size, composition, desired target and/or application, or other properties of the nanoparticle composition as well as on the properties of the therapeutic and/or prophylactic. For example, the amount of an RNA useful in a nanoparticle composition may depend on the size, sequence, and other characteristics of the RNA. The relative amounts of a therapeutic and/or prophylactic and other elements (e.g., lipids) in a nanoparticle composition may also vary. In some embodiments, the wt/wt ratio of the lipid component to a therapeutic and/or prophylactic in a nanoparticle composition may be from about 5:1 to about 60:1, such as 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, and 60:1. For example, the wt/wt ratio of the lipid component to a therapeutic and/or prophylactic may be from about 10:1 to about 40:1. In certain embodiments, the wt/wt ratio is about 20:1. The amount of a therapeutic and/or prophylactic in a nanoparticle composition may, for example, be measured using absorption spectroscopy (e.g., ultraviolet-visible spectroscopy).</div>
    </li> <li> <para-num num="[0442]"> </para-num> <div id="p-0483" num="0442" class="description-line">In some embodiments, a nanoparticle composition includes one or more RNAs, and the one or more RNAs, lipids, and amounts thereof may be selected to provide a specific N:P ratio. The N:P ratio of the composition refers to the molar ratio of nitrogen atoms in one or more lipids to the number of phosphate groups in an RNA. In general, a lower N:P ratio is preferred. The one or more RNA, lipids, and amounts thereof may be selected to provide an N:P ratio from about 2:1 to about 30:1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 12:1, 14:1, 16:1, 18:1, 20:1, 22:1, 24:1, 26:1, 28:1, or 30:1. In certain embodiments, the N:P ratio may be from about 2:1 to about 8:1. In other embodiments, the N:P ratio is from about 5:1 to about 8:1. For example, the N:P ratio may be about 5.0:1, about 5.5:1, about 5.67:1, about 6.0:1, about 6.5:1, or about 7.0:1. For example, the N:P ratio may be about 5.67:1.</div>
    </li> <heading id="h-0029">Physical Properties</heading>
    <li> <para-num num="[0443]"> </para-num> <div id="p-0484" num="0443" class="description-line">The characteristics of a nanoparticle composition may depend on the components thereof. For example, a nanoparticle composition including cholesterol as a structural lipid may have different characteristics than a nanoparticle composition that includes a different structural lipid. Similarly, the characteristics of a nanoparticle composition may depend on the absolute or relative amounts of its components. For instance, a nanoparticle composition including a higher molar fraction of a phospholipid may have different characteristics than a nanoparticle composition including a lower molar fraction of a phospholipid. Characteristics may also vary depending on the method and conditions of preparation of the nanoparticle composition.</div>
    </li> <li> <para-num num="[0444]"> </para-num> <div id="p-0485" num="0444" class="description-line">Nanoparticle compositions may be characterized by a variety of methods. For example, microscopy (e.g., transmission electron microscopy or scanning electron microscopy) may be used to examine the morphology and size distribution of a nanoparticle composition. Dynamic light scattering or potentiometry (e.g., potentiometric titrations) may be used to measure zeta potentials. Dynamic light scattering may also be utilized to determine particle sizes. Instruments such as the Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) may also be used to measure multiple characteristics of a nanoparticle composition, such as particle size, polydispersity index, and zeta potential.</div>
    </li> <li> <para-num num="[0445]"> </para-num> <div id="p-0486" num="0445" class="description-line">The mean size of a nanoparticle composition may be between 10s of nm and 100s of nm, e.g., measured by dynamic light scattering (DLS). For example, the mean size may be from about 40 nm to about 150 nm, such as about 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, or 150 nm. In some embodiments, the mean size of a nanoparticle composition may be from about 50 nm to about 100 nm, from about 50 nm to about 90 nm, from about 50 nm to about 80 nm, from about 50 nm to about 70 nm, from about 50 nm to about 60 nm, from about 60 nm to about 100 nm, from about 60 nm to about 90 nm, from about 60 nm to about 80 nm, from about 60 nm to about 70 nm, from about 70 nm to about 100 nm, from about 70 nm to about 90 nm, from about 70 nm to about 80 nm, from about 80 nm to about 100 nm, from about 80 nm to about 90 nm, or from about 90 nm to about 100 nm. In certain embodiments, the mean size of a nanoparticle composition may be from about 70 nm to about 100 nm. In a particular embodiment, the mean size may be about 80 nm. In other embodiments, the mean size may be about 100 nm.</div>
    </li> <li> <para-num num="[0446]"> </para-num> <div id="p-0487" num="0446" class="description-line">A nanoparticle composition may be relatively homogenous. A polydispersity index may be used to indicate the homogeneity of a nanoparticle composition, e.g., the particle size distribution of the nanoparticle compositions. A small (e.g., less than 0.3) polydispersity index generally indicates a narrow particle size distribution. A nanoparticle composition may have a polydispersity index from about 0 to about 0.25, such as 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.10, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.20, 0.21, 0.22, 0.23, 0.24, or 0.25. In some embodiments, the polydispersity index of a nanoparticle composition may be from about 0.10 to about 0.20.</div>
    </li> <li> <para-num num="[0447]"> </para-num> <div id="p-0488" num="0447" class="description-line">The zeta potential of a nanoparticle composition may be used to indicate the electrokinetic potential of the composition. For example, the zeta potential may describe the surface charge of a nanoparticle composition. Nanoparticle compositions with relatively low charges, positive or negative, are generally desirable, as more highly charged species may interact undesirably with cells, tissues, and other elements in the body. In some embodiments, the zeta potential of a nanoparticle composition may be from about 10 mV to about +20 mV, from about 10 mV to about +15 mV, from about 10 mV to about +10 mV, from about 10 mV to about +5 mV, from about 10 mV to about 0 mV, from about 10 mV to about 5 mV, from about 5 mV to about +20 mV, from about 5 mV to about +15 mV, from about 5 mV to about +10 mV, from about 5 mV to about +5 mV, from about 5 mV to about 0 mV, from about 0 mV to about +20 mV, from about 0 mV to about +15 mV, from about 0 mV to about +10 mV, from about 0 mV to about +5 mV, from about +5 mV to about +20 mV, from about +5 mV to about +15 mV, or from about +5 mV to about +10 mV.</div>
    </li> <li> <para-num num="[0448]"> </para-num> <div id="p-0489" num="0448" class="description-line">The efficiency of encapsulation of a therapeutic and/or prophylactic describes the amount of therapeutic and/or prophylactic that is encapsulated or otherwise associated with a nanoparticle composition after preparation, relative to the initial amount provided. The encapsulation efficiency is desirably high (e.g., close to 100%). The encapsulation efficiency may be measured, for example, by comparing the amount of therapeutic and/or prophylactic in a solution containing the nanoparticle composition before and after breaking up the nanoparticle composition with one or more organic solvents or detergents. Fluorescence may be used to measure the amount of free therapeutic and/or prophylactic (e.g., RNA) in a solution. For the nanoparticle compositions described herein, the encapsulation efficiency of a therapeutic and/or prophylactic may be at least 50%, for example 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%. In some embodiments, the encapsulation efficiency may be at least 80%. In certain embodiments, the encapsulation efficiency may be at least 90%.</div>
    </li> <li> <para-num num="[0449]"> </para-num> <div id="p-0490" num="0449" class="description-line">A nanoparticle composition may optionally comprise one or more coatings. For example, a nanoparticle composition may be formulated in a capsule, film, or tablet having a coating. A capsule, film, or tablet including a composition described herein may have any useful size, tensile strength, hardness, or density.</div>
    </li> <heading id="h-0030">Pharmaceutical Compositions</heading>
    <li> <para-num num="[0450]"> </para-num> <div id="p-0491" num="0450" class="description-line">Nanoparticle compositions may be formulated in whole or in part as pharmaceutical compositions. Pharmaceutical compositions may include one or more nanoparticle compositions. For example, a pharmaceutical composition may include one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics. Pharmaceutical compositions may further include one or more pharmaceutically acceptable excipients or accessory ingredients such as those described herein. General guidelines for the formulation and manufacture of pharmaceutical compositions and agents are available, for example, in Remington&#39;s <i>The Science and Practice of Pharmacy, </i>21<sup>st </sup>Edition, A. R. Gennaro; Lippincott, Williams &amp; Wilkins, Baltimore, Md., 2006. Conventional excipients and accessory ingredients may be used in any pharmaceutical composition, except insofar as any conventional excipient or accessory ingredient may be incompatible with one or more components of a nanoparticle composition. An excipient or accessory ingredient may be incompatible with a component of a nanoparticle composition if its combination with the component may result in any undesirable biological effect or otherwise deleterious effect.</div>
    </li> <li> <para-num num="[0451]"> </para-num> <div id="p-0492" num="0451" class="description-line">In some embodiments, one or more excipients or accessory ingredients may make up greater than 50% of the total mass or volume of a pharmaceutical composition including a nanoparticle composition. For example, the one or more excipients or accessory ingredients may make up 50%, 60%, 70%, 80%, 90%, or more of a pharmaceutical convention. In some embodiments, a pharmaceutically acceptable excipient is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, an excipient is approved for use in humans and for veterinary use. In some embodiments, an excipient is approved by United States Food and Drug Administration. In some embodiments, an excipient is pharmaceutical grade. In some embodiments, an excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and/or the International Pharmacopoeia.</div>
    </li> <li> <para-num num="[0452]"> </para-num> <div id="p-0493" num="0452" class="description-line">Relative amounts of the one or more nanoparticle compositions, the one or more pharmaceutically acceptable excipients, and/or any additional ingredients in a pharmaceutical composition in accordance with the present disclosure will vary, depending upon the identity, size, and/or condition of the subject treated and further depending upon the route by which the composition is to be administered. By way of example, a pharmaceutical composition may comprise between 0.1% and 100% (wt/wt) of one or more nanoparticle compositions.</div>
    </li> <li> <para-num num="[0453]"> </para-num> <div id="p-0494" num="0453" class="description-line">In certain embodiments, the nanoparticle compositions and/or pharmaceutical compositions of the disclosure are refrigerated or frozen for storage and/or shipment (e.g., being stored at a temperature of 4 C. or lower, such as a temperature between about 150 C. and about 0 C. or between about 80 C. and about 20 C. (e.g., about 5 C., 10 C., 15 C., 20 C., 25 C., 30 C., 40 C., 50 C., 60 C., 70 C., 80 C., 90 C., 130 C. or 150 C.). For example, the pharmaceutical composition comprising a compound of any of Formulae (I), (IA), (II), and (IIa)-(IIe) is a solution that is refrigerated for storage and/or shipment at, for example, about 20 C., 30 C., 40 C., 50 C., 60 C., 70 C., or 80 C. In certain embodiments, the disclosure also relates to a method of increasing stability of the nanoparticle compositions and/or pharmaceutical compositions comprising a compound of any of Formulae (I), (IA), (II), and (IIa)-(IIe) by storing the nanoparticle compositions and/or pharmaceutical compositions at a temperature of 4 C. or lower, such as a temperature between about 150 C. and about 0 C. or between about 80 C. and about 20 C., e.g., about 5 C., 10 C., 15 C., 20 C., 25 C., 30 C., 40 C., 50 C., 60 C., 70 C., 80 C., 90 C., 130 C. or 150 C.). For example, the nanoparticle compositions and/or pharmaceutical compositions disclosed herein are stable for about at least 1 week, at least 2 weeks, at least 3 weeks, at least 4 weeks, at least 5 weeks, at least 6 weeks, at least 1 month, at least 2 months, at least 4 months, at least 6 months, at least 8 months, at least 10 months, at least 12 months, at least 14 months, at least 16 months, at least 18 months, at least 20 months, at least 22 months, or at least 24 months, e.g., at a temperature of 4 C. or lower (e.g., between about 4 C. and 20 C.). In one embodiment, the formulation is stabilized for at least 4 weeks at about 4 C. In certain embodiments, the pharmaceutical composition of the disclosure comprises a nanoparticle composition disclosed herein and a pharmaceutically acceptable carrier selected from one or more of Tris, an acetate (e.g., sodium acetate), an citrate (e.g., sodium citrate), saline, PBS, and sucrose. In certain embodiments, the pharmaceutical composition of the disclosure has a pH value between about 7 and 8 (e.g., 6.8 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 or 8.0, or between 7.5 and 8 or between 7 and 7.8). For example, a pharmaceutical composition of the disclosure comprises a nanoparticle composition disclosed herein, Tris, saline and sucrose, and has a pH of about 7.5-8, which is suitable for storage and/or shipment at, for example, about 20 C. For example, a pharmaceutical composition of the disclosure comprises a nanoparticle composition disclosed herein and PBS and has a pH of about 7-7.8, suitable for storage and/or shipment at, for example, about 4 C. or lower. Stability, stabilized, and stable in the context of the present disclosure refers to the resistance of nanoparticle compositions and/or pharmaceutical compositions disclosed herein to chemical or physical changes (e.g., degradation, particle size change, aggregation, change in encapsulation, etc.) under given manufacturing, preparation, transportation, storage and/or in-use conditions, e.g., when stress is applied such as shear force, freeze/thaw stress, etc.</div>
    </li> <li> <para-num num="[0454]"> </para-num> <div id="p-0495" num="0454" class="description-line">Nanoparticle compositions and/or pharmaceutical compositions including one or more nanoparticle compositions may be administered to any patient or subject, including those patients or subjects that may benefit from a therapeutic effect provided by the delivery of a therapeutic and/or prophylactic to one or more particular cells, tissues, organs, or systems or groups thereof, such as the renal system. Although the descriptions provided herein of nanoparticle compositions and pharmaceutical compositions including nanoparticle compositions are principally directed to compositions which are suitable for administration to humans, it will be understood by the skilled artisan that such compositions are generally suitable for administration to any other mammal. Modification of compositions suitable for administration to humans in order to render the compositions suitable for administration to various animals is well understood, and the ordinarily skilled veterinary pharmacologist can design and/or perform such modification with merely ordinary, if any, experimentation. Subjects to which administration of the compositions is contemplated include, but are not limited to, humans, other primates, and other mammals, including commercially relevant mammals such as cattle, pigs, hoses, sheep, cats, dogs, mice, and/or rats.</div>
    </li> <li> <para-num num="[0455]"> </para-num> <div id="p-0496" num="0455" class="description-line">A pharmaceutical composition including one or more nanoparticle compositions may be prepared by any method known or hereafter developed in the art of pharmacology. In general, such preparatory methods include bringing the active ingredient into association with an excipient and/or one or more other accessory ingredients, and then, if desirable or necessary, dividing, shaping, and/or packaging the product into a desired single- or multi-dose unit.</div>
    </li> <li> <para-num num="[0456]"> </para-num> <div id="p-0497" num="0456" class="description-line">A pharmaceutical composition in accordance with the present disclosure may be prepared, packaged, and/or sold in bulk, as a single unit dose, and/or as a plurality of single unit doses. As used herein, a unit dose is discrete amount of the pharmaceutical composition comprising a predetermined amount of the active ingredient (e.g., nanoparticle composition). The amount of the active ingredient is generally equal to the dosage of the active ingredient which would be administered to a subject and/or a convenient fraction of such a dosage such as, for example, one-half or one-third of such a dosage.</div>
    </li> <li> <para-num num="[0457]"> </para-num> <div id="p-0498" num="0457" class="description-line">Pharmaceutical compositions may be prepared in a variety of forms suitable for a variety of routes and methods of administration. For example, pharmaceutical compositions may be prepared in liquid dosage forms (e.g., emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and elixirs), injectable forms, solid dosage forms (e.g., capsules, tablets, pills, powders, and granules), dosage forms for topical and/or transdermal administration (e.g., ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and patches), suspensions, powders, and other forms.</div>
    </li> <li> <para-num num="[0458]"> </para-num> <div id="p-0499" num="0458" class="description-line">Liquid dosage forms for oral and parenteral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, nanoemulsions, solutions, suspensions, syrups, and/or elixirs. In addition to active ingredients, liquid dosage forms may comprise inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, oral compositions can include additional therapeutic and/or prophylactics, additional agents such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and/or perfuming agents. In certain embodiments for parenteral administration, compositions are mixed with solubilizing agents such as Cremophor, alcohols, oils, modified oils, glycols, polysorbates, cyclodextrins, polymers, and/or combinations thereof.</div>
    </li> <li> <para-num num="[0459]"> </para-num> <div id="p-0500" num="0459" class="description-line">Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing agents, wetting agents, and/or suspending agents. Sterile injectable preparations may be sterile injectable solutions, suspensions, and/or emulsions in nontoxic parenterally acceptable diluents and/or solvents, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer&#39;s solution, U.S.P., and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. Fatty acids such as oleic acid can be used in the preparation of injectables.</div>
    </li> <li> <para-num num="[0460]"> </para-num> <div id="p-0501" num="0460" class="description-line">Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, and/or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.</div>
    </li> <li> <para-num num="[0461]"> </para-num> <div id="p-0502" num="0461" class="description-line">In order to prolong the effect of an active ingredient, it is often desirable to slow the absorption of the active ingredient from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.</div>
    </li> <li> <para-num num="[0462]"> </para-num> <div id="p-0503" num="0462" class="description-line">Compositions for rectal or vaginal administration are typically suppositories which can be prepared by mixing compositions with suitable non-irritating excipients such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active ingredient.</div>
    </li> <li> <para-num num="[0463]"> </para-num> <div id="p-0504" num="0463" class="description-line">Solid dosage forms for oral administration include capsules, tablets, pills, films, powders, and granules. In such solid dosage forms, an active ingredient is mixed with at least one inert, pharmaceutically acceptable excipient such as sodium citrate or dicalcium phosphate and/or fillers or extenders (e.g. starches, lactose, sucrose, glucose, mannitol, and silicic acid), binders (e.g., carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia), humectants (e.g., glycerol), disintegrating agents (e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate), solution retarding agents (e.g., paraffin), absorption accelerators (e.g., quaternary ammonium compounds), wetting agents (e.g., cetyl alcohol and glycerol monostearate), absorbents (e.g., kaolin and bentonite clay, silicates), and lubricants (e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate), and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may comprise buffering agents.</div>
    </li> <li> <para-num num="[0464]"> </para-num> <div id="p-0505" num="0464" class="description-line">Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. Solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally comprise opacifying agents and can be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions which can be used include polymeric substances and waxes. Solid compositions of a similar type may be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.</div>
    </li> <li> <para-num num="[0465]"> </para-num> <div id="p-0506" num="0465" class="description-line">Dosage forms for topical and/or transdermal administration of a composition may include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, and/or patches. Generally, an active ingredient is admixed under sterile conditions with a pharmaceutically acceptable excipient and/or any needed preservatives and/or buffers as may be required. Additionally, the present disclosure contemplates the use of transdermal patches, which often have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms may be prepared, for example, by dissolving and/or dispensing the compound in the proper medium. Alternatively or additionally, rate may be controlled by either providing a rate controlling membrane and/or by dispersing the compound in a polymer matrix and/or gel.</div>
    </li> <li> <para-num num="[0466]"> </para-num> <div id="p-0507" num="0466" class="description-line">Suitable devices for use in delivering intradermal pharmaceutical compositions described herein include short needle devices such as those described in U.S. Pat. Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662. Intradermal compositions may be administered by devices which limit the effective penetration length of a needle into the skin, such as those described in PCT publication WO 99/34850 and functional equivalents thereof. Jet injection devices which deliver liquid compositions to the dermis via a liquid jet injector and/or via a needle which pierces the stratum corneum and produces a jet which reaches the dermis are suitable. Jet injection devices are described, for example, in U.S. Pat. Nos. 5,480,381; 5,599,302; 5,334,144; 5,993,412; 5,649,912; 5,569,189; 5,704,911; 5,383,851; 5,893,397; 5,466,220; 5,339,163; 5,312,335; 5,503,627; 5,064,413; 5,520,639; 4,596,556; 4,790,824; 4,941,880; 4,940,460; and PCT publications WO 97/37705 and WO 97/13537. Ballistic powder/particle delivery devices which use compressed gas to accelerate vaccine in powder form through the outer layers of the skin to the dermis are suitable. Alternatively or additionally, conventional syringes may be used in the classical mantoux method of intradermal administration.</div>
    </li> <li> <para-num num="[0467]"> </para-num> <div id="p-0508" num="0467" class="description-line">Formulations suitable for topical administration include, but are not limited to, liquid and/or semi liquid preparations such as liniments, lotions, oil in water and/or water in oil emulsions such as creams, ointments and/or pastes, and/or solutions and/or suspensions. Topically-administrable formulations may, for example, comprise from about 1% to about 10% (wt/wt) active ingredient, although the concentration of active ingredient may be as high as the solubility limit of the active ingredient in the solvent. Formulations for topical administration may further comprise one or more of the additional ingredients described herein.</div>
    </li> <li> <para-num num="[0468]"> </para-num> <div id="p-0509" num="0468" class="description-line">A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for pulmonary administration via the buccal cavity. Such a formulation may comprise dry particles which comprise the active ingredient. Such compositions are conveniently in the form of dry powders for administration using a device comprising a dry powder reservoir to which a stream of propellant may be directed to disperse the powder and/or using a self-propelling solvent/powder dispensing container such as a device comprising the active ingredient dissolved and/or suspended in a low-boiling propellant in a sealed container. Dry powder compositions may include a solid fine powder diluent such as sugar and are conveniently provided in a unit dose form.</div>
    </li> <li> <para-num num="[0469]"> </para-num> <div id="p-0510" num="0469" class="description-line">Low boiling propellants generally include liquid propellants having a boiling point of below 65 F. at atmospheric pressure. Generally the propellant may constitute 50% to 99.9% (wt/wt) of the composition, and active ingredient may constitute 0.1% to 20% (wt/wt) of the composition. A propellant may further comprise additional ingredients such as a liquid non-ionic and/or solid anionic surfactant and/or a solid diluent (which may have a particle size of the same order as particles comprising the active ingredient).</div>
    </li> <li> <para-num num="[0470]"> </para-num> <div id="p-0511" num="0470" class="description-line">Pharmaceutical compositions formulated for pulmonary delivery may provide an active ingredient in the form of droplets of a solution and/or suspension. Such formulations may be prepared, packaged, and/or sold as aqueous and/or dilute alcoholic solutions and/or suspensions, optionally sterile, comprising active ingredient, and may conveniently be administered using any nebulization and/or atomization device. Such formulations may further comprise one or more additional ingredients including, but not limited to, a flavoring agent such as saccharin sodium, a volatile oil, a buffering agent, a surface active agent, and/or a preservative such as methylhydroxybenzoate. Droplets provided by this route of administration may have an average diameter in the range from about 1 nm to about 200 nm.</div>
    </li> <li> <para-num num="[0471]"> </para-num> <div id="p-0512" num="0471" class="description-line">Formulations described herein as being useful for pulmonary delivery are useful for intranasal delivery of a pharmaceutical composition. Another formulation suitable for intranasal administration is a coarse powder comprising the active ingredient and having an average particle from about 0.2 m to 500 m. Such a formulation is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held close to the nose.</div>
    </li> <li> <para-num num="[0472]"> </para-num> <div id="p-0513" num="0472" class="description-line">Formulations suitable for nasal administration may, for example, comprise from about as little as 0.1% (wt/wt) and as much as 100% (wt/wt) of active ingredient, and may comprise one or more of the additional ingredients described herein. A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for buccal administration. Such formulations may, for example, be in the form of tablets and/or lozenges made using conventional methods, and may, for example, 0.1% to 20% (wt/wt) active ingredient, the balance comprising an orally dissolvable and/or degradable composition and, optionally, one or more of the additional ingredients described herein. Alternately, formulations suitable for buccal administration may comprise a powder and/or an aerosolized and/or atomized solution and/or suspension comprising active ingredient. Such powdered, aerosolized, and/or aerosolized formulations, when dispersed, may have an average particle and/or droplet size in the range from about 0.1 nm to about 200 nm, and may further comprise one or more of any additional ingredients described herein.</div>
    </li> <li> <para-num num="[0473]"> </para-num> <div id="p-0514" num="0473" class="description-line">A pharmaceutical composition may be prepared, packaged, and/or sold in a formulation suitable for ophthalmic administration. Such formulations may, for example, be in the form of eye drops including, for example, a 0.1/1.0% (wt/wt) solution and/or suspension of the active ingredient in an aqueous or oily liquid excipient. Such drops may further comprise buffering agents, salts, and/or one or more other of any additional ingredients described herein. Other ophthalmically-administrable formulations which are useful include those which comprise the active ingredient in microcrystalline form and/or in a liposomal preparation. Ear drops and/or eye drops are contemplated as being within the scope of this present disclosure.</div>
    </li> <heading id="h-0031">Methods of Producing Polypeptides in Cells</heading>
    <li> <para-num num="[0474]"> </para-num> <div id="p-0515" num="0474" class="description-line">The present disclosure provides methods of producing a polypeptide of interest in a mammalian cell. Methods of producing polypeptides involve contacting a cell with a nanoparticle composition including an mRNA encoding the polypeptide of interest. Upon contacting the cell with the nanoparticle composition, the mRNA may be taken up and translated in the cell to produce the polypeptide of interest.</div>
    </li> <li> <para-num num="[0475]"> </para-num> <div id="p-0516" num="0475" class="description-line">In general, the step of contacting a mammalian cell with a nanoparticle composition including an mRNA encoding a polypeptide of interest may be performed in vivo, ex vivo, in culture, or in vitro. The amount of nanoparticle composition contacted with a cell, and/or the amount of mRNA therein, may depend on the type of cell or tissue being contacted, the means of administration, the physiochemical characteristics of the nanoparticle composition and the mRNA (e.g., size, charge, and chemical composition) therein, and other factors. In general, an effective amount of the nanoparticle composition will allow for efficient polypeptide production in the cell. Metrics for efficiency may include polypeptide translation (indicated by polypeptide expression), level of mRNA degradation, and immune response indicators.</div>
    </li> <li> <para-num num="[0476]"> </para-num> <div id="p-0517" num="0476" class="description-line">The step of contacting a nanoparticle composition including an mRNA with a cell may involve or cause transfection. A phospholipid including in the lipid component of a nanoparticle composition may facilitate transfection and/or increase transfection efficiency, for example, by interacting and/or fusing with a cellular or intracellular membrane. Transfection may allow for the translation of the mRNA within the cell.</div>
    </li> <li> <para-num num="[0477]"> </para-num> <div id="p-0518" num="0477" class="description-line">In some embodiments, the nanoparticle compositions described herein may be used therapeutically. For example, an mRNA included in a nanoparticle composition may encode a therapeutic polypeptide (e.g., in a translatable region) and produce the therapeutic polypeptide upon contacting and/or entry (e.g., transfection) into a cell. In other embodiments, an mRNA included in a nanoparticle composition may encode a polypeptide that may improve or increase the immunity of a subject. For example, an mRNA may encode a granulocyte-colony stimulating factor or trastuzumab.</div>
    </li> <li> <para-num num="[0478]"> </para-num> <div id="p-0519" num="0478" class="description-line">In certain embodiments, an mRNA included in a nanoparticle composition may encode a recombinant polypeptide that may replace one or more polypeptides that may be substantially absent in a cell contacted with the nanoparticle composition. The one or more substantially absent polypeptides may be lacking due to a genetic mutation of the encoding gene or a regulatory pathway thereof. Alternatively, a recombinant polypeptide produced by translation of the mRNA may antagonize the activity of an endogenous protein present in, on the surface of, or secreted from the cell. An antagonistic recombinant polypeptide may be desirable to combat deleterious effects caused by activities of the endogenous protein, such as altered activities or localization caused by mutation. In another alternative, a recombinant polypeptide produced by translation of the mRNA may indirectly or directly antagonize the activity of a biological moiety present in, on the surface of, or secreted from the cell. Antagonized biological moieties may include, but are not limited to, lipids (e.g., cholesterol), lipoproteins (e.g., low density lipoprotein), nucleic acids, carbohydrates, and small molecule toxins. Recombinant polypeptides produced by translation of the mRNA may be engineered for localization within the cell, such as within a specific compartment such as the nucleus, or may be engineered for secretion from the cell or for translocation to the plasma membrane of the cell.</div>
    </li> <li> <para-num num="[0479]"> </para-num> <div id="p-0520" num="0479" class="description-line">In some embodiments, contacting a cell with a nanoparticle composition including an mRNA may reduce the innate immune response of a cell to an exogenous nucleic acid. A cell may be contacted with a first nanoparticle composition including a first amount of a first exogenous mRNA including a translatable region and the level of the innate immune response of the cell to the first exogenous mRNA may be determined. Subsequently, the cell may be contacted with a second composition including a second amount of the first exogenous mRNA, the second amount being a lesser amount of the first exogenous mRNA compared to the first amount. Alternatively, the second composition may include a first amount of a second exogenous mRNA that is different from the first exogenous mRNA. The steps of contacting the cell with the first and second compositions may be repeated one or more times. Additionally, efficiency of polypeptide production (e.g., translation) in the cell may be optionally determined, and the cell may be re-contacted with the first and/or second composition repeatedly until a target protein production efficiency is achieved.</div>
    </li> <heading id="h-0032">Methods of Delivering Therapeutic Agents to Cells and Organs</heading>
    <li> <para-num num="[0480]"> </para-num> <div id="p-0521" num="0480" class="description-line">The present disclosure provides methods of delivering a therapeutic and/or prophylactic to a mammalian cell or organ. Delivery of a therapeutic and/or prophylactic to a cell involves administering a nanoparticle composition including the therapeutic and/or prophylactic to a subject, where administration of the composition involves contacting the cell with the composition. For example, a protein, cytotoxic agent, radioactive ion, chemotherapeutic agent, or nucleic acid (such as an RNA, e.g., mRNA) may be delivered to a cell or organ. In the instance that a therapeutic and/or prophylactic is an mRNA, upon contacting a cell with the nanoparticle composition, a translatable mRNA may be translated in the cell to produce a polypeptide of interest. However, mRNAs that are substantially not translatable may also be delivered to cells. Substantially non-translatable mRNAs may be useful as vaccines and/or may sequester translational components of a cell to reduce expression of other species in the cell.</div>
    </li> <li> <para-num num="[0481]"> </para-num> <div id="p-0522" num="0481" class="description-line">In some embodiments, a nanoparticle composition may target a particular type or class of cells (e.g., cells of a particular organ or system thereof). For example, a nanoparticle composition including a therapeutic and/or prophylactic of interest may be specifically delivered to a mammalian liver, kidney, spleen, femur, or lung. Specific delivery to a particular class of cells, an organ, or a system or group thereof implies that a higher proportion of nanoparticle compositions including a therapeutic and/or prophylactic are delivered to the destination (e.g., tissue) of interest relative to other destinations, e.g., upon administration of a nanoparticle composition to a mammal. In some embodiments, specific delivery may result in a greater than 2 fold, 5 fold, 10 fold, 15 fold, or 20 fold increase in the amount of therapeutic and/or prophylactic per 1 g of tissue of the targeted destination (e.g., tissue of interest, such as a liver) as compared to another destination (e.g., the spleen). In some embodiments, the tissue of interest is selected from the group consisting of a liver, kidney, a lung, a spleen, a femur, an ocular tissue (e.g., via intraocular, subretinal, or intravitreal injection), vascular endothelium in vessels (e.g., intra-coronary or intra-femoral) or kidney, and tumor tissue (e.g., via intratumoral injection).</div>
    </li> <li> <para-num num="[0482]"> </para-num> <div id="p-0523" num="0482" class="description-line">As another example of targeted or specific delivery, an mRNA that encodes a protein-binding partner (e.g., an antibody or functional fragment thereof, a scaffold protein, or a peptide) or a receptor on a cell surface may be included in a nanoparticle composition. An mRNA may additionally or instead be used to direct the synthesis and extracellular localization of lipids, carbohydrates, or other biological moieties. Alternatively, other therapeutic and/or prophylactics or elements (e.g., lipids or ligands) of a nanoparticle composition may be selected based on their affinity for particular receptors (e.g., low density lipoprotein receptors) such that a nanoparticle composition may more readily interact with a target cell population including the receptors. For example, ligands may include, but are not limited to, members of a specific binding pair, antibodies, monoclonal antibodies, Fv fragments, single chain Fv (scFv) fragments, Fab fragments, F(ab)2 fragments, single domain antibodies, camelized antibodies and fragments thereof, humanized antibodies and fragments thereof, and multivalent versions thereof; multivalent binding reagents including mono- or bi-specific antibodies such as disulfide stabilized Fv fragments, scFv tandems, diabodies, tribodies, or tetrabodies; and aptamers, receptors, and fusion proteins.</div>
    </li> <li> <para-num num="[0483]"> </para-num> <div id="p-0524" num="0483" class="description-line">In some embodiments, a ligand may be a surface-bound antibody, which can permit tuning of cell targeting specificity. This is especially useful since highly specific antibodies can be raised against an epitope of interest for the desired targeting site. In one embodiment, multiple antibodies are expressed on the surface of a cell, and each antibody can have a different specificity for a desired target. Such approaches can increase the avidity and specificity of targeting interactions.</div>
    </li> <li> <para-num num="[0484]"> </para-num> <div id="p-0525" num="0484" class="description-line">A ligand can be selected, e.g., by a person skilled in the biological arts, based on the desired localization or function of the cell. For example an estrogen receptor ligand, such as tamoxifen, can target cells to estrogen-dependent breast cancer cells that have an increased number of estrogen receptors on the cell surface. Other non-limiting examples of ligand/receptor interactions include CCR1 (e.g., for treatment of inflamed joint tissues or brain in rheumatoid arthritis, and/or multiple sclerosis), CCR7, CCR8 (e.g., targeting to lymph node tissue), CCR6, CCR9,CCR10 (e.g., to target to intestinal tissue), CCR4, CCR10 (e.g., for targeting to skin), CXCR4 (e.g., for general enhanced transmigration), HCELL (e.g., for treatment of inflammation and inflammatory disorders, bone marrow), Alpha4beta7 (e.g., for intestinal mucosa targeting), and VLA-4NCAM-1 (e.g., targeting to endothelium). In general, any receptor involved in targeting (e.g., cancer metastasis) can be harnessed for use in the methods and compositions described herein.</div>
    </li> <li> <para-num num="[0485]"> </para-num> <div id="p-0526" num="0485" class="description-line">Targeted cells may include, but are not limited to, hepatocytes, epithelial cells, hematopoietic cells, epithelial cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes, and tumor cells.</div>
    </li> <li> <para-num num="[0486]"> </para-num> <div id="p-0527" num="0486" class="description-line">In some embodiments, a nanoparticle composition may target hepatocytes. Apolipoprotiens such as apolipoprotein E (apoE) have been shown to associate with neutral or near neutral lipid-containing nanoparticle compositions in the body, and are known to associate with receptors such as low-density lipoprotein receptors (LDLRs) found on the surface of hepatocytes. Thus, a nanoparticle composition including a lipid component with a neutral or near neutral charge that is administered to a subject may acquire apoE in a subject&#39;s body and may subsequently deliver a therapeutic and/or prophylactic (e.g., an RNA) to hepatocytes including LDLRs in a targeted manner.</div>
    </li> <heading id="h-0033">Methods of Treating Diseases and Disorders</heading>
    <li> <para-num num="[0487]"> </para-num> <div id="p-0528" num="0487" class="description-line">Nanoparticle compositions may be useful for treating a disease, disorder, or condition. In particular, such compositions may be useful in treating a disease, disorder, or condition characterized by missing or aberrant protein or polypeptide activity. For example, a nanoparticle composition comprising an mRNA encoding a missing or aberrant polypeptide may be administered or delivered to a cell. Subsequent translation of the mRNA may produce the polypeptide, thereby reducing or eliminating an issue caused by the absence of or aberrant activity caused by the polypeptide. Because translation may occur rapidly, the methods and compositions may be useful in the treatment of acute diseases, disorders, or conditions such as sepsis, stroke, and myocardial infarction. A therapeutic and/or prophylactic included in a nanoparticle composition may also be capable of altering the rate of transcription of a given species, thereby affecting gene expression.</div>
    </li> <li> <para-num num="[0488]"> </para-num> <div id="p-0529" num="0488" class="description-line">Diseases, disorders, and/or conditions characterized by dysfunctional or aberrant protein or polypeptide activity for which a composition may be administered include, but are not limited to, rare diseases, infectious diseases (as both vaccines and therapeutics), cancer and proliferative diseases, genetic diseases (e.g., cystic fibrosis), autoimmune diseases, diabetes, neurodegenerative diseases, cardio- and reno-vascular diseases, and metabolic diseases. Multiple diseases, disorders, and/or conditions may be characterized by missing (or substantially diminished such that proper protein function does not occur) protein activity. Such proteins may not be present, or they may be essentially non-functional. A specific example of a dysfunctional protein is the missense mutation variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which produce a dysfunctional protein variant of CFTR protein, which causes cystic fibrosis. The present disclosure provides a method for treating such diseases, disorders, and/or conditions in a subject by administering a nanoparticle composition including an RNA and a lipid component including a lipid according to Formula (I), a phospholipid (optionally unsaturated), a PEG lipid, and a structural lipid, wherein the RNA may be an mRNA encoding a polypeptide that antagonizes or otherwise overcomes an aberrant protein activity present in the cell of the subject.</div>
    </li> <li> <para-num num="[0489]"> </para-num> <div id="p-0530" num="0489" class="description-line">The disclosure provides methods involving administering nanoparticle compositions including one or more therapeutic and/or prophylactic agents and pharmaceutical compositions including the same. The terms therapeutic and prophylactic can be used interchangeably herein with respect to features and embodiments of the present disclosure. Therapeutic compositions, or imaging, diagnostic, or prophylactic compositions thereof, may be administered to a subject using any reasonable amount and any route of administration effective for preventing, treating, diagnosing, or imaging a disease, disorder, and/or condition and/or any other purpose. The specific amount administered to a given subject may vary depending on the species, age, and general condition of the subject; the purpose of the administration; the particular composition; the mode of administration; and the like. Compositions in accordance with the present disclosure may be formulated in dosage unit form for ease of administration and uniformity of dosage. It will be understood, however, that the total daily usage of a composition of the present disclosure will be decided by an attending physician within the scope of sound medical judgment. The specific therapeutically effective, prophylactically effective, or otherwise appropriate dose level (e.g., for imaging) for any particular patient will depend upon a variety of factors including the severity and identify of a disorder being treated, if any; the one or more therapeutic and/or prophylactics employed; the specific composition employed; the age, body weight, general health, sex, and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific pharmaceutical composition employed; the duration of the treatment; drugs used in combination or coincidental with the specific pharmaceutical composition employed; and like factors well known in the medical arts.</div>
    </li> <li> <para-num num="[0490]"> </para-num> <div id="p-0531" num="0490" class="description-line">A nanoparticle composition including one or more therapeutic and/or prophylactics may be administered by any route. In some embodiments, compositions, including prophylactic, diagnostic, or imaging compositions including one or more nanoparticle compositions described herein, are administered by one or more of a variety of routes, including oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, trans- or intra-dermal, interdermal, rectal, intravaginal, intraperitoneal, intraocular, subretinal, intravitreal, topical (e.g. by powders, ointments, creams, gels, lotions, and/or drops), mucosal, nasal, buccal, enteral, vitreal, intratumoral, sublingual, intranasal; by intratracheal instillation, bronchial instillation, and/or inhalation; as an oral spray and/or powder, nasal spray, and/or aerosol, and/or through a portal vein catheter. In some embodiments, a composition may be administered intravenously, intramuscularly, intradermally, intra-arterially, intratumorally, subcutaneously, intraocularly, subretinally, intravitreally, or by inhalation. However, the present disclosure encompasses the delivery or administration of compositions described herein by any appropriate route taking into consideration likely advances in the sciences of drug delivery. In general, the most appropriate route of administration will depend upon a variety of factors including the nature of the nanoparticle composition including one or more therapeutic and/or prophylactics (e.g., its stability in various bodily environments such as the bloodstream and gastrointestinal tract), the condition of the patient (e.g., whether the patient is able to tolerate particular routes of administration), etc.</div>
    </li> <li> <para-num num="[0491]"> </para-num> <div id="p-0532" num="0491" class="description-line">In certain embodiments, compositions in accordance with the present disclosure may be administered at dosage levels sufficient to deliver from about 0.0001 mg/kg to about 10 mg/kg, from about 0.001 mg/kg to about 10 mg/kg, from about 0.005 mg/kg to about 10 mg/kg, from about 0.01 mg/kg to about 10 mg/kg, from about 0.05 mg/kg to about 10 mg/kg, from about 0.1 mg/kg to about 10 mg/kg, from about 1 mg/kg to about 10 mg/kg, from about 2 mg/kg to about 10 mg/kg, from about 5 mg/kg to about 10 mg/kg, from about 0.0001 mg/kg to about 5 mg/kg, from about 0.001 mg/kg to about 5 mg/kg, from about 0.005 mg/kg to about 5 mg/kg, from about 0.01 mg/kg to about 5 mg/kg, from about 0.05 mg/kg to about 5 mg/kg, from about 0.1 mg/kg to about 5 mg/kg, from about 1 mg/kg to about 5 mg/kg, from about 2 mg/kg to about 5 mg/kg, from about 0.0001 mg/kg to about 2.5 mg/kg, from about 0.001 mg/kg to about 2.5 mg/kg, from about 0.005 mg/kg to about 2.5 mg/kg, from about 0.01 mg/kg to about 2.5 mg/kg, from about 0.05 mg/kg to about 2.5 mg/kg, from about 0.1 mg/kg to about 2.5 mg/kg, from about 1 mg/kg to about 2.5 mg/kg, from about 2 mg/kg to about 2.5 mg/kg, from about 0.0001 mg/kg to about 1 mg/kg, from about 0.001 mg/kg to about 1 mg/kg, from about 0.005 mg/kg to about 1 mg/kg, from about 0.01 mg/kg to about 1 mg/kg, from about 0.05 mg/kg to about 1 mg/kg, from about 0.1 mg/kg to about 1 mg/kg, from about 0.0001 mg/kg to about 0.25 mg/kg, from about 0.001 mg/kg to about 0.25 mg/kg, from about 0.005 mg/kg to about 0.25 mg/kg, from about 0.01 mg/kg to about 0.25 mg/kg, from about 0.05 mg/kg to about 0.25 mg/kg, or from about 0.1 mg/kg to about 0.25 mg/kg of a therapeutic and/or prophylactic (e.g., an mRNA) in a given dose, where a dose of 1 mg/kg (mpk) provides 1 mg of a therapeutic and/or prophylactic per 1 kg of subject body weight. In some embodiments, a dose of about 0.001 mg/kg to about 10 mg/kg of a therapeutic and/or prophylactic (e.g., mRNA) of a nanoparticle composition may be administered. In other embodiments, a dose of about 0.005 mg/kg to about 2.5 mg/kg of a therapeutic and/or prophylactic may be administered. In certain embodiments, a dose of about 0.1 mg/kg to about 1 mg/kg may be administered. In other embodiments, a dose of about 0.05 mg/kg to about 0.25 mg/kg may be administered. A dose may be administered one or more times per day, in the same or a different amount, to obtain a desired level of mRNA expression and/or therapeutic, diagnostic, prophylactic, or imaging effect. The desired dosage may be delivered, for example, three times a day, two times a day, once a day, every other day, every third day, every week, every two weeks, every three weeks, or every four weeks. In certain embodiments, the desired dosage may be delivered using multiple administrations (e.g., two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, or more administrations). In some embodiments, a single dose may be administered, for example, prior to or after a surgical procedure or in the instance of an acute disease, disorder, or condition.</div>
    </li> <li> <para-num num="[0492]"> </para-num> <div id="p-0533" num="0492" class="description-line">Nanoparticle compositions including one or more therapeutic and/or prophylactics may be used in combination with one or more other therapeutic, prophylactic, diagnostic, or imaging agents. By in combination with, it is not intended to imply that the agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope of the present disclosure. For example, one or more nanoparticle compositions including one or more different therapeutic and/or prophylactics may be administered in combination. Compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In some embodiments, the present disclosure encompasses the delivery of compositions, or imaging, diagnostic, or prophylactic compositions thereof in combination with agents that improve their bioavailability, reduce and/or modify their metabolism, inhibit their excretion, and/or modify their distribution within the body.</div>
    </li> <li> <para-num num="[0493]"> </para-num> <div id="p-0534" num="0493" class="description-line">It will further be appreciated that therapeutically, prophylactically, diagnostically, or imaging active agents utilized in combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that agents utilized in combination will be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination may be lower than those utilized individually.</div>
    </li> <li> <para-num num="[0494]"> </para-num> <div id="p-0535" num="0494" class="description-line">The particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved. It will also be appreciated that the therapies employed may achieve a desired effect for the same disorder (for example, a composition useful for treating cancer may be administered concurrently with a chemotherapeutic agent), or they may achieve different effects (e.g., control of any adverse effects, such as infusion related reactions).</div>
    </li> <li> <para-num num="[0495]"> </para-num> <div id="p-0536" num="0495" class="description-line">A nanoparticle composition may be used in combination with an agent to increase the effectiveness and/or therapeutic window of the composition. Such an agent may be, for example, an anti-inflammatory compound, a steroid (e.g., a corticosteroid), a statin, an estradiol, a BTK inhibitor, an S1P1 agonist, a glucocorticoid receptor modulator (GRM), or an anti-histamine. In some embodiments, a nanoparticle composition may be used in combination with dexamethasone, methotrexate, acetaminophen, an H1 receptor blocker, or an H2 receptor blocker. In some embodiments, a method of treating a subject in need thereof or of delivering a therapeutic and/or prophylactic to a subject (e.g., a mammal) may involve pre-treating the subject with one or more agents prior to administering a nanoparticle composition. For example, a subject may be pre-treated with a useful amount (e.g., 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, or any other useful amount) of dexamethasone, methotrexate, acetaminophen, an H1 receptor blocker, or an H2 receptor blocker. Pre-treatment may occur 24 or fewer hours (e.g., 24 hours, 20 hours, 16 hours, 12 hours, 8 hours, 4 hours, 2 hours, 1 hour, 50 minutes, 40 minutes, 30 minutes, 20 minutes, or 10 minutes) before administration of the nanoparticle composition and may occur one, two, or more times in, for example, increasing dosage amounts.</div>
    </li> <li> <para-num num="[0496]"> </para-num> <div id="p-0537" num="0496" class="description-line">Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments in accordance with the disclosure described herein. The scope of the present disclosure is not intended to be limited to the above Description, but rather is as set forth in the appended claims.</div>
    </li> <li> <para-num num="[0497]"> </para-num> <div id="p-0538" num="0497" class="description-line">In the claims, articles such as a, an, and the may mean one or more than one unless indicated to the contrary or otherwise evident from the context. Claims or descriptions that include or between one or more members of a group are considered satisfied if one, more than one, or all of the group members are present in, employed in, or otherwise relevant to a given product or process unless indicated to the contrary or otherwise evident from the context. The disclosure includes embodiments in which exactly one member of the group is present in, employed in, or otherwise relevant to a given product or process. The disclosure includes embodiments in which more than one, or all, of the group members are present in, employed in, or otherwise relevant to a given product or process.</div>
    </li> <li> <para-num num="[0498]"> </para-num> <div id="p-0539" num="0498" class="description-line">It is also noted that the term comprising is intended to be open and permits but does not require the inclusion of additional elements or steps. When the term comprising is used herein, the terms consisting essentially of and consisting of are thus also encompassed and disclosed. Throughout the description, where compositions are described as having, including, or comprising specific components, it is contemplated that compositions also consist essentially of, or consist of, the recited components. Similarly, where methods or processes are described as having, including, or comprising specific process steps, the processes also consist essentially of, or consist of, the recited processing steps. Further, it should be understood that the order of steps or order for performing certain actions is immaterial so long as the invention remains operable. Moreover, two or more steps or actions can be conducted simultaneously.</div>
    </li> <li> <para-num num="[0499]"> </para-num> <div id="p-0540" num="0499" class="description-line">Where ranges are given, endpoints are included. Furthermore, it is to be understood that unless otherwise indicated or otherwise evident from the context and understanding of one of ordinary skill in the art, values that are expressed as ranges can assume any specific value or sub-range within the stated ranges in different embodiments of the disclosure, to the tenth of the unit of the lower limit of the range, unless the context clearly dictates otherwise.</div>
    </li> <li> <para-num num="[0500]"> </para-num> <div id="p-0541" num="0500" class="description-line">The synthetic processes of the disclosure can tolerate a wide variety of functional groups, therefore various substituted starting materials can be used. The processes generally provide the desired final compound at or near the end of the overall process, although it may be desirable in certain instances to further convert the compound to a pharmaceutically acceptable salt thereof.</div>
    </li> <li> <para-num num="[0501]"> </para-num> <div id="p-0542" num="0501" class="description-line">Compounds of the present disclosure can be prepared in a variety of ways using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, by employing standard synthetic methods and procedures either known to those skilled in the art, or which will be apparent to the skilled artisan in light of the teachings herein. Standard synthetic methods and procedures for the preparation of organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or from standard textbooks in the field. Although not limited to any one or several sources, classic texts such as Smith, M. B., March, <i>J., March&#39;s Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, </i>5<sup>th </sup>edition, John Wiley &amp; Sons: New York, 2001; Greene, T. W., Wuts, P. G. M., <i>Protective Groups in Organic Synthesis, </i>3<sup>rd </sup>edition, John Wiley &amp; Sons: New York, 1999; R. Larock, <i>Comprehensive Organic Transformations</i>, VCH Publishers (1989); L. Fieser and M. Fieser, <i>Fieser and Fieser&#39;s Reagents for Organic Synthesis</i>, John Wiley and Sons (1994); and L. Paquette, ed., <i>Encyclopedia of Reagents for Organic Synthesis</i>, John Wiley and Sons (1995), incorporated by reference herein, are useful and recognized reference textbooks of organic synthesis known to those in the art. The following descriptions of synthetic methods are designed to illustrate, but not to limit, general procedures for the preparation of compounds of the present disclosure.</div>
    </li> <li> <para-num num="[0502]"> </para-num> <div id="p-0543" num="0502" class="description-line">The compounds of this disclosure having any of the formulae described herein may be prepared according to the procedures illustrated in <figure-callout id="1" label="Schemes" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}"> <figure-callout id="2" label="Schemes" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Schemes</figure-callout> </figure-callout> 1 and 2 below, from commercially available starting materials or starting materials which can be prepared using literature procedures. The variables in the schemes (e.g., R<sub>1</sub>, R<sub>2</sub>, and R<sub>3 </sub>etc. are as defined herein). One of ordinary skill in the art will note that, during the reaction sequences and synthetic schemes described herein, the order of certain steps may be changed, such as the introduction and removal of protecting groups.</div>
    </li> <li> <para-num num="[0503]"> </para-num> <div id="p-0544" num="0503" class="description-line">One of ordinary skill in the art will recognize that certain groups may require protection from the reaction conditions via the use of protecting groups. Protecting groups may also be used to differentiate similar functional groups in molecules. A list of protecting groups and how to introduce and remove these groups can be found in Greene, T. W., Wuts, P. G. M., <i>Protective Groups in Organic Synthesis, </i>3<sup>rd </sup>edition, John Wiley &amp; Sons: New York, 1999.</div>
    </li> <li> <para-num num="[0504]"> </para-num> <div id="p-0545" num="0504" class="description-line">Preferred protecting groups include, but are not limited to:</div>
    </li> <li> <para-num num="[0505]"> </para-num> <div id="p-0546" num="0505" class="description-line">For a hydroxyl moiety: TBS, benzyl, THP, Ac;</div>
    </li> <li> <para-num num="[0506]"> </para-num> <div id="p-0547" num="0506" class="description-line">For carboxylic acids: benzyl ester, methyl ester, ethyl ester, allyl ester;</div>
    </li> <li> <para-num num="[0507]"> </para-num> <div id="p-0548" num="0507" class="description-line">For amines: Fmoc, Cbz, BOC, DMB, Ac, Bn, Tr, Ts, trifluoroacetyl, phthalimide, benzylideneamine;</div>
    </li> <li> <para-num num="[0508]"> </para-num> <div id="p-0549" num="0508" class="description-line">For diols: Ac (2) TBS (2), or when taken together acetonides;</div>
    </li> <li> <para-num num="[0509]"> </para-num> <div id="p-0550" num="0509" class="description-line">For thiols: Ac;</div>
    </li> <li> <para-num num="[0510]"> </para-num> <div id="p-0551" num="0510" class="description-line">For benzimidazoles: SEM, benzyl, PMB, DMB;</div>
    </li> <li> <para-num num="[0511]"> </para-num> <div id="p-0552" num="0511" class="description-line">For aldehydes: di-alkyl acetals such as dimethoxy acetal or diethyl acetyl.</div>
    </li> <li> <para-num num="[0512]"> </para-num> <div id="p-0553" num="0512" class="description-line">In the reaction schemes described herein, multiple stereoisomers may be produced. When no particular stereoisomer is indicated, it is understood to mean all possible stereoisomers that could be produced from the reaction. A person of ordinary skill in the art will recognize that the reactions can be optimized to give one isomer preferentially, or new schemes may be devised to produce a single isomer. If mixtures are produced, techniques such as preparative thin layer chromatography, preparative HPLC, preparative chiral HPLC, or preparative SFC may be used to separate the isomers.</div>
    </li> <li> <div id="p-0554" num="0000" class="description-line">
      <chemistry id="CHEM-US-00076" num="00076">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/14/2c/57c36f1af7e49f/US20170210697A1-20170727-C00076.png"><img id="EMI-C00076" he="97.45mm" wi="75.86mm" file="US20170210697A1-20170727-C00076.TIF" alt="Figure US20170210697A1-20170727-C00076" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="390" alt="Figure US20170210697A1-20170727-C00076" class="patent-full-image" src="https://patentimages.storage.googleapis.com/87/14/2c/57c36f1af7e49f/US20170210697A1-20170727-C00076.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00076" attachment-type="cdx" file="US20170210697A1-20170727-C00076.CDX"> </attachment>
          <attachment idref="CHEM-US-00076" attachment-type="mol" file="US20170210697A1-20170727-C00076.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0513]"> </para-num> <div id="p-0555" num="0513" class="description-line">As illustrated in <figure-callout id="1" label="Scheme" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Scheme</figure-callout> 1 above, 8-bromooctanoic acid reacts with an alcohol a1 (e.g., heptadecan-9-ol) to afford an ester b1 (e.g., heptadecan-9-yl 8-bromooctanoate). <figure-callout id="1" label="Step" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Step</figure-callout> 1 can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP. <figure-callout id="1" label="Step" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Step</figure-callout> 1 can take place at room temperature for 18 h. Next, ester b1 reacts with 2-aminoethan-1-ol to afford amine c1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate). <figure-callout id="2" label="Step" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Step</figure-callout> 2 can take place in ethanol at, e.g., a temperature of about 60 C. Then amine c1 reacts with an bromoalkyl R<sub>1</sub>Br (e.g., 1-bromotetradecane) to afford compound d1 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate). <figure-callout id="3" label="Step" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Step</figure-callout> 3 can take place in ethanol in the presence of N,N-diisopropylethylamine.</div>
    </li> <li> <div id="p-0556" num="0000" class="description-line">
      <chemistry id="CHEM-US-00077" num="00077">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/62/f0/07e2305778dac5/US20170210697A1-20170727-C00077.png"><img id="EMI-C00077" he="184.57mm" wi="75.86mm" file="US20170210697A1-20170727-C00077.TIF" alt="Figure US20170210697A1-20170727-C00077" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="738" alt="Figure US20170210697A1-20170727-C00077" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/62/f0/07e2305778dac5/US20170210697A1-20170727-C00077.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00077" attachment-type="cdx" file="US20170210697A1-20170727-C00077.CDX"> </attachment>
          <attachment idref="CHEM-US-00077" attachment-type="mol" file="US20170210697A1-20170727-C00077.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0514]"> </para-num> <div id="p-0557" num="0514" class="description-line">As illustrated in <figure-callout id="2" label="Scheme" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Scheme</figure-callout> 2 above, an acid a2 (t is an integer between 1 and 7; e.g., 8-bromooctanoic acid) reacts with an alcohol b2 (e.g., nonan-1-ol) to afford an ester c2 (e.g., nonyl-8-bromooctanoate). <figure-callout id="1" label="Step" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Step</figure-callout> 1 can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP. Alcohol e2 (e.g., heptadecan-9-ol) can be obtained from reacting aldehyde d2 (e.g., nonanal) with a Grignard reagent R<sub>3</sub>MgX (e.g., n-C<sub>8</sub>H<sub>17</sub>MgBr) via <figure-callout id="2" label="Step" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Step</figure-callout> 2. Next, 8-bromooctanoic acid reacts with an alcohol e2 (e.g., heptadecan-9-ol) to afford an ester f2 (e.g., heptadecan-9-yl 8-bromooctanoate). <figure-callout id="3" label="Step" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Step</figure-callout> 3 can take place in an organic solvent (e.g., dichloromethane) in the presence of, e.g., N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride, N,N-diisopropylethylamine and DMAP. Next, ester f2 reacts with 2-aminoethan-1-ol to afford amine g2 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate). <figure-callout id="4" label="Step" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Step</figure-callout> 4 can take place in ethanol in the presence of i-Pr<sub>2</sub>EtN. Then amine g2 reacts with ester c2 (e.g., nonyl-8-bromooctanoate) to afford compound h2 (e.g., heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate). <figure-callout id="5" label="Step" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Step</figure-callout> 5 can take place in an organic solvent (e.g., a mixture of CPME and MeCN), in the presence of a base (such as an inorganic base (e.g., K2CO<sub>3</sub>) or non-nucleophilic organic base (e.g., i-Pr2EtN)) and a catalyst (e.g., an iodide such as KI or NaI) at, e.g., an elevated temperature (such as at about 70-90 C., e.g., about 80 C.).</div>
    </li> <li> <para-num num="[0515]"> </para-num> <div id="p-0558" num="0515" class="description-line">A person of ordinary skill in the art will recognize that in the above schemes the order of certain steps may be interchangeable.</div>
    </li> <li> <para-num num="[0516]"> </para-num> <div id="p-0559" num="0516" class="description-line">In certain aspects, the disclosure also includes methods of synthesizing a compound of any of Formulae (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) and intermediate(s) for synthesizing the compound.</div>
    </li> <li> <para-num num="[0517]"> </para-num> <div id="p-0560" num="0517" class="description-line">In some embodiments, the method of synthesizing a compound of Formula (I) includes reacting a compound of Formula (X2):</div>
    </li> <li> <div id="p-0561" num="0000" class="description-line">
      <chemistry id="CHEM-US-00078" num="00078">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/49/57/72c18111853055/US20170210697A1-20170727-C00078.png"><img id="EMI-C00078" he="16.09mm" wi="26.08mm" file="US20170210697A1-20170727-C00078.TIF" alt="Figure US20170210697A1-20170727-C00078" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="104" height="64" alt="Figure US20170210697A1-20170727-C00078" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/49/57/72c18111853055/US20170210697A1-20170727-C00078.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00078" attachment-type="cdx" file="US20170210697A1-20170727-C00078.CDX"> </attachment>
          <attachment idref="CHEM-US-00078" attachment-type="mol" file="US20170210697A1-20170727-C00078.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0562" num="0000" class="description-line">with R<sub>1</sub>Br to afford the compound of Formula (I), wherein each variables are as defined herein. For example, m is 5, 6, 7, 8, or 9, preferably 5, 7, or 9. For example, each of R<sub>5</sub>, R<sub>6</sub>, and R<sub>7 </sub>is H. For example, M is C(O)O or OC(O). For example, R<sub>4 </sub>is unsubstituted C<sub>1-3 </sub>alkyl, or (CH<sub>2</sub>)<sub>n</sub>Q, in which n is 2, 3, or 4 and Q is OH, NHC(S)N(R)<sub>2</sub>, NHC(O)N(R)<sub>2</sub>, N(R)C(O)R, or N(R)S(O)<sub>2</sub>R. For example, the reaction of the compound of Formula (X2) with R<sub>1</sub>Br takes place in the presence of a base (such as an inorganic base (e.g., K<sub>2</sub>CO<sub>3</sub>) or non-nucleophilic organic base (e.g., i-Pr<sub>2</sub>EtN)). For example, the reaction takes place in the presence of an inorganic base (e.g., K<sub>2</sub>CO<sub>3</sub>) and a catalyst (e.g., an iodide such as KI or NaI). For example, the reaction takes place at an elevated temperature, e.g., about 50-100 C., 70-90 C., or about 80 C.).</div>
    </li> <li> <para-num num="[0518]"> </para-num> <div id="p-0563" num="0518" class="description-line">The method may also include reacting a compound of Formula (X1):</div>
    </li> <li> <div id="p-0564" num="0000" class="description-line">
      <chemistry id="CHEM-US-00079" num="00079">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a7/71/09/fe0cc3322c9916/US20170210697A1-20170727-C00079.png"><img id="EMI-C00079" he="13.29mm" wi="26.08mm" file="US20170210697A1-20170727-C00079.TIF" alt="Figure US20170210697A1-20170727-C00079" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="104" height="53" alt="Figure US20170210697A1-20170727-C00079" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a7/71/09/fe0cc3322c9916/US20170210697A1-20170727-C00079.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00079" attachment-type="cdx" file="US20170210697A1-20170727-C00079.CDX"> </attachment>
          <attachment idref="CHEM-US-00079" attachment-type="mol" file="US20170210697A1-20170727-C00079.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0565" num="0000" class="description-line">with R<sub>4</sub>NH<sub>2 </sub>to afford a compound of Formula (X2), wherein each variables are as defined herein.</div>
    </li> <li> <para-num num="[0519]"> </para-num> <div id="p-0566" num="0519" class="description-line">In some embodiments, the intermediate(s) include those having any of Formulae (X1) and (X2):</div>
    </li> <li> <div id="p-0567" num="0000" class="description-line">
      <chemistry id="CHEM-US-00080" num="00080">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/f5/52/f4cc0171fca747/US20170210697A1-20170727-C00080.png"><img id="EMI-C00080" he="47.58mm" wi="54.95mm" file="US20170210697A1-20170727-C00080.TIF" alt="Figure US20170210697A1-20170727-C00080" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="220" height="190" alt="Figure US20170210697A1-20170727-C00080" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/f5/52/f4cc0171fca747/US20170210697A1-20170727-C00080.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00080" attachment-type="cdx" file="US20170210697A1-20170727-C00080.CDX"> </attachment>
          <attachment idref="CHEM-US-00080" attachment-type="mol" file="US20170210697A1-20170727-C00080.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0568" num="0000" class="description-line">wherein each variables are as defined herein. For example, the intermediate includes heptadecan-9-yl 8-bromooctanoate, and heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate, and morphic forms thereof (e.g., a crystalline form).</div>
    </li> <li> <para-num num="[0520]"> </para-num> <div id="p-0569" num="0520" class="description-line">In addition, it is to be understood that any particular embodiment of the present disclosure that falls within the prior art may be explicitly excluded from any one or more of the claims. Since such embodiments are deemed to be known to one of ordinary skill in the art, they may be excluded even if the exclusion is not set forth explicitly herein.</div>
    </li> <li> <para-num num="[0521]"> </para-num> <div id="p-0570" num="0521" class="description-line">All cited sources, for example, references, publications, databases, database entries, and art cited herein, are incorporated into this application by reference, even if not expressly stated in the citation. In case of conflicting statements of a cited source and the instant application, the statement in the instant application shall control.</div>
    </li> <heading id="h-0034">Examples</heading>
    <heading id="h-0035">Example 1: Synthesis of Compounds According to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)</heading>
    <heading id="h-0036">A. General Considerations</heading>
    <li> <para-num num="[0522]"> </para-num> <div id="p-0571" num="0522" class="description-line">All solvents and reagents used were obtained commercially and used as such unless noted otherwise. <sup>1</sup>H NMR spectra were recorded in CDCl<sub>3</sub>, at 300 K using a Bruker Ultrashield 300 MHz instrument. Chemical shifts are reported as parts per million (ppm) relative to TMS (0.00) for <sup>1</sup>H. Silica gel chromatographies were performed on ISCO CombiFlash Rf+ Lumen Instruments using ISCO RediSep Rf Gold Flash Cartridges (particle size: 20-40 microns). Reverse phase chromatographies were performed on ISCO CombiFlash Rf+ Lumen Instruments using RediSep Rf Gold C18 High Performance columns. All final compounds were determined to be greater than 85% pure via analysis by reverse phase UPLC-MS (retention times, RT, in minutes) using Waters Acquity UPLC instrument with DAD and ELSD and a ZORBAX Rapid Resolution High Definition (RRHD) SB-C18 LC column, 2.1 mm, 50 mm, 1.8 m, and a gradient of 65 to 100% acetonitrile in water with 0.1% TFA over 5 minutes at 1.2 mL/min. Injection volume was 5 L and the column temperature was 80 C. Detection was based on electrospray ionization (ESI) in positive mode using Waters SQD mass spectrometer (Milford, Mass., USA) and evaporative light scattering detector.</div>
    </li> <li> <para-num num="[0523]"> </para-num> <div id="p-0572" num="0523" class="description-line">The procedures described below are useful in the synthesis of Compounds 1-147.</div>
    </li> <li> <para-num num="[0524]"> </para-num> <div id="p-0573" num="0524" class="description-line">The following abbreviations are employed herein:
</div> </li> <ul> <li id="ul0001-0001" num="0000"> <ul> <li id="ul0002-0001" num="0525">THF: Tetrahydrofuran</li> <li id="ul0002-0002" num="0526">MeCN: Acetonitrile</li> <li id="ul0002-0003" num="0527">LAH: Lithium Aluminum Hydride</li> <li id="ul0002-0004" num="0528">DCM: Dichloromethane</li> <li id="ul0002-0005" num="0529">DMAP: 4-Dimethylaminopyridine</li> <li id="ul0002-0006" num="0530">LDA: Lithium Diisopropylamide</li> <li id="ul0002-0007" num="0531">rt: Room Temperature</li> <li id="ul0002-0008" num="0532">DME: 1,2-Dimethoxyethane</li> <li id="ul0002-0009" num="0533">n-BuLi: n-Butyllithium</li> <li id="ul0002-0010" num="0534">CPME: Cyclopentyl methyl ether</li> <li id="ul0002-0011" num="0535">i-Pr2EtN: N,N-Diisopropylethylamine</li> </ul> </li> </ul>

    <heading id="h-0037">B. Compound 2: Heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate</heading>
    <heading id="h-0038"> <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1</heading>
    <li> <para-num num="[0536]"> </para-num> <div id="p-0574" num="0536" class="description-line">
      <chemistry id="CHEM-US-00081" num="00081">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/b2/fc/856743f51b028d/US20170210697A1-20170727-C00081.png"><img id="EMI-C00081" he="100.41mm" wi="119.55mm" file="US20170210697A1-20170727-C00081.TIF" alt="Figure US20170210697A1-20170727-C00081" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="478" height="402" alt="Figure US20170210697A1-20170727-C00081" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/b2/fc/856743f51b028d/US20170210697A1-20170727-C00081.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00081" attachment-type="cdx" file="US20170210697A1-20170727-C00081.CDX"> </attachment>
          <attachment idref="CHEM-US-00081" attachment-type="mol" file="US20170210697A1-20170727-C00081.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <heading id="h-0039">Heptadecan-9-yl 8-bromooctanoate (Method A)</heading>
    <li> <para-num num="[0537]"> </para-num> <div id="p-0575" num="0537" class="description-line">
      <chemistry id="CHEM-US-00082" num="00082">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/61/57/18/cebee9a89e6944/US20170210697A1-20170727-C00082.png"><img id="EMI-C00082" he="10.33mm" wi="74.34mm" file="US20170210697A1-20170727-C00082.TIF" alt="Figure US20170210697A1-20170727-C00082" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="41" alt="Figure US20170210697A1-20170727-C00082" class="patent-full-image" src="https://patentimages.storage.googleapis.com/61/57/18/cebee9a89e6944/US20170210697A1-20170727-C00082.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00082" attachment-type="cdx" file="US20170210697A1-20170727-C00082.CDX"> </attachment>
          <attachment idref="CHEM-US-00082" attachment-type="mol" file="US20170210697A1-20170727-C00082.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0538]"> </para-num> <div id="p-0576" num="0538" class="description-line">To a solution of 8-bromooctanoic acid (1.04 g, 4.6 mmol) and heptadecan-9-ol (1.5 g, 5.8 mmol) in dichloromethane (20 mL) was added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (1.1 g, 5.8 mmol), N,N-diisopropylethylamine (3.3 mL, 18.7 mmol) and DMAP (114 mg, 0.9 mmol). The reaction was allowed to stir at rt for 18 h. The reaction was diluted with dichloromethane and washed with saturated sodium bicarbonate. The organic layer was separated and washed with brine, and dried over MgSO<sub>4</sub>. The organic layer was filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-10% ethyl acetate in hexanes) to obtain heptadecan-9-yl 8-bromooctanoate (875 mg, 1.9 mmol, 41%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 3.42 (m, 2H); 2.31 (m, 2H); 1.89 (m, 2H); 1.73-1.18 (br. m, 36H); 0.88 (m, 6H).</div>
    </li> <heading id="h-0040">Heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (Method B)</heading>
    <li> <para-num num="[0539]"> </para-num> <div id="p-0577" num="0539" class="description-line">
      <chemistry id="CHEM-US-00083" num="00083">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/86/97/b4/09e9028245da8b/US20170210697A1-20170727-C00083.png"><img id="EMI-C00083" he="12.36mm" wi="105.49mm" file="US20170210697A1-20170727-C00083.TIF" alt="Figure US20170210697A1-20170727-C00083" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="49" alt="Figure US20170210697A1-20170727-C00083" class="patent-full-image" src="https://patentimages.storage.googleapis.com/86/97/b4/09e9028245da8b/US20170210697A1-20170727-C00083.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00083" attachment-type="cdx" file="US20170210697A1-20170727-C00083.CDX"> </attachment>
          <attachment idref="CHEM-US-00083" attachment-type="mol" file="US20170210697A1-20170727-C00083.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0540]"> </para-num> <div id="p-0578" num="0540" class="description-line">A solution of heptadecan-9-yl 8-bromooctanoate (3.8 g, 8.2 mmol) and 2-aminoethan-1-ol (15 mL, 248 mmol) in ethanol (3 mL) was allowed to stir at 62 C. for 18 h. The reaction mixture was concentrated in vacuo and the residue was taken-up in ethyl acetate and water. The organic layer was separated and washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The mixture was filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (3.1 g, 7 mmol, 85%). UPLC/ELSD: RT=2.67 min. MS (ES): m/z (MH<sup>+</sup>) 442.68 for C<sub>27</sub>H<sub>55</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0541]"> </para-num> <div id="p-0579" num="0541" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 3.67 (t, 2H); 2.81 (t, 2H); 2.65 (t, 2H); 2.30 (t, 2H); 2.05 (br. m, 2H); 1.72-1.41 (br. m, 8H); 1.40-1.20 (br. m, 30H); 0.88 (m, 6H).</div>
    </li> <heading id="h-0041">Heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate (Method C</heading>
    <li> <para-num num="[0542]"> </para-num> <div id="p-0580" num="0542" class="description-line">
      <chemistry id="CHEM-US-00084" num="00084">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9d/e7/32/c2b8f7c4601f19/US20170210697A1-20170727-C00084.png"><img id="EMI-C00084" he="15.66mm" wi="74.85mm" file="US20170210697A1-20170727-C00084.TIF" alt="Figure US20170210697A1-20170727-C00084" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00084" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9d/e7/32/c2b8f7c4601f19/US20170210697A1-20170727-C00084.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00084" attachment-type="cdx" file="US20170210697A1-20170727-C00084.CDX"> </attachment>
          <attachment idref="CHEM-US-00084" attachment-type="mol" file="US20170210697A1-20170727-C00084.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0543]"> </para-num> <div id="p-0581" num="0543" class="description-line">Chemical Formula: C<sub>41</sub>H<sub>83</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0544]"> </para-num> <div id="p-0582" num="0544" class="description-line">Molecular Weight: 638.12</div>
    </li> <li> <para-num num="[0545]"> </para-num> <div id="p-0583" num="0545" class="description-line">A solution of heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (125 mg, 0.28 mmol), 1-bromotetradecane (94 mg, 0.34 mmol) and N,N-diisopropylethylamine (44 mg, 0.34 mmol) in ethanol was allowed to stir at 65 C. for 18 h. The reaction was cooled to rt and solvents were evaporated in vacuo. The residue was taken-up in ethyl acetate and saturated sodium bicarbonate. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4 </sub>and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-((2-hydroxyethyl)(tetradecyl)amino)octanoate (89 mg, 0.14 mmol, 50%). UPLC/ELSD: RT=3.61 min. MS (ES): m/z (MH<sup>+</sup>) 638.91 for C<sub>41</sub>H<sub>83</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 3.72-3.47 (br. m, 2H); 2.78-2.40 (br. m, 5H); 2.28 (t, 2H); 1.70-1.40 (m, 10H); 1.38-1.17 (br. m, 54H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0042">Synthesis of Intermediates</heading>
    <heading id="h-0043">Intermediate A: 2-Octyldecanoic acid</heading>
    <li> <para-num num="[0546]"> </para-num> <div id="p-0584" num="0546" class="description-line">
      <chemistry id="CHEM-US-00085" num="00085">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/48/22/8a4f829a67fe1c/US20170210697A1-20170727-C00085.png"><img id="EMI-C00085" he="17.95mm" wi="51.65mm" file="US20170210697A1-20170727-C00085.TIF" alt="Figure US20170210697A1-20170727-C00085" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="72" alt="Figure US20170210697A1-20170727-C00085" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/48/22/8a4f829a67fe1c/US20170210697A1-20170727-C00085.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00085" attachment-type="cdx" file="US20170210697A1-20170727-C00085.CDX"> </attachment>
          <attachment idref="CHEM-US-00085" attachment-type="mol" file="US20170210697A1-20170727-C00085.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0547]"> </para-num> <div id="p-0585" num="0547" class="description-line">A solution of diisopropylamine (2.92 mL, 20.8 mmol) in THF (10 mL) was cooled to 78 C. and a solution of n-BuLi (7.5 mL, 18.9 mmol, 2.5 M in hexanes) was added. The reaction was allowed to warm to 0 C. To a solution of decanoic acid (2.96 g, 17.2 mmol) and NaH (754 mg, 18.9 mmol, 60% w/w) in THF (20 mL) at 0 C. was added the solution of LDA and the mixture was allowed to stir at rt for 30 min. After this time 1-iodooctane (5 g, 20.8 mmol) was added and the reaction mixture was heated at 45 C. for 6 h. The reaction was quenched with 1N HCl (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-20% ethyl acetate in hexanes) to yield 2-octyldecanoic acid (1.9 g, 6.6 mmol, 38%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 2.38 (br. m, 1H); 1.74-1.03 (br. m, 28H); 0.91 (m, 6H).</div>
    </li> <heading id="h-0044">Intermediate B: 7-Bromoheptyl 2-octyldecanoate</heading>
    <li> <para-num num="[0548]"> </para-num> <div id="p-0586" num="0548" class="description-line">
      <chemistry id="CHEM-US-00086" num="00086">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/8e/66/8b8b5cf3e0d380/US20170210697A1-20170727-C00086.png"><img id="EMI-C00086" he="14.99mm" wi="74.34mm" file="US20170210697A1-20170727-C00086.TIF" alt="Figure US20170210697A1-20170727-C00086" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="60" alt="Figure US20170210697A1-20170727-C00086" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/8e/66/8b8b5cf3e0d380/US20170210697A1-20170727-C00086.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00086" attachment-type="cdx" file="US20170210697A1-20170727-C00086.CDX"> </attachment>
          <attachment idref="CHEM-US-00086" attachment-type="mol" file="US20170210697A1-20170727-C00086.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0549]"> </para-num> <div id="p-0587" num="0549" class="description-line">7-bromoheptyl 2-octyldecanoate was synthesized using Method A from 2-octyldecanoic acid and 7-bromoheptan-1-ol. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.09 (br. m, 2H); 3.43 (br. m, 2H); 2.48-2.25 (br. m, 1H); 1.89 (br. m, 2H); 1.74-1.16 (br. m, 36H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0045">Intermediate C: (2-Hexylcyclopropyl)methanol</heading>
    <li> <para-num num="[0550]"> </para-num> <div id="p-0588" num="0550" class="description-line">
      <chemistry id="CHEM-US-00087" num="00087">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ae/16/b6/cac121235317cc/US20170210697A1-20170727-C00087.png"><img id="EMI-C00087" he="8.04mm" wi="47.58mm" file="US20170210697A1-20170727-C00087.TIF" alt="Figure US20170210697A1-20170727-C00087" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="190" height="32" alt="Figure US20170210697A1-20170727-C00087" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ae/16/b6/cac121235317cc/US20170210697A1-20170727-C00087.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00087" attachment-type="cdx" file="US20170210697A1-20170727-C00087.CDX"> </attachment>
          <attachment idref="CHEM-US-00087" attachment-type="mol" file="US20170210697A1-20170727-C00087.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0551]"> </para-num> <div id="p-0589" num="0551" class="description-line">A solution of diethyl zinc (20 mL, 20 mmol, 1 M in hexanes), in dichloromethane (20 mL) was allowed to cool to 40 C. for 5 min. Then a solution of diiodomethane (3.22 mL, 40 mmol) in dichloromethane (10 mL) was added dropwise. After the reaction was allowed to stir for 1 h at 40 C., a solution of trichloro-acetic acid (327 mg, 2 mmol) and DME (1 mL, 9.6 mmol) in dichloromethane (10 mL) was added. The reaction was allowed to warm to 15 C. and stir at this temperature for 1 h. A solution of (Z)-non-2-en-1-ol (1.42 g, 10 mmol) in dichloromethane (10 mL) was then added to the 15 C. solution. The reaction was then slowly allowed to warm to rt and stir for 18 h. After this time saturated NH<sub>4</sub>C<sub>1 </sub>(200 mL) was added and the reaction was extracted with dichloromethane (3), washed with brine, and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic layer was filtered, evaporated in vacuo and the residue was purified by silica gel chromatography (0-50% ethyl acetate in hexanes) to yield (2-hexylcyclopropyl)methanol (1.43 g, 9.2 mmol, 92%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.64 (m, 2H); 1.57-1.02 (m, 12H); 0.99-0.80 (m, 4H); 0.72 (m, 1H), 0.00 (m, 1H).</div>
    </li> <heading id="h-0046">C. Compound 1: Heptadecan-9-yl 8-((2-hydroxyethyl)(octadecyl)amino)octanoate</heading>
    <li> <para-num num="[0552]"> </para-num> <div id="p-0590" num="0552" class="description-line">
      <chemistry id="CHEM-US-00088" num="00088">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/b5/b7/585acf287175a6/US20170210697A1-20170727-C00088.png"><img id="EMI-C00088" he="15.66mm" wi="74.85mm" file="US20170210697A1-20170727-C00088.TIF" alt="Figure US20170210697A1-20170727-C00088" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00088" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/b5/b7/585acf287175a6/US20170210697A1-20170727-C00088.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00088" attachment-type="cdx" file="US20170210697A1-20170727-C00088.CDX"> </attachment>
          <attachment idref="CHEM-US-00088" attachment-type="mol" file="US20170210697A1-20170727-C00088.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0553]"> </para-num> <div id="p-0591" num="0553" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>91</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0554]"> </para-num> <div id="p-0592" num="0554" class="description-line">Molecular Weight: 694.23</div>
    </li> <li> <para-num num="[0555]"> </para-num> <div id="p-0593" num="0555" class="description-line"> <figure-callout id="1" label="Compound" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Compound</figure-callout> 1 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.86 min. MS (ES): m/z (MH<sup>+</sup>) 694.93 for C<sub>45</sub>H<sub>91</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 1H); 3.77-3.47 (br. m, 2H); 2.78-2.37 (br. m, 5H); 2.28 (t, 2H); 1.73-1.40 (br. m, 10H); 1.38-1.18 (br. m, 62H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0047">D. Compound 3: Heptadecan-9-yl 8-((2-hydroxyethyl)(nonyl)amino)octanoate</heading>
    <li> <para-num num="[0556]"> </para-num> <div id="p-0594" num="0556" class="description-line">
      <chemistry id="CHEM-US-00089" num="00089">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/61/a5/36/3f6aa2f597e24c/US20170210697A1-20170727-C00089.png"><img id="EMI-C00089" he="15.66mm" wi="74.85mm" file="US20170210697A1-20170727-C00089.TIF" alt="Figure US20170210697A1-20170727-C00089" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00089" class="patent-full-image" src="https://patentimages.storage.googleapis.com/61/a5/36/3f6aa2f597e24c/US20170210697A1-20170727-C00089.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00089" attachment-type="cdx" file="US20170210697A1-20170727-C00089.CDX"> </attachment>
          <attachment idref="CHEM-US-00089" attachment-type="mol" file="US20170210697A1-20170727-C00089.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0557]"> </para-num> <div id="p-0595" num="0557" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>73</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0558]"> </para-num> <div id="p-0596" num="0558" class="description-line">Molecular Weight: 567.98</div>
    </li> <li> <para-num num="[0559]"> </para-num> <div id="p-0597" num="0559" class="description-line"> <figure-callout id="3" label="Compound" filenames="US20170210697A1-20170727-D00007.png,US20170210697A1-20170727-D00008.png" state="{{state}}">Compound</figure-callout> 3 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.36 min. MS (ES): m/z (MH<sup>+</sup>) 568.80 for C<sub>36</sub>H<sub>73</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 3.72-3.45 (br. m, 2H); 2.79-2.34 (br. m, 5H); 2.28 (t, 2H); 1.70-1.38 (m, 10H); 1.38-1.16 (br. m, 44H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0048">E. Compound 4: Heptadecan-9-yl 8-((2-hydroxyethyl)(octyl)amino)octanoate</heading>
    <li> <para-num num="[0560]"> </para-num> <div id="p-0598" num="0560" class="description-line">
      <chemistry id="CHEM-US-00090" num="00090">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/25/3e/32257bb3e1dd77/US20170210697A1-20170727-C00090.png"><img id="EMI-C00090" he="15.66mm" wi="74.85mm" file="US20170210697A1-20170727-C00090.TIF" alt="Figure US20170210697A1-20170727-C00090" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00090" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/25/3e/32257bb3e1dd77/US20170210697A1-20170727-C00090.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00090" attachment-type="cdx" file="US20170210697A1-20170727-C00090.CDX"> </attachment>
          <attachment idref="CHEM-US-00090" attachment-type="mol" file="US20170210697A1-20170727-C00090.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0561]"> </para-num> <div id="p-0599" num="0561" class="description-line">Chemical Formula: C<sub>35</sub>H<sub>71</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0562]"> </para-num> <div id="p-0600" num="0562" class="description-line">Molecular Weight: 553.96</div>
    </li> <li> <para-num num="[0563]"> </para-num> <div id="p-0601" num="0563" class="description-line"> <figure-callout id="4" label="Compound" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 4 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=2.99 min. MS (ES): m/z (MH<sup>+</sup>) 554.777 for C<sub>35</sub>H<sub>71</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 3.71 (br. s, 2H); 2.70 (br. s, 5H); 2.26 (t, 2H); 1.48-1.59 (br. m., 10H); 1.24 (m, 42H); 0.86 (t, 9H).</div>
    </li> <heading id="h-0049">F. Compound 5: Heptadecan-9-yl 8-(hexyl(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0564]"> </para-num> <div id="p-0602" num="0564" class="description-line">
      <chemistry id="CHEM-US-00091" num="00091">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/aa/4e/43e6dfc5f7e3ea/US20170210697A1-20170727-C00091.png"><img id="EMI-C00091" he="15.66mm" wi="74.85mm" file="US20170210697A1-20170727-C00091.TIF" alt="Figure US20170210697A1-20170727-C00091" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00091" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/aa/4e/43e6dfc5f7e3ea/US20170210697A1-20170727-C00091.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00091" attachment-type="cdx" file="US20170210697A1-20170727-C00091.CDX"> </attachment>
          <attachment idref="CHEM-US-00091" attachment-type="mol" file="US20170210697A1-20170727-C00091.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0565]"> </para-num> <div id="p-0603" num="0565" class="description-line">Chemical Formula: C<sub>33</sub>H<sub>67</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0566]"> </para-num> <div id="p-0604" num="0566" class="description-line">Molecular Weight: 525.90</div>
    </li> <li> <para-num num="[0567]"> </para-num> <div id="p-0605" num="0567" class="description-line"> <figure-callout id="5" label="Compound" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 5 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.10 min. MS (ES): m/z (MH<sup>+</sup>) 526.73 for C<sub>33</sub>H<sub>67</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 3.67-3.48 (br. m, 2H); 2.74-2.39 (br. m, 5H); 2.28 (t, 2H); 1.68-1.39 (br. m, 10H); 1.38-1.16 (br. m, 38H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0050">G. Compound 6: Heptadecan-9-yl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate</heading>
    <li> <para-num num="[0568]"> </para-num> <div id="p-0606" num="0568" class="description-line">
      <chemistry id="CHEM-US-00092" num="00092">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/ec/9d/1bf38c30700f63/US20170210697A1-20170727-C00092.png"><img id="EMI-C00092" he="20.83mm" wi="102.11mm" file="US20170210697A1-20170727-C00092.TIF" alt="Figure US20170210697A1-20170727-C00092" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="408" height="83" alt="Figure US20170210697A1-20170727-C00092" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/ec/9d/1bf38c30700f63/US20170210697A1-20170727-C00092.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00092" attachment-type="cdx" file="US20170210697A1-20170727-C00092.CDX"> </attachment>
          <attachment idref="CHEM-US-00092" attachment-type="mol" file="US20170210697A1-20170727-C00092.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0569]"> </para-num> <div id="p-0607" num="0569" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>87</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0570]"> </para-num> <div id="p-0608" num="0570" class="description-line">Molecular Weight: 690.20</div>
    </li> <li> <para-num num="[0571]"> </para-num> <div id="p-0609" num="0571" class="description-line"> <figure-callout id="6" label="Compound" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 6 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.77 min. MS (ES): m/z (MH<sup>+</sup>) 690.84 for C<sub>45</sub>H<sub>87</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.37 (m, 4H); 4.86 (br. m, 1H); 3.53 (br. m; 2H); 2.78 (br. m, 2H); 2.58 (br. m, 2H); 2.45 (br. m, 4H); 2.28 (m, 2H); 2.05 (m, 4H); 1.68-1.15 (br. m, 57H); 0.89 (m, 9H).</div>
    </li> <heading id="h-0051">H. Compound 7: Heptadecan-9-yl 8-((3-hydroxypropyl)(nonyl)amino)octanoate</heading>
    <li> <para-num num="[0572]"> </para-num> <div id="p-0610" num="0572" class="description-line">
      <chemistry id="CHEM-US-00093" num="00093">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/34/2d/90/aec0e81ad137f4/US20170210697A1-20170727-C00093.png"><img id="EMI-C00093" he="20.83mm" wi="105.49mm" file="US20170210697A1-20170727-C00093.TIF" alt="Figure US20170210697A1-20170727-C00093" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="83" alt="Figure US20170210697A1-20170727-C00093" class="patent-full-image" src="https://patentimages.storage.googleapis.com/34/2d/90/aec0e81ad137f4/US20170210697A1-20170727-C00093.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00093" attachment-type="cdx" file="US20170210697A1-20170727-C00093.CDX"> </attachment>
          <attachment idref="CHEM-US-00093" attachment-type="mol" file="US20170210697A1-20170727-C00093.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0573]"> </para-num> <div id="p-0611" num="0573" class="description-line">Chemical Formula: C<sub>37</sub>H<sub>75</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0574]"> </para-num> <div id="p-0612" num="0574" class="description-line">Molecular Weight: 582.01</div>
    </li> <li> <para-num num="[0575]"> </para-num> <div id="p-0613" num="0575" class="description-line"> <figure-callout id="7" label="Compound" filenames="US20170210697A1-20170727-D00008.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 7 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.24 min. MS (ES): m/z (MH<sup>+</sup>) 582.987 for C<sub>37</sub>H<sub>75</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.84 (p, 1H); 3.76 (t, 2H); 2.42-2.66 (br. s, 5H); 2.25 (t, 2H); 1.47-1.68 (br. m, 12H); 1.24 (m, 42H); 0.86 (t, 9H).</div>
    </li> <heading id="h-0052">I. Compound 8: Heptadecan-9-yl 8-((3-(1H-imidazol-1-yl)propyl)(nonyl)amino)octanoate</heading>
    <heading id="h-0053">Step 1: Heptadecan-9-yl 8-((3-chloropropyl)(nonyl)amino)octanoate</heading>
    <li> <para-num num="[0576]"> </para-num> <div id="p-0614" num="0576" class="description-line">
      <chemistry id="CHEM-US-00094" num="00094">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/1e/64/75de8b851e0a56/US20170210697A1-20170727-C00094.png"><img id="EMI-C00094" he="21.51mm" wi="75.44mm" file="US20170210697A1-20170727-C00094.TIF" alt="Figure US20170210697A1-20170727-C00094" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="86" alt="Figure US20170210697A1-20170727-C00094" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/1e/64/75de8b851e0a56/US20170210697A1-20170727-C00094.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00094" attachment-type="cdx" file="US20170210697A1-20170727-C00094.CDX"> </attachment>
          <attachment idref="CHEM-US-00094" attachment-type="mol" file="US20170210697A1-20170727-C00094.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0577]"> </para-num> <div id="p-0615" num="0577" class="description-line">Chemical Formula: C<sub>37</sub>H<sub>74</sub>ClNO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0578]"> </para-num> <div id="p-0616" num="0578" class="description-line">Molecular Weight: 600.45</div>
    </li> <li> <para-num num="[0579]"> </para-num> <div id="p-0617" num="0579" class="description-line">To a 0 C. solution of heptadecan-9-yl 8-((3-hydroxypropyl)(nonyl)amino)octanoate (0.53 g, 0.91 mmol) in 4 mL of DCM was added mesyl chloride (0.070 mL, 0.91 mmol) followed by triethylamine (0.13 mL, 0.91 mmol). The reaction was allowed to slowly warm to rt and stir overnight. The reaction was quenched by the addition of water (10 mL). The mixture was extracted with DCM three times and the pooled organics were washed with brine, dried over MgSO<sub>4</sub>, filtered and concentrated in vacuo. The crude oil was purified by silica gel chromatography to afford heptadecan-9-yl 8-((3-chloropropyl)(nonyl)amino)octanoate (0.23 g, 42%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.84 (p, 1H); 3.58 (t, 2H); 2.51 (br. s, 2H); 2.35 (br. s, 2H); 2.26 (2, 2H); 1.86 (br. s, 2H); 1.40-1.60 (br. m, 12H); 1.24 (br. m, 42H); 0.86 (t, 9H).</div>
    </li> <heading id="h-0054">Step 2: Heptadecan-9-yl 8-((3-(1H-imidazol-1-yl)propyl)(nonyl)amino)octanoate</heading>
    <li> <para-num num="[0580]"> </para-num> <div id="p-0618" num="0580" class="description-line">
      <chemistry id="CHEM-US-00095" num="00095">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cb/91/f6/667f4414a0f6a4/US20170210697A1-20170727-C00095.png"><img id="EMI-C00095" he="20.83mm" wi="112.35mm" file="US20170210697A1-20170727-C00095.TIF" alt="Figure US20170210697A1-20170727-C00095" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="449" height="83" alt="Figure US20170210697A1-20170727-C00095" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cb/91/f6/667f4414a0f6a4/US20170210697A1-20170727-C00095.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00095" attachment-type="cdx" file="US20170210697A1-20170727-C00095.CDX"> </attachment>
          <attachment idref="CHEM-US-00095" attachment-type="mol" file="US20170210697A1-20170727-C00095.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0581]"> </para-num> <div id="p-0619" num="0581" class="description-line">Chemical Formula: C<sub>40</sub>H<sub>77</sub>N<sub>3</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[0582]"> </para-num> <div id="p-0620" num="0582" class="description-line">Molecular Weight: 632.08</div>
    </li> <li> <para-num num="[0583]"> </para-num> <div id="p-0621" num="0583" class="description-line">In a round bottom flask, heptadecan-9-yl 8-((3-chloropropyl)(nonyl)amino)octanoate (50 mg, 0.083 mmol) was combined with imidazole (17 mg, 0.25 mmol), K2CO<sub>3 </sub>(35 mg, 0.25 mmol) in MeCN (0.5 mL). The flask was fitted with a condenser and placed in an 82 C. heating mantle and was allowed to stir for 24 h. After this time, the reaction was allowed to cool to rt, was filtered and the filtrate was concentrated in vacuo. The crude oil was purified by silica gel chromatography (0-100% [DCM, 20% MeOH, 1% NH<sub>4</sub>OH]/MeOH) to afford the desired product as a clear oil (39 mg, 74%). UPLC/ELSD: RT=2.92 min. MS (ES): m/z (MH<sup>+</sup>) 633.994 for C<sub>40</sub>H<sub>77</sub>N<sub>3</sub>O<sub>2</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.46 (s, 1H); 7.05 (s, 1H); 6.91 (s, 1H); 4.84 (dt, 1H); 4.02 (br. s, 2H); 2.47 (br. s, 4H); 2.26 (t, 2H); 2.00 (br. s, 2H); 1.47-1.59 (br. m, 10H); 1.24 (br. m, 44H); 0.86 (t, 9H).</div>
    </li> <heading id="h-0055">J. Compound 9: Heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0584]"> </para-num> <div id="p-0622" num="0584" class="description-line">
      <chemistry id="CHEM-US-00096" num="00096">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/2f/c2/b88e98295456d3/US20170210697A1-20170727-C00096.png"><img id="EMI-C00096" he="27.18mm" wi="107.70mm" file="US20170210697A1-20170727-C00096.TIF" alt="Figure US20170210697A1-20170727-C00096" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="431" height="109" alt="Figure US20170210697A1-20170727-C00096" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/2f/c2/b88e98295456d3/US20170210697A1-20170727-C00096.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00096" attachment-type="cdx" file="US20170210697A1-20170727-C00096.CDX"> </attachment>
          <attachment idref="CHEM-US-00096" attachment-type="mol" file="US20170210697A1-20170727-C00096.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0585]"> </para-num> <div id="p-0623" num="0585" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>89</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[0586]"> </para-num> <div id="p-0624" num="0586" class="description-line">Molecular Weight: 752.22</div>
    </li> <li> <para-num num="[0587]"> </para-num> <div id="p-0625" num="0587" class="description-line">To a solution of heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (100 mg, 0.14 mmol) and acetic acid (8 mg, 0.13 mmol) in dichloromethane (1 mL) were added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (31 mg, 0.16 mmol), N,N-diisopropylethylamine (73 mg, 0.56 mmol) and DMAP (3 mg, 0.02 mmol). The reaction was allowed to stir at rt for 18 h. The reaction was diluted with dichloromethane and washed with saturated sodium bicarbonate. The organic layer was separated and washed with brine and dried over MgSO<sub>4</sub>. The organic layer was filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to yield heptadecan-9-yl 8-((2-acetoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (63 mg, 0.08 mmol). UPLC/ELSD: RT=3.63 min. MS (ES): m/z (MH<sup>+</sup>) 753.07 for C<sub>46</sub>H<sub>89</sub>NO<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.87 (p, 1H); 4.17-3.99 (m, 4H); 2.67 (m, 2H); 2.43 (m, 3H); 2.29 (m, 4H); 2.05 (s, 3H); 1.71-1.17 (br. m, 63H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0056">K. Compound 10: Heptadecan-9-yl 8-((2-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0588]"> </para-num> <div id="p-0626" num="0588" class="description-line">
      <chemistry id="CHEM-US-00097" num="00097">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/be/22/2e9dcc357da221/US20170210697A1-20170727-C00097.png"><img id="EMI-C00097" he="21.42mm" wi="74.51mm" file="US20170210697A1-20170727-C00097.TIF" alt="Figure US20170210697A1-20170727-C00097" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="86" alt="Figure US20170210697A1-20170727-C00097" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/be/22/2e9dcc357da221/US20170210697A1-20170727-C00097.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00097" attachment-type="cdx" file="US20170210697A1-20170727-C00097.CDX"> </attachment>
          <attachment idref="CHEM-US-00097" attachment-type="mol" file="US20170210697A1-20170727-C00097.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0589]"> </para-num> <div id="p-0627" num="0589" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0590]"> </para-num> <div id="p-0628" num="0590" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[0591]"> </para-num> <div id="p-0629" num="0591" class="description-line"> <figure-callout id="10" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 10 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.73 min. MS (ES): m/z (MH<sup>+</sup>) 725.10 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.80-3.54 (br. m, 1H); 2.61-2.13 (br. m, 9H); 1.69-1.03 (br. m, 67H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0057">L. Compound 11: Heptadecan-9-yl (R)-8-((2-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl) amino)octanoate</heading>
    <li> <para-num num="[0592]"> </para-num> <div id="p-0630" num="0592" class="description-line">
      <chemistry id="CHEM-US-00098" num="00098">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/57/75/8d/ddbf91d0666972/US20170210697A1-20170727-C00098.png"><img id="EMI-C00098" he="21.42mm" wi="74.51mm" file="US20170210697A1-20170727-C00098.TIF" alt="Figure US20170210697A1-20170727-C00098" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="86" alt="Figure US20170210697A1-20170727-C00098" class="patent-full-image" src="https://patentimages.storage.googleapis.com/57/75/8d/ddbf91d0666972/US20170210697A1-20170727-C00098.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00098" attachment-type="cdx" file="US20170210697A1-20170727-C00098.CDX"> </attachment>
          <attachment idref="CHEM-US-00098" attachment-type="mol" file="US20170210697A1-20170727-C00098.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0593]"> </para-num> <div id="p-0631" num="0593" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0594]"> </para-num> <div id="p-0632" num="0594" class="description-line">Molecular Weight: 724.21</div>
    </li> <li> <para-num num="[0595]"> </para-num> <div id="p-0633" num="0595" class="description-line"> <figure-callout id="11" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 11 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=5.21 min. MS (ES): m/z (MH<sup>+</sup>) 725.02 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.72 (br. m, 1H); 2.65-2.10 (br. m, 8H); 1.71-0.99 (br. m, 68H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0058">M. Compound 12: Heptadecan-9-yl (S)-8-((2-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl) amino)octanoate</heading>
    <li> <para-num num="[0596]"> </para-num> <div id="p-0634" num="0596" class="description-line">
      <chemistry id="CHEM-US-00099" num="00099">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/71/d6/70/8676d061270b45/US20170210697A1-20170727-C00099.png"><img id="EMI-C00099" he="21.42mm" wi="74.51mm" file="US20170210697A1-20170727-C00099.TIF" alt="Figure US20170210697A1-20170727-C00099" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="86" alt="Figure US20170210697A1-20170727-C00099" class="patent-full-image" src="https://patentimages.storage.googleapis.com/71/d6/70/8676d061270b45/US20170210697A1-20170727-C00099.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00099" attachment-type="cdx" file="US20170210697A1-20170727-C00099.CDX"> </attachment>
          <attachment idref="CHEM-US-00099" attachment-type="mol" file="US20170210697A1-20170727-C00099.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0597]"> </para-num> <div id="p-0635" num="0597" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0598]"> </para-num> <div id="p-0636" num="0598" class="description-line">Molecular Weight: 724.21</div>
    </li> <li> <para-num num="[0599]"> </para-num> <div id="p-0637" num="0599" class="description-line"> <figure-callout id="12" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 12 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=5.30 min. MS (ES): m/z (MH<sup>+</sup>) 725.10 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.71 (br. m, 1H); 2.64-2.10 (br. m, 8H); 1.71-1.03 (br. m, 68H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0059">N. Compound 13: Heptadecan-9-yl 8-((2-hydroxybutyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0600]"> </para-num> <div id="p-0638" num="0600" class="description-line">
      <chemistry id="CHEM-US-00100" num="00100">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/12/b3/c4/d3893b4dacdbc1/US20170210697A1-20170727-C00100.png"><img id="EMI-C00100" he="20.57mm" wi="74.85mm" file="US20170210697A1-20170727-C00100.TIF" alt="Figure US20170210697A1-20170727-C00100" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="82" alt="Figure US20170210697A1-20170727-C00100" class="patent-full-image" src="https://patentimages.storage.googleapis.com/12/b3/c4/d3893b4dacdbc1/US20170210697A1-20170727-C00100.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00100" attachment-type="cdx" file="US20170210697A1-20170727-C00100.CDX"> </attachment>
          <attachment idref="CHEM-US-00100" attachment-type="mol" file="US20170210697A1-20170727-C00100.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0601]"> </para-num> <div id="p-0639" num="0601" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0602]"> </para-num> <div id="p-0640" num="0602" class="description-line">Molecular Weight: 738.24</div>
    </li> <li> <para-num num="[0603]"> </para-num> <div id="p-0641" num="0603" class="description-line"> <figure-callout id="13" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 13 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.89 min. MS (ES): m/z (MH<sup>+</sup>) 739.21 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.58-3.38 (br. m, 1H); 2.65-2.15 (br. m, 9H); 1.72-1.12 (br. m, 66H); 0.98 (t, 3H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0060">O. Compound 14: Heptadecan-9-yl 8-((2-(dimethylamino)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0604]"> </para-num> <div id="p-0642" num="0604" class="description-line">
      <chemistry id="CHEM-US-00101" num="00101">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/c4/c3/5fb58d682663b3/US20170210697A1-20170727-C00101.png"><img id="EMI-C00101" he="27.18mm" wi="102.87mm" file="US20170210697A1-20170727-C00101.TIF" alt="Figure US20170210697A1-20170727-C00101" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="109" alt="Figure US20170210697A1-20170727-C00101" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/c4/c3/5fb58d682663b3/US20170210697A1-20170727-C00101.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00101" attachment-type="cdx" file="US20170210697A1-20170727-C00101.CDX"> </attachment>
          <attachment idref="CHEM-US-00101" attachment-type="mol" file="US20170210697A1-20170727-C00101.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0605]"> </para-num> <div id="p-0643" num="0605" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>92</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0606]"> </para-num> <div id="p-0644" num="0606" class="description-line">Molecular Weight: 737.252</div>
    </li> <li> <para-num num="[0607]"> </para-num> <div id="p-0645" num="0607" class="description-line"> <figure-callout id="14" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 14 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.51 min. MS (ES): m/z (MH<sup>+</sup>) 738.23 for C<sub>46</sub>H<sub>92</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.84 (p, 1H); 4.04 (t, 2H); 2.95 (m, 2H); 2.78 (m, 6H); 2.44 (s, 6H); 2.28 (m, 4H); 1.70-1.41 (br. m, 14H); 1.41-1.14 (br. m, 48H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0061">P. Compound 15: Heptadecan-9-yl 8-((2-methoxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0608]"> </para-num> <div id="p-0646" num="0608" class="description-line">
      <chemistry id="CHEM-US-00102" num="00102">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/e8/3b/bea6d206c3ee62/US20170210697A1-20170727-C00102.png"><img id="EMI-C00102" he="27.18mm" wi="102.87mm" file="US20170210697A1-20170727-C00102.TIF" alt="Figure US20170210697A1-20170727-C00102" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="109" alt="Figure US20170210697A1-20170727-C00102" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/e8/3b/bea6d206c3ee62/US20170210697A1-20170727-C00102.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00102" attachment-type="cdx" file="US20170210697A1-20170727-C00102.CDX"> </attachment>
          <attachment idref="CHEM-US-00102" attachment-type="mol" file="US20170210697A1-20170727-C00102.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0609]"> </para-num> <div id="p-0647" num="0609" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0610]"> </para-num> <div id="p-0648" num="0610" class="description-line">Molecular Weight: 724.21</div>
    </li> <li> <para-num num="[0611]"> </para-num> <div id="p-0649" num="0611" class="description-line"> <figure-callout id="15" label="Compound" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 15 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.90 min. MS (ES): m/z (MH<sup>+</sup>) 725.19 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.43 (m, 2H); 3.34 (s, 3H); 2.61 (m, 2H); 2.43 (m, 3H); 2.29 (m, 4H); 1.70-1.15 (br. m, 63H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0062">Q. Compound 16: Heptadecan-9-yl 8-((3-methoxypropyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0612]"> </para-num> <div id="p-0650" num="0612" class="description-line">
      <chemistry id="CHEM-US-00103" num="00103">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/13/03/db/c116fad38a0231/US20170210697A1-20170727-C00103.png"><img id="EMI-C00103" he="27.18mm" wi="107.70mm" file="US20170210697A1-20170727-C00103.TIF" alt="Figure US20170210697A1-20170727-C00103" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="431" height="109" alt="Figure US20170210697A1-20170727-C00103" class="patent-full-image" src="https://patentimages.storage.googleapis.com/13/03/db/c116fad38a0231/US20170210697A1-20170727-C00103.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00103" attachment-type="cdx" file="US20170210697A1-20170727-C00103.CDX"> </attachment>
          <attachment idref="CHEM-US-00103" attachment-type="mol" file="US20170210697A1-20170727-C00103.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0613]"> </para-num> <div id="p-0651" num="0613" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0614]"> </para-num> <div id="p-0652" num="0614" class="description-line">Molecular Weight: 738.236</div>
    </li> <li> <para-num num="[0615]"> </para-num> <div id="p-0653" num="0615" class="description-line"> <figure-callout id="16" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 16 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.90 min. MS (ES): m/z (MH<sup>+</sup>) 739.13 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.42 (m, 2H); 3.35 (s, 3H); 2.55-2.21 (m, 9H); 1.81-1.18 (br. m, 65H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0063">R. Compound 17: Heptadecan-9-yl 8-((2-(2-(dimethylamino)ethoxy)ethyl) (8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0616]"> </para-num> <div id="p-0654" num="0616" class="description-line">
      <chemistry id="CHEM-US-00104" num="00104">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/c2/02/3bd25d7aee64f2/US20170210697A1-20170727-C00104.png"><img id="EMI-C00104" he="27.18mm" wi="117.52mm" file="US20170210697A1-20170727-C00104.TIF" alt="Figure US20170210697A1-20170727-C00104" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="470" height="109" alt="Figure US20170210697A1-20170727-C00104" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/c2/02/3bd25d7aee64f2/US20170210697A1-20170727-C00104.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00104" attachment-type="cdx" file="US20170210697A1-20170727-C00104.CDX"> </attachment>
          <attachment idref="CHEM-US-00104" attachment-type="mol" file="US20170210697A1-20170727-C00104.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0617]"> </para-num> <div id="p-0655" num="0617" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>96</sub>N<sub>2</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0618]"> </para-num> <div id="p-0656" num="0618" class="description-line">Molecular Weight: 781.305</div>
    </li> <li> <para-num num="[0619]"> </para-num> <div id="p-0657" num="0619" class="description-line"> <figure-callout id="17" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 17 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.72 min. MS (ES): m/z (MH<sup>+</sup>) 782.27 for C<sub>48</sub>H<sub>96</sub>N<sub>2</sub>O<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (p, 1H); 4.08 (t, 2H); 3.57 (m, 4H); 2.72 (m, 2H); 2.52 (m, 5H); 2.38-2.13 (br. m, 12H); 1.73-1.19 (br. m, 61H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0064">S. Compound 18: Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0620]"> </para-num> <div id="p-0658" num="0620" class="description-line">
      <chemistry id="CHEM-US-00105" num="00105">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f5/82/00/0ac1d0ebda9841/US20170210697A1-20170727-C00105.png"><img id="EMI-C00105" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00105.TIF" alt="Figure US20170210697A1-20170727-C00105" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00105" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f5/82/00/0ac1d0ebda9841/US20170210697A1-20170727-C00105.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00105" attachment-type="cdx" file="US20170210697A1-20170727-C00105.CDX"> </attachment>
          <attachment idref="CHEM-US-00105" attachment-type="mol" file="US20170210697A1-20170727-C00105.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0621]"> </para-num> <div id="p-0659" num="0621" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0622]"> </para-num> <div id="p-0660" num="0622" class="description-line">Molecular Weight: 710.18</div>
    </li> <li> <para-num num="[0623]"> </para-num> <div id="p-0661" num="0623" class="description-line">Compound 18 was synthesized according to the general procedure and Representative Procedure 1 described above or according to the scheme below:</div>
    </li> <li> <div id="p-0662" num="0000" class="description-line">
      <chemistry id="CHEM-US-00106" num="00106">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/d3/3e/6bdf22b3c3d45f/US20170210697A1-20170727-C00106.png"><img id="EMI-C00106" he="213.87mm" wi="137.33mm" file="US20170210697A1-20170727-C00106.TIF" alt="Figure US20170210697A1-20170727-C00106" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="549" height="855" alt="Figure US20170210697A1-20170727-C00106" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/d3/3e/6bdf22b3c3d45f/US20170210697A1-20170727-C00106.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00106" attachment-type="cdx" file="US20170210697A1-20170727-C00106.CDX"> </attachment>
          <attachment idref="CHEM-US-00106" attachment-type="mol" file="US20170210697A1-20170727-C00106.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0624]"> </para-num> <div id="p-0663" num="0624" class="description-line">UPLC/ELSD: RT=3.59 min. MS (ES): m/z (MH<sup>+</sup>) 710.89 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 1H); 4.05 (t, 2H); 3.53 (br. m, 2H); 2.83-2.36 (br. m, 5H); 2.29 (m, 4H); 0.96-1.71 (m, 64H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0065">T. Compound 19: Heptadecan-9-yl 8-((3-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0625]"> </para-num> <div id="p-0664" num="0625" class="description-line">
      <chemistry id="CHEM-US-00107" num="00107">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/11/63/53a6938e48568b/US20170210697A1-20170727-C00107.png"><img id="EMI-C00107" he="27.26mm" wi="105.49mm" file="US20170210697A1-20170727-C00107.TIF" alt="Figure US20170210697A1-20170727-C00107" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00107" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/11/63/53a6938e48568b/US20170210697A1-20170727-C00107.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00107" attachment-type="cdx" file="US20170210697A1-20170727-C00107.CDX"> </attachment>
          <attachment idref="CHEM-US-00107" attachment-type="mol" file="US20170210697A1-20170727-C00107.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0626]"> </para-num> <div id="p-0665" num="0626" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0627]"> </para-num> <div id="p-0666" num="0627" class="description-line">Molecular Weight: 724.21</div>
    </li> <li> <para-num num="[0628]"> </para-num> <div id="p-0667" num="0628" class="description-line"> <figure-callout id="19" label="Compound" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">Compound</figure-callout> 19 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=4.51 min. MS (ES): m/z (MH<sup>+</sup>) 725.19 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.80 (m, 2H); 2.92-2.36 (br. m, 5H); 2.29 (m, 4H); 1.89-1.42 (br. m, 16H); 1.42-1.02 (br. m, 50H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0066">U. Compound 20: Heptadecan-9-yl 8-((4-hydroxybutyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0629]"> </para-num> <div id="p-0668" num="0629" class="description-line">
      <chemistry id="CHEM-US-00108" num="00108">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/1a/78/dcdb7a03376457/US20170210697A1-20170727-C00108.png"><img id="EMI-C00108" he="27.26mm" wi="110.41mm" file="US20170210697A1-20170727-C00108.TIF" alt="Figure US20170210697A1-20170727-C00108" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="442" height="109" alt="Figure US20170210697A1-20170727-C00108" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b4/1a/78/dcdb7a03376457/US20170210697A1-20170727-C00108.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00108" attachment-type="cdx" file="US20170210697A1-20170727-C00108.CDX"> </attachment>
          <attachment idref="CHEM-US-00108" attachment-type="mol" file="US20170210697A1-20170727-C00108.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0630]"> </para-num> <div id="p-0669" num="0630" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0631]"> </para-num> <div id="p-0670" num="0631" class="description-line">Molecular Weight: 738.24</div>
    </li> <li> <para-num num="[0632]"> </para-num> <div id="p-0671" num="0632" class="description-line"> <figure-callout id="20" label="Compound" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00004.png" state="{{state}}">Compound</figure-callout> 20 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.84 min. MS (ES): m/z (MH<sup>+</sup>) 739.21 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.77-3.45 (br. m, 2H); 2.63-2.20 (br. m, 8H); 1.82-1.40 (br. m, 18H); 1.40-1.15 (br. m, 51H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0067">V. Compound 21: Heptadecan-9-yl 8-((2-cyanoethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0633]"> </para-num> <div id="p-0672" num="0633" class="description-line">
      <chemistry id="CHEM-US-00109" num="00109">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3e/22/10/bc2a5abacae02f/US20170210697A1-20170727-C00109.png"><img id="EMI-C00109" he="27.26mm" wi="100.50mm" file="US20170210697A1-20170727-C00109.TIF" alt="Figure US20170210697A1-20170727-C00109" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00109" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3e/22/10/bc2a5abacae02f/US20170210697A1-20170727-C00109.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00109" attachment-type="cdx" file="US20170210697A1-20170727-C00109.CDX"> </attachment>
          <attachment idref="CHEM-US-00109" attachment-type="mol" file="US20170210697A1-20170727-C00109.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0634]"> </para-num> <div id="p-0673" num="0634" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0635]"> </para-num> <div id="p-0674" num="0635" class="description-line">Molecular Weight: 719.19</div>
    </li> <li> <para-num num="[0636]"> </para-num> <div id="p-0675" num="0636" class="description-line">Compound 21 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=4.04 min. MS (ES): m/z (MH<sup>+</sup>) 720.18 for C<sub>45</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (p, 1H); 4.07 (t, 2H); 2.81 (m, 2H); 2.44 (m, 5H); 2.30 (m, 4H); 1.73-1.18 (br. m, 63H); 0.89 (m, 9H).</div>
    </li> <heading id="h-0068">W. Compound 22: Heptadecan-9-yl 8-((2-hydroxycyclohexyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0637]"> </para-num> <div id="p-0676" num="0637" class="description-line">
      <chemistry id="CHEM-US-00110" num="00110">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/54/89/48/a6fc5333aed2c1/US20170210697A1-20170727-C00110.png"><img id="EMI-C00110" he="27.18mm" wi="97.96mm" file="US20170210697A1-20170727-C00110.TIF" alt="Figure US20170210697A1-20170727-C00110" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="392" height="109" alt="Figure US20170210697A1-20170727-C00110" class="patent-full-image" src="https://patentimages.storage.googleapis.com/54/89/48/a6fc5333aed2c1/US20170210697A1-20170727-C00110.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00110" attachment-type="cdx" file="US20170210697A1-20170727-C00110.CDX"> </attachment>
          <attachment idref="CHEM-US-00110" attachment-type="mol" file="US20170210697A1-20170727-C00110.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0638]"> </para-num> <div id="p-0677" num="0638" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>93</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0639]"> </para-num> <div id="p-0678" num="0639" class="description-line">Molecular Weight: 764.27</div>
    </li> <li> <para-num num="[0640]"> </para-num> <div id="p-0679" num="0640" class="description-line"> <figure-callout id="22" label="Compound" filenames="US20170210697A1-20170727-D00001.png" state="{{state}}">Compound</figure-callout> 22 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=4.54 min. MS (ES): m/z (MH<sup>+</sup>) 765.21 for C<sub>48</sub>H<sub>93</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 2.89-2.34 (br. m, 4H); 2.28 (m, 4H); 2.00 (m, 1H); 1.86-0.99 (br. m, 72H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0069">X. Compound 23: Heptadecan-9-yl 10-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) decanoate</heading>
    <li> <para-num num="[0641]"> </para-num> <div id="p-0680" num="0641" class="description-line">
      <chemistry id="CHEM-US-00111" num="00111">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/05/53/8e/e54ea50b64d53c/US20170210697A1-20170727-C00111.png"><img id="EMI-C00111" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00111.TIF" alt="Figure US20170210697A1-20170727-C00111" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00111" class="patent-full-image" src="https://patentimages.storage.googleapis.com/05/53/8e/e54ea50b64d53c/US20170210697A1-20170727-C00111.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00111" attachment-type="cdx" file="US20170210697A1-20170727-C00111.CDX"> </attachment>
          <attachment idref="CHEM-US-00111" attachment-type="mol" file="US20170210697A1-20170727-C00111.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0642]"> </para-num> <div id="p-0681" num="0642" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0643]"> </para-num> <div id="p-0682" num="0643" class="description-line">Molecular Weight: 738.24</div>
    </li> <li> <para-num num="[0644]"> </para-num> <div id="p-0683" num="0644" class="description-line">Compound 23 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.75 min. MS (ES): m/z (MH<sup>+</sup>) 739.13 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 1H); 4.05 (m, 2H); 3.72-3.46 (br. m, 2H); 2.81-2.35 (br. m, 5H); 2.29 (m, 4H); 1.71-1.40 (br. m, 13H); 1.40-1.15 (br. m, 55H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0070">Y. Compound 24: Heptadecan-9-yl (Z)-8-((2-hydroxyethyl) (8-(non-2-en-1-yloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0645]"> </para-num> <div id="p-0684" num="0645" class="description-line">
      <chemistry id="CHEM-US-00112" num="00112">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/47/4c/d9/50074aac09041d/US20170210697A1-20170727-C00112.png"><img id="EMI-C00112" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00112.TIF" alt="Figure US20170210697A1-20170727-C00112" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00112" class="patent-full-image" src="https://patentimages.storage.googleapis.com/47/4c/d9/50074aac09041d/US20170210697A1-20170727-C00112.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00112" attachment-type="cdx" file="US20170210697A1-20170727-C00112.CDX"> </attachment>
          <attachment idref="CHEM-US-00112" attachment-type="mol" file="US20170210697A1-20170727-C00112.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0646]"> </para-num> <div id="p-0685" num="0646" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>85</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0647]"> </para-num> <div id="p-0686" num="0647" class="description-line">Molecular Weight: 708.17</div>
    </li> <li> <para-num num="[0648]"> </para-num> <div id="p-0687" num="0648" class="description-line"> <figure-callout id="24" label="Compound" filenames="US20170210697A1-20170727-D00008.png" state="{{state}}">Compound</figure-callout> 24 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.54 min. MS (ES): m/z (MH<sup>+</sup>) 708.95 for C<sub>44</sub>H<sub>85</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.74-5.44 (br. m, 2H); 4.86 (m, 1H); 4.62 (m, 2H); 3.71-3.40 (br. m, 2H); 2.81-2.37 (br. m, 5H); 2.29 (m, 4H); 2.09 (m, 2H); 1.70-1.14 (br. m, 58H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0071">Z. Compound 25: Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate</heading>
    <li> <para-num num="[0649]"> </para-num> <div id="p-0688" num="0649" class="description-line">
      <chemistry id="CHEM-US-00113" num="00113">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/be/be/7c636bfa985a8d/US20170210697A1-20170727-C00113.png"><img id="EMI-C00113" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00113.TIF" alt="Figure US20170210697A1-20170727-C00113" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00113" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d4/be/be/7c636bfa985a8d/US20170210697A1-20170727-C00113.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00113" attachment-type="cdx" file="US20170210697A1-20170727-C00113.CDX"> </attachment>
          <attachment idref="CHEM-US-00113" attachment-type="mol" file="US20170210697A1-20170727-C00113.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0650]"> </para-num> <div id="p-0689" num="0650" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0651]"> </para-num> <div id="p-0690" num="0651" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[0652]"> </para-num> <div id="p-0691" num="0652" class="description-line"> <figure-callout id="25" label="Compound" filenames="US20170210697A1-20170727-D00005.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Compound</figure-callout> 25 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.66 min. MS (ES): m/z (MH<sup>+</sup>) 711.00 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 1H); 4.05 (t, 2H); 3.68-3.46 (br. m, 2H); 2.77-2.37 (br. m, 5H); 2.29 (m, 4H); 1.74-1.41 (br. m, 14H); 1.39-1.18 (m, 50H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0072">AA. Compound 26: Heptadecan-9-yl 8-((2-hydroxyethyl)(4-(nonyloxy)-4-oxobutyl)amino) octanoate</heading>
    <li> <para-num num="[0653]"> </para-num> <div id="p-0692" num="0653" class="description-line">
      <chemistry id="CHEM-US-00114" num="00114">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/75/4c/9949185f4c5edf/US20170210697A1-20170727-C00114.png"><img id="EMI-C00114" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00114.TIF" alt="Figure US20170210697A1-20170727-C00114" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00114" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/75/4c/9949185f4c5edf/US20170210697A1-20170727-C00114.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00114" attachment-type="cdx" file="US20170210697A1-20170727-C00114.CDX"> </attachment>
          <attachment idref="CHEM-US-00114" attachment-type="mol" file="US20170210697A1-20170727-C00114.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0654]"> </para-num> <div id="p-0693" num="0654" class="description-line">Chemical Formula: C<sub>40</sub>H<sub>79</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0655]"> </para-num> <div id="p-0694" num="0655" class="description-line">Molecular Weight: 654.07</div>
    </li> <li> <para-num num="[0656]"> </para-num> <div id="p-0695" num="0656" class="description-line"> <figure-callout id="26" label="Compound" filenames="US20170210697A1-20170727-D00003.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Compound</figure-callout> 26 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=4.29 min. MS (ES): m/z (MH<sup>+</sup>) 655.07 for C<sub>40</sub>H<sub>79</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.06 (t, 2H); 3.79 (br. m, 2H); 2.91-2.20 (br. m, 10H); 1.98-1.03 (br. m, 55H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0073">AB. Compound 27: Nonyl 8-((6-(heptadecan-9-yloxy)-6-oxohexyl)(2-hydroxyethyl)amino) octanoate</heading>
    <li> <para-num num="[0657]"> </para-num> <div id="p-0696" num="0657" class="description-line">
      <chemistry id="CHEM-US-00115" num="00115">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/65/c5/c4/ef81bb7e68c545/US20170210697A1-20170727-C00115.png"><img id="EMI-C00115" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00115.TIF" alt="Figure US20170210697A1-20170727-C00115" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00115" class="patent-full-image" src="https://patentimages.storage.googleapis.com/65/c5/c4/ef81bb7e68c545/US20170210697A1-20170727-C00115.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00115" attachment-type="cdx" file="US20170210697A1-20170727-C00115.CDX"> </attachment>
          <attachment idref="CHEM-US-00115" attachment-type="mol" file="US20170210697A1-20170727-C00115.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0658]"> </para-num> <div id="p-0697" num="0658" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0659]"> </para-num> <div id="p-0698" num="0659" class="description-line">Molecular Weight: 682.13</div>
    </li> <li> <para-num num="[0660]"> </para-num> <div id="p-0699" num="0660" class="description-line">Compound 27 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.57 min. MS (ES): m/z (MH<sup>+</sup>) 683.12 for C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 1H); 4.05 (m, 2H); 3.70-3.45 (br. m, 2H); 2.78-2.35 (br. m, 5H); 2.29 (m, 4H); 1.73-1.41 (m, 13H); 1.41-1.16 (m, 47H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0074">AC. Compound 28: Heptadecan-9-yl 8-((8-((2-hexylcyclopropyl)methoxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0661]"> </para-num> <div id="p-0700" num="0661" class="description-line">
      <chemistry id="CHEM-US-00116" num="00116">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/17/67/3bf52ab44cd7d6/US20170210697A1-20170727-C00116.png"><img id="EMI-C00116" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00116.TIF" alt="Figure US20170210697A1-20170727-C00116" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00116" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/17/67/3bf52ab44cd7d6/US20170210697A1-20170727-C00116.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00116" attachment-type="cdx" file="US20170210697A1-20170727-C00116.CDX"> </attachment>
          <attachment idref="CHEM-US-00116" attachment-type="mol" file="US20170210697A1-20170727-C00116.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0662]"> </para-num> <div id="p-0701" num="0662" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0663]"> </para-num> <div id="p-0702" num="0663" class="description-line">Molecular Weight: 722.19</div>
    </li> <li> <para-num num="[0664]"> </para-num> <div id="p-0703" num="0664" class="description-line">Compound 28 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above using Intermediate C. UPLC/ELSD: RT=5.17 min. MS (ES): m/z (MH<sup>+</sup>) 722.97 for C<sub>45</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.17 (m, 1H); 3.93 (m, 1H); 3.61 (br. m, 2H); 2.97-2.37 (br. m, 6H); 2.35-2.21 (m, 4H); 1.74-0.97 (br. m, 60H); 0.94-0.79 (m, 10H); 0.74 (m, 1H); 0.01 (m, 1H).</div>
    </li> <heading id="h-0075">AD. Compound 29: Di(heptadecan-9-yl) 8,8-((2-hydroxyethyl)azanediyl)dioctanoate</heading>
    <li> <para-num num="[0665]"> </para-num> <div id="p-0704" num="0665" class="description-line">
      <chemistry id="CHEM-US-00117" num="00117">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fa/28/d5/3988c6956cbd46/US20170210697A1-20170727-C00117.png"><img id="EMI-C00117" he="29.29mm" wi="100.58mm" file="US20170210697A1-20170727-C00117.TIF" alt="Figure US20170210697A1-20170727-C00117" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="117" alt="Figure US20170210697A1-20170727-C00117" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fa/28/d5/3988c6956cbd46/US20170210697A1-20170727-C00117.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00117" attachment-type="cdx" file="US20170210697A1-20170727-C00117.CDX"> </attachment>
          <attachment idref="CHEM-US-00117" attachment-type="mol" file="US20170210697A1-20170727-C00117.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0666]"> </para-num> <div id="p-0705" num="0666" class="description-line">Chemical Formula: C<sub>52</sub>H<sub>103</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0667]"> </para-num> <div id="p-0706" num="0667" class="description-line">Molecular Weight: 822.40</div>
    </li> <li> <para-num num="[0668]"> </para-num> <div id="p-0707" num="0668" class="description-line">Compound 29 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.98 min. MS (ES): m/z (MH<sup>+</sup>) 823.19 for C<sub>52</sub>H<sub>103</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 2H); 3.72-3.44 (br. m, 2H); 2.83-2.34 (br. m, 5H); 2.28 (m, 4H); 1.69-1.39 (br. m, 16H); 1.39-1.16 (br. m, 62H); 0.88 (m, 12H).</div>
    </li> <heading id="h-0076">AE. Compound 30: 7-((2-Hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[0669]"> </para-num> <div id="p-0708" num="0669" class="description-line">
      <chemistry id="CHEM-US-00118" num="00118">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d7/ac/c0/5124ea029cac28/US20170210697A1-20170727-C00118.png"><img id="EMI-C00118" he="32.85mm" wi="100.58mm" file="US20170210697A1-20170727-C00118.TIF" alt="Figure US20170210697A1-20170727-C00118" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="131" alt="Figure US20170210697A1-20170727-C00118" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d7/ac/c0/5124ea029cac28/US20170210697A1-20170727-C00118.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00118" attachment-type="cdx" file="US20170210697A1-20170727-C00118.CDX"> </attachment>
          <attachment idref="CHEM-US-00118" attachment-type="mol" file="US20170210697A1-20170727-C00118.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0670]"> </para-num> <div id="p-0709" num="0670" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0671]"> </para-num> <div id="p-0710" num="0671" class="description-line">Molecular Weight: 710.18</div>
    </li> <li> <para-num num="[0672]"> </para-num> <div id="p-0711" num="0672" class="description-line">Compound 30 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above using Intermediate B. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 711.16 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.06 (m, 4H); 3.69-3.44 (br. m, 2H); 2.71-2.39 (br. m, 5H); 2.29 (m, 3H); 1.70-1.16 (br. m, 64H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0077">AF. Compound 31: heptadecan-9-yl (Z)-8-((2-hydroxyethyl)(octadec-9-en-1-yl)amino) octanoate</heading>
    <li> <para-num num="[0673]"> </para-num> <div id="p-0712" num="0673" class="description-line">
      <chemistry id="CHEM-US-00119" num="00119">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/0d/f5/df85aee706c59f/US20170210697A1-20170727-C00119.png"><img id="EMI-C00119" he="20.83mm" wi="101.35mm" file="US20170210697A1-20170727-C00119.TIF" alt="Figure US20170210697A1-20170727-C00119" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="83" alt="Figure US20170210697A1-20170727-C00119" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/0d/f5/df85aee706c59f/US20170210697A1-20170727-C00119.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00119" attachment-type="cdx" file="US20170210697A1-20170727-C00119.CDX"> </attachment>
          <attachment idref="CHEM-US-00119" attachment-type="mol" file="US20170210697A1-20170727-C00119.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0674]"> </para-num> <div id="p-0713" num="0674" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0675]"> </para-num> <div id="p-0714" num="0675" class="description-line">Molecular Weight: 692.21</div>
    </li> <li> <para-num num="[0676]"> </para-num> <div id="p-0715" num="0676" class="description-line">Compound 31 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.83 min. MS (ES): m/z (MH<sup>+</sup>) 693.20 for C<sub>45</sub>H<sub>89</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.37 (m, 2H); 4.89 (p, 1H); 3.58 (br. m, 2H); 2.72-2.43 (br. m, 5H); 2.30 (m, 2H), 2.05 (m, 4H); 1.71-1.03 (br. m, 63H), 0.90 (m, 9H).</div>
    </li> <heading id="h-0078">AG. Compound 32: nonyl 8-((2-hydroxyethyl)(8-oxo-8-(pentadecan-7-yloxy)octyl)amino) octanoate</heading>
    <li> <para-num num="[0677]"> </para-num> <div id="p-0716" num="0677" class="description-line">
      <chemistry id="CHEM-US-00120" num="00120">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/23/19/8907756fe83eb0/US20170210697A1-20170727-C00120.png"><img id="EMI-C00120" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00120.TIF" alt="Figure US20170210697A1-20170727-C00120" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00120" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/23/19/8907756fe83eb0/US20170210697A1-20170727-C00120.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00120" attachment-type="cdx" file="US20170210697A1-20170727-C00120.CDX"> </attachment>
          <attachment idref="CHEM-US-00120" attachment-type="mol" file="US20170210697A1-20170727-C00120.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0678]"> </para-num> <div id="p-0717" num="0678" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0679]"> </para-num> <div id="p-0718" num="0679" class="description-line">Molecular Weight: 682.13</div>
    </li> <li> <para-num num="[0680]"> </para-num> <div id="p-0719" num="0680" class="description-line">Compound 32 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.45 min. MS (ES): m/z (MH<sup>+</sup>) 683.20 for C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.60 (br. m, 2H); 2.85-2.40 (br. m, 5H); 2.31 (m, 4H), 1.78-1.01 (m, 59H), 0.90 (m, 9H).</div>
    </li> <heading id="h-0079">AH. Compound 33: nonyl 8-((2-hydroxyethyl)(8-oxo-8-(tetradecan-6-yloxy)octyl)amino) octanoate</heading>
    <li> <para-num num="[0681]"> </para-num> <div id="p-0720" num="0681" class="description-line">
      <chemistry id="CHEM-US-00121" num="00121">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/9d/45/c79f493b493805/US20170210697A1-20170727-C00121.png"><img id="EMI-C00121" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00121.TIF" alt="Figure US20170210697A1-20170727-C00121" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00121" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/9d/45/c79f493b493805/US20170210697A1-20170727-C00121.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00121" attachment-type="cdx" file="US20170210697A1-20170727-C00121.CDX"> </attachment>
          <attachment idref="CHEM-US-00121" attachment-type="mol" file="US20170210697A1-20170727-C00121.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0682]"> </para-num> <div id="p-0721" num="0682" class="description-line">Chemical Formula: C<sub>41</sub>H<sub>81</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0683]"> </para-num> <div id="p-0722" num="0683" class="description-line">Molecular Weight: 668.10</div>
    </li> <li> <para-num num="[0684]"> </para-num> <div id="p-0723" num="0684" class="description-line">Compound 33 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.39 min. MS (ES): m/z (MH<sup>+</sup>) 669.09 for C<sub>41</sub>H<sub>81</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.84-3.54 (br. m, 2H); 2.99-2.41 (br. m, 5H); 2.31 (m, 4H), 1.76-1.02 (br. m, 57H), 0.90 (m, 9H).</div>
    </li> <heading id="h-0080">AI. Compound 34: dodecan-4-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0685]"> </para-num> <div id="p-0724" num="0685" class="description-line">
      <chemistry id="CHEM-US-00122" num="00122">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/a2/66/62705dc8c1f454/US20170210697A1-20170727-C00122.png"><img id="EMI-C00122" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00122.TIF" alt="Figure US20170210697A1-20170727-C00122" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00122" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b4/a2/66/62705dc8c1f454/US20170210697A1-20170727-C00122.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00122" attachment-type="cdx" file="US20170210697A1-20170727-C00122.CDX"> </attachment>
          <attachment idref="CHEM-US-00122" attachment-type="mol" file="US20170210697A1-20170727-C00122.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0686]"> </para-num> <div id="p-0725" num="0686" class="description-line">Chemical Formula: C<sub>39</sub>H<sub>77</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0687]"> </para-num> <div id="p-0726" num="0687" class="description-line">Molecular Weight: 640.05</div>
    </li> <li> <para-num num="[0688]"> </para-num> <div id="p-0727" num="0688" class="description-line">Compound 34 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.21 min. MS (ES): m/z (MH<sup>+</sup>) 641.05 for C<sub>39</sub>H<sub>77</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (p, 1H); 4.08 (t, 2H); 3.67 (br. m, 2H); 3.03-2.44 (br. m, 5H); 2.30 (m, 4H), 1.75-1.00 (br. m, 53H), 0.90 (m, 9H).</div>
    </li> <heading id="h-0081">AJ. Compound 35: nonyl 8-((2-hydroxyethyl)(8-oxo-8-(undecan-3-yloxy)octyl)amino) octanoate</heading>
    <li> <para-num num="[0689]"> </para-num> <div id="p-0728" num="0689" class="description-line">
      <chemistry id="CHEM-US-00123" num="00123">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/4d/e0/1903a37298f57e/US20170210697A1-20170727-C00123.png"><img id="EMI-C00123" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00123.TIF" alt="Figure US20170210697A1-20170727-C00123" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00123" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/4d/e0/1903a37298f57e/US20170210697A1-20170727-C00123.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00123" attachment-type="cdx" file="US20170210697A1-20170727-C00123.CDX"> </attachment>
          <attachment idref="CHEM-US-00123" attachment-type="mol" file="US20170210697A1-20170727-C00123.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0690]"> </para-num> <div id="p-0729" num="0690" class="description-line">Chemical Formula: C<sub>38</sub>H<sub>75</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0691]"> </para-num> <div id="p-0730" num="0691" class="description-line">Molecular Weight: 626.02</div>
    </li> <li> <para-num num="[0692]"> </para-num> <div id="p-0731" num="0692" class="description-line">Compound 35 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.16 min. MS (ES): m/z (MH<sup>+</sup>) 627.11 for C<sub>38</sub>H<sub>75</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.83 (p, 1H); 4.08 (t, 2H); 3.63 (br. m, 2H); 2.81-2.39 (br. m, 5H); 2.31 (m, 4H), 1.74-1.01 (br. m, 51H), 0.90 (m, 9H).</div>
    </li> <heading id="h-0082">AK. Compound 36: decan-2-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0693]"> </para-num> <div id="p-0732" num="0693" class="description-line">
      <chemistry id="CHEM-US-00124" num="00124">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/65/33/0028acb31cfc3d/US20170210697A1-20170727-C00124.png"><img id="EMI-C00124" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00124.TIF" alt="Figure US20170210697A1-20170727-C00124" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00124" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/65/33/0028acb31cfc3d/US20170210697A1-20170727-C00124.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00124" attachment-type="cdx" file="US20170210697A1-20170727-C00124.CDX"> </attachment>
          <attachment idref="CHEM-US-00124" attachment-type="mol" file="US20170210697A1-20170727-C00124.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0694]"> </para-num> <div id="p-0733" num="0694" class="description-line">Chemical Formula: C<sub>37</sub>H<sub>73</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0695]"> </para-num> <div id="p-0734" num="0695" class="description-line">Molecular Weight: 611.99</div>
    </li> <li> <para-num num="[0696]"> </para-num> <div id="p-0735" num="0696" class="description-line">Compound 36 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.05 min. MS (ES): m/z (MH<sup>+</sup>) 613.00 for C<sub>37</sub>H<sub>73</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (p, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.60 (m, 2H); 2.47 (m, 4H); 2.29 (m, 4H), 1.731-1.01 (m, 51H), 0.90 (m, 6H).</div>
    </li> <heading id="h-0083">AL. Compound 47: heptadecan-9-yl 8-((2-hydroxyethyl)(8-(2-octylcyclopropyl)octyl) amino)octanoate</heading>
    <li> <para-num num="[0697]"> </para-num> <div id="p-0736" num="0697" class="description-line">
      <chemistry id="CHEM-US-00125" num="00125">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0b/35/eb/5eb98f33ef5761/US20170210697A1-20170727-C00125.png"><img id="EMI-C00125" he="20.83mm" wi="101.35mm" file="US20170210697A1-20170727-C00125.TIF" alt="Figure US20170210697A1-20170727-C00125" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="83" alt="Figure US20170210697A1-20170727-C00125" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0b/35/eb/5eb98f33ef5761/US20170210697A1-20170727-C00125.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00125" attachment-type="cdx" file="US20170210697A1-20170727-C00125.CDX"> </attachment>
          <attachment idref="CHEM-US-00125" attachment-type="mol" file="US20170210697A1-20170727-C00125.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0698]"> </para-num> <div id="p-0737" num="0698" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0699]"> </para-num> <div id="p-0738" num="0699" class="description-line">Molecular Weight: 706.24</div>
    </li> <li> <para-num num="[0700]"> </para-num> <div id="p-0739" num="0700" class="description-line">Compound 47 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.92 min. MS (ES): m/z (MH<sup>+</sup>) 707.39 for C<sub>46</sub>H<sub>91</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 3.56 (br. m, 2H); 2.72-2.38 (br. m, 5H); 2.28 (t, 2H); 1.70-1.02 (br. m, 67H), 0.88 (m, 9H); 0.71-0.49 (m, 4H); 0.33 (m, 1H).</div>
    </li> <heading id="h-0084">AM. Compound 48: decan-2-yl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl) amino)octanoate</heading>
    <li> <para-num num="[0701]"> </para-num> <div id="p-0740" num="0701" class="description-line">
      <chemistry id="CHEM-US-00126" num="00126">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/7d/fd/26974d831cb99f/US20170210697A1-20170727-C00126.png"><img id="EMI-C00126" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00126.TIF" alt="Figure US20170210697A1-20170727-C00126" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00126" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f1/7d/fd/26974d831cb99f/US20170210697A1-20170727-C00126.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00126" attachment-type="cdx" file="US20170210697A1-20170727-C00126.CDX"> </attachment>
          <attachment idref="CHEM-US-00126" attachment-type="mol" file="US20170210697A1-20170727-C00126.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0702]"> </para-num> <div id="p-0741" num="0702" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0703]"> </para-num> <div id="p-0742" num="0703" class="description-line">Molecular Weight: 724.21</div>
    </li> <li> <para-num num="[0704]"> </para-num> <div id="p-0743" num="0704" class="description-line">Compound 48 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.60 min. MS (ES): m/z (MH<sup>+</sup>) 725.10 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 2H); 3.59 (br. m, 2H); 2.79-2.37 (br. m, 5H); 2.29 (m, 4H); 1.74-1.13 (m, 66H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0085">AN. Compound 49: heptadecan-9-yl 8-((2-hydroxyethyl)(8-oxo-8-(undecan-3-yloxy)octyl) amino)octanoate</heading>
    <li> <para-num num="[0705]"> </para-num> <div id="p-0744" num="0705" class="description-line">
      <chemistry id="CHEM-US-00127" num="00127">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/ee/ac/667a2c43b9e55e/US20170210697A1-20170727-C00127.png"><img id="EMI-C00127" he="29.29mm" wi="100.58mm" file="US20170210697A1-20170727-C00127.TIF" alt="Figure US20170210697A1-20170727-C00127" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="117" alt="Figure US20170210697A1-20170727-C00127" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3c/ee/ac/667a2c43b9e55e/US20170210697A1-20170727-C00127.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00127" attachment-type="cdx" file="US20170210697A1-20170727-C00127.CDX"> </attachment>
          <attachment idref="CHEM-US-00127" attachment-type="mol" file="US20170210697A1-20170727-C00127.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0706]"> </para-num> <div id="p-0745" num="0706" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0707]"> </para-num> <div id="p-0746" num="0707" class="description-line">Molecular Weight: 738.24</div>
    </li> <li> <para-num num="[0708]"> </para-num> <div id="p-0747" num="0708" class="description-line">Compound 49 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.68 min. MS (ES): m/z (MH<sup>+</sup>) 739.21 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.56 (br. m, 2H); 2.68-2.39 (br. m, 5H); 2.30 (m, 4H); 1.71-1.19 (m, 66H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0086">AO. Compound 50: dodecan-4-yl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl) amino)octanoate</heading>
    <li> <para-num num="[0709]"> </para-num> <div id="p-0748" num="0709" class="description-line">
      <chemistry id="CHEM-US-00128" num="00128">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/c3/b4/2420c13002021d/US20170210697A1-20170727-C00128.png"><img id="EMI-C00128" he="29.29mm" wi="100.58mm" file="US20170210697A1-20170727-C00128.TIF" alt="Figure US20170210697A1-20170727-C00128" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="117" alt="Figure US20170210697A1-20170727-C00128" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/c3/b4/2420c13002021d/US20170210697A1-20170727-C00128.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00128" attachment-type="cdx" file="US20170210697A1-20170727-C00128.CDX"> </attachment>
          <attachment idref="CHEM-US-00128" attachment-type="mol" file="US20170210697A1-20170727-C00128.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0710]"> </para-num> <div id="p-0749" num="0710" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>93</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0711]"> </para-num> <div id="p-0750" num="0711" class="description-line">Molecular Weight: 752.26</div>
    </li> <li> <para-num num="[0712]"> </para-num> <div id="p-0751" num="0712" class="description-line">Compound 50 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.73 min. MS (ES): m/z (MH<sup>+</sup>) 753.23 for C<sub>47</sub>H<sub>93</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.60 (br. m, 2H); 2.75-2.43 (br. m, 5H); 2.30 (m, 4H); 1.71-1.44 (m, 16H); 1.28 (m, 51H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0087">AP. Compound 51: heptadecan-9-yl 8-((4-butoxy-4-oxobutyl)(2-hydroxyethyl)amino) octanoate</heading>
    <li> <para-num num="[0713]"> </para-num> <div id="p-0752" num="0713" class="description-line">
      <chemistry id="CHEM-US-00129" num="00129">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/20/64/60c51516ce478e/US20170210697A1-20170727-C00129.png"><img id="EMI-C00129" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00129.TIF" alt="Figure US20170210697A1-20170727-C00129" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00129" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/20/64/60c51516ce478e/US20170210697A1-20170727-C00129.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00129" attachment-type="cdx" file="US20170210697A1-20170727-C00129.CDX"> </attachment>
          <attachment idref="CHEM-US-00129" attachment-type="mol" file="US20170210697A1-20170727-C00129.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0714]"> </para-num> <div id="p-0753" num="0714" class="description-line">Chemical Formula: C<sub>35</sub>H<sub>69</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0715]"> </para-num> <div id="p-0754" num="0715" class="description-line">Molecular Weight: 583.94</div>
    </li> <li> <para-num num="[0716]"> </para-num> <div id="p-0755" num="0716" class="description-line">Compound 51 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.05 min. MS (ES): m/z (MH<sup>+</sup>) 584.87 for C<sub>35</sub>H<sub>69</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.10 (t, 2H); 3.61 (br. m, 2H); 2.81-2.21 (br. m, 9H); 1.87 (br. m, 2H), 1.70-1.04 (m, 43H), 0.98-0.82 (m, 9H).</div>
    </li> <heading id="h-0088">AQ. Compound 52: heptadecan-9-yl 8-((2-hydroxyethyl)(4-oxo-4-(pentyloxy)butyl)amino) octanoate</heading>
    <li> <para-num num="[0717]"> </para-num> <div id="p-0756" num="0717" class="description-line">
      <chemistry id="CHEM-US-00130" num="00130">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/b1/12/cf1a776a5f2a3c/US20170210697A1-20170727-C00130.png"><img id="EMI-C00130" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00130.TIF" alt="Figure US20170210697A1-20170727-C00130" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00130" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5d/b1/12/cf1a776a5f2a3c/US20170210697A1-20170727-C00130.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00130" attachment-type="cdx" file="US20170210697A1-20170727-C00130.CDX"> </attachment>
          <attachment idref="CHEM-US-00130" attachment-type="mol" file="US20170210697A1-20170727-C00130.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0718]"> </para-num> <div id="p-0757" num="0718" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0719]"> </para-num> <div id="p-0758" num="0719" class="description-line">Molecular Weight: 597.97</div>
    </li> <li> <para-num num="[0720]"> </para-num> <div id="p-0759" num="0720" class="description-line">Compound 52 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.11 min. MS (ES): m/z (MH<sup>+</sup>) 598.90 for C<sub>36</sub>H<sub>71</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.09 (t, 2H); 3.61 (br. m, 2H); 2.89-2.22 (br. m, 9H); 1.87 (br. m, 2H), 1.73-1.43 (m, 11H), 1.28 (m, 34H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0089">AR. Compound 53: heptadecan-9-yl 8-((4-(hexyloxy)-4-oxobutyl)(2-hydroxyethyl)amino) octanoate</heading>
    <li> <para-num num="[0721]"> </para-num> <div id="p-0760" num="0721" class="description-line">
      <chemistry id="CHEM-US-00131" num="00131">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2e/8b/0d/687ab9333266e0/US20170210697A1-20170727-C00131.png"><img id="EMI-C00131" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00131.TIF" alt="Figure US20170210697A1-20170727-C00131" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00131" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2e/8b/0d/687ab9333266e0/US20170210697A1-20170727-C00131.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00131" attachment-type="cdx" file="US20170210697A1-20170727-C00131.CDX"> </attachment>
          <attachment idref="CHEM-US-00131" attachment-type="mol" file="US20170210697A1-20170727-C00131.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0722]"> </para-num> <div id="p-0761" num="0722" class="description-line">Chemical Formula: C<sub>37</sub>H<sub>73</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0723]"> </para-num> <div id="p-0762" num="0723" class="description-line">Molecular Weight: 611.99</div>
    </li> <li> <para-num num="[0724]"> </para-num> <div id="p-0763" num="0724" class="description-line">Compound 53 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.22 min. MS (ES): m/z (MH<sup>+</sup>) 612.92 for C<sub>37</sub>H<sub>73</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.06 (t, 2H); 3.55 (br. m, 2H); 2.68-2.38 (br. m, 5H); 2.28 (m, 4H); 1.79 (br. m, 2H); 1.71-0.96 (m, 48H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0090">AS. Compound 54: heptadecan-9-yl 8-((4-(heptyloxy)-4-oxobutyl)(2-hydroxyethyl)amino) octanoate</heading>
    <li> <para-num num="[0725]"> </para-num> <div id="p-0764" num="0725" class="description-line">
      <chemistry id="CHEM-US-00132" num="00132">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/98/b5/e6/341ac5ce549238/US20170210697A1-20170727-C00132.png"><img id="EMI-C00132" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00132.TIF" alt="Figure US20170210697A1-20170727-C00132" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00132" class="patent-full-image" src="https://patentimages.storage.googleapis.com/98/b5/e6/341ac5ce549238/US20170210697A1-20170727-C00132.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00132" attachment-type="cdx" file="US20170210697A1-20170727-C00132.CDX"> </attachment>
          <attachment idref="CHEM-US-00132" attachment-type="mol" file="US20170210697A1-20170727-C00132.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0726]"> </para-num> <div id="p-0765" num="0726" class="description-line">Chemical Formula: C<sub>38</sub>H<sub>75</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0727]"> </para-num> <div id="p-0766" num="0727" class="description-line">Molecular Weight: 626.02</div>
    </li> <li> <para-num num="[0728]"> </para-num> <div id="p-0767" num="0728" class="description-line">Compound 54 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.28 min. MS (ES): m/z (MH<sup>+</sup>) 626.94 for C<sub>38</sub>H<sub>75</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.09 (t, 2H); 3.60 (br. m, 2H); 2.77-2.42 (br. m, 5H); 2.32 (m, 4H); 1.84 (br. m, 2H); 1.75-1.03 (m, 49H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0091">AT. Compound 55: heptadecan-9-yl 8-((4-((2-hexylcyclopropyl)methoxy)-4-oxobutyl)(2-hydroxyethyl) amino)octanoate</heading>
    <li> <para-num num="[0729]"> </para-num> <div id="p-0768" num="0729" class="description-line">
      <chemistry id="CHEM-US-00133" num="00133">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/00/23/a2/7a4d9a07d8a3d2/US20170210697A1-20170727-C00133.png"><img id="EMI-C00133" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00133.TIF" alt="Figure US20170210697A1-20170727-C00133" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00133" class="patent-full-image" src="https://patentimages.storage.googleapis.com/00/23/a2/7a4d9a07d8a3d2/US20170210697A1-20170727-C00133.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00133" attachment-type="cdx" file="US20170210697A1-20170727-C00133.CDX"> </attachment>
          <attachment idref="CHEM-US-00133" attachment-type="mol" file="US20170210697A1-20170727-C00133.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0730]"> </para-num> <div id="p-0769" num="0730" class="description-line">Chemical Formula: C<sub>41</sub>H<sub>79</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0731]"> </para-num> <div id="p-0770" num="0731" class="description-line">Molecular Weight: 666.09</div>
    </li> <li> <para-num num="[0732]"> </para-num> <div id="p-0771" num="0732" class="description-line">Compound 55 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.37 min. MS (ES): m/z (MH<sup>+</sup>) 667.04 for C<sub>41</sub>H<sub>79</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.83 (p, 1H); 4.15 (m, 1H); 3.95 (m, 1H); 3.53 (br. m, 2H); 2.66-2.39 (br. m, 5H); 2.34-2.19 (m, 4H); 1.78 (br. m, 2H); 1.66-0.98 (m, 50H); 0.85 (m, 10H); 0.70 (m, 1H); 0.00 (m, 1H).</div>
    </li> <heading id="h-0092">AU. Compound 56: nonyl 8-((2-hydroxyethyl)(8-oxo-8-(tridecan-7-yloxy)octyl)amino) octanoate</heading>
    <li> <para-num num="[0733]"> </para-num> <div id="p-0772" num="0733" class="description-line">
      <chemistry id="CHEM-US-00134" num="00134">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/79/16/aacb61532282eb/US20170210697A1-20170727-C00134.png"><img id="EMI-C00134" he="27.26mm" wi="100.58mm" file="US20170210697A1-20170727-C00134.TIF" alt="Figure US20170210697A1-20170727-C00134" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00134" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/79/16/aacb61532282eb/US20170210697A1-20170727-C00134.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00134" attachment-type="cdx" file="US20170210697A1-20170727-C00134.CDX"> </attachment>
          <attachment idref="CHEM-US-00134" attachment-type="mol" file="US20170210697A1-20170727-C00134.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0734]"> </para-num> <div id="p-0773" num="0734" class="description-line">Chemical Formula: C<sub>40</sub>H<sub>79</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0735]"> </para-num> <div id="p-0774" num="0735" class="description-line">Molecular Weight: 654.07</div>
    </li> <li> <para-num num="[0736]"> </para-num> <div id="p-0775" num="0736" class="description-line">Compound 56 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.28 min. MS (ES): m/z (MH<sup>+</sup>) 654.99 for C<sub>40</sub>H<sub>79</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.60 (br. m, 2H); 2.77-2.40 (br. m, 5H); 2.30 (m, 4H); 1.78-0.99 (m, 55H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0093">AV. Compound 57: nonan-5-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0737]"> </para-num> <div id="p-0776" num="0737" class="description-line">
      <chemistry id="CHEM-US-00135" num="00135">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/65/51/5f/0b05a8b9065698/US20170210697A1-20170727-C00135.png"><img id="EMI-C00135" he="27.26mm" wi="100.58mm" file="US20170210697A1-20170727-C00135.TIF" alt="Figure US20170210697A1-20170727-C00135" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00135" class="patent-full-image" src="https://patentimages.storage.googleapis.com/65/51/5f/0b05a8b9065698/US20170210697A1-20170727-C00135.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00135" attachment-type="cdx" file="US20170210697A1-20170727-C00135.CDX"> </attachment>
          <attachment idref="CHEM-US-00135" attachment-type="mol" file="US20170210697A1-20170727-C00135.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0738]"> </para-num> <div id="p-0777" num="0738" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0739]"> </para-num> <div id="p-0778" num="0739" class="description-line">Molecular Weight: 597.97</div>
    </li> <li> <para-num num="[0740]"> </para-num> <div id="p-0779" num="0740" class="description-line">Compound 57 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=2.88 min. MS (ES): m/z (MH<sup>+</sup>) 598.98 for C<sub>36</sub>H<sub>71</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.59 (br. m, 2H); 2.82-2.37 (br. m, 5H); 2.31 (m, 4H); 1.73-1.03 (m, 47H); 0.91 (m, 9H).</div>
    </li> <heading id="h-0094">AW. Compound 58: heptan-4-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino) octanoate</heading>
    <li> <para-num num="[0741]"> </para-num> <div id="p-0780" num="0741" class="description-line">
      <chemistry id="CHEM-US-00136" num="00136">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/64/9c/99/23d9ee74c698a5/US20170210697A1-20170727-C00136.png"><img id="EMI-C00136" he="27.26mm" wi="100.58mm" file="US20170210697A1-20170727-C00136.TIF" alt="Figure US20170210697A1-20170727-C00136" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00136" class="patent-full-image" src="https://patentimages.storage.googleapis.com/64/9c/99/23d9ee74c698a5/US20170210697A1-20170727-C00136.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00136" attachment-type="cdx" file="US20170210697A1-20170727-C00136.CDX"> </attachment>
          <attachment idref="CHEM-US-00136" attachment-type="mol" file="US20170210697A1-20170727-C00136.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0742]"> </para-num> <div id="p-0781" num="0742" class="description-line">Chemical Formula: C<sub>34</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0743]"> </para-num> <div id="p-0782" num="0743" class="description-line">Molecular Weight: 569.91</div>
    </li> <li> <para-num num="[0744]"> </para-num> <div id="p-0783" num="0744" class="description-line">Compound 58 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=2.67 min. MS (ES): m/z (MH<sup>+</sup>) 570.93 for C<sub>34</sub>H<sub>67</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.93 (p, 1H); 4.08 (t, 2H); 3.57 (br. m, 2H); 2.69-2.42 (br. m, 5H); 2.30 (m, 4H); 1.72-1.04 (m, 43H); 0.93 (m, 9H).</div>
    </li> <heading id="h-0095">AX. Compound 59: nonyl 8-((2-hydroxyethyl)(8-oxo-8-(pentan-3-yloxy)octyl)amino) octanoate</heading>
    <li> <para-num num="[0745]"> </para-num> <div id="p-0784" num="0745" class="description-line">
      <chemistry id="CHEM-US-00137" num="00137">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/2a/c6/ea10d2f4b45025/US20170210697A1-20170727-C00137.png"><img id="EMI-C00137" he="27.26mm" wi="100.58mm" file="US20170210697A1-20170727-C00137.TIF" alt="Figure US20170210697A1-20170727-C00137" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00137" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/2a/c6/ea10d2f4b45025/US20170210697A1-20170727-C00137.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00137" attachment-type="cdx" file="US20170210697A1-20170727-C00137.CDX"> </attachment>
          <attachment idref="CHEM-US-00137" attachment-type="mol" file="US20170210697A1-20170727-C00137.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0746]"> </para-num> <div id="p-0785" num="0746" class="description-line">Chemical Formula: C<sub>32</sub>H<sub>63</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0747]"> </para-num> <div id="p-0786" num="0747" class="description-line">Molecular Weight: 541.86</div>
    </li> <li> <para-num num="[0748]"> </para-num> <div id="p-0787" num="0748" class="description-line">Compound 59 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=2.39 min. MS (ES): m/z (MH<sup>+</sup>) 542.80 for C<sub>32</sub>H<sub>63</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.78 (p, 1H); 4.08 (t, 2H); 3.57 (br. m, 2H); 2.71-2.39 (br. m, 5H); 2.31 (m, 4H); 1.77-1.05 (m, 39H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0096">AY. Compound 60: (5Z,12Z)-Heptadeca-5,12-dien-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0097">(5Z,12Z)-Heptadeca-5,12-dien-9-ol</heading>
    <li> <para-num num="[0749]"> </para-num> <div id="p-0788" num="0749" class="description-line">
      <chemistry id="CHEM-US-00138" num="00138">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/93/f8/c8a6d30fab734b/US20170210697A1-20170727-C00138.png"><img id="EMI-C00138" he="14.90mm" wi="47.58mm" file="US20170210697A1-20170727-C00138.TIF" alt="Figure US20170210697A1-20170727-C00138" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="190" height="60" alt="Figure US20170210697A1-20170727-C00138" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/93/f8/c8a6d30fab734b/US20170210697A1-20170727-C00138.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00138" attachment-type="cdx" file="US20170210697A1-20170727-C00138.CDX"> </attachment>
          <attachment idref="CHEM-US-00138" attachment-type="mol" file="US20170210697A1-20170727-C00138.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0750]"> </para-num> <div id="p-0789" num="0750" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>32</sub>O</div>
    </li> <li> <para-num num="[0751]"> </para-num> <div id="p-0790" num="0751" class="description-line">Molecular Weight: 252.44</div>
    </li> <li> <para-num num="[0752]"> </para-num> <div id="p-0791" num="0752" class="description-line">To a solution of (Z)-1-bromooct-3-ene (6.2 g, 32.4 mmol) in THF (45 mL) Mg turnings were added (0.843 g, 34.7 mmol). The reaction was heated to 45 C. for 3 h. The reaction was cooled to 0 C. and ethyl formate (2.4 g, 32.4 mmol) in THF (5 mL) was added dropwise. The reaction was allowed to warm to rt and stir for 30 min. The reaction was cooled to 0 C. and quenched with water (15 mL) and 6N HCl (15 mL). The reaction was stirred until all the Mg was dissolved. Water (25 mL) was added and the mixture was extracted with hexanes (325 mL). The combined organic layer was washed with brine, separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was dissolved in EtOH (20 mL), a solution of KOH in water (1.76 g in 8 mL of water) was added and allowed to stir for 15 min. EtOH was evaporated under vacuum. The residue was diluted with water (20 mL), acidified with 6N HCl (20 mL) and extracted with hexanes (3). The combined organic layers were washed with brine, separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-5%) EtOAc in hexanes to obtain (5Z,12Z)-heptadeca-5,12-dien-9-ol (2.3 g, 9.1 mmol, 28%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.41 (m, 4); 3.66 (m, 1H); 2.13 (m, 8H); 1.51 (m, 5H); 1.36 (m, 8H); 0.92 (m, 6H).</div>
    </li> <heading id="h-0098">(5Z,12Z)-Heptadeca-5,12-dien-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0753]"> </para-num> <div id="p-0792" num="0753" class="description-line">
      <chemistry id="CHEM-US-00139" num="00139">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/8a/05/5c1982bb1b5300/US20170210697A1-20170727-C00139.png"><img id="EMI-C00139" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00139.TIF" alt="Figure US20170210697A1-20170727-C00139" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00139" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5b/8a/05/5c1982bb1b5300/US20170210697A1-20170727-C00139.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00139" attachment-type="cdx" file="US20170210697A1-20170727-C00139.CDX"> </attachment>
          <attachment idref="CHEM-US-00139" attachment-type="mol" file="US20170210697A1-20170727-C00139.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0754]"> </para-num> <div id="p-0793" num="0754" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0755]"> </para-num> <div id="p-0794" num="0755" class="description-line">Molecular Weight: 706.15</div>
    </li> <li> <para-num num="[0756]"> </para-num> <div id="p-0795" num="0756" class="description-line">Compound 60 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.36 min. MS (ES): m/z (MH<sup>+</sup>) 707.10 for C<sub>44</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.37 (m, 4H); 4.92 (p, 1H); 4.08 (t, 2H); 3.57 (br. m, 2H); 2.73-2.38 (br. m, 5H); 2.31 (m, 4H); 2.04 (m, 8H); 1.73-1.01 (m, 47H); 0.92 (m, 9H).</div>
    </li> <heading id="h-0099">AZ. Compound 61: (5Z,12Z)-heptadeca-5,12-dien-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate</heading>
    <li> <para-num num="[0757]"> </para-num> <div id="p-0796" num="0757" class="description-line">
      <chemistry id="CHEM-US-00140" num="00140">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/11/6f/c6/4fc20574bea53a/US20170210697A1-20170727-C00140.png"><img id="EMI-C00140" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00140.TIF" alt="Figure US20170210697A1-20170727-C00140" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00140" class="patent-full-image" src="https://patentimages.storage.googleapis.com/11/6f/c6/4fc20574bea53a/US20170210697A1-20170727-C00140.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00140" attachment-type="cdx" file="US20170210697A1-20170727-C00140.CDX"> </attachment>
          <attachment idref="CHEM-US-00140" attachment-type="mol" file="US20170210697A1-20170727-C00140.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0758]"> </para-num> <div id="p-0797" num="0758" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0759]"> </para-num> <div id="p-0798" num="0759" class="description-line">Molecular Weight: 706.15</div>
    </li> <li> <para-num num="[0760]"> </para-num> <div id="p-0799" num="0760" class="description-line">Compound 61 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.39 min. MS (ES): m/z (MH<sup>+</sup>) 707.10 for C<sub>44</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.37 (m, 4H); 4.92 (p, 1H); 4.08 (t, 2H); 3.58 (br. m, 2H); 2.70-2.41 (br. m, 5H); 2.32 (m, 4H); 2.04 (m, 8H); 1.77-1.03 (m, 47H); 0.92 (m, 9H).</div>
    </li> <heading id="h-0100">X1. Compound 65: 1-Cyclopropylnonyl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0761]"> </para-num> <div id="p-0800" num="0761" class="description-line">
      <chemistry id="CHEM-US-00141" num="00141">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2e/ee/5c/2dad72064f0ff0/US20170210697A1-20170727-C00141.png"><img id="EMI-C00141" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00141.TIF" alt="Figure US20170210697A1-20170727-C00141" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00141" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2e/ee/5c/2dad72064f0ff0/US20170210697A1-20170727-C00141.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00141" attachment-type="cdx" file="US20170210697A1-20170727-C00141.CDX"> </attachment>
          <attachment idref="CHEM-US-00141" attachment-type="mol" file="US20170210697A1-20170727-C00141.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0762]"> </para-num> <div id="p-0801" num="0762" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0763]"> </para-num> <div id="p-0802" num="0763" class="description-line">Molecular Weight: 750.247</div>
    </li> <li> <para-num num="[0764]"> </para-num> <div id="p-0803" num="0764" class="description-line">Compound 65 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.72 min. MS (ES): m/z (MH<sup>+</sup>) 750.9 for C<sub>47</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.28 (m, 1H); 3.54 (m, 2H); 2.59 (m, 2H); 2.46 (m, 4H); 2.29 (m, 4H), 1.73-1.18 (m, 61H); 0.90 (m, 10H); 0.62-0.33 (m, 3H); 0.28 (m, 1H).</div>
    </li> <heading id="h-0101">X2. Compound 66: Heptadecan-9-yl 8-((2-hydroxyethyl)(8-oxo-8-((4-pentylcyclohexyl)oxy)octyl)amino)octanoate</heading>
    <li> <para-num num="[0765]"> </para-num> <div id="p-0804" num="0765" class="description-line">
      <chemistry id="CHEM-US-00142" num="00142">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/bf/f1/618117610e1f95/US20170210697A1-20170727-C00142.png"><img id="EMI-C00142" he="29.21mm" wi="100.58mm" file="US20170210697A1-20170727-C00142.TIF" alt="Figure US20170210697A1-20170727-C00142" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="117" alt="Figure US20170210697A1-20170727-C00142" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/bf/f1/618117610e1f95/US20170210697A1-20170727-C00142.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00142" attachment-type="cdx" file="US20170210697A1-20170727-C00142.CDX"> </attachment>
          <attachment idref="CHEM-US-00142" attachment-type="mol" file="US20170210697A1-20170727-C00142.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0766]"> </para-num> <div id="p-0805" num="0766" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0767]"> </para-num> <div id="p-0806" num="0767" class="description-line">Molecular Weight: 736.220</div>
    </li> <li> <para-num num="[0768]"> </para-num> <div id="p-0807" num="0768" class="description-line">Compound 66 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.72 min. MS (ES): m/z (MH<sup>+</sup>) 736.9 for C<sub>46</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.00 (m, 0.5H); 4.89 (m, 1H); 4.68 (m, 0.6H); 3.56 (m, 2H), 2.61 (br. m, 2H); 2.48 (m, 4H); 2.30 (m, 4H); 1.98 (m, 1H); 1.82 (m, 2H); 1.73-1.14 (m, 61H); 1.04 (m, 1H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0102">X3. Compound 67: Heptadecan-9-yl 8-((2-hydroxyethyl)(4-oxo-4-((4-pentylcyclohexyl)oxy)butyl)amino)octanoate</heading>
    <li> <para-num num="[0769]"> </para-num> <div id="p-0808" num="0769" class="description-line">
      <chemistry id="CHEM-US-00143" num="00143">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/7a/37/46819fe98c7feb/US20170210697A1-20170727-C00143.png"><img id="EMI-C00143" he="29.63mm" wi="75.18mm" file="US20170210697A1-20170727-C00143.TIF" alt="Figure US20170210697A1-20170727-C00143" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="119" alt="Figure US20170210697A1-20170727-C00143" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/7a/37/46819fe98c7feb/US20170210697A1-20170727-C00143.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00143" attachment-type="cdx" file="US20170210697A1-20170727-C00143.CDX"> </attachment>
          <attachment idref="CHEM-US-00143" attachment-type="mol" file="US20170210697A1-20170727-C00143.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0770]"> </para-num> <div id="p-0809" num="0770" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>81</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0771]"> </para-num> <div id="p-0810" num="0771" class="description-line">Molecular Weight: 680.112</div>
    </li> <li> <para-num num="[0772]"> </para-num> <div id="p-0811" num="0772" class="description-line">Compound 67 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.56 min. MS (ES): m/z (MH<sup>+</sup>) 680.8 for C<sub>42</sub>H<sub>81</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.01 (m, 0.4H); 4.89 (m, 1H); 4.68 (m, 0.6H); 3.59 (m, 2H), 2.72-2.43 (br. m, 6H); 2.30 (m, 4H); 1.98 (m, 1H); 1.83 (m, 4H); 1.69-1.44 (m, 10H); 1.28 (m, 41H); 1.03 (m, 1H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0103">X4. Compound 68: Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-((4-pentylcyclohexyl)oxy)hexyl)amino)octanoate</heading>
    <li> <para-num num="[0773]"> </para-num> <div id="p-0812" num="0773" class="description-line">
      <chemistry id="CHEM-US-00144" num="00144">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/85/1b/fbfacc9ae662cb/US20170210697A1-20170727-C00144.png"><img id="EMI-C00144" he="23.11mm" wi="75.35mm" file="US20170210697A1-20170727-C00144.TIF" alt="Figure US20170210697A1-20170727-C00144" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="92" alt="Figure US20170210697A1-20170727-C00144" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/85/1b/fbfacc9ae662cb/US20170210697A1-20170727-C00144.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00144" attachment-type="cdx" file="US20170210697A1-20170727-C00144.CDX"> </attachment>
          <attachment idref="CHEM-US-00144" attachment-type="mol" file="US20170210697A1-20170727-C00144.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0774]"> </para-num> <div id="p-0813" num="0774" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>85</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0775]"> </para-num> <div id="p-0814" num="0775" class="description-line">Molecular Weight: 708.166</div>
    </li> <li> <para-num num="[0776]"> </para-num> <div id="p-0815" num="0776" class="description-line">Compound 68 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.66 min. MS (ES): m/z (MH<sup>+</sup>) 708.9 for C<sub>44</sub>H<sub>85</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.00 (m, 0.5H); 4.89 (m, 1H); 4.68 (m, 0.6H); 3.55 (m, 2H), 2.66-2.39 (br. m, 6H); 2.30 (m, 4H); 1.97 (m, 1H); 1.83 (m, 2H); 1.73-1.41 (m, 15H); 1.41-1.17 (m, 42H); 1.04 (m, 1H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0104">XX1. Compound 69: Heptadecan-9-yl 8-((2,3-dihydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0777]"> </para-num> <div id="p-0816" num="0777" class="description-line">
      <chemistry id="CHEM-US-00145" num="00145">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/25/17/3aa3b495fbcbec/US20170210697A1-20170727-C00145.png"><img id="EMI-C00145" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00145.TIF" alt="Figure US20170210697A1-20170727-C00145" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00145" class="patent-full-image" src="https://patentimages.storage.googleapis.com/31/25/17/3aa3b495fbcbec/US20170210697A1-20170727-C00145.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00145" attachment-type="cdx" file="US20170210697A1-20170727-C00145.CDX"> </attachment>
          <attachment idref="CHEM-US-00145" attachment-type="mol" file="US20170210697A1-20170727-C00145.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0778]"> </para-num> <div id="p-0817" num="0778" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[0779]"> </para-num> <div id="p-0818" num="0779" class="description-line">Molecular Weight: 740.21</div>
    </li> <li> <para-num num="[0780]"> </para-num> <div id="p-0819" num="0780" class="description-line">Compound 69 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.60 min. MS (ES): m/z (MH<sup>+</sup>) 741.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.76 (br. m, 2H); 3.51 (m, 1H); 2.57 (m, 6H); 2.31 (m, 4H); 1.71-1.41 (m, 14H); 1.41-1.12 (m, 48H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0105">XX2. Compound 70: Heptadecan-9-yl 8-((4-(decan-2-yloxy)-4-oxobutyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0781]"> </para-num> <div id="p-0820" num="0781" class="description-line">
      <chemistry id="CHEM-US-00146" num="00146">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/48/ec/71/48e955c3f870aa/US20170210697A1-20170727-C00146.png"><img id="EMI-C00146" he="23.11mm" wi="75.52mm" file="US20170210697A1-20170727-C00146.TIF" alt="Figure US20170210697A1-20170727-C00146" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="92" alt="Figure US20170210697A1-20170727-C00146" class="patent-full-image" src="https://patentimages.storage.googleapis.com/48/ec/71/48e955c3f870aa/US20170210697A1-20170727-C00146.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00146" attachment-type="cdx" file="US20170210697A1-20170727-C00146.CDX"> </attachment>
          <attachment idref="CHEM-US-00146" attachment-type="mol" file="US20170210697A1-20170727-C00146.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0782]"> </para-num> <div id="p-0821" num="0782" class="description-line">Chemical Formula: C<sub>41</sub>H<sub>81</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0783]"> </para-num> <div id="p-0822" num="0783" class="description-line">Molecular Weight: 667.61</div>
    </li> <li> <para-num num="[0784]"> </para-num> <div id="p-0823" num="0784" class="description-line">Compound 70 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.44 min. MS (ES): m/z (MH<sup>+</sup>) 668.9 for C<sub>41</sub>H<sub>81</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 2H); 3.57 (m, 2H); 2.71-2.40 (m, 5H); 2.30 (m, 4H), 1.80 (m, 2H); 1.71-1.40 (m, 11H); 1.39-1.05 (m, 45H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0106">X5. Compound 71: Heptadecan-9-yl 8-((2-hydroxyethyl)(4-oxo-4-(tetradecan-6-yloxy)butyl)amino)octanoate</heading>
    <li> <para-num num="[0785]"> </para-num> <div id="p-0824" num="0785" class="description-line">
      <chemistry id="CHEM-US-00147" num="00147">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8b/2f/a5/9fc99b6e7bfc6c/US20170210697A1-20170727-C00147.png"><img id="EMI-C00147" he="29.72mm" wi="75.52mm" file="US20170210697A1-20170727-C00147.TIF" alt="Figure US20170210697A1-20170727-C00147" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="119" alt="Figure US20170210697A1-20170727-C00147" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8b/2f/a5/9fc99b6e7bfc6c/US20170210697A1-20170727-C00147.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00147" attachment-type="cdx" file="US20170210697A1-20170727-C00147.CDX"> </attachment>
          <attachment idref="CHEM-US-00147" attachment-type="mol" file="US20170210697A1-20170727-C00147.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0786]"> </para-num> <div id="p-0825" num="0786" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0787]"> </para-num> <div id="p-0826" num="0787" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[0788]"> </para-num> <div id="p-0827" num="0788" class="description-line">Compound 71 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.72 min. MS (ES): m/z (MH<sup>+</sup>) 724.9 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.56 (m, 2H); 2.70-2.41 (m, 6H); 2.33 (m, 4H), 1.80 (m, 2H); 1.69-1.41 (m, 13H); 1.28 (m, 48H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0107">XX3. Compound 72: Heptadecan-9-yl 8-((2-hydroxyethyl)(4-oxo-4-(undecan-3-yloxy)butyl)amino)octanoate</heading>
    <li> <para-num num="[0789]"> </para-num> <div id="p-0828" num="0789" class="description-line">
      <chemistry id="CHEM-US-00148" num="00148">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/86/07/1e46c7cedaab97/US20170210697A1-20170727-C00148.png"><img id="EMI-C00148" he="23.11mm" wi="75.52mm" file="US20170210697A1-20170727-C00148.TIF" alt="Figure US20170210697A1-20170727-C00148" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="92" alt="Figure US20170210697A1-20170727-C00148" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/86/07/1e46c7cedaab97/US20170210697A1-20170727-C00148.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00148" attachment-type="cdx" file="US20170210697A1-20170727-C00148.CDX"> </attachment>
          <attachment idref="CHEM-US-00148" attachment-type="mol" file="US20170210697A1-20170727-C00148.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0790]"> </para-num> <div id="p-0829" num="0790" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0791]"> </para-num> <div id="p-0830" num="0791" class="description-line">Molecular Weight: 682.13</div>
    </li> <li> <para-num num="[0792]"> </para-num> <div id="p-0831" num="0792" class="description-line">Compound 72 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.57 min. MS (ES): m/z (MH<sup>+</sup>) 683.0 for C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 2H); 3.58 (br. m, 2H); 2.75-2.41 (br. m, 5H); 2.30 (m, 4H), 1.81 (br. m, 2H); 1.70-1.42 (m, 13H); 1.40-1.18 (m, 42H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0108">X6. Compound 73: Heptadecan-9-yl 8-((2-hydroxyethyl)(4-oxo-4-(pentadecan-7-yloxy)butyl)amino)octanoate</heading>
    <li> <para-num num="[0793]"> </para-num> <div id="p-0832" num="0793" class="description-line">
      <chemistry id="CHEM-US-00149" num="00149">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/12/1a/c426257344d7c6/US20170210697A1-20170727-C00149.png"><img id="EMI-C00149" he="23.11mm" wi="75.52mm" file="US20170210697A1-20170727-C00149.TIF" alt="Figure US20170210697A1-20170727-C00149" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="92" alt="Figure US20170210697A1-20170727-C00149" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/12/1a/c426257344d7c6/US20170210697A1-20170727-C00149.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00149" attachment-type="cdx" file="US20170210697A1-20170727-C00149.CDX"> </attachment>
          <attachment idref="CHEM-US-00149" attachment-type="mol" file="US20170210697A1-20170727-C00149.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0794]"> </para-num> <div id="p-0833" num="0794" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0795]"> </para-num> <div id="p-0834" num="0795" class="description-line">Molecular Weight: 738.236</div>
    </li> <li> <para-num num="[0796]"> </para-num> <div id="p-0835" num="0796" class="description-line">Compound 73 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.80 min. MS (ES): m/z (MH<sup>+</sup>) 739.09 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.59 (br. m, 2H); 2.81-2.43 (br. m, 6H); 2.31 (m, 4H); 1.83 (m, 2H); 1.69-1.42 (m, 12H); 1.28 (m, 50H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0109">X7. Compound 74: Heptadecan-9-yl 8-((4-(dodecan-4-yloxy)-4-oxobutyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0797]"> </para-num> <div id="p-0836" num="0797" class="description-line">
      <chemistry id="CHEM-US-00150" num="00150">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/df/57/59eb1bf32c5315/US20170210697A1-20170727-C00150.png"><img id="EMI-C00150" he="29.72mm" wi="75.52mm" file="US20170210697A1-20170727-C00150.TIF" alt="Figure US20170210697A1-20170727-C00150" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="119" alt="Figure US20170210697A1-20170727-C00150" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/df/57/59eb1bf32c5315/US20170210697A1-20170727-C00150.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00150" attachment-type="cdx" file="US20170210697A1-20170727-C00150.CDX"> </attachment>
          <attachment idref="CHEM-US-00150" attachment-type="mol" file="US20170210697A1-20170727-C00150.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0798]"> </para-num> <div id="p-0837" num="0798" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>85</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0799]"> </para-num> <div id="p-0838" num="0799" class="description-line">Molecular Weight: 696.155</div>
    </li> <li> <para-num num="[0800]"> </para-num> <div id="p-0839" num="0800" class="description-line">Compound 74 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.68 min. MS (ES): m/z (MH<sup>+</sup>) 696.9 for C<sub>43</sub>H<sub>85</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.56 (m, 2H); 2.70-2.41 (m, 6H); 2.30 (m, 4H), 1.80 (m, 2H); 1.70-1.40 (m, 12H); 1.28 (m, 44H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0110">XX4. Compound 75: Heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecan-3-yloxy)hexyl)amino)octanoate</heading>
    <li> <para-num num="[0801]"> </para-num> <div id="p-0840" num="0801" class="description-line">
      <chemistry id="CHEM-US-00151" num="00151">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/b0/b7/f3fa513f7b891d/US20170210697A1-20170727-C00151.png"><img id="EMI-C00151" he="23.11mm" wi="75.69mm" file="US20170210697A1-20170727-C00151.TIF" alt="Figure US20170210697A1-20170727-C00151" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="92" alt="Figure US20170210697A1-20170727-C00151" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/b0/b7/f3fa513f7b891d/US20170210697A1-20170727-C00151.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00151" attachment-type="cdx" file="US20170210697A1-20170727-C00151.CDX"> </attachment>
          <attachment idref="CHEM-US-00151" attachment-type="mol" file="US20170210697A1-20170727-C00151.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0802]"> </para-num> <div id="p-0841" num="0802" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0803]"> </para-num> <div id="p-0842" num="0803" class="description-line">Molecular Weight: 710.18</div>
    </li> <li> <para-num num="[0804]"> </para-num> <div id="p-0843" num="0804" class="description-line">Compound 75 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.67 min. MS (ES): m/z (MH<sup>+</sup>) 711.1 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (m, 2H); 3.57 (m, 2H); 2.72-2.40 (br. m, 5H); 2.30 (m, 4H); 1.70-1.42 (m, 16H); 1.28 (m, 45H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0111">XX5. Compound 79: Nonyl 8-((2-hydroxyethyl)(8-oxo-8-((4-pentylcyclohexyl)oxy)octyl)amino)octanoate</heading>
    <li> <para-num num="[0805]"> </para-num> <div id="p-0844" num="0805" class="description-line">
      <chemistry id="CHEM-US-00152" num="00152">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/5d/c1/33dfb6c9ef8a5c/US20170210697A1-20170727-C00152.png"><img id="EMI-C00152" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00152.TIF" alt="Figure US20170210697A1-20170727-C00152" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00152" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/5d/c1/33dfb6c9ef8a5c/US20170210697A1-20170727-C00152.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00152" attachment-type="cdx" file="US20170210697A1-20170727-C00152.CDX"> </attachment>
          <attachment idref="CHEM-US-00152" attachment-type="mol" file="US20170210697A1-20170727-C00152.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0806]"> </para-num> <div id="p-0845" num="0806" class="description-line">Chemical Formula: C<sub>38</sub>H<sub>73</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0807]"> </para-num> <div id="p-0846" num="0807" class="description-line">Molecular Weight: 624.00</div>
    </li> <li> <para-num num="[0808]"> </para-num> <div id="p-0847" num="0808" class="description-line">Compound 79 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.10 min. MS (ES): m/z (MH<sup>+</sup>) 624.8 for C<sub>38</sub>H<sub>73</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.00 (br. m, 0.5H); 4.68 (m, 0.5H); 4.08 (t, 2H); 3.56 (m, 2H); 2.72-2.38 (m, 6H); 2.31 (m, 4H), 1.97 (m, 1H); 1.82 (m, 2H); 1.73-0.95 (m, 48H), 0.90 (m, 6H).</div>
    </li> <heading id="h-0112">XX6. Compound 80: [1,1-Bi(cyclohexan)]-4-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0809]"> </para-num> <div id="p-0848" num="0809" class="description-line">
      <chemistry id="CHEM-US-00153" num="00153">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f5/e0/e8/bbe59a08a66e14/US20170210697A1-20170727-C00153.png"><img id="EMI-C00153" he="37.68mm" wi="105.49mm" file="US20170210697A1-20170727-C00153.TIF" alt="Figure US20170210697A1-20170727-C00153" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="151" alt="Figure US20170210697A1-20170727-C00153" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f5/e0/e8/bbe59a08a66e14/US20170210697A1-20170727-C00153.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00153" attachment-type="cdx" file="US20170210697A1-20170727-C00153.CDX"> </attachment>
          <attachment idref="CHEM-US-00153" attachment-type="mol" file="US20170210697A1-20170727-C00153.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0810]"> </para-num> <div id="p-0849" num="0810" class="description-line">Chemical Formula: C<sub>39</sub>H<sub>73</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0811]"> </para-num> <div id="p-0850" num="0811" class="description-line">Molecular Weight: 636.02</div>
    </li> <li> <para-num num="[0812]"> </para-num> <div id="p-0851" num="0812" class="description-line">Compound 80 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.10 min. MS (ES): m/z (MH<sup>+</sup>) 636.9 for C<sub>39</sub>H<sub>73</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.01 (br. m, 0.5H); 4.65 (m, 0.5H); 4.08 (t, 2H); 3.56 (m, 2H); 2.69-2.36 (m, 6H); 2.31 (m, 4H); 2.07-0.84 (m, 57H).</div>
    </li> <heading id="h-0113">XX7. Compound 81: Cyclopentadecyl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0813]"> </para-num> <div id="p-0852" num="0813" class="description-line">
      <chemistry id="CHEM-US-00154" num="00154">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2e/f3/9c/35a977ac90b8d0/US20170210697A1-20170727-C00154.png"><img id="EMI-C00154" he="37.08mm" wi="105.49mm" file="US20170210697A1-20170727-C00154.TIF" alt="Figure US20170210697A1-20170727-C00154" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="148" alt="Figure US20170210697A1-20170727-C00154" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2e/f3/9c/35a977ac90b8d0/US20170210697A1-20170727-C00154.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00154" attachment-type="cdx" file="US20170210697A1-20170727-C00154.CDX"> </attachment>
          <attachment idref="CHEM-US-00154" attachment-type="mol" file="US20170210697A1-20170727-C00154.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0814]"> </para-num> <div id="p-0853" num="0814" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>81</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0815]"> </para-num> <div id="p-0854" num="0815" class="description-line">Molecular Weight: 680.11</div>
    </li> <li> <para-num num="[0816]"> </para-num> <div id="p-0855" num="0816" class="description-line">Compound 81 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.36 min. MS (ES): m/z (MH<sup>+</sup>) 681.0 for C<sub>42</sub>H<sub>81</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (p, 1H); 4.08 (t, 2H); 3.57 (br. m, 2H); 2.74-2.39 (m, 6H); 2.30 (m, 4H), 1.73-1.03 (m, 62H), 0.90 (m, 3H).</div>
    </li> <heading id="h-0114">XX8. Compound 94: Heptadecan-9-yl) 8-(benzyl(8-nonyloxy)-8-oxooctyl)amino)octanoate Heptadecan-9-yl 8-(benylamino)octanoate</heading>
    <li> <para-num num="[0817]"> </para-num> <div id="p-0856" num="0817" class="description-line">
      <chemistry id="CHEM-US-00155" num="00155">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c2/96/1b/596e7c2170f1dc/US20170210697A1-20170727-C00155.png"><img id="EMI-C00155" he="12.36mm" wi="107.78mm" file="US20170210697A1-20170727-C00155.TIF" alt="Figure US20170210697A1-20170727-C00155" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="431" height="49" alt="Figure US20170210697A1-20170727-C00155" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c2/96/1b/596e7c2170f1dc/US20170210697A1-20170727-C00155.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00155" attachment-type="cdx" file="US20170210697A1-20170727-C00155.CDX"> </attachment>
          <attachment idref="CHEM-US-00155" attachment-type="mol" file="US20170210697A1-20170727-C00155.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0818]"> </para-num> <div id="p-0857" num="0818" class="description-line">Chemical Formula: C<sub>32</sub>H<sub>57</sub>NO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0819]"> </para-num> <div id="p-0858" num="0819" class="description-line">Molecular Weight: 487.81</div>
    </li> <li> <para-num num="[0820]"> </para-num> <div id="p-0859" num="0820" class="description-line">A solution of heptadecan-9-yl 8-bromooctanoate (250 mg, 0.542 mmol) in phenylmethanamine (1.2 mL, 10.83 mmol) was allowed to stir at rt for 6 h. The reaction was cooled to rt and solvents were evaporated in vacuo. The residue was taken-up in ethyl acetate and washed with saturated aqueous sodium bicarbonate. The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4 </sub>and evaporated in vacuo. The residue was purified by silica gel chromatography (20-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-(benzylamino)octanoate (200 mg, 0.41 mmol, 76%). UPLC/ELSD: RT=2.87 min. MS (ES): m/z (MH<sup>+</sup>) 488.4 for C<sub>32</sub>H<sub>57</sub>NO<sub>2</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.35-7.25 (br. m, 5H); 4.89 (p, 1H); 3.81 (s, 2H); 2.65 (t, 2H); 2.29 (t, 2H); 1.65-1.51 (br. m, 8H); 1.28 (m, 30H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0115">Heptadecan-9-yl 8-(benzyl(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0821]"> </para-num> <div id="p-0860" num="0821" class="description-line">
      <chemistry id="CHEM-US-00156" num="00156">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/98/e0/4f45b8d401cd92/US20170210697A1-20170727-C00156.png"><img id="EMI-C00156" he="27.18mm" wi="102.87mm" file="US20170210697A1-20170727-C00156.TIF" alt="Figure US20170210697A1-20170727-C00156" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="109" alt="Figure US20170210697A1-20170727-C00156" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f1/98/e0/4f45b8d401cd92/US20170210697A1-20170727-C00156.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00156" attachment-type="cdx" file="US20170210697A1-20170727-C00156.CDX"> </attachment>
          <attachment idref="CHEM-US-00156" attachment-type="mol" file="US20170210697A1-20170727-C00156.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0822]"> </para-num> <div id="p-0861" num="0822" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>89</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0823]"> </para-num> <div id="p-0862" num="0823" class="description-line">Molecular Weight: 756.25</div>
    </li> <li> <para-num num="[0824]"> </para-num> <div id="p-0863" num="0824" class="description-line">A solution of heptadecan-9-yl 8-(benylamino)octanoate (200 mg, 0.41 mmol), nonyl 8-bromooctanoate (172 mg, 0.49 mmol) and N,N-diisopropylethylamine (100 L, 0.57 mmol) were dissolved in ethanol and was allowed to stir at 62 C. for 48 h. The reaction was cooled to rt and solvents were evaporated in vacuo. The residue was taken-up in ethyl acetate and washed with saturated aqueous sodium bicarbonate. The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4 </sub>and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-(benzyl(8-(nonyloxy)-8-oxooctyl)amino)octanoate (138 mg, 0.18 mmol, 45%). UPLC/ELSD: RT=3.78 min. MS (ES): m/z (MH<sup>+</sup>) 757.0 for C<sub>49</sub>H<sub>89</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.33-7.23 (br. m, 5H); 4.89 (p, 1H); 4.08 (t, 2H); 3.55 (s, 2H); 2.40 (m, 4H); 2.30 (m, 4H); 1.64-1.28 (br. m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0116">X8. Compound 96: 7-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)heptyl decanoate</heading>
    <li> <para-num num="[0825]"> </para-num> <div id="p-0864" num="0825" class="description-line">
      <chemistry id="CHEM-US-00157" num="00157">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/f9/ef/c5ba54d4b73a95/US20170210697A1-20170727-C00157.png"><img id="EMI-C00157" he="21.59mm" wi="105.49mm" file="US20170210697A1-20170727-C00157.TIF" alt="Figure US20170210697A1-20170727-C00157" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="86" alt="Figure US20170210697A1-20170727-C00157" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/f9/ef/c5ba54d4b73a95/US20170210697A1-20170727-C00157.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00157" attachment-type="cdx" file="US20170210697A1-20170727-C00157.CDX"> </attachment>
          <attachment idref="CHEM-US-00157" attachment-type="mol" file="US20170210697A1-20170727-C00157.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0826]"> </para-num> <div id="p-0865" num="0826" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0827]"> </para-num> <div id="p-0866" num="0827" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[0828]"> </para-num> <div id="p-0867" num="0828" class="description-line">Compound 96 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=2.74 min. MS (ES): m/z (MH<sup>+</sup>) 711.0 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.61 (m, 2H); 2.88-2.37 (br. m, 6H); 2.31 (m, 4H), 1.79-1.04 (m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0117">X9. Compound 98: 8-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octan-2-yl decanoate</heading>
    <heading id="h-0118">Octane-1,7-diol</heading>
    <li> <para-num num="[0829]"> </para-num> <div id="p-0868" num="0829" class="description-line">
      <chemistry id="CHEM-US-00158" num="00158">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/48/ba/173e020f2a819f/US20170210697A1-20170727-C00158.png"><img id="EMI-C00158" he="10.24mm" wi="41.91mm" file="US20170210697A1-20170727-C00158.TIF" alt="Figure US20170210697A1-20170727-C00158" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="168" height="41" alt="Figure US20170210697A1-20170727-C00158" class="patent-full-image" src="https://patentimages.storage.googleapis.com/31/48/ba/173e020f2a819f/US20170210697A1-20170727-C00158.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00158" attachment-type="cdx" file="US20170210697A1-20170727-C00158.CDX"> </attachment>
          <attachment idref="CHEM-US-00158" attachment-type="mol" file="US20170210697A1-20170727-C00158.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0830]"> </para-num> <div id="p-0869" num="0830" class="description-line">Chemical Formula: C<sub>8</sub>H<sub>18</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[0831]"> </para-num> <div id="p-0870" num="0831" class="description-line">Molecular Weight: 146.230</div>
    </li> <li> <para-num num="[0832]"> </para-num> <div id="p-0871" num="0832" class="description-line">A solution of 7-oxooctanoic acid (4 g, 25.29 mmol) in THF (10 mL) was added to a stirred solution of LAH in THF (70 mL) under N2 at 0 C. The mixture was allowed to warm to rt and stir at rt for 4 h, after which <figure-callout id="10" label="time" filenames="US20170210697A1-20170727-D00010.png" state="{{state}}">time</figure-callout> 10 mL of sat. Na<sub>2</sub>SO<sub>4</sub>.10H<sub>2</sub>O (aq) was added to the solution slowly. White solid crashed out. Additional solid Na<sub>2</sub>SO<sub>4</sub>O. 10H<sub>2</sub>O was added and the mixture was filtered through a plug of celite. The filtrate was diluted with EtOAc and washed with brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain octane-1,7-diol (2.97 g, 20.31 mmol, 80%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.81 (m, 1H); 3.66 (t, 2H); 1.66-1.31 (m, 12H); 1.22 (d, 3H).</div>
    </li> <heading id="h-0119">8-((tert-Butyldiphenylsilyl)oxy)octan-2-ol</heading>
    <li> <para-num num="[0833]"> </para-num> <div id="p-0872" num="0833" class="description-line">
      <chemistry id="CHEM-US-00159" num="00159">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/3b/24/7e0b6b5a79eac6/US20170210697A1-20170727-C00159.png"><img id="EMI-C00159" he="17.10mm" wi="51.73mm" file="US20170210697A1-20170727-C00159.TIF" alt="Figure US20170210697A1-20170727-C00159" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="68" alt="Figure US20170210697A1-20170727-C00159" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/3b/24/7e0b6b5a79eac6/US20170210697A1-20170727-C00159.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00159" attachment-type="cdx" file="US20170210697A1-20170727-C00159.CDX"> </attachment>
          <attachment idref="CHEM-US-00159" attachment-type="mol" file="US20170210697A1-20170727-C00159.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0834]"> </para-num> <div id="p-0873" num="0834" class="description-line">Chemical Formula: C<sub>24</sub>H<sub>36</sub>O<sub>2</sub>Si</div>
    </li> <li> <para-num num="[0835]"> </para-num> <div id="p-0874" num="0835" class="description-line">Molecular Weight: 384.635</div>
    </li> <li> <para-num num="[0836]"> </para-num> <div id="p-0875" num="0836" class="description-line">To a solution of octane-1,7-diol (1 g, 6.84 mmol) in DCM (75 mL) at 0 C. imidazole (0.94 g, 13.81 mmol) was added followed by slow addition of a solution of tert-butyl(chloro)diphenylsilane (2.14 mL, 8.21 mmol) in DCM (using dropping funnel). The reaction allowed stir at 0 C. for 1.5 h. The reaction was quenched with saturated NH<sub>4</sub>HCl<sub>(aq)</sub>. The aqueous layer was extracted 3 times with a DCM (350 mL). The organic layer was dried over anhydrous MgSO<sub>4 </sub>and filtered, and the solvent was evaporated. The crude product was purified by flash silica gel column chromatography 0-10% EtOAc in hexanes to obtain 8-((tert-butyldiphenylsilyl)oxy)octan-2-ol (2.29 g, 5.95 mmol, 87%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.69 (m, 4H); 7.42 (m, 6H); 3.80 (m, 1H); 3.68 (t, 2H); 1.59 (m, 2H); 1.50-1.26 (m, 9H); 1.21 (d, 3H); 1.07 (s, 9H).</div>
    </li> <heading id="h-0120">8-((tert-Butyldiphenylsilyl)oxy)octan-2-yl decanoate</heading>
    <li> <para-num num="[0837]"> </para-num> <div id="p-0876" num="0837" class="description-line">
      <chemistry id="CHEM-US-00160" num="00160">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e3/f0/ad/54bc10daf04eb2/US20170210697A1-20170727-C00160.png"><img id="EMI-C00160" he="14.99mm" wi="102.87mm" file="US20170210697A1-20170727-C00160.TIF" alt="Figure US20170210697A1-20170727-C00160" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="60" alt="Figure US20170210697A1-20170727-C00160" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e3/f0/ad/54bc10daf04eb2/US20170210697A1-20170727-C00160.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00160" attachment-type="cdx" file="US20170210697A1-20170727-C00160.CDX"> </attachment>
          <attachment idref="CHEM-US-00160" attachment-type="mol" file="US20170210697A1-20170727-C00160.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0838]"> </para-num> <div id="p-0877" num="0838" class="description-line">Chemical Formula: C<sub>34</sub>H<sub>54</sub>O<sub>3</sub>Si</div>
    </li> <li> <para-num num="[0839]"> </para-num> <div id="p-0878" num="0839" class="description-line">Molecular Weight: 538.888</div>
    </li> <li> <para-num num="[0840]"> </para-num> <div id="p-0879" num="0840" class="description-line">8-((tert-Butyldiphenylsilyl)oxy)octan-2-yl decanoate was synthesized according to Method A. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.69 (m, 4H); 7.42 (m, 6H); 4.92 (m, 1H); 3.67 (t, 2H); 2.29 (t, 2H); 1.67-1.42 (m, 6H); 1.41-1.17 (m, 21H); 1.07 (s, 9H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0121">8-Hydroxyoctan-2-yl decanoate</heading>
    <li> <para-num num="[0841]"> </para-num> <div id="p-0880" num="0841" class="description-line">
      <chemistry id="CHEM-US-00161" num="00161">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/75/e3/744c14f38648d7/US20170210697A1-20170727-C00161.png"><img id="EMI-C00161" he="8.13mm" wi="68.75mm" file="US20170210697A1-20170727-C00161.TIF" alt="Figure US20170210697A1-20170727-C00161" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="275" height="33" alt="Figure US20170210697A1-20170727-C00161" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/75/e3/744c14f38648d7/US20170210697A1-20170727-C00161.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00161" attachment-type="cdx" file="US20170210697A1-20170727-C00161.CDX"> </attachment>
          <attachment idref="CHEM-US-00161" attachment-type="mol" file="US20170210697A1-20170727-C00161.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0842]"> </para-num> <div id="p-0881" num="0842" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>36</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[0843]"> </para-num> <div id="p-0882" num="0843" class="description-line">Molecular Weight: 300.483</div>
    </li> <li> <para-num num="[0844]"> </para-num> <div id="p-0883" num="0844" class="description-line">To a solution of 8-[(tert-butyldiphenylsilyl)oxy]octan-2-yl decanoate (1.08 g, 2 mmol) in THF was added TBAF (8.02 mL 1 M solution in THF, 8.02 mmol) and the mixture was allowed to stir at rt for 3 h. The organic solvents were evaporated under vacuum. The residue was diluted with EtOAc and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain 8-hydroxyoctan-2-yl decanoate (0.55 g, 1.82 mmol, 91%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 1H); 3.66 (t, 2H); 2.29 (t, 2H); 1.72-1.17 (m, 28H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0122">8-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octan-2-yl decanoate</heading>
    <li> <para-num num="[0845]"> </para-num> <div id="p-0884" num="0845" class="description-line">
      <chemistry id="CHEM-US-00162" num="00162">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/a1/10/aaad2ae07c89f3/US20170210697A1-20170727-C00162.png"><img id="EMI-C00162" he="26.42mm" wi="105.49mm" file="US20170210697A1-20170727-C00162.TIF" alt="Figure US20170210697A1-20170727-C00162" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="106" alt="Figure US20170210697A1-20170727-C00162" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/a1/10/aaad2ae07c89f3/US20170210697A1-20170727-C00162.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00162" attachment-type="cdx" file="US20170210697A1-20170727-C00162.CDX"> </attachment>
          <attachment idref="CHEM-US-00162" attachment-type="mol" file="US20170210697A1-20170727-C00162.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0846]"> </para-num> <div id="p-0885" num="0846" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0847]"> </para-num> <div id="p-0886" num="0847" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[0848]"> </para-num> <div id="p-0887" num="0848" class="description-line">Compound 98 was synthesized according to the general procedure and <figure-callout id="1" label="Representative Procedure" filenames="US20170210697A1-20170727-D00001.png,US20170210697A1-20170727-D00002.png" state="{{state}}">Representative Procedure</figure-callout> 1 described above. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 2H); 3.58 (br. m, 2H); 2.77-2.40 (m, 6H); 2.29 (m, 4H); 1.72-1.41 (m, 14H); 1.28 (m, 51H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0123">X10. Compound 101: Heptadecan-9-yl 8-((2-(4-methylpiperazin-1-yl)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate Heptadecan-9-yl 8-((2-chloroethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0849]"> </para-num> <div id="p-0888" num="0849" class="description-line">
      <chemistry id="CHEM-US-00163" num="00163">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/64/57/19/2f280a6f69c6f0/US20170210697A1-20170727-C00163.png"><img id="EMI-C00163" he="29.21mm" wi="104.82mm" file="US20170210697A1-20170727-C00163.TIF" alt="Figure US20170210697A1-20170727-C00163" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="419" height="117" alt="Figure US20170210697A1-20170727-C00163" class="patent-full-image" src="https://patentimages.storage.googleapis.com/64/57/19/2f280a6f69c6f0/US20170210697A1-20170727-C00163.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00163" attachment-type="cdx" file="US20170210697A1-20170727-C00163.CDX"> </attachment>
          <attachment idref="CHEM-US-00163" attachment-type="mol" file="US20170210697A1-20170727-C00163.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0850]"> </para-num> <div id="p-0889" num="0850" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>86</sub>ClNO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0851]"> </para-num> <div id="p-0890" num="0851" class="description-line">Molecular Weight: 728.63</div>
    </li> <li> <para-num num="[0852]"> </para-num> <div id="p-0891" num="0852" class="description-line">A solution of heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (1100 mg, 1.55 mmol) in dichloromethane (25 mL) at 0 C. was added N-Chlorosuccinimide in one portion. The reaction was allowed to stir at 0 C. for 1 h followed by 1 h at room temperature. Added 90 mL of hexanes and allowed the reaction to stir at room temperature for 20 min. Filtered off white solid through a silica gel plug and washed three times with hexanes. Organic layers were concentrated in vacuo. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.57 (m, 2H); 2.85 (m, 2H); 2.54 (m, 4H); 2.33-2.27 (m, 4H); 1.66-1.28 (br. m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0124">Heptadecan-9-yl 8-((2-(4-methylpiperazin-1-yl)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0853]"> </para-num> <div id="p-0892" num="0853" class="description-line">
      <chemistry id="CHEM-US-00164" num="00164">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e1/9a/2f/874c218d79baf3/US20170210697A1-20170727-C00164.png"><img id="EMI-C00164" he="36.91mm" wi="117.52mm" file="US20170210697A1-20170727-C00164.TIF" alt="Figure US20170210697A1-20170727-C00164" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="470" height="148" alt="Figure US20170210697A1-20170727-C00164" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e1/9a/2f/874c218d79baf3/US20170210697A1-20170727-C00164.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00164" attachment-type="cdx" file="US20170210697A1-20170727-C00164.CDX"> </attachment>
          <attachment idref="CHEM-US-00164" attachment-type="mol" file="US20170210697A1-20170727-C00164.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0854]"> </para-num> <div id="p-0893" num="0854" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>97</sub>N<sub>3</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0855]"> </para-num> <div id="p-0894" num="0855" class="description-line">Molecular Weight: 792.33</div>
    </li> <li> <para-num num="[0856]"> </para-num> <div id="p-0895" num="0856" class="description-line">A solution of 1-methylpiperazine (15 mg, 0.151 mmol), heptadecan-9-yl 8-((2-chloroethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (110 mg, 0.151 mmol), K2CO<sub>3 </sub>(42 mg, 0.302 mmol) and KI (3 mg, 0.0151 mmol) were dissolved in 1:1 THF:MeCN (1 mL:1 mL). The reaction was allowed to stir at 65 C. for 18 hours. The reaction was cooled to room temperature, filtered and washed with hexanes and EtOAc. The organic filtrate was transferred to separatory funnel and washed with water and brine. Dried organic layers over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography [0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane] to obtain heptadecan-9-yl 8-((2-(4-methylpiperazin-1-yl)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (36 mg, 0.045 mmol, 30%). UPLC/ELSD: RT=3.25 min. MS (ES): m/z (MH<sup>+</sup>) 792.8 for C<sub>49</sub>H<sub>97</sub>N<sub>3</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (p, 1H); 4.08 (t, 2H); 2.57-2.45 (br. m, 20H); 2.31 (m, 3H); 1.64-1.28 (br. m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0125">X11. Compound 103: Heptadecan-9-yl 8-((2-(4-methylpiperazin-1-yl)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate Heptadecan-9-yl 8-((2-chloroethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0857]"> </para-num> <div id="p-0896" num="0857" class="description-line">
      <chemistry id="CHEM-US-00165" num="00165">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/7f/0e/efcb535838beb4/US20170210697A1-20170727-C00165.png"><img id="EMI-C00165" he="29.29mm" wi="104.82mm" file="US20170210697A1-20170727-C00165.TIF" alt="Figure US20170210697A1-20170727-C00165" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="419" height="117" alt="Figure US20170210697A1-20170727-C00165" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9b/7f/0e/efcb535838beb4/US20170210697A1-20170727-C00165.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00165" attachment-type="cdx" file="US20170210697A1-20170727-C00165.CDX"> </attachment>
          <attachment idref="CHEM-US-00165" attachment-type="mol" file="US20170210697A1-20170727-C00165.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0858]"> </para-num> <div id="p-0897" num="0858" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>86</sub>ClNO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0859]"> </para-num> <div id="p-0898" num="0859" class="description-line">Molecular Weight: 728.63</div>
    </li> <li> <para-num num="[0860]"> </para-num> <div id="p-0899" num="0860" class="description-line">To a stirred solution of heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (1100 mg, 1.55 mmol) in dichloromethane (25 mL) at 0 C. was added N-Chlorosuccinimide in one portion. The reaction was allowed to stir at 0 C. for 1 h followed by 1 h at room temperature. Added 90 mL of hexanes and allowed the reaction to stir at room temperature for 20 min. Filtered off white solid through a silica gel plug and washed three times with hexanes. Organic layers were concentrated in vacuo. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 3.57 (m, 2H); 2.85 (m, 2H); 2.54 (m, 4H); 2.33-2.27 (m, 4H); 1.66-1.28 (br. m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0126">Heptadecan-9-yl 8-((2-morpholinoethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0861]"> </para-num> <div id="p-0900" num="0861" class="description-line">
      <chemistry id="CHEM-US-00166" num="00166">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/63/b4/ea337cbdf153a6/US20170210697A1-20170727-C00166.png"><img id="EMI-C00166" he="36.91mm" wi="113.45mm" file="US20170210697A1-20170727-C00166.TIF" alt="Figure US20170210697A1-20170727-C00166" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="454" height="148" alt="Figure US20170210697A1-20170727-C00166" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/63/b4/ea337cbdf153a6/US20170210697A1-20170727-C00166.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00166" attachment-type="cdx" file="US20170210697A1-20170727-C00166.CDX"> </attachment>
          <attachment idref="CHEM-US-00166" attachment-type="mol" file="US20170210697A1-20170727-C00166.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0862]"> </para-num> <div id="p-0901" num="0862" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>94</sub>N<sub>2</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0863]"> </para-num> <div id="p-0902" num="0863" class="description-line">Molecular Weight: 779.29</div>
    </li> <li> <para-num num="[0864]"> </para-num> <div id="p-0903" num="0864" class="description-line">A solution of morpholine (13 mg, 0.151 mmol), heptadecan-9-yl 8-((2-chloroethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (110 mg, 0.151 mmol), K2CO<sub>3 </sub>(42 mg, 0.302 mmol) and KI (3 mg, 0.0151 mmol) were dissolved in 1:1 THF:MeCN (1 mL:1 mL). The reaction was allowed to stir at 65 C. for 18 hours. The reaction was cooled to room temperature, filtered and washed with hexanes and EtOAc. The organic filtrate was transferred to separatory funnel and washed with water and brine. Dried organic layers over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography [0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane] to obtain heptadecan-9-yl 8-((2-(4-methylpiperazin-1-yl)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (58 mg, 0.074 mmol, 49%). UPLC/ELSD: RT=3.53 min. MS (ES): m/z (MH<sup>+</sup>) 779.8 for C<sub>48</sub>H<sub>94</sub>N<sub>2</sub>O<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H); 4.05 (t, 2H); 3.70 (m, 4H); 2.59-2.54 (m, 2H); 2.48-2.38 (m, 10H); 2.31-2.25 (m, 4H); 1.64-1.26 (br. m, 62H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0127">XX9. Compound 108: Heptadecan-9-yl 8-((3-acetamidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0865]"> </para-num> <div id="p-0904" num="0865" class="description-line">
      <chemistry id="CHEM-US-00167" num="00167">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8b/94/7c/f084d02301470d/US20170210697A1-20170727-C00167.png"><img id="EMI-C00167" he="34.88mm" wi="117.52mm" file="US20170210697A1-20170727-C00167.TIF" alt="Figure US20170210697A1-20170727-C00167" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="470" height="140" alt="Figure US20170210697A1-20170727-C00167" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8b/94/7c/f084d02301470d/US20170210697A1-20170727-C00167.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00167" attachment-type="cdx" file="US20170210697A1-20170727-C00167.CDX"> </attachment>
          <attachment idref="CHEM-US-00167" attachment-type="mol" file="US20170210697A1-20170727-C00167.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0866]"> </para-num> <div id="p-0905" num="0866" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0867]"> </para-num> <div id="p-0906" num="0867" class="description-line">Molecular Weight: 765.26</div>
    </li> <li> <para-num num="[0868]"> </para-num> <div id="p-0907" num="0868" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol) and triethylamine (0.15 mL, 1.10 mmol) in 10 mL dichloromethane was added dropwise at 0 C. acetyl chloride (47 L, 0.66 mmol), and the reaction mixture was allowed to warm to room temperature for 16 h. MS showed the product, and the mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to provide the product as a colorless oil (300 mg, 71%). LC/UV (202 nm): RT=9.14 min. MS (APCI): m/z (MH<sup>+</sup>) 765.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.41 (bs, 1H); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.40-3.25 (m, 2H); 2.53-2.23 (m, 10H); 1.91 (s, 3H); 1.65-1.16 (m, 64H); 0.86 (m, 9H).</div>
    </li> <heading id="h-0128">XX10. Compound 109: Heptadecan-9-yl 8-((3-(methylsulfonamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0869]"> </para-num> <div id="p-0908" num="0869" class="description-line">
      <chemistry id="CHEM-US-00168" num="00168">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/e1/ef/7085276e8e5621/US20170210697A1-20170727-C00168.png"><img id="EMI-C00168" he="34.12mm" wi="117.52mm" file="US20170210697A1-20170727-C00168.TIF" alt="Figure US20170210697A1-20170727-C00168" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="470" height="136" alt="Figure US20170210697A1-20170727-C00168" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/e1/ef/7085276e8e5621/US20170210697A1-20170727-C00168.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00168" attachment-type="cdx" file="US20170210697A1-20170727-C00168.CDX"> </attachment>
          <attachment idref="CHEM-US-00168" attachment-type="mol" file="US20170210697A1-20170727-C00168.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0870]"> </para-num> <div id="p-0909" num="0870" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6</sub>S</div>
    </li> <li> <para-num num="[0871]"> </para-num> <div id="p-0910" num="0871" class="description-line">Molecular Weight: 801.31</div>
    </li> <li> <para-num num="[0872]"> </para-num> <div id="p-0911" num="0872" class="description-line">Methanesulfonyl chloride (51 L, 0.66 mmol) was added dropwise to a 0 C. solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol) and triethylamine (0.15 mL, 1.10 mmol) in 10 mL dichloromethane, and the reaction mixture was allowed to warm to room temperature for 16 h. MS showed the product, and the mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After drying over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to provide the product as a colorless oil (296 mg, 88%). LC/UV (214 nm): RT=11.51 min. MS (APCI): m/z (MH<sup>+</sup>) 801.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.22 (t, 2H, J=5.8 Hz); 2.88 (s, 3H); 2.53-2.23 (m, 10H); 1.73-1.16 (m, 64H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0129">XX11. Compound 110: Heptadecan-9-yl 8-((3-(3,3-dimethylureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0873]"> </para-num> <div id="p-0912" num="0873" class="description-line">
      <chemistry id="CHEM-US-00169" num="00169">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d7/62/06/a8b7ab9efb9473/US20170210697A1-20170727-C00169.png"><img id="EMI-C00169" he="34.88mm" wi="122.43mm" file="US20170210697A1-20170727-C00169.TIF" alt="Figure US20170210697A1-20170727-C00169" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="140" alt="Figure US20170210697A1-20170727-C00169" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d7/62/06/a8b7ab9efb9473/US20170210697A1-20170727-C00169.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00169" attachment-type="cdx" file="US20170210697A1-20170727-C00169.CDX"> </attachment>
          <attachment idref="CHEM-US-00169" attachment-type="mol" file="US20170210697A1-20170727-C00169.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0874]"> </para-num> <div id="p-0913" num="0874" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>95</sub>N<sub>3</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0875]"> </para-num> <div id="p-0914" num="0875" class="description-line">Molecular Weight: 794.30</div>
    </li> <li> <para-num num="[0876]"> </para-num> <div id="p-0915" num="0876" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol), dimethylaminopyridine (7 mg, 0.0553 mmol) and triethylamine (0.15 mL, 1.10 mmol) in 10 mL dichloromethane, dimethylcarbamic chloride (56 L, 0.61 mmol) was added dropwise at 0 C., and the reaction mixture was allowed to stir at room temperature for 16 h. MS showed the product. The mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a colorless oil (267 mg, 60%). LC/UV (202 nm): RT=9.81 min. MS (APCI): m/z (MH<sup>+</sup>) 794.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 6.13 (t, 1H, J=4.5 Hz); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.32-3.26 (m, 2H); 2.85 (s, 6H); 2.52-2.23 (m, 10H); 1.67-1.18 (m, 64H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0130">XX12. Compound 111: Heptadecan-9-yl 8-((3-(3,3-dimethylthioureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0877]"> </para-num> <div id="p-0916" num="0877" class="description-line">
      <chemistry id="CHEM-US-00170" num="00170">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/7c/8c/4b6315e4e2a80f/US20170210697A1-20170727-C00170.png"><img id="EMI-C00170" he="34.88mm" wi="122.43mm" file="US20170210697A1-20170727-C00170.TIF" alt="Figure US20170210697A1-20170727-C00170" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="140" alt="Figure US20170210697A1-20170727-C00170" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/7c/8c/4b6315e4e2a80f/US20170210697A1-20170727-C00170.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00170" attachment-type="cdx" file="US20170210697A1-20170727-C00170.CDX"> </attachment>
          <attachment idref="CHEM-US-00170" attachment-type="mol" file="US20170210697A1-20170727-C00170.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0878]"> </para-num> <div id="p-0917" num="0878" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>95</sub>N<sub>3</sub>O<sub>4</sub>S</div>
    </li> <li> <para-num num="[0879]"> </para-num> <div id="p-0918" num="0879" class="description-line">Molecular Weight: 810.37</div>
    </li> <li> <para-num num="[0880]"> </para-num> <div id="p-0919" num="0880" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol) and triethylamine (0.15 mL, 1.10 mmol) in 10 mL dichloromethane was added dropwise at 0 C. thiophosgene (51 L, 0.664 mmol), and the reaction mixture was allowed to stir at room temperature for 6 h. After this time, the reaction was cooled to 0 C., and a solution of dimethylamine in THF (2.0 M, 0.55 mL, 1.10 mmol) was added. The reaction was then allowed to stir at room temperature for 16 h. MS showed the product, and the mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After drying over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a brown oil (346 mg, 77%). LC/UV (202 nm): RT=9.89 min. MS (APCI): m/z (MH<sup>+</sup>) 810.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 8.12 (bs, 1H); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.74-3.64 (m, 2H); 3.20 (s, 6H); 2.62-2.23 (m, 10H); 1.77-1.17 (m, 64H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0131">XX13. Compound 112: Heptadecan-9-yl 8-((3-(3-methylureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0881]"> </para-num> <div id="p-0920" num="0881" class="description-line">
      <chemistry id="CHEM-US-00171" num="00171">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cd/56/32/2ed3d8f1bc23dc/US20170210697A1-20170727-C00171.png"><img id="EMI-C00171" he="34.88mm" wi="122.43mm" file="US20170210697A1-20170727-C00171.TIF" alt="Figure US20170210697A1-20170727-C00171" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="140" alt="Figure US20170210697A1-20170727-C00171" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cd/56/32/2ed3d8f1bc23dc/US20170210697A1-20170727-C00171.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00171" attachment-type="cdx" file="US20170210697A1-20170727-C00171.CDX"> </attachment>
          <attachment idref="CHEM-US-00171" attachment-type="mol" file="US20170210697A1-20170727-C00171.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0882]"> </para-num> <div id="p-0921" num="0882" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>93</sub>N<sub>3</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0883]"> </para-num> <div id="p-0922" num="0883" class="description-line">Molecular Weight: 780.28</div>
    </li> <li> <para-num num="[0884]"> </para-num> <div id="p-0923" num="0884" class="description-line">To a 0 C. solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol) in 10 mL dichloromethane was methyl isocyanate (38 mg, 0.664 mmol), and the reaction mixture was allowed to stir at room temperature for 16 h. MS showed the product. The mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a colorless oil (320 mg, 70%). LC/UV (202 nm): RT=9.63 min. MS (APCI): m/z (MH<sup>+</sup>) 780.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.54 (bs, 1H); 4.85 (p, 1H, J=6.0 Hz); 4.76 (bs, 1H); 4.04 (t, 2H, J=6.6 Hz); 3.23 (t, 2H, J=5.8 Hz); 2.74 (d, 3H, J=2.0 Hz); 2.47 (t, 2H, J=6.0 Hz); 2.37 (t, 4H, J=7.4 Hz); 2.31-2.23 (m, 4H); 1.68-1.17 (m, 64H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0132">XX14. Compound 113: Heptadecan-9-yl 8-((3-(3-methylthioureido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0885]"> </para-num> <div id="p-0924" num="0885" class="description-line">
      <chemistry id="CHEM-US-00172" num="00172">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/20/38/6148b3f9026ea0/US20170210697A1-20170727-C00172.png"><img id="EMI-C00172" he="34.88mm" wi="122.43mm" file="US20170210697A1-20170727-C00172.TIF" alt="Figure US20170210697A1-20170727-C00172" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="140" alt="Figure US20170210697A1-20170727-C00172" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/20/38/6148b3f9026ea0/US20170210697A1-20170727-C00172.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00172" attachment-type="cdx" file="US20170210697A1-20170727-C00172.CDX"> </attachment>
          <attachment idref="CHEM-US-00172" attachment-type="mol" file="US20170210697A1-20170727-C00172.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0886]"> </para-num> <div id="p-0925" num="0886" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>93</sub>N<sub>3</sub>O<sub>4</sub>S</div>
    </li> <li> <para-num num="[0887]"> </para-num> <div id="p-0926" num="0887" class="description-line">Molecular Weight: 795.69</div>
    </li> <li> <para-num num="[0888]"> </para-num> <div id="p-0927" num="0888" class="description-line">To a 0 C. solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (400 mg, 0.553 mmol) in 10 mL dichloromethane was added methyl isothiocyanate (45 L, 0.664 mmol), and the reaction mixture was allowed to stir at room temperature for 16 h. MS showed the product. The mixture was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a colorless oil (312 mg, 70%). LC/UV (202 nm): RT=9.96 min. MS (APCI): m/z (MH<sup>+</sup>) 796.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.51 (bs, 2H); 2.93 (bs, 3H); 2.52 (t, 2H, J=6.0 Hz); 2.41 (t, 4H, J=7.8 Hz); 2.31-2.23 (m, 4H); 1.68-1.17 (m, 66H); 0.86 (m, 9H).</div>
    </li> <heading id="h-0133">XX15. Compound 114: Heptadecan-9-yl 8-((3-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0889]"> </para-num> <div id="p-0928" num="0889" class="description-line">
      <chemistry id="CHEM-US-00173" num="00173">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/7e/59/fefeb3b739a8b8/US20170210697A1-20170727-C00173.png"><img id="EMI-C00173" he="34.97mm" wi="123.27mm" file="US20170210697A1-20170727-C00173.TIF" alt="Figure US20170210697A1-20170727-C00173" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="493" height="140" alt="Figure US20170210697A1-20170727-C00173" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/7e/59/fefeb3b739a8b8/US20170210697A1-20170727-C00173.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00173" attachment-type="cdx" file="US20170210697A1-20170727-C00173.CDX"> </attachment>
          <attachment idref="CHEM-US-00173" attachment-type="mol" file="US20170210697A1-20170727-C00173.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0890]"> </para-num> <div id="p-0929" num="0890" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>91</sub>N<sub>3</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[0891]"> </para-num> <div id="p-0930" num="0891" class="description-line">Molecular Weight: 818.28</div>
    </li> <li> <para-num num="[0892]"> </para-num> <div id="p-0931" num="0892" class="description-line">A mixture of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (500 mg, 0.67 mmol), uracil (300 mg, 2.67 mmol) and 1,8-diazabicycloundec-7-ene (150 L, 1.07 mmol) in 3 mL DMF was heated at 100 C. in a sealed tube for 16 h. The reaction mixture was concentrated to dryness and partitioned between dichloromethane and water. The organic layer was washed with brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a yellow oil (268 mg, 49%). LC/UV (202 nm): RT=8.91 min. MS (APCI): m/z (MH<sup>+</sup>) 818.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 8.19 (bs, 1H); 7.24 (d, 1H, J=7.7 Hz); 5.64 (d, 1H, J=7.7 Hz); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.76 (t, 2H, J=7.0 Hz); 2.45-2.24 (m, 10H); 1.81 (p, 2H, J=6.6 Hz); 1.68-1.17 (m, 62H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0134">XX16. Compound 115: Heptadecan-9-yl 8-((3-(4-amino-2-oxopyrimidin-1(2H)-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0893]"> </para-num> <div id="p-0932" num="0893" class="description-line">
      <chemistry id="CHEM-US-00174" num="00174">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/d5/62/76fa72f9ad5da6/US20170210697A1-20170727-C00174.png"><img id="EMI-C00174" he="34.88mm" wi="125.90mm" file="US20170210697A1-20170727-C00174.TIF" alt="Figure US20170210697A1-20170727-C00174" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="504" height="140" alt="Figure US20170210697A1-20170727-C00174" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/d5/62/76fa72f9ad5da6/US20170210697A1-20170727-C00174.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00174" attachment-type="cdx" file="US20170210697A1-20170727-C00174.CDX"> </attachment>
          <attachment idref="CHEM-US-00174" attachment-type="mol" file="US20170210697A1-20170727-C00174.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0894]"> </para-num> <div id="p-0933" num="0894" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>92</sub>N<sub>4</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[0895]"> </para-num> <div id="p-0934" num="0895" class="description-line">Molecular Weight: 817.30</div>
    </li> <li> <para-num num="[0896]"> </para-num> <div id="p-0935" num="0896" class="description-line">To a suspension of cytosine (82 mg, 0.74 mmol) in 1 mL DMF was added NaH (30 mg, 0.74 mmol) and the reaction mixture was stirred at room temperature for 30 min. A solution of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (500 mg, 0.67 mmol) in 2 mL DMF was then added and the mixture was heated at 100 C. in a sealed tube for 16 h. MS showed product. The reaction was quenched with saturated sodium bicarbonate and extracted with hexanes (2). The combined organic layer was washed with water and brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a yellow oil (310 mg, 56%). LC/UV (202 nm): RT=8.32 min. MS (APCI): m/z (MH<sup>+</sup>) 817.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.34 (d, 1H, J=7.1 Hz); 5.61 (d, 1H, J=7.1 Hz); 5.44 (bs, 2H); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 3.79 (t, 2H, J=7.0 Hz); 2.42-2.22 (m, 9H); 1.84 (t, 2H, J=6.6 Hz); 1.68-1.17 (m, 63H); 0.86 (m, 9H).</div>
    </li> <heading id="h-0135">XX17. Compound 116: Heptadecan-9-yl 8-((3-(6-amino-9H-purin-9-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0897]"> </para-num> <div id="p-0936" num="0897" class="description-line">
      <chemistry id="CHEM-US-00175" num="00175">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/e6/78/f2e0f14e042479/US20170210697A1-20170727-C00175.png"><img id="EMI-C00175" he="33.36mm" wi="128.44mm" file="US20170210697A1-20170727-C00175.TIF" alt="Figure US20170210697A1-20170727-C00175" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="514" height="133" alt="Figure US20170210697A1-20170727-C00175" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/e6/78/f2e0f14e042479/US20170210697A1-20170727-C00175.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00175" attachment-type="cdx" file="US20170210697A1-20170727-C00175.CDX"> </attachment>
          <attachment idref="CHEM-US-00175" attachment-type="mol" file="US20170210697A1-20170727-C00175.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0898]"> </para-num> <div id="p-0937" num="0898" class="description-line">Chemical Formula: C<sub>50</sub>H<sub>92</sub>N<sub>6</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0899]"> </para-num> <div id="p-0938" num="0899" class="description-line">Molecular Weight: 841.32</div>
    </li> <li> <para-num num="[0900]"> </para-num> <div id="p-0939" num="0900" class="description-line">A mixture of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (500 mg, 0.67 mmol), adenine (135 mg, 1.0 mmol) and 1,8-diazabicycloundec-7-ene (137 L, 1.0 mmol) in 2 mL DMF was heated at 90 C. in a sealed tube for 16 h. The reaction mixture was concentrated to dryness and partitioned between dichloromethane and water. The organic layer was washed with brine. After it was dried over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to afford the product as a yellow oil (325 mg, 57%). LC/UV (202 nm): RT=8.47 min. MS (APCI): m/z (MH<sup>+</sup>) 841.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 8.36 (s, 1H); 7.80 (s, 1H); 5.51 (bs, 2H); 4.85 (p, 1H, J=6.0 Hz); 4.24 (t, 2H, J=7.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 2.45-2.24 (m, 10H); 2.01 (p, 2H, J=6.9 Hz); 1.68-1.17 (m, 62H); 0.86 (m, 9H).</div>
    </li> <heading id="h-0136">XX18. Compound 118: 3,4-Dipentylphenyl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0137">5-Methoxy-2-(pent-1-yn-1-yl)benzaldehyde (see e.g., <i>Bioorg. Med. Chem. Lett. </i>2013, 23, 1365)</heading>
    <li> <para-num num="[0901]"> </para-num> <div id="p-0940" num="0901" class="description-line">
      <chemistry id="CHEM-US-00176" num="00176">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/22/f6/e8/6038ce4356076a/US20170210697A1-20170727-C00176.png"><img id="EMI-C00176" he="17.95mm" wi="43.35mm" file="US20170210697A1-20170727-C00176.TIF" alt="Figure US20170210697A1-20170727-C00176" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="173" height="72" alt="Figure US20170210697A1-20170727-C00176" class="patent-full-image" src="https://patentimages.storage.googleapis.com/22/f6/e8/6038ce4356076a/US20170210697A1-20170727-C00176.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00176" attachment-type="cdx" file="US20170210697A1-20170727-C00176.CDX"> </attachment>
          <attachment idref="CHEM-US-00176" attachment-type="mol" file="US20170210697A1-20170727-C00176.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0902]"> </para-num> <div id="p-0941" num="0902" class="description-line">Chemical Formula: C<sub>13</sub>H<sub>1402 </sub> </div>
    </li> <li> <para-num num="[0903]"> </para-num> <div id="p-0942" num="0903" class="description-line">Molecular Weight: 202.25</div>
    </li> <li> <para-num num="[0904]"> </para-num> <div id="p-0943" num="0904" class="description-line">A mixture of 2-bromo-5-methoxybenzaldehyde (4.30 g, 20 mmol), 1-pentyne (3.0 mL, 30 mmol), bis(triphenylphosphino)palladium chloride (702 mg, 1 mmol), CuI (380 mg, 2.0 mmol) and triethylamine (5.6 mL, 40 mmol) in 60 mL THF was heated to 50 C. for 16 h under nitrogen. TLC showed the disappearance of starting material. The reaction mixture was concentrated to dryness. The residue was dissolved in dichloromethane and washed with water and brine. After drying over sodium sulfate, the filtrate was concentrated and the residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 5%) to afford the product as a dark brown oil (3.00 g, 74%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 10.49 (s, 1H); 7.42 (d, 1H, J=8.5 Hz); 7.36 (d, 1H, J=2.8 Hz); 7.07 (dd, 1H, J=8.5 Hz, 2.8 Hz); 3.84 (s, 3H); 2.44 (t, 2H, J=7.0 Hz); 1.62 (m, 2H); 1.05 (t, 3H, J=7.2 Hz).</div>
    </li> <heading id="h-0138">4-Methoxy-2-(pent-1-en-1-yl)-1-(pent-1-yn-1-yl)benzene</heading>
    <li> <para-num num="[0905]"> </para-num> <div id="p-0944" num="0905" class="description-line">
      <chemistry id="CHEM-US-00177" num="00177">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/10/68/86/22931026856dff/US20170210697A1-20170727-C00177.png"><img id="EMI-C00177" he="17.95mm" wi="43.35mm" file="US20170210697A1-20170727-C00177.TIF" alt="Figure US20170210697A1-20170727-C00177" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="173" height="72" alt="Figure US20170210697A1-20170727-C00177" class="patent-full-image" src="https://patentimages.storage.googleapis.com/10/68/86/22931026856dff/US20170210697A1-20170727-C00177.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00177" attachment-type="cdx" file="US20170210697A1-20170727-C00177.CDX"> </attachment>
          <attachment idref="CHEM-US-00177" attachment-type="mol" file="US20170210697A1-20170727-C00177.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0906]"> </para-num> <div id="p-0945" num="0906" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>22</sub>O</div>
    </li> <li> <para-num num="[0907]"> </para-num> <div id="p-0946" num="0907" class="description-line">Molecular Weight: 242.36</div>
    </li> <li> <para-num num="[0908]"> </para-num> <div id="p-0947" num="0908" class="description-line">To a suspension of butyl triphenylphosphonium bromide (8.88 g, 22.2 mmol) in 75 mL THF was added at 0 C. potassium tert-butoxide (2.50 g, 22.2 mmol). After 30 min, a solution of 5-methoxy-2-(pent-1-yn-1-yl)benzaldehyde (3.00 g, 14.8 mmol) in 25 mL THF was then added slowly into the orange suspension. The reaction mixture was allowed to warm up to room temperature and stir for 60 h. Saturated ammonium chloride solution was added and the mixture was extracted with ether (2), and the combined organic layer was washed with brine. After drying over sodium sulfate, the filtrate was concentrated and the residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 5%) to afford the product as a brown oil (3.46 g, 96%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.33 (d, 0.5H, J=8.5 Hz); 7.26 (d, 0.5H, J=8.5 Hz); 6.99 (d, 0.5H, J=2.8 Hz); 6.88-6.80 (m, 1H); 6.73-6.61 (m, 1.5H); 6.25 (dt, 0.5H, J=15.9 Hz, 6.9 Hz); 5.73 (dt, 0.5H, J=11.5 Hz, 7.4 Hz); 3.80 (s, 3H); 2.45-2.37 (m, 2H); 2.31-2.18 (m, 2H); 1.71-1.41 (m, 4H); 1.09-0.90 (m, 6H).</div>
    </li> <heading id="h-0139">4-Methoxy-1,2-dipentylbenzene</heading>
    <li> <para-num num="[0909]"> </para-num> <div id="p-0948" num="0909" class="description-line">
      <chemistry id="CHEM-US-00178" num="00178">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b0/bb/f7/bbdfb55cc43ba9/US20170210697A1-20170727-C00178.png"><img id="EMI-C00178" he="12.36mm" wi="43.35mm" file="US20170210697A1-20170727-C00178.TIF" alt="Figure US20170210697A1-20170727-C00178" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="173" height="49" alt="Figure US20170210697A1-20170727-C00178" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b0/bb/f7/bbdfb55cc43ba9/US20170210697A1-20170727-C00178.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00178" attachment-type="cdx" file="US20170210697A1-20170727-C00178.CDX"> </attachment>
          <attachment idref="CHEM-US-00178" attachment-type="mol" file="US20170210697A1-20170727-C00178.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0910]"> </para-num> <div id="p-0949" num="0910" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>28</sub>O</div>
    </li> <li> <para-num num="[0911]"> </para-num> <div id="p-0950" num="0911" class="description-line">Molecular Weight: 248.41</div>
    </li> <li> <para-num num="[0912]"> </para-num> <div id="p-0951" num="0912" class="description-line">A mixture of 4-methoxy-2-(pent-1-en-1-yl)-1-(pent-1-yn-1-yl)benzene (3.46 g, 14.3 mmol) and Pd/C (10%, 300 mg) in 60 mL EtOH was stirred for 60 h under a hydrogen balloon. TLC showed complete reaction. The reaction mixture was filtered through Celite and concentrated to afford the product as a yellow oil (3.70 g, quant.), which was used for the next step without purification. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.05 (d, 1H, J=8.2 Hz); 6.72-6.55 (m, 2H); 3.78 (s, 3H); 2.59-2.50 (m, 4H); 1.62-1.48 (m, 4H); 1.39-1.28 (m, 8H); 0.93-0.86 (m, 6H).</div>
    </li> <heading id="h-0140">3,4-Dipentylphenol</heading>
    <li> <para-num num="[0913]"> </para-num> <div id="p-0952" num="0913" class="description-line">
      <chemistry id="CHEM-US-00179" num="00179">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/51/05/e20901ef00e9cc/US20170210697A1-20170727-C00179.png"><img id="EMI-C00179" he="12.36mm" wi="41.91mm" file="US20170210697A1-20170727-C00179.TIF" alt="Figure US20170210697A1-20170727-C00179" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="168" height="49" alt="Figure US20170210697A1-20170727-C00179" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/51/05/e20901ef00e9cc/US20170210697A1-20170727-C00179.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00179" attachment-type="cdx" file="US20170210697A1-20170727-C00179.CDX"> </attachment>
          <attachment idref="CHEM-US-00179" attachment-type="mol" file="US20170210697A1-20170727-C00179.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0914]"> </para-num> <div id="p-0953" num="0914" class="description-line">Chemical Formula: C<sub>16</sub>H<sub>26</sub>O</div>
    </li> <li> <para-num num="[0915]"> </para-num> <div id="p-0954" num="0915" class="description-line">Molecular Weight: 234.38</div>
    </li> <li> <para-num num="[0916]"> </para-num> <div id="p-0955" num="0916" class="description-line">To a solution of 4-methoxy-1,2-dipentylbenzene (3.40 g, 13.7 mmol) in 75 mL dichloromethane was added dropwise at 78 C. BBr<sub>3 </sub>(1.65 mL, 17.1 mmol), and then the reaction was allowed to warm to room temperature over 3 h. TLC showed complete reaction. The reaction was quenched by addition of saturated sodium bicarbonate, and then it was extracted with dichloromethane (2). The combined organic layer was washed with brine and dried over sodium sulfate. After concentration, the residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 30%) to afford the product as a brown oil (3.35 g, 97%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 6.99 (d, 1H, J=8.0 Hz); 6.64-6.59 (m, 2H); 4.45 (bs, 1H); 2.55-2.47 (m, 4H); 1.66-1.43 (m, 4H); 1.39-1.28 (m, 8H); 0.93-0.86 (m, 6H).</div>
    </li> <heading id="h-0141">3,4-Dipentylphenyl 8-bromooctanoate</heading>
    <li> <para-num num="[0917]"> </para-num> <div id="p-0956" num="0917" class="description-line">
      <chemistry id="CHEM-US-00180" num="00180">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e6/9e/b2/5e5fa1f11c80bc/US20170210697A1-20170727-C00180.png"><img id="EMI-C00180" he="10.84mm" wi="74.17mm" file="US20170210697A1-20170727-C00180.TIF" alt="Figure US20170210697A1-20170727-C00180" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="43" alt="Figure US20170210697A1-20170727-C00180" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e6/9e/b2/5e5fa1f11c80bc/US20170210697A1-20170727-C00180.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00180" attachment-type="cdx" file="US20170210697A1-20170727-C00180.CDX"> </attachment>
          <attachment idref="CHEM-US-00180" attachment-type="mol" file="US20170210697A1-20170727-C00180.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0918]"> </para-num> <div id="p-0957" num="0918" class="description-line">Chemical Formula: C<sub>24</sub>H<sub>39</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0919]"> </para-num> <div id="p-0958" num="0919" class="description-line">Molecular Weight: 439.48</div>
    </li> <li> <para-num num="[0920]"> </para-num> <div id="p-0959" num="0920" class="description-line">To a solution of 8-bromooctanoic acid (2.23 g, 10 mmol) and 3,4-dipentylphenol (2.34 g, 10 mmol) in dichloromethane (50 mL) were added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (1.92 g, 10 mmol) and DMAP (244 mg, 2 mmol). The reaction was allowed to stir at room temperature for 18 h. The reaction was diluted with dichloromethane and extracted with saturated sodium bicarbonate. The organic layer was separated and washed with brine, dried over sodium sulfate. The organic layer was filtered and evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 10%) to afford the product as a brown oil (4.30 g, 98%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.11 (d, 1H, J=7.7 Hz); 6.84-6.77 (m, 2H); 3.41 (t, 2H, J=6.9 Hz); 2.60-2.49 (m, 6H); 1.92-1.69 (m, 4H); 1.62-1.29 (m, 18H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0142">Nonyl 8-((2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0921]"> </para-num> <div id="p-0960" num="0921" class="description-line">
      <chemistry id="CHEM-US-00181" num="00181">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/25/04/5f8935fc1df55f/US20170210697A1-20170727-C00181.png"><img id="EMI-C00181" he="10.24mm" wi="105.49mm" file="US20170210697A1-20170727-C00181.TIF" alt="Figure US20170210697A1-20170727-C00181" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="41" alt="Figure US20170210697A1-20170727-C00181" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/25/04/5f8935fc1df55f/US20170210697A1-20170727-C00181.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00181" attachment-type="cdx" file="US20170210697A1-20170727-C00181.CDX"> </attachment>
          <attachment idref="CHEM-US-00181" attachment-type="mol" file="US20170210697A1-20170727-C00181.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0922]"> </para-num> <div id="p-0961" num="0922" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>39</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[0923]"> </para-num> <div id="p-0962" num="0923" class="description-line">Molecular Weight: 329.53</div>
    </li> <li> <para-num num="[0924]"> </para-num> <div id="p-0963" num="0924" class="description-line">A mixture of nonyl 8-bromooctanoate (2.50 g, 7.15 mmol) and 2-aminoethanol (4.3 mL, 71.5 mmol) in 10 mL EtOH was stirred at room temperature for 60 h. The reaction mixture was partitioned with hexanes and water, and the organic layer was washed with brine. After drying over sodium sulfate, the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 20%) to afford the product as white solid (1.57 g, 66%). MS (APCI): m/z (MH<sup>+</sup>) 330.3. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.04 (t, 2H, J=6.6 Hz); 3.63 (t, 2H, J=5.2 Hz); 2.77 (t, 2H, J=5.1 Hz); 2.61 (t, 2H, J=7.1 Hz); 2.28 (t, 2H, J=7.4 Hz); 1.99 (bs, 2H); 1.67-1.20 (m, 4H); 1.62-1.29 (m, 17H); 0.87 (m, 6H).</div>
    </li> <heading id="h-0143">3,4-Dipentylphenyl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0925]"> </para-num> <div id="p-0964" num="0925" class="description-line">
      <chemistry id="CHEM-US-00182" num="00182">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/26/ea/9f/fabf3a9375fb45/US20170210697A1-20170727-C00182.png"><img id="EMI-C00182" he="29.29mm" wi="105.49mm" file="US20170210697A1-20170727-C00182.TIF" alt="Figure US20170210697A1-20170727-C00182" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00182" class="patent-full-image" src="https://patentimages.storage.googleapis.com/26/ea/9f/fabf3a9375fb45/US20170210697A1-20170727-C00182.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00182" attachment-type="cdx" file="US20170210697A1-20170727-C00182.CDX"> </attachment>
          <attachment idref="CHEM-US-00182" attachment-type="mol" file="US20170210697A1-20170727-C00182.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0926]"> </para-num> <div id="p-0965" num="0926" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>77</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0927]"> </para-num> <div id="p-0966" num="0927" class="description-line">Molecular Weight: 688.09</div>
    </li> <li> <para-num num="[0928]"> </para-num> <div id="p-0967" num="0928" class="description-line">A solution of nonyl 8-((2-hydroxyethyl)amino)octanoate (500 mg, 1.52 mmol), 3,4-dipentylphenyl 8-bromooctanoate (1.00 g, 2.27 mmol) and N, N-diisopropylethylamine (0.40 mL, 2.27 mmol) in tert-butanol (3 mL) was heated to 60 C. in a sealed tube for 60 h. The reaction was cooled to room temperature and solvents were evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to obtain mixture (365 mg), and then the mixture was purified by ISCO (EtOAc/Hexanes/0.5% Et<sub>3</sub>N 0 to 50%) to afford product as a colorless oil (80 mg). LC/UV (214 nm): RT=10.23 min. MS (APCI): m/z (MH<sup>+</sup>) 688.6. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.11 (d, 1H, J=8.0 Hz); 6.84-6.77 (m, 2H); 4.04 (t, 2H, J=6.6 Hz); 3.51 (t, 2H, J=5.5 Hz); 2.60-2.38 (m, 12H); 2.28 (t, 2H, J=7.4 Hz); 1.79-1.19 (m, 37H); 0.92-0.82 (m, 9H).</div>
    </li> <heading id="h-0144">XX19. Compound 119: Nonyl 8-((2-hydroxyethyl)(8-oxo-8-(4-pentylphenoxy)octyl)amino)octanoate</heading>
    <heading id="h-0145">4-Pentylphenyl 8-bromooctanoate</heading>
    <li> <para-num num="[0929]"> </para-num> <div id="p-0968" num="0929" class="description-line">
      <chemistry id="CHEM-US-00183" num="00183">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9c/26/aa/dbeff2e41b8e74/US20170210697A1-20170727-C00183.png"><img id="EMI-C00183" he="10.58mm" wi="72.31mm" file="US20170210697A1-20170727-C00183.TIF" alt="Figure US20170210697A1-20170727-C00183" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="289" height="42" alt="Figure US20170210697A1-20170727-C00183" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9c/26/aa/dbeff2e41b8e74/US20170210697A1-20170727-C00183.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00183" attachment-type="cdx" file="US20170210697A1-20170727-C00183.CDX"> </attachment>
          <attachment idref="CHEM-US-00183" attachment-type="mol" file="US20170210697A1-20170727-C00183.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0930]"> </para-num> <div id="p-0969" num="0930" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>29</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0931]"> </para-num> <div id="p-0970" num="0931" class="description-line">Molecular Weight: 369.34</div>
    </li> <li> <para-num num="[0932]"> </para-num> <div id="p-0971" num="0932" class="description-line">To a solution of 8-bromooctanoic acid (2.00 g, 8.96 mmol) and 4-pentylphenol (3.07 mL g, 17.9 mmol) in dichloromethane (50 mL) were added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (1.72 g, 8.96 mmol) and DMAP (220 mg, 1.79 mmol). The reaction was allowed to stir at room temperature for 60 h. The reaction was diluted with dichloromethane and extracted with saturated sodium bicarbonate. The organic layer was separated and washed with brine, and dried over sodium sulfate. The organic layer was filtered and evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 10%) to afford the product as a colorless oil (3.12 g, 94%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.16 (d, 2H, J=8.5 Hz); 6.96 (d, 2H, J=8.5 Hz); 3.41 (t, 2H, J=6.9 Hz); 2.61-2.49 (m, 4H); 1.92-1.69 (m, 4H); 1.65-1.25 (m, 10H); 0.88 (m, 3H).</div>
    </li> <heading id="h-0146">Nonyl 8-((2-hydroxyethyl)(8-oxo-8-(4-pentylphenoxy)octyl)amino)octanoate</heading>
    <li> <para-num num="[0933]"> </para-num> <div id="p-0972" num="0933" class="description-line">
      <chemistry id="CHEM-US-00184" num="00184">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/46/f3/c85d74c3304545/US20170210697A1-20170727-C00184.png"><img id="EMI-C00184" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00184.TIF" alt="Figure US20170210697A1-20170727-C00184" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00184" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/46/f3/c85d74c3304545/US20170210697A1-20170727-C00184.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00184" attachment-type="cdx" file="US20170210697A1-20170727-C00184.CDX"> </attachment>
          <attachment idref="CHEM-US-00184" attachment-type="mol" file="US20170210697A1-20170727-C00184.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0934]"> </para-num> <div id="p-0973" num="0934" class="description-line">Chemical Formula: C<sub>38</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0935]"> </para-num> <div id="p-0974" num="0935" class="description-line">Molecular Weight: 617.96</div>
    </li> <li> <para-num num="[0936]"> </para-num> <div id="p-0975" num="0936" class="description-line">A solution of nonyl 8-((2-hydroxyethyl)amino)octanoate (500 mg, 1.52 mmol), 4-pentylphenyl 8-bromooctanoate (840 mg, 2.28 mmol) and N, N-diisopropylethylamine (0.40 mL, 2.28 mmol) in tert-butanol (3 mL) was heated to 60 C. in a sealed tube for 48 h. The reaction was cooled to room temperature and solvents were evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to obtain mixture (360 mg), and then the mixture was purified by ISCO (EtOAc/Hexanes/0.5% Et<sub>3</sub>N 0 to 50%) to afford the product as a colorless oil (95 mg). LC/UV (214 nm): RT=9.63 min. MS (APCI): m/z (MH<sup>+</sup>) 618.5. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.11 (d, 1H, J=8.0 Hz); 6.84-6.77 (m, 2H); 4.04 (t, 2H, J=6.6 Hz); 3.51 (t, 2H, J=5.5 Hz); 2.60-2.38 (m, 12H); 2.28 (t, 2H, J=7.4 Hz); 1.79-1.19 (m, 37H); 0.92-0.82 (m, 9H).</div>
    </li> <heading id="h-0147">XX20. Compound 120: Nonyl 8-((2-hydroxyethyl)(8-oxo-8-(3-pentylphenoxy)octyl)amino)octanoate</heading>
    <heading id="h-0148">3-Pentylphenol (Ref: <i>Tetrahedron Lett. </i>2013, 54, 52)</heading>
    <li> <para-num num="[0937]"> </para-num> <div id="p-0976" num="0937" class="description-line">
      <chemistry id="CHEM-US-00185" num="00185">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/e8/60/0e0255b6b90b4d/US20170210697A1-20170727-C00185.png"><img id="EMI-C00185" he="12.28mm" wi="41.91mm" file="US20170210697A1-20170727-C00185.TIF" alt="Figure US20170210697A1-20170727-C00185" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="168" height="49" alt="Figure US20170210697A1-20170727-C00185" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/e8/60/0e0255b6b90b4d/US20170210697A1-20170727-C00185.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00185" attachment-type="cdx" file="US20170210697A1-20170727-C00185.CDX"> </attachment>
          <attachment idref="CHEM-US-00185" attachment-type="mol" file="US20170210697A1-20170727-C00185.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0938]"> </para-num> <div id="p-0977" num="0938" class="description-line">Chemical Formula: C<sub>11</sub>H<sub>16</sub>O</div>
    </li> <li> <para-num num="[0939]"> </para-num> <div id="p-0978" num="0939" class="description-line">Molecular Weight: 164.25</div>
    </li> <li> <para-num num="[0940]"> </para-num> <div id="p-0979" num="0940" class="description-line">At 78 C., to a suspension of potassium tert-butoxide (6.73 g, 60 mmol) in 15 mL pentane were added sequentially tetramethylethylenediamine (9.0 mL, 60 mmol) and BuLi (2.5 M in hexane, 24 mL, 60 mmol), and a solution of m-cresol (2.6 mL, 25 mmol) in 10 mL pentane was added slowly. The reaction mixture was warmed up to 20 C. for 3 h. 30 mL THF was added and the reaction was cooled to 60 C. Butyl bromide (4.8 mL, 45 mmol) was added slowly, and the mixture was allowed warm to room temperature and stir for 16 h. After cooled to 0 C., the reaction mixture was acidified with 4 M HCl to pH3, and then extracted with ether. The combined organic layer was washed with brine and dried over sodium sulfate. After concentration, the residue was purified by ISCO (EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 5%) to provide a mixture of product with starting material, which was distilled under vacuum to provide the product as a colorless oil (1.23 g, 65%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.14 (t, 1H, J=7.7 Hz); 6.75 (d, 1H, J=7.7 Hz); 6.67-6.61 (m, 2H); 4.62 (s, 1H); 2.55 (t, 2H, J=7.7 Hz); 1.67-1.52 (m, 2H); 1.38-1.24 (m, 4H); 0.88 (t, 3H, J=6.9 Hz).</div>
    </li> <heading id="h-0149">3-Pentylphenyl 8-bromooctanoate</heading>
    <li> <para-num num="[0941]"> </para-num> <div id="p-0980" num="0941" class="description-line">
      <chemistry id="CHEM-US-00186" num="00186">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3d/76/a3/2cd80d18acb632/US20170210697A1-20170727-C00186.png"><img id="EMI-C00186" he="11.01mm" wi="75.18mm" file="US20170210697A1-20170727-C00186.TIF" alt="Figure US20170210697A1-20170727-C00186" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="44" alt="Figure US20170210697A1-20170727-C00186" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3d/76/a3/2cd80d18acb632/US20170210697A1-20170727-C00186.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00186" attachment-type="cdx" file="US20170210697A1-20170727-C00186.CDX"> </attachment>
          <attachment idref="CHEM-US-00186" attachment-type="mol" file="US20170210697A1-20170727-C00186.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0942]"> </para-num> <div id="p-0981" num="0942" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>29</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0943]"> </para-num> <div id="p-0982" num="0943" class="description-line">Molecular Weight: 369.34</div>
    </li> <li> <para-num num="[0944]"> </para-num> <div id="p-0983" num="0944" class="description-line">To a solution of 8-bromooctanoic acid (1.84 g, 8.20 mmol) and 3-pentylphenol (1.23 g, 7.49 mmol) in dichloromethane (40 mL) were added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (1.58 g, 8.20 mmol) and DMAP (183 mg, 1.50 mmol). The reaction was allowed to stir at room temperature for 16 h. The reaction was diluted with dichloromethane and extracted with saturated sodium bicarbonate. The organic layer was separated and washed with brine, dried over sodium sulfate. The organic layer was filtered and evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/<figure-callout id="0" label="Hexanes" filenames="US20170210697A1-20170727-D00006.png,US20170210697A1-20170727-D00007.png" state="{{state}}">Hexanes</figure-callout> 0 to 10%) to provide the product as a colorless oil (2.23 g, 80%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.26 (t, 1H, J=8.5 Hz); 7.03 (d, 1H, J=7.6 Hz); 6.91-6.84 (m, 2H); 3.41 (t, 2H, J=6.9 Hz); 2.61-2.49 (m, 4H); 1.92-1.69 (m, 4H); 1.65-1.25 (m, 12H); 0.88 (t, 3H, J=6.9 Hz).</div>
    </li> <heading id="h-0150">Nonyl 8-((2-hydroxyethyl)(8-oxo-8-(3-pentylphenoxy)octyl)amino)octanoate</heading>
    <li> <para-num num="[0945]"> </para-num> <div id="p-0984" num="0945" class="description-line">
      <chemistry id="CHEM-US-00187" num="00187">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/2b/ab/32d001c247d2c9/US20170210697A1-20170727-C00187.png"><img id="EMI-C00187" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00187.TIF" alt="Figure US20170210697A1-20170727-C00187" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00187" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/2b/ab/32d001c247d2c9/US20170210697A1-20170727-C00187.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00187" attachment-type="cdx" file="US20170210697A1-20170727-C00187.CDX"> </attachment>
          <attachment idref="CHEM-US-00187" attachment-type="mol" file="US20170210697A1-20170727-C00187.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0946]"> </para-num> <div id="p-0985" num="0946" class="description-line">Chemical Formula: C<sub>38</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0947]"> </para-num> <div id="p-0986" num="0947" class="description-line">Molecular Weight: 617.96</div>
    </li> <li> <para-num num="[0948]"> </para-num> <div id="p-0987" num="0948" class="description-line">A solution of nonyl 8-((2-hydroxyethyl)amino)octanoate (500 mg, 1.52 mmol), 3-pentylphenyl 8-bromooctanoate (840 mg, 2.28 mmol) and N, N-diisopropylethylamine (0.40 mL, 2.28 mmol) in tert-butanol (3 mL) was stirred at 60 C. in a sealed tube for 16 h. The reaction was cooled to room temperature and solvents were evaporated under vacuum. The residue was purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to obtain a mixture (247 mg), and then the mixture was purified by ISCO (EtOAc/Hexanes/0.5% Et<sub>3</sub>N 0 to 50%) to afford the product as a colorless oil (150 mg). LC/UV (202 nm): RT=7.45 min. MS (APCI): m/z (MH<sup>+</sup>) 618.5. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.26 (t, 1H, J=8.5 Hz); 7.03 (d, 1H, J=7.6 Hz); 6.91-6.84 (m, 2H); 4.05 (t, 2H, J=6.6 Hz); 3.51 (t, 2H, J=5.5 Hz); 2.64-2.38 (m, 10H); 2.28 (t, 2H, J=7.8 Hz); 1.79-1.19 (m, 41H); 0.91-0.82 (m, 6H).</div>
    </li> <heading id="h-0151">XX21. Compound 121: Heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoateHeptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0949]"> </para-num> <div id="p-0988" num="0949" class="description-line">
      <chemistry id="CHEM-US-00188" num="00188">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/49/0a/fe341c3b572a89/US20170210697A1-20170727-C00188.png"><img id="EMI-C00188" he="29.21mm" wi="109.64mm" file="US20170210697A1-20170727-C00188.TIF" alt="Figure US20170210697A1-20170727-C00188" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="439" height="117" alt="Figure US20170210697A1-20170727-C00188" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/49/0a/fe341c3b572a89/US20170210697A1-20170727-C00188.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00188" attachment-type="cdx" file="US20170210697A1-20170727-C00188.CDX"> </attachment>
          <attachment idref="CHEM-US-00188" attachment-type="mol" file="US20170210697A1-20170727-C00188.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0950]"> </para-num> <div id="p-0989" num="0950" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>88</sub>ClNO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0951]"> </para-num> <div id="p-0990" num="0951" class="description-line">Molecular Weight: 742.65</div>
    </li> <li> <para-num num="[0952]"> </para-num> <div id="p-0991" num="0952" class="description-line">To a solution of heptadecan-9-yl 8-((3-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (8.00 g, 11.0 mmol) and triethylamine (2.0 mL, 14.4 mmol) in dichloromethane (200 mL) was added dropwise methanesulfonyl chloride (1.07 mL, 13.8 mmol) at 0 C., and the reaction mixture was allowed to room temperature for 16 h. TLC and MS showed complete reaction. The reaction mixture was diluted with dichloromethane and washed with saturated sodium bicarbonate and brine. After drying over sodium sulfate, the solvent was removed under vacuum to give the product as a brown oil (7.30 g, 89%). NMR showed the crude contained a small amount of mesylate and desired chloride. This was used for the next step without purification. MS (APCI): m/z (MH<sup>+</sup>) 742.6. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (p, 1H, J=6.0 Hz); 4.05 (t, 2H, J=6.9 Hz); 3.58 (t, 2H, J=6.6 Hz); 2.58-2.22 (m, 9H); 1.92-1.16 (m, 65H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0152">Heptadecan-9-yl 8-((3-azidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0953]"> </para-num> <div id="p-0992" num="0953" class="description-line">
      <chemistry id="CHEM-US-00189" num="00189">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/17/2b/2c6789f4c57313/US20170210697A1-20170727-C00189.png"><img id="EMI-C00189" he="29.21mm" wi="109.73mm" file="US20170210697A1-20170727-C00189.TIF" alt="Figure US20170210697A1-20170727-C00189" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="439" height="117" alt="Figure US20170210697A1-20170727-C00189" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/17/2b/2c6789f4c57313/US20170210697A1-20170727-C00189.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00189" attachment-type="cdx" file="US20170210697A1-20170727-C00189.CDX"> </attachment>
          <attachment idref="CHEM-US-00189" attachment-type="mol" file="US20170210697A1-20170727-C00189.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0954]"> </para-num> <div id="p-0993" num="0954" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>88</sub>N<sub>4</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0955]"> </para-num> <div id="p-0994" num="0955" class="description-line">Molecular Weight: 749.22</div>
    </li> <li> <para-num num="[0956]"> </para-num> <div id="p-0995" num="0956" class="description-line">A mixture of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (4.20 g, 5.66 mmol) and sodium azide (1.75 g, 28.28 mmol) in 20 mL DMF in a sealed tube was heated to 100 C. for 16 h. After it was cooled to room temperature, the reaction mixture was diluted with water and extracted with hexanes. The combined organic layer was washed with water and brine, and then dried over sodium sulfate. After filtration and concentration, the residue was purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 5%) to provide the product as a brown oil (3.66 g, 86%). MS (APCI): m/z (MH<sup>+</sup>) 749.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.7 Hz); 3.32 (t, 2H, J=6.9 Hz); 2.58-2.22 (m, 10H); 1.72-1.19 (m, 64H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0153">Heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0957]"> </para-num> <div id="p-0996" num="0957" class="description-line">
      <chemistry id="CHEM-US-00190" num="00190">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/6d/ce/86c742204a61ea/US20170210697A1-20170727-C00190.png"><img id="EMI-C00190" he="29.21mm" wi="111.25mm" file="US20170210697A1-20170727-C00190.TIF" alt="Figure US20170210697A1-20170727-C00190" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="445" height="117" alt="Figure US20170210697A1-20170727-C00190" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/6d/ce/86c742204a61ea/US20170210697A1-20170727-C00190.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00190" attachment-type="cdx" file="US20170210697A1-20170727-C00190.CDX"> </attachment>
          <attachment idref="CHEM-US-00190" attachment-type="mol" file="US20170210697A1-20170727-C00190.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0958]"> </para-num> <div id="p-0997" num="0958" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>90</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[0959]"> </para-num> <div id="p-0998" num="0959" class="description-line">Molecular Weight: 723.23</div>
    </li> <li> <para-num num="[0960]"> </para-num> <div id="p-0999" num="0960" class="description-line">A mixture of heptadecan-9-yl 8-((3-azidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (3.66 g, 4.89 mmol) and Pd/C (10%, 400 mg) in 150 mL EtOH was stirred under hydrogen balloon for 16 h. MS showed complete reaction. The reaction mixture was filtered through Celite, and the filtrate was concentrated and purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2</sub>/1% NH<sub>4</sub>OH 0 to 20%) to afford the product as a brown oil (3.08 g, 87%). LC/UV (202 nm): RT=8.39 min. MS (APCI): m/z (MH<sup>+</sup>) 723.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 2.70 (t, 2H, J=6.9 Hz); 2.46-2.24 (m, 10H); 1.65-1.16 (m, 66H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0154">XX22. Compound 122: Heptadecan-9-yl 8-((6-(decan-2-yloxy)-6-oxohexyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0961]"> </para-num> <div id="p-1000" num="0961" class="description-line">
      <chemistry id="CHEM-US-00191" num="00191">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7c/48/9c/7f3c7706414917/US20170210697A1-20170727-C00191.png"><img id="EMI-C00191" he="23.03mm" wi="75.35mm" file="US20170210697A1-20170727-C00191.TIF" alt="Figure US20170210697A1-20170727-C00191" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="92" alt="Figure US20170210697A1-20170727-C00191" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7c/48/9c/7f3c7706414917/US20170210697A1-20170727-C00191.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00191" attachment-type="cdx" file="US20170210697A1-20170727-C00191.CDX"> </attachment>
          <attachment idref="CHEM-US-00191" attachment-type="mol" file="US20170210697A1-20170727-C00191.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0962]"> </para-num> <div id="p-1001" num="0962" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>85</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0963]"> </para-num> <div id="p-1002" num="0963" class="description-line">Molecular Weight: 696.16</div>
    </li> <li> <para-num num="[0964]"> </para-num> <div id="p-1003" num="0964" class="description-line">Compound 122 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.58 min. MS (ES): m/z (MH<sup>+</sup>) 697.1 for C<sub>43</sub>H<sub>85</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 2H); 3.62 (m, 2H); 2.81-2.42 (br. m, 5H); 2.30 (m, 4H); 1.73-1.43 (m, 14H); 1.28 (m, 48H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0155">XX23. Compound 123: Heptadecan-9-yl) 8-(methyl(8-nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0965]"> </para-num> <div id="p-1004" num="0965" class="description-line">
      <chemistry id="CHEM-US-00192" num="00192">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/02/eb/c838f81fe09d42/US20170210697A1-20170727-C00192.png"><img id="EMI-C00192" he="10.24mm" wi="75.27mm" file="US20170210697A1-20170727-C00192.TIF" alt="Figure US20170210697A1-20170727-C00192" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="41" alt="Figure US20170210697A1-20170727-C00192" class="patent-full-image" src="https://patentimages.storage.googleapis.com/eb/02/eb/c838f81fe09d42/US20170210697A1-20170727-C00192.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00192" attachment-type="cdx" file="US20170210697A1-20170727-C00192.CDX"> </attachment>
          <attachment idref="CHEM-US-00192" attachment-type="mol" file="US20170210697A1-20170727-C00192.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0966]"> </para-num> <div id="p-1005" num="0966" class="description-line">Chemical Formula: C<sub>26</sub>H<sub>53</sub>NO<sub>2 </sub> </div>
    </li> <li> <para-num num="[0967]"> </para-num> <div id="p-1006" num="0967" class="description-line">Molecular Weight: 411.72</div>
    </li> <li> <para-num num="[0968]"> </para-num> <div id="p-1007" num="0968" class="description-line">A solution of heptadecan-9-yl 8-bromooctanoate (200 mg, 0.433 mmol) in methanamine (10 mL, 19.92 mmol, 2M in THF) was allowed to stir at rt for 18 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (10-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-(methylamino)octanoate (113 mg, 0.27 mmol, 63%). UPLC/ELSD: RT=2.76 min. MS (ES): m/z (MH<sup>+</sup>) 412.4 for C<sub>26</sub>H<sub>53</sub>NO<sub>2</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.92 (p, 1H); 2.62 (t, 2H); 2.48 (s, 3H); 2.32-2.27 (m, 2H); 1.66-1.52 (br. m, 8H); 1.28 (m, 30H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0156">Heptadecan-9-yl 8-(methyl(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0969]"> </para-num> <div id="p-1008" num="0969" class="description-line">
      <chemistry id="CHEM-US-00193" num="00193">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/ad/c1/4a8003aad989b2/US20170210697A1-20170727-C00193.png"><img id="EMI-C00193" he="23.45mm" wi="75.10mm" file="US20170210697A1-20170727-C00193.TIF" alt="Figure US20170210697A1-20170727-C00193" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="94" alt="Figure US20170210697A1-20170727-C00193" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/ad/c1/4a8003aad989b2/US20170210697A1-20170727-C00193.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00193" attachment-type="cdx" file="US20170210697A1-20170727-C00193.CDX"> </attachment>
          <attachment idref="CHEM-US-00193" attachment-type="mol" file="US20170210697A1-20170727-C00193.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0970]"> </para-num> <div id="p-1009" num="0970" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>85</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0971]"> </para-num> <div id="p-1010" num="0971" class="description-line">Molecular Weight: 680.16</div>
    </li> <li> <para-num num="[0972]"> </para-num> <div id="p-1011" num="0972" class="description-line">A solution of heptadecan-9-yl 8-(methylamino)octanoate (113 mg, 0.27 mmol), nonyl 8-bromooctanoate (115 mg, 0.33 mmol) and N,N-diisopropylethylamine (67 L, 0.38 mmol) and potassium iodide (5 mg, 0.027 mmol) were dissolved in ethanol and was allowed to stir at 62 C. for 48 h. The reaction was cooled to rt and solvents were evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-(methyl(8-(nonyloxy)-8-oxooctyl)amino)octanoate (75 mg, 0.11 mmol, 41%). UPLC/ELSD: RT=3.84 min. MS (ES): m/z (MH<sup>+</sup>) 681.0 for C<sub>43</sub>H<sub>85</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (p, 1H); 4.08 (t, 2H); 2.88-2.67 (br. m, 7H); 2.34-2.27 (m, 4H); 1.80 (m, 4H); 1.63-1.52 (br. m, 10H); 1.37-1.28 (br. m, 48H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0157">XX24. Compound 124: Di(heptadecan-9-yl) 8,8-(methylazanediyl)dioctanoate</heading>
    <li> <para-num num="[0973]"> </para-num> <div id="p-1012" num="0973" class="description-line">
      <chemistry id="CHEM-US-00194" num="00194">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a8/f1/8e/863e41b692bf4b/US20170210697A1-20170727-C00194.png"><img id="EMI-C00194" he="25.15mm" wi="75.10mm" file="US20170210697A1-20170727-C00194.TIF" alt="Figure US20170210697A1-20170727-C00194" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="101" alt="Figure US20170210697A1-20170727-C00194" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a8/f1/8e/863e41b692bf4b/US20170210697A1-20170727-C00194.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00194" attachment-type="cdx" file="US20170210697A1-20170727-C00194.CDX"> </attachment>
          <attachment idref="CHEM-US-00194" attachment-type="mol" file="US20170210697A1-20170727-C00194.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0974]"> </para-num> <div id="p-1013" num="0974" class="description-line">Chemical Formula: C<sub>51</sub>H<sub>101</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0975]"> </para-num> <div id="p-1014" num="0975" class="description-line">Molecular Weight: 792.37</div>
    </li> <li> <para-num num="[0976]"> </para-num> <div id="p-1015" num="0976" class="description-line">A solution of heptadecan-9-yl 8-bromooctanoate (500 mg, 1.08 mmol) in methanamine (11 mL, 21.67 mmol, 2M in THF) was allowed to stir at rt for 6 h. The reaction mixture was concentrated in vacuo. The residue was purified by silica gel chromatography (20-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain di(heptadecan-9-yl) 8,8-(methylazanediyl)dioctanoate (26 mg, 0.03 mmol, 3%). UPLC/ELSD: RT=4.03 min. MS (ES): m/z (MH<sup>+</sup>) 793.3 for C<sub>51</sub>H<sub>101</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 2H); 2.32-2.24 (m, 11H); 1.66-1.28 (br. m, 76H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0158">XX25. Compound 125: 3-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(8-(nonyloxy)-8-oxooctyl)amino)propanoic acid Heptadecan-9-yl 8-((8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0977]"> </para-num> <div id="p-1016" num="0977" class="description-line">
      <chemistry id="CHEM-US-00195" num="00195">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/04/48/fd/b0e4cbf0c28001/US20170210697A1-20170727-C00195.png"><img id="EMI-C00195" he="24.13mm" wi="74.85mm" file="US20170210697A1-20170727-C00195.TIF" alt="Figure US20170210697A1-20170727-C00195" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="97" alt="Figure US20170210697A1-20170727-C00195" class="patent-full-image" src="https://patentimages.storage.googleapis.com/04/48/fd/b0e4cbf0c28001/US20170210697A1-20170727-C00195.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00195" attachment-type="cdx" file="US20170210697A1-20170727-C00195.CDX"> </attachment>
          <attachment idref="CHEM-US-00195" attachment-type="mol" file="US20170210697A1-20170727-C00195.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0978]"> </para-num> <div id="p-1017" num="0978" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0979]"> </para-num> <div id="p-1018" num="0979" class="description-line">Molecular Weight: 666.13</div>
    </li> <li> <para-num num="[0980]"> </para-num> <div id="p-1019" num="0980" class="description-line">At 78 C., to a solution of oxalyl chloride (0.25 mL, 3.0 mmol) in 3 mL dichloromethane was added dropwise a solution of DMSO (0.43 mL, 6.0 mmol) in 2 mL dichloromethane, and then a solution of heptadecan-9-yl 8-((3-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (1.45 g, 2.0 mmol) in dichloromethane (10 mL) was added immediately. After it was stirred for 30 min at this temperature, triethylamine (1.45 mL, 10.4 mmol) was added and the reaction mixture was warmed up to room temperature. TLC and MS showed complete reaction (M+1: 722.7), and the reaction mixture was diluted with water and extracted with hexanes (2). The combined organic layer was washed with brine. After drying over sodium sulfate, the filtrate was concentrated and the residue was purified by ISCO (SiO<sub>2</sub>: EtOAc/Hexanes/0.5% Et<sub>3</sub>N 0 to 50%) to afford the product as a brown oil (810 mg, 61%). MS (APCI): m/z (MH<sup>+</sup>) 666.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.05 (t, 2H, J=6.9 Hz); 2.56 (t, 4H, J=7.1 Hz); 2.31-2.24 (m, 4H); 1.67-1.19 (m, 63H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0159">Heptadecan-9-yl 8-((3-(benzyloxy)-3-oxopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[0981]"> </para-num> <div id="p-1020" num="0981" class="description-line">
      <chemistry id="CHEM-US-00196" num="00196">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/b7/9e/f3bd03cde57d47/US20170210697A1-20170727-C00196.png"><img id="EMI-C00196" he="34.88mm" wi="111.42mm" file="US20170210697A1-20170727-C00196.TIF" alt="Figure US20170210697A1-20170727-C00196" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="446" height="140" alt="Figure US20170210697A1-20170727-C00196" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/b7/9e/f3bd03cde57d47/US20170210697A1-20170727-C00196.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00196" attachment-type="cdx" file="US20170210697A1-20170727-C00196.CDX"> </attachment>
          <attachment idref="CHEM-US-00196" attachment-type="mol" file="US20170210697A1-20170727-C00196.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0982]"> </para-num> <div id="p-1021" num="0982" class="description-line">Chemical Formula: C<sub>52</sub>H<sub>93</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[0983]"> </para-num> <div id="p-1022" num="0983" class="description-line">Molecular Weight: 828.32</div>
    </li> <li> <para-num num="[0984]"> </para-num> <div id="p-1023" num="0984" class="description-line">A solution of heptadecan-9-yl 8-((8-(nonyloxy)-8-oxooctyl)amino)octanoate (798 mg, 1.2 mmol) and benzyl acrylate (293 mg, 1.8 mmol) in dichloromethane (20 mL) was stirred at room temperature for 16 h. TLC and MS showed almost no reaction, 10 mL MeOH was added and the reaction mixture was stirred at room temperature for 16 h. MS showed the product with a small amount of methyl ester (M+1: 829.8, 752.7). The reaction mixture was concentrated to dryness and purified by ISCO (SiO<sub>2</sub>: EtOAc/hexanes 0 to 35%) to afford the product as a colorless oil (280 mg, 28%). MS (APCI): m/z (MH<sup>+</sup>) 829.8. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.36-7.32 (m, 5H); 5.10 (s, 2H); 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.9 Hz); 2.78 (t, 2H, J=6.9 Hz); 2.46 (t, 2H, J=7.0 Hz); 2.36 (t, 4H, J=6.9 Hz); 2.30-2.24 (m, 4H); 1.67-1.19 (m, 62H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0160">3-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(8-(nonyloxy)-8-oxooctyl)amino)propanoic acid</heading>
    <li> <para-num num="[0985]"> </para-num> <div id="p-1024" num="0985" class="description-line">
      <chemistry id="CHEM-US-00197" num="00197">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2d/55/d0/5d2f976305839f/US20170210697A1-20170727-C00197.png"><img id="EMI-C00197" he="34.88mm" wi="110.32mm" file="US20170210697A1-20170727-C00197.TIF" alt="Figure US20170210697A1-20170727-C00197" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="441" height="140" alt="Figure US20170210697A1-20170727-C00197" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2d/55/d0/5d2f976305839f/US20170210697A1-20170727-C00197.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00197" attachment-type="cdx" file="US20170210697A1-20170727-C00197.CDX"> </attachment>
          <attachment idref="CHEM-US-00197" attachment-type="mol" file="US20170210697A1-20170727-C00197.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0986]"> </para-num> <div id="p-1025" num="0986" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>87</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[0987]"> </para-num> <div id="p-1026" num="0987" class="description-line">Molecular Weight: 738.19</div>
    </li> <li> <para-num num="[0988]"> </para-num> <div id="p-1027" num="0988" class="description-line">A mixture of heptadecan-9-yl 8-((3-(benzyloxy)-3-oxopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (280 mg, 0.34 mmol) and Pd/C (10%, 28 mg) in 20 mL EtOAc was stirred under hydrogen balloon for 1 h. MS showed complete reaction. The reaction mixture was filtered and the filtrate was concentrated. The residue was purified by ISCO (SiO<sub>2</sub>: MeOH/CH<sub>2</sub>Cl<sub>2 </sub>0 to 10%) to afford the product as a colorless oil (230 mg, 91%). LC/UV (214 nm): RT=12.38 min. MS (APCI): m/z (MH<sup>+</sup>) 838.7. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.85 (p, 1H, J=6.0 Hz); 4.04 (t, 2H, J=6.6 Hz); 2.85 (t, 2H, J=6.0 Hz); 2.65 (t, 4H, J=7.7 Hz); 2.48 (t, 2H, J=6.0 Hz); 2.32-2.24 (m, 4H); 1.67-1.17 (m, 63H); 0.87 (m, 9H).</div>
    </li> <heading id="h-0161">XX26. Compound 126: Heptadecan-9-yl 8-(methyl(4-(nonyloxy)-4-oxobutyl)amino)octanoate</heading>
    <li> <para-num num="[0989]"> </para-num> <div id="p-1028" num="0989" class="description-line">
      <chemistry id="CHEM-US-00198" num="00198">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/81/03/3d036489c21463/US20170210697A1-20170727-C00198.png"><img id="EMI-C00198" he="23.45mm" wi="75.10mm" file="US20170210697A1-20170727-C00198.TIF" alt="Figure US20170210697A1-20170727-C00198" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="94" alt="Figure US20170210697A1-20170727-C00198" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/81/03/3d036489c21463/US20170210697A1-20170727-C00198.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00198" attachment-type="cdx" file="US20170210697A1-20170727-C00198.CDX"> </attachment>
          <attachment idref="CHEM-US-00198" attachment-type="mol" file="US20170210697A1-20170727-C00198.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0990]"> </para-num> <div id="p-1029" num="0990" class="description-line">Chemical Formula: C<sub>39</sub>H<sub>77</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[0991]"> </para-num> <div id="p-1030" num="0991" class="description-line">Molecular Weight: 624.05</div>
    </li> <li> <para-num num="[0992]"> </para-num> <div id="p-1031" num="0992" class="description-line">A solution of heptadecan-9-yl 8-(methylamino)octanoate (103 mg, 0.25 mmol), nonyl 4-bromobutanoate (88 mg, 0.30 mmol) and N,N-diisopropylethylamine (61 L, 0.35 mmol) were dissolved in ethanol and was allowed to stir at 62 C. for 48 h. The reaction was cooled to rt and solvents were evaporated in vacuo. The residue was taken-up in ethyl acetate and washed with saturated aqueous sodium bicarbonate. The organic layer was separated and washed with brine, dried over Na<sub>2</sub>SO<sub>4 </sub>and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain heptadecan-9-yl 8-(methyl(4-(nonyloxy)-4-oxobutyl)amino)octanoate (90 mg, 0.14 mmol, 58%). UPLC/ELSD: RT=3.58 min. MS (ES): m/z (MH<sup>+</sup>) 624.8 for C<sub>39</sub>H<sub>77</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (p, 1H); 4.08 (t, 2H); 2.38-2.24 (br. m, 11H); 1.82 (m, 2H); 1.64-1.28 (br. m, 52H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0162">XX27. Compound 127: Nonyl 8-((9-((bis(nonyloxy)phosphoryl)oxy)nonyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0993]"> </para-num> <div id="p-1032" num="0993" class="description-line">
      <chemistry id="CHEM-US-00199" num="00199">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7e/fb/92/d379964bbca284/US20170210697A1-20170727-C00199.png"><img id="EMI-C00199" he="47.33mm" wi="110.41mm" file="US20170210697A1-20170727-C00199.TIF" alt="Figure US20170210697A1-20170727-C00199" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="442" height="189" alt="Figure US20170210697A1-20170727-C00199" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7e/fb/92/d379964bbca284/US20170210697A1-20170727-C00199.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00199" attachment-type="cdx" file="US20170210697A1-20170727-C00199.CDX"> </attachment>
          <attachment idref="CHEM-US-00199" attachment-type="mol" file="US20170210697A1-20170727-C00199.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0994]"> </para-num> <div id="p-1033" num="0994" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>94</sub>NO<sub>7</sub>P</div>
    </li> <li> <para-num num="[0995]"> </para-num> <div id="p-1034" num="0995" class="description-line">Molecular Weight: 804.232</div>
    </li> <li> <para-num num="[0996]"> </para-num> <div id="p-1035" num="0996" class="description-line">Compound 127 was synthesized in the same manner as Compound 131 and according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.58 min. MS (ES): m/z (MH<sup>+</sup>) 805.1 for C<sub>46</sub>H<sub>94</sub>NO<sub>7</sub>P. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (m, 8H); 3.55 (m, 2H); 2.59 (m, 2H); 2.46 (m, 4H); 2.31 (t, 2H), 1.67 (m, 11H); 1.29 (m, 55H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0163">XX28. Compound 128: Heptadecan-9-yl 8-((6-((1-cyclopropylnonyl)oxy)-6-oxohexyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[0997]"> </para-num> <div id="p-1036" num="0997" class="description-line">
      <chemistry id="CHEM-US-00200" num="00200">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/ea/7c/e97179ac8008ef/US20170210697A1-20170727-C00200.png"><img id="EMI-C00200" he="23.20mm" wi="75.52mm" file="US20170210697A1-20170727-C00200.TIF" alt="Figure US20170210697A1-20170727-C00200" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="93" alt="Figure US20170210697A1-20170727-C00200" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/ea/7c/e97179ac8008ef/US20170210697A1-20170727-C00200.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00200" attachment-type="cdx" file="US20170210697A1-20170727-C00200.CDX"> </attachment>
          <attachment idref="CHEM-US-00200" attachment-type="mol" file="US20170210697A1-20170727-C00200.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0998]"> </para-num> <div id="p-1037" num="0998" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[0999]"> </para-num> <div id="p-1038" num="0999" class="description-line">Molecular Weight: 722.193</div>
    </li> <li> <para-num num="[1000]"> </para-num> <div id="p-1039" num="1000" class="description-line">Compound 128 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.67 min. MS (ES): m/z (MH<sup>+</sup>) 722.9 for C<sub>45</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.30 (m, 1H); 3.56 (m, 2H); 2.72-2.39 (m, 6H); 2.30 (m, 4H), 1.76-1.17 (m, 58H); 0.90 (m, 10H); 0.61-0.35 (m, 3H); 0.28 (m, 1H).</div>
    </li> <heading id="h-0164">XX29. Compound 129: Undecyl 6-((8-(dioctylamino)-8-oxooctyl)(2-hydroxyethyl)amino)hexanoate</heading>
    <li> <para-num num="[1001]"> </para-num> <div id="p-1040" num="1001" class="description-line">
      <chemistry id="CHEM-US-00201" num="00201">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/82/4b/18a178ee46185e/US20170210697A1-20170727-C00201.png"><img id="EMI-C00201" he="27.26mm" wi="105.49mm" file="US20170210697A1-20170727-C00201.TIF" alt="Figure US20170210697A1-20170727-C00201" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00201" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/82/4b/18a178ee46185e/US20170210697A1-20170727-C00201.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00201" attachment-type="cdx" file="US20170210697A1-20170727-C00201.CDX"> </attachment>
          <attachment idref="CHEM-US-00201" attachment-type="mol" file="US20170210697A1-20170727-C00201.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1002]"> </para-num> <div id="p-1041" num="1002" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1003]"> </para-num> <div id="p-1042" num="1003" class="description-line">Molecular Weight: 695.171</div>
    </li> <li> <para-num num="[1004]"> </para-num> <div id="p-1043" num="1004" class="description-line">Compound 129 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.45 min. MS (ES): m/z (MH<sup>+</sup>) 695.9 for C<sub>43</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 2H); 3.54 (m, 2H), 3.28 (m, 4H); 2.59 (m, 2H); 2.47 (m, 4H); 2.32 (q, 4H); 1.73-1.19 (m, 58H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0165">XX30. Compound 130: Decan-2-yl 8-((8-(dioctylamino)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1005]"> </para-num> <div id="p-1044" num="1005" class="description-line">
      <chemistry id="CHEM-US-00202" num="00202">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6f/2f/dd/c746d391c3e85f/US20170210697A1-20170727-C00202.png"><img id="EMI-C00202" he="37.76mm" wi="100.58mm" file="US20170210697A1-20170727-C00202.TIF" alt="Figure US20170210697A1-20170727-C00202" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="151" alt="Figure US20170210697A1-20170727-C00202" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6f/2f/dd/c746d391c3e85f/US20170210697A1-20170727-C00202.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00202" attachment-type="cdx" file="US20170210697A1-20170727-C00202.CDX"> </attachment>
          <attachment idref="CHEM-US-00202" attachment-type="mol" file="US20170210697A1-20170727-C00202.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1006]"> </para-num> <div id="p-1045" num="1006" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>88</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1007]"> </para-num> <div id="p-1046" num="1007" class="description-line">Molecular Weight: 709.198</div>
    </li> <li> <para-num num="[1008]"> </para-num> <div id="p-1047" num="1008" class="description-line">Compound 130 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.46 min. MS (ES): m/z (MH<sup>+</sup>) 709.9 for C<sub>44</sub>H<sub>88</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.90 (m, 1H); 3.70 (br. m, 2H), 3.35-3.15 (m, 4H); 2.96-2.41 (br. m, 6H); 2.29 (m, 4H); 1.74-1.43 (m, 14H); 1.41-1.115 (m, 47H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0166">XX31. Compound 131: Nonyl 8-((7-((bis(octyloxy)phosphoryl)oxy)heptyl)(2-hydroxyethyl)amino)octanoate</heading>
    <heading id="h-0167">7-Bromoheptyl dioctyl phosphate</heading>
    <li> <para-num num="[1009]"> </para-num> <div id="p-1048" num="1009" class="description-line">
      <chemistry id="CHEM-US-00203" num="00203">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/61/34/bc/e2200f7c788fc0/US20170210697A1-20170727-C00203.png"><img id="EMI-C00203" he="33.53mm" wi="75.52mm" file="US20170210697A1-20170727-C00203.TIF" alt="Figure US20170210697A1-20170727-C00203" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="134" alt="Figure US20170210697A1-20170727-C00203" class="patent-full-image" src="https://patentimages.storage.googleapis.com/61/34/bc/e2200f7c788fc0/US20170210697A1-20170727-C00203.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00203" attachment-type="cdx" file="US20170210697A1-20170727-C00203.CDX"> </attachment>
          <attachment idref="CHEM-US-00203" attachment-type="mol" file="US20170210697A1-20170727-C00203.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1010]"> </para-num> <div id="p-1049" num="1010" class="description-line">Chemical Formula: C<sub>23</sub>H<sub>48</sub>BrO<sub>4</sub>P</div>
    </li> <li> <para-num num="[1011]"> </para-num> <div id="p-1050" num="1011" class="description-line">Molecular Weight: 499.511</div>
    </li> <li> <para-num num="[1012]"> </para-num> <div id="p-1051" num="1012" class="description-line">To a solution of POCl<sub>3 </sub>(1.91 mL, 20.5 mmol) in DCM (20 mL) at 0 C., Et<sub>3</sub>N (2.85 mL, 20.4 mmol) was slowly added followed by 7-bromoheptan-1-ol (4.0 g, 20.5 mmol). The reaction was allowed to stir for 4 h at 0 C. A solution of octan-1-ol (7.10 mL, 45.11 mmol) and Et<sub>3</sub>N (8.9 mL, 63.8 mmol) in DCM were added and the reaction was allowed to stir at rt for 16 h. The reaction was diluted with DCM and washed with saturated NaHCO<sub>3</sub>. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by ISCO with (0-30%) EtOAc in hexanes to obtain 7-bromoheptyl dioctyl phosphate (0.58 g, 1.16 mmol, 6%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.03 (m, 6H); 3.43 (t, 2H); 1.88 (m, 2H); 1.70 (m, 6H); 1.54-1.23 (m, 26H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0168">Nonyl 8-((7-((bis(octyloxy)phosphoryl)oxy)heptyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1013]"> </para-num> <div id="p-1052" num="1013" class="description-line">
      <chemistry id="CHEM-US-00204" num="00204">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/fb/4d/35a0dad6396b5f/US20170210697A1-20170727-C00204.png"><img id="EMI-C00204" he="42.42mm" wi="105.49mm" file="US20170210697A1-20170727-C00204.TIF" alt="Figure US20170210697A1-20170727-C00204" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="170" alt="Figure US20170210697A1-20170727-C00204" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/fb/4d/35a0dad6396b5f/US20170210697A1-20170727-C00204.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00204" attachment-type="cdx" file="US20170210697A1-20170727-C00204.CDX"> </attachment>
          <attachment idref="CHEM-US-00204" attachment-type="mol" file="US20170210697A1-20170727-C00204.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1014]"> </para-num> <div id="p-1053" num="1014" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>86</sub>NO<sub>7</sub>P</div>
    </li> <li> <para-num num="[1015]"> </para-num> <div id="p-1054" num="1015" class="description-line">Molecular Weight: 748.124</div>
    </li> <li> <para-num num="[1016]"> </para-num> <div id="p-1055" num="1016" class="description-line">Compound 131 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.22 min. MS (ES): m/z (MH<sup>+</sup>) 750.0 for C<sub>42</sub>H<sub>86</sub>NO<sub>7</sub>P. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (m, 8H); 3.51 (m, 2H); 2.60 (br. m, 2H); 2.46 (m, 4H); 2.31 (t, 2H); 1.76-1.15 (m, 58H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0169">XX32. Compound 132: Decan-2-yl 8-((7-((bis(octyloxy)phosphoryl)oxy)heptyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1017]"> </para-num> <div id="p-1056" num="1017" class="description-line">
      <chemistry id="CHEM-US-00205" num="00205">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/b9/35/f6cf8aca4cf235/US20170210697A1-20170727-C00205.png"><img id="EMI-C00205" he="42.42mm" wi="105.49mm" file="US20170210697A1-20170727-C00205.TIF" alt="Figure US20170210697A1-20170727-C00205" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="170" alt="Figure US20170210697A1-20170727-C00205" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/b9/35/f6cf8aca4cf235/US20170210697A1-20170727-C00205.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00205" attachment-type="cdx" file="US20170210697A1-20170727-C00205.CDX"> </attachment>
          <attachment idref="CHEM-US-00205" attachment-type="mol" file="US20170210697A1-20170727-C00205.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1018]"> </para-num> <div id="p-1057" num="1018" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>88</sub>NO<sub>7</sub>P</div>
    </li> <li> <para-num num="[1019]"> </para-num> <div id="p-1058" num="1019" class="description-line">Molecular Weight: 762.15</div>
    </li> <li> <para-num num="[1020]"> </para-num> <div id="p-1059" num="1020" class="description-line">Compound 132 was synthesized in the same manner as Compound 131 and according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.27 min. MS (ES): m/z (MH<sup>+</sup>) 764.00 for C<sub>43</sub>H<sub>88</sub>NO<sub>7</sub>P. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 1H); 4.03 (m, 6H); 3.56 (m, 2H); 2.73-2.38 (br. m, 6H); 2.29 (t, 2H); 1.79-1.16 (m, 61H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0170">XX33. Compound 133: ((2-Hydroxyethyl)azanediyl)bis(nonane-9,1-diyl) bis(2-hexyldecanoate)</heading>
    <li> <para-num num="[1021]"> </para-num> <div id="p-1060" num="1021" class="description-line">
      <chemistry id="CHEM-US-00206" num="00206">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/34/62/38ca0b1f4bdd57/US20170210697A1-20170727-C00206.png"><img id="EMI-C00206" he="43.35mm" wi="110.41mm" file="US20170210697A1-20170727-C00206.TIF" alt="Figure US20170210697A1-20170727-C00206" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="442" height="173" alt="Figure US20170210697A1-20170727-C00206" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/34/62/38ca0b1f4bdd57/US20170210697A1-20170727-C00206.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00206" attachment-type="cdx" file="US20170210697A1-20170727-C00206.CDX"> </attachment>
          <attachment idref="CHEM-US-00206" attachment-type="mol" file="US20170210697A1-20170727-C00206.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1022]"> </para-num> <div id="p-1061" num="1022" class="description-line">Chemical Formula: C<sub>52</sub>H<sub>103</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1023]"> </para-num> <div id="p-1062" num="1023" class="description-line">Molecular Weight: 822.398</div>
    </li> <li> <para-num num="[1024]"> </para-num> <div id="p-1063" num="1024" class="description-line">Compound 133 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.91 min. MS (ES): m/z (MH<sup>+</sup>) 824.0 for C<sub>52</sub>H<sub>103</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.09 (t, 4H); 3.60 (m, 2H); 2.74-2.42 (br. m, 6H); 2.33 (m, 3H); 1.72-1.17 (m, 76H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0171">XX34. Compound 134: 9-((2-Hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)nonyl 2-hexyldecanoate</heading>
    <li> <para-num num="[1025]"> </para-num> <div id="p-1064" num="1025" class="description-line">
      <chemistry id="CHEM-US-00207" num="00207">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/75/18/bc/4ef7216a9d029f/US20170210697A1-20170727-C00207.png"><img id="EMI-C00207" he="37.76mm" wi="105.49mm" file="US20170210697A1-20170727-C00207.TIF" alt="Figure US20170210697A1-20170727-C00207" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="151" alt="Figure US20170210697A1-20170727-C00207" class="patent-full-image" src="https://patentimages.storage.googleapis.com/75/18/bc/4ef7216a9d029f/US20170210697A1-20170727-C00207.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00207" attachment-type="cdx" file="US20170210697A1-20170727-C00207.CDX"> </attachment>
          <attachment idref="CHEM-US-00207" attachment-type="mol" file="US20170210697A1-20170727-C00207.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1026]"> </para-num> <div id="p-1065" num="1026" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1027]"> </para-num> <div id="p-1066" num="1027" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[1028]"> </para-num> <div id="p-1067" num="1028" class="description-line">Compound 134 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.48 min. MS (ES): m/z (MH<sup>+</sup>) 712.0 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (m, 4H); 3.55 (m, 2H); 2.67-2.39 (br. m, 6H); 2.31 (m, 3H); 1.71-1.19 (m, 62H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0172">XX35. Compound 135: 7-((8-(Decan-2-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[1029]"> </para-num> <div id="p-1068" num="1029" class="description-line">
      <chemistry id="CHEM-US-00208" num="00208">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/eb/2d/f67ae1f75afac9/US20170210697A1-20170727-C00208.png"><img id="EMI-C00208" he="29.29mm" wi="105.49mm" file="US20170210697A1-20170727-C00208.TIF" alt="Figure US20170210697A1-20170727-C00208" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00208" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2b/eb/2d/f67ae1f75afac9/US20170210697A1-20170727-C00208.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00208" attachment-type="cdx" file="US20170210697A1-20170727-C00208.CDX"> </attachment>
          <attachment idref="CHEM-US-00208" attachment-type="mol" file="US20170210697A1-20170727-C00208.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1030]"> </para-num> <div id="p-1069" num="1030" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1031]"> </para-num> <div id="p-1070" num="1031" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1032]"> </para-num> <div id="p-1071" num="1032" class="description-line">Compound 135 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.63 min. MS (ES): m/z (MH<sup>+</sup>) 726.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 1H); 4.08 (t, 2H); 3.57 (m, 2H); 2.73-2.40 (br. m, 6H); 2.29 (m, 3H); 1.71-1.16 (m, 66H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0173">BA. Compound 136: Nonyl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate</heading>
    <heading id="h-0174">Representative Procedure 2</heading>
    <heading id="h-0175">Nonyl 8-bromooctanoate (Method A)</heading>
    <li> <para-num num="[1033]"> </para-num> <div id="p-1072" num="1033" class="description-line">
      <chemistry id="CHEM-US-00209" num="00209">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/f3/57/8c3d7b7391f26d/US20170210697A1-20170727-C00209.png"><img id="EMI-C00209" he="8.81mm" wi="75.52mm" file="US20170210697A1-20170727-C00209.TIF" alt="Figure US20170210697A1-20170727-C00209" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="35" alt="Figure US20170210697A1-20170727-C00209" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/f3/57/8c3d7b7391f26d/US20170210697A1-20170727-C00209.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00209" attachment-type="cdx" file="US20170210697A1-20170727-C00209.CDX"> </attachment>
          <attachment idref="CHEM-US-00209" attachment-type="mol" file="US20170210697A1-20170727-C00209.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1034]"> </para-num> <div id="p-1073" num="1034" class="description-line">To a solution of 8-bromooctanoic acid (5 g, 22 mmol) and nonan-1-ol (6.46 g, 45 mmol) in dichloromethane (100 mL) were added N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (4.3 g, 22 mmol) and DMAP (547 mg, 4.5 mmol). The reaction was allowed to stir at rt for 18 h. The reaction was diluted with dichloromethane and washed with saturated sodium bicarbonate. The organic layer was separated and washed with brine, dried over MgSO<sub>4</sub>. The organic layer was filtered and evaporated under vacuum. The residue was purified by silica gel chromatography (0-10% ethyl acetate in hexanes) to obtain nonyl 8-bromooctanoate (6.1 g, 17 mmol, 77%).</div>
    </li> <li> <para-num num="[1035]"> </para-num> <div id="p-1074" num="1035" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.06 (t, 2H); 3.40 (t, 2H); 2.29 (t, 2H); 1.85 (m, 2H); 1.72-0.97 (m, 22H); 0.88 (m, 3H).</div>
    </li> <heading id="h-0176">Nonyl 8-((2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1036]"> </para-num> <div id="p-1075" num="1036" class="description-line">
      <chemistry id="CHEM-US-00210" num="00210">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/6b/26/22a9d406fceac9/US20170210697A1-20170727-C00210.png"><img id="EMI-C00210" he="10.33mm" wi="105.49mm" file="US20170210697A1-20170727-C00210.TIF" alt="Figure US20170210697A1-20170727-C00210" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="41" alt="Figure US20170210697A1-20170727-C00210" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/6b/26/22a9d406fceac9/US20170210697A1-20170727-C00210.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00210" attachment-type="cdx" file="US20170210697A1-20170727-C00210.CDX"> </attachment>
          <attachment idref="CHEM-US-00210" attachment-type="mol" file="US20170210697A1-20170727-C00210.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1037]"> </para-num> <div id="p-1076" num="1037" class="description-line">A solution of nonyl 8-bromooctanoate (1.2 g, 3.4 mmol) and 2-aminoethan-1-ol (5 mL, 83 mmol) in ethanol (2 mL) was allowed to stir at 62 C. for 18 h. The reaction mixture was concentrated in vacuum and the residue was extracted with ethyl acetate and water. The organic layer was separated and washed with water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>. The organic layer was filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to obtain nonyl 8-((2-hydroxyethyl)amino)octanoate (295 mg, 0.9 mmol, 26%).</div>
    </li> <li> <para-num num="[1038]"> </para-num> <div id="p-1077" num="1038" class="description-line">UPLC/ELSD: RT=1.29 min. MS (ES): m/z (MH<sup>+</sup>) 330.42 for C<sub>19</sub>H<sub>39</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1039]"> </para-num> <div id="p-1078" num="1039" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.07 (t, 2H); 3.65 (t, 2H); 2.78 (t, 2H); 2.63 (t, 2H); 2.32-2.19 (m, 4H); 1.73-1.20 (m, 24H); 0.89 (m, 3H)</div>
    </li> <heading id="h-0177">Nonyl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate</heading>
    <li> <para-num num="[1040]"> </para-num> <div id="p-1079" num="1040" class="description-line">
      <chemistry id="CHEM-US-00211" num="00211">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/00/12/cf263ee259ea12/US20170210697A1-20170727-C00211.png"><img id="EMI-C00211" he="20.83mm" wi="102.11mm" file="US20170210697A1-20170727-C00211.TIF" alt="Figure US20170210697A1-20170727-C00211" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="408" height="83" alt="Figure US20170210697A1-20170727-C00211" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/00/12/cf263ee259ea12/US20170210697A1-20170727-C00211.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00211" attachment-type="cdx" file="US20170210697A1-20170727-C00211.CDX"> </attachment>
          <attachment idref="CHEM-US-00211" attachment-type="mol" file="US20170210697A1-20170727-C00211.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1041]"> </para-num> <div id="p-1080" num="1041" class="description-line">Chemical Formula: C<sub>37</sub>H<sub>71</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1042]"> </para-num> <div id="p-1081" num="1042" class="description-line">Molecular Weight: 577.98</div>
    </li> <li> <para-num num="[1043]"> </para-num> <div id="p-1082" num="1043" class="description-line">A solution of nonyl 8-((2-hydroxyethyl)amino)octanoate (150 mg, 0.46 mmol), (6Z,9Z)-18-bromooctadeca-6,9-diene (165 mg, 0.5 mmol) and N,N-diisopropylethylamine (65 mg, 0.5 mmol) in ethanol (2 mL) was allowed to stir at reflux for 48 h. The reaction was allowed to cool to rt and solvents were evaporated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH in dichloromethane) to obtain nonyl 8-((2-hydroxyethyl)((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)octanoate (81 mg, 0.14 mmol, 30%) as a HBr salt.</div>
    </li> <li> <para-num num="[1044]"> </para-num> <div id="p-1083" num="1044" class="description-line">UPLC/ELSD: RT=3.24 min. MS (ES): m/z (MH<sup>+</sup>) 578.64 for C<sub>37</sub>H<sub>71</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1045]"> </para-num> <div id="p-1084" num="1045" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 10.71 (br., 1H); 5.36 (br. m, 4H); 4.04 (m, 4H); 3.22-2.96 (br. m, 5H); 2.77 (m, 2H); 2.29 (m, 2H); 2.04 (br. m, 4H); 1.86 (br. m, 4H); 1.66-1.17 (br. m, 40H); 0.89 (m, 6H)</div>
    </li> <heading id="h-0178">BB. Compound 137: Methyl 12-(dodecyl(2-hydroxyethyl)amino)dodecanoate</heading>
    <heading id="h-0179">Methyl 12-bromododecanoate</heading>
    <li> <para-num num="[1046]"> </para-num> <div id="p-1085" num="1046" class="description-line">
      <chemistry id="CHEM-US-00212" num="00212">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/94/48/db2b0c3bef632a/US20170210697A1-20170727-C00212.png"><img id="EMI-C00212" he="15.83mm" wi="64.52mm" file="US20170210697A1-20170727-C00212.TIF" alt="Figure US20170210697A1-20170727-C00212" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="258" height="63" alt="Figure US20170210697A1-20170727-C00212" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8d/94/48/db2b0c3bef632a/US20170210697A1-20170727-C00212.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00212" attachment-type="cdx" file="US20170210697A1-20170727-C00212.CDX"> </attachment>
          <attachment idref="CHEM-US-00212" attachment-type="mol" file="US20170210697A1-20170727-C00212.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1047]"> </para-num> <div id="p-1086" num="1047" class="description-line">Chemical Formula: C<sub>13</sub>H<sub>25</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[1048]"> </para-num> <div id="p-1087" num="1048" class="description-line">Molecular Weight: 293.25</div>
    </li> <li> <para-num num="[1049]"> </para-num> <div id="p-1088" num="1049" class="description-line">To a solution of 12-bromododecanoic acid (2.5 g, 8.95 mmol) in THF (7 mL) was added methanol (7.2 mL, 179 mmol). Sulfuric acid (0.50 mL, 8.95 mmol) was added dropwise and the reaction was allowed to stir at 65 C. for two hours. The reaction mixture was washed with 5% NaHCO<sub>3 </sub>and brine. The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by silica gel chromatography (0-20% EtOAc/hexanes) provided methyl 12-bromododecanoate (2.40 g, 92%).</div>
    </li> <li> <para-num num="[1050]"> </para-num> <div id="p-1089" num="1050" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.69 (s, 3H); 3.44 (t, 2H); 2.33 (t, 2H); 1.88 (br. m, 2H); 1.64 (br. m, 2H); 1.45 (br. m, 2H); 1.31 (br. m, 12H).</div>
    </li> <heading id="h-0180">Methyl 12-(dodecyl(2-hydroxyethyl)amino)dodecanoate</heading>
    <li> <para-num num="[1051]"> </para-num> <div id="p-1090" num="1051" class="description-line">
      <chemistry id="CHEM-US-00213" num="00213">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/42/7e/12/d7ca321013f2d9/US20170210697A1-20170727-C00213.png"><img id="EMI-C00213" he="17.53mm" wi="75.18mm" file="US20170210697A1-20170727-C00213.TIF" alt="Figure US20170210697A1-20170727-C00213" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="70" alt="Figure US20170210697A1-20170727-C00213" class="patent-full-image" src="https://patentimages.storage.googleapis.com/42/7e/12/d7ca321013f2d9/US20170210697A1-20170727-C00213.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00213" attachment-type="cdx" file="US20170210697A1-20170727-C00213.CDX"> </attachment>
          <attachment idref="CHEM-US-00213" attachment-type="mol" file="US20170210697A1-20170727-C00213.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1052]"> </para-num> <div id="p-1091" num="1052" class="description-line">Chemical Formula: C<sub>27</sub>H<sub>55</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1053]"> </para-num> <div id="p-1092" num="1053" class="description-line">Molecular Weight: 441.74</div>
    </li> <li> <para-num num="[1054]"> </para-num> <div id="p-1093" num="1054" class="description-line">To a solution of methyl 12-((2-hydroxyethyl)amino)dodecanoate (413 mg, 1.51 mmol) (isolated from the synthesis of 12,12-((2-Hydroxyethyl)azanediyl)didodecanoate) in MeCN (5 mL) was added 1-bromododecane (452 mg, 1.81 mmol), K2CO<sub>3 </sub>(418 mg, 3.02 mmol), and KI (25 mg, 0.151 mmol). The reaction was allowed to stir at 82 C. for 16 hours. The reaction mixture was cooled to room temperature, diluted with H<sub>2</sub>O, and extracted with EtOAc. The combined organic layers were washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. Purification by silica gel chromatography (0-100% [DCM, 20% MeOH, 1% NH<sub>4</sub>OH]/MeOH) provided methyl 12-(dodecyl(2-hydroxyethyl)amino)dodecanoate (409 mg, 61%).</div>
    </li> <li> <para-num num="[1055]"> </para-num> <div id="p-1094" num="1055" class="description-line">UPLC/ELSD: RT=2.39 min. MS (ES): m/z (MH<sup>+</sup>) 442.60 for C<sub>27</sub>H<sub>55</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1056]"> </para-num> <div id="p-1095" num="1056" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.69 (s, 3H); 3.61 (t, 2H); 2.68 (t, 2H); 2.54 (t, 4H); 2.32 (t, 2H); 1.64 (m, 2H); 1.50 (br. m, 4H); 1.28 (br. m, 32H); 0.90 (t, 3H).</div>
    </li> <heading id="h-0181">BC. Compound 138: Dinonyl 8,8-((2-hydroxyethyl)azanediyl)dioctanoate</heading>
    <heading id="h-0182">Representative Procedure 3</heading>
    <heading id="h-0183">Dinonyl 8,8-((2-hydroxyethyl)azanediyl)dioctanoate</heading>
    <li> <para-num num="[1057]"> </para-num> <div id="p-1096" num="1057" class="description-line">
      <chemistry id="CHEM-US-00214" num="00214">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/c7/12/5c15aaa82526aa/US20170210697A1-20170727-C00214.png"><img id="EMI-C00214" he="27.26mm" wi="100.58mm" file="US20170210697A1-20170727-C00214.TIF" alt="Figure US20170210697A1-20170727-C00214" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00214" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/c7/12/5c15aaa82526aa/US20170210697A1-20170727-C00214.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00214" attachment-type="cdx" file="US20170210697A1-20170727-C00214.CDX"> </attachment>
          <attachment idref="CHEM-US-00214" attachment-type="mol" file="US20170210697A1-20170727-C00214.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1058]"> </para-num> <div id="p-1097" num="1058" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1059]"> </para-num> <div id="p-1098" num="1059" class="description-line">Molecular Weight: 597.97</div>
    </li> <li> <para-num num="[1060]"> </para-num> <div id="p-1099" num="1060" class="description-line">A solution of nonyl 8-bromooctanoate (200 mg, 0.6 mmol) and 2-aminoethan-1-ol (16 mg, 0.3 mmol) and N, N-diisopropylethylamine (74 mg, 0.6 mmol) in THF/CH<sub>3</sub>CN (1:1) (3 mL) was allowed to stir at 63 C. for 72 h. The reaction was cooled to rt and solvents were evaporated under vacuum. The residue was extracted with ethyl acetate and saturated sodium bicarbonate. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4 </sub>and evaporated under vacuum. The residue was purified by silica gel chromatography (0-10% MeOH in dichloromethane) to obtain dinonyl 8,8-((2-hydroxyethyl)azanediyl)dioctanoate (80 mg, 0.13 mmol, 43%).</div>
    </li> <li> <para-num num="[1061]"> </para-num> <div id="p-1100" num="1061" class="description-line">UPLC/ELSD: RT=3.09 min. MS (ES): m/z (MH<sup>+</sup>) 598.85 for C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1062]"> </para-num> <div id="p-1101" num="1062" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (m, 4H); 3.57 (br. m, 2H); 2.71-2.38 (br. m, 6H); 2.29 (m, 4H), 1.71-1.01 (br. m, 49H), 0.88 (m, 6H).</div>
    </li> <heading id="h-0184">BD. Compound 139: Di((Z)-non-2-en-1-yl) 8,8-((2-hydroxyethyl)azanediyl)dioctanoate</heading>
    <li> <para-num num="[1063]"> </para-num> <div id="p-1102" num="1063" class="description-line">Compound 139 was synthesized following the Representative Procedure 3.</div>
    </li> <li> <div id="p-1103" num="0000" class="description-line">
      <chemistry id="CHEM-US-00215" num="00215">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/1b/d7/d3ff5e4448091b/US20170210697A1-20170727-C00215.png"><img id="EMI-C00215" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00215.TIF" alt="Figure US20170210697A1-20170727-C00215" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00215" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/1b/d7/d3ff5e4448091b/US20170210697A1-20170727-C00215.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00215" attachment-type="cdx" file="US20170210697A1-20170727-C00215.CDX"> </attachment>
          <attachment idref="CHEM-US-00215" attachment-type="mol" file="US20170210697A1-20170727-C00215.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1064]"> </para-num> <div id="p-1104" num="1064" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1065]"> </para-num> <div id="p-1105" num="1065" class="description-line">Molecular Weight: 593.93</div>
    </li> <li> <para-num num="[1066]"> </para-num> <div id="p-1106" num="1066" class="description-line">UPLC/ELSD: RT=2.88 min. MS (ES): m/z (MH<sup>+</sup>) 594.78 for C<sub>36</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1067]"> </para-num> <div id="p-1107" num="1067" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.60 (m, 2H); 5.50 (m, 2H); 4.59 (m, 4H); 3.96 (br. m, 2H); 3.20-2.94 (br. m, 5H); 2.28 (m, 4H); 2.07 (m, 4H); 1.80 (br. m 4H); 1.59 (br. m, 6H); 1.43-1.14 (br. m, 28H), 0.85 (m, 6H).</div>
    </li> <heading id="h-0185">BE. Compound 140: Di((Z)-undec-2-en-1-yl) 6,6-((2-hydroxyethyl)azanediyl)dihexanoate</heading>
    <li> <para-num num="[1068]"> </para-num> <div id="p-1108" num="1068" class="description-line">Compound 140 was synthesized following the Representative Procedure 3.</div>
    </li> <li> <div id="p-1109" num="0000" class="description-line">
      <chemistry id="CHEM-US-00216" num="00216">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/85/71/ef27aa4f57e2d8/US20170210697A1-20170727-C00216.png"><img id="EMI-C00216" he="27.18mm" wi="101.35mm" file="US20170210697A1-20170727-C00216.TIF" alt="Figure US20170210697A1-20170727-C00216" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20170210697A1-20170727-C00216" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/85/71/ef27aa4f57e2d8/US20170210697A1-20170727-C00216.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00216" attachment-type="cdx" file="US20170210697A1-20170727-C00216.CDX"> </attachment>
          <attachment idref="CHEM-US-00216" attachment-type="mol" file="US20170210697A1-20170727-C00216.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1069]"> </para-num> <div id="p-1110" num="1069" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1070]"> </para-num> <div id="p-1111" num="1070" class="description-line">Molecular Weight: 593.93</div>
    </li> <li> <para-num num="[1071]"> </para-num> <div id="p-1112" num="1071" class="description-line">UPLC/ELSD: RT=2.87 min. MS (ES): m/z (MH<sup>+</sup>) 594.74 for C<sub>36</sub>H<sub>67</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1072]"> </para-num> <div id="p-1113" num="1072" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.73-5.44 (m, 4H); 4.62 (m, 4H); 3.55 (m, 2H); 2.73-2.39 (br. m, 6H); 2.39 (m, 4H); 2.09 (m, 4H); 1.64 (m, 4H); 1.55-1.14 (br. m, 33H); 0.88 (m, 6H).</div>
    </li> <heading id="h-0186">BF. Compound 141: Diundecyl 6,6-((2-hydroxyethyl)azanediyl)dihexanoate</heading>
    <li> <para-num num="[1073]"> </para-num> <div id="p-1114" num="1073" class="description-line">Compound 141 was synthesized following Representative Procedure 3.</div>
    </li> <li> <div id="p-1115" num="0000" class="description-line">
      <chemistry id="CHEM-US-00217" num="00217">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/68/59/017bf6564b0c51/US20170210697A1-20170727-C00217.png"><img id="EMI-C00217" he="27.18mm" wi="100.58mm" file="US20170210697A1-20170727-C00217.TIF" alt="Figure US20170210697A1-20170727-C00217" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="109" alt="Figure US20170210697A1-20170727-C00217" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/68/59/017bf6564b0c51/US20170210697A1-20170727-C00217.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00217" attachment-type="cdx" file="US20170210697A1-20170727-C00217.CDX"> </attachment>
          <attachment idref="CHEM-US-00217" attachment-type="mol" file="US20170210697A1-20170727-C00217.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1074]"> </para-num> <div id="p-1116" num="1074" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1075]"> </para-num> <div id="p-1117" num="1075" class="description-line">Molecular Weight: 597.97</div>
    </li> <li> <para-num num="[1076]"> </para-num> <div id="p-1118" num="1076" class="description-line">UPLC/ELSD: RT=3.03 min. MS (ES): m/z (MH<sup>+</sup>) 598.63 for C<sub>36</sub>H<sub>71</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1077]"> </para-num> <div id="p-1119" num="1077" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (m, 4H); 3.53 (m, 2H); 2.95 (br. m, 1H); 2.65-2.35 (m, 6H); 2.30 (m, 4H); 1.73-1.54 (m, 8H); 1.54-1.15 (m, 40H); 0.88 (m, 6H).</div>
    </li> <heading id="h-0187">BG. Compound 142: 12,12-((2-Hydroxyethyl)azanediyl)didodecanoate</heading>
    <heading id="h-0188">12,12-((2-Hydroxyethyl)azanediyl)didodecanoate</heading>
    <li> <para-num num="[1078]"> </para-num> <div id="p-1120" num="1078" class="description-line">
      <chemistry id="CHEM-US-00218" num="00218">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/2a/e5/31f9d59cb3d962/US20170210697A1-20170727-C00218.png"><img id="EMI-C00218" he="25.23mm" wi="75.01mm" file="US20170210697A1-20170727-C00218.TIF" alt="Figure US20170210697A1-20170727-C00218" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="101" alt="Figure US20170210697A1-20170727-C00218" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/2a/e5/31f9d59cb3d962/US20170210697A1-20170727-C00218.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00218" attachment-type="cdx" file="US20170210697A1-20170727-C00218.CDX"> </attachment>
          <attachment idref="CHEM-US-00218" attachment-type="mol" file="US20170210697A1-20170727-C00218.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1079]"> </para-num> <div id="p-1121" num="1079" class="description-line">Chemical Formula: C<sub>28</sub>H<sub>55</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1080]"> </para-num> <div id="p-1122" num="1080" class="description-line">Molecular Weight: 485.75</div>
    </li> <li> <para-num num="[1081]"> </para-num> <div id="p-1123" num="1081" class="description-line">To a solution of methyl 12-bromododecanoate (1.5 g, 5.12 mmol) in MeCN (11 mL) was added ethanolamine (0.310 mL, 5.12 mmol), K2CO<sub>3 </sub>(1.42 g, 10.2 mmol), and KI (85 mg, 0.512 mmol). The reaction was allowed to stir at 82 C. for 16 hours. The reaction mixture was cooled to room temperature, filtered, and the solids were washed with hexanes. The filtrate was extracted with hexanes, and the combined extracts were concentrated in vacuo. Purification by silica gel chromatography (0-100% [DCM, 20% MeOH, 1% NH<sub>4</sub>OH]/MeOH) provided 12,12-((2-hydroxyethyl)azanediyl)didodecanoate (563 mg, 45%).</div>
    </li> <li> <para-num num="[1082]"> </para-num> <div id="p-1124" num="1082" class="description-line">UPLC/ELSD: RT=1.81 min. MS (ES): m/z (MH<sup>+</sup>) 486.63 for C<sub>28</sub>H<sub>55</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1083]"> </para-num> <div id="p-1125" num="1083" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.69 (s, 6H); 3.59 (br. m, 2H); 2.75-2.40 (br. m, 6H); 2.32 (t, 4H); 1.64 (m, 4H); 1.48 (br. m, 4H); 1.29 (br. m, 28H).</div>
    </li> <heading id="h-0189">BH. Compound 143: Nonyl 8-((2-hydroxyethyl)(7-((2-octyldecyl)oxy)-7-oxoheptyl)amino)octanoate</heading>
    <li> <para-num num="[1084]"> </para-num> <div id="p-1126" num="1084" class="description-line">
      <chemistry id="CHEM-US-00219" num="00219">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cb/94/ec/0a95b0ebb1abf6/US20170210697A1-20170727-C00219.png"><img id="EMI-C00219" he="17.95mm" wi="51.65mm" file="US20170210697A1-20170727-C00219.TIF" alt="Figure US20170210697A1-20170727-C00219" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="72" alt="Figure US20170210697A1-20170727-C00219" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cb/94/ec/0a95b0ebb1abf6/US20170210697A1-20170727-C00219.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00219" attachment-type="cdx" file="US20170210697A1-20170727-C00219.CDX"> </attachment>
          <attachment idref="CHEM-US-00219" attachment-type="mol" file="US20170210697A1-20170727-C00219.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1085]"> </para-num> <div id="p-1127" num="1085" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>36</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[1086]"> </para-num> <div id="p-1128" num="1086" class="description-line">Molecular Weight: 284.48</div>
    </li> <li> <para-num num="[1087]"> </para-num> <div id="p-1129" num="1087" class="description-line">A solution of diisopropylamine (2.92 mL, 20.8 mmol) in THF (10 mL) was cooled to 78 C. and a solution of n-BuLi (7.5 mL, 18.9 mmol, 2.5 M in hexanes) was added. The reaction was allowed to warm to 0 C. To a solution of decanoic acid (2.96 g, 17.2 mmol) and NaH (754 mg, 18.9 mmol, 60% w/w) in THF (20 mL) at 0 C. was added the solution of LDA and the mixture was allowed to stir at rt for 30 min. After this time 1-iodooctane (5 g, 20.8 mmol) was added and the reaction mixture was heated at 45 C. for 6 h. The reaction was quenched with 1N HCl (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered and evaporated under vacuum. The residue was purified by silica gel chromatography (0-20% ethyl acetate in hexanes) to yield 2-octyldecanoic acid (1.9 g, 6.6 mmol).</div>
    </li> <li> <para-num num="[1088]"> </para-num> <div id="p-1130" num="1088" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 2.38 (br. m, 1H); 1.74-1.03 (br. m, 28H); 0.91 (m, 6H).</div>
    </li> <heading id="h-0190">2-Octyldecan-1-ol</heading>
    <li> <para-num num="[1089]"> </para-num> <div id="p-1131" num="1089" class="description-line">
      <chemistry id="CHEM-US-00220" num="00220">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/65/4d/709a3115b81421/US20170210697A1-20170727-C00220.png"><img id="EMI-C00220" he="11.60mm" wi="51.65mm" file="US20170210697A1-20170727-C00220.TIF" alt="Figure US20170210697A1-20170727-C00220" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="46" alt="Figure US20170210697A1-20170727-C00220" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/65/4d/709a3115b81421/US20170210697A1-20170727-C00220.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00220" attachment-type="cdx" file="US20170210697A1-20170727-C00220.CDX"> </attachment>
          <attachment idref="CHEM-US-00220" attachment-type="mol" file="US20170210697A1-20170727-C00220.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1090]"> </para-num> <div id="p-1132" num="1090" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>38</sub>O</div>
    </li> <li> <para-num num="[1091]"> </para-num> <div id="p-1133" num="1091" class="description-line">Molecular Weight: 270.50</div>
    </li> <li> <para-num num="[1092]"> </para-num> <div id="p-1134" num="1092" class="description-line">A solution of 2-octyldecanoic acid (746 mg, 2.6 mmol) in dry THF (12 mL) was added to a stirred solution of LAH (5.2 mL, 5.2 mmol, 1M solution in THF) in dry THF (6 mL) under nitrogen at 0 C. The reaction was allowed to warm to rt and stirred at rt for 12 h. A solution of saturated Na<sub>2</sub>SO<sub>4*10</sub>H<sub>2</sub>O solution (10 mL) was added. The solids were filtered through a plug of Celite. The filtrate was evaporated under vacuum and the residue was purified by silica gel chromatography (0-20% ethyl acetate in hexanes) to yield 2-octyldecan-1-ol (635 mg, 2.3 mmol).</div>
    </li> <li> <para-num num="[1093]"> </para-num> <div id="p-1135" num="1093" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.54 (d, 2H); 1.56-1.21 (br. m, 30H); 0.91 (t, 6H).</div>
    </li> <li> <div id="p-1136" num="0000" class="description-line">
      <chemistry id="CHEM-US-00221" num="00221">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/c1/07/a6c7e91ed88cac/US20170210697A1-20170727-C00221.png"><img id="EMI-C00221" he="15.07mm" wi="74.93mm" file="US20170210697A1-20170727-C00221.TIF" alt="Figure US20170210697A1-20170727-C00221" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="60" alt="Figure US20170210697A1-20170727-C00221" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/c1/07/a6c7e91ed88cac/US20170210697A1-20170727-C00221.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00221" attachment-type="cdx" file="US20170210697A1-20170727-C00221.CDX"> </attachment>
          <attachment idref="CHEM-US-00221" attachment-type="mol" file="US20170210697A1-20170727-C00221.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1094]"> </para-num> <div id="p-1137" num="1094" class="description-line">2-Octyldecyl 7-bromoheptanoate was synthesized according to Method A.</div>
    </li> <li> <para-num num="[1095]"> </para-num> <div id="p-1138" num="1095" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.96 (d, 2H); 3.40 (t, 2H); 2.31 (t, 2H); 1.86 (m, 2H); 1.71-1.19 (m, 35H); 0.88 (m, 6H).</div>
    </li> <li> <para-num num="[1096]"> </para-num> <div id="p-1139" num="1096" class="description-line">Nonyl 8-((2-hydroxyethyl)(7-((2-octyldecyl)oxy)-7-oxoheptyl)amino)octanoate was synthesized using Representative Procedure 2.</div>
    </li> <li> <div id="p-1140" num="0000" class="description-line">
      <chemistry id="CHEM-US-00222" num="00222">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/c4/e4/aed7cea5f091ce/US20170210697A1-20170727-C00222.png"><img id="EMI-C00222" he="32.85mm" wi="100.58mm" file="US20170210697A1-20170727-C00222.TIF" alt="Figure US20170210697A1-20170727-C00222" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="131" alt="Figure US20170210697A1-20170727-C00222" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/c4/e4/aed7cea5f091ce/US20170210697A1-20170727-C00222.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00222" attachment-type="cdx" file="US20170210697A1-20170727-C00222.CDX"> </attachment>
          <attachment idref="CHEM-US-00222" attachment-type="mol" file="US20170210697A1-20170727-C00222.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1097]"> </para-num> <div id="p-1141" num="1097" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1098]"> </para-num> <div id="p-1142" num="1098" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[1099]"> </para-num> <div id="p-1143" num="1099" class="description-line">UPLC/ELSD: RT=5.23 min. MS (ES): m/z (MH<sup>+</sup>) 711.08 for C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1100]"> </para-num> <div id="p-1144" num="1100" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (t, 2H); 3.96 (d, 2H); 3.58 (br. m, 2H); 2.79-2.36 (br. m, 5H); 2.30 (m, 4H); 1.72-1.01 (br. m, 63H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0191">BI. Compound 144: Nonyl 8-((8-(dioctylamino)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate 8-Bromo-N,N-dioctyloctanamide</heading>
    <li> <para-num num="[1101]"> </para-num> <div id="p-1145" num="1101" class="description-line">
      <chemistry id="CHEM-US-00223" num="00223">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/c6/49/e3d25903e99b76/US20170210697A1-20170727-C00223.png"><img id="EMI-C00223" he="15.83mm" wi="74.76mm" file="US20170210697A1-20170727-C00223.TIF" alt="Figure US20170210697A1-20170727-C00223" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="63" alt="Figure US20170210697A1-20170727-C00223" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/c6/49/e3d25903e99b76/US20170210697A1-20170727-C00223.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00223" attachment-type="cdx" file="US20170210697A1-20170727-C00223.CDX"> </attachment>
          <attachment idref="CHEM-US-00223" attachment-type="mol" file="US20170210697A1-20170727-C00223.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1102]"> </para-num> <div id="p-1146" num="1102" class="description-line">Chemical Formula: C<sub>24</sub>H<sub>48</sub>BrNO</div>
    </li> <li> <para-num num="[1103]"> </para-num> <div id="p-1147" num="1103" class="description-line">Molecular Weight: 446.56</div>
    </li> <li> <para-num num="[1104]"> </para-num> <div id="p-1148" num="1104" class="description-line">To a solution of 8-bromooctanoic acid (1 g, 2.2 mmol) and DMF (1 drop) in dichloromethane was added oxalyl chloride (0.416 mL, 2.5 mmol) dropwise. The reaction was allowed to stir for 1 h at room temperature. Solvents were evaporated and the residue was added to a solution of dioctylamine (1.14 g, 4.8 mmol) and DMAP (100 mg, 0.8 mmol). Triethylamine was added to the reaction dropwise and the reaction was allowed to stir for 18 h. The solvents were evaporated and the residue was taken up in ethyl acetate and saturated NaHCO<sub>3</sub>. The organic layer was separated and washed with water and brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and evaporated in vacuo. The residue was purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane to yield a mixture of 8-bromo-N,N-dioctyloctanamide and chloro-N,N-dioctyloctanamide (736 mg, 1.6 mmol).</div>
    </li> <li> <para-num num="[1105]"> </para-num> <div id="p-1149" num="1105" class="description-line">UPLC/ELSD: RT=4.02 min. MS (ES): m/z (MH<sup>+</sup>) 446.53 for C<sub>24</sub>H<sub>48</sub>BrNO</div>
    </li> <li> <para-num num="[1106]"> </para-num> <div id="p-1150" num="1106" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.55 (t, 0.6H); 3.42 (t, 1.4H); 3.36-3.15 (m, 4H); 2.31 (t, 2H); 1.96-1.18 (m, 34H); 0.91 (m, 6H).</div>
    </li> <li> <para-num num="[1107]"> </para-num> <div id="p-1151" num="1107" class="description-line">Nonyl 8-((8-(dioctylamino)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate was synthesized utilizing Representative Procedure 2.</div>
    </li> <li> <div id="p-1152" num="0000" class="description-line">
      <chemistry id="CHEM-US-00224" num="00224">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/43/d4/60fb4f7ae49dc4/US20170210697A1-20170727-C00224.png"><img id="EMI-C00224" he="34.88mm" wi="100.58mm" file="US20170210697A1-20170727-C00224.TIF" alt="Figure US20170210697A1-20170727-C00224" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="140" alt="Figure US20170210697A1-20170727-C00224" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/43/d4/60fb4f7ae49dc4/US20170210697A1-20170727-C00224.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00224" attachment-type="cdx" file="US20170210697A1-20170727-C00224.CDX"> </attachment>
          <attachment idref="CHEM-US-00224" attachment-type="mol" file="US20170210697A1-20170727-C00224.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1108]"> </para-num> <div id="p-1153" num="1108" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1109]"> </para-num> <div id="p-1154" num="1109" class="description-line">Molecular Weight: 695.17</div>
    </li> <li> <para-num num="[1110]"> </para-num> <div id="p-1155" num="1110" class="description-line">UPLC/ELSD: RT=4.24 min. MS (ES): m/z (MH<sup>+</sup>) 696.16 for C<sub>43</sub>H<sub>86</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1111]"> </para-num> <div id="p-1156" num="1111" class="description-line"> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.05 (t, 2H); 3.57 (br. m, 2H); 3.35-3.14 (m, 4H); 2.80-.2.20 (m, 10H); 1.74-1.00 (br. m, 59H); 0.88 (m, 9H).</div>
    </li> <heading id="h-0192">XX45. Compound 145: Heptadecan-9-yl 8-((2-hydroxyethyl)(8-(methyl(octyl)amino)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1112]"> </para-num> <div id="p-1157" num="1112" class="description-line">
      <chemistry id="CHEM-US-00225" num="00225">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e6/df/4e/9345d18b16e1b4/US20170210697A1-20170727-C00225.png"><img id="EMI-C00225" he="34.04mm" wi="100.58mm" file="US20170210697A1-20170727-C00225.TIF" alt="Figure US20170210697A1-20170727-C00225" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="402" height="136" alt="Figure US20170210697A1-20170727-C00225" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e6/df/4e/9345d18b16e1b4/US20170210697A1-20170727-C00225.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00225" attachment-type="cdx" file="US20170210697A1-20170727-C00225.CDX"> </attachment>
          <attachment idref="CHEM-US-00225" attachment-type="mol" file="US20170210697A1-20170727-C00225.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1113]"> </para-num> <div id="p-1158" num="1113" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>88</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1114]"> </para-num> <div id="p-1159" num="1114" class="description-line">Molecular Weight: 709.198</div>
    </li> <li> <para-num num="[1115]"> </para-num> <div id="p-1160" num="1115" class="description-line">Compound 145 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.17 min. MS (ES): m/z (MH<sup>+</sup>) 710.0 for C<sub>44</sub>H<sub>88</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 3.55 (m, 2H); 3.37 (t, 1H); 3.27 (t, 1H); 2.98 (s, 1.5H); 2.93 (s, 1.5H); 2.59 (m, 2H); 2.47 (m, 4H); 2.30 (m, 4H), 1.75-1.20 (m, 60H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0193">XX46. Compound 146: Heptadecan-9-yl 8-((2-hydroxyethyl)(6-(methyl(octyl)amino)-6-oxohexyl)amino)octanoate</heading>
    <li> <para-num num="[1116]"> </para-num> <div id="p-1161" num="1116" class="description-line">
      <chemistry id="CHEM-US-00226" num="00226">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/59/c9/7d/ae57169f5f8a58/US20170210697A1-20170727-C00226.png"><img id="EMI-C00226" he="26.59mm" wi="75.18mm" file="US20170210697A1-20170727-C00226.TIF" alt="Figure US20170210697A1-20170727-C00226" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="106" alt="Figure US20170210697A1-20170727-C00226" class="patent-full-image" src="https://patentimages.storage.googleapis.com/59/c9/7d/ae57169f5f8a58/US20170210697A1-20170727-C00226.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00226" attachment-type="cdx" file="US20170210697A1-20170727-C00226.CDX"> </attachment>
          <attachment idref="CHEM-US-00226" attachment-type="mol" file="US20170210697A1-20170727-C00226.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1117]"> </para-num> <div id="p-1162" num="1117" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>84</sub>N<sub>2</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1118]"> </para-num> <div id="p-1163" num="1118" class="description-line">Molecular Weight: 681.144</div>
    </li> <li> <para-num num="[1119]"> </para-num> <div id="p-1164" num="1119" class="description-line">Compound 146 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.01 min. MS (ES): m/z (MH<sup>+</sup>) 682.0 for C<sub>42</sub>H<sub>84</sub>N<sub>2</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (m, 1H); 3.55 (m, 2H); 3.37 (t, 1H); 3.26 (t, 1H); 2.98 (s, 1.5H); 2.93 (s, 1.5H); 2.59 (m, 2H); 2.48 (m, 4H); 2.31 (m, 4H), 1.76-1.18 (m, 56H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0194">XX47. Compound 147: Tridecan-7-yl 10-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)decanoate</heading>
    <li> <para-num num="[1120]"> </para-num> <div id="p-1165" num="1120" class="description-line">
      <chemistry id="CHEM-US-00227" num="00227">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/e2/d8/23a5546ad2c9bb/US20170210697A1-20170727-C00227.png"><img id="EMI-C00227" he="29.29mm" wi="105.49mm" file="US20170210697A1-20170727-C00227.TIF" alt="Figure US20170210697A1-20170727-C00227" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00227" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5b/e2/d8/23a5546ad2c9bb/US20170210697A1-20170727-C00227.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00227" attachment-type="cdx" file="US20170210697A1-20170727-C00227.CDX"> </attachment>
          <attachment idref="CHEM-US-00227" attachment-type="mol" file="US20170210697A1-20170727-C00227.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1121]"> </para-num> <div id="p-1166" num="1121" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1122]"> </para-num> <div id="p-1167" num="1122" class="description-line">Molecular Weight: 682.128</div>
    </li> <li> <para-num num="[1123]"> </para-num> <div id="p-1168" num="1123" class="description-line">Compound 147 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.16 min. MS (ES): m/z (MH<sup>+</sup>) 683.0 for C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (m, 2H); 3.55 (m, 2H); 2.59 (m, 2H); 2.46 (m, 4H); 2.30 (m, 4H), 1.72-1.18 (m, 58H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0195">XX48. Compound 148: Heptadecan-9-yl 8-((2-hydroxyethyl)(8-((2-methoxynonyl)oxy)-8-oxooctyl)amino)octanoate 1-((tert-Butyldiphenylsilyl)oxy)nonan-2-ol</heading>
    <li> <para-num num="[1124]"> </para-num> <div id="p-1169" num="1124" class="description-line">
      <chemistry id="CHEM-US-00228" num="00228">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d5/c2/4a/6634f771922d42/US20170210697A1-20170727-C00228.png"><img id="EMI-C00228" he="17.86mm" wi="58.84mm" file="US20170210697A1-20170727-C00228.TIF" alt="Figure US20170210697A1-20170727-C00228" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="235" height="71" alt="Figure US20170210697A1-20170727-C00228" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d5/c2/4a/6634f771922d42/US20170210697A1-20170727-C00228.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00228" attachment-type="cdx" file="US20170210697A1-20170727-C00228.CDX"> </attachment>
          <attachment idref="CHEM-US-00228" attachment-type="mol" file="US20170210697A1-20170727-C00228.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1125]"> </para-num> <div id="p-1170" num="1125" class="description-line">Chemical Formula: C<sub>25</sub>H<sub>38</sub>O<sub>2</sub>Si</div>
    </li> <li> <para-num num="[1126]"> </para-num> <div id="p-1171" num="1126" class="description-line">Molecular Weight: 398.662</div>
    </li> <li> <para-num num="[1127]"> </para-num> <div id="p-1172" num="1127" class="description-line">TBDPSCl (8.58 g, 31.2 mmol) was added to a mixture of nonane-1,2-diol (5.0 g, 31.2 mmol) and imidazole (4.24 g, 62.4 mmol) in DMF at RT. The reaction was stirred at RT overnight. The reaction was diluted with water (150 mL) and extracted with EtOAc/hexanes (1:1) (4). The combined organic layer was washed with brine, separated, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by ISCO with (0-10%) EtOAc in hexanes to obtain 1-((tert-butyldiphenylsilyl)oxy)nonan-2-ol (7.75 g, 19.4 mmol). <sup>1</sup>H NMR (300 MHz, DMSO) : ppm 7.63 (m, 4H); 7.43 (m, 6H); 4.51 (d, 1H); 3.54 (m, 2H); 3.43 (m, 1H); 1.57 (m, 1H); 1.24 (m, 11H); 1.00 (s, 9H); 0.85 (m, 3H).</div>
    </li> <heading id="h-0196">2-Methoxynonyl 8-bronmooctanoate</heading>
    <li> <para-num num="[1128]"> </para-num> <div id="p-1173" num="1128" class="description-line">
      <chemistry id="CHEM-US-00229" num="00229">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/43/e6/24b0cf13ca937f/US20170210697A1-20170727-C00229.png"><img id="EMI-C00229" he="14.73mm" wi="73.66mm" file="US20170210697A1-20170727-C00229.TIF" alt="Figure US20170210697A1-20170727-C00229" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="295" height="59" alt="Figure US20170210697A1-20170727-C00229" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7b/43/e6/24b0cf13ca937f/US20170210697A1-20170727-C00229.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00229" attachment-type="cdx" file="US20170210697A1-20170727-C00229.CDX"> </attachment>
          <attachment idref="CHEM-US-00229" attachment-type="mol" file="US20170210697A1-20170727-C00229.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1129]"> </para-num> <div id="p-1174" num="1129" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>35</sub>BrO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1130]"> </para-num> <div id="p-1175" num="1130" class="description-line">Molecular Weight: 379.379</div>
    </li> <li> <para-num num="[1131]"> </para-num> <div id="p-1176" num="1131" class="description-line">2-Methoxynonyl 8-bromooctanoate was synthesized following Method A in Representative Procedure 1. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.19 (m, 1H); 4.04 (m, 1H); 3.42 (m, 6H); 2.36 (t, 2H); 1.87 (m, 2H); 1.73-1.22 (m, 20H); 0.93 (m, 3H).</div>
    </li> <heading id="h-0197">Heptadecan-9-yl 8-((2-hydroxyethyl)(8-((2-methoxynonyl)oxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1132]"> </para-num> <div id="p-1177" num="1132" class="description-line">
      <chemistry id="CHEM-US-00230" num="00230">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f6/6d/e7/a0beb864fc2cdb/US20170210697A1-20170727-C00230.png"><img id="EMI-C00230" he="37.00mm" wi="105.49mm" file="US20170210697A1-20170727-C00230.TIF" alt="Figure US20170210697A1-20170727-C00230" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="148" alt="Figure US20170210697A1-20170727-C00230" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f6/6d/e7/a0beb864fc2cdb/US20170210697A1-20170727-C00230.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00230" attachment-type="cdx" file="US20170210697A1-20170727-C00230.CDX"> </attachment>
          <attachment idref="CHEM-US-00230" attachment-type="mol" file="US20170210697A1-20170727-C00230.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1133]"> </para-num> <div id="p-1178" num="1133" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[1134]"> </para-num> <div id="p-1179" num="1134" class="description-line">Molecular Weight: 740.208</div>
    </li> <li> <para-num num="[1135]"> </para-num> <div id="p-1180" num="1135" class="description-line">Compound 148 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.48 min. MS (ES): m/z (MH<sup>+</sup>) 741.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.19 (m, 1H); 4.04 (m, 1H); 3.57 (m, 2H); 3.42 (s, 3H); 3.37 (m, 1H); 2.73-2.41 (m, 6H); 2.33 (m, 4H), 1.73-1.19 (m, 61H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0198">XX49. Compound 149: Heptyl 10-((8-(heptadecan-9-yloxy)-8-oxooctyl)(methyl)amino)decanoate</heading>
    <li> <para-num num="[1136]"> </para-num> <div id="p-1181" num="1136" class="description-line">
      <chemistry id="CHEM-US-00231" num="00231">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/3e/86/f34f1e43b7f39f/US20170210697A1-20170727-C00231.png"><img id="EMI-C00231" he="22.44mm" wi="75.69mm" file="US20170210697A1-20170727-C00231.TIF" alt="Figure US20170210697A1-20170727-C00231" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="90" alt="Figure US20170210697A1-20170727-C00231" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/3e/86/f34f1e43b7f39f/US20170210697A1-20170727-C00231.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00231" attachment-type="cdx" file="US20170210697A1-20170727-C00231.CDX"> </attachment>
          <attachment idref="CHEM-US-00231" attachment-type="mol" file="US20170210697A1-20170727-C00231.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1137]"> </para-num> <div id="p-1182" num="1137" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>85</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[1138]"> </para-num> <div id="p-1183" num="1138" class="description-line">Molecular Weight: 680.156</div>
    </li> <li> <para-num num="[1139]"> </para-num> <div id="p-1184" num="1139" class="description-line">Compound 149 was synthesized similarly to Compound 123 and according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.55 min. MS (ES): m/z (MH<sup>+</sup>) 681.0 for C<sub>43</sub>H<sub>85</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 2.42-2.14 (m, 11H); 1.73-1.17 (m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0199">XX50. Compound 150: Pentyl 12-((8-(heptadecan-9-yloxy)-8-oxooctyl)(methyl)amino)dodecanoate</heading>
    <li> <para-num num="[1140]"> </para-num> <div id="p-1185" num="1140" class="description-line">
      <chemistry id="CHEM-US-00232" num="00232">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cb/0d/b6/4da7be2bf9ebd6/US20170210697A1-20170727-C00232.png"><img id="EMI-C00232" he="22.10mm" wi="74.51mm" file="US20170210697A1-20170727-C00232.TIF" alt="Figure US20170210697A1-20170727-C00232" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="88" alt="Figure US20170210697A1-20170727-C00232" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cb/0d/b6/4da7be2bf9ebd6/US20170210697A1-20170727-C00232.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00232" attachment-type="cdx" file="US20170210697A1-20170727-C00232.CDX"> </attachment>
          <attachment idref="CHEM-US-00232" attachment-type="mol" file="US20170210697A1-20170727-C00232.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1141]"> </para-num> <div id="p-1186" num="1141" class="description-line">Chemical Formula: C<sub>43</sub>H<sub>85</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[1142]"> </para-num> <div id="p-1187" num="1142" class="description-line">Molecular Weight: 680.156</div>
    </li> <li> <para-num num="[1143]"> </para-num> <div id="p-1188" num="1143" class="description-line">Compound 150 was synthesized similarly to Compound 123 and according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.47 min. MS (ES): m/z (MH<sup>+</sup>) 681.0 for C<sub>43</sub>H<sub>85</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 2.42-2.16 (m, 10H); 1.73-1.20 (m, 63H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0200">XX51. Compound 151: 7-((7-(Decanoyloxy)heptyl)(2-hydroxyethyl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[1144]"> </para-num> <div id="p-1189" num="1144" class="description-line">
      <chemistry id="CHEM-US-00233" num="00233">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6f/e8/12/7c6e467b539d98/US20170210697A1-20170727-C00233.png"><img id="EMI-C00233" he="27.18mm" wi="105.49mm" file="US20170210697A1-20170727-C00233.TIF" alt="Figure US20170210697A1-20170727-C00233" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00233" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6f/e8/12/7c6e467b539d98/US20170210697A1-20170727-C00233.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00233" attachment-type="cdx" file="US20170210697A1-20170727-C00233.CDX"> </attachment>
          <attachment idref="CHEM-US-00233" attachment-type="mol" file="US20170210697A1-20170727-C00233.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1145]"> </para-num> <div id="p-1190" num="1145" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1146]"> </para-num> <div id="p-1191" num="1146" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[1147]"> </para-num> <div id="p-1192" num="1147" class="description-line">Compound 151 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.83 min. MS (ES): m/z (MH<sup>+</sup>) 711.0 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.07 (m, 4H); 3.57 (m, 2H); 2.63 (br. m, 2H); 2.50 (m, 4H); 2.31 (m, 3H), 1.71-1.19 (m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0201">XX52. Compound 152: Nonyl (Z)-8-((2-hydroxyethyl)(10-octyloctadec-8-en-1-yl)amino)octanoate</heading>
    <heading id="h-0202">N-Methoxy-N-methyl-2-octyldecanamide</heading>
    <li> <para-num num="[1148]"> </para-num> <div id="p-1193" num="1148" class="description-line">
      <chemistry id="CHEM-US-00234" num="00234">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/ff/2e/73a4c72d5ec141/US20170210697A1-20170727-C00234.png"><img id="EMI-C00234" he="17.95mm" wi="54.02mm" file="US20170210697A1-20170727-C00234.TIF" alt="Figure US20170210697A1-20170727-C00234" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="216" height="72" alt="Figure US20170210697A1-20170727-C00234" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/ff/2e/73a4c72d5ec141/US20170210697A1-20170727-C00234.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00234" attachment-type="cdx" file="US20170210697A1-20170727-C00234.CDX"> </attachment>
          <attachment idref="CHEM-US-00234" attachment-type="mol" file="US20170210697A1-20170727-C00234.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1149]"> </para-num> <div id="p-1194" num="1149" class="description-line">Chemical Formula: C<sub>20</sub>H<sub>41</sub>NO<sub>2 </sub> </div>
    </li> <li> <para-num num="[1150]"> </para-num> <div id="p-1195" num="1150" class="description-line">Molecular Weight: 327.553</div>
    </li> <li> <para-num num="[1151]"> </para-num> <div id="p-1196" num="1151" class="description-line">To a solution of 2-octyl-decanoic acid (11.1 g, 39.02 mmol) and DMF (0.05 mL, 3.9 mmol) in DCM (100 mL) oxalyl chloride (3.63 mL, 42.92 mmol) was added dropwise. The reaction was allowed to stir for 2 h at rt. Solvents and volatiles were evaporated under vacuum. The resulting residue (crude 2-octyldecanoyl chloride) (11.82 g, 39.02 mmol) was taken up in DCM (100 mL) and N,O-dimethylhydroxylamine hydrochloride (4 g, 40.97 mmol) and 4-dimethylaminopyridine (0.48 g, 3.9 mmol) were added. The mixture was allowed to cool to 0 C. and triethylamine (19.04 mL, 136.57 mmol) was slowly added. The reaction was allowed to warm to rt and stir for 1 h. Solvents were evaporated under vacuum. The residue was diluted with EtOAc and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain N-methoxy-N-methyl-2-octyldecanamide (7.10 g, 21.68 mmol, 56%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.70 (s, 3H); 3.22 (s, 3H); 2.82 (br. m, 1H); 1.62 (m, 2H); 1.51-1.19 (m, 26H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0203">2-Octyldecanol</heading>
    <li> <para-num num="[1152]"> </para-num> <div id="p-1197" num="1152" class="description-line">
      <chemistry id="CHEM-US-00235" num="00235">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/03/c9/b7cef9a0061ebb/US20170210697A1-20170727-C00235.png"><img id="EMI-C00235" he="17.95mm" wi="49.95mm" file="US20170210697A1-20170727-C00235.TIF" alt="Figure US20170210697A1-20170727-C00235" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="200" height="72" alt="Figure US20170210697A1-20170727-C00235" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/03/c9/b7cef9a0061ebb/US20170210697A1-20170727-C00235.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00235" attachment-type="cdx" file="US20170210697A1-20170727-C00235.CDX"> </attachment>
          <attachment idref="CHEM-US-00235" attachment-type="mol" file="US20170210697A1-20170727-C00235.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1153]"> </para-num> <div id="p-1198" num="1153" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>36</sub>O</div>
    </li> <li> <para-num num="[1154]"> </para-num> <div id="p-1199" num="1154" class="description-line">Molecular Weight: 268.485</div>
    </li> <li> <para-num num="[1155]"> </para-num> <div id="p-1200" num="1155" class="description-line">A solution of N-methoxy-N-methyl-2-octyldecanamide (7.1 g, 21.68 mmol) in dry THF (2 ml) was added to a suspension of LAH (27.53 mL 1 M in THF, 27.53 mmol) in dry THF (5 ml) at 45 C. The resulting suspension was stirred for 1 h at 45 C., after which time it was allowed to warm to room temperature and stir for 0.5 h. The reaction was cooled back to 45 C. and quenched with a sat. aqueous solution of sodium sulfate decahydrate (2 mL) The mixture was stirred for 20 min at room temperature and filtered through plug of Celite. The filtrate was washed with brine. The organic layer was separated, dried over sodium sulfate, filtered and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-10%) EtOAc in hexanes to obtain 2-octyldecanol (4.45 g, 16.57 mmol, 76%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 9.58 (d, 1H); 2.23 (m, 1H); 1.63 (m, 2H); 1.53-1.19 (m, 26H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0204">(Z)-10-Octyloctadec-8-en-1-ol</heading>
    <li> <para-num num="[1156]"> </para-num> <div id="p-1201" num="1156" class="description-line">
      <chemistry id="CHEM-US-00236" num="00236">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b2/f0/ca/14e76ca71117a0/US20170210697A1-20170727-C00236.png"><img id="EMI-C00236" he="13.46mm" wi="75.18mm" file="US20170210697A1-20170727-C00236.TIF" alt="Figure US20170210697A1-20170727-C00236" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="54" alt="Figure US20170210697A1-20170727-C00236" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b2/f0/ca/14e76ca71117a0/US20170210697A1-20170727-C00236.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00236" attachment-type="cdx" file="US20170210697A1-20170727-C00236.CDX"> </attachment>
          <attachment idref="CHEM-US-00236" attachment-type="mol" file="US20170210697A1-20170727-C00236.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1157]"> </para-num> <div id="p-1202" num="1157" class="description-line">Chemical Formula: C<sub>26</sub>H<sub>52</sub>O</div>
    </li> <li> <para-num num="[1158]"> </para-num> <div id="p-1203" num="1158" class="description-line">Molecular Weight: 380.701</div>
    </li> <li> <para-num num="[1159]"> </para-num> <div id="p-1204" num="1159" class="description-line">A solution of (8-hydroxyoctyl)triphenylphosphonium bromide (3.68 g, 7.81 mmol) in THF (16 mL) and HMPA was cooled in an ice bath and NaHMDS (19.52 mL 1 M, 19.52 mmol) was added. 2-Octyldecanal (1.05 g, 3.9 mmol) in THF (5 mL) was slowly added and the reaction was warmed to 30 C. After 16 h the reaction was diluted with 20 mL of water and acidified with 2N HCl. The reaction was extracted with EtOAc (350 mL). The combined organic extracts were dried over sodium sulfate, filtered and concentrated under reduce pressure. The residue was purified by silica gel chromatography (0-50%) EtOAc in hexanes to obtain (Z)-10-octyloctadec-8-en-1-ol (0.5 g, 1.30 mmol, 33%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.24 (m, 1H); 4.90 (m, 1H); 3.53 (t, 2H); 2.14 (m, 1H); 1.89 (m, 2H); 1.45 (m, 3H); 1.33-0.95 (m, 36H); 0.77 (m, 6H).</div>
    </li> <heading id="h-0205">(Z)-1-Bromo-10-octyloctadec-8-ene</heading>
    <li> <para-num num="[1160]"> </para-num> <div id="p-1205" num="1160" class="description-line">
      <chemistry id="CHEM-US-00237" num="00237">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/7d/6e/7b7f9032461af0/US20170210697A1-20170727-C00237.png"><img id="EMI-C00237" he="13.46mm" wi="74.68mm" file="US20170210697A1-20170727-C00237.TIF" alt="Figure US20170210697A1-20170727-C00237" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="54" alt="Figure US20170210697A1-20170727-C00237" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2b/7d/6e/7b7f9032461af0/US20170210697A1-20170727-C00237.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00237" attachment-type="cdx" file="US20170210697A1-20170727-C00237.CDX"> </attachment>
          <attachment idref="CHEM-US-00237" attachment-type="mol" file="US20170210697A1-20170727-C00237.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1161]"> </para-num> <div id="p-1206" num="1161" class="description-line">Chemical Formula: C<sub>26</sub>H<sub>51</sub>Br</div>
    </li> <li> <para-num num="[1162]"> </para-num> <div id="p-1207" num="1162" class="description-line">Molecular Weight: 443.598</div>
    </li> <li> <para-num num="[1163]"> </para-num> <div id="p-1208" num="1163" class="description-line">To a solution of PPh<sub>3 </sub>(0.29 g, 1.11 mmol) and (8Z)-10-octyloctadec-8-en-1-ol (0.4 g, 1.05 mmol) in DCM (10 mL) at 0 C., NBS (0.22 g, 1.22 mmol) was added in one portion. The reaction was allowed to stir at 0 C. for 1 h and then warm to rt and stir for 1 h. 300 mL of hexanes were added and the mixture was filtered through a silica plug and evaporated under vacuum. 200 mL of hexanes were added and the mixture was filtered through a silica plug and evaporated under vacuum to obtain (Z)-1-bromo-10-octyloctadec-8-ene (0.39 g, 0.88 mmol, 83%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.24 (m, 1H); 4.90 (m, 1H); 3.53 (t, 2H); 2.14 (m, 1H); 1.89 (m, 2H); 1.45 (m, 3H); 1.33-0.95 (m, 36H); 0.77 (m, 6H).</div>
    </li> <heading id="h-0206">Nonyl (Z)-8-((2-hydroxyethyl)(10-octyloctadec-8-en-1-yl)amino)octanoate</heading>
    <li> <para-num num="[1164]"> </para-num> <div id="p-1209" num="1164" class="description-line">
      <chemistry id="CHEM-US-00238" num="00238">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/30/31/8323b6acdc51ba/US20170210697A1-20170727-C00238.png"><img id="EMI-C00238" he="29.29mm" wi="105.49mm" file="US20170210697A1-20170727-C00238.TIF" alt="Figure US20170210697A1-20170727-C00238" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00238" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/30/31/8323b6acdc51ba/US20170210697A1-20170727-C00238.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00238" attachment-type="cdx" file="US20170210697A1-20170727-C00238.CDX"> </attachment>
          <attachment idref="CHEM-US-00238" attachment-type="mol" file="US20170210697A1-20170727-C00238.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1165]"> </para-num> <div id="p-1210" num="1165" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1166]"> </para-num> <div id="p-1211" num="1166" class="description-line">Molecular Weight: 693.211</div>
    </li> <li> <para-num num="[1167]"> </para-num> <div id="p-1212" num="1167" class="description-line">Compound 152 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.00 min. MS (ES): m/z (MH<sup>+</sup>) 694.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.36 (m, 1H); 5.03 (m, 1H); 4.07 (t, 2H); 3.54 (t, 2H); 2.59 (t, 2H); 2.46 (m, 4H); 2.30 (m, 3H); 2.01 (m, 2H); 1.63 (m, 4H); 1.53-1.03 (m, 58H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0207">XX53. Compound 153: Nonyl 8-((2-hydroxyethyl)(10-octyloctadecyl)amino)octanoate</heading>
    <li> <para-num num="[1168]"> </para-num> <div id="p-1213" num="1168" class="description-line">
      <chemistry id="CHEM-US-00239" num="00239">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d5/33/65/dcf72e89242beb/US20170210697A1-20170727-C00239.png"><img id="EMI-C00239" he="29.21mm" wi="105.49mm" file="US20170210697A1-20170727-C00239.TIF" alt="Figure US20170210697A1-20170727-C00239" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="117" alt="Figure US20170210697A1-20170727-C00239" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d5/33/65/dcf72e89242beb/US20170210697A1-20170727-C00239.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00239" attachment-type="cdx" file="US20170210697A1-20170727-C00239.CDX"> </attachment>
          <attachment idref="CHEM-US-00239" attachment-type="mol" file="US20170210697A1-20170727-C00239.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1169]"> </para-num> <div id="p-1214" num="1169" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>91</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1170]"> </para-num> <div id="p-1215" num="1170" class="description-line">Molecular Weight: 694.227</div>
    </li> <li> <para-num num="[1171]"> </para-num> <div id="p-1216" num="1171" class="description-line">A flask was charged with Pd(OH)<sub>2 </sub>(20 mg) and purged with N2. A solution of nonyl 8-[(2-hydroxyethyl)[(8Z)-10-octyloctadec-8-en-1-yl]amino]octanoate (100 mg, 0.14 mmol) in EtOH (1 mL) was added. The reaction was purged with H<sub>2 </sub>and was kept under H<sub>2 </sub>(balloon) with stirring for 16 h at rt. After this time the reaction was purged with N2. The reaction was filtered through a plug of Celite and washed with EtOH (50 mL). The filtrate was evaporated under vacuum. The residue was dissolved in EtOAc and washed with water. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-50%) (1%, 20% MeOH in DCM) in DCM to obtain nonyl 8-((2-hydroxyethyl)(10-octyloctadecyl)amino)octanoate (0.069 g, 0.099 mmol, 69%). UPLC/ELSD: RT=3.21 min. MS (ES): m/z (MH<sup>+</sup>) 695.08 for C<sub>45</sub>H<sub>91</sub>NO<sub>3</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 2H); 3.56 (t, 2H); 2.62 (m, 2H); 2.48 (m, 4H); 2.31 (m, 2H); 1.64 (m, 4H); 1.54-1.16 (m, 66H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0208">XX54. Compound 154: Heptadecan-9-yl 8-((2-(2-hydroxyethoxy)ethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1172]"> </para-num> <div id="p-1217" num="1172" class="description-line">
      <chemistry id="CHEM-US-00240" num="00240">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/5a/a2/014d57e59d80af/US20170210697A1-20170727-C00240.png"><img id="EMI-C00240" he="29.29mm" wi="120.14mm" file="US20170210697A1-20170727-C00240.TIF" alt="Figure US20170210697A1-20170727-C00240" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="481" height="117" alt="Figure US20170210697A1-20170727-C00240" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/5a/a2/014d57e59d80af/US20170210697A1-20170727-C00240.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00240" attachment-type="cdx" file="US20170210697A1-20170727-C00240.CDX"> </attachment>
          <attachment idref="CHEM-US-00240" attachment-type="mol" file="US20170210697A1-20170727-C00240.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1173]"> </para-num> <div id="p-1218" num="1173" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[1174]"> </para-num> <div id="p-1219" num="1174" class="description-line">Molecular Weight: 754.235</div>
    </li> <li> <para-num num="[1175]"> </para-num> <div id="p-1220" num="1175" class="description-line">Compound 154 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.54 min. MS (ES): m/z (MH<sup>+</sup>) 755.0 for C<sub>46</sub>H<sub>91</sub>NO<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (m, 1H); 4.62 (m, 1H); 4.08 (t, 2H); 3.79-3.56 (m, 6H); 2.64 (m, 2H); 2.47 (m, 4H); 2.31 (m, 4H), 1.73-1.20 (m, 61H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0209">XX55. Compound 155: tert-Butyl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <heading id="h-0210">tert-Butyl 8-bromooctanoate</heading>
    <li> <para-num num="[1176]"> </para-num> <div id="p-1221" num="1176" class="description-line">
      <chemistry id="CHEM-US-00241" num="00241">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/ef/fe/25e575f3206c13/US20170210697A1-20170727-C00241.png"><img id="EMI-C00241" he="10.24mm" wi="56.05mm" file="US20170210697A1-20170727-C00241.TIF" alt="Figure US20170210697A1-20170727-C00241" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="224" height="41" alt="Figure US20170210697A1-20170727-C00241" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/ef/fe/25e575f3206c13/US20170210697A1-20170727-C00241.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00241" attachment-type="cdx" file="US20170210697A1-20170727-C00241.CDX"> </attachment>
          <attachment idref="CHEM-US-00241" attachment-type="mol" file="US20170210697A1-20170727-C00241.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1177]"> </para-num> <div id="p-1222" num="1177" class="description-line">Chemical Formula: C<sub>12</sub>H<sub>23</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[1178]"> </para-num> <div id="p-1223" num="1178" class="description-line">Molecular Weight: 279.218</div>
    </li> <li> <para-num num="[1179]"> </para-num> <div id="p-1224" num="1179" class="description-line">To a solution of 8-bromooctanoic acid (2 g, 8.96 mmol) in DCM (20 mL) at 0 C. trifluoroacetic anhydride (2.77 mL, 19.9 mmol) was added dropwise. After 2.5 h. <sup>t</sup>BuOH (3.1 mL, 32.27 mmol) was slowly added. After 1 h the reaction was warmed to rt and allowed to stir for 2.5 h. The reaction was quenched with water and extracted with diethylether. The organic layer was separated, dried over MgSO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-10%) EtOAc in hexanes to obtain tert-butyl 8-bromooctanoate (1.5 g, 5.37 mmol, 60%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.42 (t, 2H); 2.23 (t, 2H); 1.87 (m, 2H); 1.60 (m, 2H); 1.47 (s, 11H); 1.35 (m, 4H).</div>
    </li> <heading id="h-0211">tert-Butyl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1180]"> </para-num> <div id="p-1225" num="1180" class="description-line">
      <chemistry id="CHEM-US-00242" num="00242">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/b6/a3/682abb3ff5a552/US20170210697A1-20170727-C00242.png"><img id="EMI-C00242" he="27.18mm" wi="105.49mm" file="US20170210697A1-20170727-C00242.TIF" alt="Figure US20170210697A1-20170727-C00242" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00242" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/b6/a3/682abb3ff5a552/US20170210697A1-20170727-C00242.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00242" attachment-type="cdx" file="US20170210697A1-20170727-C00242.CDX"> </attachment>
          <attachment idref="CHEM-US-00242" attachment-type="mol" file="US20170210697A1-20170727-C00242.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1181]"> </para-num> <div id="p-1226" num="1181" class="description-line">Chemical Formula: C<sub>39</sub>H<sub>77</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1182]"> </para-num> <div id="p-1227" num="1182" class="description-line">Molecular Weight: 640.047</div>
    </li> <li> <para-num num="[1183]"> </para-num> <div id="p-1228" num="1183" class="description-line">Compound 155 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.18 min. MS (ES): m/z (MH<sup>+</sup>) 641.0 for C<sub>39</sub>H<sub>77</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 3.58 (br. m, 2H); 2.75-2.36 (br. m, 6H); 2.26 (m, 4H); 1.71-1.40 (m, 22H); 1.28 (m, 35H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0212">XX56. Compound 156: Heptadecan-9-yl 8-((1,3-dihydroxypropan-2-yl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1184]"> </para-num> <div id="p-1229" num="1184" class="description-line">
      <chemistry id="CHEM-US-00243" num="00243">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/97/35/38c9aa8ae97990/US20170210697A1-20170727-C00243.png"><img id="EMI-C00243" he="37.76mm" wi="105.49mm" file="US20170210697A1-20170727-C00243.TIF" alt="Figure US20170210697A1-20170727-C00243" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="151" alt="Figure US20170210697A1-20170727-C00243" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/97/35/38c9aa8ae97990/US20170210697A1-20170727-C00243.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00243" attachment-type="cdx" file="US20170210697A1-20170727-C00243.CDX"> </attachment>
          <attachment idref="CHEM-US-00243" attachment-type="mol" file="US20170210697A1-20170727-C00243.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1185]"> </para-num> <div id="p-1230" num="1185" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>6 </sub> </div>
    </li> <li> <para-num num="[1186]"> </para-num> <div id="p-1231" num="1186" class="description-line">Molecular Weight: 740.208</div>
    </li> <li> <para-num num="[1187]"> </para-num> <div id="p-1232" num="1187" class="description-line">Compound 156 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.53 min. MS (ES): m/z (MH<sup>+</sup>) 741.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (m, 1H); 4.08 (t, 2H); 3.67 (br. m, 4H); 3.04 (m, 1H); 2.65 (m, 4H); 2.32 (m, 4H), 1.72-1.44 (m, 15H); 1.28 (m, 48H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0213">XX57. Compound 157: Heptadecan-9-yl 8-((1-hydroxypropan-2-yl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1188]"> </para-num> <div id="p-1233" num="1188" class="description-line">
      <chemistry id="CHEM-US-00244" num="00244">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/78/ab/95608a587046ed/US20170210697A1-20170727-C00244.png"><img id="EMI-C00244" he="34.04mm" wi="105.49mm" file="US20170210697A1-20170727-C00244.TIF" alt="Figure US20170210697A1-20170727-C00244" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="136" alt="Figure US20170210697A1-20170727-C00244" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/78/ab/95608a587046ed/US20170210697A1-20170727-C00244.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00244" attachment-type="cdx" file="US20170210697A1-20170727-C00244.CDX"> </attachment>
          <attachment idref="CHEM-US-00244" attachment-type="mol" file="US20170210697A1-20170727-C00244.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1189]"> </para-num> <div id="p-1234" num="1189" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1190]"> </para-num> <div id="p-1235" num="1190" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1191]"> </para-num> <div id="p-1236" num="1191" class="description-line">Compound 157 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.56 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.45-3.17 (br. m, 2H); 2.94 (br. m, 1H); 2.55-2.22 (m, 8H); 1.70-1.17 (m, 62H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0214">XX58. Compound 158: tert-Butyl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1192]"> </para-num> <div id="p-1237" num="1192" class="description-line">
      <chemistry id="CHEM-US-00245" num="00245">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/36/ea/67/67d7a7ac5b419c/US20170210697A1-20170727-C00245.png"><img id="EMI-C00245" he="27.18mm" wi="105.49mm" file="US20170210697A1-20170727-C00245.TIF" alt="Figure US20170210697A1-20170727-C00245" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00245" class="patent-full-image" src="https://patentimages.storage.googleapis.com/36/ea/67/67d7a7ac5b419c/US20170210697A1-20170727-C00245.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00245" attachment-type="cdx" file="US20170210697A1-20170727-C00245.CDX"> </attachment>
          <attachment idref="CHEM-US-00245" attachment-type="mol" file="US20170210697A1-20170727-C00245.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1193]"> </para-num> <div id="p-1238" num="1193" class="description-line">Chemical Formula: C<sub>31</sub>H<sub>61</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1194]"> </para-num> <div id="p-1239" num="1194" class="description-line">Molecular Weight: 527.831</div>
    </li> <li> <para-num num="[1195]"> </para-num> <div id="p-1240" num="1195" class="description-line">Compound 158 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.23 min. MS (ES): m/z (MH<sup>+</sup>) 528.0 for C<sub>31</sub>H<sub>61</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 2H); 3.55 (br. m, 2H); 2.60 (br. m, 2H); 2.47 (m, 4H); 2.31 (t, 2H); 2.22 (t, 2H); 1.64 (br. m, 6H); 1.53-1.23 (m, 37H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0215">XX59. Compound 159: Heptadecan-9-yl 8-((2-hydroxyethyl)(2-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)ethyl)amino)octanoate</heading>
    <li> <para-num num="[1196]"> </para-num> <div id="p-1241" num="1196" class="description-line">
      <chemistry id="CHEM-US-00246" num="00246">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/6c/6c/d31fce2daf00e7/US20170210697A1-20170727-C00246.png"><img id="EMI-C00246" he="45.47mm" wi="115.23mm" file="US20170210697A1-20170727-C00246.TIF" alt="Figure US20170210697A1-20170727-C00246" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="461" height="182" alt="Figure US20170210697A1-20170727-C00246" class="patent-full-image" src="https://patentimages.storage.googleapis.com/95/6c/6c/d31fce2daf00e7/US20170210697A1-20170727-C00246.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00246" attachment-type="cdx" file="US20170210697A1-20170727-C00246.CDX"> </attachment>
          <attachment idref="CHEM-US-00246" attachment-type="mol" file="US20170210697A1-20170727-C00246.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1197]"> </para-num> <div id="p-1242" num="1197" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>96</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1198]"> </para-num> <div id="p-1243" num="1198" class="description-line">Molecular Weight: 797.304</div>
    </li> <li> <para-num num="[1199]"> </para-num> <div id="p-1244" num="1199" class="description-line">Compound 159 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.15 min. MS (ES): m/z (MH<sup>+</sup>) 798.0 for C<sub>48</sub>H<sub>96</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (m, 1H); 4.07 (t, 2H); 3.62 (br. m, 4H); 2.72-2.47 (br. m, 12H); 2.31 (m, 4H); 1.72-1.42 (m, 14H); 1.28 (m, 47H); 0.90 (m, 12H).</div>
    </li> <heading id="h-0216">XX60. Compound 160: 1,5-Bis(2-butylcyclopropyl)pentan-3-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0217">2-(2-Butylcyclopropyl)ethan-1-ol</heading>
    <li> <para-num num="[1200]"> </para-num> <div id="p-1245" num="1200" class="description-line">
      <chemistry id="CHEM-US-00247" num="00247">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/1d/68/0a3c791183bf6a/US20170210697A1-20170727-C00247.png"><img id="EMI-C00247" he="8.81mm" wi="42.67mm" file="US20170210697A1-20170727-C00247.TIF" alt="Figure US20170210697A1-20170727-C00247" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="171" height="35" alt="Figure US20170210697A1-20170727-C00247" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/1d/68/0a3c791183bf6a/US20170210697A1-20170727-C00247.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00247" attachment-type="cdx" file="US20170210697A1-20170727-C00247.CDX"> </attachment>
          <attachment idref="CHEM-US-00247" attachment-type="mol" file="US20170210697A1-20170727-C00247.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1201]"> </para-num> <div id="p-1246" num="1201" class="description-line">Chemical Formula: C<sub>9</sub>H<sub>18</sub>O</div>
    </li> <li> <para-num num="[1202]"> </para-num> <div id="p-1247" num="1202" class="description-line">Molecular Weight: 142.242</div>
    </li> <li> <para-num num="[1203]"> </para-num> <div id="p-1248" num="1203" class="description-line">2-(2-Butylcyclopropyl)ethan-1-ol was synthesized in the same manner as Intermediate C. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm: 3.94 (t, 2H); 1.93 (m, 1H); 1.59 (m, 7H); 1.39 (m, 1H); 1.12 (m, 3H); 0.90 (m, 3H); 0.00 (m, 1H).</div>
    </li> <heading id="h-0218">1-(2-Bromoethyl)-2-butylcyclopropane</heading>
    <li> <para-num num="[1204]"> </para-num> <div id="p-1249" num="1204" class="description-line">
      <chemistry id="CHEM-US-00248" num="00248">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a7/9a/29/1862030d2b8b59/US20170210697A1-20170727-C00248.png"><img id="EMI-C00248" he="8.81mm" wi="41.99mm" file="US20170210697A1-20170727-C00248.TIF" alt="Figure US20170210697A1-20170727-C00248" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="168" height="35" alt="Figure US20170210697A1-20170727-C00248" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a7/9a/29/1862030d2b8b59/US20170210697A1-20170727-C00248.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00248" attachment-type="cdx" file="US20170210697A1-20170727-C00248.CDX"> </attachment>
          <attachment idref="CHEM-US-00248" attachment-type="mol" file="US20170210697A1-20170727-C00248.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1205]"> </para-num> <div id="p-1250" num="1205" class="description-line">Chemical Formula: C<sub>9</sub>H<sub>17</sub>Br</div>
    </li> <li> <para-num num="[1206]"> </para-num> <div id="p-1251" num="1206" class="description-line">Molecular Weight: 205.139</div>
    </li> <li> <para-num num="[1207]"> </para-num> <div id="p-1252" num="1207" class="description-line">1-(2-Bromoethyl)-2-butylcyclopropane was synthesized in the same manner as (Z)-1-Bromo-10-octyloctadec-8-ene. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm: 3.64 (t, 2H); 2.18 (m, 1H); 1.92 (m, 1H); 1.47 (m, 6H); 0.96 (m, 6H); 0.00 (m, 1H).</div>
    </li> <heading id="h-0219">1,5-Bis(2-butylcyclopropyl)pentan-3-ol oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1208]"> </para-num> <div id="p-1253" num="1208" class="description-line">
      <chemistry id="CHEM-US-00249" num="00249">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/41/58/c5/4aa4aac817a287/US20170210697A1-20170727-C00249.png"><img id="EMI-C00249" he="18.71mm" wi="47.58mm" file="US20170210697A1-20170727-C00249.TIF" alt="Figure US20170210697A1-20170727-C00249" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="190" height="75" alt="Figure US20170210697A1-20170727-C00249" class="patent-full-image" src="https://patentimages.storage.googleapis.com/41/58/c5/4aa4aac817a287/US20170210697A1-20170727-C00249.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00249" attachment-type="cdx" file="US20170210697A1-20170727-C00249.CDX"> </attachment>
          <attachment idref="CHEM-US-00249" attachment-type="mol" file="US20170210697A1-20170727-C00249.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1209]"> </para-num> <div id="p-1254" num="1209" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>36</sub>O</div>
    </li> <li> <para-num num="[1210]"> </para-num> <div id="p-1255" num="1210" class="description-line">Molecular Weight: 280.496</div>
    </li> <li> <para-num num="[1211]"> </para-num> <div id="p-1256" num="1211" class="description-line">1,5-Bis(2-butylcyclopropyl)pentan-3-ol was synthesized in the same manner as (5Z,12Z)-heptadeca-5,12-dien-9-ol. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm: 3.96 (t, 1H); 1.64 (m, 21H); 1.16 (m, 6H); 0.91 (m, 6H); 0.03 (m, 2H).</div>
    </li> <heading id="h-0220">1,5-Bis(2-butylcyclopropyl)pentan-3-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1212]"> </para-num> <div id="p-1257" num="1212" class="description-line">
      <chemistry id="CHEM-US-00250" num="00250">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/80/65/7c/ec1957fec0d7b6/US20170210697A1-20170727-C00250.png"><img id="EMI-C00250" he="30.73mm" wi="74.51mm" file="US20170210697A1-20170727-C00250.TIF" alt="Figure US20170210697A1-20170727-C00250" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="123" alt="Figure US20170210697A1-20170727-C00250" class="patent-full-image" src="https://patentimages.storage.googleapis.com/80/65/7c/ec1957fec0d7b6/US20170210697A1-20170727-C00250.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00250" attachment-type="cdx" file="US20170210697A1-20170727-C00250.CDX"> </attachment>
          <attachment idref="CHEM-US-00250" attachment-type="mol" file="US20170210697A1-20170727-C00250.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1213]"> </para-num> <div id="p-1258" num="1213" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1214]"> </para-num> <div id="p-1259" num="1214" class="description-line">Molecular Weight: 734.204</div>
    </li> <li> <para-num num="[1215]"> </para-num> <div id="p-1260" num="1215" class="description-line">Compound 160 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.51 min. MS (ES): m/z (MH<sup>+</sup>) 735.0 for C<sub>46</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.97 (m, 1H); 4.08 (t, 2H); 3.56 (br. m, 2H); 2.75-2.37 (br. m, 6H); 2.31 (m, 4H); 1.74-1.05 (m, 54H); 0.92 (m, 9H); 0.67 (m, 6H); 0.31 (m, 2H).</div>
    </li> <heading id="h-0221">XX61. Compound 161: Heptadecan-9-yl 8-((2-hydroxyethyl)(10-(octanoyloxy)decan-2-yl)amino)octanoate</heading>
    <heading id="h-0222">10-(Benzyloxy)decan-2-ol</heading>
    <li> <para-num num="[1216]"> </para-num> <div id="p-1261" num="1216" class="description-line">
      <chemistry id="CHEM-US-00251" num="00251">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/d6/e1/d08f29e0f0f424/US20170210697A1-20170727-C00251.png"><img id="EMI-C00251" he="20.74mm" wi="58.93mm" file="US20170210697A1-20170727-C00251.TIF" alt="Figure US20170210697A1-20170727-C00251" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="236" height="83" alt="Figure US20170210697A1-20170727-C00251" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d9/d6/e1/d08f29e0f0f424/US20170210697A1-20170727-C00251.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00251" attachment-type="cdx" file="US20170210697A1-20170727-C00251.CDX"> </attachment>
          <attachment idref="CHEM-US-00251" attachment-type="mol" file="US20170210697A1-20170727-C00251.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1217]"> </para-num> <div id="p-1262" num="1217" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>28</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[1218]"> </para-num> <div id="p-1263" num="1218" class="description-line">Molecular Weight: 264.409</div>
    </li> <li> <para-num num="[1219]"> </para-num> <div id="p-1264" num="1219" class="description-line">A solution of 10-(benzyloxy)decan-2-one (3.5 g, 13.34 mmol) in THF (10 mL) was added to a stirred solution of LAH in THF (10 mL) under N2 at 0 C. The mixture was allowed to warm to rt and stir for 2 h after which time 10 mL of sat. Na<sub>2</sub>SO<sub>4</sub>0.10H<sub>2</sub>O (aq) solution was slowly added. White solid precipitated. Additional solid Na<sub>2</sub>SO<sub>4</sub>. 10H<sub>2</sub>O was added and the mixture was filtered through a plug of Celite. The filtrate was diluted with EtOAc and washed with brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain 10-(benzyloxy)decan-2-ol (3.2 g, 12.1 mmol, 91%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.32 (m, 5H); 4.53 (s, 2H); 3.80 (m, 1H); 3.49 (t, 2H); 1.64 (m, 2H); 1.55-1.25 (m, 132H); 1.21 (d, 3H).</div>
    </li> <heading id="h-0223">9-Hydroxydecyl octanoate</heading>
    <li> <para-num num="[1220]"> </para-num> <div id="p-1265" num="1220" class="description-line">
      <chemistry id="CHEM-US-00252" num="00252">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/89/b1/08/1b7a94a16bc55e/US20170210697A1-20170727-C00252.png"><img id="EMI-C00252" he="8.89mm" wi="74.34mm" file="US20170210697A1-20170727-C00252.TIF" alt="Figure US20170210697A1-20170727-C00252" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="36" alt="Figure US20170210697A1-20170727-C00252" class="patent-full-image" src="https://patentimages.storage.googleapis.com/89/b1/08/1b7a94a16bc55e/US20170210697A1-20170727-C00252.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00252" attachment-type="cdx" file="US20170210697A1-20170727-C00252.CDX"> </attachment>
          <attachment idref="CHEM-US-00252" attachment-type="mol" file="US20170210697A1-20170727-C00252.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1221]"> </para-num> <div id="p-1266" num="1221" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>36</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1222]"> </para-num> <div id="p-1267" num="1222" class="description-line">Molecular Weight: 300.483</div>
    </li> <li> <para-num num="[1223]"> </para-num> <div id="p-1268" num="1223" class="description-line">9-Hydroxydecyl octanoate was synthesized following Method A. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 2H); 3.80 (m, 1H); 2.30 (t, 2H); 1.64 (m, 4H); 1.52-1.17 (m, 23H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0224">Heptadecan-9-yl 8-((2-hydroxyethyl)(10-(octanoyloxy)decan-2-yl)amino)octanoate</heading>
    <li> <para-num num="[1224]"> </para-num> <div id="p-1269" num="1224" class="description-line">
      <chemistry id="CHEM-US-00253" num="00253">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/87/2c/5f170b30a8b627/US20170210697A1-20170727-C00253.png"><img id="EMI-C00253" he="26.42mm" wi="105.49mm" file="US20170210697A1-20170727-C00253.TIF" alt="Figure US20170210697A1-20170727-C00253" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="106" alt="Figure US20170210697A1-20170727-C00253" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/87/2c/5f170b30a8b627/US20170210697A1-20170727-C00253.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00253" attachment-type="cdx" file="US20170210697A1-20170727-C00253.CDX"> </attachment>
          <attachment idref="CHEM-US-00253" attachment-type="mol" file="US20170210697A1-20170727-C00253.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1225]"> </para-num> <div id="p-1270" num="1225" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1226]"> </para-num> <div id="p-1271" num="1226" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1227]"> </para-num> <div id="p-1272" num="1227" class="description-line">Compound 161 was synthesized in a manner similar to Compound 152 and according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.46 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.49 (br. m, 2H); 2.77-2.55 (m, 2H); 2.54-2.23 (m, 7H); 1.71-1.20 (m, 63H); 0.91 (m, 12H).</div>
    </li> <heading id="h-0225">XX62. Compound 162: 7-((2-Hydroxyethyl)(10-(octanoyloxy)decan-2-yl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[1228]"> </para-num> <div id="p-1273" num="1228" class="description-line">
      <chemistry id="CHEM-US-00254" num="00254">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/52/58/9d54982cd39ed3/US20170210697A1-20170727-C00254.png"><img id="EMI-C00254" he="25.91mm" wi="74.68mm" file="US20170210697A1-20170727-C00254.TIF" alt="Figure US20170210697A1-20170727-C00254" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="104" alt="Figure US20170210697A1-20170727-C00254" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/52/58/9d54982cd39ed3/US20170210697A1-20170727-C00254.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00254" attachment-type="cdx" file="US20170210697A1-20170727-C00254.CDX"> </attachment>
          <attachment idref="CHEM-US-00254" attachment-type="mol" file="US20170210697A1-20170727-C00254.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1229]"> </para-num> <div id="p-1274" num="1229" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1230]"> </para-num> <div id="p-1275" num="1230" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1231]"> </para-num> <div id="p-1276" num="1231" class="description-line">Compound 162 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.49 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.99 (m, 4H); 2.72-2.48 (m, 2H); 2.48-2.17 (m, 6H); 1.55 (m, 8H); 1.44-1.10 (m, 56H); 0.92-0.75 (m, 12H).</div>
    </li> <heading id="h-0226">XX63. Compound 163: 7-((2-Hydroxyethyl)(7-methyl-8-(nonyloxy)-8-oxooctyl)amino)heptyl 2-octyldecanoate</heading>
    <heading id="h-0227">8-Methoxyoctanoic acid</heading>
    <li> <para-num num="[1232]"> </para-num> <div id="p-1277" num="1232" class="description-line">
      <chemistry id="CHEM-US-00255" num="00255">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a0/a6/d5/71a5232edff43a/US20170210697A1-20170727-C00255.png"><img id="EMI-C00255" he="10.24mm" wi="51.65mm" file="US20170210697A1-20170727-C00255.TIF" alt="Figure US20170210697A1-20170727-C00255" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="41" alt="Figure US20170210697A1-20170727-C00255" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a0/a6/d5/71a5232edff43a/US20170210697A1-20170727-C00255.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00255" attachment-type="cdx" file="US20170210697A1-20170727-C00255.CDX"> </attachment>
          <attachment idref="CHEM-US-00255" attachment-type="mol" file="US20170210697A1-20170727-C00255.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1233]"> </para-num> <div id="p-1278" num="1233" class="description-line">Chemical Formula: C<sub>9</sub>H<sub>18</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1234]"> </para-num> <div id="p-1279" num="1234" class="description-line">Molecular Weight: 174.240</div>
    </li> <li> <para-num num="[1235]"> </para-num> <div id="p-1280" num="1235" class="description-line">To anhydrous MeOH (80 mL) at 0 C. KOH was added (7.54 g, 134.46 mmol) and stirred for 30 min. A solution of 8-bromooctanoic acid (10 g, 44.82 mmol) in anhydrous MeOH (70 mL) was added and the resulting solution was refluxed for 18 h. MeOH was removed under vacuum and the residue was acidified with 1N HCl and extracted with diethylether. The organic layer was washed with brine, separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-50%) EtOAc in hexanes to obtain 8-methoxyoctanoic acid (6.3 g, 36.16 mmol, 81%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.35 (m, 5H); 2.37 (t, 2H); 1.61 (m, 4H); 1.36 (m, 6H).</div>
    </li> <heading id="h-0228">8-Methoxy-2-methyloctanoic acid</heading>
    <li> <para-num num="[1236]"> </para-num> <div id="p-1281" num="1236" class="description-line">
      <chemistry id="CHEM-US-00256" num="00256">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/22/78/a078e4797e7498/US20170210697A1-20170727-C00256.png"><img id="EMI-C00256" he="15.07mm" wi="51.65mm" file="US20170210697A1-20170727-C00256.TIF" alt="Figure US20170210697A1-20170727-C00256" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="60" alt="Figure US20170210697A1-20170727-C00256" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/22/78/a078e4797e7498/US20170210697A1-20170727-C00256.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00256" attachment-type="cdx" file="US20170210697A1-20170727-C00256.CDX"> </attachment>
          <attachment idref="CHEM-US-00256" attachment-type="mol" file="US20170210697A1-20170727-C00256.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1237]"> </para-num> <div id="p-1282" num="1237" class="description-line">Chemical Formula: C<sub>10</sub>H<sub>20</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1238]"> </para-num> <div id="p-1283" num="1238" class="description-line">Molecular Weight: 188.267</div>
    </li> <li> <para-num num="[1239]"> </para-num> <div id="p-1284" num="1239" class="description-line">To a suspension of NaH in THF (100 mL) at 0 C., 8-methoxyoctanoic acid (5.6 g, 32.14 mmol) in THF (30 mL) was added dropwise. The reaction was allowed to stir at rt for 30 min. The reaction was cooled to 0 C. and LDA (17.86 mL, 2M in THF, 35.71 mmol) was added dropwise. After complete addition, the reaction was allowed to stir at 45 C. for 2 h. The reaction was cooled to rt and methyl iodide (2.45 mL, 39.28 mmol) in THF (15 mL) was slowly added. The reaction was stirred at 45 C. for 16 h. The reaction was quenched with 1N HCl (20 mL). The quenched reaction was evaporated under vacuum to remove volatiles. The residue was dissolved in hexanes/EtOAc (1:1) and washed with 1N HCl (100 mL2) followed by brine. The organic layer was separated, dried over sodium sulfate, filtered and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-15%) EtOAc in hexanes to obtain 8-methoxy-2-methyloctanoic acid (3.25 g, 17.26 mmol, 54%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.35 (m, 5H); 2.49 (m, 1H); 1.70 (m, 1H); 1.59 (m, 2H); 1.36 (m, 7H); 1.21 (d, 3H).</div>
    </li> <heading id="h-0229">8-Hydroxy-2-methyloctanoic acid</heading>
    <li> <para-num num="[1240]"> </para-num> <div id="p-1285" num="1240" class="description-line">
      <chemistry id="CHEM-US-00257" num="00257">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/92/3d/88/8231b332d2c44f/US20170210697A1-20170727-C00257.png"><img id="EMI-C00257" he="15.07mm" wi="49.45mm" file="US20170210697A1-20170727-C00257.TIF" alt="Figure US20170210697A1-20170727-C00257" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="198" height="60" alt="Figure US20170210697A1-20170727-C00257" class="patent-full-image" src="https://patentimages.storage.googleapis.com/92/3d/88/8231b332d2c44f/US20170210697A1-20170727-C00257.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00257" attachment-type="cdx" file="US20170210697A1-20170727-C00257.CDX"> </attachment>
          <attachment idref="CHEM-US-00257" attachment-type="mol" file="US20170210697A1-20170727-C00257.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1241]"> </para-num> <div id="p-1286" num="1241" class="description-line">Chemical Formula: C<sub>9</sub>H<sub>18</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1242]"> </para-num> <div id="p-1287" num="1242" class="description-line">Molecular Weight: 174.240</div>
    </li> <li> <para-num num="[1243]"> </para-num> <div id="p-1288" num="1243" class="description-line">To a solution of 8-methoxy-2-methyloctanoic acid (1 g, 5.31 mmol) in DCM (20 mL) at 78 C., boron tribromide (13.28 mL 1 M in DCM, 13.28 mmol) was added dropwise. The reaction was allowed to warm to rt and stir at rt for 2 h. The reaction was poured into ice and extracted with DCM. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain 8-hydroxy-2-methyloctanoic acid (0.77 g, 4.41 mmol, 83%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.43 (t, 2H); 2.50 (m, 1H); 1.94-1.64 (m, 4H); 1.56-1.26 (m, 7H); 1.20 (d, 3H).</div>
    </li> <heading id="h-0230">Nonyl 8-hydroxy-2-methyloctanoate</heading>
    <li> <para-num num="[1244]"> </para-num> <div id="p-1289" num="1244" class="description-line">
      <chemistry id="CHEM-US-00258" num="00258">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/cb/d6/13fbb55b00bcf5/US20170210697A1-20170727-C00258.png"><img id="EMI-C00258" he="12.36mm" wi="74.34mm" file="US20170210697A1-20170727-C00258.TIF" alt="Figure US20170210697A1-20170727-C00258" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="49" alt="Figure US20170210697A1-20170727-C00258" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/cb/d6/13fbb55b00bcf5/US20170210697A1-20170727-C00258.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00258" attachment-type="cdx" file="US20170210697A1-20170727-C00258.CDX"> </attachment>
          <attachment idref="CHEM-US-00258" attachment-type="mol" file="US20170210697A1-20170727-C00258.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1245]"> </para-num> <div id="p-1290" num="1245" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>36</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1246]"> </para-num> <div id="p-1291" num="1246" class="description-line">Molecular Weight: 300.483</div>
    </li> <li> <para-num num="[1247]"> </para-num> <div id="p-1292" num="1247" class="description-line">A solution of 8-hydroxy-2-methyloctanoic acid (0.75 g, 4.31 mmol), nonan-1-ol (6.22 g, 43.1 mmol), 4-dimethylaminopyridine (0.11 g, 0.86 mmol) in DCM (20 mL) under N2 was added to (3-{[(ethylimino)methylidene]amino}propyl)dimethylamine hydrochloride (0.83 g, 4.31 mmol). The reaction allowed to stir at rt for 16 h. The reaction was diluted with DCM and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-20%) EtOAc in hexanes to obtain nonyl 8-hydroxy-2-methyloctanoate (0.68 g, 2.26 mmol, 53%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 2H); 3.42 (t, 2H); 2.45 (m, 1H); 1.87 (m, 2H); 1.75-1.57 (m, 4H); 1.52-1.22 (m, 19H); 1.15 (d, 3H); 0.91 (m, 3H).</div>
    </li> <heading id="h-0231">7-((2-Hydroxyethyl)(7-methyl-8-(nonyloxy)-8-oxooctyl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[1248]"> </para-num> <div id="p-1293" num="1248" class="description-line">
      <chemistry id="CHEM-US-00259" num="00259">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/36/0c/dd/0c2a152fe7c3eb/US20170210697A1-20170727-C00259.png"><img id="EMI-C00259" he="34.04mm" wi="105.49mm" file="US20170210697A1-20170727-C00259.TIF" alt="Figure US20170210697A1-20170727-C00259" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="136" alt="Figure US20170210697A1-20170727-C00259" class="patent-full-image" src="https://patentimages.storage.googleapis.com/36/0c/dd/0c2a152fe7c3eb/US20170210697A1-20170727-C00259.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00259" attachment-type="cdx" file="US20170210697A1-20170727-C00259.CDX"> </attachment>
          <attachment idref="CHEM-US-00259" attachment-type="mol" file="US20170210697A1-20170727-C00259.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1249]"> </para-num> <div id="p-1294" num="1249" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1250]"> </para-num> <div id="p-1295" num="1250" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1251]"> </para-num> <div id="p-1296" num="1251" class="description-line">Compound 163 was synthesized in a manner similar to Compound 152 according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.50 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (t, 4H); 3.55 (m, 2H); 2.67 (m, 2H); 2.53-2.24 (m, 6H); 1.72-1.10 (m, 65H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0232">XX64. Compound 164: Nonyl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)-2-methyloctanoate</heading>
    <li> <para-num num="[1252]"> </para-num> <div id="p-1297" num="1252" class="description-line">
      <chemistry id="CHEM-US-00260" num="00260">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/46/c3/2e33aa6449b81c/US20170210697A1-20170727-C00260.png"><img id="EMI-C00260" he="34.04mm" wi="105.49mm" file="US20170210697A1-20170727-C00260.TIF" alt="Figure US20170210697A1-20170727-C00260" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="136" alt="Figure US20170210697A1-20170727-C00260" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/46/c3/2e33aa6449b81c/US20170210697A1-20170727-C00260.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00260" attachment-type="cdx" file="US20170210697A1-20170727-C00260.CDX"> </attachment>
          <attachment idref="CHEM-US-00260" attachment-type="mol" file="US20170210697A1-20170727-C00260.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1253]"> </para-num> <div id="p-1298" num="1253" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1254]"> </para-num> <div id="p-1299" num="1254" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1255]"> </para-num> <div id="p-1300" num="1255" class="description-line">Compound 164 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.51 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.69-2.38 (m, 8H); 2.30 (t, 2H); 1.74-1.09 (m, 65H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0233">XX65. Compound 165: 7-((7-(Decanoyloxy)octyl)(2-hydroxyethyl)amino)heptyl 2-octyldecanoate</heading>
    <li> <para-num num="[1256]"> </para-num> <div id="p-1301" num="1256" class="description-line">
      <chemistry id="CHEM-US-00261" num="00261">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/dd/5f/259024941c1fad/US20170210697A1-20170727-C00261.png"><img id="EMI-C00261" he="34.88mm" wi="105.49mm" file="US20170210697A1-20170727-C00261.TIF" alt="Figure US20170210697A1-20170727-C00261" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="140" alt="Figure US20170210697A1-20170727-C00261" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/dd/5f/259024941c1fad/US20170210697A1-20170727-C00261.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00261" attachment-type="cdx" file="US20170210697A1-20170727-C00261.CDX"> </attachment>
          <attachment idref="CHEM-US-00261" attachment-type="mol" file="US20170210697A1-20170727-C00261.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1257]"> </para-num> <div id="p-1302" num="1257" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1258]"> </para-num> <div id="p-1303" num="1258" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1259]"> </para-num> <div id="p-1304" num="1259" class="description-line">Compound 165 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.68-2.39 (m, 8H); 2.29 (m, 3H); 1.72-1.15 (m, 64H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0234">XX66. Compound 166: 8-((8-(Heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoic acid</heading>
    <li> <para-num num="[1260]"> </para-num> <div id="p-1305" num="1260" class="description-line">
      <chemistry id="CHEM-US-00262" num="00262">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/fc/89/3fdf12f7192549/US20170210697A1-20170727-C00262.png"><img id="EMI-C00262" he="23.11mm" wi="75.35mm" file="US20170210697A1-20170727-C00262.TIF" alt="Figure US20170210697A1-20170727-C00262" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="301" height="92" alt="Figure US20170210697A1-20170727-C00262" class="patent-full-image" src="https://patentimages.storage.googleapis.com/95/fc/89/3fdf12f7192549/US20170210697A1-20170727-C00262.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00262" attachment-type="cdx" file="US20170210697A1-20170727-C00262.CDX"> </attachment>
          <attachment idref="CHEM-US-00262" attachment-type="mol" file="US20170210697A1-20170727-C00262.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1261]"> </para-num> <div id="p-1306" num="1261" class="description-line">Chemical Formula: C<sub>35</sub>H<sub>69</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1262]"> </para-num> <div id="p-1307" num="1262" class="description-line">Molecular Weight: 583.939</div>
    </li> <li> <para-num num="[1263]"> </para-num> <div id="p-1308" num="1263" class="description-line">To a solution of heptadecan-9-yl 8-{[8-(tert-butoxy)-8-oxooctyl](2-hydroxyethyl)amino}octanoate (0.11 g, 0.17 mmol) in DCM was added trifluoroacetic acid (0.06 mL, 0.69 mmol) and the reaction was allowed to stir at rt for 40 h. Volatiles were evaporated under vacuum. The residue was dissolved in ethylacetate and water and extracted with ethylacetate. The organic layer was separated, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under vacuum. The residue was purified by silica gel chromatography (0-50%) (1%, 20% MeOH in DCM) in DCM to obtain 8-{[8-(heptadecan-9-yloxy)-8-oxooctyl](2-hydroxyethyl)amino}octanoic acid (0.023 g, 0.04 mmol) as a colorless liquid. UPLC/ELSD: RT=2.72 min. MS (ES): m/z (MH<sup>+</sup>) 585.0 for C<sub>35</sub>H<sub>69</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.87 (m, 1H); 3.98 (m, 2H); 3.25-3.05 (m, 6H); 2.32 (m, 4H); 1.82-1.45 (m, 12H); 1.45-1.19 (m, 37H); 0.89 (m, 6H).</div>
    </li> <heading id="h-0235">XX67. Compound 167: 8-((2-Hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoic acid</heading>
    <li> <para-num num="[1264]"> </para-num> <div id="p-1309" num="1264" class="description-line">
      <chemistry id="CHEM-US-00263" num="00263">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/b5/cd/9e9e7ba00978f5/US20170210697A1-20170727-C00263.png"><img id="EMI-C00263" he="27.18mm" wi="105.49mm" file="US20170210697A1-20170727-C00263.TIF" alt="Figure US20170210697A1-20170727-C00263" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="109" alt="Figure US20170210697A1-20170727-C00263" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/b5/cd/9e9e7ba00978f5/US20170210697A1-20170727-C00263.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00263" attachment-type="cdx" file="US20170210697A1-20170727-C00263.CDX"> </attachment>
          <attachment idref="CHEM-US-00263" attachment-type="mol" file="US20170210697A1-20170727-C00263.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1265]"> </para-num> <div id="p-1310" num="1265" class="description-line">Chemical Formula: C<sub>27</sub>H<sub>53</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1266]"> </para-num> <div id="p-1311" num="1266" class="description-line">Molecular Weight: 471.723</div>
    </li> <li> <para-num num="[1267]"> </para-num> <div id="p-1312" num="1267" class="description-line">Compound 167 was synthesized following the same procedure as Compound 166. UPLC/ELSD: RT=1.57 min. MS (ES): m/z (MH<sup>+</sup>) 472.0 for C<sub>27</sub>H<sub>53</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.08 (m, 2H); 4.00 (m, 2H); 3.44-2.98 (m, 10H); 2.35 (t, 4H); 1.85-1.55 (m, 10H); 1.33 (m, 23H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0236">XX68. Compound 168: Heptadecan-9-yl (Z)-8-((3-(2-cyano-3,3-dimethylguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1268]"> </para-num> <div id="p-1313" num="1268" class="description-line">
      <chemistry id="CHEM-US-00264" num="00264">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/9d/96/2a3fe258f67e94/US20170210697A1-20170727-C00264.png"><img id="EMI-C00264" he="38.44mm" wi="123.19mm" file="US20170210697A1-20170727-C00264.TIF" alt="Figure US20170210697A1-20170727-C00264" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="493" height="154" alt="Figure US20170210697A1-20170727-C00264" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/9d/96/2a3fe258f67e94/US20170210697A1-20170727-C00264.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00264" attachment-type="cdx" file="US20170210697A1-20170727-C00264.CDX"> </attachment>
          <attachment idref="CHEM-US-00264" attachment-type="mol" file="US20170210697A1-20170727-C00264.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1269]"> </para-num> <div id="p-1314" num="1269" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>95</sub>N<sub>5</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1270]"> </para-num> <div id="p-1315" num="1270" class="description-line">Molecular Weight: 818.33</div>
    </li> <li> <para-num num="[1271]"> </para-num> <div id="p-1316" num="1271" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (220 mg, 0.3 mmol) in 5 mL 2-propanol was added triethylamine (0.04 mL, 0.3 mmol) followed by diphenyl cyanocarbonimidate (72 mg, 0.3 mmol) and the mixture stirred at rt for two hours. To the reaction mixture was added a 2M dimethylamine solution in THF (0.75 mL, 1.5 mmol) and the resulting solution heated to 75 C. for 18 hours. Additional 2M dimethylamine/THF solution (0.75 mL, 1.5 mmol) was added and the temperature increased to 85 C. After six hours the reaction was complete by LC/MS so the solution was reduced under vacuum, diluted with DCM and washed once with a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO<sub>4</sub>), filtered and the filtrate evaporated in vacuo. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl (Z)-8-((3-(2-cyano-3,3-dimethylguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (119.2 mg, 0.14 mmol, 49%) as a colorless syrup. UPLC/ELSD: RT=3.52 min. MS (ES): m/z (MH<sup>+</sup>) 819.0 for C<sub>49</sub>H<sub>95</sub>N<sub>5</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.62 (br. s., 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=7.5 Hz); 3.68 (d, 2H, J=3 Hz); 2.99 (s, 6H); 2.59 (br. s, 2H); 2.43 (br. s, 3H); 2.28 (m, 4H); 1.71 (br. s, 2H); 1.62 (m, 8H); 1.49 (m, 5H); 1.26 (br. m, 50H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0237">XX69. Compound 169: Heptadecan-9-yl 8-((3-((2-(dimethylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0238">3-(Dimethylamino)-4-methoxycyclobut-3-ene-1,2-dione</heading>
    <li> <para-num num="[1272]"> </para-num> <div id="p-1317" num="1272" class="description-line">
      <chemistry id="CHEM-US-00265" num="00265">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a3/da/87/59773f89595928/US20170210697A1-20170727-C00265.png"><img id="EMI-C00265" he="19.98mm" wi="24.72mm" file="US20170210697A1-20170727-C00265.TIF" alt="Figure US20170210697A1-20170727-C00265" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="99" height="80" alt="Figure US20170210697A1-20170727-C00265" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a3/da/87/59773f89595928/US20170210697A1-20170727-C00265.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00265" attachment-type="cdx" file="US20170210697A1-20170727-C00265.CDX"> </attachment>
          <attachment idref="CHEM-US-00265" attachment-type="mol" file="US20170210697A1-20170727-C00265.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1273]"> </para-num> <div id="p-1318" num="1273" class="description-line">Chemical Formula: C<sub>7</sub>H<sub>9</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1274]"> </para-num> <div id="p-1319" num="1274" class="description-line">Molecular Weight: 155.15</div>
    </li> <li> <para-num num="[1275]"> </para-num> <div id="p-1320" num="1275" class="description-line">To a solution of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1 g, 7 mmol) in 100 mL diethyl ether was added a 2M dimethylamine solution in THF (3.8 mL, 7.6 mmol) and a ppt. formed almost immediately. The mixture was stirred at rt for 24 hours and then filtered. The filter solids were washed with diethyl ether and air-dried. The filter solids were dissolved in hot MeOH, filtered, the filtrate allowed to cool to room temp., then cooled to 0 C. to give a ppt. This was isolated via filtration, washed with cold MeOH, air-dried, then dried under vacuum to give 3-(dimethylamino)-4-methoxycyclobut-3-ene-1,2-dione (0.42 g, 2.7 mmol, 39%) as a pale yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-d6) : ppm 4.28 (s, 3H); 3.21 (s, 3H); 3.05 (s, 3H).</div>
    </li> <heading id="h-0239">Heptadecan-9-yl 8-((3-((2-(dimethylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1276]"> </para-num> <div id="p-1321" num="1276" class="description-line">
      <chemistry id="CHEM-US-00266" num="00266">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/98/f0/76/7d44b8d1082bf5/US20170210697A1-20170727-C00266.png"><img id="EMI-C00266" he="37.51mm" wi="126.49mm" file="US20170210697A1-20170727-C00266.TIF" alt="Figure US20170210697A1-20170727-C00266" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="506" height="150" alt="Figure US20170210697A1-20170727-C00266" class="patent-full-image" src="https://patentimages.storage.googleapis.com/98/f0/76/7d44b8d1082bf5/US20170210697A1-20170727-C00266.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00266" attachment-type="cdx" file="US20170210697A1-20170727-C00266.CDX"> </attachment>
          <attachment idref="CHEM-US-00266" attachment-type="mol" file="US20170210697A1-20170727-C00266.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1277]"> </para-num> <div id="p-1322" num="1277" class="description-line">Chemical Formula: C<sub>51</sub>H<sub>95</sub>N<sub>3</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1278]"> </para-num> <div id="p-1323" num="1278" class="description-line">Molecular Weight: 846.34</div>
    </li> <li> <para-num num="[1279]"> </para-num> <div id="p-1324" num="1279" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (220 mg, 0.3 mmol) in 10 mL ethanol was added 3-(dimethylamino)-4-methoxycyclobut-3-ene-1,2-dione (47 mg, 0.3 mmol) and the resulting colorless solution stirred at rt for 20 hours after which no starting amine remained by LC/MS. The solution was concentrated in vacuo and the residue purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-((2-(dimethylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (135 mg, 0.16 mmol, 53%) as a colorless syrup. UPLC/ELSD: RT=3.51 min. MS (ES): m/z (MH<sup>+</sup>) 847.3 for C<sub>51</sub>H<sub>95</sub>N<sub>3</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.86 (br. s., 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.92 (d, 2H, J=3 Hz); 3.20 (s, 6H); 2.63 (br. s, 2H); 2.42 (br. s, 3H); 2.28 (m, 4H); 1.74 (br. s, 2H); 1.61 (m, 8H); 1.50 (m, 5H); 1.41 (m, 3H); 1.25 (br. m, 47H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0240">XX70. Compound 170: Heptadecan-9-yl (E)-8-((3-((1-(methylamino)-2-nitrovinyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1280]"> </para-num> <div id="p-1325" num="1280" class="description-line">
      <chemistry id="CHEM-US-00267" num="00267">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f4/26/4b/7f1b7df75904ab/US20170210697A1-20170727-C00267.png"><img id="EMI-C00267" he="35.64mm" wi="122.43mm" file="US20170210697A1-20170727-C00267.TIF" alt="Figure US20170210697A1-20170727-C00267" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="490" height="143" alt="Figure US20170210697A1-20170727-C00267" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f4/26/4b/7f1b7df75904ab/US20170210697A1-20170727-C00267.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00267" attachment-type="cdx" file="US20170210697A1-20170727-C00267.CDX"> </attachment>
          <attachment idref="CHEM-US-00267" attachment-type="mol" file="US20170210697A1-20170727-C00267.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1281]"> </para-num> <div id="p-1326" num="1281" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>94</sub>N<sub>4</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1282]"> </para-num> <div id="p-1327" num="1282" class="description-line">Molecular Weight: 823.30</div>
    </li> <li> <para-num num="[1283]"> </para-num> <div id="p-1328" num="1283" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (220 mg, 0.3 mmol) in 5 mL methanol was added 1-methylthio-1-methylamino-2-nitroethene (45 mg, 0.3 mmol), the resulting solution heated to 70 C. and stirred for 24 hours after which no starting amine remained by LC/MS. The solution was diluted with DCM and washed once with a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO<sub>4</sub>), filtered and the filtrate evaporated in vacuo. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl (E)-8-((3-((1-(methylamino)-2-nitrovinyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (90 mg, 0.11 mmol, 36%) as a pale yellow syrup. UPLC/ELSD: RT=3.33 min. MS (ES): m/z (MH<sup>+</sup>) 824.3 for C<sub>48</sub>H<sub>94</sub>N<sub>4</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 10.15 (d, 1H, J=9 Hz); 8.26 (d, 1H, J=27 Hz); 6.55 (d, 1H, J=9 Hz); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.32 (br. s, 1H); 3.24 (br. s, 1H); 2.81 (dd, 3H, J=3 Hz, 12 Hz); 2.63 (br. s, 1H); 2.47 (br. s, 4H); 2.28 (m, 4H); 1.77 (br. s, 2H); 1.62 (m, 5H); 1.59 (m, 6H); 1.49 (m, 3H); 1.43 (m, 3H); 1.26 (br. m, 46H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0241">XX71. Compound 171: Heptadecan-9-yl 8-((9-hydroxy-9-methyloctadecyl)(2-hydroxyethyl)amino)octanoate</heading>
    <heading id="h-0242">((Dec-9-en-1-yloxy)methyl)benzene</heading>
    <li> <para-num num="[1284]"> </para-num> <div id="p-1329" num="1284" class="description-line">
      <chemistry id="CHEM-US-00268" num="00268">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/fb/ba/5db8cccbb2fc30/US20170210697A1-20170727-C00268.png"><img id="EMI-C00268" he="4.57mm" wi="56.05mm" file="US20170210697A1-20170727-C00268.TIF" alt="Figure US20170210697A1-20170727-C00268" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="224" height="18" alt="Figure US20170210697A1-20170727-C00268" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/fb/ba/5db8cccbb2fc30/US20170210697A1-20170727-C00268.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00268" attachment-type="cdx" file="US20170210697A1-20170727-C00268.CDX"> </attachment>
          <attachment idref="CHEM-US-00268" attachment-type="mol" file="US20170210697A1-20170727-C00268.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1285]"> </para-num> <div id="p-1330" num="1285" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>26</sub>O</div>
    </li> <li> <para-num num="[1286]"> </para-num> <div id="p-1331" num="1286" class="description-line">Molecular Weight: 246.394</div>
    </li> <li> <para-num num="[1287]"> </para-num> <div id="p-1332" num="1287" class="description-line">To a suspension of sodium hydride (3.88 g, 96.99 mmol) in THF (100 mL) was added 9-decen-1-ol (10 g, 63.99 mmol) slowly. After 30 min. benzyl bromide (10.57 mL, 88.9 mmol) was added. The reaction was allowed to stir at rt for 18 h. The reaction was quenched with water. Solvents were evaporated under vacuum. The residue was diluted with EtOAc and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-20%) EtOAc in hexanes to obtain ((dec-9-en-1-yloxy)methyl)benzene (8.5 g, 34.5 mmol, 54%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.32 (m, 5H); 5.83 (m, 1H); 4.98 (m, 2H); 4.53 (s, 2H); 3.49 (t, 2H); 2.06 (m, 2H); 1.64 (m, 2H); 1.46-1.26 (br. m, 10H).</div>
    </li> <heading id="h-0243">10-(Benzyloxy)decan-2-one</heading>
    <li> <para-num num="[1288]"> </para-num> <div id="p-1333" num="1288" class="description-line">
      <chemistry id="CHEM-US-00269" num="00269">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/72/5e/5f920938d70a70/US20170210697A1-20170727-C00269.png"><img id="EMI-C00269" he="10.33mm" wi="56.05mm" file="US20170210697A1-20170727-C00269.TIF" alt="Figure US20170210697A1-20170727-C00269" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="224" height="41" alt="Figure US20170210697A1-20170727-C00269" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/72/5e/5f920938d70a70/US20170210697A1-20170727-C00269.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00269" attachment-type="cdx" file="US20170210697A1-20170727-C00269.CDX"> </attachment>
          <attachment idref="CHEM-US-00269" attachment-type="mol" file="US20170210697A1-20170727-C00269.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1289]"> </para-num> <div id="p-1334" num="1289" class="description-line">Chemical Formula: C<sub>17</sub>H<sub>26</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[1290]"> </para-num> <div id="p-1335" num="1290" class="description-line">Molecular Weight: 262.393</div>
    </li> <li> <para-num num="[1291]"> </para-num> <div id="p-1336" num="1291" class="description-line">To a solution of palladium chloride (0.09 g, 0.52 mmol) and benzoquinone (3.09 g, 28.57 mmol) in DMF/Water (7:1, 12.8 mL), [(dec-9-en-1-yloxy)methyl]benzene (6.4 g, 25.98 mmol) was slowly added and the dark brown solution was allowed to stir for 3 days at rt. The mixture was dissolved in 2N HCl (50 mL) and extracted with ether (350 mL). The combined organic phase was washed with 2N NaOH (350 mL) and dried over MgSO<sub>4</sub>. Solvents were removed under vacuum and the residue was purified by silica gel chromatography (0-40%) ethyl acetate in hexanes to obtain 10-(benzyloxy)decan-2-one (3.44 g, 13.11 mmol, 50%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.36 (m, 5H); 4.52 (s, 2H); 3.48 (t, 2H); 2.43 (t, 2H); 2.15 (s, 3H); 1.61 (m, 4H); 1.45-1.24 (br. m, 8H).</div>
    </li> <heading id="h-0244">1-(Benzyloxy)-9-methyloctadecan-9-ol</heading>
    <li> <para-num num="[1292]"> </para-num> <div id="p-1337" num="1292" class="description-line">
      <chemistry id="CHEM-US-00270" num="00270">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b2/0e/f0/b0c7649965696d/US20170210697A1-20170727-C00270.png"><img id="EMI-C00270" he="17.44mm" wi="75.01mm" file="US20170210697A1-20170727-C00270.TIF" alt="Figure US20170210697A1-20170727-C00270" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="300" height="70" alt="Figure US20170210697A1-20170727-C00270" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b2/0e/f0/b0c7649965696d/US20170210697A1-20170727-C00270.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00270" attachment-type="cdx" file="US20170210697A1-20170727-C00270.CDX"> </attachment>
          <attachment idref="CHEM-US-00270" attachment-type="mol" file="US20170210697A1-20170727-C00270.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1293]"> </para-num> <div id="p-1338" num="1293" class="description-line">Chemical Formula: C<sub>26</sub>H<sub>46</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[1294]"> </para-num> <div id="p-1339" num="1294" class="description-line">Molecular Weight: 390.652</div>
    </li> <li> <para-num num="[1295]"> </para-num> <div id="p-1340" num="1295" class="description-line">To a solution of 10-(benzyloxy)decan-2-one (1 g, 3.81 mmol) in THF (30 mL) at 0 C., bromo(nonyl)magnesium (4.57 mL 1 M in diethylether, 4.57 mmol) was added dropwise. The reaction was allowed to warm to rt and stir for 4 h. The reaction was quenched with water (2 mL), diethylether was added (200 mL) and the resulting white solid was filtered through a silica plug. The filtrate was extracted with ether. The organic layer was washed with water, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain 1-(benzyloxy)-9-methyloctadecan-9-ol (0.99 g). The product was impure but taken to the next step without further purification.</div>
    </li> <heading id="h-0245">9-Methyloctadecane-1,9-diol</heading>
    <li> <para-num num="[1296]"> </para-num> <div id="p-1341" num="1296" class="description-line">
      <chemistry id="CHEM-US-00271" num="00271">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/4b/5c/56d4b2da770f98/US20170210697A1-20170727-C00271.png"><img id="EMI-C00271" he="10.33mm" wi="75.69mm" file="US20170210697A1-20170727-C00271.TIF" alt="Figure US20170210697A1-20170727-C00271" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="41" alt="Figure US20170210697A1-20170727-C00271" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/4b/5c/56d4b2da770f98/US20170210697A1-20170727-C00271.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00271" attachment-type="cdx" file="US20170210697A1-20170727-C00271.CDX"> </attachment>
          <attachment idref="CHEM-US-00271" attachment-type="mol" file="US20170210697A1-20170727-C00271.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1297]"> </para-num> <div id="p-1342" num="1297" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>40</sub>O<sub>2 </sub> </div>
    </li> <li> <para-num num="[1298]"> </para-num> <div id="p-1343" num="1298" class="description-line">Molecular Weight: 300.527</div>
    </li> <li> <para-num num="[1299]"> </para-num> <div id="p-1344" num="1299" class="description-line">Under N<sub>2 </sub>a flask was charged with 1-(benzyloxy)-9-methyloctadecan-9-ol (1 g, 2.56 mmol), Pd(OH)<sub>2 </sub>(100 mg) and EtOH. The reaction was purged with H<sub>2 </sub>and was kept under H<sub>2 </sub>(balloon) with stirring for 16 h at rt. The reaction was purged with N<sub>2</sub>. The reaction was filtered through a plug of Celite and the Celite was washed with EtOAc (200 mL). The filtrate was evaporated under vacuum. The residue was dissolved in EtOAc and was washed with water. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with EtOAc in hexanes (0-40%) to obtain 9-methyloctadecane-1,9-diol (0.65 g, 2.16 mmol, 84%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.66 (t, 2H); 1.59 (m, 2H); 1.49-1.22 (br. m, 29H); 1.17 (s, 3H); 0.90 (m, 3H).</div>
    </li> <heading id="h-0246">1-Bromo-9-methyloctadecan-9-ol</heading>
    <li> <para-num num="[1300]"> </para-num> <div id="p-1345" num="1300" class="description-line">
      <chemistry id="CHEM-US-00272" num="00272">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/27/21/5f6e1ce9c1c539/US20170210697A1-20170727-C00272.png"><img id="EMI-C00272" he="10.33mm" wi="74.68mm" file="US20170210697A1-20170727-C00272.TIF" alt="Figure US20170210697A1-20170727-C00272" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="41" alt="Figure US20170210697A1-20170727-C00272" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/27/21/5f6e1ce9c1c539/US20170210697A1-20170727-C00272.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00272" attachment-type="cdx" file="US20170210697A1-20170727-C00272.CDX"> </attachment>
          <attachment idref="CHEM-US-00272" attachment-type="mol" file="US20170210697A1-20170727-C00272.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1301]"> </para-num> <div id="p-1346" num="1301" class="description-line">Chemical Formula: C<sub>19</sub>H<sub>39</sub>BrO</div>
    </li> <li> <para-num num="[1302]"> </para-num> <div id="p-1347" num="1302" class="description-line">Molecular Weight: 363.42</div>
    </li> <li> <para-num num="[1303]"> </para-num> <div id="p-1348" num="1303" class="description-line">1-Bromo-9-methyloctadecan-9-ol was synthesized in the same manner as (Z)-1-bromo-10-octyloctadec-8-ene. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.43 (t, 2H); 1.88 (m, 2H); 1.53-1.23 (br. m, 28H); 1.17 (s, 3H); 0.91 (m, 3H).</div>
    </li> <heading id="h-0247">Heptadecan-9-yl 8-((9-hydroxy-9-methyloctadecyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1304]"> </para-num> <div id="p-1349" num="1304" class="description-line">
      <chemistry id="CHEM-US-00273" num="00273">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/cb/8d/2e316a0efe94b9/US20170210697A1-20170727-C00273.png"><img id="EMI-C00273" he="26.42mm" wi="105.49mm" file="US20170210697A1-20170727-C00273.TIF" alt="Figure US20170210697A1-20170727-C00273" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="106" alt="Figure US20170210697A1-20170727-C00273" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/cb/8d/2e316a0efe94b9/US20170210697A1-20170727-C00273.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00273" attachment-type="cdx" file="US20170210697A1-20170727-C00273.CDX"> </attachment>
          <attachment idref="CHEM-US-00273" attachment-type="mol" file="US20170210697A1-20170727-C00273.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1305]"> </para-num> <div id="p-1350" num="1305" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>93</sub>NO<sub>4 </sub> </div>
    </li> <li> <para-num num="[1306]"> </para-num> <div id="p-1351" num="1306" class="description-line">Molecular Weight: 724.253</div>
    </li> <li> <para-num num="[1307]"> </para-num> <div id="p-1352" num="1307" class="description-line">Compound 171 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.56 min. MS (ES): m/z (MH+) 725.0 for C<sub>46</sub>H<sub>93</sub>NO<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 3.55 (m, 2H); 2.60 (m, 2H); 2.47 (m, 4H); 2.30 (t, 2H); 1.74-1.21 (m, 69H); 1.17 (s, 3H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0248">XX72. Compound 172: (R)-Decan-2-yl 8-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)octanoate</heading>
    <li> <para-num num="[1308]"> </para-num> <div id="p-1353" num="1308" class="description-line">
      <chemistry id="CHEM-US-00274" num="00274">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7d/56/e4/26b66896f2609c/US20170210697A1-20170727-C00274.png"><img id="EMI-C00274" he="29.21mm" wi="102.79mm" file="US20170210697A1-20170727-C00274.TIF" alt="Figure US20170210697A1-20170727-C00274" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="117" alt="Figure US20170210697A1-20170727-C00274" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7d/56/e4/26b66896f2609c/US20170210697A1-20170727-C00274.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00274" attachment-type="cdx" file="US20170210697A1-20170727-C00274.CDX"> </attachment>
          <attachment idref="CHEM-US-00274" attachment-type="mol" file="US20170210697A1-20170727-C00274.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1309]"> </para-num> <div id="p-1354" num="1309" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1310]"> </para-num> <div id="p-1355" num="1310" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1311]"> </para-num> <div id="p-1356" num="1311" class="description-line">Compound 172 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.53 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.91 (m, 2H); 3.54 (m, 2H); 2.59 (m, 2H); 2.46 (m, 4H); 2.30 (m, 4H); 1.70-1.19 (m, 66H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0249">XX73. Compound 173: Heptadecan-9-yl 8-((3-(N-methylmethylsulfonamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1312]"> </para-num> <div id="p-1357" num="1312" class="description-line">
      <chemistry id="CHEM-US-00275" num="00275">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/49/aa/69f2ee59e927b8/US20170210697A1-20170727-C00275.png"><img id="EMI-C00275" he="32.60mm" wi="119.04mm" file="US20170210697A1-20170727-C00275.TIF" alt="Figure US20170210697A1-20170727-C00275" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="476" height="130" alt="Figure US20170210697A1-20170727-C00275" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/49/aa/69f2ee59e927b8/US20170210697A1-20170727-C00275.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00275" attachment-type="cdx" file="US20170210697A1-20170727-C00275.CDX"> </attachment>
          <attachment idref="CHEM-US-00275" attachment-type="mol" file="US20170210697A1-20170727-C00275.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1313]"> </para-num> <div id="p-1358" num="1313" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>94</sub>N<sub>2</sub>O<sub>6</sub>S</div>
    </li> <li> <para-num num="[1314]"> </para-num> <div id="p-1359" num="1314" class="description-line">Molecular Weight: 815.34</div>
    </li> <li> <para-num num="[1315]"> </para-num> <div id="p-1360" num="1315" class="description-line">To a solution of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and N-methyl methanesulfonamide (50 uL, 0.54 mmol) in 4 mL dry DMF was added cesium carbonate (130 mg, 0.40 mmol), the resulting mixture heated to 60 C. and stirred for 24 hours, after which no starting chloride remained by LC/MS. The mixture was allowed to cool to rt, diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. to a yellow oil. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(N-methylmethylsulfonamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (85 mg, 0.11 mmol, 39%) as a pale yellow oil. UPLC/ELSD: RT=3.57 min. MS (ES): m/z (MH<sup>+</sup>) 816.1 for C<sub>47</sub>H<sub>94</sub>N2O<sub>6</sub>S. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.15 (t, 2H, J=7.5 Hz); 2.85 (s, 3H); 2.79 (3, 3H); 2.40 (br. m, 5H); 2.28 (m, 4H); 1.72 (br. m, 2H); 1.64-1.49 (m, 13H); 1.26 (br. m, 50H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0250">XX74. Compound 174: Heptadecan-9-yl 8-((3-(2,5-dioxoimidazolidin-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1316]"> </para-num> <div id="p-1361" num="1316" class="description-line">
      <chemistry id="CHEM-US-00276" num="00276">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/9a/4f/040dd1ca21f479/US20170210697A1-20170727-C00276.png"><img id="EMI-C00276" he="30.73mm" wi="120.48mm" file="US20170210697A1-20170727-C00276.TIF" alt="Figure US20170210697A1-20170727-C00276" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="482" height="123" alt="Figure US20170210697A1-20170727-C00276" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/9a/4f/040dd1ca21f479/US20170210697A1-20170727-C00276.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00276" attachment-type="cdx" file="US20170210697A1-20170727-C00276.CDX"> </attachment>
          <attachment idref="CHEM-US-00276" attachment-type="mol" file="US20170210697A1-20170727-C00276.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1317]"> </para-num> <div id="p-1362" num="1317" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>91</sub>N<sub>3</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1318]"> </para-num> <div id="p-1363" num="1318" class="description-line">Molecular Weight: 806.27</div>
    </li> <li> <para-num num="[1319]"> </para-num> <div id="p-1364" num="1319" class="description-line">To a solution of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and hydantoin (50 mg, 0.54 mmol) in 4 mL dry DMF was added cesium carbonate (130 mg, 0.40 mmol), the resulting mixture heated to 60 C. and stirred for 24 hours, after which no starting chloride remained by LC/MS. The mixture was allowed to cool to rt, diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(2,5-dioxoimidazolidin-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (35 mg, 0.05 mmol, 18%) as a pale yellow oil. UPLC/ELSD: RT=3.52 min. MS (ES): m/z (MH<sup>+</sup>) 807.2 for C<sub>48</sub>H<sub>91</sub>N<sub>3</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.27 (br. s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.95 (s, 2H); 3.55 (t, 2H, J=7.5 Hz); 2.50-2.34 (br. m, 5H); 2.26 (m, 4H); 1.77 (br. s, 2H); 1.64-1.49 (m, 15H); 1.26 (br. m, 48H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0251">XX75. Compound 175: Heptadecan-9-yl 8-((3-((methylcarbamoyl)oxy)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1320]"> </para-num> <div id="p-1365" num="1320" class="description-line">
      <chemistry id="CHEM-US-00277" num="00277">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/e8/77/5f1dad67a8fdb9/US20170210697A1-20170727-C00277.png"><img id="EMI-C00277" he="32.60mm" wi="123.95mm" file="US20170210697A1-20170727-C00277.TIF" alt="Figure US20170210697A1-20170727-C00277" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="496" height="130" alt="Figure US20170210697A1-20170727-C00277" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/e8/77/5f1dad67a8fdb9/US20170210697A1-20170727-C00277.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00277" attachment-type="cdx" file="US20170210697A1-20170727-C00277.CDX"> </attachment>
          <attachment idref="CHEM-US-00277" attachment-type="mol" file="US20170210697A1-20170727-C00277.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1321]"> </para-num> <div id="p-1366" num="1321" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1322]"> </para-num> <div id="p-1367" num="1322" class="description-line">Molecular Weight: 781.26</div>
    </li> <li> <para-num num="[1323]"> </para-num> <div id="p-1368" num="1323" class="description-line">To a solution of heptadecan-9-yl 8-((3-hydroxypropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and triethylamine (60 uL, 0.41 mmol) in 5 mL dry DCM at 0 C. was added methyl isocyanate (22 uL, 0.35 mmol) dropwise. The cooling bath was removed and the solution stirred at rt for 2 hours, after which no starting alcohol remained by LC/MS. The reaction was quenched with three drops of methanol, the mixture reduced in a stream of nitrogen and the residue purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-((methylcarbamoyl)oxy)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (115 mg, 0.15 mmol, 53%) as a colorless oil. UPLC/ELSD: RT=3.54 min. MS (ES): m/z (MH<sup>+</sup>) 782.3 for C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (quint., 1H, J=6 Hz); 4.62 (br. s, 1H); 4.05 (m, 4H); 2.79 (d, 3H, J=3 Hz); 2.47 (br. s, 2H); 2.37 (br. m, 3H); 2.27 (m, 4H); 1.73 (br. s, 2H); 1.61 (m, 7H); 1.50 (br. m, 4H); 1.40 (br. m, 4H); 1.25 (br. m, 48H); 0.87 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0252">XX76. Compound 176: Heptadecan-9-yl 8-((3-(2,5-dioxopyrrolidin-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1324]"> </para-num> <div id="p-1369" num="1324" class="description-line">
      <chemistry id="CHEM-US-00278" num="00278">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/64/5a/2f/7608a1eca2351a/US20170210697A1-20170727-C00278.png"><img id="EMI-C00278" he="30.73mm" wi="118.28mm" file="US20170210697A1-20170727-C00278.TIF" alt="Figure US20170210697A1-20170727-C00278" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="473" height="123" alt="Figure US20170210697A1-20170727-C00278" class="patent-full-image" src="https://patentimages.storage.googleapis.com/64/5a/2f/7608a1eca2351a/US20170210697A1-20170727-C00278.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00278" attachment-type="cdx" file="US20170210697A1-20170727-C00278.CDX"> </attachment>
          <attachment idref="CHEM-US-00278" attachment-type="mol" file="US20170210697A1-20170727-C00278.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1325]"> </para-num> <div id="p-1370" num="1325" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1326]"> </para-num> <div id="p-1371" num="1326" class="description-line">Molecular Weight: 805.28</div>
    </li> <li> <para-num num="[1327]"> </para-num> <div id="p-1372" num="1327" class="description-line">To a solution of heptadecan-9-yl 8-((3-chloropropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and succinimide (50 mg, 0.54 mmol) in 4 mL dry DMSO was added cesium carbonate (130 mg, 0.40 mmol), the resulting mixture heated to 80 C. and stirred for 48 hours, after which no starting chloride remained by LC/MS. The mixture was allowed to cool to rt, diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted three times with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified twice by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(2,5-dioxopyrrolidin-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (44 mg, 0.05 mmol, 19%) as a slightly yellow oil. UPLC/ELSD: RT=3.56 min. MS (ES): m/z (MH<sup>+</sup>) 806.1 for C<sub>49</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.52 (t, 2H, J=7.5 Hz); 2.69 (s, 4H); 2.42-2.25 (br. m, 9H); 1.71-1.58 (m, 10H); 1.50 (br. d, 4H, J=3 Hz); 1.26 (br. m, 51H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0253">XX77. Compound 177: Heptadecan-9-yl 8-((3-(4-(tert-butoxymethyl)-1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1328]"> </para-num> <div id="p-1373" num="1328" class="description-line">
      <chemistry id="CHEM-US-00279" num="00279">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/5d/4c/8482ffdc0a6d2e/US20170210697A1-20170727-C00279.png"><img id="EMI-C00279" he="27.26mm" wi="130.98mm" file="US20170210697A1-20170727-C00279.TIF" alt="Figure US20170210697A1-20170727-C00279" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="524" height="109" alt="Figure US20170210697A1-20170727-C00279" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/5d/4c/8482ffdc0a6d2e/US20170210697A1-20170727-C00279.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00279" attachment-type="cdx" file="US20170210697A1-20170727-C00279.CDX"> </attachment>
          <attachment idref="CHEM-US-00279" attachment-type="mol" file="US20170210697A1-20170727-C00279.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1329]"> </para-num> <div id="p-1374" num="1329" class="description-line">Chemical Formula: C<sub>52</sub>H<sub>100</sub>N<sub>4</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[1330]"> </para-num> <div id="p-1375" num="1330" class="description-line">Molecular Weight: 861.40</div>
    </li> <li> <para-num num="[1331]"> </para-num> <div id="p-1376" num="1331" class="description-line">To a solution of heptadecan-9-yl 8-((3-azidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (500 mg, 0.67 mmol) and tert-butyl propargyl ether (100 uL, 0.73 mmol) in 4 mL THF was added a suspension of anhydrous copper(II) sulfate (5 mg, 0.03 mmol) and sodium ascorbate (14 mg, 0.07 mmol) in 1 mL water and the mixture stirred at rt for 24 hours, after which no starting azide remained by LC/MS. The mixture was diluted with a saturated aqueous sodium bicarbonate solution and extracted three times with DCM. The organics were combined, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(4-(tert-butoxymethyl)-1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (485 mg, 0.56 mmol, 84%) as a slightly yellow oil. UPLC/ELSD: RT=3.63 min. MS (ES): m/z (MH<sup>+</sup>) 862.2 for C<sub>52</sub>H<sub>100</sub>N<sub>4</sub>O<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.50 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.59 (s, 2H); 4.36 (t, 2H, J=7.5 Hz); 4.05 (t, 2H, J=6 Hz); 2.36 (br. m, 5H); 2.28 (m, 4H); 2.02 (br. m, 2H); 1.62 (br. m, 8H); 1.50 (br. d, 4H, J=3 Hz); 1.28 (br. m, 60H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0254">XX78. Compound 178: Heptadecan-9-yl 8-((3-(2-methoxyacetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1332]"> </para-num> <div id="p-1377" num="1332" class="description-line">
      <chemistry id="CHEM-US-00280" num="00280">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/96/f2/939329d620123e/US20170210697A1-20170727-C00280.png"><img id="EMI-C00280" he="32.60mm" wi="128.78mm" file="US20170210697A1-20170727-C00280.TIF" alt="Figure US20170210697A1-20170727-C00280" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="515" height="130" alt="Figure US20170210697A1-20170727-C00280" class="patent-full-image" src="https://patentimages.storage.googleapis.com/84/96/f2/939329d620123e/US20170210697A1-20170727-C00280.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00280" attachment-type="cdx" file="US20170210697A1-20170727-C00280.CDX"> </attachment>
          <attachment idref="CHEM-US-00280" attachment-type="mol" file="US20170210697A1-20170727-C00280.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1333]"> </para-num> <div id="p-1378" num="1333" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>94</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1334]"> </para-num> <div id="p-1379" num="1334" class="description-line">Molecular Weight: 795.29</div>
    </li> <li> <para-num num="[1335]"> </para-num> <div id="p-1380" num="1335" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and triethylamine (60 uL, 0.41 mmol) in 5 mL dry DCM at 0 C. was added methoxyacetyl chloride (30 uL, 0.33 mmol) dropwise. The cooling bath was removed and the solution stirred at rt for 24 hours, after which no starting amine remained by LC/MS. The mixture was diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(2-methoxyacetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (50 mg, 0.06 mmol, 23%) as a colorless oil. UPLC/ELSD: RT=3.56 min. MS (ES): m/z (MH<sup>+</sup>) 796.2 for C<sub>48</sub>H<sub>94</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.53 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.87 (s, 2H); 3.39 (m, 5H); 2.47 (br. s, 2H); 2.36 (br. m, 3H); 2.27 (m, 4H); 1.61 (m, 8H); 1.46 (br. m, 9H); 1.26 (br. m, 48H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0255">XX79. Compound 179: Heptadecan-9-yl 8-((3-(1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0256">Heptadecan-9-yl 8-((8-(nonyloxy)-8-oxooctyl)(3-(4-(trimethylsilyl)-1H-1,2,3-triazol-1-yl)propyl)amino)octanoate</heading>
    <li> <para-num num="[1336]"> </para-num> <div id="p-1381" num="1336" class="description-line">
      <chemistry id="CHEM-US-00281" num="00281">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/84/f3/849709e7171d77/US20170210697A1-20170727-C00281.png"><img id="EMI-C00281" he="27.26mm" wi="123.02mm" file="US20170210697A1-20170727-C00281.TIF" alt="Figure US20170210697A1-20170727-C00281" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="492" height="109" alt="Figure US20170210697A1-20170727-C00281" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/84/f3/849709e7171d77/US20170210697A1-20170727-C00281.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00281" attachment-type="cdx" file="US20170210697A1-20170727-C00281.CDX"> </attachment>
          <attachment idref="CHEM-US-00281" attachment-type="mol" file="US20170210697A1-20170727-C00281.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1337]"> </para-num> <div id="p-1382" num="1337" class="description-line">Chemical Formula: C<sub>50</sub>H<sub>98</sub>N<sub>4</sub>O<sub>4</sub>Si</div>
    </li> <li> <para-num num="[1338]"> </para-num> <div id="p-1383" num="1338" class="description-line">Molecular Weight: 847.44</div>
    </li> <li> <para-num num="[1339]"> </para-num> <div id="p-1384" num="1339" class="description-line">To a solution of heptadecan-9-yl 8-((3-azidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and ethynyltrimethylsilane (41 uL, 0.29 mmol) in 2 mL THF was added a suspension of anhydrous copper(II) sulfate (2 mg, 0.01 mmol) and sodium ascorbate (5 mg, 0.02 mmol) in 0.5 mL water and the mixture stirred at rt for 20 hours, after which no starting azide remained by LC/MS. The mixture was diluted with a saturated aqueous sodium bicarbonate solution and extracted three times with DCM. The organics were combined, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((8-(nonyloxy)-8-oxooctyl)(3-(4-(trimethyl silyl)-1H-1,2,3-triazol-1-yl)propyl)amino)octanoate (150 mg, 0.18 mmol, 66%) as a slightly yellow oil which is a 2:1 mixture of TMS/des-TMS product by <sup>1</sup>H-NMR. Carried through as is. UPLC/ELSD: RT=3.63 min. MS (ES): m/z (MH<sup>+</sup>) 848.3 for C<sub>50</sub>H<sub>98</sub>N<sub>4</sub>O<sub>4</sub>Si. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.55 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.45 (t, 2H, J=7.5 Hz); 4.05 (t, 2H, J=6 Hz); 3.42 (br. s, 1H); 2.28 (m, 5H); 1.65-1.45 (br. m, 14H); 1.25 (br. m, 48H); 0.87 (t, 9H, J=7.5 Hz); 0.33 (s, 6H).</div>
    </li> <heading id="h-0257">Heptadecan-9-yl 8-((3-(1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1340]"> </para-num> <div id="p-1385" num="1340" class="description-line">
      <chemistry id="CHEM-US-00282" num="00282">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/1f/04/0d470d21b988ad/US20170210697A1-20170727-C00282.png"><img id="EMI-C00282" he="27.26mm" wi="118.70mm" file="US20170210697A1-20170727-C00282.TIF" alt="Figure US20170210697A1-20170727-C00282" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="475" height="109" alt="Figure US20170210697A1-20170727-C00282" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/1f/04/0d470d21b988ad/US20170210697A1-20170727-C00282.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00282" attachment-type="cdx" file="US20170210697A1-20170727-C00282.CDX"> </attachment>
          <attachment idref="CHEM-US-00282" attachment-type="mol" file="US20170210697A1-20170727-C00282.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1341]"> </para-num> <div id="p-1386" num="1341" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>90</sub>N<sub>4</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1342]"> </para-num> <div id="p-1387" num="1342" class="description-line">Molecular Weight: 775.26</div>
    </li> <li> <para-num num="[1343]"> </para-num> <div id="p-1388" num="1343" class="description-line">To a solution of (150 mg, 0.18 mmol) in 5 mL THF was added a 1M tetrabutylammonium fluoride solution in THF (0.21 mL, 0.21 mmol) and the solution stirred at rt for 24 hours after which the reaction had progressed ca. 25%. The solution was heated to 55 C. and stirred for 24 hours, after which the reaction was complete by LC/MS. The solution was diluted with a saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (53 mg, 0.07 mmol, 39%) as a colorless oil. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 776.2 for C<sub>47</sub>H<sub>90</sub>N<sub>4</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.69 (s, 1H); 7.55 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.44 (t, 2H, J=7.5 Hz); 4.05 (t, 2H, J=6 Hz); 2.37 (br. m, 5H); 2.28 (m, 4H); 2.05 (br. m, 2H); 1.61 (br. m, 8H); 1.49 (br. m, 4H); 1.26 (br. m, 51H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0258">XX81. Compound 181: Heptadecan-9-yl 8-((3-((methoxycarbonyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1344]"> </para-num> <div id="p-1389" num="1344" class="description-line">
      <chemistry id="CHEM-US-00283" num="00283">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/60/8c/b9/73cb83b643eb9a/US20170210697A1-20170727-C00283.png"><img id="EMI-C00283" he="32.60mm" wi="123.95mm" file="US20170210697A1-20170727-C00283.TIF" alt="Figure US20170210697A1-20170727-C00283" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="496" height="130" alt="Figure US20170210697A1-20170727-C00283" class="patent-full-image" src="https://patentimages.storage.googleapis.com/60/8c/b9/73cb83b643eb9a/US20170210697A1-20170727-C00283.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00283" attachment-type="cdx" file="US20170210697A1-20170727-C00283.CDX"> </attachment>
          <attachment idref="CHEM-US-00283" attachment-type="mol" file="US20170210697A1-20170727-C00283.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1345]"> </para-num> <div id="p-1390" num="1345" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1346]"> </para-num> <div id="p-1391" num="1346" class="description-line">Molecular Weight: 781.26</div>
    </li> <li> <para-num num="[1347]"> </para-num> <div id="p-1392" num="1347" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.27 mmol) and triethylamine (60 uL, 0.41 mmol) in 5 mL dry DCM at 0 C. was added methyl chloroformate (27 uL, 0.33 mmol) dropwise. The cooling bath was removed and the solution stirred at rt for 24 hours, after which no starting amine remained by LC/MS. The mixture was diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-((methoxycarbonyl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (120 mg, 0.15 mmol, 54%) as a colorless oil. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 782.1 for C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 6.11 (br. s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.64 (s, 3H); 3.25 (br. d, 2H, J=6 Hz); 2.46 (br. s, 2H); 2.38-2.24 (m, 7H); 1.61 (br. t, 9H, J=7.5 Hz); 1.50 (m, 4H); 1.42 (br. m, 3H); 1.26 (br. m, 49H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0259">XX82. Compound 182: Heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0260">3-Methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione</heading>
    <li> <para-num num="[1348]"> </para-num> <div id="p-1393" num="1348" class="description-line">
      <chemistry id="CHEM-US-00284" num="00284">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/c4/97/bc926e6bd43fea/US20170210697A1-20170727-C00284.png"><img id="EMI-C00284" he="17.27mm" wi="24.64mm" file="US20170210697A1-20170727-C00284.TIF" alt="Figure US20170210697A1-20170727-C00284" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="99" height="69" alt="Figure US20170210697A1-20170727-C00284" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/c4/97/bc926e6bd43fea/US20170210697A1-20170727-C00284.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00284" attachment-type="cdx" file="US20170210697A1-20170727-C00284.CDX"> </attachment>
          <attachment idref="CHEM-US-00284" attachment-type="mol" file="US20170210697A1-20170727-C00284.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1349]"> </para-num> <div id="p-1394" num="1349" class="description-line">Chemical Formula: C<sub>6</sub>H<sub>7</sub>NO<sub>3 </sub> </div>
    </li> <li> <para-num num="[1350]"> </para-num> <div id="p-1395" num="1350" class="description-line">Molecular Weight: 141.13</div>
    </li> <li> <para-num num="[1351]"> </para-num> <div id="p-1396" num="1351" class="description-line">To a solution of 3,4-dimethoxy-3-cyclobutene-1,2-dione (1 g, 7 mmol) in 100 mL diethyl ether was added a 2M methylamine solution in THF (3.8 mL, 7.6 mmol) and a ppt. formed almost immediately. The mixture was stirred at rt for 24 hours, then filtered, the filter solids washed with diethyl ether and air-dried. The filter solids were dissolved in hot EtOAc, filtered, the filtrate allowed to cool to room temp., then cooled to 0 C. to give a ppt. This was isolated via filtration, washed with cold EtOAc, air-dried, then dried under vacuum to give 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione (0.70 g, 5 mmol, 73%) as a white solid. <sup>1</sup>H NMR (300 MHz, DMSO-d6) : ppm 8.50 (br. d, 1H, J=69 Hz); 4.27 (s, 3H); 3.02 (sdd, 3H, J=42 Hz, 4.5 Hz).</div>
    </li> <heading id="h-0261">Heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1352]"> </para-num> <div id="p-1397" num="1352" class="description-line">
      <chemistry id="CHEM-US-00285" num="00285">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/44/f2/dd6ca295f03def/US20170210697A1-20170727-C00285.png"><img id="EMI-C00285" he="37.25mm" wi="126.83mm" file="US20170210697A1-20170727-C00285.TIF" alt="Figure US20170210697A1-20170727-C00285" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="507" height="149" alt="Figure US20170210697A1-20170727-C00285" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/44/f2/dd6ca295f03def/US20170210697A1-20170727-C00285.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00285" attachment-type="cdx" file="US20170210697A1-20170727-C00285.CDX"> </attachment>
          <attachment idref="CHEM-US-00285" attachment-type="mol" file="US20170210697A1-20170727-C00285.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1353]"> </para-num> <div id="p-1398" num="1353" class="description-line">Chemical Formula: C<sub>50</sub>H<sub>93</sub>N<sub>3</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1354]"> </para-num> <div id="p-1399" num="1354" class="description-line">Molecular Weight: 832.31</div>
    </li> <li> <para-num num="[1355]"> </para-num> <div id="p-1400" num="1355" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.28 mmol) in 10 mL ethanol was added 3-methoxy-4-(methylamino)cyclobut-3-ene-1,2-dione (39 mg, 0.28 mmol) and the resulting colorless solution stirred at rt for 20 hours after which no starting amine remained by LC/MS. The solution was concentrated in vacuo and the residue purified by silica gel chromatography (0-100% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-((2-(methylamino)-3,4-dioxocyclobut-1-en-1-yl)amino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (138 mg, 0.17 mmol, 60%) as a gummy white solid. UPLC/ELSD: RT=3. min. MS (ES): m/z (MH<sup>+</sup>) 833.4 for C<sub>51</sub>H<sub>95</sub>N<sub>3</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.86 (br. s., 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.92 (d, 2H, J=3 Hz); 3.20 (s, 6H); 2.63 (br. s, 2H); 2.42 (br. s, 3H); 2.28 (m, 4H); 1.74 (br. s, 2H); 1.61 (m, 8H); 1.50 (m, 5H); 1.41 (m, 3H); 1.25 (br. m, 47H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0262">XX83. Compound 183: 1,3-Bis(hexyloxy)propan-2-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0263">(((1,3-Bis(hexyloxy)propan-2-yl)oxy)methyl)benzene</heading>
    <li> <para-num num="[1356]"> </para-num> <div id="p-1401" num="1356" class="description-line">
      <chemistry id="CHEM-US-00286" num="00286">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2c/a2/d8/81a55a5ebdbcd6/US20170210697A1-20170727-C00286.png"><img id="EMI-C00286" he="13.04mm" wi="51.22mm" file="US20170210697A1-20170727-C00286.TIF" alt="Figure US20170210697A1-20170727-C00286" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="205" height="52" alt="Figure US20170210697A1-20170727-C00286" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2c/a2/d8/81a55a5ebdbcd6/US20170210697A1-20170727-C00286.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00286" attachment-type="cdx" file="US20170210697A1-20170727-C00286.CDX"> </attachment>
          <attachment idref="CHEM-US-00286" attachment-type="mol" file="US20170210697A1-20170727-C00286.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1357]"> </para-num> <div id="p-1402" num="1357" class="description-line">Chemical Formula: C<sub>22</sub>H<sub>38</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1358]"> </para-num> <div id="p-1403" num="1358" class="description-line">Molecular Weight: 350.543</div>
    </li> <li> <para-num num="[1359]"> </para-num> <div id="p-1404" num="1359" class="description-line">To a slurry of NaH (1.76 g, 43.9 mmol) in THF (40 mL) under N2 was added 2-(benzyloxy)propane-1,3-diol (2 g, 10.98 mmol) and the mixture was allowed to stir at 40 C. for 2 h. After this time 1-bromohexane (4.35 g, 26.34 mmol) in DMF (2 ml) and a catalytic amount of KI were added. The reaction was refluxed for 16 h. Solvents were evaporated under vacuum. The residue was diluted with EtOAc and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-40%) EtOAc in hexanes to obtain (((1,3-bis(hexyloxy)propan-2-yl)oxy)methyl)benzene (1.7 g, 4.75 mmol, 43%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.34 (m, 5H); 4.73 (s, 2H); 3.75 (m, 1H); 3.61-3.40 (m, 8H); 1.59 (m, 4H); 1.32 (m, 12H); 0.91 (m, 6H).</div>
    </li> <heading id="h-0264">1,3-Bis(hexyloxy)propan-2-ol</heading>
    <li> <para-num num="[1360]"> </para-num> <div id="p-1405" num="1360" class="description-line">
      <chemistry id="CHEM-US-00287" num="00287">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e6/8f/66/ff1a24373c6185/US20170210697A1-20170727-C00287.png"><img id="EMI-C00287" he="13.12mm" wi="46.82mm" file="US20170210697A1-20170727-C00287.TIF" alt="Figure US20170210697A1-20170727-C00287" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="187" height="52" alt="Figure US20170210697A1-20170727-C00287" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e6/8f/66/ff1a24373c6185/US20170210697A1-20170727-C00287.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00287" attachment-type="cdx" file="US20170210697A1-20170727-C00287.CDX"> </attachment>
          <attachment idref="CHEM-US-00287" attachment-type="mol" file="US20170210697A1-20170727-C00287.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1361]"> </para-num> <div id="p-1406" num="1361" class="description-line">Chemical Formula: C<sub>15</sub>H<sub>32</sub>O<sub>3 </sub> </div>
    </li> <li> <para-num num="[1362]"> </para-num> <div id="p-1407" num="1362" class="description-line">Molecular Weight: 260.418</div>
    </li> <li> <para-num num="[1363]"> </para-num> <div id="p-1408" num="1363" class="description-line">1,3-Bis(hexyloxy)propan-2-ol was synthesized using the same manner as 9-Methyloctadecane-1,9-diol. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.96 (m, 1H); 3.48 (m, 8H); 2.37 (br. S, 1H); 1.64 (m, 2H); 1.60 (m, 4H); 1.32 (m, 12H); 0.91 (m, 6H).</div>
    </li> <heading id="h-0265">1,3-Bis(hexyloxy)propan-2-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1364]"> </para-num> <div id="p-1409" num="1364" class="description-line">
      <chemistry id="CHEM-US-00288" num="00288">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bf/a4/f1/b05d2f0c2a67f6/US20170210697A1-20170727-C00288.png"><img id="EMI-C00288" he="30.06mm" wi="102.79mm" file="US20170210697A1-20170727-C00288.TIF" alt="Figure US20170210697A1-20170727-C00288" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="411" height="120" alt="Figure US20170210697A1-20170727-C00288" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bf/a4/f1/b05d2f0c2a67f6/US20170210697A1-20170727-C00288.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00288" attachment-type="cdx" file="US20170210697A1-20170727-C00288.CDX"> </attachment>
          <attachment idref="CHEM-US-00288" attachment-type="mol" file="US20170210697A1-20170727-C00288.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1365]"> </para-num> <div id="p-1410" num="1365" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>7 </sub> </div>
    </li> <li> <para-num num="[1366]"> </para-num> <div id="p-1411" num="1366" class="description-line">Molecular Weight: 714.126</div>
    </li> <li> <para-num num="[1367]"> </para-num> <div id="p-1412" num="1367" class="description-line">Compound 183 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.17 min. MS (ES): m/z (MH<sup>+</sup>) 715.0 for C<sub>42</sub>H<sub>83</sub>NO<sub>7</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.15 (m, 1H); 4.08 (t, 2H); 3.66-3.34 (m, 10H); 2.71-2.41 (m, 6H); 2.34 (m, 4H); 1.74-1.20 (m, 50H); 0.91 (m, 9H).</div>
    </li> <heading id="h-0266">XX84. Compound 184: Heptadecan-9-yl 8-((2-hydroxyethyl)(8-((2-methylnonyl)oxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0267">2-Methylnonyl 8-bromooctanoate</heading>
    <li> <para-num num="[1368]"> </para-num> <div id="p-1413" num="1368" class="description-line">
      <chemistry id="CHEM-US-00289" num="00289">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/46/b6/53/1ab04f47bcfb4f/US20170210697A1-20170727-C00289.png"><img id="EMI-C00289" he="12.62mm" wi="74.42mm" file="US20170210697A1-20170727-C00289.TIF" alt="Figure US20170210697A1-20170727-C00289" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="50" alt="Figure US20170210697A1-20170727-C00289" class="patent-full-image" src="https://patentimages.storage.googleapis.com/46/b6/53/1ab04f47bcfb4f/US20170210697A1-20170727-C00289.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00289" attachment-type="cdx" file="US20170210697A1-20170727-C00289.CDX"> </attachment>
          <attachment idref="CHEM-US-00289" attachment-type="mol" file="US20170210697A1-20170727-C00289.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1369]"> </para-num> <div id="p-1414" num="1369" class="description-line">Chemical Formula: C<sub>18</sub>H<sub>35</sub>BrO<sub>2 </sub> </div>
    </li> <li> <para-num num="[1370]"> </para-num> <div id="p-1415" num="1370" class="description-line">Molecular Weight: 363.380</div>
    </li> <li> <para-num num="[1371]"> </para-num> <div id="p-1416" num="1371" class="description-line">To a solution of 8-bromooctanoic acid (3.83 g, 17.18 mmol), 2-methylnonan-1-ol (2.72 g, 17.18 mmol), 4-dimethylaminopyridine (0.42 g, 3.44 mmol) in DCM (25 mL) under N2 was added (3-{[(ethylimino)methylidene]amino}propyl)dimethylamine hydrochloride (3.29 g, 17.18 mmol). The reaction was allowed to stir at rt for 16 h. The reaction was diluted with DCM and washed with sat. NaHCO<sub>3</sub>, followed by brine. The organic layer was separated, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated under vacuum. The residue was purified by silica gel chromatography with (0-20%) EtOAc in hexanes to obtain 2-methylnonyl 8-bromooctanoate (5.1 g, 14.04 mmol, 82%). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 3.98 (m, 2H); 3.43 (t, 2H); 2.33 (t, 2H); 1.93-1.74 (m, 3H); 1.72-1.09 (m, 20H); 0.93 (m, 6H).</div>
    </li> <heading id="h-0268">Heptadecan-9-yl 8-((2-hydroxyethyl)(8-((2-methylnonyl)oxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1372]"> </para-num> <div id="p-1417" num="1372" class="description-line">
      <chemistry id="CHEM-US-00290" num="00290">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/d5/78/4fecfb3ef21473/US20170210697A1-20170727-C00290.png"><img id="EMI-C00290" he="25.06mm" wi="74.76mm" file="US20170210697A1-20170727-C00290.TIF" alt="Figure US20170210697A1-20170727-C00290" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="299" height="100" alt="Figure US20170210697A1-20170727-C00290" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/d5/78/4fecfb3ef21473/US20170210697A1-20170727-C00290.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00290" attachment-type="cdx" file="US20170210697A1-20170727-C00290.CDX"> </attachment>
          <attachment idref="CHEM-US-00290" attachment-type="mol" file="US20170210697A1-20170727-C00290.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1373]"> </para-num> <div id="p-1418" num="1373" class="description-line">Chemical Formula: C<sub>45</sub>H<sub>89</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1374]"> </para-num> <div id="p-1419" num="1374" class="description-line">Molecular Weight: 724.209</div>
    </li> <li> <para-num num="[1375]"> </para-num> <div id="p-1420" num="1375" class="description-line">Compound 184 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.60 min. MS (ES): m/z (MH<sup>+</sup>) 725.0 for C<sub>45</sub>H<sub>89</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 3.92 (m, 2H); 3.57 (m, 2H); 2.70-2.41 (m, 6H); 2.31 (m, 4H); 1.79 (m, 1H); 1.70-1.07 (m, 60H); 0.93 (m, 12H).</div>
    </li> <heading id="h-0269">XX85. Compound 185: Henicosan-11-yl 6-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)hexanoate</heading>
    <li> <para-num num="[1376]"> </para-num> <div id="p-1421" num="1376" class="description-line">
      <chemistry id="CHEM-US-00291" num="00291">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/27/23/1d/feda9734d0168b/US20170210697A1-20170727-C00291.png"><img id="EMI-C00291" he="20.40mm" wi="74.25mm" file="US20170210697A1-20170727-C00291.TIF" alt="Figure US20170210697A1-20170727-C00291" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="82" alt="Figure US20170210697A1-20170727-C00291" class="patent-full-image" src="https://patentimages.storage.googleapis.com/27/23/1d/feda9734d0168b/US20170210697A1-20170727-C00291.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00291" attachment-type="cdx" file="US20170210697A1-20170727-C00291.CDX"> </attachment>
          <attachment idref="CHEM-US-00291" attachment-type="mol" file="US20170210697A1-20170727-C00291.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1377]"> </para-num> <div id="p-1422" num="1377" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>91</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1378]"> </para-num> <div id="p-1423" num="1378" class="description-line">Molecular Weight: 738.236</div>
    </li> <li> <para-num num="[1379]"> </para-num> <div id="p-1424" num="1379" class="description-line">Compound 185 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.72 min. MS (ES): m/z (MH<sup>+</sup>) 739.0 for C<sub>46</sub>H<sub>91</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.88 (m, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.60 (m, 2H); 2.48 (m, 4H); 2.32 (m, 4H); 1.72-1.41 (m, 15H); 1.28 (m, 52H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0270">XX86. Compound 186: Heptyl 10-((2-hydroxyethyl)(10-oxo-10-(tridecan-7-yloxy)decyl)amino)decanoate</heading>
    <li> <para-num num="[1380]"> </para-num> <div id="p-1425" num="1380" class="description-line">
      <chemistry id="CHEM-US-00292" num="00292">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/4e/3f/0ca3cec49958c1/US20170210697A1-20170727-C00292.png"><img id="EMI-C00292" he="21.51mm" wi="73.58mm" file="US20170210697A1-20170727-C00292.TIF" alt="Figure US20170210697A1-20170727-C00292" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="294" height="86" alt="Figure US20170210697A1-20170727-C00292" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2b/4e/3f/0ca3cec49958c1/US20170210697A1-20170727-C00292.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00292" attachment-type="cdx" file="US20170210697A1-20170727-C00292.CDX"> </attachment>
          <attachment idref="CHEM-US-00292" attachment-type="mol" file="US20170210697A1-20170727-C00292.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1381]"> </para-num> <div id="p-1426" num="1381" class="description-line">Chemical Formula: C<sub>42</sub>H<sub>83</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1382]"> </para-num> <div id="p-1427" num="1382" class="description-line">Molecular Weight: 682.128</div>
    </li> <li> <para-num num="[1383]"> </para-num> <div id="p-1428" num="1383" class="description-line">Compound 186 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.31 min. MS (ES): m/z (MH<sup>+</sup>) 739.0 for C<sub>42</sub>H<sub>83</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.58 (m, 2H); 2.47 (m, 4H); 2.30 (m, 4H); 1.71-1.18 (m, 58H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0271">XX89. Compound 189: Heptyl 10-((8-(heptadecan-9-yloxy)-8-oxooctyl)(2-hydroxyethyl)amino)decanoate</heading>
    <li> <para-num num="[1384]"> </para-num> <div id="p-1429" num="1384" class="description-line">
      <chemistry id="CHEM-US-00293" num="00293">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/10/66/8f33346e37dfc7/US20170210697A1-20170727-C00293.png"><img id="EMI-C00293" he="54.61mm" wi="105.41mm" file="US20170210697A1-20170727-C00293.TIF" alt="Figure US20170210697A1-20170727-C00293" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="422" height="218" alt="Figure US20170210697A1-20170727-C00293" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/10/66/8f33346e37dfc7/US20170210697A1-20170727-C00293.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00293" attachment-type="cdx" file="US20170210697A1-20170727-C00293.CDX"> </attachment>
          <attachment idref="CHEM-US-00293" attachment-type="mol" file="US20170210697A1-20170727-C00293.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1385]"> </para-num> <div id="p-1430" num="1385" class="description-line">Chemical Formula: C<sub>44</sub>H<sub>87</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1386]"> </para-num> <div id="p-1431" num="1386" class="description-line">Molecular Weight: 710.182</div>
    </li> <li> <para-num num="[1387]"> </para-num> <div id="p-1432" num="1387" class="description-line">Compound 189 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=3.47 min. MS (ES): m/z (MH<sup>+</sup>) 710.98 for C<sub>44</sub>H<sub>87</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 4.89 (m, 1H); 4.08 (t, 2H); 3.55 (m, 2H); 2.61 (m, 2H); 2.47 (m, 4H); 2.31 (m, 4H); 1.70-1.20 (m, 62H); 0.90 (m, 9H).</div>
    </li> <heading id="h-0272">XX94. Compound 194: Heptadecan-9-yl 8-((3-isobutyramidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1388]"> </para-num> <div id="p-1433" num="1388" class="description-line">
      <chemistry id="CHEM-US-00294" num="00294">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e5/52/82/d87aad1ec9491d/US20170210697A1-20170727-C00294.png"><img id="EMI-C00294" he="32.85mm" wi="122.34mm" file="US20170210697A1-20170727-C00294.TIF" alt="Figure US20170210697A1-20170727-C00294" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="489" height="131" alt="Figure US20170210697A1-20170727-C00294" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e5/52/82/d87aad1ec9491d/US20170210697A1-20170727-C00294.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00294" attachment-type="cdx" file="US20170210697A1-20170727-C00294.CDX"> </attachment>
          <attachment idref="CHEM-US-00294" attachment-type="mol" file="US20170210697A1-20170727-C00294.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1389]"> </para-num> <div id="p-1434" num="1389" class="description-line">Chemical Formula: C<sub>49</sub>H<sub>96</sub>N<sub>2</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[1390]"> </para-num> <div id="p-1435" num="1390" class="description-line">Molecular Weight: 793.32</div>
    </li> <li> <para-num num="[1391]"> </para-num> <div id="p-1436" num="1391" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (150 mg, 0.21 mmol) and triethylamine (90 uL, 0.62 mmol) in 5 mL dry DCM at 0 C. was added isobutyryl chloride (35 uL, 0.31 mmol) dropwise. After 30 minutes the cooling bath was removed and the solution stirred at rt for 90 minutes, after which no starting amine remained by LC/MS. The mixture was diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-isobutyramidopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (65 mg, 0.08 mmol, 39%) as a colorless oil. UPLC/ELSD: RT=3.65 min. MS (ES): m/z (MH<sup>+</sup>) 794.3 for C<sub>49</sub>H<sub>96</sub>N<sub>2</sub>O<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.53 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.87 (s, 2H); 3.39 (m, 5H); 2.47 (br. s, 2H); 2.36 (br. m, 3H); 2.27 (m, 4H); 1.61 (m, 8H); 1.46 (br. m, 9H); 1.26 (br. m, 48H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0273">XX97. Compound 197: Heptadecan-9-yl 8-((3-(2-(benzyloxy)acetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1392]"> </para-num> <div id="p-1437" num="1392" class="description-line">
      <chemistry id="CHEM-US-00295" num="00295">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/01/d9/36/276b51a87a3732/US20170210697A1-20170727-C00295.png"><img id="EMI-C00295" he="34.88mm" wi="141.99mm" file="US20170210697A1-20170727-C00295.TIF" alt="Figure US20170210697A1-20170727-C00295" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="568" height="140" alt="Figure US20170210697A1-20170727-C00295" class="patent-full-image" src="https://patentimages.storage.googleapis.com/01/d9/36/276b51a87a3732/US20170210697A1-20170727-C00295.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00295" attachment-type="cdx" file="US20170210697A1-20170727-C00295.CDX"> </attachment>
          <attachment idref="CHEM-US-00295" attachment-type="mol" file="US20170210697A1-20170727-C00295.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1393]"> </para-num> <div id="p-1438" num="1393" class="description-line">Chemical Formula: C<sub>54</sub>H<sub>98</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1394]"> </para-num> <div id="p-1439" num="1394" class="description-line">Molecular Weight: 871.39</div>
    </li> <li> <para-num num="[1395]"> </para-num> <div id="p-1440" num="1395" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (300 mg, 0.41 mmol) and triethylamine (145 uL, 1 mmol) in 10 mL dry DCM at 0 C. was added benzyloxyacetyl chloride (82 uL, 0.52 mmol) dropwise. The cooling bath was removed and the solution stirred at rt for 24 hours, after which no starting amine remained by LC/MS. The mixture was diluted with a 50% saturated aqueous sodium bicarbonate solution and extracted twice with DCM. The organics were combined, washed once with water, dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(2-(benzyloxy)acetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (179 mg, 0.21 mmol, 50%) as a colorless oil. UPLC/ELSD: RT=3.66 min. MS (ES): m/z (MH<sup>+</sup>) 872.4 for C<sub>54</sub>H<sub>98</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.55 (s, 1H); 7.33 (m, 5H); 4.86 (quint., 1H, J=6 Hz); 4.55 (s, 2H); 4.05 (t, 2H, J=6 Hz); 3.97 (s, 2H); 3.35 (quart., 2H, J=6 Hz); 2.46 (br. m, 2H); 2.28 (m, 7H); 1.65-1.48 (m, 15H); 1.26 (br. m, 50H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0274">XX98. Compound 198: Heptadecan-9-yl 8-((3-(2-hydroxyacetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1396]"> </para-num> <div id="p-1441" num="1396" class="description-line">
      <chemistry id="CHEM-US-00296" num="00296">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/e3/77/c0bb2b6458cdc4/US20170210697A1-20170727-C00296.png"><img id="EMI-C00296" he="32.85mm" wi="124.97mm" file="US20170210697A1-20170727-C00296.TIF" alt="Figure US20170210697A1-20170727-C00296" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="500" height="131" alt="Figure US20170210697A1-20170727-C00296" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/e3/77/c0bb2b6458cdc4/US20170210697A1-20170727-C00296.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00296" attachment-type="cdx" file="US20170210697A1-20170727-C00296.CDX"> </attachment>
          <attachment idref="CHEM-US-00296" attachment-type="mol" file="US20170210697A1-20170727-C00296.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1397]"> </para-num> <div id="p-1442" num="1397" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1398]"> </para-num> <div id="p-1443" num="1398" class="description-line">Molecular Weight: 781.26</div>
    </li> <li> <para-num num="[1399]"> </para-num> <div id="p-1444" num="1399" class="description-line">To a solution of heptadecan-9-yl 8-((3-(2-(benzyloxy)acetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (130 mg, 0.15 mmol) in 5 mL ethanol under nitrogen was added palladium 10 wt. % on carbon (approx. 20, cat.) added, the sides of the flask washed down with ethanol and the flask fitted with a hydrogen balloon. The flask was evacuated and back-filled with hydrogen three times, then stirred at rt for 24 hours after which no starting ether remained by LC/MS. The flask was flushed with nitrogen, the mixture filtered through diatomaceous earth, the filter solids washed with ethanol and the filtrate conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(2-hydroxyacetamido)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (55 mg, 0.07 mmol, 47%) as a colorless oil. UPLC/ELSD: RT=3.46 min. MS (ES): m/z (MH<sup>+</sup>) 782.2 for C<sub>47</sub>H<sub>92</sub>N<sub>2</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.73 (br. s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (m, 4H); 3.40 (quart., 2H, J=6 Hz); 2.50 (m, 2H); 2.37 (t, 4H, J=6 Hz); 2.28 (m, 4H); 1.63 (m, 8H); 1.46 (br. m, 8H); 1.26 (br. m, 49H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0275">XX100. Compound 200: Heptadecan-9-yl (E)-8-((3-(3-methyl-2-nitroguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0276">Methyl (E/Z)N-methyl-N-nitrocarbamimidothioate</heading>
    <li> <para-num num="[1400]"> </para-num> <div id="p-1445" num="1400" class="description-line">
      <chemistry id="CHEM-US-00297" num="00297">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/46/25/7a72f89162a4e2/US20170210697A1-20170727-C00297.png"><img id="EMI-C00297" he="14.99mm" wi="19.73mm" file="US20170210697A1-20170727-C00297.TIF" alt="Figure US20170210697A1-20170727-C00297" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="79" height="60" alt="Figure US20170210697A1-20170727-C00297" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/46/25/7a72f89162a4e2/US20170210697A1-20170727-C00297.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00297" attachment-type="cdx" file="US20170210697A1-20170727-C00297.CDX"> </attachment>
          <attachment idref="CHEM-US-00297" attachment-type="mol" file="US20170210697A1-20170727-C00297.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1401]"> </para-num> <div id="p-1446" num="1401" class="description-line">Chemical Formula: C<sub>3</sub>H<sub>7</sub>N<sub>3</sub>O<sub>2</sub>S</div>
    </li> <li> <para-num num="[1402]"> </para-num> <div id="p-1447" num="1402" class="description-line">Molecular Weight: 149.17</div>
    </li> <li> <para-num num="[1403]"> </para-num> <div id="p-1448" num="1403" class="description-line">To a suspension of 2-methyl-1-nitro-2-thiopseudourea (1.0 g, 7.4 mmol) and cesium carbonate (2.5 g, 7.8 mmol in 8 mL dry DMF was added iodomethane (0.69 mL, 11.1 mmol) and the mixture stirred at room temp for 24 hours. The yellow mixture was diluted with water and extracted twice with EtOAc. The organics were combined, washed three times with a 50% saturated aqueous sodium bicarbonate solution, once with brine, dried (MgSO<sub>4</sub>), filtered and conc. to a yellow solid. This was dissolved in hot water, the solution filtered and the filtrate cooled to 4 C. for three days. The resulting solids were isolated via filtration, washed with water, air-dried, then dried under vacuum to give methyl (E/Z)N-methyl-N-nitrocarbamimidothioate (85 mg, 0.57 mmol, 8%) as a pale yellow solid. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 10.02 (br. s, 1H); 3.12 (d, 1H, J=6 Hz); 2.53 (s, 3H).</div>
    </li> <li> <div id="p-1449" num="0000" class="description-line">
      <chemistry id="CHEM-US-00298" num="00298">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a2/ab/3d/2ecf0375186aff/US20170210697A1-20170727-C00298.png"><img id="EMI-C00298" he="35.64mm" wi="122.34mm" file="US20170210697A1-20170727-C00298.TIF" alt="Figure US20170210697A1-20170727-C00298" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="489" height="143" alt="Figure US20170210697A1-20170727-C00298" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a2/ab/3d/2ecf0375186aff/US20170210697A1-20170727-C00298.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00298" attachment-type="cdx" file="US20170210697A1-20170727-C00298.CDX"> </attachment>
          <attachment idref="CHEM-US-00298" attachment-type="mol" file="US20170210697A1-20170727-C00298.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1404]"> </para-num> <div id="p-1450" num="1404" class="description-line">Chemical Formula: C<sub>47</sub>H<sub>93</sub>N<sub>5</sub>O<sub>6 </sub> </div>
    </li> <li> <para-num num="[1405]"> </para-num> <div id="p-1451" num="1405" class="description-line">Molecular Weight: 824.29</div>
    </li> <li> <para-num num="[1406]"> </para-num> <div id="p-1452" num="1406" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (200 mg, 0.28 mmol) in 5 mL methanol was added methyl (E/Z)N-methyl-N-nitrocarbamimidothioate (45 mg, 0.3 mmol), the resulting solution heated to 70 C. and stirred for 24 hours after which no starting amine remained by LC/MS. The solution was diluted with DCM and washed once with a saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO<sub>4</sub>), filtered and the filtrate evaporated in vacuo. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl (E)-8-((3-(3-methyl-2-nitroguanidino)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (75 mg, 0.09 mmol, 33%) as a pale yellow syrup. UPLC/ELSD: RT=3.55 min. MS (ES): m/z (MH<sup>+</sup>) 825.3 for C<sub>47</sub>H<sub>93</sub>N<sub>5</sub>O<sub>6</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 9.26 (br. s, 1H); 8.27 (br. s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.42 (br. s, 2H); 2.86 (d, 3H, J=6 Hz); 2.60-2.40 (br. m, 5H); 2.28 (m, 4H); 1.73 (br. s, 2H); 1.65-1.40 (m, 16H); 1.26 (br. m, 47H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0277">XX107. Compound 207: Heptadecan-9-yl 8-((3-guanidinopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <heading id="h-0278">Heptadecan-9-yl 6-((tert-butoxycarbonyl)amino)-2,2-dimethyl-11-(8-(nonyloxy)-8-oxooctyl)-4-oxo-3-oxa-5,7,11-triazanonadec-6-en-19-oate</heading>
    <li> <para-num num="[1407]"> </para-num> <div id="p-1453" num="1407" class="description-line">
      <chemistry id="CHEM-US-00299" num="00299">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/92/40/27b1df21e15a1b/US20170210697A1-20170727-C00299.png"><img id="EMI-C00299" he="41.32mm" wi="132.16mm" file="US20170210697A1-20170727-C00299.TIF" alt="Figure US20170210697A1-20170727-C00299" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="529" height="165" alt="Figure US20170210697A1-20170727-C00299" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/92/40/27b1df21e15a1b/US20170210697A1-20170727-C00299.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00299" attachment-type="cdx" file="US20170210697A1-20170727-C00299.CDX"> </attachment>
          <attachment idref="CHEM-US-00299" attachment-type="mol" file="US20170210697A1-20170727-C00299.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1408]"> </para-num> <div id="p-1454" num="1408" class="description-line">Chemical Formula: C<sub>56</sub>H<sub>108</sub>N<sub>4</sub>O<sub>8 </sub> </div>
    </li> <li> <para-num num="[1409]"> </para-num> <div id="p-1455" num="1409" class="description-line">Molecular Weight: 965.50</div>
    </li> <li> <para-num num="[1410]"> </para-num> <div id="p-1456" num="1410" class="description-line">To a solution of heptadecan-9-yl 8-((3-aminopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (300 mg, 0.41 mmol) and triethylamine (230 uL, 1.66 mmol) in 10 mL dry DCM at 0 C. was added 1,3-bis(tert-butoxycarbonyl)-2-(trifluoromethylsulfonyl)guanidine (325 mg, 0.83 mmol) in one portion and the resulting solution allowed to gradually warm to rt with stirring overnight. LC/MS showed no starting material remained so the solution was diluted with DCM, washed with a 50% saturated aqueous sodium bicarbonate solution, the organic layer dried (MgSO<sub>4</sub>), filtered and conc. The residue was purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 6-((tert-butoxycarbonyl)amino)-2,2-dimethyl-11-(8-(nonyloxy)-8-oxooctyl)-4-oxo-3-oxa-5,7,11-triazanonadec-6-en-19-oate (310 mg, 0.32 mmol, 77%) as a colorless oil in ca. 95% purity. Largest single impurity has mass corresponding to product with loss of one Boc group. Carried through as is. UPLC/ELSD: RT=3.90 min. MS (ES): m/z (MH<sup>+</sup>) 966.0 for C<sub>56</sub>H<sub>108</sub>N<sub>4</sub>O<sub>8</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 11.49 (s, 1H); 8.55 (br. s., 1H); 4.86 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=7.5 Hz); 3.45 (quart., 2H, J=6 Hz); 2.46 (m, 2H); 2.36 (m, 4H); 2.27 (m, 4H); 1.61 (m, 8H); 1.50 (m, 22H); 1.40 (m, 4H); 1.25 (br. m, 48H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <li> <div id="p-1457" num="0000" class="description-line">
      <chemistry id="CHEM-US-00300" num="00300">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fa/63/22/7bc162918dd253/US20170210697A1-20170727-C00300.png"><img id="EMI-C00300" he="32.85mm" wi="120.99mm" file="US20170210697A1-20170727-C00300.TIF" alt="Figure US20170210697A1-20170727-C00300" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="484" height="131" alt="Figure US20170210697A1-20170727-C00300" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fa/63/22/7bc162918dd253/US20170210697A1-20170727-C00300.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00300" attachment-type="cdx" file="US20170210697A1-20170727-C00300.CDX"> </attachment>
          <attachment idref="CHEM-US-00300" attachment-type="mol" file="US20170210697A1-20170727-C00300.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1411]"> </para-num> <div id="p-1458" num="1411" class="description-line">Chemical Formula: C<sub>46</sub>H<sub>92</sub>N<sub>4</sub>O<sub>4 </sub> </div>
    </li> <li> <para-num num="[1412]"> </para-num> <div id="p-1459" num="1412" class="description-line">Molecular Weight: 765.27</div>
    </li> <li> <para-num num="[1413]"> </para-num> <div id="p-1460" num="1413" class="description-line">To a solution of heptadecan-9-yl 6-((tert-butoxycarbonyl)amino)-2,2-dimethyl-11-(8-(nonyloxy)-8-oxooctyl)-4-oxo-3-oxa-5,7,11-triazanonadec-6-en-19-oate (310 mg, 0.32 mmol) in 10 mL DCM was added trifluoroacetic acid (500 uL, excess) and the solution stirred at rt for 48 hours after which no starting material remained by LC/MS. The solution was conc., the residue codistilled with DCM twice and purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-guanidinopropyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (210 mg, 0.27 mmol, 84%) as a colorless oil. UPLC/ELSD: RT=3.16 min. MS (ES): m/z (MH<sup>+</sup>) 766.3 for C<sub>46</sub>H<sub>92</sub>N<sub>4</sub>O<sub>4</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 10.92 (br. s, 1H); 8.82 (br. s, 1H); 7.25 (br. s, 2H); 4.85 (quint., 1H, J=6 Hz); 4.05 (t, 2H, J=6 Hz); 3.38 (br. s, 2H); 3.15 (br. s, 2H); 3.00 (br. s, 4H); 2.29 (m, 4H); 2.05 (br. s, 2H); 1.91 (br. s, 3H); 1.70-1.45 (br. m, 12H); 1.26 (br. m, 47H); 0.88 (t, 9H, J=7.5 Hz).</div>
    </li> <heading id="h-0279">XX118. Compound 218: Heptadecan-9-yl 8-((3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate</heading>
    <li> <para-num num="[1414]"> </para-num> <div id="p-1461" num="1414" class="description-line">
      <chemistry id="CHEM-US-00301" num="00301">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/4c/13/824855b9de6f9f/US20170210697A1-20170727-C00301.png"><img id="EMI-C00301" he="27.26mm" wi="124.12mm" file="US20170210697A1-20170727-C00301.TIF" alt="Figure US20170210697A1-20170727-C00301" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="496" height="109" alt="Figure US20170210697A1-20170727-C00301" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/4c/13/824855b9de6f9f/US20170210697A1-20170727-C00301.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00301" attachment-type="cdx" file="US20170210697A1-20170727-C00301.CDX"> </attachment>
          <attachment idref="CHEM-US-00301" attachment-type="mol" file="US20170210697A1-20170727-C00301.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1415]"> </para-num> <div id="p-1462" num="1415" class="description-line">Chemical Formula: C<sub>48</sub>H<sub>92</sub>N<sub>4</sub>O<sub>5 </sub> </div>
    </li> <li> <para-num num="[1416]"> </para-num> <div id="p-1463" num="1416" class="description-line">Molecular Weight: 805.29</div>
    </li> <li> <para-num num="[1417]"> </para-num> <div id="p-1464" num="1417" class="description-line">To a solution of heptadecan-9-yl 8-((3-(4-(tert-butoxymethyl)-1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (190 mg, 0.22 mmol) in 4 mL DCM was added trifluoroacetic acid (675 uL, excess) and the solution stirred at rt for 72 hours after which no starting material remained by LC/MS. The solution was conc., the residue codistilled with DCM twice and purified by silica gel chromatography (0-50% (mixture of 1% NH<sub>4</sub>OH, 20% MeOH in dichloromethane) in dichloromethane) to give heptadecan-9-yl 8-((3-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)propyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (113 mg, 0.14 mmol, 64%) as a colorless oil. UPLC/ELSD: RT=3.41 min. MS (ES): m/z (MH<sup>+</sup>) 806.1 for C<sub>48</sub>H<sub>92</sub>N<sub>4</sub>O<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 7.54 (s, 1H); 4.86 (quint., 1H, J=6 Hz); 4.80 (s, 2H); 4.40 (t, 2H, J=7.5 Hz); 4.05 (t, 2H, J=6 Hz); 2.38 (br. m, 5H); 2.28 (m, 5H); 2.04 (br. m, 2H); 1.61 (br. m, 7H); 1.50 (br. d, 4H, J=3 Hz); 1.26 (br. m, 51H); 0.88 (t, 9H, J=7.5 Hz) (hydroxyl proton not observed).</div>
    </li> <heading id="h-0280">XX132. Compound 232: Nonyl 8-((2-hydroxyethyl)(6-oxo-6-((4-pentylcyclohexyl)oxy)hexyl)amino)octanoate</heading>
    <li> <para-num num="[1418]"> </para-num> <div id="p-1465" num="1418" class="description-line">
      <chemistry id="CHEM-US-00302" num="00302">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/1b/aa/2c7cc115de1591/US20170210697A1-20170727-C00302.png"><img id="EMI-C00302" he="21.51mm" wi="73.74mm" file="US20170210697A1-20170727-C00302.TIF" alt="Figure US20170210697A1-20170727-C00302" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="295" height="86" alt="Figure US20170210697A1-20170727-C00302" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/1b/aa/2c7cc115de1591/US20170210697A1-20170727-C00302.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00302" attachment-type="cdx" file="US20170210697A1-20170727-C00302.CDX"> </attachment>
          <attachment idref="CHEM-US-00302" attachment-type="mol" file="US20170210697A1-20170727-C00302.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1419]"> </para-num> <div id="p-1466" num="1419" class="description-line">Chemical Formula: C<sub>36</sub>H<sub>69</sub>NO<sub>5 </sub> </div>
    </li> <li> <para-num num="[1420]"> </para-num> <div id="p-1467" num="1420" class="description-line">Molecular Weight: 595.950</div>
    </li> <li> <para-num num="[1421]"> </para-num> <div id="p-1468" num="1421" class="description-line">Compound 232 was synthesized according to the general procedure and Representative Procedure 1 described above. UPLC/ELSD: RT=2.84 min. MS (ES): m/z (MH<sup>+</sup>) 596.84 for C<sub>36</sub>H<sub>69</sub>NO<sub>5</sub>. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) : ppm 5.01 (m, 0.5H); 4.68 (m, 0.5H); 4.08 (t, 2H); 3.56 (m, 2H), 2.67-2.55 (br. m, 2H); 2.55-2.40 (br. m, 4H); 2.31 (m, 4H); 1.97 (m, 1H); 1.82 (m, 2H); 1.73-1.15 (m, 43H); 1.02 (m, 1H); 0.90 (m, 6H).</div>
    </li> <heading id="h-0281">Example 2: Production of Nanoparticle Compositions</heading>
    <heading id="h-0282">A. Production of Nanoparticle Compositions</heading>
    <li> <para-num num="[1422]"> </para-num> <div id="p-1469" num="1422" class="description-line">In order to investigate safe and efficacious nanoparticle compositions for use in the delivery of therapeutic and/or prophylactics to cells, a range of formulations are prepared and tested. Specifically, the particular elements and ratios thereof in the lipid component of nanoparticle compositions are optimized.</div>
    </li> <li> <para-num num="[1423]"> </para-num> <div id="p-1470" num="1423" class="description-line">Nanoparticles can be made with mixing processes such as microfluidics and T-junction mixing of two fluid streams, one of which contains the therapeutic and/or prophylactic and the other has the lipid components.</div>
    </li> <li> <para-num num="[1424]"> </para-num> <div id="p-1471" num="1424" class="description-line">Lipid compositions are prepared by combining a lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), a phospholipid (such as DOPE or DSPC, obtainable from Avanti Polar Lipids, Alabaster, Ala.), a PEG lipid (such as 1,2-dimyristoyl-sn-glycerol methoxypolyethylene glycol, also known as PEG-DMG, obtainable from Avanti Polar Lipids, Alabaster, Ala.), and a structural lipid (such as cholesterol, obtainable from Sigma-Aldrich, Taufkirchen, Germany, or a corticosteroid (such as prednisolone, dexamethasone, prednisone, and hydrocortisone), or a combination thereof) at concentrations of about 50 mM in ethanol. Solutions should be refrigeration for storage at, for example, 20 C. Lipids are combined to yield desired molar ratios (see, for example, Table 23) and diluted with water and ethanol to a final lipid concentration of between about 5.5 mM and about 25 mM.</div>
    </li> <li> <para-num num="[1425]"> </para-num> <div id="p-1472" num="1425" class="description-line">Nanoparticle compositions including a therapeutic and/or prophylactic and a lipid component are prepared by combining the lipid solution with a solution including the therapeutic and/or prophylactic at lipid component to therapeutic and/or prophylactic wt:wt ratios between about 5:1 and about 50:1. The lipid solution is rapidly injected using a NanoAssemblr microfluidic based system at flow rates between about 10 m1/min and about 18 m1/min into the therapeutic and/or prophylactic solution to produce a suspension with a water to ethanol ratio between about 1:1 and about 4:1.</div>
    </li> <li> <para-num num="[1426]"> </para-num> <div id="p-1473" num="1426" class="description-line">For nanoparticle compositions including an RNA, solutions of the RNA at concentrations of 0.1 mg/ml in deionized water are diluted in 50 mM sodium citrate buffer at a pH between 3 and 4 to form a stock solution.</div>
    </li> <li> <para-num num="[1427]"> </para-num> <div id="p-1474" num="1427" class="description-line">Nanoparticle compositions can be processed by dialysis to remove ethanol and achieve buffer exchange. Formulations are dialyzed twice against phosphate buffered saline (PBS), pH 7.4, at volumes 200 times that of the primary product using Slide-A-Lyzer cassettes (Thermo Fisher Scientific Inc., Rockford, Ill.) with a molecular weight cutoff of 10 kD. The first dialysis is carried out at room temperature for 3 hours. The formulations are then dialyzed overnight at 4 C. The resulting nanoparticle suspension is filtered through 0.2 m sterile filters (Sarstedt, Nmbrecht, Germany) into glass vials and sealed with crimp closures. Nanoparticle composition solutions of 0.01 mg/ml to 0.10 mg/ml are generally obtained.</div>
    </li> <li> <para-num num="[1428]"> </para-num> <div id="p-1475" num="1428" class="description-line">The method described above induces nano-precipitation and particle formation. Alternative processes including, but not limited to, T-junction and direct injection, may be used to achieve the same nano-precipitation.</div>
    </li> <heading id="h-0283">B. Characterization of Nanoparticle Compositions</heading>
    <li> <para-num num="[1429]"> </para-num> <div id="p-1476" num="1429" class="description-line">A Zetasizer Nano ZS (Malvern Instruments Ltd, Malvern, Worcestershire, UK) can be used to determine the particle size, the polydispersity index (PDI) and the zeta potential of the nanoparticle compositions in 1PBS in determining particle size and 15 mM PBS in determining zeta potential.</div>
    </li> <li> <para-num num="[1430]"> </para-num> <div id="p-1477" num="1430" class="description-line">Ultraviolet-visible spectroscopy can be used to determine the concentration of a therapeutic and/or prophylactic (e.g., RNA) in nanoparticle compositions. 100 L of the diluted formulation in 1PBS is added to 900 L of a 4:1 (v/v) mixture of methanol and chloroform. After mixing, the absorbance spectrum of the solution is recorded, for example, between 230 nm and 330 nm on a DU 800 spectrophotometer (Beckman Coulter, Beckman Coulter, Inc., Brea, Calif.). The concentration of therapeutic and/or prophylactic in the nanoparticle composition can be calculated based on the extinction coefficient of the therapeutic and/or prophylactic used in the composition and on the difference between the absorbance at a wavelength of, for example, 260 nm and the baseline value at a wavelength of, for example, 330 nm.</div>
    </li> <li> <para-num num="[1431]"> </para-num> <div id="p-1478" num="1431" class="description-line">For nanoparticle compositions including an RNA, a QUANT-IT RIBOGREEN RNA assay (Invitrogen Corporation Carlsbad, Calif.) can be used to evaluate the encapsulation of an RNA by the nanoparticle composition. The samples are diluted to a concentration of approximately 5 g/mL in a TE buffer solution (10 mM Tris-HCl, 1 mM EDTA, pH 7.5). 50 L of the diluted samples are transferred to a polystyrene 96 well plate and either 50 L of TE buffer or 50 L of a 2% Triton X-100 solution is added to the wells. The plate is incubated at a temperature of 37 C. for 15 minutes. The RIBOGREEN reagent is diluted 1:100 in TE buffer, and 100 L of this solution is added to each well. The fluorescence intensity can be measured using a fluorescence plate reader (Wallac Victor 1420 Multilablel Counter; Perkin Elmer, Waltham, Mass.) at an excitation wavelength of, for example, about 480 nm and an emission wavelength of, for example, about 520 nm. The fluorescence values of the reagent blank are subtracted from that of each of the samples and the percentage of free RNA is determined by dividing the fluorescence intensity of the intact sample (without addition of Triton X-100) by the fluorescence value of the disrupted sample (caused by the addition of Triton X-100).</div>
    </li> <heading id="h-0284">C. In Vivo Formulation Studies</heading>
    <li> <para-num num="[1432]"> </para-num> <div id="p-1479" num="1432" class="description-line">In order to monitor how effectively various nanoparticle compositions deliver therapeutic and/or prophylactics to targeted cells, different nanoparticle compositions including a particular therapeutic and/or prophylactic (for example, a modified or naturally occurring RNA such as an mRNA) are prepared and administered to rodent populations. Mice are intravenously, intramuscularly, intraarterially, or intratumorally administered a single dose including a nanoparticle composition with a formulation such as those provided in Example 3. In some instances, mice may be made to inhale doses. Dose sizes may range from 0.001 mg/kg to 10 mg/kg, where 10 mg/kg describes a dose including 10 mg of a therapeutic and/or prophylactic in a nanoparticle composition for each 1 kg of body mass of the mouse. A control composition including PBS may also be employed.</div>
    </li> <li> <para-num num="[1433]"> </para-num> <div id="p-1480" num="1433" class="description-line">Upon administration of nanoparticle compositions to mice, dose delivery profiles, dose responses, and toxicity of particular formulations and doses thereof can be measured by enzyme-linked immunosorbent assays (ELISA), bioluminescent imaging, or other methods. For nanoparticle compositions including mRNA, time courses of protein expression can also be evaluated. Samples collected from the rodents for evaluation may include blood, sera, and tissue (for example, muscle tissue from the site of an intramuscular injection and internal tissue); sample collection may involve sacrifice of the animals.</div>
    </li> <li> <para-num num="[1434]"> </para-num> <div id="p-1481" num="1434" class="description-line">Nanoparticle compositions including mRNA are useful in the evaluation of the efficacy and usefulness of various formulations for the delivery of therapeutic and/or prophylactics. Higher levels of protein expression induced by administration of a composition including an mRNA will be indicative of higher mRNA translation and/or nanoparticle composition mRNA delivery efficiencies. As the non-RNA components are not thought to affect translational machineries themselves, a higher level of protein expression is likely indicative of a higher efficiency of delivery of the therapeutic and/or prophylactic by a given nanoparticle composition relative to other nanoparticle compositions or the absence thereof.</div>
    </li> <heading id="h-0285">Example 3: Sample Formulations</heading>
    <li> <para-num num="[1435]"> </para-num> <div id="p-1482" num="1435" class="description-line">Nanoparticle compositions including a therapeutic and/or prophylactic can be optimized according to the selection of a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), the selection of additional lipids, the amount of each lipid in the lipid component, and the wt:wt ratio of the lipid component to the therapeutic and/or prophylactic, as described herein.</div>
    </li> <li> <para-num num="[1436]"> </para-num> <div id="p-1483" num="1436" class="description-line">Initial studies were performed to compare the delivery efficiency of nanoparticle compositions including various compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe). The cationic lipid MC3 is a current standard in the art. Accordingly, the standard MC3 formulation including about 50 mol % MC3, about 10 mol % DSPC, about 38.5 mol % cholesterol, and about 1.5 mol % PEG-DMG was used as a basis for this study. Nanoparticle compositions including DSPC as a phospholipid, cholesterol as a structural lipid, PEG-DMG as a PEG lipid, an RNA, and a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) selected from Compounds 1-159, 168-170, and 173-175 were prepared according to or via methods similar to those described in Examples 1 and 2. The ratios of the lipids were 50:10:38.5:1.5 mol % for the lipid according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe):DSPC:cholesterol:PEG-DMG. The RNA used was an mRNA encoding G5 luciferase (Luc) or G5 hEPO. Tables 1A-1B summarize the content and characteristics of the formulations.</div>
    </li> <li> <para-num num="[1437]"> </para-num> <div id="p-1484" num="1437" class="description-line">As shown in Tables 1A-1B, the choice of compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) dramatically affects the size (e.g., diameter), polydispersity index, and encapsulation efficiency (EE) of the compositions. Compositions had sizes between approximately 53 nm and 237 nm. Compositions including Compounds 5, 35, 36, 51, 59, 131, 132, 137-139, 145, 148, 155 and 158 produced the largest particles, while compositions including Compounds 9, 21, 29, 30, 65, 7175, 94, 107, 114-116, 119, 124, 133, 149, 150, 152, 174 and 175produced the smallest particles. Polydispersity indices varied between 0.04 and 0.99, while encapsulation efficiencies exceeded 75% for compositions including every tested compound except for Compounds 21, 94107, 132, 148, 155 and 158. The highest encapsulation efficiencies were observed for Compounds 1, 6, 18, 19, 24, 26, 28, 29, 49, 50, 55, 60, 61, 65-70, 72, 74, 75, 101, 109-116, 118, 119, 121, 122, 124, 126, 128, 130, 149, 152, 153, 156, 159, 169, 170 and 174.</div>
    </li> <li> <div id="p-1485" num="0000" class="description-line">
      <tables id="TABLE-US-00001" num="00001">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1A</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characteristics of nanoparticle compositions including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">EE (%)</td>
                <td class="description-td">pKa</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">72.7</td>
                <td class="description-td">0.091</td>
                <td class="description-td">97.04</td>
                <td class="description-td">6.50</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">83.9</td>
                <td class="description-td">0.14</td>
                <td class="description-td">93.88</td>
                <td class="description-td">6.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">97.5</td>
                <td class="description-td">0.20</td>
                <td class="description-td">92.25</td>
                <td class="description-td">6.72</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">120.5</td>
                <td class="description-td">0.21</td>
                <td class="description-td">95.10</td>
                <td class="description-td">6.33</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">196.4</td>
                <td class="description-td">0.21</td>
                <td class="description-td">77.07</td>
                <td class="description-td">6.84</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">73.1</td>
                <td class="description-td">0.066</td>
                <td class="description-td">97.60</td>
                <td class="description-td">6.32</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">118.9</td>
                <td class="description-td">0.22</td>
                <td class="description-td">86.10</td>
                <td class="description-td">6.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">121.0</td>
                <td class="description-td">0.15</td>
                <td class="description-td">95.8</td>
                <td class="description-td">6.64</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">68.5</td>
                <td class="description-td">0.12</td>
                <td class="description-td">75.7</td>
                <td class="description-td">4.87</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">102.9</td>
                <td class="description-td">0.18</td>
                <td class="description-td">89.60</td>
                <td class="description-td">6.09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">129.6</td>
                <td class="description-td">0.13</td>
                <td class="description-td">92.47</td>
                <td class="description-td">5.97</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">116.7</td>
                <td class="description-td">0.17</td>
                <td class="description-td">92.44</td>
                <td class="description-td">5.99</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">79.4</td>
                <td class="description-td">0.13</td>
                <td class="description-td">92.28</td>
                <td class="description-td">5.67</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">130.1</td>
                <td class="description-td">0.15</td>
                <td class="description-td">95.24</td>
                <td class="description-td">6.58</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">111.1</td>
                <td class="description-td">0.094</td>
                <td class="description-td">92.47</td>
                <td class="description-td">5.58</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">119.0</td>
                <td class="description-td">0.16</td>
                <td class="description-td">91.32</td>
                <td class="description-td">5.52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">85.2</td>
                <td class="description-td">0.24</td>
                <td class="description-td">91.84</td>
                <td class="description-td">7.76</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">86.2</td>
                <td class="description-td">0.042</td>
                <td class="description-td">97.50</td>
                <td class="description-td">6.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">101.1</td>
                <td class="description-td">0.17</td>
                <td class="description-td">97.21</td>
                <td class="description-td">6.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">111.5</td>
                <td class="description-td">0.13</td>
                <td class="description-td">96.72</td>
                <td class="description-td">6.87</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">21</td>
                <td class="description-td">53.5</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">15.1</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">80.2</td>
                <td class="description-td">0.22</td>
                <td class="description-td">96.00</td>
                <td class="description-td">6.21</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">104.5</td>
                <td class="description-td">0.09</td>
                <td class="description-td">92.68</td>
                <td class="description-td">6.84</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">99.5</td>
                <td class="description-td">0.13</td>
                <td class="description-td">97.16</td>
                <td class="description-td">6.71</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">85.8</td>
                <td class="description-td">0.10</td>
                <td class="description-td">95.80</td>
                <td class="description-td">6.68</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">91.9</td>
                <td class="description-td">0.16</td>
                <td class="description-td">97.43</td>
                <td class="description-td">6.64</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">82.3</td>
                <td class="description-td">0.18</td>
                <td class="description-td">94.27</td>
                <td class="description-td">6.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">99.4</td>
                <td class="description-td">0.20</td>
                <td class="description-td">97.03</td>
                <td class="description-td">6.04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">66.8</td>
                <td class="description-td">0.11</td>
                <td class="description-td">96.99</td>
                <td class="description-td">6.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">59.4</td>
                <td class="description-td">0.15</td>
                <td class="description-td">95.69</td>
                <td class="description-td">6.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">31</td>
                <td class="description-td">73.9</td>
                <td class="description-td">0.15</td>
                <td class="description-td">95.11</td>
                <td class="description-td">6.64</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">105.6</td>
                <td class="description-td">0.18</td>
                <td class="description-td">94.87</td>
                <td class="description-td">6.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">107.3</td>
                <td class="description-td">0.13</td>
                <td class="description-td">95.66</td>
                <td class="description-td">6.80</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">34</td>
                <td class="description-td">133.8</td>
                <td class="description-td">0.14</td>
                <td class="description-td">92.52</td>
                <td class="description-td">6.64</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">151.1</td>
                <td class="description-td">0.18</td>
                <td class="description-td">90.82</td>
                <td class="description-td">6.85</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">36</td>
                <td class="description-td">163.5</td>
                <td class="description-td">0.17</td>
                <td class="description-td">81.45</td>
                <td class="description-td">7.38</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">80.6</td>
                <td class="description-td">0.10</td>
                <td class="description-td">96.40</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">82.3</td>
                <td class="description-td">0.092</td>
                <td class="description-td">96.55</td>
                <td class="description-td">6.68</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">73.1</td>
                <td class="description-td">0.110</td>
                <td class="description-td">96.86</td>
                <td class="description-td">6.52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">68.4</td>
                <td class="description-td">0.100</td>
                <td class="description-td">97.33</td>
                <td class="description-td">6.42</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">148.8</td>
                <td class="description-td">0.17</td>
                <td class="description-td">89.83</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">130.5</td>
                <td class="description-td">0.19</td>
                <td class="description-td">93.25</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">125.4</td>
                <td class="description-td">0.13</td>
                <td class="description-td">95.8</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">112.9</td>
                <td class="description-td">0.19</td>
                <td class="description-td">96.71</td>
                <td class="description-td">6.51</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">91.6</td>
                <td class="description-td">0.16</td>
                <td class="description-td">97.03</td>
                <td class="description-td">6.44</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">112.1</td>
                <td class="description-td">0.17</td>
                <td class="description-td">95.18</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">128.4</td>
                <td class="description-td">0.16</td>
                <td class="description-td">94.33</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">58</td>
                <td class="description-td">130.8</td>
                <td class="description-td">0.14</td>
                <td class="description-td">92.54</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">237.0</td>
                <td class="description-td">0.24</td>
                <td class="description-td">94.44</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">95.1</td>
                <td class="description-td">0.12</td>
                <td class="description-td">97.6</td>
                <td class="description-td">6.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">61</td>
                <td class="description-td">89.1</td>
                <td class="description-td">0.11</td>
                <td class="description-td">97.2</td>
                <td class="description-td">6.70</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">65</td>
                <td class="description-td">63.9</td>
                <td class="description-td">0.12</td>
                <td class="description-td">98.2</td>
                <td class="description-td">6.36</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">66</td>
                <td class="description-td">76.7</td>
                <td class="description-td">0.120</td>
                <td class="description-td">96.52</td>
                <td class="description-td">76.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">67</td>
                <td class="description-td">77</td>
                <td class="description-td">0.13</td>
                <td class="description-td">98</td>
                <td class="description-td">6.38</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">68</td>
                <td class="description-td">76.8</td>
                <td class="description-td">0.14</td>
                <td class="description-td">97.7</td>
                <td class="description-td">6.69</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">69</td>
                <td class="description-td">77.2</td>
                <td class="description-td">0.13</td>
                <td class="description-td">98.4</td>
                <td class="description-td">6.92</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">70</td>
                <td class="description-td">73.7</td>
                <td class="description-td">0.15</td>
                <td class="description-td">97.5</td>
                <td class="description-td">6.51</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">71</td>
                <td class="description-td">60.1</td>
                <td class="description-td">0.11</td>
                <td class="description-td">96.1</td>
                <td class="description-td">5.88</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">72</td>
                <td class="description-td">65.4</td>
                <td class="description-td">0.11</td>
                <td class="description-td">97.3</td>
                <td class="description-td">6.29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">73</td>
                <td class="description-td">59.2</td>
                <td class="description-td">0.13</td>
                <td class="description-td">95.7</td>
                <td class="description-td">5.95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">74</td>
                <td class="description-td">65.6</td>
                <td class="description-td">0.15</td>
                <td class="description-td">97</td>
                <td class="description-td">6.08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">75</td>
                <td class="description-td">64.2</td>
                <td class="description-td">0.10</td>
                <td class="description-td">98.1</td>
                <td class="description-td">6.67</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">79</td>
                <td class="description-td">93.7</td>
                <td class="description-td">0.18</td>
                <td class="description-td">89.1</td>
                <td class="description-td">7.53</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">80</td>
                <td class="description-td">118</td>
                <td class="description-td">0.19</td>
                <td class="description-td">90.7</td>
                <td class="description-td">7.52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">81</td>
                <td class="description-td">99.2</td>
                <td class="description-td">0.14</td>
                <td class="description-td">95.4</td>
                <td class="description-td">7.14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">94</td>
                <td class="description-td">62.4</td>
                <td class="description-td">0.24</td>
                <td class="description-td">0</td>
                <td class="description-td">4.43</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">96</td>
                <td class="description-td">120.5</td>
                <td class="description-td">0.160</td>
                <td class="description-td">79.04</td>
                <td class="description-td">6.600</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">101</td>
                <td class="description-td">91.7</td>
                <td class="description-td">0.230</td>
                <td class="description-td">98.96</td>
                <td class="description-td">7.27</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">103</td>
                <td class="description-td">78.8</td>
                <td class="description-td">0.160</td>
                <td class="description-td">90.77</td>
                <td class="description-td">6.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">107</td>
                <td class="description-td">55</td>
                <td class="description-td">0.74</td>
                <td class="description-td">0</td>
                <td class="description-td">4.802</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">108</td>
                <td class="description-td">119</td>
                <td class="description-td">0.14</td>
                <td class="description-td">96</td>
                <td class="description-td">7.17</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">109</td>
                <td class="description-td">81.1</td>
                <td class="description-td">0.13</td>
                <td class="description-td">98.6</td>
                <td class="description-td">6.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">110</td>
                <td class="description-td">118</td>
                <td class="description-td">0.13</td>
                <td class="description-td">97.4</td>
                <td class="description-td">8.03</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">111</td>
                <td class="description-td">79.3</td>
                <td class="description-td">0.14</td>
                <td class="description-td">98.2</td>
                <td class="description-td">7.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">112</td>
                <td class="description-td">85.7</td>
                <td class="description-td">0.12</td>
                <td class="description-td">99</td>
                <td class="description-td">7.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">113</td>
                <td class="description-td">69.2</td>
                <td class="description-td">0.15</td>
                <td class="description-td">99</td>
                <td class="description-td">6.93</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">114</td>
                <td class="description-td">65.1</td>
                <td class="description-td">0.11</td>
                <td class="description-td">98.8</td>
                <td class="description-td">6.42</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">115</td>
                <td class="description-td">64.5</td>
                <td class="description-td">0.11</td>
                <td class="description-td">99.7</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">116</td>
                <td class="description-td">63.3</td>
                <td class="description-td">0.14</td>
                <td class="description-td">99.4</td>
                <td class="description-td">5.66</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">118</td>
                <td class="description-td">72.1</td>
                <td class="description-td">0.08</td>
                <td class="description-td">98</td>
                <td class="description-td">6.14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">119</td>
                <td class="description-td">60.8</td>
                <td class="description-td">0.24</td>
                <td class="description-td">98.1</td>
                <td class="description-td">5.29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">121</td>
                <td class="description-td">98.4</td>
                <td class="description-td">0.18</td>
                <td class="description-td">100</td>
                <td class="description-td">8.50</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">122</td>
                <td class="description-td">69.3</td>
                <td class="description-td">0.09</td>
                <td class="description-td">98.2</td>
                <td class="description-td">6.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">123</td>
                <td class="description-td">81.6</td>
                <td class="description-td">0.23</td>
                <td class="description-td">94.4</td>
                <td class="description-td">6.27</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">124</td>
                <td class="description-td">61.3</td>
                <td class="description-td">0.1</td>
                <td class="description-td">97.7</td>
                <td class="description-td">5.89</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">125</td>
                <td class="description-td">90.9</td>
                <td class="description-td">0.16</td>
                <td class="description-td">79.6</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">126</td>
                <td class="description-td">77.4</td>
                <td class="description-td">0.18</td>
                <td class="description-td">96.8</td>
                <td class="description-td">6.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">127</td>
                <td class="description-td">110.4</td>
                <td class="description-td">0.19</td>
                <td class="description-td">89.5</td>
                <td class="description-td">6.98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">128</td>
                <td class="description-td">69.4</td>
                <td class="description-td">0.14</td>
                <td class="description-td">98.2</td>
                <td class="description-td">6.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">129</td>
                <td class="description-td">86.3</td>
                <td class="description-td">0.19</td>
                <td class="description-td">77.2</td>
                <td class="description-td">7.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">130</td>
                <td class="description-td">107.1</td>
                <td class="description-td">0.13</td>
                <td class="description-td">97</td>
                <td class="description-td">6.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">131</td>
                <td class="description-td">167.9</td>
                <td class="description-td">0.095</td>
                <td class="description-td">75.44</td>
                <td class="description-td">7.76</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">132</td>
                <td class="description-td">298.0</td>
                <td class="description-td">0.180</td>
                <td class="description-td">30.77</td>
                <td class="description-td">7.34</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">133</td>
                <td class="description-td">66.0</td>
                <td class="description-td">0.098</td>
                <td class="description-td">91.48</td>
                <td class="description-td">6.38</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">134</td>
                <td class="description-td">85.6</td>
                <td class="description-td">0.110</td>
                <td class="description-td">94.62</td>
                <td class="description-td">6.66</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">135</td>
                <td class="description-td">89.5</td>
                <td class="description-td">0.130</td>
                <td class="description-td">90.20</td>
                <td class="description-td">6.47</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">136</td>
                <td class="description-td">140.4</td>
                <td class="description-td">0.5</td>
                <td class="description-td">90.9</td>
                <td class="description-td">6.95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">137</td>
                <td class="description-td">184.4</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">85.7</td>
                <td class="description-td">7.06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">138</td>
                <td class="description-td">179.4</td>
                <td class="description-td">&lt;0.5</td>
                <td class="description-td">91.8</td>
                <td class="description-td">7.39</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">139</td>
                <td class="description-td">174.0</td>
                <td class="description-td">0.54</td>
                <td class="description-td">78.2</td>
                <td class="description-td">7.04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">140</td>
                <td class="description-td">120.3</td>
                <td class="description-td">0.84</td>
                <td class="description-td">89.2</td>
                <td class="description-td">7.71</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">141</td>
                <td class="description-td">91.3</td>
                <td class="description-td">0.99</td>
                <td class="description-td">94.1</td>
                <td class="description-td">7.47</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">143</td>
                <td class="description-td">93.3</td>
                <td class="description-td">0.19</td>
                <td class="description-td">96.4</td>
                <td class="description-td">6.47</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">144</td>
                <td class="description-td">135.9</td>
                <td class="description-td">0.22</td>
                <td class="description-td">90.3</td>
                <td class="description-td">7.09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">145</td>
                <td class="description-td">176.5</td>
                <td class="description-td">0.140</td>
                <td class="description-td">89.15</td>
                <td class="description-td">7.25</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">146</td>
                <td class="description-td">97.0</td>
                <td class="description-td">0.210</td>
                <td class="description-td">91.94</td>
                <td class="description-td">7.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">147</td>
                <td class="description-td">99.5</td>
                <td class="description-td">0.130</td>
                <td class="description-td">88.31</td>
                <td class="description-td">6.66</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">148</td>
                <td class="description-td">192.7</td>
                <td class="description-td">0.200</td>
                <td class="description-td">25.49</td>
                <td class="description-td">6.646</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">149</td>
                <td class="description-td">62.1</td>
                <td class="description-td">0.110</td>
                <td class="description-td">98.00</td>
                <td class="description-td">6.284</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">150</td>
                <td class="description-td">63.1</td>
                <td class="description-td">0.082</td>
                <td class="description-td">96.72</td>
                <td class="description-td">6.101</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">151</td>
                <td class="description-td">105.7</td>
                <td class="description-td">0.140</td>
                <td class="description-td">87.86</td>
                <td class="description-td">6.593</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">152</td>
                <td class="description-td">62.6</td>
                <td class="description-td">0.072</td>
                <td class="description-td">99.29</td>
                <td class="description-td">6.465</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">153</td>
                <td class="description-td">83.7</td>
                <td class="description-td">0.150</td>
                <td class="description-td">98.39</td>
                <td class="description-td">6.580</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">154</td>
                <td class="description-td">92.9</td>
                <td class="description-td">0.110</td>
                <td class="description-td">94.28</td>
                <td class="description-td">6.827</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">155</td>
                <td class="description-td">208.3</td>
                <td class="description-td">0.240</td>
                <td class="description-td">37.36</td>
                <td class="description-td">6.576</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">156</td>
                <td class="description-td">74.3</td>
                <td class="description-td">0.072</td>
                <td class="description-td">98.90</td>
                <td class="description-td">6.572</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">157</td>
                <td class="description-td">69.6</td>
                <td class="description-td">0.096</td>
                <td class="description-td">96.43</td>
                <td class="description-td">6.275</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">158</td>
                <td class="description-td">251.8</td>
                <td class="description-td">0.080</td>
                <td class="description-td">35.70</td>
                <td class="description-td">6.953</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">159</td>
                <td class="description-td">75.9</td>
                <td class="description-td">0.190</td>
                <td class="description-td">99.29</td>
                <td class="description-td">7.873</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">168</td>
                <td class="description-td">80.7</td>
                <td class="description-td">0.1</td>
                <td class="description-td">94.35</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">169</td>
                <td class="description-td">75.4</td>
                <td class="description-td">0.18</td>
                <td class="description-td">99.04</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">170</td>
                <td class="description-td">71.7</td>
                <td class="description-td">0.12</td>
                <td class="description-td">98.24</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">173</td>
                <td class="description-td">75.5</td>
                <td class="description-td">0.16</td>
                <td class="description-td">92.89</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">174</td>
                <td class="description-td">61.4</td>
                <td class="description-td">0.12</td>
                <td class="description-td">98.52</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">175</td>
                <td class="description-td">65.4</td>
                <td class="description-td">0.2</td>
                <td class="description-td">93.23</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">79.7</td>
                <td class="description-td">0.11</td>
                <td class="description-td">97.3</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="left" id="FOO-00001" class="description-td" colspan="5">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1486" num="0000" class="description-line">
      <tables id="TABLE-US-00002" num="00002">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1B</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characteristics of nanoparticle compositions including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Endotoxin</td>
                <td class="description-td">Apparent</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">EE (%)</td>
                <td class="description-td">(EU/mL)</td>
                <td class="description-td">pKa</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">18<sup>#</sup> </td>
                <td class="description-td">73.7</td>
                <td class="description-td">0.14</td>
                <td class="description-td">96.95</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">6.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25<sup>#</sup> </td>
                <td class="description-td">69.7</td>
                <td class="description-td">0.14</td>
                <td class="description-td">97.92</td>
                <td class="description-td">1.8</td>
                <td class="description-td">6.68</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30<sup>#</sup> </td>
                <td class="description-td">76.3</td>
                <td class="description-td">0.13</td>
                <td class="description-td">96.32</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">6.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">108<sup>#</sup> </td>
                <td class="description-td">89.6</td>
                <td class="description-td">0.22</td>
                <td class="description-td">95.38</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">7.17</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">109<sup>#</sup> </td>
                <td class="description-td">75</td>
                <td class="description-td">0.099</td>
                <td class="description-td">98.29</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">6.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">110<sup>#</sup> </td>
                <td class="description-td">73.3</td>
                <td class="description-td">0.24</td>
                <td class="description-td">92.39</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">8.03</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">111<sup>#</sup> </td>
                <td class="description-td">93.3</td>
                <td class="description-td">0.13</td>
                <td class="description-td">91.23</td>
                <td class="description-td">1.4</td>
                <td class="description-td">7.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">112<sup>#</sup> </td>
                <td class="description-td">60.6</td>
                <td class="description-td">0.21</td>
                <td class="description-td">96.40</td>
                <td class="description-td">1.8</td>
                <td class="description-td">7.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60<sup>#</sup> </td>
                <td class="description-td">88.9</td>
                <td class="description-td">0.15</td>
                <td class="description-td">95.20</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">6.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">122<sup>#</sup> </td>
                <td class="description-td">70.2</td>
                <td class="description-td">0.12</td>
                <td class="description-td">96.27</td>
                <td class="description-td">1.2</td>
                <td class="description-td">6.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3<sup>#</sup> </td>
                <td class="description-td">57.7</td>
                <td class="description-td">0.12</td>
                <td class="description-td">99.01</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">6.35</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="left" id="FOO-00002" class="description-td" colspan="6"> <sup>#</sup>= Formulated with hEPO mRNA</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0286">Example 4: Expression of Luc Induced by Sample Formulations</heading>
    <li> <para-num num="[1438]"> </para-num> <div id="p-1487" num="1438" class="description-line">The efficacy of the nanoparticle compositions presented in Table 1A was evaluated with a bioluminescence study. Formulations were administered intravenously to mice (n=6) at a dosage of 0.5 mg/kg (mpk) and bioluminescence measured at 3, 6, and 24 hour time points. The standard MC3 formulation and, in some instances, a control (e.g., a PBS control) were evaluated for comparison. As is evident in Table 2, at 3 hours, the total flux was highest for compositions including Compounds 4, 28, 32, 48, 66, 128 and 135 and the total flux at 3 h was higher than or comparable to that of MC3 formulations for Compounds 2, 3, 18, 19, 20, 24, 26, 25, 27, 31, 33, 47, 49, 50, 53-55, 60, 61, 65-68, 70, 72, 74, 75, 96, 111, 122, 130, 133, 134, 143, 147, 148, 150, 151 and 153. These compositions also demonstrated higher total flux at 6 and 24 hour time points. Compositions including Compounds 9, 17, 57, 58, 59, 121, 125, 137, 140, 141 and 158 had significantly lower flux at all time points measured. In general, flux decreased as time progressed to less than 10% of the initial flux. These results suggest that the compounds described herein may be useful in transfection applications.</div>
    </li> <li> <div id="p-1488" num="0000" class="description-line">
      <tables id="TABLE-US-00003" num="00003">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 2</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase induced by administration of nanoparticle</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compositions including compounds according to Formula (I),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Total Flux</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">3 hours</td>
                <td class="description-td">6 hours</td>
                <td class="description-td">24 hours</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1</td>
                <td class="description-td">3.48E+09</td>
                <td class="description-td">3.40E+09</td>
                <td class="description-td">4.10E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2</td>
                <td class="description-td">1.93E+10</td>
                <td class="description-td">4.31E+10</td>
                <td class="description-td">2.43E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">6.55E+10</td>
                <td class="description-td">7.37E+10</td>
                <td class="description-td">4.96E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">4</td>
                <td class="description-td">1.37E+11</td>
                <td class="description-td">6.01E+10</td>
                <td class="description-td">1.13E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">5</td>
                <td class="description-td">2.77E+08</td>
                <td class="description-td">1.76E+08</td>
                <td class="description-td">2.40E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6</td>
                <td class="description-td">5.38E+09</td>
                <td class="description-td">7.60E+09</td>
                <td class="description-td">7.69E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">7</td>
                <td class="description-td">4.13E+10</td>
                <td class="description-td">4.03E+10</td>
                <td class="description-td">1.68E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">8</td>
                <td class="description-td">7.43E+09</td>
                <td class="description-td">6.71E+09</td>
                <td class="description-td">7.84E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">9</td>
                <td class="description-td">1.43E+08</td>
                <td class="description-td">3.46E+06</td>
                <td class="description-td">1.01E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">10</td>
                <td class="description-td">6.03E+08</td>
                <td class="description-td">2.37E+09</td>
                <td class="description-td">4.04E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">11</td>
                <td class="description-td">3.38E+09</td>
                <td class="description-td">7.11E+09</td>
                <td class="description-td">1.15E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">12</td>
                <td class="description-td">5.14E+09</td>
                <td class="description-td">1.27E+10</td>
                <td class="description-td">2.45E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">13</td>
                <td class="description-td">1.02E+08</td>
                <td class="description-td">1.56E+08</td>
                <td class="description-td">1.47E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">14</td>
                <td class="description-td">4.43E+08</td>
                <td class="description-td">2.29E+09</td>
                <td class="description-td">1.39E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">15</td>
                <td class="description-td">4.31E+08</td>
                <td class="description-td">4.41E+07</td>
                <td class="description-td">2.05E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">16</td>
                <td class="description-td">2.58E+08</td>
                <td class="description-td">5.45E+08</td>
                <td class="description-td">2.37E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">17</td>
                <td class="description-td">7.72E+06</td>
                <td class="description-td">3.58E+06</td>
                <td class="description-td">6.79E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">1.71E+10</td>
                <td class="description-td">2.13E+10</td>
                <td class="description-td">2.51E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">19</td>
                <td class="description-td">3.38E+10</td>
                <td class="description-td">3.56E+09</td>
                <td class="description-td">4.68E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">20</td>
                <td class="description-td">1.71E+10</td>
                <td class="description-td">2.48E+10</td>
                <td class="description-td">5.40E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">22</td>
                <td class="description-td">6.57E+08</td>
                <td class="description-td">3.89E+08</td>
                <td class="description-td">2.73E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">23</td>
                <td class="description-td">1.83E+09</td>
                <td class="description-td">1.15E+09</td>
                <td class="description-td">3.71E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">1.72E+10</td>
                <td class="description-td">2.25E+10</td>
                <td class="description-td">1.83E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">2.27E+10</td>
                <td class="description-td">1.59E+10</td>
                <td class="description-td">9.77E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">26</td>
                <td class="description-td">6.75E+10</td>
                <td class="description-td">1.57E+10</td>
                <td class="description-td">1.54E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">27</td>
                <td class="description-td">1.64E+10</td>
                <td class="description-td">1.03E+10</td>
                <td class="description-td">1.94E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">28</td>
                <td class="description-td">8.98E+10</td>
                <td class="description-td">1.13E+11</td>
                <td class="description-td">1.20E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">29</td>
                <td class="description-td">4.61E+09</td>
                <td class="description-td">2.89E+09</td>
                <td class="description-td">3.55E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">1.19E+10</td>
                <td class="description-td">2.09E+10</td>
                <td class="description-td">1.21E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">31</td>
                <td class="description-td">4.19E+10</td>
                <td class="description-td">5.31E+10</td>
                <td class="description-td">1.68E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">32</td>
                <td class="description-td">8.65E+10</td>
                <td class="description-td">6.08E+10</td>
                <td class="description-td">1.92E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">33</td>
                <td class="description-td">6.53E+10</td>
                <td class="description-td">1.20E+11</td>
                <td class="description-td">3.71E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">34</td>
                <td class="description-td">1.06E+10</td>
                <td class="description-td">1.48E+10</td>
                <td class="description-td">6.69E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">35</td>
                <td class="description-td">9.82E+08</td>
                <td class="description-td">1.24E+09</td>
                <td class="description-td">5.09E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">36</td>
                <td class="description-td">6.97E+07</td>
                <td class="description-td">1.72E+08</td>
                <td class="description-td">4.44E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">47</td>
                <td class="description-td">6.55E+10</td>
                <td class="description-td">5.38E+10</td>
                <td class="description-td">2.09E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">48</td>
                <td class="description-td">8.73E+10</td>
                <td class="description-td">1.10E+11</td>
                <td class="description-td">2.92E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">49</td>
                <td class="description-td">4.48E+10</td>
                <td class="description-td">1.08E+11</td>
                <td class="description-td">1.24E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50</td>
                <td class="description-td">3.81E+10</td>
                <td class="description-td">7.49E+10</td>
                <td class="description-td">5.02E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">51</td>
                <td class="description-td">1.34E+08</td>
                <td class="description-td">2.80E+08</td>
                <td class="description-td">6.20E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">52</td>
                <td class="description-td">2.91E+09</td>
                <td class="description-td">4.63E+09</td>
                <td class="description-td">2.55E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">53</td>
                <td class="description-td">1.91E+10</td>
                <td class="description-td">2.32E+10</td>
                <td class="description-td">1.01E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">54</td>
                <td class="description-td">5.36E+10</td>
                <td class="description-td">4.18E+10</td>
                <td class="description-td">9.07E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55</td>
                <td class="description-td">5.07E+10</td>
                <td class="description-td">1.68E+10</td>
                <td class="description-td">4.06E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">56</td>
                <td class="description-td">1.27E+10</td>
                <td class="description-td">8.06E+09</td>
                <td class="description-td">2.53E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">57</td>
                <td class="description-td">6.69E+06</td>
                <td class="description-td">6.21E+06</td>
                <td class="description-td">4.16E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">58</td>
                <td class="description-td">5.69E+05</td>
                <td class="description-td">7.60E+05</td>
                <td class="description-td">3.64E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">59</td>
                <td class="description-td">2.75E+05</td>
                <td class="description-td">2.79E+05</td>
                <td class="description-td">1.45E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60</td>
                <td class="description-td">7.91E+10</td>
                <td class="description-td">9.04E+10</td>
                <td class="description-td">2.90E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">61</td>
                <td class="description-td">6.54E+10</td>
                <td class="description-td">6.20E+10</td>
                <td class="description-td">1.78E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">65</td>
                <td class="description-td">6.56E+10</td>
                <td class="description-td">7.01E+10</td>
                <td class="description-td">7.50E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">66</td>
                <td class="description-td">9.66E+10</td>
                <td class="description-td">4.577E+10</td>
                <td class="description-td">5.56E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">67</td>
                <td class="description-td">4.24E+10</td>
                <td class="description-td">4.62E+10</td>
                <td class="description-td">4.51E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">68</td>
                <td class="description-td">5.22E+10</td>
                <td class="description-td">8.16E+10</td>
                <td class="description-td">2.15E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">69</td>
                <td class="description-td">3.38E+09</td>
                <td class="description-td">7.95E+09</td>
                <td class="description-td">1.15E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">70</td>
                <td class="description-td">4.70E+10</td>
                <td class="description-td">2.49E+10</td>
                <td class="description-td">9.27E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">71</td>
                <td class="description-td">4.09E+09</td>
                <td class="description-td">9.28E+09</td>
                <td class="description-td">6.51E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">72</td>
                <td class="description-td">1.73E+10</td>
                <td class="description-td">4.07E+10</td>
                <td class="description-td">7.12E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">73</td>
                <td class="description-td">8.10E+09</td>
                <td class="description-td">1.07E+10</td>
                <td class="description-td">1.27E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">74</td>
                <td class="description-td">3.27E+10</td>
                <td class="description-td">2.23E+10</td>
                <td class="description-td">2.75E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">75</td>
                <td class="description-td">3.51E+10</td>
                <td class="description-td">8.80E+10</td>
                <td class="description-td">2.13E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">79</td>
                <td class="description-td">3.23E+08</td>
                <td class="description-td">5.27E+08</td>
                <td class="description-td">3.08E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">80</td>
                <td class="description-td">2.76E+08</td>
                <td class="description-td">3.26E+08</td>
                <td class="description-td">1.54E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">81</td>
                <td class="description-td">7.87E+09</td>
                <td class="description-td">9.96E+09</td>
                <td class="description-td">5.13E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">96</td>
                <td class="description-td">4.54E+10</td>
                <td class="description-td">1.05E+11</td>
                <td class="description-td">3.86E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">101</td>
                <td class="description-td">1.89E+08</td>
                <td class="description-td">1.41E+08</td>
                <td class="description-td">3.64E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">103</td>
                <td class="description-td">2.68E+09</td>
                <td class="description-td">1.82E+09</td>
                <td class="description-td">9.45E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">108</td>
                <td class="description-td">5.04E+09</td>
                <td class="description-td">5.53E+09</td>
                <td class="description-td">1.50E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">109</td>
                <td class="description-td">3.82E+09</td>
                <td class="description-td">4.88E+09</td>
                <td class="description-td">8.06E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">110</td>
                <td class="description-td">1.89E+09</td>
                <td class="description-td">2.57E+09</td>
                <td class="description-td">1.11E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">111</td>
                <td class="description-td">1.89E+10</td>
                <td class="description-td">3.57E+10</td>
                <td class="description-td">8.86E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">112</td>
                <td class="description-td">9.69E+08</td>
                <td class="description-td">1.04E+09</td>
                <td class="description-td">2.75E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">113</td>
                <td class="description-td">5.16E+09</td>
                <td class="description-td">8.09E+09</td>
                <td class="description-td">1.30E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">114</td>
                <td class="description-td">8.41E+07</td>
                <td class="description-td">5.98E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">115</td>
                <td class="description-td">2.13E+07</td>
                <td class="description-td">2.91E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">116</td>
                <td class="description-td">3.13E+07</td>
                <td class="description-td">3.86E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">118</td>
                <td class="description-td">1.46E+09</td>
                <td class="description-td">1.16E+09</td>
                <td class="description-td">4.37E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">119</td>
                <td class="description-td">1.02E+07</td>
                <td class="description-td">3.74E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">121</td>
                <td class="description-td">1.29E+06</td>
                <td class="description-td">1.36E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">122</td>
                <td class="description-td">3.64E+10</td>
                <td class="description-td">8.64E+10</td>
                <td class="description-td">1.95E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">123</td>
                <td class="description-td">4.06E+09</td>
                <td class="description-td">1.81E+10</td>
                <td class="description-td">5.18E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">124</td>
                <td class="description-td">6.62E+07</td>
                <td class="description-td">3.91E+09</td>
                <td class="description-td">5.13E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">125</td>
                <td class="description-td">2.44E+05</td>
                <td class="description-td">3.16E+05</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">126</td>
                <td class="description-td">7.59E+09</td>
                <td class="description-td">1.09E+10</td>
                <td class="description-td">1.40E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">127</td>
                <td class="description-td">3.81E+09</td>
                <td class="description-td">2.09E+09</td>
                <td class="description-td">4.56E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">128</td>
                <td class="description-td">1.04E+11</td>
                <td class="description-td">8.99E+10</td>
                <td class="description-td">1.00E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">129</td>
                <td class="description-td">5.97E+09</td>
                <td class="description-td">4.51E+09</td>
                <td class="description-td">2.22E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">130</td>
                <td class="description-td">6.26E+10</td>
                <td class="description-td">8.92E+10</td>
                <td class="description-td">1.08E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">131</td>
                <td class="description-td">6.97E+09</td>
                <td class="description-td">7.64E+09</td>
                <td class="description-td">2.47E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">132</td>
                <td class="description-td">1.77E+09</td>
                <td class="description-td">1.36E+09</td>
                <td class="description-td">5.31E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">133</td>
                <td class="description-td">3.32E+10</td>
                <td class="description-td">2.93E+10</td>
                <td class="description-td">4.74E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">134</td>
                <td class="description-td">2.01E+10</td>
                <td class="description-td">2.91E+10</td>
                <td class="description-td">8.00E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">135</td>
                <td class="description-td">1.24E+11</td>
                <td class="description-td">9.90E+10</td>
                <td class="description-td">2.51E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">136</td>
                <td class="description-td">7.21E+08</td>
                <td class="description-td">7.33E+08</td>
                <td class="description-td">3.39E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">137</td>
                <td class="description-td">3.77E+05</td>
                <td class="description-td">5.02E+05</td>
                <td class="description-td">4.49E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">138</td>
                <td class="description-td">2.97E+07</td>
                <td class="description-td">2.30E+07</td>
                <td class="description-td">1.63E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">139</td>
                <td class="description-td">3.50E+07</td>
                <td class="description-td">1.17E+07</td>
                <td class="description-td">5.89E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">140</td>
                <td class="description-td">3.74E+06</td>
                <td class="description-td">1.70E+06</td>
                <td class="description-td">5.67E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">141</td>
                <td class="description-td">2.16E+.06</td>
                <td class="description-td">1.21E+06</td>
                <td class="description-td">3.49E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">143</td>
                <td class="description-td">1.76E+10</td>
                <td class="description-td">2.03E+10</td>
                <td class="description-td">2.47E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">144</td>
                <td class="description-td">9.50E+09</td>
                <td class="description-td">1.82E+09</td>
                <td class="description-td">3.36E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">145</td>
                <td class="description-td">7.11E+09</td>
                <td class="description-td">6.50E+09</td>
                <td class="description-td">2.38E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">146</td>
                <td class="description-td">9.48E+07</td>
                <td class="description-td">8.39E+07</td>
                <td class="description-td">2.30E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">147</td>
                <td class="description-td">3.24E+10</td>
                <td class="description-td">4.87E+10</td>
                <td class="description-td">3.32E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">148</td>
                <td class="description-td">6.28E+10</td>
                <td class="description-td">3.71E+10</td>
                <td class="description-td">1.43E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">149</td>
                <td class="description-td">1.01E+10</td>
                <td class="description-td">8.33E+09</td>
                <td class="description-td">3.45E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">150</td>
                <td class="description-td">1.66E+10</td>
                <td class="description-td">2.31E+10</td>
                <td class="description-td">3.86E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">151</td>
                <td class="description-td">5.63E+10</td>
                <td class="description-td">5.68E+10</td>
                <td class="description-td">2.23E+09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">152</td>
                <td class="description-td">1.56E+09</td>
                <td class="description-td">2.45E+09</td>
                <td class="description-td">4.95E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">153</td>
                <td class="description-td">1.69E+10</td>
                <td class="description-td">2.28E+10</td>
                <td class="description-td">5.10E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">154</td>
                <td class="description-td">2.49E+09</td>
                <td class="description-td">4.89E+09</td>
                <td class="description-td">6.26E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">155</td>
                <td class="description-td">2.49E+09</td>
                <td class="description-td">1.15E+10</td>
                <td class="description-td">1.99E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">156</td>
                <td class="description-td">5.68E+09</td>
                <td class="description-td">1.03E+10</td>
                <td class="description-td">6.53E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">157</td>
                <td class="description-td">8.54E+09</td>
                <td class="description-td">2.22E+10</td>
                <td class="description-td">1.90E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">158</td>
                <td class="description-td">2.69E+05</td>
                <td class="description-td">9.82E+05</td>
                <td class="description-td">1.55E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">159</td>
                <td class="description-td">3.32E+06</td>
                <td class="description-td">1.20E+07</td>
                <td class="description-td">4.98E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">1.58E+10</td>
                <td class="description-td">2.12E+10</td>
                <td class="description-td">7.19E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00003" class="description-td" colspan="5">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1439]"> </para-num> <div id="p-1489" num="1439" class="description-line">The total flux (measured by area under the curve, AUC) induced by administration of a formulation including a given lipid relative to that induced by administration of a formulation including MC3 was also measured for several lipids. As shown in Table 3A (i.v. administration), the flux induced by formulations including Compounds 48 and 49 measured at 6 h was ten times higher than that induced by the MC3 formulation. Formulations including Compounds 50, 54, and 55 also demonstrated higher flux than MC3 formulations. As shown in Table 3B, the flux induced by formulations including Compounds 108 and 168 measured at 6 h was fourteen and sixteen times higher than that induced by the MC3 formulation via intramuscular administration (i.m.). Results are also shown in <figref idrefs="DRAWINGS">FIG. 8</figref>. As shown in Table 3C (i.v. administration), the flux induced by formulations including Compounds 66, 133-135, and 147 measured at 6 h and the total flux were noticeably higher than those induced by the MC3 formulation. As shown in Table 3D, the total flux induced by formulations including Compounds 96, 148, and 151 measured at 6 h was noticeably higher than that induced by the MC3 formulation.</div>
    </li> <li> <div id="p-1490" num="0000" class="description-line">
      <tables id="TABLE-US-00004" num="00004">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3A</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase upon administration of formulations</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">including compounds according to Formula (I), (IA), (II),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIa), (IIb), (IIc), (IId) or (IIe) relative to administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of formulations including MC3.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Fold increase in total body Luc</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">Flux relative to MC3 at 6 h</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1</td>
                <td class="description-td">0.40</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2</td>
                <td class="description-td">1.31</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">2.24</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">4</td>
                <td class="description-td">1.31</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">5</td>
                <td class="description-td">0.005</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6</td>
                <td class="description-td">1.15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">16</td>
                <td class="description-td">0.02</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">3.22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">19</td>
                <td class="description-td">0.96</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">20</td>
                <td class="description-td">0.80</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">2.67</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">1.89</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">26</td>
                <td class="description-td">4.24</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">27</td>
                <td class="description-td">0.31</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">28</td>
                <td class="description-td">2.46</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">29</td>
                <td class="description-td">0.78</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">2.49</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">31</td>
                <td class="description-td">1.21</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">32</td>
                <td class="description-td">1.39</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">33</td>
                <td class="description-td">2.74</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">34</td>
                <td class="description-td">0.34</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">35</td>
                <td class="description-td">0.028</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">36</td>
                <td class="description-td">0.004</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">48</td>
                <td class="description-td">10.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">49</td>
                <td class="description-td">9.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50</td>
                <td class="description-td">6.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">51</td>
                <td class="description-td">0.025</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">53</td>
                <td class="description-td">2.11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">54</td>
                <td class="description-td">3.80</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55</td>
                <td class="description-td">1.52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">56</td>
                <td class="description-td">0.733</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">57</td>
                <td class="description-td">0.00056</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">58</td>
                <td class="description-td">0.00007</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">59</td>
                <td class="description-td">0.00003</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">65</td>
                <td class="description-td">3.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">66</td>
                <td class="description-td">0.103</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">67</td>
                <td class="description-td">2.08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">68</td>
                <td class="description-td">3.68</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">71</td>
                <td class="description-td">0.418</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">73</td>
                <td class="description-td">0.48</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">74</td>
                <td class="description-td">1.005</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">127</td>
                <td class="description-td">0.094</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">128</td>
                <td class="description-td">4.05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">129</td>
                <td class="description-td">0.203</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">130</td>
                <td class="description-td">4.02</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">1.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1491" num="0000" class="description-line">
      <tables id="TABLE-US-00005" num="00005">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3B</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase upon administration of formulations including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIe) relative to administration of formulations including MC3.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">i.v.</td>
                <td class="description-td">i.m.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid/MC3</td>
                <td class="description-td">Lipid/MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">0.5 mpk, Luc, 6 h</td>
                <td class="description-td">0.01 mpk, Luc, 6 h</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">108</td>
                <td class="description-td">0.4</td>
                <td class="description-td">14.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">109</td>
                <td class="description-td">0.3</td>
                <td class="description-td">3.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">111</td>
                <td class="description-td">2.6</td>
                <td class="description-td">4.9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">168</td>
                <td class="description-td">ND</td>
                <td class="description-td">16.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">169</td>
                <td class="description-td">ND</td>
                <td class="description-td">3.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">170</td>
                <td class="description-td">ND</td>
                <td class="description-td">5.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">173</td>
                <td class="description-td">ND</td>
                <td class="description-td">0.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">174</td>
                <td class="description-td">ND</td>
                <td class="description-td">0.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">175</td>
                <td class="description-td">ND</td>
                <td class="description-td">0.1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="left" id="FOO-00004" class="description-td" colspan="3">ND = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1492" num="0000" class="description-line">
      <tables id="TABLE-US-00006" num="00006">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3C</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase upon administration of formulations including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">or (IIe) relative to administration of formulations including MC3.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Fold</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h Lipid/MC3</td>
                <td class="description-td">6 h Lipid/MC3</td>
                <td class="description-td"> </td>
                <td class="description-td">increase</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Avg. Luc</td>
                <td class="description-td">G.M. Luc</td>
                <td class="description-td">AUC</td>
                <td class="description-td">AUC</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">Expression</td>
                <td class="description-td">Expression</td>
                <td class="description-td">(h * p/s)</td>
                <td class="description-td">Lipid/MC3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">66</td>
                <td class="description-td">6.28</td>
                <td class="description-td">5.23</td>
                <td class="description-td">6.76E+11</td>
                <td class="description-td">8.20</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">101</td>
                <td class="description-td">0.019</td>
                <td class="description-td">0.011</td>
                <td class="description-td">1.8E+09</td>
                <td class="description-td">0.022</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">103</td>
                <td class="description-td">0.250</td>
                <td class="description-td">0.171</td>
                <td class="description-td">2.4E+10</td>
                <td class="description-td">0.291</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">131</td>
                <td class="description-td">1.05</td>
                <td class="description-td">1.27</td>
                <td class="description-td">9.29E+10</td>
                <td class="description-td">1.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">132</td>
                <td class="description-td">0.187</td>
                <td class="description-td">0.112</td>
                <td class="description-td">1.75E+10</td>
                <td class="description-td">0.212</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">133</td>
                <td class="description-td">4.02</td>
                <td class="description-td">4.18</td>
                <td class="description-td">3.62E+11</td>
                <td class="description-td">4.39</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">134</td>
                <td class="description-td">3.99</td>
                <td class="description-td">3.27</td>
                <td class="description-td">3.43E+11</td>
                <td class="description-td">4.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">135</td>
                <td class="description-td">13.6</td>
                <td class="description-td">10.5</td>
                <td class="description-td">1.25E+12</td>
                <td class="description-td">15.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">145</td>
                <td class="description-td">0.89</td>
                <td class="description-td">0.979</td>
                <td class="description-td">8.1E+10</td>
                <td class="description-td">0.983</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">146</td>
                <td class="description-td">0.011</td>
                <td class="description-td">0.012</td>
                <td class="description-td">1.04E+09</td>
                <td class="description-td">0.013</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">147</td>
                <td class="description-td">6.68</td>
                <td class="description-td">8.13</td>
                <td class="description-td">5.63E+11</td>
                <td class="description-td">6.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">8.24E+10</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="left" id="FOO-00005" class="description-td" colspan="5">Avg. = average;</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="left" id="FOO-00006" class="description-td" colspan="5">G.M. = geometric mean</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1493" num="0000" class="description-line">
      <tables id="TABLE-US-00007" num="00007">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 3D</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase and lipid clearance upon</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">administration of formulations including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">or (IIe) relative to administration of formulations including MC3.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">% Dose</td>
                <td class="description-td">% Dose</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Remaining</td>
                <td class="description-td">Remaining</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Lipid/MC3</td>
                <td class="description-td">in Liver</td>
                <td class="description-td">in Liver</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid</td>
                <td class="description-td">AUC (p/s * h)</td>
                <td class="description-td">AUC</td>
                <td class="description-td">6 h</td>
                <td class="description-td">6 h</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">148</td>
                <td class="description-td">4.965E+011</td>
                <td class="description-td">2.6</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">149</td>
                <td class="description-td">1.057E+011</td>
                <td class="description-td">0.55</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">150</td>
                <td class="description-td">2.704E+011</td>
                <td class="description-td">1.4</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">96</td>
                <td class="description-td">1.209E+012</td>
                <td class="description-td">6.3</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">151</td>
                <td class="description-td">7.010E+011</td>
                <td class="description-td">3.7</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">152</td>
                <td class="description-td">2.855E+010</td>
                <td class="description-td">0.15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">153</td>
                <td class="description-td">2.697E+011</td>
                <td class="description-td">1.4</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">154</td>
                <td class="description-td">5.560E+010</td>
                <td class="description-td">0.29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">155</td>
                <td class="description-td">1.266E+011</td>
                <td class="description-td">0.66</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">156</td>
                <td class="description-td">1.170E+011</td>
                <td class="description-td">0.61</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">157</td>
                <td class="description-td">2.481E+011</td>
                <td class="description-td">1.3</td>
                <td class="description-td">&lt;1</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">158</td>
                <td class="description-td">1.211E+007</td>
                <td class="description-td">&lt;0.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">159</td>
                <td class="description-td">1.355E+008</td>
                <td class="description-td">&lt;0.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">1.909E+011</td>
                <td class="description-td">1</td>
                <td class="description-td">80</td>
                <td class="description-td">54</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0287">Example 5: Expression of Luc Induced by Sample Formulations in Different Organs</heading>
    <li> <para-num num="[1440]"> </para-num> <div id="p-1494" num="1440" class="description-line">The efficacy of the nanoparticle compositions presented in Table 1A was further evaluated by measuring the expression of modified luciferase in the liver, lung, spleen, and femur upon administration of a given composition. Formulations were administered intravenously to mice (n=3) at a dosage of 0.5 mpk and bioluminescence measured after 6 hours. The standard MC3 formulation and a PBS control were also tested. As is evident in Table 4, flux for nearly all species was higher in the liver compared to other tissues. Flux in the liver was highest for compositions including 3, 28, 33, 48, 96 and 135 and comparable to that of MC3 formulations for compositions including Compounds 2, 4, 6, 7, 18, 20, 24-27, 30-32, 34, 47, 49, 50, 53-56, 60, 65, 67, 68, 74, 75, 111, 113, 122, 128, 130, 133, 134, 143, 147-151, 153 and 157. Flux in the liver was lowest for compositions including Compounds 58, 59, 137, and 141. Flux in the spleen was highest for compositions including Compounds 4, 7, 33, 34, 48, 53, 108, 129, 130, and 148, and lowest for compositions including Compounds 9, 59, 124, and 141. Similar results were observed in the lung and femur.</div>
    </li> <li> <div id="p-1495" num="0000" class="description-line">
      <tables id="TABLE-US-00008" num="00008">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 4</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of luciferase in various organs 6 hours after administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of nanoparticle compositions including compounds according</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Total Flux</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">Liver</td>
                <td class="description-td">Lung</td>
                <td class="description-td">Spleen</td>
                <td class="description-td">Femur</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">4.02E+08</td>
                <td class="description-td">1.72E+06</td>
                <td class="description-td">4.27E+06</td>
                <td class="description-td">7.52E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">4.87E+09</td>
                <td class="description-td">2.52E+07</td>
                <td class="description-td">5.77E+07</td>
                <td class="description-td">3.86E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">1.39E+10</td>
                <td class="description-td">4.76E+07</td>
                <td class="description-td">1.47E+08</td>
                <td class="description-td">7.36E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">5.26E+09</td>
                <td class="description-td">6.22E+07</td>
                <td class="description-td">4.09E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">5.84E+07</td>
                <td class="description-td">1.89E+06</td>
                <td class="description-td">1.55E+08</td>
                <td class="description-td">1.22E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">1.09E+09</td>
                <td class="description-td">4.30E+06</td>
                <td class="description-td">3.03E+07</td>
                <td class="description-td">2.15E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">2.49E+09</td>
                <td class="description-td">3.95E+07</td>
                <td class="description-td">4.83E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">7.87E+08</td>
                <td class="description-td">4.06E+06</td>
                <td class="description-td">1.51E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">4.30E+05</td>
                <td class="description-td">2.56E+04</td>
                <td class="description-td">5.51E+04</td>
                <td class="description-td">2.57E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">3.22E+08</td>
                <td class="description-td">8.85E+05</td>
                <td class="description-td">8.17E+06</td>
                <td class="description-td">5.09E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">8.03E+08</td>
                <td class="description-td">1.35E+07</td>
                <td class="description-td">1.04E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">6.84E+08</td>
                <td class="description-td">7.45E+06</td>
                <td class="description-td">6.82E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">2.25E+07</td>
                <td class="description-td">2.21E+05</td>
                <td class="description-td">7.09E+05</td>
                <td class="description-td">1.35E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">1.91E+08</td>
                <td class="description-td">4.74E+06</td>
                <td class="description-td">1.92E+08</td>
                <td class="description-td">4.91E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">6.23E+06</td>
                <td class="description-td">6.41E+04</td>
                <td class="description-td">9.01E+05</td>
                <td class="description-td">5.93E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">3.17E+07</td>
                <td class="description-td">4.18E+05</td>
                <td class="description-td">5.43E+06</td>
                <td class="description-td">2.55E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">5.52E+05</td>
                <td class="description-td">9.95E+04</td>
                <td class="description-td">5.58E+06</td>
                <td class="description-td">9.55E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">2.76E+09</td>
                <td class="description-td">1.25E+07</td>
                <td class="description-td">5.15E+07</td>
                <td class="description-td">4.68E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">6.33E+08</td>
                <td class="description-td">5.99E+06</td>
                <td class="description-td">1.77E+07</td>
                <td class="description-td">1.68E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">1.84E+09</td>
                <td class="description-td">2.66E+07</td>
                <td class="description-td">1.43E+08</td>
                <td class="description-td">1.31E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">4.00E+07</td>
                <td class="description-td">4.73E+05</td>
                <td class="description-td">1.57E+06</td>
                <td class="description-td">1.16E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">2.92E+08</td>
                <td class="description-td">1.82E+06</td>
                <td class="description-td">3.08E+07</td>
                <td class="description-td">1.19E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">4.19E+09</td>
                <td class="description-td">1.71E+07</td>
                <td class="description-td">8.78E+07</td>
                <td class="description-td">4.54E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">2.41E+09</td>
                <td class="description-td">1.51E+07</td>
                <td class="description-td">3.11E+07</td>
                <td class="description-td">4.40E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">2.90E+09</td>
                <td class="description-td">1.18E+07</td>
                <td class="description-td">1.56E+07</td>
                <td class="description-td">4.67E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">2.16E+09</td>
                <td class="description-td">6.35E+06</td>
                <td class="description-td">3.78E+06</td>
                <td class="description-td">2.00E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">1.22E+10</td>
                <td class="description-td">2.17E+08</td>
                <td class="description-td">1.80E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">5.20E+08</td>
                <td class="description-td">9.83E+05</td>
                <td class="description-td">5.99E+06</td>
                <td class="description-td">9.56E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">2.68E+09</td>
                <td class="description-td">1.02E+07</td>
                <td class="description-td">3.55E+07</td>
                <td class="description-td">6.38E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">31</td>
                <td class="description-td">5.17E+09</td>
                <td class="description-td">7.55E+06</td>
                <td class="description-td">9.42E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">8.52E+09</td>
                <td class="description-td">1.16E+07</td>
                <td class="description-td">1.70E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">1.78E+10</td>
                <td class="description-td">2.92E+07</td>
                <td class="description-td">3.77E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">34</td>
                <td class="description-td">2.08E+09</td>
                <td class="description-td">9.49E+06</td>
                <td class="description-td">2.40E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">1.63E+08</td>
                <td class="description-td">2.06E+06</td>
                <td class="description-td">1.23E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">36</td>
                <td class="description-td">2.65E+07</td>
                <td class="description-td">5.82E+05</td>
                <td class="description-td">6.14E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">4.86E+09</td>
                <td class="description-td">8.71E+06</td>
                <td class="description-td">8.33E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">1.08E+10</td>
                <td class="description-td">3.31E+07</td>
                <td class="description-td">3.49E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">5.68E+09</td>
                <td class="description-td">2.52E+07</td>
                <td class="description-td">1.87E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">6.30E+09</td>
                <td class="description-td">2.81E+07</td>
                <td class="description-td">1.14E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">2.49E+07</td>
                <td class="description-td">3.67E+05</td>
                <td class="description-td">2.80E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">5.86E+08</td>
                <td class="description-td">2.80E+06</td>
                <td class="description-td">8.30E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">2.02E+09</td>
                <td class="description-td">2.47E+07</td>
                <td class="description-td">8.54E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">5.57E+09</td>
                <td class="description-td">1.12E+07</td>
                <td class="description-td">1.64E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">1.92E+09</td>
                <td class="description-td">7.02E+06</td>
                <td class="description-td">2.63E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">1.04E+09</td>
                <td class="description-td">4.62E+06</td>
                <td class="description-td">1.98E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">9.36E+05</td>
                <td class="description-td">3.18E+04</td>
                <td class="description-td">2.47E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">58</td>
                <td class="description-td">8.71E+04</td>
                <td class="description-td">1.21E+04</td>
                <td class="description-td">2.38E+05</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">2.87E+05</td>
                <td class="description-td">4.41E+04</td>
                <td class="description-td">9.68E+04</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">1.54E+09</td>
                <td class="description-td">6.25E+06</td>
                <td class="description-td">7.12E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">61</td>
                <td class="description-td">6.37E+08</td>
                <td class="description-td">3.56E+06</td>
                <td class="description-td">1.61E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">65</td>
                <td class="description-td">9.56E+09</td>
                <td class="description-td">3.79E+07</td>
                <td class="description-td">6.57E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">66</td>
                <td class="description-td">5.01E+09</td>
                <td class="description-td">4.20E+06</td>
                <td class="description-td">2.00E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">67</td>
                <td class="description-td">3.60E+09</td>
                <td class="description-td">1.68E+07</td>
                <td class="description-td">2.55E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">68</td>
                <td class="description-td">8.42E+09</td>
                <td class="description-td">3.98E+07</td>
                <td class="description-td">6.69E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">69</td>
                <td class="description-td">2.24E+08</td>
                <td class="description-td">7.34E+05</td>
                <td class="description-td">2.54E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">70</td>
                <td class="description-td">8.55E+08</td>
                <td class="description-td">6.32E+06</td>
                <td class="description-td">2.06E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">71</td>
                <td class="description-td">7.93E+08</td>
                <td class="description-td">4.86E+06</td>
                <td class="description-td">8.04E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">72</td>
                <td class="description-td">7.97E+08</td>
                <td class="description-td">1.05E+07</td>
                <td class="description-td">6.40E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">73</td>
                <td class="description-td">7.93E+08</td>
                <td class="description-td">6.17E+06</td>
                <td class="description-td">9.45E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">74</td>
                <td class="description-td">1.99E+09</td>
                <td class="description-td">6.93E+06</td>
                <td class="description-td">2.26E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">75</td>
                <td class="description-td">1.45E+09</td>
                <td class="description-td">3.92E+06</td>
                <td class="description-td">5.66E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">79</td>
                <td class="description-td">3.15E+06</td>
                <td class="description-td">6.13E+04</td>
                <td class="description-td">6.45E+05</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">80</td>
                <td class="description-td">1.09E+07</td>
                <td class="description-td">8.97E+04</td>
                <td class="description-td">4.71E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">81</td>
                <td class="description-td">2.74E+08</td>
                <td class="description-td">6.23E+06</td>
                <td class="description-td">4.49E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">96</td>
                <td class="description-td">1.56E+10</td>
                <td class="description-td">3.43E+07</td>
                <td class="description-td">3.39E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">101</td>
                <td class="description-td">1.27E+07</td>
                <td class="description-td">1.77E+05</td>
                <td class="description-td">5.60E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">103</td>
                <td class="description-td">8.48E+07</td>
                <td class="description-td">2.06E+05</td>
                <td class="description-td">2.65E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">108</td>
                <td class="description-td">4.63E+08</td>
                <td class="description-td">9.81E+06</td>
                <td class="description-td">7.82E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">109</td>
                <td class="description-td">8.17E+08</td>
                <td class="description-td">6.03E+06</td>
                <td class="description-td">4.81E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">110</td>
                <td class="description-td">2.30E+08</td>
                <td class="description-td">5.76E+06</td>
                <td class="description-td">1.41E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">111</td>
                <td class="description-td">4.83E+09</td>
                <td class="description-td">2.57E+07</td>
                <td class="description-td">2.44E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">112</td>
                <td class="description-td">1.48E+08</td>
                <td class="description-td">1.83E+06</td>
                <td class="description-td">2.75E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">113</td>
                <td class="description-td">1.11E+09</td>
                <td class="description-td">5.55E+06</td>
                <td class="description-td">5.22E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">118</td>
                <td class="description-td">1.72E+08</td>
                <td class="description-td">1.98E+06</td>
                <td class="description-td">2.49E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">122</td>
                <td class="description-td">2.63E+09</td>
                <td class="description-td">2.77E+07</td>
                <td class="description-td">1.56E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">123</td>
                <td class="description-td">2.50E+08</td>
                <td class="description-td">1.78E+06</td>
                <td class="description-td">4.04E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">124</td>
                <td class="description-td">8.46E+06</td>
                <td class="description-td">5.67E+04</td>
                <td class="description-td">8.06E+04</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">126</td>
                <td class="description-td">7.41E+08</td>
                <td class="description-td">2.68E+06</td>
                <td class="description-td">1.87E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">127</td>
                <td class="description-td">1.94E+08</td>
                <td class="description-td">5.26E+06</td>
                <td class="description-td">3.21E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">128</td>
                <td class="description-td">5.98E+09</td>
                <td class="description-td">2.16E+07</td>
                <td class="description-td">7.09E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">129</td>
                <td class="description-td">6.65E+08</td>
                <td class="description-td">9.89E+06</td>
                <td class="description-td">5.09E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">130</td>
                <td class="description-td">8.17E+09</td>
                <td class="description-td">5.88E+07</td>
                <td class="description-td">1.35E+09</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">131</td>
                <td class="description-td">3.52E+08</td>
                <td class="description-td">1.45E+07</td>
                <td class="description-td">8.32E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">132</td>
                <td class="description-td">1.49E+08</td>
                <td class="description-td">1.39E+07</td>
                <td class="description-td">3.37E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">133</td>
                <td class="description-td">2.94E+09</td>
                <td class="description-td">3.18E+06</td>
                <td class="description-td">1.77E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">134</td>
                <td class="description-td">1.73E+09</td>
                <td class="description-td">2.82E+06</td>
                <td class="description-td">1.85E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">135</td>
                <td class="description-td">1.65E+10</td>
                <td class="description-td">2.71E+07</td>
                <td class="description-td">1.39E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">136</td>
                <td class="description-td">1.34E+08</td>
                <td class="description-td">8.91E+05</td>
                <td class="description-td">2.77E+07</td>
                <td class="description-td">6.60E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">137</td>
                <td class="description-td">6.48E+04</td>
                <td class="description-td">1.66E+04</td>
                <td class="description-td">1.32E+05</td>
                <td class="description-td">2.02E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">138</td>
                <td class="description-td">3.66E+06</td>
                <td class="description-td">9.47E+04</td>
                <td class="description-td">4.04E+06</td>
                <td class="description-td">1.58E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">139</td>
                <td class="description-td">8.27E+05</td>
                <td class="description-td">5.26E+04</td>
                <td class="description-td">2.10E+06</td>
                <td class="description-td">5.12E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">140</td>
                <td class="description-td">4.21E+05</td>
                <td class="description-td">2.14E+04</td>
                <td class="description-td">2.22E+05</td>
                <td class="description-td">3.26E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">141</td>
                <td class="description-td">1.59E+05</td>
                <td class="description-td">3.85E+04</td>
                <td class="description-td">6.29E+04</td>
                <td class="description-td">2.86E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">143</td>
                <td class="description-td">1.76E+09</td>
                <td class="description-td">3.60E+07</td>
                <td class="description-td">1.42E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">144</td>
                <td class="description-td">3.75E+08</td>
                <td class="description-td">4.81E+06</td>
                <td class="description-td">5.11E+07</td>
                <td class="description-td">2.44E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">145</td>
                <td class="description-td">5.01E+08</td>
                <td class="description-td">1.36E+07</td>
                <td class="description-td">4.25E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">146</td>
                <td class="description-td">7.24E+06</td>
                <td class="description-td">3.88E+06</td>
                <td class="description-td">5.11E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">147</td>
                <td class="description-td">5.24E+09</td>
                <td class="description-td">6.73E+06</td>
                <td class="description-td">8.57E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">148</td>
                <td class="description-td">4.39E+09</td>
                <td class="description-td">3.27E+07</td>
                <td class="description-td">2.71E+09</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">149</td>
                <td class="description-td">1.11E+09</td>
                <td class="description-td">2.69E+06</td>
                <td class="description-td">2.71E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">150</td>
                <td class="description-td">1.54E+09</td>
                <td class="description-td">2.20E+06</td>
                <td class="description-td">3.43E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">151</td>
                <td class="description-td">4.72E+09</td>
                <td class="description-td">9.20E+06</td>
                <td class="description-td">9.27E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">152</td>
                <td class="description-td">1.43E+08</td>
                <td class="description-td">3.16E+05</td>
                <td class="description-td">6.63E+06</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">153</td>
                <td class="description-td">1.18E+09</td>
                <td class="description-td">6.42E+06</td>
                <td class="description-td">1.42E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">154</td>
                <td class="description-td">3.62E+08</td>
                <td class="description-td">2.89E+06</td>
                <td class="description-td">1.30E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">155</td>
                <td class="description-td">8.58E+08</td>
                <td class="description-td">1.00E+07</td>
                <td class="description-td">2.77E+08</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">156</td>
                <td class="description-td">6.51E+08</td>
                <td class="description-td">1.92E+06</td>
                <td class="description-td">1.82E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">157</td>
                <td class="description-td">2.27E+09</td>
                <td class="description-td">6.70E+06</td>
                <td class="description-td">5.15E+07</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">158</td>
                <td class="description-td">1.99E+05</td>
                <td class="description-td">1.71E+04</td>
                <td class="description-td">1.17E+05</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">159</td>
                <td class="description-td">1.13E+06</td>
                <td class="description-td">2.17E+05</td>
                <td class="description-td">7.24E+05</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">2.57E+09</td>
                <td class="description-td">1.27E+07</td>
                <td class="description-td">2.85E+07</td>
                <td class="description-td">2.56E+06</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="left" id="FOO-00007" class="description-td" colspan="5">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0288">Example 6A: Expression Induced by Sample Formulations Upon Intramuscular Administration</heading>
    <li> <para-num num="[1441]"> </para-num> <div id="p-1496" num="1441" class="description-line">Sample formulations including both modified luciferase (Luc) mRNA and H10 mRNA were prepared and administered intramuscularly and the resulting expression and immunogenicity were evaluated simultaneously. Formulations including compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) were prepared and administered at doses of 0.001 and 0.01 mpk (e.g., doses of 0.0005 mpk of a formulation including Luc mRNA and a formulation including H10 mRNA or doses of 0.005 mpk of a formulation including Luc mRNA and a formulation including H10 mRNA). As shown in Table 5A, Compound 20 exhibited the highest expression at both dose levels. The low dose of Compound 20 showed equivalent expression to the high dose of MC3. Formulations including other compounds also showed multi-fold enhancement in expression relative to MC3.</div>
    </li> <li> <div id="p-1497" num="0000" class="description-line">
      <tables id="TABLE-US-00009" num="00009">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 5A</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Total flux (p/s) measured 6 hours after intramuscular administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of nanoparticle compositions including compounds according to</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">0.001 mpk Dose</td>
                <td class="description-td">0.01 mpk Dose</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">3.55E+06</td>
                <td class="description-td">6.16E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">3.58E+06</td>
                <td class="description-td">4.95E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">9.84E+05</td>
                <td class="description-td">3.55E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">3.65E+06</td>
                <td class="description-td">7.48E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">7.81E+05</td>
                <td class="description-td">3.32E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">8.02E+04</td>
                <td class="description-td">8.90E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">8.84E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">3.28E+06</td>
                <td class="description-td">2.96E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">2.59E+07</td>
                <td class="description-td">9.72E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">8.27E+06</td>
                <td class="description-td">2.20E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">3.78E+06</td>
                <td class="description-td">3.97E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">3.53E+06</td>
                <td class="description-td">9.96E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">3.90E+06</td>
                <td class="description-td">6.13E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">2.55E+06</td>
                <td class="description-td">3.17E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">6.73E+05</td>
                <td class="description-td">5.56E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">7.64E+05</td>
                <td class="description-td">1.12E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">2.47E+06</td>
                <td class="description-td">3.77E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">7.37E+05</td>
                <td class="description-td">1.03E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">2.45E+06</td>
                <td class="description-td">8.12E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">4.69E+05</td>
                <td class="description-td">8.78E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">6.56E+05</td>
                <td class="description-td">1.13E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">1.16E+05</td>
                <td class="description-td">2.23E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">137</td>
                <td class="description-td">7.57E+04</td>
                <td class="description-td">8.09E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">138</td>
                <td class="description-td">2.72E+05</td>
                <td class="description-td">1.19E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">140</td>
                <td class="description-td">2.03E+05</td>
                <td class="description-td">6.09E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">144</td>
                <td class="description-td">2.72E+06</td>
                <td class="description-td">2.18E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">2.76E+06</td>
                <td class="description-td">3.68E+07</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="left" id="FOO-00008" class="description-td" colspan="3">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0289">Example 6B: Expression Induced by Sample Formulations Upon Intramuscular Administration</heading>
    <li> <para-num num="[1442]"> </para-num> <div id="p-1498" num="1442" class="description-line">Sample formulations including modified luciferase (Luc) mRNA prepared and administered intramuscularly and the resulting expression and immunogenicity were evaluated simultaneously. Formulations including compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) were prepared and administered at dose of and 0.01 mpk. As shown in Table 5B, Compound 108 exhibited the highest expression. Formulations including other compounds also showed multi-fold enhancement in expression relative to MC3.</div>
    </li> <li> <div id="p-1499" num="0000" class="description-line">
      <tables id="TABLE-US-00010" num="00010">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 5B</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Total flux (p/s) measured 6 hours after intramuscular administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of nanoparticle compositions including compounds according to</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">0.01 mpk Dose</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60</td>
                <td class="description-td">9.48E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">69</td>
                <td class="description-td">8.83E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">108</td>
                <td class="description-td">4.60E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">109</td>
                <td class="description-td">1.18E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">110</td>
                <td class="description-td">1.21E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">111</td>
                <td class="description-td">1.58E+08</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">112</td>
                <td class="description-td">9.47E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">114</td>
                <td class="description-td">3.31E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">121</td>
                <td class="description-td">1.06E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">122</td>
                <td class="description-td">9.19E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">123</td>
                <td class="description-td">1.08E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">3.23E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1443]"> </para-num> <div id="p-1500" num="1443" class="description-line">The fluxes measured upon intravenous and intramuscular administration are compared in Table 6. Fluxes are presented as fold increase over that measured for MC3 formulations. Formulations including Compound 20 displayed the highest fold increase in Luc expression upon intramuscular administration, while those including Compounds 18 and 26 displayed the highest fold increase upon intravenous administration. Notably, the intravenous data included in Table 6 was measured at higher doses than the intramuscular data.</div>
    </li> <li> <div id="p-1501" num="0000" class="description-line">
      <tables id="TABLE-US-00011" num="00011">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 6</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Relative flux measured after intravenous or intramuscular</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">administration of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Fold increase in Luc expression relative to MC3</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Intramuscular</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Intravenous</td>
                <td class="description-td">Intramuscular</td>
                <td class="description-td">(0.001 mpk</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">pKa</td>
                <td class="description-td">(0.5 mpk dose)</td>
                <td class="description-td">(0.01 mpk dose)</td>
                <td class="description-td">dose)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">6.72</td>
                <td class="description-td">2.24</td>
                <td class="description-td">1.13</td>
                <td class="description-td">0.51</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">6.56</td>
                <td class="description-td">3.23</td>
                <td class="description-td">2.01</td>
                <td class="description-td">n.d.</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">6.87</td>
                <td class="description-td">0.80</td>
                <td class="description-td">2.21</td>
                <td class="description-td">3.70</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">6.64</td>
                <td class="description-td">4.24</td>
                <td class="description-td">1.39</td>
                <td class="description-td">0.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">6.00</td>
                <td class="description-td">1.03</td>
                <td class="description-td">0.25</td>
                <td class="description-td">0.11</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="left" id="FOO-00009" class="description-td" colspan="5">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0290">Example 7: Cytokine Production Induced by Sample Formulations</heading>
    <li> <para-num num="[1444]"> </para-num> <div id="p-1502" num="1444" class="description-line">The introduction of foreign material into a mammalian body induces an innate immune response that promotes cytokine production. Such immune responses to, for example, nanoparticle compositions including therapeutic and/or prophylactics, are undesirable. The induction of certain cytokines is thus measured to evaluate the efficacy of nanoparticle compositions. The concentrations of various cytokines in mice upon intravenous administration of nanoparticle compositions presented in Table 1A at a dosage of 0.5 mpk was measured at 6 hours. The standard MC3 formulation and a PBS control were also tested. As is evident in Table 7, IL-6 induction was highest for compositions including Compounds 1, 3, 9, 19, and 26, while IP-10 induction was highest for compositions including Compounds 3, 4, 7, 20, and 26. IL-6 induction was lowest for compositions including Compounds 4, 11, 12, and 28. IP-10 induction was lowest for compositions including Compounds 10, 11, 12, 13, 15, 17, and 18.</div>
    </li> <li> <div id="p-1503" num="0000" class="description-line">
      <tables id="TABLE-US-00012" num="00012">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 7</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cytokine induction 6 hours after administration of nanoparticle </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compositions including compounds according to Formula (I),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">IL-6</td>
                <td class="description-td">IP-10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">267.24</td>
                <td class="description-td">687.14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">70.95</td>
                <td class="description-td">468.86</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">282.88</td>
                <td class="description-td">2052.87</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">13.1375</td>
                <td class="description-td">2253.09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">94.07</td>
                <td class="description-td">487.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">136.18</td>
                <td class="description-td">316.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">116.35</td>
                <td class="description-td">4959.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">317.45</td>
                <td class="description-td">366.53</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">88.81</td>
                <td class="description-td">138.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">0.14</td>
                <td class="description-td">44.84</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">3.88</td>
                <td class="description-td">32.03</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">29.07</td>
                <td class="description-td">126.29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">75.29</td>
                <td class="description-td">621.49</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">64.65</td>
                <td class="description-td">184.30</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">32.01</td>
                <td class="description-td">206.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">138.43</td>
                <td class="description-td">156.41</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">78.76</td>
                <td class="description-td">139.92</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">285.56</td>
                <td class="description-td">1468.94</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">126.83</td>
                <td class="description-td">2468.24</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">90.54</td>
                <td class="description-td">976.50</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">94.00</td>
                <td class="description-td">1015.95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">163.53</td>
                <td class="description-td">1172.93</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">233.45</td>
                <td class="description-td">1194.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">273.56</td>
                <td class="description-td">2330.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">161.07</td>
                <td class="description-td">345.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">17.47</td>
                <td class="description-td">283.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">69.54</td>
                <td class="description-td">1362.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">152.51</td>
                <td class="description-td">1638.77</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">136</td>
                <td class="description-td">28.69</td>
                <td class="description-td">887.91</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">137</td>
                <td class="description-td">130.82</td>
                <td class="description-td">234.35</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">138</td>
                <td class="description-td">23.38</td>
                <td class="description-td">172.56</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">139</td>
                <td class="description-td">23.57</td>
                <td class="description-td">153.36</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">140</td>
                <td class="description-td">282.82</td>
                <td class="description-td">187.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">141</td>
                <td class="description-td">327.15</td>
                <td class="description-td">1072.04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">143</td>
                <td class="description-td">6.245</td>
                <td class="description-td">209.63</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">144</td>
                <td class="description-td">319.46</td>
                <td class="description-td">4220.55</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">124.42</td>
                <td class="description-td">504.90</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0291">Example 8: Complement Activation Induced by Sample Formulations</heading>
    <li> <para-num num="[1445]"> </para-num> <div id="p-1504" num="1445" class="description-line">Complement activation assists in the clearance of pathogens from an organism. As it is undesirable that a subject&#39;s body recognize a nanoparticle composition as a foreign invader, low complement system activation upon administration of such a composition is preferred. The complex sC5b-9 is a marker for the activation of the complement system. Thus, human cells were contacted in vitro with nanoparticle compositions according to Table 1A and were evaluated for sC5b-9 levels. Table 8 shows the fold increase in sC5b-9 levels relative to saline for nanoparticle compositions including Compounds 1, 6, 9, 18, 24, 25, 29, and 30. Compositions including Compounds 6 and 18 somewhat increase sC5b-9 levels relative to saline, while compositions including Compounds 1, 9, 24, 29, and 30 slightly decrease sC5b-9 levels relative to saline.</div>
    </li> <li> <div id="p-1505" num="0000" class="description-line">
      <tables id="TABLE-US-00013" num="00013">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 8</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Fold increases in sC5b-9 levels upon administration of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">nanoparticle compositions including compounds according</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Fold increase</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">versus saline</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">1</td>
                <td class="description-td">0.82</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6</td>
                <td class="description-td">1.39</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">9</td>
                <td class="description-td">0.92</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">1.28</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">0.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">1.02</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">29</td>
                <td class="description-td">0.93</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">0.94</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">136</td>
                <td class="description-td">0.69</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">139</td>
                <td class="description-td">0.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">140</td>
                <td class="description-td">0.75</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">141</td>
                <td class="description-td">1.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">0.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0292">Example 9: Clinical Chemistry and Hematology</heading>
    <li> <para-num num="[1446]"> </para-num> <div id="p-1506" num="1446" class="description-line">Sample formulations of nanoparticle compositions including different lipids were administered intravenously to rat at a dose of 2 mpk. The expression of various clinical markers was evaluated at 48 h post dose and compared to that induced by administration of MC3 formulations or phosphate buffered saline (PBS).</div>
    </li> <li> <div id="p-1507" num="0000" class="description-line">
      <tables id="TABLE-US-00014" num="00014">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 9</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Levels of clinical markers induced by administration of nanoparticle compositions</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">including a compound of Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Concentration</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Alanine</td>
                <td class="description-td">Aspartate</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">aminotransferase</td>
                <td class="description-td">aminotransferase</td>
                <td class="description-td">Neutrophils</td>
                <td class="description-td">Lymphocytes</td>
                <td class="description-td">Monocytes</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">53.5</td>
                <td class="description-td">87.5</td>
                <td class="description-td">3388.5</td>
                <td class="description-td">12051</td>
                <td class="description-td">2103</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">51.5</td>
                <td class="description-td">90</td>
                <td class="description-td">1790.5</td>
                <td class="description-td">14100</td>
                <td class="description-td">1834</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">52</td>
                <td class="description-td">124.5</td>
                <td class="description-td">1998</td>
                <td class="description-td">15924</td>
                <td class="description-td">2122</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">56</td>
                <td class="description-td">95</td>
                <td class="description-td">3195</td>
                <td class="description-td">10408.5</td>
                <td class="description-td">877</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">339</td>
                <td class="description-td">325</td>
                <td class="description-td">4962.5</td>
                <td class="description-td">19976</td>
                <td class="description-td">1429</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">PBS</td>
                <td class="description-td">55.5</td>
                <td class="description-td">108</td>
                <td class="description-td">920</td>
                <td class="description-td">8004</td>
                <td class="description-td">276</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0293">Example 10: Expression of hEPO Induced by Sample Formulations</heading>
    <li> <para-num num="[1447]"> </para-num> <div id="p-1508" num="1447" class="description-line">Sample formulations of nanoparticle compositions including different lipids are generally first evaluated according to Luc expression in vivo. The activity of several such compositions was further evaluated using an mRNA encoding hEPO. Nanoparticle compositions including Compounds 6, 18, 25, 30, 108-112, 60, and 122, or MC3 were prepared according to Example 2. As shown in Tables 10 and 1B supra, each composition had a similar particle size and encapsulation efficiency.</div>
    </li> <li> <div id="p-1509" num="0000" class="description-line">
      <tables id="TABLE-US-00015" num="00015">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 10</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characteristics of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td">EE</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">Formulation</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">(%)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">Compound 6:DSPC:Chol:PEG-DMG</td>
                <td class="description-td">70.5</td>
                <td class="description-td">0.082</td>
                <td class="description-td">97.84</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(50:10:38.5:1.5)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">Compound 18:DSPC:Chol:PEG-</td>
                <td class="description-td">78.6</td>
                <td class="description-td">0.095</td>
                <td class="description-td">97.34</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">DMG (50:10:38.5:1.5)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">MC3:DSPC:Chol:PEG-DMG</td>
                <td class="description-td">73.7</td>
                <td class="description-td">0.114</td>
                <td class="description-td">97.22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(50:10:38.5:1.5)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1448]"> </para-num> <div id="p-1510" num="1448" class="description-line">The expression of hEPO and cytokine induction in mice intravenously administered a nanoparticle composition at a dose of 0.5 mpk were measured at 3, 6, and 24 hours. The resultant hEPO and cytokine levels are summarized in Table 11A. Compositions including Compounds 6 and 18 yielded higher hEPO concentrations than MC3 formulations at each time point. The expression of hEPO in mice intramuscularly administered a nanoparticle composition from Table 1B at a dose of 0.01 mpk were measured at 3, 6, and 24 hours. The resultant hEPO levels are summarized in Table 11B. Compositions including Compounds 18, 25, 30, 108-112, 60, and 122 yielded higher hEPO concentrations than MC3 formulations at 6 hr time point. (see also <figref idrefs="DRAWINGS">FIG. 9</figref>.)</div>
    </li> <li> <div id="p-1511" num="0000" class="description-line">
      <tables id="TABLE-US-00016" num="00016">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 11A</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Evaluation of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Cytokine expression</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(pg/ml)</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hEPO expression (pg/ml)</td>
                <td class="description-td"> </td>
                <td class="description-td">IL-6</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">3 h</td>
                <td class="description-td">6 h</td>
                <td class="description-td">24 h</td>
                <td class="description-td">IP-10 (6 h)</td>
                <td class="description-td">(6 h)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">2.31E+06</td>
                <td class="description-td">3.17E+06</td>
                <td class="description-td">1.11E+06</td>
                <td class="description-td">116.66</td>
                <td class="description-td">10.15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">3.00E+06</td>
                <td class="description-td">3.38E+06</td>
                <td class="description-td">1.80E+06</td>
                <td class="description-td">299.93</td>
                <td class="description-td">10.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">1.57E+06</td>
                <td class="description-td">1.83E+06</td>
                <td class="description-td">0.81E+06</td>
                <td class="description-td">117.94</td>
                <td class="description-td">19.85</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1512" num="0000" class="description-line">
      <tables id="TABLE-US-00017" num="00017">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 11B</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Evaluation of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Fold increase in hEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">concentration relative to MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">8.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">7.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">9.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">108</td>
                <td class="description-td">3.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">109</td>
                <td class="description-td">5.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">110</td>
                <td class="description-td">1.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">111</td>
                <td class="description-td">10.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">112</td>
                <td class="description-td">1.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60</td>
                <td class="description-td">11.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">122</td>
                <td class="description-td">10.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1449]"> </para-num> <div id="p-1513" num="1449" class="description-line">Table 12 compares the nanoparticle compositions including compounds according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) to the compositions including MC3 on the basis of expression and flux levels. As is evident in Table 12, both Compounds 6 and 18 outperform MC3 in both hEPO expression and average total flux. Thus, these lipids may be useful in nanoparticle composition therapeutics.</div>
    </li> <li> <div id="p-1514" num="0000" class="description-line">
      <tables id="TABLE-US-00018" num="00018">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 12</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound 6</td>
                <td class="description-td">18</td>
                <td class="description-td">MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Average hEPO concentration</td>
                <td class="description-td">3.17  10<sup>6</sup> </td>
                <td class="description-td">3.38  10<sup>6</sup> </td>
                <td class="description-td">1.83  10<sup>6</sup> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml, 6 h)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Fold increase in hEPO</td>
                <td class="description-td">1.73</td>
                <td class="description-td">1.85</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">concentration relative to MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Average total flux (6 h, ffluc)</td>
                <td class="description-td">7.60  10<sup>9</sup> </td>
                <td class="description-td">2.13  10<sup>10</sup> </td>
                <td class="description-td">6.59  10<sup>9</sup> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Fold increase in average total</td>
                <td class="description-td">1.15</td>
                <td class="description-td">3.23</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">flux relative to MC3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="4" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0294">Example 11: Expression of hEPO Induced by Sample Formulations in Rat and Residual Lipid Levels in the Liver</heading>
    <li> <para-num num="[1450]"> </para-num> <div id="p-1515" num="1450" class="description-line">The expression of hEPO and cytokine induction in rats intravenously administered a nanoparticle composition at a dose of 2.0 mpk was measured at 6 h.</div>
    </li> <li> <para-num num="[1451]"> </para-num> <div id="p-1516" num="1451" class="description-line">At 48 h liver tissue was harvested for lipid quantification. To pre-weighed tissues, Milli-Q water was added (900 L water per 100 mg tissue). Tissues were homogenized using an Omni probe homogenizer until uniform. 50 L of samples and matrix calibration standards were aliquoted into a 96-well plate. 50 L of blank matrix for matrix blanks and control blanks were aliquoted. 400 L IS spiking solution were manually added to all samples except matrix blanks. 400 L of 50:50 ACN:IPA were manually added to matrix blanks. The plate was covered and the samples vortexed and centrifuged for 5 minutes at &gt;3000 rpm. 200 L of the samples were transferred into a clean 96-well plate for analysis. Samples were analyzed on a Waters Acquity UPLC using a Higgins Analytical Clipeus C<sub>8 </sub>column (5 M, 302.1 mm) and a gradient of either 70-95% or 60-95% (Mobile Phase A: 5 mM ammonium formate in 50:50:1 H<sub>2</sub>O:MeOH:formic acid; Mobile Phase B: 5 mM ammonium formate in 100:1 MeOH:formic acid) over 1.3 min at 1.2 mL/min (column temperature 55 C.). Detection was based on electrospray ionization (ESI) in positive mode using a Sciex API5500 Mass Spectrometer.</div>
    </li> <li> <div id="p-1517" num="0000" class="description-line">
      <tables id="TABLE-US-00019" num="00019">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 13</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of hEPO induced by administration of nanoparticle</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compositions including compounds according to Formula (I),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) in rat, 6 h, 2 mpk.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">hEPO expression (pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">1.74E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">9.96E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">1.44E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">3.05E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">1.63E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">1.33E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1518" num="0000" class="description-line">
      <tables id="TABLE-US-00020" num="00020">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 14</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cytokine induction 6 hours after administration of hEPO</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">nanoparticle compositions including compounds according to</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">IP-10 (pg/mL)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">542</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">517.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">323.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">533.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">214.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">688.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1519" num="0000" class="description-line">
      <tables id="TABLE-US-00021" num="00021">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 15</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Liver levels in rats administered compositions including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II), (IIa),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIb), (IIc), (IId) or (IIe) after 48 h.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">% remaining dose in liver, 48 h</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">14.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">1.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">&lt;1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">74</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1452]"> </para-num> <div id="p-1520" num="1452" class="description-line">The expression of hEPO in rats intravenously administered a nanoparticle composition at a dose of 0.2 mpk or 2.0 mpk was measured at 6 hours. Table 16 summarize the ratio of hEPO expression levels using various nanoparticle compositions as compared to the hEPO expression level using MC3 formulation and the lipid levels in the liver measured 48 hours after administration, as described above. Tables 17 and 18 summarize the lipid levels in the liver and spleen measured 48 hours after administration of Compounds 28, 33, 53, and 54. Liver and spleen levels represent the average values calculated for 3 rats in each group. As is shown in Tables 17 and 18, less than 10% of Compounds 28, 33, 53, and 54 remained in the liver after 48 hours, while greater than 60% of MC3 remained.</div>
    </li> <li> <div id="p-1521" num="0000" class="description-line">
      <tables id="TABLE-US-00022" num="00022">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 16</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Ratio of expression of hEPO and lipid levels remaining</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">in liver after 48 h.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid/MC3</td>
                <td class="description-td">% Lipid Remaining</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hEPO conc. ratio</td>
                <td class="description-td">in liver, 48 h*</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">0.2 mpk</td>
                <td class="description-td">2 mpk</td>
                <td class="description-td">2 mpk</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">1</td>
                <td class="description-td">1</td>
                <td class="description-td">87</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">0.81</td>
                <td class="description-td">0.018</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">25</td>
                <td class="description-td">2.41</td>
                <td class="description-td">2.13</td>
                <td class="description-td">1.32</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24</td>
                <td class="description-td">1.75</td>
                <td class="description-td">1.01</td>
                <td class="description-td">0.016</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">30</td>
                <td class="description-td">1.87</td>
                <td class="description-td">1.14</td>
                <td class="description-td">&lt;0.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">3</td>
                <td class="description-td">2.41</td>
                <td class="description-td">1.21</td>
                <td class="description-td">14</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">26</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">4.95</td>
                <td class="description-td">20</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">48</td>
                <td class="description-td">5.39</td>
                <td class="description-td">3.84</td>
                <td class="description-td">7.22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">49</td>
                <td class="description-td">4.13</td>
                <td class="description-td">3.28</td>
                <td class="description-td">12.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50</td>
                <td class="description-td">3.41</td>
                <td class="description-td">3.03</td>
                <td class="description-td">15.9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="left" id="FOO-00010" class="description-td" colspan="5">*Assuming 300 g rat and 15 g liver</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1522" num="0000" class="description-line">
      <tables id="TABLE-US-00023" num="00023">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 17</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Liver levels in rats administered 0.2 mpk doses of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compositions including compounds according to Formula</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) after 48 h.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Liver level</td>
                <td class="description-td">Spleen level</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">(ng/g)</td>
                <td class="description-td">(ng/g)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">49.6</td>
                <td class="description-td">268</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">115</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">4810</td>
                <td class="description-td">1181</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">6067</td>
                <td class="description-td">6357</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">25033</td>
                <td class="description-td">9440</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1523" num="0000" class="description-line">
      <tables id="TABLE-US-00024" num="00024">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 18</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Liver levels in rats administered 2 mpk doses of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compositions including compounds according to Formula</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) after 48 h.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Liver level</td>
                <td class="description-td">Spleen level</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">(ng/g)</td>
                <td class="description-td">(ng/g)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">665</td>
                <td class="description-td">551</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">103</td>
                <td class="description-td">287</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">47033</td>
                <td class="description-td">201333</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">56100</td>
                <td class="description-td">49367</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">285333</td>
                <td class="description-td">129000</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1453]"> </para-num> <div id="p-1524" num="1453" class="description-line">Table 19 summarizes the hEPO expression, IP-10 induction, liver and spleen levels, and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) measured upon intravenous administration of formulations including Compounds 48, 49, and 50 to rat at 0.2 and 2 mpk and hEPO mRNA. hEPO concentrations were measured 6 hours after administration, while cytokine induction and liver and spleen levels were measured 48 hours after administration. hEPO and IP-10 concentrations are presented in pg/ml, while liver levels are provided in ng/g. ALT and AST levels are presented in international units.</div>
    </li> <li> <div id="p-1525" num="0000" class="description-line">
      <tables id="TABLE-US-00025" num="00025">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 19</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">hEPO expression, IP-10 induction, and liver levels measured after administration of compositions including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to one of formulas (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound 48</td>
                <td class="description-td">Compound 49</td>
                <td class="description-td">Compound 50</td>
                <td class="description-td">MC3</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">0.2 mpk</td>
                <td class="description-td">2 mpk</td>
                <td class="description-td">0.2 mpk</td>
                <td class="description-td">2 mpk</td>
                <td class="description-td">0.2 mpk</td>
                <td class="description-td">2 mpk</td>
                <td class="description-td">0.2 mpk</td>
                <td class="description-td">2 mpk</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="8" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">hEPO</td>
                <td class="description-td">4.06E+06</td>
                <td class="description-td">3.57E+07</td>
                <td class="description-td">3.17E+06</td>
                <td class="description-td">3.04E+07</td>
                <td class="description-td">2.62E+06</td>
                <td class="description-td">2.81E+07</td>
                <td class="description-td">7.68E+06</td>
                <td class="description-td">9.29E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">expression</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IP-10</td>
                <td class="description-td">134</td>
                <td class="description-td">970</td>
                <td class="description-td">66</td>
                <td class="description-td">932</td>
                <td class="description-td">20</td>
                <td class="description-td">1065</td>
                <td class="description-td">2</td>
                <td class="description-td">596</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">induction</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Liver</td>
                <td class="description-td">5448</td>
                <td class="description-td">34520</td>
                <td class="description-td">6490</td>
                <td class="description-td">61400</td>
                <td class="description-td">5822</td>
                <td class="description-td">79200</td>
                <td class="description-td">11300</td>
                <td class="description-td">140520</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">level</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(ng/g)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Spleen</td>
                <td class="description-td">0.31</td>
                <td class="description-td">0.21</td>
                <td class="description-td">0.36</td>
                <td class="description-td">0.37</td>
                <td class="description-td">0.22</td>
                <td class="description-td">0.17</td>
                <td class="description-td">0.74</td>
                <td class="description-td">0.65</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">level</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(ng/g)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">ALT</td>
                <td class="description-td">59.6</td>
                <td class="description-td">66.0</td>
                <td class="description-td">54.0</td>
                <td class="description-td">77.8</td>
                <td class="description-td">59.2</td>
                <td class="description-td">78.8</td>
                <td class="description-td">63.6</td>
                <td class="description-td">79.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">AST</td>
                <td class="description-td">140.8</td>
                <td class="description-td">131.2</td>
                <td class="description-td">99.4</td>
                <td class="description-td">132.4</td>
                <td class="description-td">143.2</td>
                <td class="description-td">158.4</td>
                <td class="description-td">134.8</td>
                <td class="description-td">139.0</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0295">Example 12: Dose Response of Sample Formulations in Rats</heading>
    <li> <para-num num="[1454]"> </para-num> <div id="p-1526" num="1454" class="description-line">The expression of hEPO induced by intravenous administration to rats of nanoparticle compositions at various doses was measured at 2, 4, 6, 8, 24, and 48 hour time points. <figref idrefs="DRAWINGS">FIGS. 3-6</figref> respectively summarize the hEPO expression measured upon intravenous administration of formulations including Compounds 26, 18, 25, and MC3 to rat at various doses. The lipid levels of Compound 26 in the liver after 48 hours were about 19%.</div>
    </li> <li> <para-num num="[1455]"> </para-num> <div id="p-1527" num="1455" class="description-line"> <figref idrefs="DRAWINGS">FIG. 7</figref> shows the area under the curve for compositions including Compounds 18, 25, and 26 and MC3 at different dosages: 0.005 mpk, 0.01 mpk, 0.025 mpk, 0.05 mpk, 0.1 mpk, 0.25 mpk, 0.5 mpk, 1 mpk or 2 mpk.</div>
    </li> <heading id="h-0296">Example 13: Pharmacokinetics of Sample Formulations in Rats</heading>
    <li> <para-num num="[1456]"> </para-num> <div id="p-1528" num="1456" class="description-line">The expression of hEPO and lipid levels in the liver and spleen in rats intravenously administered a nanoparticle composition at a dose of 0.2 mpk was measured at various timepoints. Compounds 18 and 25 were selected for comparison with MC3. Lipids were formulated according to the standard MC3 formulation described above. Rats were administered intravenously a single 0.2 mpk dose and expression monitored at 0.25, 0.5, 1, 2, 4, 8, 24, and 48 hours after administration.</div>
    </li> <li> <div id="p-1529" num="0000" class="description-line">
      <tables id="TABLE-US-00026" num="00026">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 20</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Expression of hEPO induced by administration of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">nanoparticle compositions in rat, 6 h, 0.2 mpk.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hEPO expression</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(pg/mL)</td>
                <td class="description-td">18</td>
                <td class="description-td">25</td>
                <td class="description-td">MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">0.25</td>
                <td class="description-td">h</td>
                <td class="description-td">20227</td>
                <td class="description-td">0</td>
                <td class="description-td">0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">0.5</td>
                <td class="description-td">h</td>
                <td class="description-td">20743</td>
                <td class="description-td">19553</td>
                <td class="description-td">42457</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">h</td>
                <td class="description-td">194353</td>
                <td class="description-td">434299</td>
                <td class="description-td">93720</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">h</td>
                <td class="description-td">238107</td>
                <td class="description-td">2042807</td>
                <td class="description-td">524093</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">h</td>
                <td class="description-td">514807</td>
                <td class="description-td">3176560</td>
                <td class="description-td">601307</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">h</td>
                <td class="description-td">915320</td>
                <td class="description-td">2631633</td>
                <td class="description-td">1536833</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">h</td>
                <td class="description-td">412051</td>
                <td class="description-td">869374</td>
                <td class="description-td">703619</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">h</td>
                <td class="description-td">52361</td>
                <td class="description-td">103089</td>
                <td class="description-td">64687</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1530" num="0000" class="description-line">
      <tables id="TABLE-US-00027" num="00027">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 21</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid level in liver induced by administration of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">nanoparticle compositions in rat, 6 h, 0.2 mpk.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid level</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(ng/g)</td>
                <td class="description-td">18</td>
                <td class="description-td">25</td>
                <td class="description-td">MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">0.25</td>
                <td class="description-td">h</td>
                <td class="description-td">5374</td>
                <td class="description-td">12037</td>
                <td class="description-td">13180</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">0.5</td>
                <td class="description-td">h</td>
                <td class="description-td">6023</td>
                <td class="description-td">16447</td>
                <td class="description-td">20500</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">h</td>
                <td class="description-td">6053</td>
                <td class="description-td">17900</td>
                <td class="description-td">16777</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">h</td>
                <td class="description-td">2037</td>
                <td class="description-td">11733</td>
                <td class="description-td">25967</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">h</td>
                <td class="description-td">839</td>
                <td class="description-td">6687</td>
                <td class="description-td">24730</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">h</td>
                <td class="description-td">296</td>
                <td class="description-td">2357</td>
                <td class="description-td">32633</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">h</td>
                <td class="description-td">5</td>
                <td class="description-td">199</td>
                <td class="description-td">33000</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">h</td>
                <td class="description-td">5374</td>
                <td class="description-td">12037</td>
                <td class="description-td">13180</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1531" num="0000" class="description-line">
      <tables id="TABLE-US-00028" num="00028">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 22</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid level in spleen induced by administration of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">nanoparticle compositions in rat, 6 h, 0.2 mpk.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid level</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(ng/g)</td>
                <td class="description-td">18</td>
                <td class="description-td">25</td>
                <td class="description-td">MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">0.25</td>
                <td class="description-td">h</td>
                <td class="description-td">1230</td>
                <td class="description-td">4037</td>
                <td class="description-td">4100</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">0.5</td>
                <td class="description-td">h</td>
                <td class="description-td">2017</td>
                <td class="description-td">6880</td>
                <td class="description-td">6237</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">h</td>
                <td class="description-td">3213</td>
                <td class="description-td">8590</td>
                <td class="description-td">4197</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">h</td>
                <td class="description-td">3070</td>
                <td class="description-td">13733</td>
                <td class="description-td">8613</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">h</td>
                <td class="description-td">3770</td>
                <td class="description-td">20400</td>
                <td class="description-td">11920</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">h</td>
                <td class="description-td">1345</td>
                <td class="description-td">10787</td>
                <td class="description-td">21200</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">h</td>
                <td class="description-td">271</td>
                <td class="description-td">2023</td>
                <td class="description-td">19067</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">h</td>
                <td class="description-td">92</td>
                <td class="description-td">1547</td>
                <td class="description-td">11563</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0297">Example 14: Optimization of Lipid:Therapeutic Agent Ratios</heading>
    <li> <para-num num="[1457]"> </para-num> <div id="p-1532" num="1457" class="description-line">The relative amounts of lipid component and therapeutic and/or prophylactic in a nanoparticle composition can be optimized according to considerations of efficacy and tolerability. For compositions including an RNA as a therapeutic and/or prophylactic, the N:P ratio can serve as a useful metric.</div>
    </li> <li> <para-num num="[1458]"> </para-num> <div id="p-1533" num="1458" class="description-line">As the N:P ratio of a nanoparticle composition controls both expression and tolerability, nanoparticle compositions with low N:P ratios and strong expression are desirable. N:P ratios vary according to the ratio of lipids to RNA in a nanoparticle composition. Thus, the wt/wt ratio of total lipid to RNA is varied between 10:1, 15:1, 20:1, 32:1, 40:1, 50:1, and 60:1 for a lipid formulation including about 50 mol % of a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe), about 10 mol % phospholipid (e.g., DOPE or DSPC), about 38.5 mol % structural lipid (e.g., cholesterol), and about 1.5 mol % PEG lipid (e.g., PEG-DMG). N:P ratios are calculated for each nanoparticle composition assuming a single protonated nitrogen atom. The encapsulation efficiency (EE), size, and polydispersity index of each composition are also measured.</div>
    </li> <li> <para-num num="[1459]"> </para-num> <div id="p-1534" num="1459" class="description-line">Generally, compositions with higher total lipid:RNA ratios yield smaller particles with higher encapsulation efficiencies, both of which are desirable. However, the N:P ratio for such formulations generally exceeds 4. Current standards in the art such as the MC3 formulation described above have N:P ratios of 5.67. Thus, a balance between the N:P ratio, size, and encapsulation efficiency should be struck.</div>
    </li> <li> <para-num num="[1460]"> </para-num> <div id="p-1535" num="1460" class="description-line">In order to explore the efficacy of nanoparticle compositions with different N:P ratios, the expression of luciferase (Luc) or human erythropoietin (hEPO) in mice after low (0.05 mg/kg) or high (0.5 mg/kg) doses of intravenously administered nanoparticle compositions is examined. The concentration of Luc or hEPO expressed is measured 3, 6, and/or 24 hours after administration.</div>
    </li> <heading id="h-0298">Example 15: Optimization of Content of a Compound According to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe)</heading>
    <li> <para-num num="[1461]"> </para-num> <div id="p-1536" num="1461" class="description-line">As smaller particles with higher encapsulation efficiencies are generally desirable, the relative amounts of various elements in lipid components of nanoparticle compositions are optimized according to these parameters.</div>
    </li> <li> <para-num num="[1462]"> </para-num> <div id="p-1537" num="1462" class="description-line">A compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) is selected for optimization. The relative amount of the compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) is varied between 30 mol % and 60 mol % in compositions including DOPE or DSPC as phospholipids to determine the optimal amount of the compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) in the formulations. Formulations are prepared using a standardized process with a water to ethanol ratio in the lipid-mRNA solution of 3:1 and a rate of injection of the lipid solution into the mRNA solution of 12 mL/min on a NanoAssemblr microfluidic based system. This method induces nano-precipitation and particle formation. Alternative processes including, but not limited to, T-junction or direct injection, may also be used to achieve the same nano-precipitation.</div>
    </li> <li> <para-num num="[1463]"> </para-num> <div id="p-1538" num="1463" class="description-line">Formulations producing the smallest particles with the highest encapsulation efficiencies are generally preferred, however larger or smaller particle sizes may be desirable based on a given application (e.g., based on the fenestration size of a target organ). Compositions are also evaluated for their Luc or hEPO expression levels and cytokine profiles.</div>
    </li> <heading id="h-0299">Example 16: Optimization of Phospholipid</heading>
    <li> <para-num num="[1464]"> </para-num> <div id="p-1539" num="1464" class="description-line">The relative amount of phospholipid in a lipid component of a nanoparticle composition is varied to further optimize the formulation. A compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) is selected for use in the nanoparticle composition and DOPE and DSPC are selected as phospholipids. Additional phospholipids can also be evaluated. Nanoparticle compositions are prepared with the relative phospholipid content varying between 0 mol % and 30 mol %. Compositions are evaluated for their size, encapsulation efficiency, Luc or hEPO expression levels, and cytokine profiles.</div>
    </li> <heading id="h-0300">Example 17: Optimization of Structural Lipid</heading>
    <li> <para-num num="[1465]"> </para-num> <div id="p-1540" num="1465" class="description-line">The relative amount of structural lipid in a lipid component of a nanoparticle composition is varied to further optimize the formulation. A compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) is selected for use in the nanoparticle composition and cholesterol is selected as a structural lipid. Additional structural lipids can also be evaluated. Nanoparticle compositions are prepared with the relative structural lipid content varying between 18.5 mol % and 48.5 mol %. Compositions are evaluated for their size, encapsulation efficiency, Luc or hEPO expression levels, and cytokine profiles.</div>
    </li> <heading id="h-0301">Example 18: Optimization of PEG Lipid</heading>
    <li> <para-num num="[1466]"> </para-num> <div id="p-1541" num="1466" class="description-line">The relative amount of PEG lipid in a lipid component of a nanoparticle composition is varied to further optimize the formulation. A compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe) is selected for use in the nanoparticle composition and PEG-DMG is selected as a PEG lipid. Additional PEG lipids can also be evaluated. Nanoparticle compositions are prepared with the relative PEG lipid content varying between 0 mol % and 10 mol %. Compositions are evaluated for their size, encapsulation efficiency, Luc or hEPO expression levels, and cytokine profiles.</div>
    </li> <li> <para-num num="[1467]"> </para-num> <div id="p-1542" num="1467" class="description-line">Exemplary formulations useful in the optimization of nanoparticle composition formulations are presented in Table 23.</div>
    </li> <li> <div id="p-1543" num="0000" class="description-line">
      <tables id="TABLE-US-00029" num="00029">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 23</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Exemplary formulations including compounds according to</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Composition (mol %)</td>
                <td class="description-td">Components</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:20:38.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:15:38.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:10:38.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:5:38.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:5:33.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:20:33.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:20:28.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:20:23.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:20:18.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:15:43.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:15:33.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:15:28.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:15:23.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:10:48.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:10:43.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:10:33.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:10:28.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:5:53.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:5:48.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:5:43.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:20:40:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:20:35:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:20:30:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:20:25:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:20:20:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:15:45:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:15:40:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:15:35:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:15:30:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:15:25:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">40:10:50:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">45:10:45:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:0:48.5:1.5</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">50:10:40:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">55:10:35:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">60:10:30:0</td>
                <td class="description-td">Compound:Phospholipid:Chol:PEG-DMG</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0302">Example 19: Optimization of Particle Sizes</heading>
    <li> <para-num num="[1468]"> </para-num> <div id="p-1544" num="1468" class="description-line">The fenestration sizes for different bodily organs often vary; for example, the kidney is known to have a smaller fenestration size than the liver. Thus, targeting delivery of a therapeutic and/or prophylactic (e.g., specifically delivering) to a particular organ or group of organs may require the administration of nanoparticle compositions with different particle sizes. In order to investigate this effect, nanoparticle compositions with formulations such as those included in Table 23 are prepared with a variety of particle sizes using a Nanoassemblr instrument. Nanoparticle compositions include an RNA encoding Luc. Each differently sized nanoparticle composition is subsequently administered to mice to evaluate the effect of particle size on delivery selectivity. Luc expression in two or more organs or groups of organs can be measured using bioluminescence to evaluate the relative expression in each organ.</div>
    </li> <heading id="h-0303">Example 20: Administration Following Pretreatment</heading>
    <li> <para-num num="[1469]"> </para-num> <div id="p-1545" num="1469" class="description-line">Administration of nanoparticle compositions to subjects can result in inflammation, infusion related reactions, and other undesirable effects indicative of low tolerability. These effects can be attributed to undesirable immunoactivity.</div>
    </li> <li> <para-num num="[1470]"> </para-num> <div id="p-1546" num="1470" class="description-line">In order to combat negative effects, nanoparticle compositions are co-administered with one or more substances (e.g., co-medications or additional therapeutic and/or prophylactics) to subjects. Potentially useful additional therapeutic and/or prophylactics include steroids (e.g., corticosteroids), anti-histamines, H1 receptor blockers, H2 receptor blockers, anti-inflammatory compounds, statins, BTK inhibitors, S1P1 agonists, glucocorticoid receptor modulators (GRMs), and estradiols. Non-human primates are pretreated with one or more additional therapeutic agents selected from dexamethasone and acetaminophen. The additional therapeutic agent is administered either 24 hours, 1 hour, or both 24 hours and 1 hour before administration of a nanoparticle composition. Sample protocol are summarized in Table 24. Cytokine profiles, inflammation, and other parameters are measured and compared to evaluate the effectiveness of pretreatment.</div>
    </li> <li> <div id="p-1547" num="0000" class="description-line">
      <tables id="TABLE-US-00030" num="00030">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 24</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Sample protocol for pretreatment study.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Pretreatment</td>
                <td class="description-td">Additional Therapeutic Agent(s)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Group</td>
                <td class="description-td">Time</td>
                <td class="description-td">Administered</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">None</td>
                <td class="description-td">None</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">24 hours</td>
                <td class="description-td">Dexamethasone</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">24 hours</td>
                <td class="description-td">Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">24 hours</td>
                <td class="description-td">Dexamethasone and Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">1 hour</td>
                <td class="description-td">Dexamethasone</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">1 hour</td>
                <td class="description-td">Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">1 hour</td>
                <td class="description-td">Dexamethasone and Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">24 hours and 1</td>
                <td class="description-td">Dexamethasone</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hour</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">24 hours and 1</td>
                <td class="description-td">Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hour</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">24 hours and 1</td>
                <td class="description-td">Dexamethasone and Acetaminophen</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hour</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1471]"> </para-num> <div id="p-1548" num="1471" class="description-line">For example, a useful therapeutic treatment course may involve administering an additional therapeutic and/or prophylactic both the day before and the day of (one hour prior) to administration of a nanoparticle composition at a dose level of 1.3 mpk. Additional therapeutic and/or prophylactics can be formulated for delivery by a variety of different routes. For example, dexamethasone may be delivered orally. In general, additional therapeutic and/or prophylactics are administered at clinically approved or typical dosage levels.</div>
    </li> <heading id="h-0304">Example 21: Administration to Non-Human Primates</heading>
    <li> <para-num num="[1472]"> </para-num> <div id="p-1549" num="1472" class="description-line">The tolerability and efficacy of nanoparticle compositions to non-human primates was evaluated in Cynomolgus monkeys. Monkeys were administered an optimized nanoparticle composition including an mRNA encoding hEPO once weekly for four weeks. The levels of hEPO protein, mRNA, and cytokine profiles were measured using ELISA-based techniques before and 2, 6, 12, 24, 48, 72, and 120 hours after each administration.</div>
    </li> <li> <para-num num="[1473]"> </para-num> <div id="p-1550" num="1473" class="description-line">The effects of pretreatment to non-human primates were evaluated using a standard MC3 formulation including an mRNA encoding hEPO. The study design is summarized in Table 25. Male monkeys were administered the nanoparticle composition once weekly for four weeks at a dose rate of 5 ml/kg/h and were pretreated with either methotrexate or dexamethasone.</div>
    </li> <li> <div id="p-1551" num="0000" class="description-line">
      <tables id="TABLE-US-00031" num="00031">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 25</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Protocol for pretreatment study in Cynomolgus monkeys.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Additional</td>
                <td class="description-td">Dose</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td">Therapeutic</td>
                <td class="description-td">concen-</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">level</td>
                <td class="description-td">Agent</td>
                <td class="description-td">tration</td>
                <td class="description-td">Number of</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Group</td>
                <td class="description-td">Test Material</td>
                <td class="description-td">(mg/kg)</td>
                <td class="description-td">Administered</td>
                <td class="description-td">(mg/ml)</td>
                <td class="description-td">monkeys</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">MC3</td>
                <td class="description-td">0</td>
                <td class="description-td">None</td>
                <td class="description-td">0</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">hEPO mRNA</td>
                <td class="description-td">0.3</td>
                <td class="description-td">None</td>
                <td class="description-td">0.06</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">in MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">hEPO mRNA</td>
                <td class="description-td">0.3</td>
                <td class="description-td">Methotrexate</td>
                <td class="description-td">0.06</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">in MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">hEPO mRNA</td>
                <td class="description-td">0.3</td>
                <td class="description-td">Dexamethasone</td>
                <td class="description-td">0.06</td>
                <td class="description-td">3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">in MC3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1474]"> </para-num> <div id="p-1552" num="1474" class="description-line">Results of the pretreatment study are shown in <figref idrefs="DRAWINGS">FIG. 1</figref>. As shown, in the absence of any pretreatment, maximal expression levels decreased nearly 70% over the course of the study. Methotrexate did not confer any particular beneficial effect. However, pre-administration of dexamethasone resulted in increased protein expression compared to treatment courses not involving pretreatment. Notably, minimal decrease in plasma/serum protein expression was observed over time for animals pretreated with dexamethasone. These results suggest that pretreatment of corticosteroids such as dexamethasone improves the tolerability and efficacy of nanoparticle compositions containing, for example, a compound according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</div>
    </li> <li> <para-num num="[1475]"> </para-num> <div id="p-1553" num="1475" class="description-line">The tolerability and efficacy of nanoparticle compositions to non-human primates was also investigated using a sample formulation including Compound 18. The formulation was prepared according to the standard MC3 formulation described above and included an hEPO mRNA. Primates were administered a single dose of 0.05 (Group 1), 0.3 (Group 2), or 1.0 (Group 3) mpk via intravenous infusion for 60 minutes. Three primates were administered each dose. Expression of hEPO was measured prior to dosing and at 2, 6, 24, 48, and 96 hours post-treatment (Table 26). Pharmacokinetic parameters including Tmax, Cmax, and the AUC were also determined and are presented in Table 27. Table 28 includes levels of indicators of complement activation, while Table 29 includes cytokine induction data.</div>
    </li> <li> <div id="p-1554" num="0000" class="description-line">
      <tables id="TABLE-US-00032" num="00032">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 26</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">hEPO expression measured at various time points upon</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">administration of nanoparticle compositions to non-human</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">primates.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">hEPO</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">concentration</td>
                <td class="description-td">Group 1</td>
                <td class="description-td">Group 2</td>
                <td class="description-td">Group 3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">(0.05 mpk)</td>
                <td class="description-td">(0.3 mpk)</td>
                <td class="description-td">(1.0 mpk)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Predose</td>
                <td class="description-td">1000</td>
                <td class="description-td">1000</td>
                <td class="description-td">1000</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">2 h</td>
                <td class="description-td">142588</td>
                <td class="description-td">363272</td>
                <td class="description-td">312006</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">379362</td>
                <td class="description-td">341285</td>
                <td class="description-td">502663</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">103055</td>
                <td class="description-td">148789</td>
                <td class="description-td">467598</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">48 h</td>
                <td class="description-td">25382</td>
                <td class="description-td">57095</td>
                <td class="description-td">175953</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">96 h</td>
                <td class="description-td">2084</td>
                <td class="description-td">6095</td>
                <td class="description-td">24795</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1555" num="0000" class="description-line">
      <tables id="TABLE-US-00033" num="00033">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 27</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pharmacokinetic parameters measured upon administration</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">of nanoparticle compositions to non-human primates.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="4" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Group 1</td>
                <td class="description-td">Group 2</td>
                <td class="description-td">Group 3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(0.05 mpk)</td>
                <td class="description-td">(0.3 mpk)</td>
                <td class="description-td">(1.0 mpk)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="3" align="center" rowsep="1" class="description-td" colspan="4"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Tmax</td>
                <td class="description-td">Mean</td>
                <td class="description-td">6.00</td>
                <td class="description-td">3.33</td>
                <td class="description-td">12.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(hours)</td>
                <td class="description-td">SD</td>
                <td class="description-td">0.00</td>
                <td class="description-td">2.31</td>
                <td class="description-td">10.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CV %</td>
                <td class="description-td">0.00</td>
                <td class="description-td">69.3</td>
                <td class="description-td">86.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cmax</td>
                <td class="description-td">Mean</td>
                <td class="description-td">3.79E+05</td>
                <td class="description-td">3.84E+05</td>
                <td class="description-td">5.51E+05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">SD</td>
                <td class="description-td">2.64E+05</td>
                <td class="description-td">2.45E+05</td>
                <td class="description-td">6.24E+04</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CV %</td>
                <td class="description-td">69.7</td>
                <td class="description-td">63.8</td>
                <td class="description-td">11.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">AUCall</td>
                <td class="description-td">Mean</td>
                <td class="description-td">7.72E+06</td>
                <td class="description-td">1.02E+07</td>
                <td class="description-td">2.32E+07</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(hr  pg/ml)</td>
                <td class="description-td">SD</td>
                <td class="description-td">6.26E+06</td>
                <td class="description-td">7.34E+06</td>
                <td class="description-td">4.20E+06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CV %</td>
                <td class="description-td">81.1</td>
                <td class="description-td">72.3</td>
                <td class="description-td">18.1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1556" num="0000" class="description-line">
      <tables id="TABLE-US-00034" num="00034">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 28</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Complement activation indicators measured at various</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">time points upon administration of nanoparticle compositions</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">to non-human primates.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Group 1</td>
                <td class="description-td">Group 2</td>
                <td class="description-td">Group 3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Time point</td>
                <td class="description-td">(0.05 mpk)</td>
                <td class="description-td">(0.3 mpk)</td>
                <td class="description-td">(1.0 mpk)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">C3a</td>
                <td class="description-td">Predose</td>
                <td class="description-td">10600</td>
                <td class="description-td">9827</td>
                <td class="description-td">12792</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(ng/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">19236</td>
                <td class="description-td">42897</td>
                <td class="description-td">75936</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">12385</td>
                <td class="description-td">32436</td>
                <td class="description-td">51996</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">11596</td>
                <td class="description-td">19721</td>
                <td class="description-td">35843</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">11945</td>
                <td class="description-td">16207</td>
                <td class="description-td">19101</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Bb</td>
                <td class="description-td">Predose</td>
                <td class="description-td">1375</td>
                <td class="description-td">1461</td>
                <td class="description-td">1529</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">fragment</td>
                <td class="description-td">2 h</td>
                <td class="description-td">5341</td>
                <td class="description-td">5356</td>
                <td class="description-td">8849</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(ng/ml)</td>
                <td class="description-td">6 h</td>
                <td class="description-td">3037</td>
                <td class="description-td">7157</td>
                <td class="description-td">12820</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">1496</td>
                <td class="description-td">3680</td>
                <td class="description-td">8601</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">1273</td>
                <td class="description-td">2400</td>
                <td class="description-td">2834</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">C5b9</td>
                <td class="description-td">Predose</td>
                <td class="description-td">169</td>
                <td class="description-td">157</td>
                <td class="description-td">238</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(ng/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">1959</td>
                <td class="description-td">393</td>
                <td class="description-td">801</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">786</td>
                <td class="description-td">1333</td>
                <td class="description-td">2928</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">265</td>
                <td class="description-td">614</td>
                <td class="description-td">4798</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">163</td>
                <td class="description-td">405</td>
                <td class="description-td">534</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1557" num="0000" class="description-line">
      <tables id="TABLE-US-00035" num="00035">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 29</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Cytokine induction measured at various time points upon</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">administration of nanoparticle compositions to non-human</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">primates.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Group 1</td>
                <td class="description-td">Group 2</td>
                <td class="description-td">Group 3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Time point</td>
                <td class="description-td">(0.05 mpk)</td>
                <td class="description-td">(0.3 mpk)</td>
                <td class="description-td">(1.0 mpk)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">IFNg</td>
                <td class="description-td">Predose</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">35.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">38.9</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">39.3</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IFN</td>
                <td class="description-td">Predose</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IL-1b</td>
                <td class="description-td">Predose</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">33.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IL-6</td>
                <td class="description-td">Predose</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">191</td>
                <td class="description-td">834</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">33.0</td>
                <td class="description-td">398</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">31.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MCP-1</td>
                <td class="description-td">Predose</td>
                <td class="description-td">192</td>
                <td class="description-td">168</td>
                <td class="description-td">235</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">342</td>
                <td class="description-td">3018</td>
                <td class="description-td">4221</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">543</td>
                <td class="description-td">2011</td>
                <td class="description-td">3945</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">236</td>
                <td class="description-td">404</td>
                <td class="description-td">1444</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">232</td>
                <td class="description-td">211</td>
                <td class="description-td">225</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">TNF-</td>
                <td class="description-td">Predose</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(pg/ml)</td>
                <td class="description-td">2 h</td>
                <td class="description-td">18.8</td>
                <td class="description-td">38.2</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">6 h</td>
                <td class="description-td">41.5</td>
                <td class="description-td">32.5</td>
                <td class="description-td">18.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">24 h</td>
                <td class="description-td">17.6</td>
                <td class="description-td">59.6</td>
                <td class="description-td">46.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Day 5</td>
                <td class="description-td">63.5</td>
                <td class="description-td">18.8</td>
                <td class="description-td">41.9</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1476]"> </para-num> <div id="p-1558" num="1476" class="description-line">In general, the formulation was tolerated similarly to the MC3 formulation with dose-response effects. Aspartate aminotransferase (AST) increased in the high dose group on Day 2 and returned to baseline by Day 5. Alanine aminotransferase (ALT) levels did not increase, however. In general, lower doses were better tolerated. High doses induced body temperature elevation and hunched posture, which is similar to the behavior observed for primates administered higher doses of MC3 formulations. White blood cell counts were slightly elevated in animals in the high dose group, however all groups showed a marked increase in reticulocyte counts on Day 5, indicating a strong pharmacological response. Complement activation and cytokine release (IL-6 and MCP-1) were dose-related and reversible within 24 hours for the low and mid-dose groups and by Day 5 in the high dose group. hEPO levels were higher than those measured upon administration of comparable doses of MC3 formulations to non-human primates.</div>
    </li> <heading id="h-0305">Example 22: Administration to Non-Human Primates</heading>
    <li> <para-num num="[1477]"> </para-num> <div id="p-1559" num="1477" class="description-line">The tolerability and efficacy of nanoparticle compositions to non-human primates was also investigated using sample formulations including Compounds 18, 25, 26, and 48 and MC3 to determine if these compounds are differentiated in terms of protein expression. The formulations were prepared according to the standard MC3 formulation described above and included an hEPO mRNA. Table 30 includes details of the compositions tested, while Table 31 summarizes the relative expression of Luc and hEPO mRNA in mice and rats. Expression was measured 6 hours after administration.</div>
    </li> <li> <div id="p-1560" num="0000" class="description-line">
      <tables id="TABLE-US-00036" num="00036">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 30</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Characteristics of nanoparticle compositions including</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">compounds according to Formula (I), (IA), (II),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Zeta</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Size</td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Osmolality</td>
                <td class="description-td">potential</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
                <td class="description-td">EE (%)</td>
                <td class="description-td">pH</td>
                <td class="description-td">(mOsm/kg)</td>
                <td class="description-td">(mV)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="7" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">102.6</td>
                <td class="description-td">0.230</td>
                <td class="description-td">85.56</td>
                <td class="description-td">7.64</td>
                <td class="description-td">312</td>
                <td class="description-td">3.53</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">98.8</td>
                <td class="description-td">0.230</td>
                <td class="description-td">87.01</td>
                <td class="description-td">7.60</td>
                <td class="description-td">304</td>
                <td class="description-td">3.88</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">79.2</td>
                <td class="description-td">0.120</td>
                <td class="description-td">95.60</td>
                <td class="description-td">7.54</td>
                <td class="description-td">305</td>
                <td class="description-td">3.73</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">70.6</td>
                <td class="description-td">0.176</td>
                <td class="description-td">91.92</td>
                <td class="description-td">7.58</td>
                <td class="description-td">311</td>
                <td class="description-td">3.61</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">106.0</td>
                <td class="description-td">0.220</td>
                <td class="description-td">91.66</td>
                <td class="description-td">7.52</td>
                <td class="description-td">318</td>
                <td class="description-td">3.64</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="center" rowsep="1" class="description-td" colspan="7"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="7" align="left" id="FOO-00011" class="description-td" colspan="7">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1561" num="0000" class="description-line">
      <tables id="TABLE-US-00037" num="00037">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 31</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Comparison of nanoparticle compositions including compounds</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">according to Formula (I), (IA), (II), (IIa), (IIb), (IIc), (IId) or (IIe).</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">18</td>
                <td class="description-td">25</td>
                <td class="description-td">26</td>
                <td class="description-td">48</td>
                <td class="description-td">MC3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="5" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="6" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Lipid/MC3 Luc expression</td>
                <td class="description-td">3.23</td>
                <td class="description-td">1.89</td>
                <td class="description-td">4.24</td>
                <td class="description-td">10.0</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(0.5 mpk dose to mouse)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid/MC3 hEPO</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">2.41</td>
                <td class="description-td">n.d.</td>
                <td class="description-td">5.39</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">expression</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(0.2 mpk dose to rat)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Lipid/MC3 hEPO</td>
                <td class="description-td">0.81</td>
                <td class="description-td">2.13</td>
                <td class="description-td">4.95</td>
                <td class="description-td">3.84</td>
                <td class="description-td">1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">expression</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(2 mpk dose to rat)</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">% lipid remaining in liver</td>
                <td class="description-td">0.018</td>
                <td class="description-td">1.32</td>
                <td class="description-td">20</td>
                <td class="description-td">11.4</td>
                <td class="description-td">87</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">after 48 hours</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="center" rowsep="1" class="description-td" colspan="6"> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="6" align="left" id="FOO-00012" class="description-td" colspan="6">n.d. = not determined</td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1478]"> </para-num> <div id="p-1562" num="1478" class="description-line"> <figref idrefs="DRAWINGS">FIG. 2</figref> shows the hEPO mRNA expression measured after intravenous administration of a 0.01 mpk dose with 60 minutes infusion to naive cynomolgus monkeys. As is evident in the figure, expression was highest 6 hours post administration for all formulations tested, and was highest for those formulations including Compound 18.</div>
    </li> <li> <para-num num="[1479]"> </para-num> <div id="p-1563" num="1479" class="description-line">Table 32 summarizes pharmacokinetic parameters measured upon administration of 0.01 mpk doses of formulations to non-human primates.</div>
    </li> <li> <div id="p-1564" num="0000" class="description-line">
      <tables id="TABLE-US-00038" num="00038">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="1" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 32</td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Pharmacokinetic parameters measured upon administration of formulations</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">including compounds according to Formula (I), (IA), (II), (IIa),</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">(IIb), (IIc), (IId) or (IIe) to non-human primates.</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">T<sub>max</sub> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">AUC</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">(hr)</td>
                <td class="description-td">C<sub>max </sub>(ng/mL)</td>
                <td class="description-td">AUC<sub>0-t </sub>(hr*ng/mL)</td>
                <td class="description-td">Lipid/MC3</td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">Lipid</td>
                <td class="description-td">Mean</td>
                <td class="description-td">Mean</td>
                <td class="description-td">SD</td>
                <td class="description-td">CV %</td>
                <td class="description-td">Mean</td>
                <td class="description-td">SD</td>
                <td class="description-td">CV %</td>
                <td class="description-td">Ratio</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="9" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">MC3</td>
                <td class="description-td">8</td>
                <td class="description-td">14.1</td>
                <td class="description-td">2.36</td>
                <td class="description-td">16.8</td>
                <td class="description-td">284</td>
                <td class="description-td">97.4</td>
                <td class="description-td">34.2</td>
                <td class="description-td">1.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound 18</td>
                <td class="description-td">8</td>
                <td class="description-td">91</td>
                <td class="description-td">34.7</td>
                <td class="description-td">38.1</td>
                <td class="description-td">1690</td>
                <td class="description-td">1060</td>
                <td class="description-td">63.1</td>
                <td class="description-td">6.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound 25</td>
                <td class="description-td">6</td>
                <td class="description-td">56.9</td>
                <td class="description-td">15.1</td>
                <td class="description-td">26.5</td>
                <td class="description-td">930</td>
                <td class="description-td">249</td>
                <td class="description-td">26.8</td>
                <td class="description-td">3.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound 26</td>
                <td class="description-td">6</td>
                <td class="description-td">28.2</td>
                <td class="description-td">17.7</td>
                <td class="description-td">62.7</td>
                <td class="description-td">365</td>
                <td class="description-td">302</td>
                <td class="description-td">82.7</td>
                <td class="description-td">1.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound 48</td>
                <td class="description-td">6</td>
                <td class="description-td">17.7</td>
                <td class="description-td">9.49</td>
                <td class="description-td">53.6</td>
                <td class="description-td">245</td>
                <td class="description-td">117</td>
                <td class="description-td">47.9</td>
                <td class="description-td">0.9</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="9" align="center" rowsep="1" class="description-td" colspan="9"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0306">Example 23: Administration to Non-Human Primates</heading>
    <li> <para-num num="[1480]"> </para-num> <div id="p-1565" num="1480" class="description-line">Results of hEPO expression studies were validated using a standard MC3 formulation and a nanoparticle composition containing Compound 18 including an mRNA encoding an anti-hemagglutinin (anti-HA) antibody. Cynomolgus monkeys were administered a single dose of 0.1 mpk or 0.3 mpk of a nanoparticle composition containing Compound 18 (see Table 33; prepared according to Example 2) including an mRNA encoding anti-HA antibody via intravenous infusion for 60 minutes.</div>
    </li> <li> <div id="p-1566" num="0000" class="description-line">
      <tables id="TABLE-US-00039" num="00039">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" rowsep="1" class="description-td" colspan="5">TABLE 33</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Diameter</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid</td>
                <td class="description-td">EE (%)</td>
                <td class="description-td">(nm)</td>
                <td class="description-td">PDI</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound 18</td>
                <td class="description-td">79.3</td>
                <td class="description-td">76.8</td>
                <td class="description-td">0.16</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1481]"> </para-num> <div id="p-1567" num="1481" class="description-line">The results of anti-HA (anti-hemagglutinin) antibody expression are shown in Table 34 and in <figref idrefs="DRAWINGS">FIG. 11</figref>.</div>
    </li> <li> <div id="p-1568" num="0000" class="description-line">
      <tables id="TABLE-US-00040" num="00040">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" rowsep="1" class="description-td" colspan="5">TABLE 34</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
                <td class="description-td">Dose</td>
                <td class="description-td">AUC</td>
                <td class="description-td">AUC Compound</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Lipid</td>
                <td class="description-td">(mpk)</td>
                <td class="description-td">(g/mL * h)</td>
                <td class="description-td">18/MC3 Ratio</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="5" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">0.1</td>
                <td class="description-td">77.05</td>
                <td class="description-td"></td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound 18</td>
                <td class="description-td">0.1</td>
                <td class="description-td">354.3</td>
                <td class="description-td">4.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">MC3</td>
                <td class="description-td">0.3</td>
                <td class="description-td">235.7</td>
                <td class="description-td"></td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound 18</td>
                <td class="description-td">0.3</td>
                <td class="description-td">1055</td>
                <td class="description-td">4.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="4" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1482]"> </para-num> <div id="p-1569" num="1482" class="description-line">A five times higher protein expression was observed with the nanoparticle composition containing Compound 18 versus the MC3 counterpart, and a clear dose response between 0.1 and 0.3 mpk with Compound 18 was found (e.g., 0.3 mpk AUC is about three times of that from 0.1 mpk dose).</div>
    </li> <heading id="h-0307">Example 24: Methods of Treating Diseases and Disorders</heading>
    <li> <para-num num="[1483]"> </para-num> <div id="p-1570" num="1483" class="description-line">A nanoparticle composition formulation having high tolerability (e.g., provoking a low immune response) and efficacy (e.g., facilitating efficient and effective encapsulation of a therapeutic and/or prophylactic and delivery of the agent to a desired target) is selected for use. A therapeutic and/or prophylactic for formulation with the nanoparticle composition is selected for use based on the condition of a subject. For example, an mRNA encoding a vascular endothelial growth factor A (VEGF-A) may be selected to promote angiogenesis to treat atherosclerotic renovascular disease, while an siRNA capable of knocking down apolipoprotein B (apoB) may be selected to treat a metabolic disease or disorder such as dyslipidemia.</div>
    </li> <li> <para-num num="[1484]"> </para-num> <div id="p-1571" num="1484" class="description-line">A subject in need of treatment is pretreated with a small dose of dexamethasone one or more hours prior to treatment with the nanoparticle composition. The nanoparticle composition is preferably administered to the subject intravenously, however intramuscular, intradermal, subcutaneous, intranasal, or inhalation administration routes are also acceptable. Treatment is provided in a dose of about 0.001 mg/kg to about 10 mg/kg of therapeutic and/or prophylactic and is repeated daily, weekly, biweekly, or monthly according to needs of the subject.</div>
    </li> <heading id="h-0308">EQUIVALENTS</heading>
    <li> <para-num num="[1485]"> </para-num> <div id="p-1572" num="1485" class="description-line">It is to be understood that while the present disclosure has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the present disclosure, which is defined by the scope of the appended claims. Other aspects, advantages, and alterations are within the scope of the following claims.</div>
    
  </li> </ul>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims (<span itemprop="count">30</span>)</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM111730330" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text"> <b>1</b>. An ionizable lipid of Formula A:</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00303" num="00303">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/05/04/e0/621d4c888877fc/US20170210697A1-20170727-C00303.png"><img id="EMI-C00303" he="32.17mm" wi="121.50mm" file="US20170210697A1-20170727-C00303.TIF" alt="Figure US20170210697A1-20170727-C00303" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="486" height="129" alt="Figure US20170210697A1-20170727-C00303" class="patent-full-image" src="https://patentimages.storage.googleapis.com/05/04/e0/621d4c888877fc/US20170210697A1-20170727-C00303.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00303" attachment-type="cdx" file="US20170210697A1-20170727-C00303.CDX"> </attachment>
            <attachment idref="CHEM-US-00303" attachment-type="mol" file="US20170210697A1-20170727-C00303.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
      <div class="claim-text">or a salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text"> <b>2</b>. The ionizable lipid of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the salt is a pharmaceutically acceptable salt.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text"> <b>3</b>. A nanoparticle composition comprising a lipid component comprising an ionizable lipid of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text"> <b>4</b>. The nanoparticle composition of <claim-ref idref="CLM-00003">claim 3</claim-ref>, wherein the lipid component further comprises a phospholipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text"> <b>5</b>. The nanoparticle composition of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the phospholipid is selected from the group consisting of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC),
<div class="claim-text">1,2-dimyristoyl-sn-glycero-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC),</div> <div class="claim-text">1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-diundecanoyl-sn-glycero-phosphocholine (DUPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC),</div> <div class="claim-text">1,2-di-O-octadecenyl-sn-glycero-3-phosphocholine (18:0 Diether PC),</div> <div class="claim-text">1-oleoyl-2-cholesterylhemisuccinoyl-sn-glycero-3-phosphocholine (OChemsPC),</div> <div class="claim-text">1-hexadecyl-sn-glycero-3-phosphocholine (C 16 Lyso PC),</div> <div class="claim-text">1,2-dilinolenoyl-sn-glycero-3-phosphocholine, 1,2-diarachidonoyl-sn-glycero-3-phosphocholine,</div> <div class="claim-text">1,2-didocosahexaenoyl-sn-glycero-3-phosphocholine, 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (ME 16.0 PE),</div> <div class="claim-text">1,2-distearoyl-sn-glycero-3-phosphoethanolamine,</div> <div class="claim-text">1,2-dilinoleoyl-sn-glycero-3-phosphoethanolamine,</div> <div class="claim-text">1,2-dilinolenoyl-sn-glycero-3-phosphoethanolamine,</div> <div class="claim-text">1,2-diarachidonoyl-sn-glycero-3-phosphoethanolamine,</div> <div class="claim-text">1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine,</div> <div class="claim-text">1,2-dioleoyl-sn-glycero-3-phospho-rac-(1-glycerol) sodium salt (DOPG), sphingomyelin, and mixtures thereof.</div> </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text"> <b>6</b>. The nanoparticle composition of <claim-ref idref="CLM-00005">claim 5</claim-ref>, wherein the phospholipid is DSPC or DOPE.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00007" num="00007" class="claim">
      <div class="claim-text"> <b>7</b>. The nanoparticle composition of <claim-ref idref="CLM-00004">claim 4</claim-ref>, wherein the lipid component further comprises a structural lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00008" num="00008" class="claim">
      <div class="claim-text"> <b>8</b>. The nanoparticle composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the structural lipid is selected from the group consisting of cholesterol, fecosterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatidine, ursolic acid, alpha-tocopherol, and mixtures thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00009" num="00009" class="claim">
      <div class="claim-text"> <b>9</b>. The nanoparticle composition of <claim-ref idref="CLM-00008">claim 8</claim-ref>, wherein the structural lipid is cholesterol.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00010" num="00010" class="claim">
      <div class="claim-text"> <b>10</b>. The nanoparticle composition of <claim-ref idref="CLM-00007">claim 7</claim-ref>, wherein the lipid component further comprises a PEG lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00011" num="00011" class="claim">
      <div class="claim-text"> <b>11</b>. The nanoparticle composition of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the PEG lipid is selected from the group consisting of a PEG-modified phosphatidylethanolamine, a PEG-modified phosphatidic acid, a PEG-modified ceramide, a PEG-modified dialkylamine, a PEG-modified diacylglycerol, a PEG-modified dialkylglycerol, and mixtures thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00012" num="00012" class="claim">
      <div class="claim-text"> <b>12</b>. The nanoparticle composition of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the lipid component comprises about 30 mol % to about 60 mol % said ionizable lipid, about 0 mol % to about 30 mol % phospholipid, about 18.5 mol % to about 48.5 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00013" num="00013" class="claim">
      <div class="claim-text"> <b>13</b>. The nanoparticle composition of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the lipid component comprises about 35 mol % to about 55 mol % said ionizable lipid, about 5 mol % to about 25 mol % phospholipid, about 30 mol % to about 40 mol % structural lipid, and about 0 mol % to about 10 mol % PEG lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00014" num="00014" class="claim">
      <div class="claim-text"> <b>14</b>. The nanoparticle composition of <claim-ref idref="CLM-00010">claim 10</claim-ref>, wherein the lipid component comprises about 50 mol % said ionizable lipid, about 10 mol % phospholipid, about 38.5 mol % structural lipid, and about 1.5 mol % PEG lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00015" num="00015" class="claim">
      <div class="claim-text"> <b>15</b>. The nanoparticle composition of <claim-ref idref="CLM-00010">claim 10</claim-ref>, further comprising a therapeutic and/or prophylactic agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00016" num="00016" class="claim">
      <div class="claim-text"> <b>16</b>. The nanoparticle composition of <claim-ref idref="CLM-00012">claim 12</claim-ref>, further comprising a therapeutic and/or prophylactic agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00017" num="00017" class="claim">
      <div class="claim-text"> <b>17</b>. The nanoparticle composition of <claim-ref idref="CLM-00013">claim 13</claim-ref>, further comprising a therapeutic and/or prophylactic agent.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00018" num="00018" class="claim">
      <div class="claim-text"> <b>18</b>. The nanoparticle composition of <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein the therapeutic and/or prophylactic agent is a nucleic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00019" num="00019" class="claim">
      <div class="claim-text"> <b>19</b>. The nanoparticle composition of <claim-ref idref="CLM-00015">claim 15</claim-ref>, wherein the therapeutic and/or prophylactic agent is a ribonucleic acid (RNA).</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00020" num="00020" class="claim">
      <div class="claim-text"> <b>20</b>. The nanoparticle composition of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the RNA is selected from the group consisting of a small interfering RNA (siRNA), an asymmetrical interfering RNA (aiRNA), a microRNA (miRNA), a Dicer-substrate RNA (dsRNA), a small hairpin RNA (shRNA), a messenger RNA (mRNA), and mixtures thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00021" num="00021" class="claim">
      <div class="claim-text"> <b>21</b>. The nanoparticle composition of <claim-ref idref="CLM-00019">claim 19</claim-ref>, wherein the RNA is an mRNA.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00022" num="00022" class="claim">
      <div class="claim-text"> <b>22</b>. The nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the mRNA includes one or more of a stem loop, a chain terminating nucleoside, a polyA sequence, a polyadenylation signal, and/or a 5 cap structure.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00023" num="00023" class="claim">
      <div class="claim-text"> <b>23</b>. The nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the encapsulation efficiency of the therapeutic and/or prophylactic agent is at least 80% or at least 90%.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00024" num="00024" class="claim">
      <div class="claim-text"> <b>24</b>. The nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the wt/wt ratio of the lipid component to the mRNA is from about 10:1 to about 60:1.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00025" num="00025" class="claim">
      <div class="claim-text"> <b>25</b>. The nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the wt/wt ratio of the lipid component to the mRNA is about 20:1.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00026" num="00026" class="claim">
      <div class="claim-text"> <b>26</b>. The nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the N:P ratio is from about 5:1 to about 8:1.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00027" num="00027" class="claim">
      <div class="claim-text"> <b>27</b>. A pharmaceutical composition comprising the nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref> and a pharmaceutically acceptable carrier.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text"> <b>28</b>. A method of delivering a therapeutic and/or prophylactic agent to a mammalian cell, the method comprising administering to a subject the nanoparticle composition of <claim-ref idref="CLM-00015">claim 15</claim-ref>, said administering comprising contacting the cell with the nanoparticle composition, whereby the therapeutic and/or prophylactic agent is delivered to the cell.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text"> <b>29</b>. A method of producing a polypeptide of interest in a mammalian cell, the method comprising contacting the cell with the nanoparticle composition of <claim-ref idref="CLM-00021">claim 21</claim-ref>, wherein the mRNA encodes the polypeptide of interest, whereby the mRNA is capable of being translated in the cell to produce the polypeptide of interest.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00030" num="00030" class="claim">
      <div class="claim-text"> <b>30</b>. A method of synthesizing an ionizable lipid of <claim-ref idref="CLM-00001">claim 1</claim-ref>, comprising reacting heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate with nonyl-8-bromooctanoate under a suitable condition to provide the ionizable lipid of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</div>
    </div>
  </div> </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">US15/476,253</span>
      <span itemprop="priorityDate">2015-09-17</span>
      <span itemprop="filingDate">2017-03-31</span>
      <span itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </span>
      <span itemprop="ifiStatus">Active</span>
      
      <a href="/patent/US9868691B2/en">
        <span itemprop="representativePublication">US9868691B2</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    <h2>Priority Applications (9)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/476,253</span>
            
            <a href="/patent/US9868691B2/en">
              <span itemprop="representativePublication">US9868691B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-03-31</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/493,281</span>
            
            <a href="/patent/US9867888B2/en">
              <span itemprop="representativePublication">US9867888B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-21</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/498,698</span>
            
            <a href="/patent/US9868693B2/en">
              <span itemprop="representativePublication">US9868693B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-27</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/846,084</span>
            
            <a href="/patent/US10442756B2/en">
              <span itemprop="representativePublication">US10442756B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-12-18</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/005,286</span>
            
            <a href="/patent/US10266485B2/en">
              <span itemprop="representativePublication">US10266485B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-06-11</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/148,822</span>
            
            <a href="/patent/US10392341B2/en">
              <span itemprop="representativePublication">US10392341B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-10-01</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/555,045</span>
            
            <a href="/patent/US11220476B2/en">
              <span itemprop="representativePublication">US11220476B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2019-08-29</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/538,217</span>
            
            <a href="/patent/US12404232B2/en">
              <span itemprop="representativePublication">US12404232B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2021-11-30</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="priorityApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/467,190</span>
            
            <a href="/patent/US12151995B2/en">
              <span itemprop="representativePublication">US12151995B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2023-09-14</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Applications Claiming Priority (10)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201562220085P</span>
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2015-09-17</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201562220091P</span>
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2015-09-17</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201562252316P</span>
            
          </td>
          <td itemprop="priorityDate">2015-11-06</td>
          <td itemprop="filingDate">2015-11-06</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201562253433P</span>
            
          </td>
          <td itemprop="priorityDate">2015-11-10</td>
          <td itemprop="filingDate">2015-11-10</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201562266460P</span>
            
          </td>
          <td itemprop="priorityDate">2015-12-11</td>
          <td itemprop="filingDate">2015-12-11</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662333557P</span>
            
          </td>
          <td itemprop="priorityDate">2016-05-09</td>
          <td itemprop="filingDate">2016-05-09</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662382740P</span>
            
          </td>
          <td itemprop="priorityDate">2016-09-01</td>
          <td itemprop="filingDate">2016-09-01</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US201662393940P</span>
            
          </td>
          <td itemprop="priorityDate">2016-09-13</td>
          <td itemprop="filingDate">2016-09-13</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2016/052352</span>
            <a href="/patent/WO2017049245A2/en">
              <span itemprop="representativePublication">WO2017049245A2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2016-09-16</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/476,253</span>
            <a href="/patent/US9868691B2/en">
              <span itemprop="representativePublication">US9868691B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-03-31</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Parent Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="parentApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/US2016/052352</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/WO2017049245A2/en">
              <span itemprop="representativePublication">WO2017049245A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2016-09-16</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Related Child Applications (3)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="childApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/493,281</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/US9867888B2/en">
              <span itemprop="representativePublication">US9867888B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-21</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="childApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/498,698</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/US9868693B2/en">
              <span itemprop="representativePublication">US9868693B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-27</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="childApps" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/846,084</span>
            <span itemprop="relationType">Continuation</span>
            <a href="/patent/US10442756B2/en">
              <span itemprop="representativePublication">US10442756B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-12-18</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Publications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US20170210697A1</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/US20170210697A1/en">
              US20170210697A1
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-07-27</td>
        </tr>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US9868691B2</span>
            
            <a href="/patent/US9868691B2/en">
              US9868691B2
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-16</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=57137238</h2>

    <h2>Family Applications (10)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/476,263</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9868692B2/en">
              <span itemprop="representativePublication">US9868692B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-03-31</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/476,253</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9868691B2/en">
              <span itemprop="representativePublication">US9868691B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-03-31</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/493,281</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9867888B2/en">
              <span itemprop="representativePublication">US9867888B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-21</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/498,698</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9868693B2/en">
              <span itemprop="representativePublication">US9868693B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-27</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/846,084</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10442756B2/en">
              <span itemprop="representativePublication">US10442756B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-12-18</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/005,286</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10266485B2/en">
              <span itemprop="representativePublication">US10266485B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-06-11</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/148,822</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10392341B2/en">
              <span itemprop="representativePublication">US10392341B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-10-01</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/555,045</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2037-03-07</span>
            <a href="/patent/US11220476B2/en">
              <span itemprop="representativePublication">US11220476B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2019-08-29</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/538,217</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2038-04-03</span>
            <a href="/patent/US12404232B2/en">
              <span itemprop="representativePublication">US12404232B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2021-11-30</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/467,190</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US12151995B2/en">
              <span itemprop="representativePublication">US12151995B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2023-09-14</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Family Applications Before (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="beforeApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/476,263</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9868692B2/en">
                <span itemprop="representativePublication">US9868692B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-03-31</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Family Applications After (8)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/493,281</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9867888B2/en">
                <span itemprop="representativePublication">US9867888B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-21</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/498,698</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US9868693B2/en">
                <span itemprop="representativePublication">US9868693B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-04-27</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US15/846,084</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10442756B2/en">
                <span itemprop="representativePublication">US10442756B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2017-12-18</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/005,286</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10266485B2/en">
                <span itemprop="representativePublication">US10266485B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-06-11</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/148,822</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US10392341B2/en">
                <span itemprop="representativePublication">US10392341B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2018-10-01</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/555,045</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2037-03-07</span>
            <a href="/patent/US11220476B2/en">
                <span itemprop="representativePublication">US11220476B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2019-08-29</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US17/538,217</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2038-04-03</span>
            <a href="/patent/US12404232B2/en">
                <span itemprop="representativePublication">US12404232B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2021-11-30</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="afterApplications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US18/467,190</span>
            <span itemprop="ifiStatus">Active</span>
            
            <a href="/patent/US12151995B2/en">
                <span itemprop="representativePublication">US12151995B2</span>
                  (<span itemprop="primaryLanguage">en</span>)
              </a>
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="filingDate">2023-09-14</td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Country Status (18)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">US</span>
            (<span itemprop="num">10</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/US9868692B2/en">
              <span itemprop="representativePublication">US9868692B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">EP</span>
            (<span itemprop="num">3</span>)
            
          </td>
          <td>
            <a href="/patent/EP3350157B1/en">
              <span itemprop="representativePublication">EP3350157B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">JP</span>
            (<span itemprop="num">3</span>)
            
          </td>
          <td>
            <a href="/patent/JP6948313B6/en">
              <span itemprop="representativePublication">JP6948313B6</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">AU</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/AU2016324310B2/en">
              <span itemprop="representativePublication">AU2016324310B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CA</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CA2998810A1/en">
              <span itemprop="representativePublication">CA2998810A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CY</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CY1125154T1/en">
              <span itemprop="representativePublication">CY1125154T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">DK</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/DK3350157T3/en">
              <span itemprop="representativePublication">DK3350157T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">ES</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/ES2969082T3/en">
              <span itemprop="representativePublication">ES2969082T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">HR</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/HRP20220156T1/en">
              <span itemprop="representativePublication">HRP20220156T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">HU</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/HUE057613T2/en">
              <span itemprop="representativePublication">HUE057613T2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">LT</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/LT3350157T/en">
              <span itemprop="representativePublication">LT3350157T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">PL</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/PL3350157T3/en">
              <span itemprop="representativePublication">PL3350157T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">PT</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/PT3350157T/en">
              <span itemprop="representativePublication">PT3350157T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">RS</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/RS63030B1/en">
              <span itemprop="representativePublication">RS63030B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">SI</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/SI3350157T1/en">
              <span itemprop="representativePublication">SI3350157T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">SM</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/SMT202200178T1/en">
              <span itemprop="representativePublication">SMT202200178T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">TW</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/TWI757248B/en">
              <span itemprop="representativePublication">TWI757248B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/WO2017049245A2/en">
              <span itemprop="representativePublication">WO2017049245A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (62)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20180126005A1/en">
              <span itemprop="publicationNumber">US20180126005A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2007-09-04</td>
          <td itemprop="publicationDate">2018-05-10</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Complexes of rna and cationic peptides for transfection and for immunostimulation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20190321464A1/en">
              <span itemprop="publicationNumber">US20190321464A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2019-10-24</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Human cytomegalovirus rna vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021113777A2/en">
              <span itemprop="publicationNumber">WO2021113777A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-12-04</td>
          <td itemprop="publicationDate">2021-06-10</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021189059A2/en">
              <span itemprop="publicationNumber">WO2021189059A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-03-20</td>
          <td itemprop="publicationDate">2021-09-23</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021195218A1/en">
              <span itemprop="publicationNumber">WO2021195218A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-03-24</td>
          <td itemprop="publicationDate">2021-09-30</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Non-viral dna vectors and uses thereof for expressing gaucher therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021195214A1/en">
              <span itemprop="publicationNumber">WO2021195214A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-03-24</td>
          <td itemprop="publicationDate">2021-09-30</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Non-viral dna vectors and uses thereof for expressing factor ix therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2021236855A1/en">
              <span itemprop="publicationNumber">WO2021236855A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-19</td>
          <td itemprop="publicationDate">2021-11-25</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11406703B2/en">
              <span itemprop="publicationNumber">US11406703B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-08-25</td>
          <td itemprop="publicationDate">2022-08-09</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Human cytomegalovirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11464848B2/en">
              <span itemprop="publicationNumber">US11464848B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2022-10-11</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Respiratory syncytial virus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022226396A1/en">
              <span itemprop="publicationNumber">WO2022226396A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-23</td>
          <td itemprop="publicationDate">2022-10-27</td>
          <td><span itemprop="assigneeOriginal">Ganna Bio, Inc.</span></td>
          <td itemprop="title">Glycan modified nucleic acids, methods of preparation, and therapeutic uses 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022232286A1/en">
              <span itemprop="publicationNumber">WO2022232286A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-27</td>
          <td itemprop="publicationDate">2022-11-03</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022232289A1/en">
              <span itemprop="publicationNumber">WO2022232289A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-27</td>
          <td itemprop="publicationDate">2022-11-03</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Non-viral dna vectors expressing therapeutic antibodies and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11497807B2/en">
              <span itemprop="publicationNumber">US11497807B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-17</td>
          <td itemprop="publicationDate">2022-11-15</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Zoonotic disease RNA vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2022261490A2/en">
              <span itemprop="publicationNumber">WO2022261490A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-06-10</td>
          <td itemprop="publicationDate">2022-12-15</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023279836A1/en">
              <span itemprop="publicationNumber">WO2023279836A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-07</td>
          <td itemprop="publicationDate">2023-01-12</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Ionizable lipid compound for nucleic acid delivery and lnp composition thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023023055A1/en">
              <span itemprop="publicationNumber">WO2023023055A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-08-16</td>
          <td itemprop="publicationDate">2023-02-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Compositions and methods for optimizing tropism of delivery systems for rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044343A1/en">
              <span itemprop="publicationNumber">WO2023044343A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023044333A1/en">
              <span itemprop="publicationNumber">WO2023044333A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-03-23</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023056033A1/en">
              <span itemprop="publicationNumber">WO2023056033A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-30</td>
          <td itemprop="publicationDate">2023-04-06</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023081526A1/en">
              <span itemprop="publicationNumber">WO2023081526A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-08</td>
          <td itemprop="publicationDate">2023-05-11</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023081756A1/en">
              <span itemprop="publicationNumber">WO2023081756A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-03</td>
          <td itemprop="publicationDate">2023-05-11</td>
          <td><span itemprop="assigneeOriginal">The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone</span></td>
          <td itemprop="title">Precise genome editing using retrons 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023122752A1/en">
              <span itemprop="publicationNumber">WO2023122752A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-23</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Constrained lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023141602A2/en">
              <span itemprop="publicationNumber">WO2023141602A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-21</td>
          <td itemprop="publicationDate">2023-07-27</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Engineered retrons and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023141586A1/en">
              <span itemprop="publicationNumber">WO2023141586A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-21</td>
          <td itemprop="publicationDate">2023-07-27</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11744801B2/en">
              <span itemprop="publicationNumber">US11744801B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-31</td>
          <td itemprop="publicationDate">2023-09-05</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods of making lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023177655A1/en">
              <span itemprop="publicationNumber">WO2023177655A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-03-14</td>
          <td itemprop="publicationDate">2023-09-21</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Heterologous prime boost vaccine compositions and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023196931A1/en">
              <span itemprop="publicationNumber">WO2023196931A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-07</td>
          <td itemprop="publicationDate">2023-10-12</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11786607B2/en">
              <span itemprop="publicationNumber">US11786607B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-15</td>
          <td itemprop="publicationDate">2023-10-17</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">RNA formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023239756A1/en">
              <span itemprop="publicationNumber">WO2023239756A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-06-07</td>
          <td itemprop="publicationDate">2023-12-14</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN117377651A/en">
              <span itemprop="publicationNumber">CN117377651A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-12-31</td>
          <td itemprop="publicationDate">2024-01-09</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A cationic lipid with functional groups in its side chain and its application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024020346A2/en">
              <span itemprop="publicationNumber">WO2024020346A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-07-18</td>
          <td itemprop="publicationDate">2024-01-25</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Gene editing components, systems, and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024040222A1/en">
              <span itemprop="publicationNumber">WO2024040222A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-19</td>
          <td itemprop="publicationDate">2024-02-22</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Cleavable closed-ended dna (cedna) and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024044723A1/en">
              <span itemprop="publicationNumber">WO2024044723A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-25</td>
          <td itemprop="publicationDate">2024-02-29</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Engineered retrons and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024051825A1/en">
              <span itemprop="publicationNumber">WO2024051825A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-09-09</td>
          <td itemprop="publicationDate">2024-03-14</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Carbon nucleus cationic lipid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024102677A1/en">
              <span itemprop="publicationNumber">WO2024102677A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-08</td>
          <td itemprop="publicationDate">2024-05-16</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024102730A1/en">
              <span itemprop="publicationNumber">WO2024102730A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-08</td>
          <td itemprop="publicationDate">2024-05-16</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids and nanoparticle compositions for delivering polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024102762A1/en">
              <span itemprop="publicationNumber">WO2024102762A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-08</td>
          <td itemprop="publicationDate">2024-05-16</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticle compositions for delivering polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024119039A2/en">
              <span itemprop="publicationNumber">WO2024119039A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-01</td>
          <td itemprop="publicationDate">2024-06-06</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Stealth lipid nanoparticles and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024119051A1/en">
              <span itemprop="publicationNumber">WO2024119051A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-01</td>
          <td itemprop="publicationDate">2024-06-06</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024119074A1/en">
              <span itemprop="publicationNumber">WO2024119074A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-01</td>
          <td itemprop="publicationDate">2024-06-06</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Stealth lipid nanoparticle compositions for cell targeting 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024119103A1/en">
              <span itemprop="publicationNumber">WO2024119103A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-01</td>
          <td itemprop="publicationDate">2024-06-06</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12090235B2/en">
              <span itemprop="publicationNumber">US12090235B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-20</td>
          <td itemprop="publicationDate">2024-09-17</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Preparation of lipid nanoparticles and methods of administration thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024192291A1/en">
              <span itemprop="publicationNumber">WO2024192291A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Delivery of gene editing systems and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024192277A2/en">
              <span itemprop="publicationNumber">WO2024192277A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024205657A2/en">
              <span itemprop="publicationNumber">WO2024205657A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-29</td>
          <td itemprop="publicationDate">2024-10-03</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticle compositions for delivering polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024233308A2/en">
              <span itemprop="publicationNumber">WO2024233308A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-05</td>
          <td itemprop="publicationDate">2024-11-14</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025007148A1/en">
              <span itemprop="publicationNumber">WO2025007148A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-30</td>
          <td itemprop="publicationDate">2025-01-02</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025049959A2/en">
              <span itemprop="publicationNumber">WO2025049959A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-01</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Gene editing systems, compositions, and methods for treatment of vexas syndrome 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025049690A1/en">
              <span itemprop="publicationNumber">WO2025049690A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-29</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular polyethylene glycol lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025052180A2/en">
              <span itemprop="publicationNumber">WO2025052180A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-07</td>
          <td itemprop="publicationDate">2025-03-13</td>
          <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025081042A1/en">
              <span itemprop="publicationNumber">WO2025081042A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-12</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Nickase-retron template-based precision editing system and methods of use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025101501A1/en">
              <span itemprop="publicationNumber">WO2025101501A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-07</td>
          <td itemprop="publicationDate">2025-05-15</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025109173A1/en">
              <span itemprop="publicationNumber">WO2025109173A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-22</td>
          <td itemprop="publicationDate">2025-05-30</td>
          <td><span itemprop="assigneeOriginal">Advantage Therapeutics, Inc.</span></td>
          <td itemprop="title">Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/EP4566618A1/en">
              <span itemprop="publicationNumber">EP4566618A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-06</td>
          <td itemprop="publicationDate">2025-06-11</td>
          <td><span itemprop="assigneeOriginal">ADvantage Therapeutics, Inc.</span></td>
          <td itemprop="title">Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025128871A2/en">
              <span itemprop="publicationNumber">WO2025128871A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-13</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025144938A1/en">
              <span itemprop="publicationNumber">WO2025144938A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-26</td>
          <td itemprop="publicationDate">2025-07-03</td>
          <td><span itemprop="assigneeOriginal">Emmune, Inc.</span></td>
          <td itemprop="title">Systems for nucleic acid transfer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025155753A2/en">
              <span itemprop="publicationNumber">WO2025155753A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-17</td>
          <td itemprop="publicationDate">2025-07-24</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Improved gene editing system, guides, and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025166238A1/en">
              <span itemprop="publicationNumber">WO2025166238A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-31</td>
          <td itemprop="publicationDate">2025-08-07</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025174765A1/en">
              <span itemprop="publicationNumber">WO2025174765A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-02-12</td>
          <td itemprop="publicationDate">2025-08-21</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US12458604B2/en">
              <span itemprop="publicationNumber">US12458604B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-10-14</td>
          <td itemprop="publicationDate">2025-11-04</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Methods of lipid nanoparticle manufacture and compositions derived therefrom 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025250751A1/en">
              <span itemprop="publicationNumber">WO2025250751A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-31</td>
          <td itemprop="publicationDate">2025-12-04</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2026003582A2/en">
              <span itemprop="publicationNumber">WO2026003582A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-06-27</td>
          <td itemprop="publicationDate">2026-01-02</td>
          <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Families Citing this family (437)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2590626B1/en">
              <span itemprop="publicationNumber">EP2590626B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2015-10-28</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Liposomes with lipids having an advantageous pka-value for rna delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DK3243526T3/en">
              <span itemprop="publicationNumber">DK3243526T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2020-02-17</td>
          <td><span itemprop="assigneeOriginal">Glaxosmithkline Biologicals Sa</span></td>
          <td itemprop="title">
        SUPPLY OF RNA TO TRACT MULTIPLE IMMUNE SIGNAL WAYS
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5940064B2/en">
              <span itemprop="publicationNumber">JP5940064B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2016-06-29</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Immunization of large mammals with low doses of RNA
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4066857B1/en">
              <span itemprop="publicationNumber">EP4066857B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-31</td>
          <td itemprop="publicationDate">2022-12-21</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Pegylated liposomes for delivery of immunogen-encoding rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4098325A1/en">
              <span itemprop="publicationNumber">EP4098325A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-10-11</td>
          <td itemprop="publicationDate">2022-12-07</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals S.A.</span></td>
          <td itemprop="title">Antigen delivery platforms 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2729165B1/en">
              <span itemprop="publicationNumber">EP2729165B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2017-11-08</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Immunogenic combination compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9464124B2/en">
              <span itemprop="publicationNumber">US9464124B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-09-12</td>
          <td itemprop="publicationDate">2016-10-11</td>
          <td><span itemprop="assigneeOriginal">Moderna Therapeutics, Inc.</span></td>
          <td itemprop="title">Engineered nucleic acids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG11201602503TA/en">
              <span itemprop="publicationNumber">SG11201602503TA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-10-03</td>
          <td itemprop="publicationDate">2016-04-28</td>
          <td><span itemprop="assigneeOriginal">Moderna Therapeutics Inc</span></td>
          <td itemprop="title">Polynucleotides encoding low density lipoprotein receptor 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HUE057800T2/en">
              <span itemprop="publicationNumber">HUE057800T2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-04-23</td>
          <td itemprop="publicationDate">2022-06-28</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Nucleic acid vaccines
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3766916T1/en">
              <span itemprop="publicationNumber">SI3766916T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-06-25</td>
          <td itemprop="publicationDate">2023-01-31</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117164657A/en">
              <span itemprop="publicationNumber">CN117164657A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-08-12</td>
          <td itemprop="publicationDate">2023-12-05</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Prodrugs of directed lymphatics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3283059B1/en">
              <span itemprop="publicationNumber">EP3283059B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-04-13</td>
          <td itemprop="publicationDate">2024-01-03</td>
          <td><span itemprop="assigneeOriginal">CureVac Manufacturing GmbH</span></td>
          <td itemprop="title">Method for producing rna compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016176330A1/en">
              <span itemprop="publicationNumber">WO2016176330A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-04-27</td>
          <td itemprop="publicationDate">2016-11-03</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Nucleoside-modified rna for inducing an adaptive immune response 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DK3313829T3/en">
              <span itemprop="publicationNumber">DK3313829T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-06-29</td>
          <td itemprop="publicationDate">2024-06-17</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc</span></td>
          <td itemprop="title">
  Lipids and lipid nanoparticle formulations for delivery of nucleic acids
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11007260B2/en">
              <span itemprop="publicationNumber">US11007260B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-07-21</td>
          <td itemprop="publicationDate">2021-05-18</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Infectious disease vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11364292B2/en">
              <span itemprop="publicationNumber">US11364292B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-07-21</td>
          <td itemprop="publicationDate">2022-06-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">CHIKV RNA vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12150980B2/en">
              <span itemprop="publicationNumber">US12150980B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-07-30</td>
          <td itemprop="publicationDate">2024-11-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Concatemeric peptide epitope RNAs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017031232A1/en">
              <span itemprop="publicationNumber">WO2017031232A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-08-17</td>
          <td itemprop="publicationDate">2017-02-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods for preparing particles and related compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7118888B2/en">
              <span itemprop="publicationNumber">JP7118888B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-09-08</td>
          <td itemprop="publicationDate">2022-08-16</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        lymphotropic prodrug
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3350157B1/en">
              <span itemprop="publicationNumber">EP3350157B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="publicationDate">2022-01-05</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3364950A4/en">
              <span itemprop="publicationNumber">EP3364950A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2019-10-23</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">
        VACCINES AGAINST TROPICAL DISEASES
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TN2018000152A1/en">
              <span itemprop="publicationNumber">TN2018000152A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2019-10-04</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">Nucleic acid vaccines for varicella zoster virus (vzv) 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3003090A1/en">
              <span itemprop="publicationNumber">CA3003090A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2017-04-27</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Cancer vaccines 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2922760T3/en">
              <span itemprop="publicationNumber">ES2922760T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2022-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Respiratory virus vaccines
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2018531290A/en">
              <span itemprop="publicationNumber">JP2018531290A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2018-10-25</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Sexually transmitted disease vaccine
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3368507T1/en">
              <span itemprop="publicationNumber">SI3368507T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-10-28</td>
          <td itemprop="publicationDate">2023-04-28</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">
        Novel lipids and lipid nanoparticle formulations for nucleic acid delivery
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3386484T1/en">
              <span itemprop="publicationNumber">SI3386484T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-10</td>
          <td itemprop="publicationDate">2022-06-30</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7065036B2/en">
              <span itemprop="publicationNumber">JP7065036B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-17</td>
          <td itemprop="publicationDate">2022-05-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding methylmalonyl CoA mutase
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2913626T5/en">
              <span itemprop="publicationNumber">ES2913626T5</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-22</td>
          <td itemprop="publicationDate">2025-05-12</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10465190B1/en">
              <span itemprop="publicationNumber">US10465190B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-23</td>
          <td itemprop="publicationDate">2019-11-05</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">In vitro transcription methods and constructs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190298657A1/en">
              <span itemprop="publicationNumber">US20190298657A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2019-10-03</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017201333A1/en">
              <span itemprop="publicationNumber">WO2017201333A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2973443T3/en">
              <span itemprop="publicationNumber">ES2973443T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2024-06-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
  Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017266932B2/en">
              <span itemprop="publicationNumber">AU2017266932B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-04-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3458107B1/en">
              <span itemprop="publicationNumber">EP3458107B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2024-03-13</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding jagged1 for the treatment of alagille syndrome 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2019519601A/en">
              <span itemprop="publicationNumber">JP2019519601A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2019-07-11</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Polynucleotide encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7246930B2/en">
              <span itemprop="publicationNumber">JP7246930B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-03-28</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Polynucleotides encoding interleukin-12 (IL12) and uses thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017201347A1/en">
              <span itemprop="publicationNumber">WO2017201347A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115837014A/en">
              <span itemprop="publicationNumber">CN115837014A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-03-24</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding relaxin
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7210287B2/en">
              <span itemprop="publicationNumber">JP7210287B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-01-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotides encoding citrine for the treatment of type II citrullinemia
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HRP20211569T1/en">
              <span itemprop="publicationNumber">HRP20211569T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-06-07</td>
          <td itemprop="publicationDate">2022-01-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG11201901941YA/en">
              <span itemprop="publicationNumber">SG11201901941YA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-09-14</td>
          <td itemprop="publicationDate">2019-04-29</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">High purity rna compositions and methods for preparation thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017345766A1/en">
              <span itemprop="publicationNumber">AU2017345766A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-21</td>
          <td itemprop="publicationDate">2019-05-16</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Human cytomegalovirus vaccine 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2019004913A/en">
              <span itemprop="publicationNumber">MX2019004913A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-10-26</td>
          <td itemprop="publicationDate">2019-09-16</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Lipid nanoparticle mrna vaccines. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12491261B2/en">
              <span itemprop="publicationNumber">US12491261B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-26</td>
          <td itemprop="publicationDate">2025-12-09</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3538067A1/en">
              <span itemprop="publicationNumber">EP3538067A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="publicationDate">2019-09-18</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Stabilized formulations of lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA46766A/en">
              <span itemprop="publicationNumber">MA46766A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-11-11</td>
          <td itemprop="publicationDate">2019-09-18</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
  INFLUENZA VACCINE
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018107088A2/en">
              <span itemprop="publicationNumber">WO2018107088A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-12-08</td>
          <td itemprop="publicationDate">2018-06-14</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Respiratory virus nucleic acid vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3555289A1/en">
              <span itemprop="publicationNumber">EP3555289A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-12-13</td>
          <td itemprop="publicationDate">2019-10-23</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Rna affinity purification 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018115525A1/en">
              <span itemprop="publicationNumber">WO2018115525A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-12-23</td>
          <td itemprop="publicationDate">2018-06-28</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Lassa virus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7317715B2/en">
              <span itemprop="publicationNumber">JP7317715B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-01-11</td>
          <td itemprop="publicationDate">2023-07-31</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Nucleoside modified RNA for inducing immune response against Zika virus
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20190110612A/en">
              <span itemprop="publicationNumber">KR20190110612A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-02-01</td>
          <td itemprop="publicationDate">2019-09-30</td>
          <td><span itemprop="assigneeOriginal">, .</span></td>
          <td itemprop="title">
        Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3582790A4/en">
              <span itemprop="publicationNumber">EP3582790A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-02-16</td>
          <td itemprop="publicationDate">2020-11-25</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">High potency immunogenic compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3595727B1/en">
              <span itemprop="publicationNumber">EP3595727B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2024-11-27</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulation 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018170270A1/en">
              <span itemprop="publicationNumber">WO2018170270A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2018-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Varicella zoster virus (vzv) vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11576961B2/en">
              <span itemprop="publicationNumber">US11576961B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2023-02-14</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Broad spectrum influenza virus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018170256A1/en">
              <span itemprop="publicationNumber">WO2018170256A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2018-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Herpes simplex virus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7220154B2/en">
              <span itemprop="publicationNumber">JP7220154B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2023-02-09</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Crystalline forms of amino lipids
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL3596041T3/en">
              <span itemprop="publicationNumber">PL3596041T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2023-03-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compound and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3607074A4/en">
              <span itemprop="publicationNumber">EP3607074A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-04-05</td>
          <td itemprop="publicationDate">2021-07-07</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">
        REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS, E.G. SUBcutaneously ADMINISTERED THERAPEUTIC PROTEINS
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018191657A1/en">
              <span itemprop="publicationNumber">WO2018191657A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-04-13</td>
          <td itemprop="publicationDate">2018-10-18</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for delivery of active agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018200737A1/en">
              <span itemprop="publicationNumber">WO2018200737A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-04-26</td>
          <td itemprop="publicationDate">2018-11-01</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Herpes simplex virus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7464954B2/en">
              <span itemprop="publicationNumber">JP7464954B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-04-27</td>
          <td itemprop="publicationDate">2024-04-10</td>
          <td><span itemprop="assigneeOriginal">      </span></td>
          <td itemprop="title">
        Nucleoside-modified mRNA-lipid nanoparticle-based vaccine against hepatitis C virus
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3615510B1/en">
              <span itemprop="publicationNumber">EP3615510B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-04-28</td>
          <td itemprop="publicationDate">2024-03-27</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11173190B2/en">
              <span itemprop="publicationNumber">US11173190B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-05-16</td>
          <td itemprop="publicationDate">2021-11-16</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11421011B2/en">
              <span itemprop="publicationNumber">US11421011B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-05-18</td>
          <td itemprop="publicationDate">2022-08-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018225871A1/en">
              <span itemprop="publicationNumber">WO2018225871A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-06-09</td>
          <td itemprop="publicationDate">2018-12-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Compound serving as cationic lipid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018232120A1/en">
              <span itemprop="publicationNumber">WO2018232120A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-14</td>
          <td itemprop="publicationDate">2018-12-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3638292A1/en">
              <span itemprop="publicationNumber">EP3638292A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-06-14</td>
          <td itemprop="publicationDate">2020-04-22</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding coagulation factor viii 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3641834B1/en">
              <span itemprop="publicationNumber">EP3641834B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-19</td>
          <td itemprop="publicationDate">2023-10-04</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Messenger rna therapy for the treatment of friedreich&#39;s ataxia 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3644977B1/en">
              <span itemprop="publicationNumber">EP3644977B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-30</td>
          <td itemprop="publicationDate">2025-02-26</td>
          <td><span itemprop="assigneeOriginal">Industrial Technology Research Institute</span></td>
          <td itemprop="title">Sobrerol and related compounds for use in a method for treating an autoimmune neurological disease and pharmaceutical formulations for a liquid dosage form and a controlled release dosage form 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3662913A4/en">
              <span itemprop="publicationNumber">EP3662913A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-08-04</td>
          <td itemprop="publicationDate">2021-06-30</td>
          <td><span itemprop="assigneeOriginal">Kyowa Kirin Co., Ltd.</span></td>
          <td itemprop="title">
        LIPID NANOPARTICLES CONTAINING NUCLEIC ACID
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11639329B2/en">
              <span itemprop="publicationNumber">US11639329B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-16</td>
          <td itemprop="publicationDate">2023-05-02</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2997124T3/en">
              <span itemprop="publicationNumber">ES2997124T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-17</td>
          <td itemprop="publicationDate">2025-02-14</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019036030A1/en">
              <span itemprop="publicationNumber">WO2019036030A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-17</td>
          <td itemprop="publicationDate">2019-02-21</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019036028A1/en">
              <span itemprop="publicationNumber">WO2019036028A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-17</td>
          <td itemprop="publicationDate">2019-02-21</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019036683A1/en">
              <span itemprop="publicationNumber">WO2019036683A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-18</td>
          <td itemprop="publicationDate">2019-02-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Analytical hplc methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019036685A1/en">
              <span itemprop="publicationNumber">WO2019036685A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-18</td>
          <td itemprop="publicationDate">2019-02-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods for hplc analysis 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN111212905A/en">
              <span itemprop="publicationNumber">CN111212905A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-18</td>
          <td itemprop="publicationDate">2020-05-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">RNA polymerase variants 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20200254086A1/en">
              <span itemprop="publicationNumber">US20200254086A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-18</td>
          <td itemprop="publicationDate">2020-08-13</td>
          <td><span itemprop="assigneeOriginal">Moderna TX, Inc.</span></td>
          <td itemprop="title">Efficacious mrna vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2018324037A1/en">
              <span itemprop="publicationNumber">AU2018324037A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-29</td>
          <td itemprop="publicationDate">2020-04-16</td>
          <td><span itemprop="assigneeOriginal">Monash University</span></td>
          <td itemprop="title">Lymphatic system-directing lipid prodrugs 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11883497B2/en">
              <span itemprop="publicationNumber">US11883497B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-29</td>
          <td itemprop="publicationDate">2024-01-30</td>
          <td><span itemprop="assigneeOriginal">Puretech Lyt, Inc.</span></td>
          <td itemprop="title">Lymphatic system-directing lipid prodrugs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3681514A4/en">
              <span itemprop="publicationNumber">EP3681514A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-09-14</td>
          <td itemprop="publicationDate">2021-07-14</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Zika virus rna vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA50522B1/en">
              <span itemprop="publicationNumber">MA50522B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-10-31</td>
          <td itemprop="publicationDate">2022-09-30</td>
          <td><span itemprop="assigneeOriginal">Astrazeneca Ab 151 85 Soedertaelje</span></td>
          <td itemprop="title">
  Lipid nanoparticles for delivery of a modified rna encoding a vegf-a polypeptide
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7423522B2/en">
              <span itemprop="publicationNumber">JP7423522B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-11-22</td>
          <td itemprop="publicationDate">2024-01-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding ornithine transcarbamylase for the treatment of urea cycle disorders
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7424976B2/en">
              <span itemprop="publicationNumber">JP7424976B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2017-11-22</td>
          <td itemprop="publicationDate">2024-01-30</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding propionyl-CoA carboxylase alpha and beta subunits for the treatment of propionic acidemia
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA50801A/en">
              <span itemprop="publicationNumber">MA50801A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-11-22</td>
          <td itemprop="publicationDate">2020-09-30</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
  POLYNUCLEOTIDES CODING FOR PHENYLALANINE HYDROXYLASE FOR THE TREATMENT OF PHENYLKETONURIS
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2018392716B2/en">
              <span itemprop="publicationNumber">AU2018392716B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-12-20</td>
          <td itemprop="publicationDate">2025-03-13</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved composition and methods for treatment of ornithine transcarbamylase deficiency 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3735270A1/en">
              <span itemprop="publicationNumber">EP3735270A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-01-05</td>
          <td itemprop="publicationDate">2020-11-11</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding anti-chikungunya virus antibodies 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA54676A/en">
              <span itemprop="publicationNumber">MA54676A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-01-29</td>
          <td itemprop="publicationDate">2021-11-17</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        RSV RNA VACCINES
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019147749A2/en">
              <span itemprop="publicationNumber">WO2019147749A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-01-29</td>
          <td itemprop="publicationDate">2019-08-01</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Stabilized rsv f proteins and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019152557A1/en">
              <span itemprop="publicationNumber">WO2019152557A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-01-30</td>
          <td itemprop="publicationDate">2019-08-08</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivery of agents to immune cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3094057C/en">
              <span itemprop="publicationNumber">CA3094057C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-03-27</td>
          <td itemprop="publicationDate">2025-04-08</td>
          <td><span itemprop="assigneeOriginal">Nof Corporation</span></td>
          <td itemprop="title">Cationic lipid exhibiting improved intracellular dynamics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019204451A1/en">
              <span itemprop="publicationNumber">WO2019204451A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-04-17</td>
          <td itemprop="publicationDate">2019-10-24</td>
          <td><span itemprop="assigneeOriginal">Carnegie Mellon University</span></td>
          <td itemprop="title">Enhanced lipid nanoparticle drug delivery using a negatively charged polymer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3097912A1/en">
              <span itemprop="publicationNumber">CA3097912A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-15</td>
          <td itemprop="publicationDate">2019-11-21</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Subcutaneous delivery of messenger rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019226650A1/en">
              <span itemprop="publicationNumber">WO2019226650A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-05-23</td>
          <td itemprop="publicationDate">2019-11-28</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Delivery of dna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN112437767B/en">
              <span itemprop="publicationNumber">CN112437767B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-24</td>
          <td itemprop="publicationDate">2023-10-27</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        thioester cationic lipids
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4442831A3/en">
              <span itemprop="publicationNumber">EP4442831A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-30</td>
          <td itemprop="publicationDate">2024-10-30</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Cationic lipids comprising a steroidal moiety 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3101454A1/en">
              <span itemprop="publicationNumber">CA3101454A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-30</td>
          <td itemprop="publicationDate">2019-12-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Messenger rna vaccines and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12240824B2/en">
              <span itemprop="publicationNumber">US12240824B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-30</td>
          <td itemprop="publicationDate">2025-03-04</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Vitamin cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN112672761A/en">
              <span itemprop="publicationNumber">CN112672761A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-05-30</td>
          <td itemprop="publicationDate">2021-04-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Phosphate cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019236673A1/en">
              <span itemprop="publicationNumber">WO2019236673A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-06-06</td>
          <td itemprop="publicationDate">2019-12-12</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Circular rna for translation in eukaryotic cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN120514877A/en">
              <span itemprop="publicationNumber">CN120514877A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-07-23</td>
          <td itemprop="publicationDate">2025-08-22</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Messenger RNA dry powder formulation
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3108920A1/en">
              <span itemprop="publicationNumber">CA3108920A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-08-29</td>
          <td itemprop="publicationDate">2020-03-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved process of preparing mrna-loaded lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3846776A1/en">
              <span itemprop="publicationNumber">EP3846776A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-09-02</td>
          <td itemprop="publicationDate">2021-07-14</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3849617A1/en">
              <span itemprop="publicationNumber">EP3849617A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-14</td>
          <td itemprop="publicationDate">2021-07-21</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Composition and methods for treatment of methylmalonic acidemia 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MA53615A/en">
              <span itemprop="publicationNumber">MA53615A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-09-14</td>
          <td itemprop="publicationDate">2021-07-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
  POLYNUCLEOTIDES ENCODED FOR POLYPEPTIDE A1, OF THE URIDINE DIPHOSPHATE GLYCOSYLTRANSFERASE 1 FAMILY, FOR THE TREATMENT OF CRIGLER-NAJJAR SYNDROME
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN112996854B/en">
              <span itemprop="publicationNumber">CN112996854B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-19</td>
          <td itemprop="publicationDate">2024-08-30</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        High-purity PEG lipids and their uses
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020061284A1/en">
              <span itemprop="publicationNumber">WO2020061284A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-19</td>
          <td itemprop="publicationDate">2020-03-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Peg lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3113436A1/en">
              <span itemprop="publicationNumber">CA3113436A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-09-19</td>
          <td itemprop="publicationDate">2020-03-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL322436A/en">
              <span itemprop="publicationNumber">IL322436A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-21</td>
          <td itemprop="publicationDate">2025-09-01</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc</span></td>
          <td itemprop="title">Systems and methods for manufacturing lipid nanoparticles and liposomes 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118307422A/en">
              <span itemprop="publicationNumber">CN118307422A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-10-01</td>
          <td itemprop="publicationDate">2024-07-09</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Biodegradable lipids for delivery of active agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20210093871A/en">
              <span itemprop="publicationNumber">KR20210093871A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-02</td>
          <td itemprop="publicationDate">2021-07-28</td>
          <td><span itemprop="assigneeOriginal"> , .</span></td>
          <td itemprop="title">
        Ionizable amine lipids
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119320803A/en">
              <span itemprop="publicationNumber">CN119320803A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-09</td>
          <td itemprop="publicationDate">2025-01-17</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Compositions and systems comprising transfection-active vesicles devoid of organic solvents and detergents and methods related thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020081933A1/en">
              <span itemprop="publicationNumber">WO2020081933A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-19</td>
          <td itemprop="publicationDate">2020-04-23</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Pumpless encapsulation of messenger rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20230071228A1/en">
              <span itemprop="publicationNumber">US20230071228A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2023-03-09</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">2,5-dioxopiperazine lipids with intercalated ester, thioester, disulfide and anhydride moieities 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3876994A2/en">
              <span itemprop="publicationNumber">EP3876994A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2021-09-15</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Peg lipidoid compounds 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3117866A1/en">
              <span itemprop="publicationNumber">CA3117866A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2020-05-14</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Multi-peg lipid compounds 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020097511A2/en">
              <span itemprop="publicationNumber">WO2020097511A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-09</td>
          <td itemprop="publicationDate">2020-05-14</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Messenger rna therapy for treatment of ocular diseases 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220096612A1/en">
              <span itemprop="publicationNumber">US20220096612A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-12</td>
          <td itemprop="publicationDate">2022-03-31</td>
          <td><span itemprop="assigneeOriginal">Translatebioinc</span></td>
          <td itemprop="title">Methods for inducing immune tolerance 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN109320479B/en">
              <span itemprop="publicationNumber">CN109320479B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-11-13</td>
          <td itemprop="publicationDate">2021-03-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A kind of simple synthetic method of ascorbic acid tetraisopalmitate
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3119976A1/en">
              <span itemprop="publicationNumber">CA3119976A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-11-21</td>
          <td itemprop="publicationDate">2020-05-28</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Cationic lipid compounds 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112021010853A2/en">
              <span itemprop="publicationNumber">BR112021010853A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-12-05</td>
          <td itemprop="publicationDate">2021-08-31</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">
        MODIFIED AMINE LIPIDS
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3908597A1/en">
              <span itemprop="publicationNumber">EP3908597A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-01-07</td>
          <td itemprop="publicationDate">2021-11-17</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Composition and methods for treatment of primary ciliary dyskinesia 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL284535B2/en">
              <span itemprop="publicationNumber">IL284535B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-01-11</td>
          <td itemprop="publicationDate">2025-03-01</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc</span></td>
          <td itemprop="title">Lipids for lipid nanoparticle delivery of active agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020160430A1/en">
              <span itemprop="publicationNumber">WO2020160430A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-01-31</td>
          <td itemprop="publicationDate">2020-08-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Vortex mixers and associated methods, systems, and apparatuses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220062175A1/en">
              <span itemprop="publicationNumber">US20220062175A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-01-31</td>
          <td itemprop="publicationDate">2022-03-03</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods of preparing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11351242B1/en">
              <span itemprop="publicationNumber">US11351242B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-02-12</td>
          <td itemprop="publicationDate">2022-06-07</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">HMPV/hPIV3 mRNA vaccine composition 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11851694B1/en">
              <span itemprop="publicationNumber">US11851694B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-02-20</td>
          <td itemprop="publicationDate">2023-12-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">High fidelity in vitro transcription 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020224103A1/en">
              <span itemprop="publicationNumber">AU2020224103A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-02-20</td>
          <td itemprop="publicationDate">2021-09-16</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Rna polymerase variants for co-transcriptional capping 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220088049A1/en">
              <span itemprop="publicationNumber">US20220088049A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-03-01</td>
          <td itemprop="publicationDate">2022-03-24</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Compositions, methods, and kits for delivery of polyribonucleotides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020239037A1/en">
              <span itemprop="publicationNumber">AU2020239037A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-03-11</td>
          <td itemprop="publicationDate">2021-09-30</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Fed-batch in vitro transcription process 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020190750A1/en">
              <span itemprop="publicationNumber">WO2020190750A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-03-15</td>
          <td itemprop="publicationDate">2020-09-24</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Hiv rna vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220177423A1/en">
              <span itemprop="publicationNumber">US20220177423A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-04-18</td>
          <td itemprop="publicationDate">2022-06-09</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Cystine cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3959195B1/en">
              <span itemprop="publicationNumber">EP3959195B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-04-22</td>
          <td itemprop="publicationDate">2023-11-08</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Thioester cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2021012934A/en">
              <span itemprop="publicationNumber">MX2021012934A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-04-25</td>
          <td itemprop="publicationDate">2022-04-06</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics Inc</span></td>
          <td itemprop="title">
        IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES.
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12453759B2/en">
              <span itemprop="publicationNumber">US12453759B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-05-03</td>
          <td itemprop="publicationDate">2025-10-28</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Di-thioester cationic lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020227690A1/en">
              <span itemprop="publicationNumber">WO2020227690A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-05-08</td>
          <td itemprop="publicationDate">2020-11-12</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020237227A1/en">
              <span itemprop="publicationNumber">WO2020237227A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-05-22</td>
          <td itemprop="publicationDate">2020-11-26</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Circular rna compositions and methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220226244A1/en">
              <span itemprop="publicationNumber">US20220226244A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-05-31</td>
          <td itemprop="publicationDate">2022-07-21</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Macrocyclic lipids 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3144457A1/en">
              <span itemprop="publicationNumber">CA3144457A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-06-21</td>
          <td itemprop="publicationDate">2020-12-24</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Tricine and citric acid lipids 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020257611A1/en">
              <span itemprop="publicationNumber">WO2020257611A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-06-21</td>
          <td itemprop="publicationDate">2020-12-24</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Cationic lipids comprising an hydroxy moiety 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2992127T3/en">
              <span itemprop="publicationNumber">ES2992127T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-07-08</td>
          <td itemprop="publicationDate">2024-12-09</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">
        Improved mRNA-loaded lipid nanoparticles and their manufacturing processes
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12144871B2/en">
              <span itemprop="publicationNumber">US12144871B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-07-23</td>
          <td itemprop="publicationDate">2024-11-19</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Stable compositions of MRNA-loaded lipid nanoparticles and processes of making 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020325221A1/en">
              <span itemprop="publicationNumber">AU2020325221A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-08-07</td>
          <td itemprop="publicationDate">2022-03-03</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions and methods for enhanced delivery of agents 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20230172858A1/en">
              <span itemprop="publicationNumber">US20230172858A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-08-30</td>
          <td itemprop="publicationDate">2023-06-08</td>
          <td><span itemprop="assigneeOriginal">Glaxosmithkline Biologicals Sa</span></td>
          <td itemprop="title">Jet mixing lipid nanoparticle manufacturing process 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3154720A1/en">
              <span itemprop="publicationNumber">CA3154720A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2021-03-25</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20220101077A/en">
              <span itemprop="publicationNumber">KR20220101077A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2022-07-19</td>
          <td><span itemprop="assigneeOriginal">, .</span></td>
          <td itemprop="title">
        Branched tail lipid compounds and compositions for intracellular delivery of therapeutics
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020351220A1/en">
              <span itemprop="publicationNumber">AU2020351220A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2022-04-07</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240197825A1/en">
              <span itemprop="publicationNumber">US20240197825A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-20</td>
          <td itemprop="publicationDate">2024-06-20</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">mRNA Encoding Engineered CFTR 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20210145860A1/en">
              <span itemprop="publicationNumber">US20210145860A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-10-21</td>
          <td itemprop="publicationDate">2021-05-20</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Compositions, methods and uses of messenger rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12378560B2/en">
              <span itemprop="publicationNumber">US12378560B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-10-29</td>
          <td itemprop="publicationDate">2025-08-05</td>
          <td><span itemprop="assigneeOriginal">Northwestern University</span></td>
          <td itemprop="title">Sequence multiplicity within spherical nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240122854A1/en">
              <span itemprop="publicationNumber">US20240122854A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2019-11-27</td>
          <td itemprop="publicationDate">2024-04-18</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4076393A2/en">
              <span itemprop="publicationNumber">EP4076393A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-12-20</td>
          <td itemprop="publicationDate">2022-10-26</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Rectal delivery of messenger rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2021127641A1/en">
              <span itemprop="publicationNumber">WO2021127641A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-12-20</td>
          <td itemprop="publicationDate">2021-06-24</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved process of preparing mrna-loaded lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2021141969A1/en">
              <span itemprop="publicationNumber">WO2021141969A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-01-09</td>
          <td itemprop="publicationDate">2021-07-15</td>
          <td><span itemprop="assigneeOriginal">Guide Therapeutics, Inc.</span></td>
          <td itemprop="title">Nanomaterials 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2021142245A1/en">
              <span itemprop="publicationNumber">WO2021142245A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-01-10</td>
          <td itemprop="publicationDate">2021-07-15</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL294866A/en">
              <span itemprop="publicationNumber">IL294866A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-01-31</td>
          <td itemprop="publicationDate">2022-09-01</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Methods for preparing fat nanoparticles
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11241493B2/en">
              <span itemprop="publicationNumber">US11241493B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-02-04</td>
          <td itemprop="publicationDate">2022-02-08</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12194089B2/en">
              <span itemprop="publicationNumber">US12194089B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-02-04</td>
          <td itemprop="publicationDate">2025-01-14</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20230346914A1/en">
              <span itemprop="publicationNumber">US20230346914A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-02-07</td>
          <td itemprop="publicationDate">2023-11-02</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Sars-cov-2 mrna domain vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20210259976A1/en">
              <span itemprop="publicationNumber">US20210259976A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-02-21</td>
          <td itemprop="publicationDate">2021-08-26</td>
          <td><span itemprop="assigneeOriginal">GIE Medical, Inc.</span></td>
          <td itemprop="title">Polymer-encapsulated drug particles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4110296A1/en">
              <span itemprop="publicationNumber">EP4110296A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-02-25</td>
          <td itemprop="publicationDate">2023-01-04</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved processes of preparing mrna-loaded lipid nanoparticles 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN111349014A/en">
              <span itemprop="publicationNumber">CN111349014A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-03-30</td>
          <td itemprop="publicationDate">2020-06-30</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Preparation method of methyl squarate 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12194157B2/en">
              <span itemprop="publicationNumber">US12194157B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2025-01-14</td>
          <td><span itemprop="assigneeOriginal">Finncure Oy</span></td>
          <td itemprop="title">Carrier for targeted delivery to a host 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113874507A/en">
              <span itemprop="publicationNumber">CN113874507A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2021-12-31</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Nucleic acid vaccine for coronavirus
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114206827B/en">
              <span itemprop="publicationNumber">CN114206827B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2023-05-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/FI20215508A1/en">
              <span itemprop="publicationNumber">FI20215508A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2021-10-10</td>
          <td><span itemprop="assigneeOriginal">Niemelae Erik Johan</span></td>
          <td itemprop="title">
        Mimetic nanoparticles to prevent the spread and to reduce the infection rate of new coronaviruses
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115811986A/en">
              <span itemprop="publicationNumber">CN115811986A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-22</td>
          <td itemprop="publicationDate">2023-03-17</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        coronavirus vaccine
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4146342A1/en">
              <span itemprop="publicationNumber">EP4146342A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-07</td>
          <td itemprop="publicationDate">2023-03-15</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Improved compositions for cftr mrna therapy 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4146680A1/en">
              <span itemprop="publicationNumber">EP4146680A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-07</td>
          <td itemprop="publicationDate">2023-03-15</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Composition and methods for treatment of primary ciliary dyskinesia 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2023524767A/en">
              <span itemprop="publicationNumber">JP2023524767A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-07</td>
          <td itemprop="publicationDate">2023-06-13</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Optimized Nucleotide Sequences Encoding SARS-CoV-2 Antigens
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20230226096A1/en">
              <span itemprop="publicationNumber">US20230226096A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-05-08</td>
          <td itemprop="publicationDate">2023-07-20</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular rna compositions and methods 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4149556B1/en">
              <span itemprop="publicationNumber">EP4149556B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-14</td>
          <td itemprop="publicationDate">2026-01-07</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Peg lipidoid compounds 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3183399A1/en">
              <span itemprop="publicationNumber">CA3183399A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-15</td>
          <td itemprop="publicationDate">2021-11-18</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations for mrna delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4153224A1/en">
              <span itemprop="publicationNumber">EP4153224A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-20</td>
          <td itemprop="publicationDate">2023-03-29</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations VI, LLC</span></td>
          <td itemprop="title">Coronavirus antigen compositions and their uses 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2021236930A1/en">
              <span itemprop="publicationNumber">WO2021236930A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-20</td>
          <td itemprop="publicationDate">2021-11-25</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Immunogenic compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL298539A/en">
              <span itemprop="publicationNumber">IL298539A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-29</td>
          <td itemprop="publicationDate">2023-01-01</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi Llc</span></td>
          <td itemprop="title">
        trem compositions and methods related thereto
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4158032A2/en">
              <span itemprop="publicationNumber">EP4158032A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-05-29</td>
          <td itemprop="publicationDate">2023-04-05</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations VI, LLC</span></td>
          <td itemprop="title">Trem compositions and methods relating thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220331414A1/en">
              <span itemprop="publicationNumber">US20220331414A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-06-30</td>
          <td itemprop="publicationDate">2022-10-20</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Lipid compounds and lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240307556A1/en">
              <span itemprop="publicationNumber">US20240307556A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-07-02</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Maritime Therapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for reverse gene therapy 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7798855B2/en">
              <span itemprop="publicationNumber">JP7798855B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-07-16</td>
          <td itemprop="publicationDate">2026-01-14</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Cationic lipids for use in lipid nanoparticles - Patent Application 20070122999
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4181948A4/en">
              <span itemprop="publicationNumber">EP4181948A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-07-17</td>
          <td itemprop="publicationDate">2024-12-04</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
          <td itemprop="title">
        METHOD FOR ENCAPSULATING POLYNUCLEOTIDES IN REDUCED SIZES OF LIPID DNANOPARTICLES AND NOVEL FORMULATION THEREOF
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BR112023001648A2/en">
              <span itemprop="publicationNumber">BR112023001648A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-07-27</td>
          <td itemprop="publicationDate">2023-04-04</td>
          <td><span itemprop="assigneeOriginal">Anjarium Biosciences Ag</span></td>
          <td itemprop="title">
  DOUBLE-STRAINED DNA MOLECULES, DELIVERY VEHICLE AND METHOD FOR PREPARING A CLAMP-ENDED DNA MOLECULE
 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL300404A/en">
              <span itemprop="publicationNumber">IL300404A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-08-06</td>
          <td itemprop="publicationDate">2023-04-01</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">Methods of preparing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116322747A/en">
              <span itemprop="publicationNumber">CN116322747A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-08-18</td>
          <td itemprop="publicationDate">2023-06-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Bioinspired lipid derivatives and uses thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12419948B2/en">
              <span itemprop="publicationNumber">US12419948B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-08-31</td>
          <td itemprop="publicationDate">2025-09-23</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Immunogenic compositions and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022051629A1/en">
              <span itemprop="publicationNumber">WO2022051629A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-09-03</td>
          <td itemprop="publicationDate">2022-03-10</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Immunogenic compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4213882A4/en">
              <span itemprop="publicationNumber">EP4213882A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-09-15</td>
          <td itemprop="publicationDate">2025-02-26</td>
          <td><span itemprop="assigneeOriginal">Verve Therapeutics, Inc.</span></td>
          <td itemprop="title">
        TAL EFFECTOR NUCLEASES FOR GENE EDITING
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2023544197A/en">
              <span itemprop="publicationNumber">JP2023544197A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-10-06</td>
          <td itemprop="publicationDate">2023-10-20</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Improved methods and formulations of lipid nanoparticles
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220133631A1/en">
              <span itemprop="publicationNumber">US20220133631A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-10-12</td>
          <td itemprop="publicationDate">2022-05-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Process of preparing ice-based lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2023004147A/en">
              <span itemprop="publicationNumber">MX2023004147A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-10-12</td>
          <td itemprop="publicationDate">2023-10-04</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">Improved process of preparing mrna-loaded lipid nanoparticles. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220160633A1/en">
              <span itemprop="publicationNumber">US20220160633A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-11-09</td>
          <td itemprop="publicationDate">2022-05-26</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Compositions for delivery of codon-optimized mrna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022115547A1/en">
              <span itemprop="publicationNumber">WO2022115547A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-11-25</td>
          <td itemprop="publicationDate">2022-06-02</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Stable liquid lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MY207980A/en">
              <span itemprop="publicationNumber">MY207980A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-11-27</td>
          <td itemprop="publicationDate">2025-03-31</td>
          <td><span itemprop="assigneeOriginal">Guangzhou Ribobio Co Ltd</span></td>
          <td itemprop="title">Lipid compound and the composition thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113185421B/en">
              <span itemprop="publicationNumber">CN113185421B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-11-27</td>
          <td itemprop="publicationDate">2022-01-25</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid compounds and compositions thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3133528A1/en">
              <span itemprop="publicationNumber">CA3133528A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-11-27</td>
          <td itemprop="publicationDate">2022-05-27</td>
          <td><span itemprop="assigneeOriginal">Guangzhou Ribobio Co., Ltd</span></td>
          <td itemprop="title">Lipid compound and the comosition thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022112855A1/en">
              <span itemprop="publicationNumber">WO2022112855A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-11-27</td>
          <td itemprop="publicationDate">2022-06-02</td>
          <td><span itemprop="assigneeOriginal">Guangzhou Ribobio Co., Ltd</span></td>
          <td itemprop="title">Lipid compound and the composition thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022110099A1/en">
              <span itemprop="publicationNumber">WO2022110099A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-11-30</td>
          <td itemprop="publicationDate">2022-06-02</td>
          <td><span itemprop="assigneeOriginal">Guangzhou Argorna Biopharmaceuticals Co., Ltd.</span></td>
          <td itemprop="title">Coronavirus vaccines and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4262819A4/en">
              <span itemprop="publicationNumber">EP4262819A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-12-21</td>
          <td itemprop="publicationDate">2024-12-04</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials comprising ester-linked acetals 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2023007574A/en">
              <span itemprop="publicationNumber">MX2023007574A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-12-22</td>
          <td itemprop="publicationDate">2023-09-29</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Rna vaccine against sars-cov-2 variants. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2023007630A/en">
              <span itemprop="publicationNumber">MX2023007630A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-12-23</td>
          <td itemprop="publicationDate">2023-08-25</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi Llc</span></td>
          <td itemprop="title">Compositions of modified trems and uses thereof. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022150717A1/en">
              <span itemprop="publicationNumber">WO2022150717A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-11</td>
          <td itemprop="publicationDate">2022-07-14</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Seasonal rna influenza virus vaccines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2022207550C1/en">
              <span itemprop="publicationNumber">AU2022207550C1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-01-14</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Lipid compounds and lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024504614A/en">
              <span itemprop="publicationNumber">JP2024504614A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-14</td>
          <td itemprop="publicationDate">2024-02-01</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Methods and compositions for delivering mRNA-encoded antibodies
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL303845A/en">
              <span itemprop="publicationNumber">IL303845A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-20</td>
          <td itemprop="publicationDate">2023-08-01</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc</span></td>
          <td itemprop="title">Nanomaterials comprising a biodegradable feature 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024502954A/en">
              <span itemprop="publicationNumber">JP2024502954A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-20</td>
          <td itemprop="publicationDate">2024-01-24</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        nano material
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117157049A/en">
              <span itemprop="publicationNumber">CN117157049A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-01-24</td>
          <td itemprop="publicationDate">2023-12-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">ATP synthase inhibitor-cosmetic and therapeutic use 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117157101A/en">
              <span itemprop="publicationNumber">CN117157101A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-02-08</td>
          <td itemprop="publicationDate">2023-12-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Unsaturated dendrimer compositions, related formulations, and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115427432A/en">
              <span itemprop="publicationNumber">CN115427432A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-02-10</td>
          <td itemprop="publicationDate">2022-12-02</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Vaccine agent for treating or preventing coronavirus disease mutant strain 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024506908A/en">
              <span itemprop="publicationNumber">JP2024506908A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-02-12</td>
          <td itemprop="publicationDate">2024-02-15</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        LNP compositions containing payloads for in vivo therapy
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11524023B2/en">
              <span itemprop="publicationNumber">US11524023B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-02-19</td>
          <td itemprop="publicationDate">2022-12-13</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions and methods of formulating the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2023011243A/en">
              <span itemprop="publicationNumber">MX2023011243A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-03-23</td>
          <td itemprop="publicationDate">2023-12-14</td>
          <td><span itemprop="assigneeOriginal">Recode Therapeutics Inc</span></td>
          <td itemprop="title">
        COMPOSITIONS OF POLINUCLEOTIDES, RELATED FORMULATIONS AND METHODS OF USE THEREOF.
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250268994A1/en">
              <span itemprop="publicationNumber">US20250268994A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-03-25</td>
          <td itemprop="publicationDate">2025-08-28</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Optimized Nucleotide Sequences Encoding the Extracellular Domain of Human ACE2 Protein or a Portion Thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20230165276A/en">
              <span itemprop="publicationNumber">KR20230165276A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-03-31</td>
          <td itemprop="publicationDate">2023-12-05</td>
          <td><span itemprop="assigneeOriginal">   , .</span></td>
          <td itemprop="title">
        Thanotransmission polypeptides and their use in the treatment of cancer
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CR20230535A/en">
              <span itemprop="publicationNumber">CR20230535A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-17</td>
          <td itemprop="publicationDate">2024-02-16</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics Inc</span></td>
          <td itemprop="title">
        DNA-DEPENDENT PROTEIN KINASE INHIBITORS AND COMPOSITIONS AND USES OF THESE
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202308597A/en">
              <span itemprop="publicationNumber">TW202308597A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-17</td>
          <td itemprop="publicationDate">2023-03-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticle compositions 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20240017793A/en">
              <span itemprop="publicationNumber">KR20240017793A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-17</td>
          <td itemprop="publicationDate">2024-02-08</td>
          <td><span itemprop="assigneeOriginal"> , .</span></td>
          <td itemprop="title">
        Lipid Nanoparticle Composition
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024515668A/en">
              <span itemprop="publicationNumber">JP2024515668A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-19</td>
          <td itemprop="publicationDate">2024-04-10</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Improved compositions for delivery of mRNA
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4326860A1/en">
              <span itemprop="publicationNumber">EP4326860A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-04-20</td>
          <td itemprop="publicationDate">2024-02-28</td>
          <td><span itemprop="assigneeOriginal">Anjarium Biosciences AG</span></td>
          <td itemprop="title">Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115515927A/en">
              <span itemprop="publicationNumber">CN115515927A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-05-06</td>
          <td itemprop="publicationDate">2022-12-23</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Lipid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240277616A1/en">
              <span itemprop="publicationNumber">US20240277616A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-05-07</td>
          <td itemprop="publicationDate">2024-08-22</td>
          <td><span itemprop="assigneeOriginal">Carnegie Mellon University</span></td>
          <td itemprop="title">Lipid Nanoparticle-Mediated mRNA Delivery to the Pancreas 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2022234003A1/en">
              <span itemprop="publicationNumber">WO2022234003A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-05-07</td>
          <td itemprop="publicationDate">2022-11-10</td>
          <td><span itemprop="assigneeOriginal">Avacta Life Sciences Limited</span></td>
          <td itemprop="title">Cd33 binding polypeptides with stefin a protein 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220363937A1/en">
              <span itemprop="publicationNumber">US20220363937A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-05-14</td>
          <td itemprop="publicationDate">2022-11-17</td>
          <td><span itemprop="assigneeOriginal">Armstrong World Industries, Inc.</span></td>
          <td itemprop="title">Stabilization of antimicrobial coatings 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113387825A/en">
              <span itemprop="publicationNumber">CN113387825A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-06-10</td>
          <td itemprop="publicationDate">2021-09-14</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Long-chain alkyl ester amine compound or fluorine-containing long-chain alkyl ester amine compound and kilogram-level preparation method thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL309145A/en">
              <span itemprop="publicationNumber">IL309145A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-06-14</td>
          <td itemprop="publicationDate">2024-02-01</td>
          <td><span itemprop="assigneeOriginal">Generation Bio Co</span></td>
          <td itemprop="title">Cationic lipids and compositions thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023278754A1/en">
              <span itemprop="publicationNumber">WO2023278754A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-07-01</td>
          <td itemprop="publicationDate">2023-01-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Compositions for delivery of mrna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115611757A/en">
              <span itemprop="publicationNumber">CN115611757A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-16</td>
          <td itemprop="publicationDate">2023-01-17</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Synthesis of mRNA delivery Agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12251471B2/en">
              <span itemprop="publicationNumber">US12251471B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-26</td>
          <td itemprop="publicationDate">2025-03-18</td>
          <td><span itemprop="assigneeOriginal">Oregon State University</span></td>
          <td itemprop="title">Inhalable therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023009547A1/en">
              <span itemprop="publicationNumber">WO2023009547A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-07-26</td>
          <td itemprop="publicationDate">2023-02-02</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Trem compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024530672A/en">
              <span itemprop="publicationNumber">JP2024530672A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-11</td>
          <td itemprop="publicationDate">2024-08-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Compositions and methods for mRNA vaccines against novel coronavirus infections
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115703713B/en">
              <span itemprop="publicationNumber">CN115703713B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-13</td>
          <td itemprop="publicationDate">2025-06-10</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Cationic lipid compounds
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115703714B/en">
              <span itemprop="publicationNumber">CN115703714B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-08-13</td>
          <td itemprop="publicationDate">2025-06-10</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Cationic lipid compounds
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4395748A1/en">
              <span itemprop="publicationNumber">EP4395748A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-03</td>
          <td itemprop="publicationDate">2024-07-10</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Novel lipid nanoparticles for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024534428A/en">
              <span itemprop="publicationNumber">JP2024534428A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-17</td>
          <td itemprop="publicationDate">2024-09-20</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">
        Compositions and methods for producing circular polyribonucleotides
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250017867A1/en">
              <span itemprop="publicationNumber">US20250017867A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-10-01</td>
          <td itemprop="publicationDate">2025-01-16</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250243277A1/en">
              <span itemprop="publicationNumber">US20250243277A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-07</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">Avacta Life Sciences Limited</span></td>
          <td itemprop="title">Pd-l1 binding affimers 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240409638A1/en">
              <span itemprop="publicationNumber">US20240409638A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-07</td>
          <td itemprop="publicationDate">2024-12-12</td>
          <td><span itemprop="assigneeOriginal">Avacta Life Sciences Limited</span></td>
          <td itemprop="title">Serum half-life extended pd-l1 binding polypeptides 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240252650A1/en">
              <span itemprop="publicationNumber">US20240252650A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-10-08</td>
          <td itemprop="publicationDate">2024-08-01</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Lipid compounds and lipid nanoparticle compositions 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AR127312A1/en">
              <span itemprop="publicationNumber">AR127312A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-08</td>
          <td itemprop="publicationDate">2024-01-10</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co Ltd</span></td>
          <td itemprop="title">
        LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250281583A1/en">
              <span itemprop="publicationNumber">US20250281583A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-13</td>
          <td itemprop="publicationDate">2025-09-11</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Composition of mrna-encoded il15 fusion proteins and methods of use thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2024004618A/en">
              <span itemprop="publicationNumber">MX2024004618A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-18</td>
          <td itemprop="publicationDate">2024-07-12</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi Llc</span></td>
          <td itemprop="title">Compositions and methods for purifying polyribonucleotides. 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250295755A1/en">
              <span itemprop="publicationNumber">US20250295755A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-22</td>
          <td itemprop="publicationDate">2025-09-25</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Mrna vaccine composition 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4422698A1/en">
              <span itemprop="publicationNumber">EP4422698A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-10-29</td>
          <td itemprop="publicationDate">2024-09-04</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Improved circular rna for expressing therapeutic proteins 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4426829A1/en">
              <span itemprop="publicationNumber">EP4426829A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-01</td>
          <td itemprop="publicationDate">2024-09-11</td>
          <td><span itemprop="assigneeOriginal">Dana-Farber Cancer Institute, Inc.</span></td>
          <td itemprop="title">Biologically selected nucleic acid artificial mini-proteome libraries 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023086893A1/en">
              <span itemprop="publicationNumber">WO2023086893A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-10</td>
          <td itemprop="publicationDate">2023-05-19</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Composition and methods for treatment of primary ciliary dyskinesia 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118488834A/en">
              <span itemprop="publicationNumber">CN118488834A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-23</td>
          <td itemprop="publicationDate">2024-08-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Bacteria-derived lipid compositions and uses thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4436983A1/en">
              <span itemprop="publicationNumber">EP4436983A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-24</td>
          <td itemprop="publicationDate">2024-10-02</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations VI, LLC</span></td>
          <td itemprop="title">Varicella-zoster virus immunogen compositions and their uses 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118900845A/en">
              <span itemprop="publicationNumber">CN118900845A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-24</td>
          <td itemprop="publicationDate">2024-11-05</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Coronavirus immunogen composition and its use
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024541465A/en">
              <span itemprop="publicationNumber">JP2024541465A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-24</td>
          <td itemprop="publicationDate">2024-11-08</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">
        Immunogenic compositions and uses thereof
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12186387B2/en">
              <span itemprop="publicationNumber">US12186387B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-11-29</td>
          <td itemprop="publicationDate">2025-01-07</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AR127892A1/en">
              <span itemprop="publicationNumber">AR127892A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-10</td>
          <td itemprop="publicationDate">2024-03-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023114943A2/en">
              <span itemprop="publicationNumber">WO2023114943A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-16</td>
          <td itemprop="publicationDate">2023-06-22</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023114889A1/en">
              <span itemprop="publicationNumber">WO2023114889A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-16</td>
          <td itemprop="publicationDate">2023-06-22</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Processes for preparing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118510896A/en">
              <span itemprop="publicationNumber">CN118510896A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-17</td>
          <td itemprop="publicationDate">2024-08-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Method for enriching circular RNA under denaturing conditions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4452942A1/en">
              <span itemprop="publicationNumber">EP4452942A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2024-10-30</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials comprising disulfides 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023122080A1/en">
              <span itemprop="publicationNumber">WO2023122080A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Senda Biosciences, Inc.</span></td>
          <td itemprop="title">Compositions comprising mrna and lipid reconstructed plant messenger packs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023121975A1/en">
              <span itemprop="publicationNumber">WO2023121975A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Ionizable amine lipids and lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023121970A1/en">
              <span itemprop="publicationNumber">WO2023121970A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2023-06-29</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Ionizable amine and ester lipids and lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025500824A/en">
              <span itemprop="publicationNumber">JP2025500824A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2025-01-15</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Nanomaterials containing tetravalent lipid compounds
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4452925A1/en">
              <span itemprop="publicationNumber">EP4452925A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-20</td>
          <td itemprop="publicationDate">2024-10-30</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterial comprising diamines 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20240117149A/en">
              <span itemprop="publicationNumber">KR20240117149A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-22</td>
          <td itemprop="publicationDate">2024-07-31</td>
          <td><span itemprop="assigneeOriginal">   , </span></td>
          <td itemprop="title">
        Compositions and methods for purifying polyribonucleotides
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2022420620A1/en">
              <span itemprop="publicationNumber">AU2022420620A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-23</td>
          <td itemprop="publicationDate">2024-07-04</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Circular polyribonucleotides encoding antifusogenic polypeptides 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250064750A1/en">
              <span itemprop="publicationNumber">US20250064750A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-29</td>
          <td itemprop="publicationDate">2025-02-27</td>
          <td><span itemprop="assigneeOriginal">Jiangsu Hengrui Pharmaceuticals Co., Ltd.</span></td>
          <td itemprop="title">Lipid and composition used for delivery 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114957027B/en">
              <span itemprop="publicationNumber">CN114957027B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-13</td>
          <td itemprop="publicationDate">2023-05-19</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A kind of cationic lipid compound, its composition and application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4463475A2/en">
              <span itemprop="publicationNumber">EP4463475A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-14</td>
          <td itemprop="publicationDate">2024-11-20</td>
          <td><span itemprop="assigneeOriginal">Anjarium Biosciences AG</span></td>
          <td itemprop="title">Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4457207A4/en">
              <span itemprop="publicationNumber">EP4457207A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-19</td>
          <td itemprop="publicationDate">2025-12-31</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co Ltd</span></td>
          <td itemprop="title">
        Lipid compounds and lipid nanoparticle compositions
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023144330A1/en">
              <span itemprop="publicationNumber">WO2023144330A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-01-28</td>
          <td itemprop="publicationDate">2023-08-03</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Nucleic acid encoded transcription factor inhibitors 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES3017428T3/en">
              <span itemprop="publicationNumber">ES3017428T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-31</td>
          <td itemprop="publicationDate">2025-05-12</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Ionizable cationic lipids for lipid nanoparticles 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023154818A1/en">
              <span itemprop="publicationNumber">WO2023154818A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-02-09</td>
          <td itemprop="publicationDate">2023-08-17</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Mucosal administration methods and formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023156487A1/en">
              <span itemprop="publicationNumber">WO2023156487A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-02-15</td>
          <td itemprop="publicationDate">2023-08-24</td>
          <td><span itemprop="assigneeOriginal">INSERM (Institut National de la Sant et de la Recherche Mdicale)</span></td>
          <td itemprop="title">Methods and pharmaceutical compositions for modulating tear film composition to treat corneal defects 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114456081B/en">
              <span itemprop="publicationNumber">CN114456081B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-15</td>
          <td itemprop="publicationDate">2025-03-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Ionizable lipid and its preparation method and application
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4479085A1/en">
              <span itemprop="publicationNumber">EP4479085A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-18</td>
          <td itemprop="publicationDate">2024-12-25</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Mrnas encoding checkpoint cancer vaccines and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025508807A/en">
              <span itemprop="publicationNumber">JP2025508807A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-02-24</td>
          <td itemprop="publicationDate">2025-04-10</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Novel ionizable cationic lipids
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116813493A/en">
              <span itemprop="publicationNumber">CN116813493A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-21</td>
          <td itemprop="publicationDate">2023-09-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A lipid compound and lipid carrier based on it, nucleic acid lipid nanoparticle composition and pharmaceutical preparation
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023183082A1/en">
              <span itemprop="publicationNumber">WO2023183082A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-03-24</td>
          <td itemprop="publicationDate">2023-09-28</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of California</span></td>
          <td itemprop="title">Silyl lipids suitable for enhanced delivery of anti-viral therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119072464A/en">
              <span itemprop="publicationNumber">CN119072464A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-03-25</td>
          <td itemprop="publicationDate">2024-12-03</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Novel ionizable lipids and lipid nanoparticles and methods of using the same
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250214046A1/en">
              <span itemprop="publicationNumber">US20250214046A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-01</td>
          <td itemprop="publicationDate">2025-07-03</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Cross mixers for lipid nanoparticle production, and methods of operating the same 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023196615A1/en">
              <span itemprop="publicationNumber">WO2023196615A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-07</td>
          <td itemprop="publicationDate">2023-10-12</td>
          <td><span itemprop="assigneeOriginal">RNAimmune, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for drug delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4504252A2/en">
              <span itemprop="publicationNumber">EP4504252A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-08</td>
          <td itemprop="publicationDate">2025-02-12</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations VII, LLC</span></td>
          <td itemprop="title">Vaccines and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250288659A1/en">
              <span itemprop="publicationNumber">US20250288659A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-04-27</td>
          <td itemprop="publicationDate">2025-09-18</td>
          <td><span itemprop="assigneeOriginal">Shanghai Regenelead Therapies Co., Ltd.</span></td>
          <td itemprop="title">Nucleic acid construct and use thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250295687A1/en">
              <span itemprop="publicationNumber">US20250295687A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-09</td>
          <td itemprop="publicationDate">2025-09-25</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Trem compositions and methods of use for treating proliferative disorders 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023218243A1/en">
              <span itemprop="publicationNumber">WO2023218243A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-12</td>
          <td itemprop="publicationDate">2023-11-16</td>
          <td><span itemprop="assigneeOriginal">Avacta Life Sciences Limited</span></td>
          <td itemprop="title">Lag-3/pd-l1 binding fusion proteins 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023217267A1/en">
              <span itemprop="publicationNumber">WO2023217267A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-13</td>
          <td itemprop="publicationDate">2023-11-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Nucleic acid construct comprising utr and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2023220729A2/en">
              <span itemprop="publicationNumber">WO2023220729A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-13</td>
          <td itemprop="publicationDate">2023-11-16</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Double stranded dna compositions and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4522650A1/en">
              <span itemprop="publicationNumber">EP4522650A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-13</td>
          <td itemprop="publicationDate">2025-03-19</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna compositions targeting hiv 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023277551A1/en">
              <span itemprop="publicationNumber">AU2023277551A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-25</td>
          <td itemprop="publicationDate">2024-12-05</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna compositions for delivery of monkeypox antigens and related methods 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025517508A/en">
              <span itemprop="publicationNumber">JP2025517508A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-25</td>
          <td itemprop="publicationDate">2025-06-05</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Nucleic Acid-Based Vaccines
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119562807A/en">
              <span itemprop="publicationNumber">CN119562807A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-05-30</td>
          <td itemprop="publicationDate">2025-03-04</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Complexes for delivery of nucleic acids
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117285474A/en">
              <span itemprop="publicationNumber">CN117285474A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-06-16</td>
          <td itemprop="publicationDate">2023-12-26</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        A new class of lipid compounds and their uses
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4544043A1/en">
              <span itemprop="publicationNumber">EP4544043A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-06-22</td>
          <td itemprop="publicationDate">2025-04-30</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations VI, LLC</span></td>
          <td itemprop="title">Compositions of modified trems and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12297285B2/en">
              <span itemprop="publicationNumber">US12297285B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-06-24</td>
          <td itemprop="publicationDate">2025-05-13</td>
          <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
          <td itemprop="title">Circular RNA encoding chimeric antigen receptors targeting BCMA 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11878055B1/en">
              <span itemprop="publicationNumber">US11878055B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-06-26</td>
          <td itemprop="publicationDate">2024-01-23</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023311822A1/en">
              <span itemprop="publicationNumber">AU2023311822A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-07-20</td>
          <td itemprop="publicationDate">2025-01-09</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Nanomaterials comprising triols 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IL318711A/en">
              <span itemprop="publicationNumber">IL318711A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-01</td>
          <td itemprop="publicationDate">2025-03-01</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii Llc</span></td>
          <td itemprop="title">Immunomodulatory proteins and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024031051A1/en">
              <span itemprop="publicationNumber">WO2024031051A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-08-05</td>
          <td itemprop="publicationDate">2024-02-08</td>
          <td><span itemprop="assigneeOriginal">Life Technologies Corporation</span></td>
          <td itemprop="title">Lipids for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119654136A/en">
              <span itemprop="publicationNumber">CN119654136A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-08-09</td>
          <td itemprop="publicationDate">2025-03-18</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">
        A lipid composition
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024035932A1/en">
              <span itemprop="publicationNumber">WO2024035932A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-11</td>
          <td itemprop="publicationDate">2024-02-15</td>
          <td><span itemprop="assigneeOriginal">RNAimmune, Inc.</span></td>
          <td itemprop="title">Lyophilized nanoparticle compositions and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4569112A1/en">
              <span itemprop="publicationNumber">EP4569112A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-12</td>
          <td itemprop="publicationDate">2025-06-18</td>
          <td><span itemprop="assigneeOriginal">Remix Therapeutics Inc.</span></td>
          <td itemprop="title">Methods and compositions for modulating splicing at alternative splice sites 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4577519A1/en">
              <span itemprop="publicationNumber">EP4577519A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-23</td>
          <td itemprop="publicationDate">2025-07-02</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Methods for purification of ionizable lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250056256A/en">
              <span itemprop="publicationNumber">KR20250056256A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-08-31</td>
          <td itemprop="publicationDate">2025-04-25</td>
          <td><span itemprop="assigneeOriginal"> , .</span></td>
          <td itemprop="title">
        Novel ionizable lipids and lipid nanoparticles, and methods of using them
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4585591A1/en">
              <span itemprop="publicationNumber">EP4585591A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-09-06</td>
          <td itemprop="publicationDate">2025-07-16</td>
          <td><span itemprop="assigneeOriginal">Kyushu University, National University Corporation</span></td>
          <td itemprop="title">Lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN120152960A/en">
              <span itemprop="publicationNumber">CN120152960A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-09-08</td>
          <td itemprop="publicationDate">2025-06-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Compounds, compositions and methods for intracellular delivery of nucleic acid drugs
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115197431B/en">
              <span itemprop="publicationNumber">CN115197431B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-09-15</td>
          <td itemprop="publicationDate">2022-11-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Synthesis and application of lipid-coupled completely degradable water-soluble polymer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4342460A1/en">
              <span itemprop="publicationNumber">EP4342460A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-09-21</td>
          <td itemprop="publicationDate">2024-03-27</td>
          <td><span itemprop="assigneeOriginal">NovoArc GmbH</span></td>
          <td itemprop="title">Lipid nanoparticle with nucleic acid cargo 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024077191A1/en">
              <span itemprop="publicationNumber">WO2024077191A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-10-05</td>
          <td itemprop="publicationDate">2024-04-11</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations V, Inc.</span></td>
          <td itemprop="title">Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB202215200D0/en">
              <span itemprop="publicationNumber">GB202215200D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-10-14</td>
          <td itemprop="publicationDate">2022-11-30</td>
          <td><span itemprop="assigneeOriginal">Mercurna B V</span></td>
          <td itemprop="title">Novel ionizable lipids 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024089638A1/en">
              <span itemprop="publicationNumber">WO2024089638A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-10-28</td>
          <td itemprop="publicationDate">2024-05-02</td>
          <td><span itemprop="assigneeOriginal">Glaxosmithkline Biologicals Sa</span></td>
          <td itemprop="title">Nucleic acid based vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024089229A1/en">
              <span itemprop="publicationNumber">WO2024089229A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-10-28</td>
          <td itemprop="publicationDate">2024-05-02</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Improved formulations comprising lipid-based carriers encapsulating rna 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023372397A1/en">
              <span itemprop="publicationNumber">AU2023372397A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-10-31</td>
          <td itemprop="publicationDate">2025-05-08</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Compositions and methods for purifying polyribonucleotides 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12280104B2/en">
              <span itemprop="publicationNumber">US12280104B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-01</td>
          <td itemprop="publicationDate">2025-04-22</td>
          <td><span itemprop="assigneeOriginal">RNAimmune, Inc.</span></td>
          <td itemprop="title">Composition and methods for MRNA vaccines against novel omicron coronavirus infections 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AR131008A1/en">
              <span itemprop="publicationNumber">AR131008A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-08</td>
          <td itemprop="publicationDate">2025-02-05</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi Llc</span></td>
          <td itemprop="title">
        COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4615424A1/en">
              <span itemprop="publicationNumber">EP4615424A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-10</td>
          <td itemprop="publicationDate">2025-09-17</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2025538217A/en">
              <span itemprop="publicationNumber">JP2025538217A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-11-14</td>
          <td itemprop="publicationDate">2025-11-26</td>
          <td><span itemprop="assigneeOriginal">      </span></td>
          <td itemprop="title">
        Aerosolized lipid nanoparticles and uses thereof
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN120265279A/en">
              <span itemprop="publicationNumber">CN120265279A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-11-21</td>
          <td itemprop="publicationDate">2025-07-04</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Compositions of dry powder formulations of messenger RNA and methods of use thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4626858A1/en">
              <span itemprop="publicationNumber">EP4626858A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-12-02</td>
          <td itemprop="publicationDate">2025-10-08</td>
          <td><span itemprop="assigneeOriginal">University of Cincinnati</span></td>
          <td itemprop="title">Novel ionizable lipids and lipid nanoparticles comprising the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024119098A1/en">
              <span itemprop="publicationNumber">WO2024119098A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-12-02</td>
          <td itemprop="publicationDate">2024-06-06</td>
          <td><span itemprop="assigneeOriginal">Prime Medicine, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle (lnp) delivery systems and formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4630057A1/en">
              <span itemprop="publicationNumber">EP4630057A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-08</td>
          <td itemprop="publicationDate">2025-10-15</td>
          <td><span itemprop="assigneeOriginal">Recode Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024123978A1/en">
              <span itemprop="publicationNumber">WO2024123978A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-08</td>
          <td itemprop="publicationDate">2024-06-13</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Ionizable lipids with malonate tails 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024129988A1/en">
              <span itemprop="publicationNumber">WO2024129988A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-14</td>
          <td itemprop="publicationDate">2024-06-20</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Compositions and methods for delivery of therapeutic agents to bone 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023394992A1/en">
              <span itemprop="publicationNumber">AU2023394992A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-15</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">Sanofi Pasteur Inc.</span></td>
          <td itemprop="title">Mrna encoding influenza virus-like particle 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4637813A1/en">
              <span itemprop="publicationNumber">EP4637813A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-20</td>
          <td itemprop="publicationDate">2025-10-29</td>
          <td><span itemprop="assigneeOriginal">Sanofi Pasteur</span></td>
          <td itemprop="title">Rhinovirus mrna vaccine 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119095585A/en">
              <span itemprop="publicationNumber">CN119095585A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-12-21</td>
          <td itemprop="publicationDate">2024-12-06</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Lipid nanoparticles comprising sterol-modified phospholipids
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4638783A2/en">
              <span itemprop="publicationNumber">EP4638783A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-22</td>
          <td itemprop="publicationDate">2025-10-29</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">Methods for analyzing nucleic acid cargos of lipid nucleic acid assemblies 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2023413766A1/en">
              <span itemprop="publicationNumber">AU2023413766A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-23</td>
          <td itemprop="publicationDate">2025-05-29</td>
          <td><span itemprop="assigneeOriginal">Biontech Delivery Technologies Gmbh</span></td>
          <td itemprop="title">Composition 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4642797A1/en">
              <span itemprop="publicationNumber">EP4642797A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-28</td>
          <td itemprop="publicationDate">2025-11-05</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna compositions targeting hiv 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240263196A1/en">
              <span itemprop="publicationNumber">US20240263196A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-12-29</td>
          <td itemprop="publicationDate">2024-08-08</td>
          <td><span itemprop="assigneeOriginal">Life Technologies Corporation</span></td>
          <td itemprop="title">Lipid Compositions and Methods for Delivery to Immune Cells 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4642481A2/en">
              <span itemprop="publicationNumber">EP4642481A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-29</td>
          <td itemprop="publicationDate">2025-11-05</td>
          <td><span itemprop="assigneeOriginal">Popvax Private Limited</span></td>
          <td itemprop="title">Multitarget vaccines and therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024141784A2/en">
              <span itemprop="publicationNumber">WO2024141784A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-29</td>
          <td itemprop="publicationDate">2024-07-04</td>
          <td><span itemprop="assigneeOriginal">Popvax Private Limited</span></td>
          <td itemprop="title">Broadly protective betacoronavirus vaccines and compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4644552A1/en">
              <span itemprop="publicationNumber">EP4644552A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2022-12-29</td>
          <td itemprop="publicationDate">2025-11-05</td>
          <td><span itemprop="assigneeOriginal">Rinuagene Biotechnology Co., Ltd.</span></td>
          <td itemprop="title">Polynucleotide molecule for preventing or treating hpv infection-related diseases 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN116178193B/en">
              <span itemprop="publicationNumber">CN116178193B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-05</td>
          <td itemprop="publicationDate">2023-07-28</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Cationic lipid compound with high efficiency, low toxicity and stable expression and composition thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115677518B/en">
              <span itemprop="publicationNumber">CN115677518B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-05</td>
          <td itemprop="publicationDate">2023-04-14</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Ionizable cationic lipid compounds and compositions and uses for delivery of nucleic acids
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024147060A1/en">
              <span itemprop="publicationNumber">WO2024147060A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-01-05</td>
          <td itemprop="publicationDate">2024-07-11</td>
          <td><span itemprop="assigneeOriginal">Celon Pharma S.A.</span></td>
          <td itemprop="title">Novel ionizable lipid compounds for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115745820B/en">
              <span itemprop="publicationNumber">CN115745820B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-01-05</td>
          <td itemprop="publicationDate">2023-04-28</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Novel long-acting low-toxicity cationic lipid compounds and compositions thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024151685A1/en">
              <span itemprop="publicationNumber">WO2024151685A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-09</td>
          <td itemprop="publicationDate">2024-07-18</td>
          <td><span itemprop="assigneeOriginal">Beth Israel Deaconess Medical Center, Inc.</span></td>
          <td itemprop="title">Recombinant nucleic acid molecules and their use in wound healing 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024151673A2/en">
              <span itemprop="publicationNumber">WO2024151673A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-09</td>
          <td itemprop="publicationDate">2024-07-18</td>
          <td><span itemprop="assigneeOriginal">President And Fellows Of Harvard College</span></td>
          <td itemprop="title">Recombinant nucleic acid molecules and their use in wound healing 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202438673A/en">
              <span itemprop="publicationNumber">TW202438673A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-09</td>
          <td itemprop="publicationDate">2024-10-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Vaccines and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024151687A1/en">
              <span itemprop="publicationNumber">WO2024151687A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-09</td>
          <td itemprop="publicationDate">2024-07-18</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations V, Inc.</span></td>
          <td itemprop="title">Genetic switches and their use in treating cancer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024159172A1/en">
              <span itemprop="publicationNumber">WO2024159172A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-01-27</td>
          <td itemprop="publicationDate">2024-08-02</td>
          <td><span itemprop="assigneeOriginal">Senda Biosciences, Inc.</span></td>
          <td itemprop="title">A modified lipid composition and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024161249A1/en">
              <span itemprop="publicationNumber">WO2024161249A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-01-31</td>
          <td itemprop="publicationDate">2024-08-08</td>
          <td><span itemprop="assigneeOriginal">Pfizer Inc.</span></td>
          <td itemprop="title">Lipid compounds and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024167885A1/en">
              <span itemprop="publicationNumber">WO2024167885A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-02-06</td>
          <td itemprop="publicationDate">2024-08-15</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Immunomodulatory compositions and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115784921B/en">
              <span itemprop="publicationNumber">CN115784921B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-02-08</td>
          <td itemprop="publicationDate">2023-05-05</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Extrahepatic targeting high-efficiency low-toxicity cationic lipid compound and composition thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250151427A/en">
              <span itemprop="publicationNumber">KR20250151427A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-02-13</td>
          <td itemprop="publicationDate">2025-10-21</td>
          <td><span itemprop="assigneeOriginal">   Vii, </span></td>
          <td itemprop="title">
        Ionizable lipids and lipid carriers containing cleavable linkers for therapeutic compositions
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202446956A/en">
              <span itemprop="publicationNumber">TW202446956A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-02-17</td>
          <td itemprop="publicationDate">2024-12-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Dna compositions comprising modified cytosine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240285805A1/en">
              <span itemprop="publicationNumber">US20240285805A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-02-17</td>
          <td itemprop="publicationDate">2024-08-29</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Dna compositions comprising modified uracil 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4669330A1/en">
              <span itemprop="publicationNumber">EP4669330A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-02-21</td>
          <td itemprop="publicationDate">2025-12-31</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">
        METHOD AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TYPE IIIB SANFILIPPO SYNDROME
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024178305A1/en">
              <span itemprop="publicationNumber">WO2024178305A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-02-24</td>
          <td itemprop="publicationDate">2024-08-29</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2024233180A1/en">
              <span itemprop="publicationNumber">AU2024233180A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-08</td>
          <td itemprop="publicationDate">2025-09-25</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Novel lipid nanoparticle formulations for delivery of nucleic acids 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250162610A/en">
              <span itemprop="publicationNumber">KR20250162610A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2025-11-18</td>
          <td><span itemprop="assigneeOriginal">   , </span></td>
          <td itemprop="title">
        Composition comprising polyribonucleotide and use thereof
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024192422A1/en">
              <span itemprop="publicationNumber">WO2024192422A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-15</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Immunogenic compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20240159310A/en">
              <span itemprop="publicationNumber">KR20240159310A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-04-28</td>
          <td itemprop="publicationDate">2024-11-05</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Lipid nanoparticle compositions using novel ionizable lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024197310A1/en">
              <span itemprop="publicationNumber">WO2024197310A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-23</td>
          <td itemprop="publicationDate">2024-09-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Peg targeting compounds for delivery of therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024197307A1/en">
              <span itemprop="publicationNumber">WO2024197307A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-23</td>
          <td itemprop="publicationDate">2024-09-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Peg targeting compounds for delivery of therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024197309A1/en">
              <span itemprop="publicationNumber">WO2024197309A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-23</td>
          <td itemprop="publicationDate">2024-09-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Peg targeting compounds for delivery of therapeutics 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024200823A1/en">
              <span itemprop="publicationNumber">WO2024200823A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-30</td>
          <td itemprop="publicationDate">2024-10-03</td>
          <td><span itemprop="assigneeOriginal">Ose Immunotherapeutics</span></td>
          <td itemprop="title">Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024200826A1/en">
              <span itemprop="publicationNumber">WO2024200826A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-03-30</td>
          <td itemprop="publicationDate">2024-10-03</td>
          <td><span itemprop="assigneeOriginal">Ose Immunotherapeutics</span></td>
          <td itemprop="title">Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024216191A1/en">
              <span itemprop="publicationNumber">WO2024216191A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-12</td>
          <td itemprop="publicationDate">2024-10-17</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Modified trems, compositions, and related methods thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250171373A/en">
              <span itemprop="publicationNumber">KR20250171373A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-12</td>
          <td itemprop="publicationDate">2025-12-08</td>
          <td><span itemprop="assigneeOriginal">   , </span></td>
          <td itemprop="title">
        TREM for correcting missense mutations
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20250169625A/en">
              <span itemprop="publicationNumber">KR20250169625A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-17</td>
          <td itemprop="publicationDate">2025-12-03</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Reconstitutable dry powder formulation and method of use thereof
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024220712A2/en">
              <span itemprop="publicationNumber">WO2024220712A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-19</td>
          <td itemprop="publicationDate">2024-10-24</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Vaccine compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024220752A2/en">
              <span itemprop="publicationNumber">WO2024220752A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-19</td>
          <td itemprop="publicationDate">2024-10-24</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Rna therapeutic compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024220625A1/en">
              <span itemprop="publicationNumber">WO2024220625A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-19</td>
          <td itemprop="publicationDate">2024-10-24</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024220746A2/en">
              <span itemprop="publicationNumber">WO2024220746A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-04-21</td>
          <td itemprop="publicationDate">2024-10-24</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Rnai agents targeting fatty acid synthase and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117384055B/en">
              <span itemprop="publicationNumber">CN117384055B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-04-27</td>
          <td itemprop="publicationDate">2024-11-19</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Ionizable lipids for delivery of therapeutic agents and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202511244A/en">
              <span itemprop="publicationNumber">TW202511244A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-04-28</td>
          <td itemprop="publicationDate">2025-03-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipids, pharmaceutical compositions comprising the same and methods of delivering active pharmaceutical ingredients 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024230934A1/en">
              <span itemprop="publicationNumber">WO2024230934A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-11</td>
          <td itemprop="publicationDate">2024-11-14</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Therapeutic nucleic acid for the treatment of ophthalmic diseases 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024236336A1/en">
              <span itemprop="publicationNumber">WO2024236336A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-17</td>
          <td itemprop="publicationDate">2024-11-21</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Lipc variant in the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2024275548A1/en">
              <span itemprop="publicationNumber">AU2024275548A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-19</td>
          <td itemprop="publicationDate">2026-01-08</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">Ionizable amine lipids 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024249954A1/en">
              <span itemprop="publicationNumber">WO2024249954A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-05-31</td>
          <td itemprop="publicationDate">2024-12-05</td>
          <td><span itemprop="assigneeOriginal">Capstan Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations and compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024258829A1/en">
              <span itemprop="publicationNumber">WO2024258829A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-12</td>
          <td itemprop="publicationDate">2024-12-19</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Sars-cov-2 vaccine compositions and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024259373A1/en">
              <span itemprop="publicationNumber">WO2024259373A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-14</td>
          <td itemprop="publicationDate">2024-12-19</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024259322A1/en">
              <span itemprop="publicationNumber">WO2024259322A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-06-16</td>
          <td itemprop="publicationDate">2024-12-19</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024260570A1/en">
              <span itemprop="publicationNumber">WO2024260570A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-23</td>
          <td itemprop="publicationDate">2024-12-26</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Nucleic acid encoded antibodies 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025006684A1/en">
              <span itemprop="publicationNumber">WO2025006684A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-28</td>
          <td itemprop="publicationDate">2025-01-02</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Circular polyribonucleotides encoding antifusogenic polypeptides 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025003760A1/en">
              <span itemprop="publicationNumber">WO2025003760A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-06-28</td>
          <td itemprop="publicationDate">2025-01-02</td>
          <td><span itemprop="assigneeOriginal">Sanofi</span></td>
          <td itemprop="title">Sterol analogs in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025011529A2/en">
              <span itemprop="publicationNumber">WO2025011529A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-07-07</td>
          <td itemprop="publicationDate">2025-01-16</td>
          <td><span itemprop="assigneeOriginal">Shanghai Circode Biomed Co., Ltd.</span></td>
          <td itemprop="title">Circular rna vaccines for seasonal flu and methods of uses 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202516001A/en">
              <span itemprop="publicationNumber">TW202516001A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-07-25</td>
          <td itemprop="publicationDate">2025-04-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Cas endonucleases and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025027116A1/en">
              <span itemprop="publicationNumber">WO2025027116A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-01</td>
          <td itemprop="publicationDate">2025-02-06</td>
          <td><span itemprop="assigneeOriginal">Institut Curie</span></td>
          <td itemprop="title">Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025027579A2/en">
              <span itemprop="publicationNumber">WO2025027579A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-03</td>
          <td itemprop="publicationDate">2025-02-06</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna compositions targeting hiv 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025027576A2/en">
              <span itemprop="publicationNumber">WO2025027576A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-03</td>
          <td itemprop="publicationDate">2025-02-06</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna compositions targeting hiv 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025032158A1/en">
              <span itemprop="publicationNumber">WO2025032158A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-08</td>
          <td itemprop="publicationDate">2025-02-13</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Method to treat tauopathies 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025038864A1/en">
              <span itemprop="publicationNumber">WO2025038864A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-08-16</td>
          <td itemprop="publicationDate">2025-02-20</td>
          <td><span itemprop="assigneeOriginal">Beam Therapeutics Inc.</span></td>
          <td itemprop="title">Ionizable lipids with linear head groups 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN117088820B/en">
              <span itemprop="publicationNumber">CN117088820B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-08-18</td>
          <td itemprop="publicationDate">2025-11-28</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Novel cationic LNP delivery system and preparation method 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025042786A1/en">
              <span itemprop="publicationNumber">WO2025042786A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-18</td>
          <td itemprop="publicationDate">2025-02-27</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vi, Llc</span></td>
          <td itemprop="title">Compositions comprising circular polyribonucleotides and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025045142A1/en">
              <span itemprop="publicationNumber">WO2025045142A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-08-29</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Shanghai Circode Biomed Co., Ltd.</span></td>
          <td itemprop="title">Circular rna encoding vegf polypeptides, formulations, and methods of uses 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025048714A1/en">
              <span itemprop="publicationNumber">WO2025048714A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-08-30</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Agency For Science, Technology And Research</span></td>
          <td itemprop="title">A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025046121A1/en">
              <span itemprop="publicationNumber">WO2025046121A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-01</td>
          <td itemprop="publicationDate">2025-03-06</td>
          <td><span itemprop="assigneeOriginal">Novoarc Gmbh</span></td>
          <td itemprop="title">Lipid nanoparticle with nucleic acid cargo and ionizable lipid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025054236A2/en">
              <span itemprop="publicationNumber">WO2025054236A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-06</td>
          <td itemprop="publicationDate">2025-03-13</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Sars-cov-2 vaccine compositions and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119591513A/en">
              <span itemprop="publicationNumber">CN119591513A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-09-11</td>
          <td itemprop="publicationDate">2025-03-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Material for local delivery of drugs and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025062315A2/en">
              <span itemprop="publicationNumber">WO2025062315A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-18</td>
          <td itemprop="publicationDate">2025-03-27</td>
          <td><span itemprop="assigneeOriginal">University Of The Witwatersrand, Johannesburg</span></td>
          <td itemprop="title">Methods of valorising cashew nut shell liquid (cnsl) and/or a component thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250268826A1/en">
              <span itemprop="publicationNumber">US20250268826A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-18</td>
          <td itemprop="publicationDate">2025-08-28</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Ionizable lipidoid compositions and therapeutic uses thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025064850A1/en">
              <span itemprop="publicationNumber">WO2025064850A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-22</td>
          <td itemprop="publicationDate">2025-03-27</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna constructs with n-terminal degrons to enhance an immune response 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025072383A1/en">
              <span itemprop="publicationNumber">WO2025072383A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-25</td>
          <td itemprop="publicationDate">2025-04-03</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Viral open reading frames, uses thereof, and methods of detecting the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025072331A1/en">
              <span itemprop="publicationNumber">WO2025072331A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-09-26</td>
          <td itemprop="publicationDate">2025-04-03</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Cas nucleases and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025073890A1/en">
              <span itemprop="publicationNumber">WO2025073890A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-06</td>
          <td itemprop="publicationDate">2025-04-10</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Method to capture circulating tumor extracellular vesicles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025080867A1/en">
              <span itemprop="publicationNumber">WO2025080867A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-10</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">The Board Of Regents Of The University Of Texas System</span></td>
          <td itemprop="title">Ionizable lipids for improved mrna delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025081002A1/en">
              <span itemprop="publicationNumber">WO2025081002A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-11</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">RNAimmune, Inc.</span></td>
          <td itemprop="title">Ionizable lipids for the delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119330848B/en">
              <span itemprop="publicationNumber">CN119330848B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-19</td>
          <td itemprop="publicationDate">2025-07-08</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">
        Lipid compounds and lipid nanoparticles for delivery
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN119912351A/en">
              <span itemprop="publicationNumber">CN119912351A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-30</td>
          <td itemprop="publicationDate">2025-05-02</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Lipid compounds and compositions thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025096807A2/en">
              <span itemprop="publicationNumber">WO2025096807A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-10-31</td>
          <td itemprop="publicationDate">2025-05-08</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Novel therapeutic dna forms 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025096681A1/en">
              <span itemprop="publicationNumber">WO2025096681A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-31</td>
          <td itemprop="publicationDate">2025-05-08</td>
          <td><span itemprop="assigneeOriginal">Tiba Biotech Llc</span></td>
          <td itemprop="title">Novel gene delivery agents 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025097055A2/en">
              <span itemprop="publicationNumber">WO2025097055A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-02</td>
          <td itemprop="publicationDate">2025-05-08</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Compositions and methods of use of t cells in immunotherapy 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025103803A1/en">
              <span itemprop="publicationNumber">WO2025103803A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-13</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Immunotherapy against neuronal and brain tumors 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250162981A1/en">
              <span itemprop="publicationNumber">US20250162981A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-14</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Ionizable lipidoid compositions and therapeutic uses thereof 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102024133412A1/en">
              <span itemprop="publicationNumber">DE102024133412A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-15</td>
          <td itemprop="publicationDate">2025-05-15</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">
        SARS-COV-2 IMMUNOGENIC COMPOSITIONS
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025106754A1/en">
              <span itemprop="publicationNumber">WO2025106754A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-15</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Coronavirus vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025104695A1/en">
              <span itemprop="publicationNumber">WO2025104695A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-11-16</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">Corti Therapeutics Pte. Ltd.</span></td>
          <td itemprop="title">Ionizable cationic lipids and lipid nanoparticles thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025106930A1/en">
              <span itemprop="publicationNumber">WO2025106930A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-17</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025106915A1/en">
              <span itemprop="publicationNumber">WO2025106915A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-17</td>
          <td itemprop="publicationDate">2025-05-22</td>
          <td><span itemprop="assigneeOriginal">Sail Biomedicines, Inc.</span></td>
          <td itemprop="title">Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202523695A/en">
              <span itemprop="publicationNumber">TW202523695A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-11-22</td>
          <td itemprop="publicationDate">2025-06-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Methods and compositions for treating non-alcoholic fatty liver disease 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025117877A2/en">
              <span itemprop="publicationNumber">WO2025117877A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-01</td>
          <td itemprop="publicationDate">2025-06-05</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Cas nucleases and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US12364773B2/en">
              <span itemprop="publicationNumber">US12364773B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-01</td>
          <td itemprop="publicationDate">2025-07-22</td>
          <td><span itemprop="assigneeOriginal">Recode Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025124711A1/en">
              <span itemprop="publicationNumber">WO2025124711A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-13</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Glycolipid compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202527910A/en">
              <span itemprop="publicationNumber">TW202527910A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-12-13</td>
          <td itemprop="publicationDate">2025-07-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">A cationic lipid and its application 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025129158A1/en">
              <span itemprop="publicationNumber">WO2025129158A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-15</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">The Broad Institute, Inc.</span></td>
          <td itemprop="title">Engineered arc delivery vesicles and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025129201A1/en">
              <span itemprop="publicationNumber">WO2025129201A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-15</td>
          <td itemprop="publicationDate">2025-06-19</td>
          <td><span itemprop="assigneeOriginal">Capstan Therapeutics, Inc.</span></td>
          <td itemprop="title">Humanized anti-cd8 antibodies and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025133115A1/en">
              <span itemprop="publicationNumber">WO2025133115A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-21</td>
          <td itemprop="publicationDate">2025-06-26</td>
          <td><span itemprop="assigneeOriginal">Ose Immunotherapeutics</span></td>
          <td itemprop="title">Lipid-based nanoparticles comprising il-35 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025137646A1/en">
              <span itemprop="publicationNumber">WO2025137646A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-22</td>
          <td itemprop="publicationDate">2025-06-26</td>
          <td><span itemprop="assigneeOriginal">Recode Therapeutics, Inc.</span></td>
          <td itemprop="title">Gene editing methods and compositions for treating cystic fibrosis 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025141521A1/en">
              <span itemprop="publicationNumber">WO2025141521A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2023-12-29</td>
          <td itemprop="publicationDate">2025-07-03</td>
          <td><span itemprop="assigneeOriginal">Sanofi</span></td>
          <td itemprop="title">Lipids having dendritic moieties 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025149492A1/en">
              <span itemprop="publicationNumber">WO2025149492A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-08</td>
          <td itemprop="publicationDate">2025-07-17</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Rna encoding an immune inhibitory il-1 family member 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025157848A1/en">
              <span itemprop="publicationNumber">WO2025157848A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-23</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Methods for the intravenous treatment of sanfilippo syndrome type iiib 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025160381A1/en">
              <span itemprop="publicationNumber">WO2025160381A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-26</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods of preparing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025160334A1/en">
              <span itemprop="publicationNumber">WO2025160334A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-01-26</td>
          <td itemprop="publicationDate">2025-07-31</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Immunoreceptor inhibitory proteins and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025186293A1/en">
              <span itemprop="publicationNumber">WO2025186293A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-03-06</td>
          <td itemprop="publicationDate">2025-09-12</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Chmp2b mutants for use for treating infection 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025194019A1/en">
              <span itemprop="publicationNumber">WO2025194019A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-03-14</td>
          <td itemprop="publicationDate">2025-09-18</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Methods for treating liver fibrosis and non-alcoholic fatty liver disease 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025196065A1/en">
              <span itemprop="publicationNumber">WO2025196065A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-03-20</td>
          <td itemprop="publicationDate">2025-09-25</td>
          <td><span itemprop="assigneeOriginal">Sanofi</span></td>
          <td itemprop="title">Novel homocysteine based lipids and their use for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025202213A1/en">
              <span itemprop="publicationNumber">WO2025202213A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-03-26</td>
          <td itemprop="publicationDate">2025-10-02</td>
          <td><span itemprop="assigneeOriginal">Institut National de la Sant et de la Recherche Mdicale</span></td>
          <td itemprop="title">Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025210520A1/en">
              <span itemprop="publicationNumber">WO2025210520A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-04</td>
          <td itemprop="publicationDate">2025-10-09</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Lipid nanoparticles for inducing an immunological response 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025210521A1/en">
              <span itemprop="publicationNumber">WO2025210521A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-04</td>
          <td itemprop="publicationDate">2025-10-09</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Lipid nanoparticles for stimulating t cells 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025217275A2/en">
              <span itemprop="publicationNumber">WO2025217275A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-10</td>
          <td itemprop="publicationDate">2025-10-16</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Immune cell targeted compositions and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN118388360B/en">
              <span itemprop="publicationNumber">CN118388360B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-04-17</td>
          <td itemprop="publicationDate">2025-04-04</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Long-acting spleen-targeted cationic lipid compound containing benzene ring structure, composition containing same and use thereof
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20250353881A1/en">
              <span itemprop="publicationNumber">US20250353881A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-16</td>
          <td itemprop="publicationDate">2025-11-20</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Immunoreceptor inhibitory proteins and related methods 
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025240946A1/en">
              <span itemprop="publicationNumber">WO2025240946A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-17</td>
          <td itemprop="publicationDate">2025-11-20</td>
          <td><span itemprop="assigneeOriginal">Intellia Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticles and lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025245188A2/en">
              <span itemprop="publicationNumber">WO2025245188A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-21</td>
          <td itemprop="publicationDate">2025-11-27</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Methods of treating liver steatosis and non-alcoholic fatty liver disease 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025245111A1/en">
              <span itemprop="publicationNumber">WO2025245111A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-05-22</td>
          <td itemprop="publicationDate">2025-11-27</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Immunoreceptor targeting proteins and related methods 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2026006577A1/en">
              <span itemprop="publicationNumber">WO2026006577A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-06-26</td>
          <td itemprop="publicationDate">2026-01-02</td>
          <td><span itemprop="assigneeOriginal">Flagship Pioneering Innovations Vii, Llc</span></td>
          <td itemprop="title">Therapeutic circular dna forms 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2026008743A1/en">
              <span itemprop="publicationNumber">WO2026008743A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2024-07-02</td>
          <td itemprop="publicationDate">2026-01-08</td>
          <td><span itemprop="assigneeOriginal">Sanofi Pasteur Inc.</span></td>
          <td itemprop="title">Water-soluble polyanionic polymer as adjuvant for carrier-formulated nucleic acid 
       </td>
        </tr>
      </tbody>
    </table>

    

    <h2>Family Cites Families (369)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US3324182A/en">
              <span itemprop="publicationNumber">US3324182A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1962-12-26</td>
          <td itemprop="publicationDate">1967-06-06</td>
          <td><span itemprop="assigneeOriginal">Monsanto Res Corp</span></td>
          <td itemprop="title">Penta-alkyldialkylenetriamines 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US3872171A/en">
              <span itemprop="publicationNumber">US3872171A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1971-05-24</td>
          <td itemprop="publicationDate">1975-03-18</td>
          <td><span itemprop="assigneeOriginal">Pfizer</span></td>
          <td itemprop="title">Polyamines as antiviral agents in animals 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US3799876A/en">
              <span itemprop="publicationNumber">US3799876A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1970-12-11</td>
          <td itemprop="publicationDate">1974-03-26</td>
          <td><span itemprop="assigneeOriginal">Texaco Inc</span></td>
          <td itemprop="title">Corrosion inhibiting lubrication method 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4125544A/en">
              <span itemprop="publicationNumber">US4125544A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1977-06-09</td>
          <td itemprop="publicationDate">1978-11-14</td>
          <td><span itemprop="assigneeOriginal">G. D. Searle</span></td>
          <td itemprop="title">20/22/23/24-Oxa-7-oxocholesterols and esters thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4270537A/en">
              <span itemprop="publicationNumber">US4270537A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1979-11-19</td>
          <td itemprop="publicationDate">1981-06-02</td>
          <td><span itemprop="assigneeOriginal">Romaine Richard A</span></td>
          <td itemprop="title">Automatic hypodermic syringe 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4957735A/en">
              <span itemprop="publicationNumber">US4957735A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1984-06-12</td>
          <td itemprop="publicationDate">1990-09-18</td>
          <td><span itemprop="assigneeOriginal">The University Of Tennessee Research Corporation</span></td>
          <td itemprop="title">Target-sensitive immunoliposomes- preparation and characterization 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4596556A/en">
              <span itemprop="publicationNumber">US4596556A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1985-03-25</td>
          <td itemprop="publicationDate">1986-06-24</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Hypodermic injection apparatus 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4886499A/en">
              <span itemprop="publicationNumber">US4886499A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1986-12-18</td>
          <td itemprop="publicationDate">1989-12-12</td>
          <td><span itemprop="assigneeOriginal">Hoffmann-La Roche Inc.</span></td>
          <td itemprop="title">Portable injection appliance 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB8704027D0/en">
              <span itemprop="publicationNumber">GB8704027D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1987-02-20</td>
          <td itemprop="publicationDate">1987-03-25</td>
          <td><span itemprop="assigneeOriginal">Owen Mumford Ltd</span></td>
          <td itemprop="title">Syringe needle combination 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4790824A/en">
              <span itemprop="publicationNumber">US4790824A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1987-06-19</td>
          <td itemprop="publicationDate">1988-12-13</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Non-invasive hypodermic injection device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4941880A/en">
              <span itemprop="publicationNumber">US4941880A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1987-06-19</td>
          <td itemprop="publicationDate">1990-07-17</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Pre-filled ampule and non-invasive hypodermic injection device assembly 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US4940460A/en">
              <span itemprop="publicationNumber">US4940460A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1987-06-19</td>
          <td itemprop="publicationDate">1990-07-10</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Patient-fillable and non-invasive hypodermic injection device assembly 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5339163A/en">
              <span itemprop="publicationNumber">US5339163A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1988-03-16</td>
          <td itemprop="publicationDate">1994-08-16</td>
          <td><span itemprop="assigneeOriginal">Canon Kabushiki Kaisha</span></td>
          <td itemprop="title">Automatic exposure control device using plural image plane detection areas 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/FR2638359A1/en">
              <span itemprop="publicationNumber">FR2638359A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1988-11-03</td>
          <td itemprop="publicationDate">1990-05-04</td>
          <td><span itemprop="assigneeOriginal">Tino Dalto</span></td>
          <td itemprop="title">
  SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE69034168T3/en">
              <span itemprop="publicationNumber">DE69034168T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-03-21</td>
          <td itemprop="publicationDate">2013-04-11</td>
          <td><span itemprop="assigneeOriginal">Vical, Inc.</span></td>
          <td itemprop="title">
        Expression of exogenous polynucleotide sequences in vertebrates
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5312335A/en">
              <span itemprop="publicationNumber">US5312335A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-11-09</td>
          <td itemprop="publicationDate">1994-05-17</td>
          <td><span itemprop="assigneeOriginal">Bioject Inc.</span></td>
          <td itemprop="title">Needleless hypodermic injection device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5064413A/en">
              <span itemprop="publicationNumber">US5064413A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1989-11-09</td>
          <td itemprop="publicationDate">1991-11-12</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Needleless hypodermic injection device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5190521A/en">
              <span itemprop="publicationNumber">US5190521A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1990-08-22</td>
          <td itemprop="publicationDate">1993-03-02</td>
          <td><span itemprop="assigneeOriginal">Tecnol Medical Products, Inc.</span></td>
          <td itemprop="title">Apparatus and method for raising a skin wheal and anesthetizing skin 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5527288A/en">
              <span itemprop="publicationNumber">US5527288A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1990-12-13</td>
          <td itemprop="publicationDate">1996-06-18</td>
          <td><span itemprop="assigneeOriginal">Elan Medical Technologies Limited</span></td>
          <td itemprop="title">Intradermal drug delivery device and method for intradermal delivery of drugs 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/FR2676072B1/en">
              <span itemprop="publicationNumber">FR2676072B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1991-05-03</td>
          <td itemprop="publicationDate">1994-11-18</td>
          <td><span itemprop="assigneeOriginal">Transgene Sa</span></td>
          <td itemprop="title">
  RNA DELIVERY VECTOR.
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB9118204D0/en">
              <span itemprop="publicationNumber">GB9118204D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1991-08-23</td>
          <td itemprop="publicationDate">1991-10-09</td>
          <td><span itemprop="assigneeOriginal">Weston Terence E</span></td>
          <td itemprop="title">Needle-less injector 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SE9102652D0/en">
              <span itemprop="publicationNumber">SE9102652D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1991-09-13</td>
          <td itemprop="publicationDate">1991-09-13</td>
          <td><span itemprop="assigneeOriginal">Kabi Pharmacia Ab</span></td>
          <td itemprop="title">
        INJECTION NEEDLE ARRANGEMENT
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2128616A1/en">
              <span itemprop="publicationNumber">CA2128616A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-01-23</td>
          <td itemprop="publicationDate">1993-08-05</td>
          <td><span itemprop="assigneeOriginal">Gary H. Rhodes</span></td>
          <td itemprop="title">Ex vivo gene transfer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5328483A/en">
              <span itemprop="publicationNumber">US5328483A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-02-27</td>
          <td itemprop="publicationDate">1994-07-12</td>
          <td><span itemprop="assigneeOriginal">Jacoby Richard M</span></td>
          <td itemprop="title">Intradermal injection device with medication and needle guard 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5383851A/en">
              <span itemprop="publicationNumber">US5383851A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-07-24</td>
          <td itemprop="publicationDate">1995-01-24</td>
          <td><span itemprop="assigneeOriginal">Bioject Inc.</span></td>
          <td itemprop="title">Needleless hypodermic injection device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5569189A/en">
              <span itemprop="publicationNumber">US5569189A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-09-28</td>
          <td itemprop="publicationDate">1996-10-29</td>
          <td><span itemprop="assigneeOriginal">Equidyne Systems, Inc.</span></td>
          <td itemprop="title">hypodermic jet injector 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5334144A/en">
              <span itemprop="publicationNumber">US5334144A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1992-10-30</td>
          <td itemprop="publicationDate">1994-08-02</td>
          <td><span itemprop="assigneeOriginal">Becton, Dickinson And Company</span></td>
          <td itemprop="title">Single use disposable needleless injector 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO1995024176A1/en">
              <span itemprop="publicationNumber">WO1995024176A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-03-07</td>
          <td itemprop="publicationDate">1995-09-14</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Ampule filling device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5466220A/en">
              <span itemprop="publicationNumber">US5466220A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1994-03-08</td>
          <td itemprop="publicationDate">1995-11-14</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Drug vial mixing and transfer device 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5807861A/en">
              <span itemprop="publicationNumber">US5807861A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1994-03-24</td>
          <td itemprop="publicationDate">1998-09-15</td>
          <td><span itemprop="assigneeOriginal">Cell Therapeutics, Inc.</span></td>
          <td itemprop="title">Amine substituted xanthinyl compounds 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5599302A/en">
              <span itemprop="publicationNumber">US5599302A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-01-09</td>
          <td itemprop="publicationDate">1997-02-04</td>
          <td><span itemprop="assigneeOriginal">Medi-Ject Corporation</span></td>
          <td itemprop="title">Medical injection system and method, gas spring thereof and launching device using gas spring 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5795587A/en">
              <span itemprop="publicationNumber">US5795587A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-01-23</td>
          <td itemprop="publicationDate">1998-08-18</td>
          <td><span itemprop="assigneeOriginal">University Of Pittsburgh</span></td>
          <td itemprop="title">Stable lipid-comprising drug delivery complexes and methods for their production 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5730723A/en">
              <span itemprop="publicationNumber">US5730723A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-10-10</td>
          <td itemprop="publicationDate">1998-03-24</td>
          <td><span itemprop="assigneeOriginal">Visionary Medical Products Corporation, Inc.</span></td>
          <td itemprop="title">Gas pressured needle-less injection device and method 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5893397A/en">
              <span itemprop="publicationNumber">US5893397A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1996-01-12</td>
          <td itemprop="publicationDate">1999-04-13</td>
          <td><span itemprop="assigneeOriginal">Bioject Inc.</span></td>
          <td itemprop="title">Medication vial/syringe liquid-transfer apparatus 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB9607549D0/en">
              <span itemprop="publicationNumber">GB9607549D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1996-04-11</td>
          <td itemprop="publicationDate">1996-06-12</td>
          <td><span itemprop="assigneeOriginal">Weston Medical Ltd</span></td>
          <td itemprop="title">Spring-powered dispensing device 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7288266B2/en">
              <span itemprop="publicationNumber">US7288266B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1996-08-19</td>
          <td itemprop="publicationDate">2007-10-30</td>
          <td><span itemprop="assigneeOriginal">United States Of America As Represented By The Secretary, Department Of Health And Human Services</span></td>
          <td itemprop="title">Liposome complexes for increased systemic delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6143276A/en">
              <span itemprop="publicationNumber">US6143276A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-03-21</td>
          <td itemprop="publicationDate">2000-11-07</td>
          <td><span itemprop="assigneeOriginal">Imarx Pharmaceutical Corp.</span></td>
          <td itemprop="title">Methods for delivering bioactive agents to regions of elevated temperatures 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5993412A/en">
              <span itemprop="publicationNumber">US5993412A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-05-19</td>
          <td itemprop="publicationDate">1999-11-30</td>
          <td><span itemprop="assigneeOriginal">Bioject, Inc.</span></td>
          <td itemprop="title">Injection apparatus 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO1999014346A2/en">
              <span itemprop="publicationNumber">WO1999014346A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-09-19</td>
          <td itemprop="publicationDate">1999-03-25</td>
          <td><span itemprop="assigneeOriginal">Sequitur, Inc.</span></td>
          <td itemprop="title">SENSE mRNA THERAPY 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6673192B1/en">
              <span itemprop="publicationNumber">US6673192B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-09-25</td>
          <td itemprop="publicationDate">2004-01-06</td>
          <td><span itemprop="assigneeOriginal">Loctite Corporation</span></td>
          <td itemprop="title">Multi-amine compound primers for bonding of polyolefins with cyanoacrylate adhesives 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2001520889A/en">
              <span itemprop="publicationNumber">JP2001520889A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-10-24</td>
          <td itemprop="publicationDate">2001-11-06</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
  Methods for preparing polynucleotide transfection complexes
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2001521759A/en">
              <span itemprop="publicationNumber">JP2001521759A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-11-12</td>
          <td itemprop="publicationDate">2001-11-13</td>
          <td><span itemprop="assigneeOriginal">        </span></td>
          <td itemprop="title">
  Translational enhancer element of human amyloid precursor protein gene
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2001523480A/en">
              <span itemprop="publicationNumber">JP2001523480A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-11-20</td>
          <td itemprop="publicationDate">2001-11-27</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
  Treatment of cancer with cytokine-expressed polynucleotides and their compositions
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/IT1298087B1/en">
              <span itemprop="publicationNumber">IT1298087B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1998-01-08</td>
          <td itemprop="publicationDate">1999-12-20</td>
          <td><span itemprop="assigneeOriginal">Fiderm S R L</span></td>
          <td itemprop="title">
  DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6432925B1/en">
              <span itemprop="publicationNumber">US6432925B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1998-04-16</td>
          <td itemprop="publicationDate">2002-08-13</td>
          <td><span itemprop="assigneeOriginal">John Wayne Cancer Institute</span></td>
          <td itemprop="title">RNA cancer vaccine and methods for its use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/GB9808268D0/en">
              <span itemprop="publicationNumber">GB9808268D0</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">1998-04-17</td>
          <td itemprop="publicationDate">1998-06-17</td>
          <td><span itemprop="assigneeOriginal">Imp College Innovations Ltd</span></td>
          <td itemprop="title">Compound 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6395253B2/en">
              <span itemprop="publicationNumber">US6395253B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1998-04-23</td>
          <td itemprop="publicationDate">2002-05-28</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of Michigan</span></td>
          <td itemprop="title">Microspheres containing condensed polyanionic bioactive agents and methods for their production 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2000169864A/en">
              <span itemprop="publicationNumber">JP2000169864A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1998-12-07</td>
          <td itemprop="publicationDate">2000-06-20</td>
          <td><span itemprop="assigneeOriginal">New Japan Chem Co Ltd</span></td>
          <td itemprop="title">Model engine fuel composition 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2286792A1/en">
              <span itemprop="publicationNumber">EP2286792A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1999-02-26</td>
          <td itemprop="publicationDate">2011-02-23</td>
          <td><span itemprop="assigneeOriginal">Novartis Vaccines and Diagnostics, Inc.</span></td>
          <td itemprop="title">Microemulsions with an adsorbent surface, comprising a microdroplet emulsion 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2001023002A1/en">
              <span itemprop="publicationNumber">WO2001023002A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1999-09-30</td>
          <td itemprop="publicationDate">2001-04-05</td>
          <td><span itemprop="assigneeOriginal">National Jewish Medical And Research Center</span></td>
          <td itemprop="title">Method for inhibition of pathogenic microorganisms 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7060291B1/en">
              <span itemprop="publicationNumber">US7060291B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1999-11-24</td>
          <td itemprop="publicationDate">2006-06-13</td>
          <td><span itemprop="assigneeOriginal">Transave, Inc.</span></td>
          <td itemprop="title">Modular targeted liposomal delivery system 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2001055369A1/en">
              <span itemprop="publicationNumber">WO2001055369A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-01-28</td>
          <td itemprop="publicationDate">2001-08-02</td>
          <td><span itemprop="assigneeOriginal">The Scripps Research Institute</span></td>
          <td itemprop="title">Synthetic internal ribosome entry sites and methods of identifying same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7468275B2/en">
              <span itemprop="publicationNumber">US7468275B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-01-28</td>
          <td itemprop="publicationDate">2008-12-23</td>
          <td><span itemprop="assigneeOriginal">The Scripps Research Institute</span></td>
          <td itemprop="title">Synthetic internal ribosome entry sites and methods of identifying same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20040142474A1/en">
              <span itemprop="publicationNumber">US20040142474A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-09-14</td>
          <td itemprop="publicationDate">2004-07-22</td>
          <td><span itemprop="assigneeOriginal">Expression Genetics, Inc.</span></td>
          <td itemprop="title">Novel cationic lipopolymer as a biocompatible gene delivery agent 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6696038B1/en">
              <span itemprop="publicationNumber">US6696038B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2000-09-14</td>
          <td itemprop="publicationDate">2004-02-24</td>
          <td><span itemprop="assigneeOriginal">Expression Genetics, Inc.</span></td>
          <td itemprop="title">Cationic lipopolymer as biocompatible gene delivery agent 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7708915B2/en">
              <span itemprop="publicationNumber">US7708915B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-05-06</td>
          <td itemprop="publicationDate">2010-05-04</td>
          <td><span itemprop="assigneeOriginal">Castor Trevor P</span></td>
          <td itemprop="title">Polymer microspheres/nanospheres and encapsulating therapeutic proteins therein 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US6652886B2/en">
              <span itemprop="publicationNumber">US6652886B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-02-16</td>
          <td itemprop="publicationDate">2003-11-25</td>
          <td><span itemprop="assigneeOriginal">Expression Genetics</span></td>
          <td itemprop="title">Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE10109897A1/en">
              <span itemprop="publicationNumber">DE10109897A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-02-21</td>
          <td itemprop="publicationDate">2002-11-07</td>
          <td><span itemprop="assigneeOriginal">Novosom Ag</span></td>
          <td itemprop="title">
  Optional cationic liposomes and their use
 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR100904954B1/en">
              <span itemprop="publicationNumber">KR100904954B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-05-30</td>
          <td itemprop="publicationDate">2009-06-26</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">
        Delivery System for Nucleic Acids
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2356934T3/en">
              <span itemprop="publicationNumber">ES2356934T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-06-05</td>
          <td itemprop="publicationDate">2011-04-14</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        MRNA STABILIZED WITH AN INCREASED G / C CONTENT THAT CODIFIES FOR A VIRAL ANTIGEN.
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE10162480A1/en">
              <span itemprop="publicationNumber">DE10162480A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2001-12-19</td>
          <td itemprop="publicationDate">2003-08-07</td>
          <td><span itemprop="assigneeOriginal">Ingmar Hoerr</span></td>
          <td itemprop="title">
  The application of mRNA for use as a therapeutic agent against tumor diseases
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE10207178A1/en">
              <span itemprop="publicationNumber">DE10207178A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-02-19</td>
          <td itemprop="publicationDate">2003-09-04</td>
          <td><span itemprop="assigneeOriginal">Novosom Ag</span></td>
          <td itemprop="title">
  Components for the production of amphoteric liposomes
 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20050222064A1/en">
              <span itemprop="publicationNumber">US20050222064A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-02-20</td>
          <td itemprop="publicationDate">2005-10-06</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Polycationic compositions for cellular delivery of polynucleotides 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1485070A1/en">
              <span itemprop="publicationNumber">EP1485070A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-03-13</td>
          <td itemprop="publicationDate">2004-12-15</td>
          <td><span itemprop="assigneeOriginal">Novartis AG</span></td>
          <td itemprop="title">Pharmaceutical microparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RU2302865C2/en">
              <span itemprop="publicationNumber">RU2302865C2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-04-04</td>
          <td itemprop="publicationDate">2007-07-20</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">Immunostimulating g,u-containing olygoribonucleotides 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1519714B1/en">
              <span itemprop="publicationNumber">EP1519714B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-06-28</td>
          <td itemprop="publicationDate">2010-10-20</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc.</span></td>
          <td itemprop="title">Method and apparatus for producing liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE10229872A1/en">
              <span itemprop="publicationNumber">DE10229872A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-07-03</td>
          <td itemprop="publicationDate">2004-01-29</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Immune stimulation through chemically modified RNA
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE10335833A1/en">
              <span itemprop="publicationNumber">DE10335833A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-08-05</td>
          <td itemprop="publicationDate">2005-03-03</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Transfection of blood cells with mRNA for immune stimulation and gene therapy
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8668926B1/en">
              <span itemprop="publicationNumber">US8668926B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-09-15</td>
          <td itemprop="publicationDate">2014-03-11</td>
          <td><span itemprop="assigneeOriginal">Shaker A. Mousa</span></td>
          <td itemprop="title">Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2542099A1/en">
              <span itemprop="publicationNumber">CA2542099A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-10-11</td>
          <td itemprop="publicationDate">2005-04-21</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7927873B2/en">
              <span itemprop="publicationNumber">US7927873B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-12-19</td>
          <td itemprop="publicationDate">2011-04-19</td>
          <td><span itemprop="assigneeOriginal">University Of Cincinnati</span></td>
          <td itemprop="title">Polyamides for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ATE537263T1/en">
              <span itemprop="publicationNumber">ATE537263T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-06-07</td>
          <td itemprop="publicationDate">2011-12-15</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">
  CATIONIC LIPIDS AND METHODS OF USE
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2005121348A1/en">
              <span itemprop="publicationNumber">WO2005121348A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-06-07</td>
          <td itemprop="publicationDate">2005-12-22</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Lipid encapsulated interfering rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MXPA06015234A/en">
              <span itemprop="publicationNumber">MXPA06015234A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-06-30</td>
          <td itemprop="publicationDate">2007-11-22</td>
          <td><span itemprop="assigneeOriginal">Nektar Therapeutics Al Corp</span></td>
          <td itemprop="title">Polymer-factor ix moiety conjugates. 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102004042546A1/en">
              <span itemprop="publicationNumber">DE102004042546A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-09-02</td>
          <td itemprop="publicationDate">2006-03-09</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Combination therapy for immune stimulation
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8663599B1/en">
              <span itemprop="publicationNumber">US8663599B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-10-05</td>
          <td itemprop="publicationDate">2014-03-04</td>
          <td><span itemprop="assigneeOriginal">Gp Medical, Inc.</span></td>
          <td itemprop="title">Pharmaceutical composition of nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1856179B1/en">
              <span itemprop="publicationNumber">EP1856179B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-12-10</td>
          <td itemprop="publicationDate">2013-05-15</td>
          <td><span itemprop="assigneeOriginal">Kala Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Functionalized poly (ether-anhydride) block copolymers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102005023170A1/en">
              <span itemprop="publicationNumber">DE102005023170A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-05-19</td>
          <td itemprop="publicationDate">2006-11-23</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Optimized formulation for mRNA
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1912679A4/en">
              <span itemprop="publicationNumber">EP1912679A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-06-15</td>
          <td itemprop="publicationDate">2009-07-29</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Inst Technology</span></td>
          <td itemprop="title">
        LIPIDS CONTAINING AMINES AND USES
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2479254A1/en">
              <span itemprop="publicationNumber">EP2479254A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-08-24</td>
          <td itemprop="publicationDate">2012-07-25</td>
          <td><span itemprop="assigneeOriginal">The Scripps Research Institute</span></td>
          <td itemprop="title">Translation enhancer-element dependent vector systems 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102006007433A1/en">
              <span itemprop="publicationNumber">DE102006007433A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-02-17</td>
          <td itemprop="publicationDate">2007-08-23</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Adjuvant in the form of a lipid-modified nucleic acid
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2012751A4/en">
              <span itemprop="publicationNumber">EP2012751A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-03-21</td>
          <td itemprop="publicationDate">2010-11-24</td>
          <td><span itemprop="assigneeOriginal">Morehouse School Of Medicine</span></td>
          <td itemprop="title">
        NEW NANOPARTICLES FOR THE ACTIVE COMPOSITION
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2776100T3/en">
              <span itemprop="publicationNumber">ES2776100T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-03-31</td>
          <td itemprop="publicationDate">2020-07-29</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Inst Technology</span></td>
          <td itemprop="title">
        System for targeted delivery of therapeutic agents
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2019691B1/en">
              <span itemprop="publicationNumber">EP2019691B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-05-15</td>
          <td itemprop="publicationDate">2020-08-12</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute of Technology</span></td>
          <td itemprop="title">Polymers for functional particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8728527B2/en">
              <span itemprop="publicationNumber">US8728527B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-07-24</td>
          <td itemprop="publicationDate">2014-05-20</td>
          <td><span itemprop="assigneeOriginal">Luminus Biosciences, Inc.</span></td>
          <td itemprop="title">Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2659301A1/en">
              <span itemprop="publicationNumber">CA2659301A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-07-28</td>
          <td itemprop="publicationDate">2008-02-07</td>
          <td><span itemprop="assigneeOriginal">Applera Corporation</span></td>
          <td itemprop="title">Dinucleotide mrna cap analogs 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2008014979A2/en">
              <span itemprop="publicationNumber">WO2008014979A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-07-31</td>
          <td itemprop="publicationDate">2008-02-07</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2848238C/en">
              <span itemprop="publicationNumber">CA2848238C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-10-03</td>
          <td itemprop="publicationDate">2016-07-19</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Lipid containing formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RU2492872C2/en">
              <span itemprop="publicationNumber">RU2492872C2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-10-05</td>
          <td itemprop="publicationDate">2013-09-20</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">Water-dispersible oral, enteral and local compositions for poorly water-soluble drug preparations containing polymer nanoparticles improving properties thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102006051516A1/en">
              <span itemprop="publicationNumber">DE102006051516A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-10-31</td>
          <td itemprop="publicationDate">2008-05-08</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        (Base) modified RNA to increase the expression of a protein
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102006061015A1/en">
              <span itemprop="publicationNumber">DE102006061015A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2006-12-22</td>
          <td itemprop="publicationDate">2008-06-26</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Process for the purification of RNA on a preparative scale by HPLC
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102007001370A1/en">
              <span itemprop="publicationNumber">DE102007001370A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-01-09</td>
          <td itemprop="publicationDate">2008-07-10</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        RNA-encoded antibodies
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US7943168B2/en">
              <span itemprop="publicationNumber">US7943168B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-03-05</td>
          <td itemprop="publicationDate">2011-05-17</td>
          <td><span itemprop="assigneeOriginal">Washington University</span></td>
          <td itemprop="title">Nanoparticle delivery systems comprising a hydrophobic core and a lipid/surfactant layer comprising a membrane-lytic peptide 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2008127688A1/en">
              <span itemprop="publicationNumber">WO2008127688A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-04-13</td>
          <td itemprop="publicationDate">2008-10-23</td>
          <td><span itemprop="assigneeOriginal">Hart Communication Foundation</span></td>
          <td itemprop="title">Synchronizing timeslots in a wireless communication protocol 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8703204B2/en">
              <span itemprop="publicationNumber">US8703204B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-05-03</td>
          <td itemprop="publicationDate">2014-04-22</td>
          <td><span itemprop="assigneeOriginal">Bend Research, Inc.</span></td>
          <td itemprop="title">Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI2494993T1/en">
              <span itemprop="publicationNumber">SI2494993T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-05-04</td>
          <td itemprop="publicationDate">2019-01-31</td>
          <td><span itemprop="assigneeOriginal">Marina Biotech, Inc.</span></td>
          <td itemprop="title">Amino acid lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20090042825A1/en">
              <span itemprop="publicationNumber">US20090042825A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-08-06</td>
          <td itemprop="publicationDate">2009-02-12</td>
          <td><span itemprop="assigneeOriginal">Majed Matar</span></td>
          <td itemprop="title">Composition, method of preparation &amp; application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9144546B2/en">
              <span itemprop="publicationNumber">US9144546B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-08-06</td>
          <td itemprop="publicationDate">2015-09-29</td>
          <td><span itemprop="assigneeOriginal">Clsn Laboratories, Inc.</span></td>
          <td itemprop="title">Nucleic acid-lipopolymer compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/BRPI0815725A2/en">
              <span itemprop="publicationNumber">BRPI0815725A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-08-23</td>
          <td itemprop="publicationDate">2015-02-10</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">
  OLIGONUCLEOTIDE DETECTION METHODS
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009030254A1/en">
              <span itemprop="publicationNumber">WO2009030254A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-09-04</td>
          <td itemprop="publicationDate">2009-03-12</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Complexes of rna and cationic peptides for transfection and for immunostimulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2632052T3/en">
              <span itemprop="publicationNumber">ES2632052T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-09-28</td>
          <td itemprop="publicationDate">2017-09-08</td>
          <td><span itemprop="assigneeOriginal">Pfizer Inc.</span></td>
          <td itemprop="title">
        Addressing to cancer cells using nanoparticles
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN101861165A/en">
              <span itemprop="publicationNumber">CN101861165A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-10-12</td>
          <td itemprop="publicationDate">2010-10-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Vaccine Nanotechnology
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW200927915A/en">
              <span itemprop="publicationNumber">TW200927915A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-10-25</td>
          <td itemprop="publicationDate">2009-07-01</td>
          <td><span itemprop="assigneeOriginal">Croda Int Plc</span></td>
          <td itemprop="title">Laundry formulations and method of cleaning 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2610340B1/en">
              <span itemprop="publicationNumber">EP2610340B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-12-11</td>
          <td itemprop="publicationDate">2014-10-01</td>
          <td><span itemprop="assigneeOriginal">The Scripps Research Institute</span></td>
          <td itemprop="title">Compositions and methods related to mRNA translational enhancer elements 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20110117125A1/en">
              <span itemprop="publicationNumber">US20110117125A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2008-01-02</td>
          <td itemprop="publicationDate">2011-05-19</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">Compositions and methods for the delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2537703T3/en">
              <span itemprop="publicationNumber">ES2537703T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-01-31</td>
          <td itemprop="publicationDate">2015-06-11</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">
        Nucleic acids comprising the formula (NuGlXmGnNv) a and its derivatives as immunostimulatory agents / adjuvants
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NZ588583A/en">
              <span itemprop="publicationNumber">NZ588583A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-15</td>
          <td itemprop="publicationDate">2012-08-31</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">Novel lipid formulations for nucleic acid delivery 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009129385A1/en">
              <span itemprop="publicationNumber">WO2009129385A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2008-04-16</td>
          <td itemprop="publicationDate">2009-10-22</td>
          <td><span itemprop="assigneeOriginal">Abbott Laboratories</span></td>
          <td itemprop="title">Cationic lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009127230A1/en">
              <span itemprop="publicationNumber">WO2009127230A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-16</td>
          <td itemprop="publicationDate">2009-10-22</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009129395A1/en">
              <span itemprop="publicationNumber">WO2009129395A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-16</td>
          <td itemprop="publicationDate">2009-10-22</td>
          <td><span itemprop="assigneeOriginal">Abbott Laboratories</span></td>
          <td itemprop="title">Cationic lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2010011680A/en">
              <span itemprop="publicationNumber">MX2010011680A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-25</td>
          <td itemprop="publicationDate">2011-05-03</td>
          <td><span itemprop="assigneeOriginal">Univ Northwestern</span></td>
          <td itemprop="title">Nanostructures suitable for sequestering cholesterol. 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8697098B2/en">
              <span itemprop="publicationNumber">US8697098B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-02-25</td>
          <td itemprop="publicationDate">2014-04-15</td>
          <td><span itemprop="assigneeOriginal">South Dakota State University</span></td>
          <td itemprop="title">Polymer conjugated protein micelles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL215513B1/en">
              <span itemprop="publicationNumber">PL215513B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-06-06</td>
          <td itemprop="publicationDate">2013-12-31</td>
          <td><span itemprop="assigneeOriginal">Univ Warszawski</span></td>
          <td itemprop="title">New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20170127069A/en">
              <span itemprop="publicationNumber">KR20170127069A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-06-16</td>
          <td itemprop="publicationDate">2017-11-20</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Drug loaded polymeric nanoparticles and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010005726A2/en">
              <span itemprop="publicationNumber">WO2010005726A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-06-16</td>
          <td itemprop="publicationDate">2010-01-14</td>
          <td><span itemprop="assigneeOriginal">Bind Biosciences Inc.</span></td>
          <td itemprop="title">Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL2285350T3/en">
              <span itemprop="publicationNumber">PL2285350T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-06-16</td>
          <td itemprop="publicationDate">2018-03-30</td>
          <td><span itemprop="assigneeOriginal">Pfizer Inc.</span></td>
          <td itemprop="title">Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201019963A/en">
              <span itemprop="publicationNumber">TW201019963A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-09-10</td>
          <td itemprop="publicationDate">2010-06-01</td>
          <td><span itemprop="assigneeOriginal">Abbott Lab</span></td>
          <td itemprop="title">Polyethylene glycol lipid conjugates and uses thereof 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010037408A1/en">
              <span itemprop="publicationNumber">WO2010037408A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-09-30</td>
          <td itemprop="publicationDate">2010-04-08</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2475065T3/en">
              <span itemprop="publicationNumber">ES2475065T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-10-09</td>
          <td itemprop="publicationDate">2014-07-10</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">
        Enhanced amino acids and methods for nucleic acid administration
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102245559B/en">
              <span itemprop="publicationNumber">CN102245559B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-07</td>
          <td itemprop="publicationDate">2015-05-27</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Aminoalcohol lipidoids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5747282B2/en">
              <span itemprop="publicationNumber">JP5747282B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-10</td>
          <td itemprop="publicationDate">2015-07-15</td>
          <td><span itemprop="assigneeOriginal">    </span></td>
          <td itemprop="title">
        Novel lipids and compositions for delivering therapeutic agents
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010057203A2/en">
              <span itemprop="publicationNumber">WO2010057203A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-17</td>
          <td itemprop="publicationDate">2010-05-20</td>
          <td><span itemprop="assigneeOriginal">The Board Of Regents Of The University Of Texas System</span></td>
          <td itemprop="title">Hdl particles for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010060818A1/en">
              <span itemprop="publicationNumber">WO2010060818A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-25</td>
          <td itemprop="publicationDate">2010-06-03</td>
          <td><span itemprop="assigneeOriginal">Basf Se</span></td>
          <td itemprop="title">Alkoxylated oligoamines or polyamines as oxidation stabilizers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010068866A2/en">
              <span itemprop="publicationNumber">WO2010068866A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-12-12</td>
          <td itemprop="publicationDate">2010-06-17</td>
          <td><span itemprop="assigneeOriginal">Bind Biosciences</span></td>
          <td itemprop="title">Therapeutic particles suitable for parenteral administration and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EA201100765A1/en">
              <span itemprop="publicationNumber">EA201100765A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-12-15</td>
          <td itemprop="publicationDate">2012-04-30</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
  Long-term circulation nanoparticles
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2010208035B2/en">
              <span itemprop="publicationNumber">AU2010208035B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-01-29</td>
          <td itemprop="publicationDate">2016-06-23</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">Improved lipid formulation for the delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010088927A1/en">
              <span itemprop="publicationNumber">WO2010088927A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-02-09</td>
          <td itemprop="publicationDate">2010-08-12</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20140141089A1/en">
              <span itemprop="publicationNumber">US20140141089A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-02-11</td>
          <td itemprop="publicationDate">2014-05-22</td>
          <td><span itemprop="assigneeOriginal">Colorado School Of Mines</span></td>
          <td itemprop="title">Nanoparticles, Compositions Thereof, and Methods of Use, and Methods of Making the Same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5782602B2/en">
              <span itemprop="publicationNumber">JP5782602B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-03-20</td>
          <td itemprop="publicationDate">2015-09-24</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Polyamine derivatives
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010127159A2/en">
              <span itemprop="publicationNumber">WO2010127159A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-04-30</td>
          <td itemprop="publicationDate">2010-11-04</td>
          <td><span itemprop="assigneeOriginal">Intezyne Technologies, Incorporated</span></td>
          <td itemprop="title">Polymeric micelles for polynucleotide encapsulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8715736B2/en">
              <span itemprop="publicationNumber">US8715736B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-04-30</td>
          <td itemprop="publicationDate">2014-05-06</td>
          <td><span itemprop="assigneeOriginal">Florida Agricultural And Mechanical University</span></td>
          <td itemprop="title">Nanoparticle formulations for skin delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010129687A1/en">
              <span itemprop="publicationNumber">WO2010129687A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-05-05</td>
          <td itemprop="publicationDate">2010-11-11</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc</span></td>
          <td itemprop="title">Methods of delivering oligonucleotides to immune cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102421417B/en">
              <span itemprop="publicationNumber">CN102421417B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-05-05</td>
          <td itemprop="publicationDate">2016-03-02</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid composition 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102985548B/en">
              <span itemprop="publicationNumber">CN102985548B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-05-16</td>
          <td itemprop="publicationDate">2016-10-26</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Compositions comprising cationic amphiphiles and colipids for delivery of therapeutic molecules
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NZ712719A/en">
              <span itemprop="publicationNumber">NZ712719A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-06-10</td>
          <td itemprop="publicationDate">2017-03-31</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corp</span></td>
          <td itemprop="title">Improved lipid formulation 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5894913B2/en">
              <span itemprop="publicationNumber">JP5894913B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-06-15</td>
          <td itemprop="publicationDate">2016-03-30</td>
          <td><span itemprop="assigneeOriginal">    </span></td>
          <td itemprop="title">
  DSRNA formulated with lipids targeting the PCSK9 gene
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011000106A1/en">
              <span itemprop="publicationNumber">WO2011000106A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-07-01</td>
          <td itemprop="publicationDate">2011-01-06</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Improved cationic lipids and methods for the delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2767127A1/en">
              <span itemprop="publicationNumber">CA2767127A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-07-01</td>
          <td itemprop="publicationDate">2011-01-06</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Novel lipid formulations for delivery of therapeutic agents to solid tumors 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9018187B2/en">
              <span itemprop="publicationNumber">US9018187B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-07-01</td>
          <td itemprop="publicationDate">2015-04-28</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Cationic lipids and methods for the delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2281579A1/en">
              <span itemprop="publicationNumber">EP2281579A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-08-05</td>
          <td itemprop="publicationDate">2011-02-09</td>
          <td><span itemprop="assigneeOriginal">BioNTech AG</span></td>
          <td itemprop="title">Vaccine composition comprising 5&#39;-Cap modified RNA 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011017548A1/en">
              <span itemprop="publicationNumber">WO2011017548A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-08-05</td>
          <td itemprop="publicationDate">2011-02-10</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20110053829A1/en">
              <span itemprop="publicationNumber">US20110053829A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-09-03</td>
          <td itemprop="publicationDate">2011-03-03</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8449916B1/en">
              <span itemprop="publicationNumber">US8449916B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-11-06</td>
          <td itemprop="publicationDate">2013-05-28</td>
          <td><span itemprop="assigneeOriginal">Iowa State University Research Foundation, Inc.</span></td>
          <td itemprop="title">Antimicrobial compositions and methods 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PH12012500929A1/en">
              <span itemprop="publicationNumber">PH12012500929A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-11-12</td>
          <td itemprop="publicationDate">2012-11-26</td>
          <td><span itemprop="assigneeOriginal">Kao Corp</span></td>
          <td itemprop="title">Method for producing olefins 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3403647A1/en">
              <span itemprop="publicationNumber">EP3403647A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-01</td>
          <td itemprop="publicationDate">2018-11-21</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2010328336B2/en">
              <span itemprop="publicationNumber">AU2010328336B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-07</td>
          <td itemprop="publicationDate">2017-03-02</td>
          <td><span itemprop="assigneeOriginal">Arbutus Biopharma Corporation</span></td>
          <td itemprop="title">Compositions for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011069529A1/en">
              <span itemprop="publicationNumber">WO2011069529A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-09</td>
          <td itemprop="publicationDate">2011-06-16</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EA036522B1/en">
              <span itemprop="publicationNumber">EA036522B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-11</td>
          <td itemprop="publicationDate">2020-11-19</td>
          <td><span itemprop="assigneeOriginal"> .</span></td>
          <td itemprop="title">Pharmaceutical composition suitable for lyophilization comprising a plurality of therapeutic particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NZ600725A/en">
              <span itemprop="publicationNumber">NZ600725A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-18</td>
          <td itemprop="publicationDate">2015-08-28</td>
          <td><span itemprop="assigneeOriginal">Univ British Colombia</span></td>
          <td itemprop="title">Methods and compositions for delivery of nucleic acids 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2010334911A1/en">
              <span itemprop="publicationNumber">AU2010334911A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-23</td>
          <td itemprop="publicationDate">2012-07-12</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Lipids, lipid compositions, and methods of using them 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9149432B2/en">
              <span itemprop="publicationNumber">US9149432B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-03-19</td>
          <td itemprop="publicationDate">2015-10-06</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Lipid vesicle compositions and methods of use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8207290B2/en">
              <span itemprop="publicationNumber">US8207290B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-03-26</td>
          <td itemprop="publicationDate">2012-06-26</td>
          <td><span itemprop="assigneeOriginal">Cerulean Pharma Inc.</span></td>
          <td itemprop="title">Methods and systems for generating nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2558074B1/en">
              <span itemprop="publicationNumber">EP2558074B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-04-08</td>
          <td itemprop="publicationDate">2018-06-06</td>
          <td><span itemprop="assigneeOriginal">The Trustees of Princeton University</span></td>
          <td itemprop="title">Preparation of lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2745113T3/en">
              <span itemprop="publicationNumber">ES2745113T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-04-09</td>
          <td itemprop="publicationDate">2020-02-27</td>
          <td><span itemprop="assigneeOriginal">Pacira Pharmaceuticals Inc</span></td>
          <td itemprop="title">
  Method for formulating multivesicular liposomes
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011136368A1/en">
              <span itemprop="publicationNumber">WO2011136368A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-04-28</td>
          <td itemprop="publicationDate">2011-11-03</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20130156845A1/en">
              <span itemprop="publicationNumber">US20130156845A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-04-29</td>
          <td itemprop="publicationDate">2013-06-20</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Lipid formulated single stranded rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9254327B2/en">
              <span itemprop="publicationNumber">US9254327B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-10</td>
          <td itemprop="publicationDate">2016-02-09</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Methods and compositions for delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20130123338A1/en">
              <span itemprop="publicationNumber">US20130123338A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-12</td>
          <td itemprop="publicationDate">2013-05-16</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Novel cationic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011141704A1/en">
              <span itemprop="publicationNumber">WO2011141704A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-12</td>
          <td itemprop="publicationDate">2011-11-17</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc</span></td>
          <td itemprop="title">Novel cyclic cationic lipids and methods of use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2387999A1/en">
              <span itemprop="publicationNumber">EP2387999A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-21</td>
          <td itemprop="publicationDate">2011-11-23</td>
          <td><span itemprop="assigneeOriginal">CureVac GmbH</span></td>
          <td itemprop="title">Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8802863B2/en">
              <span itemprop="publicationNumber">US8802863B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-24</td>
          <td itemprop="publicationDate">2014-08-12</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Amino alcohol cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8748667B2/en">
              <span itemprop="publicationNumber">US8748667B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-06-04</td>
          <td itemprop="publicationDate">2014-06-10</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Low molecular weight cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012000104A1/en">
              <span itemprop="publicationNumber">WO2012000104A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-06-30</td>
          <td itemprop="publicationDate">2012-01-05</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Non-liposomal systems for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5635690B2/en">
              <span itemprop="publicationNumber">JP5635690B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-01</td>
          <td itemprop="publicationDate">2014-12-03</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        Cancer treatment and diagnosis method using bacteria-derived microvesicles
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2590626B1/en">
              <span itemprop="publicationNumber">EP2590626B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2015-10-28</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Liposomes with lipids having an advantageous pka-value for rna delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9192661B2/en">
              <span itemprop="publicationNumber">US9192661B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2015-11-24</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Delivery of self-replicating RNA using biodegradable polymer particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2804494A1/en">
              <span itemprop="publicationNumber">CA2804494A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-06</td>
          <td itemprop="publicationDate">2012-01-12</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Virion-like delivery particles for self-replicating rna molecules 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20130230884A1/en">
              <span itemprop="publicationNumber">US20130230884A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-16</td>
          <td itemprop="publicationDate">2013-09-05</td>
          <td><span itemprop="assigneeOriginal">John Chaput</span></td>
          <td itemprop="title">Methods to Identify Synthetic and Natural RNA Elements that Enhance Protein Translation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8968746B2/en">
              <span itemprop="publicationNumber">US8968746B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-07-30</td>
          <td itemprop="publicationDate">2015-03-03</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012019630A1/en">
              <span itemprop="publicationNumber">WO2012019630A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-13</td>
          <td itemprop="publicationDate">2012-02-16</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012024595A2/en">
              <span itemprop="publicationNumber">WO2012024595A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-20</td>
          <td itemprop="publicationDate">2012-02-23</td>
          <td><span itemprop="assigneeOriginal">University Of Washington</span></td>
          <td itemprop="title">Circumferential aerosol device for delivering drugs to olfactory epithelium and brain 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN103384515B/en">
              <span itemprop="publicationNumber">CN103384515B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-31</td>
          <td itemprop="publicationDate">2017-02-15</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipids suitable for liposomal delivery of protein-coding RNA 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4066857B1/en">
              <span itemprop="publicationNumber">EP4066857B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-31</td>
          <td itemprop="publicationDate">2022-12-21</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Pegylated liposomes for delivery of immunogen-encoding rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4008357B1/en">
              <span itemprop="publicationNumber">EP4008357B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-08-31</td>
          <td itemprop="publicationDate">2022-12-28</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Small liposomes for delivery of immunogen-encoding rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9549901B2/en">
              <span itemprop="publicationNumber">US9549901B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-03</td>
          <td itemprop="publicationDate">2017-01-24</td>
          <td><span itemprop="assigneeOriginal">The Brigham And Women&#39;s Hospital, Inc.</span></td>
          <td itemprop="title">Lipid-polymer hybrid particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10307372B2/en">
              <span itemprop="publicationNumber">US10307372B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-10</td>
          <td itemprop="publicationDate">2019-06-04</td>
          <td><span itemprop="assigneeOriginal">The Johns Hopkins University</span></td>
          <td itemprop="title">Rapid diffusion of large polymeric nanoparticles in the mammalian brain 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2987915T3/en">
              <span itemprop="publicationNumber">ES2987915T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-20</td>
          <td itemprop="publicationDate">2024-11-18</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics Inc</span></td>
          <td itemprop="title">
        Novel low molecular weight cationic lipids for oligonucleotide delivery
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2013540757A/en">
              <span itemprop="publicationNumber">JP2013540757A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-24</td>
          <td itemprop="publicationDate">2013-11-07</td>
          <td><span itemprop="assigneeOriginal">          </span></td>
          <td itemprop="title">
        Nanostructured gel with the ability to control the release of encapsulated agent
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2621480B1/en">
              <span itemprop="publicationNumber">EP2621480B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-30</td>
          <td itemprop="publicationDate">2018-08-15</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Low molecular weight cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3485913A1/en">
              <span itemprop="publicationNumber">EP3485913A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-10-21</td>
          <td itemprop="publicationDate">2019-05-22</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Low molecular weight cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113214102A/en">
              <span itemprop="publicationNumber">CN113214102A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-11-15</td>
          <td itemprop="publicationDate">2021-08-06</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Amine-containing transfection reagents and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012089225A1/en">
              <span itemprop="publicationNumber">WO2012089225A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-12-29</td>
          <td itemprop="publicationDate">2012-07-05</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Combination of vaccination and inhibition of mhc class i restricted antigen presentation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102068701B/en">
              <span itemprop="publicationNumber">CN102068701B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-01-18</td>
          <td itemprop="publicationDate">2012-11-07</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Application of cleavable polyethylene glycol (PEG) lipid derivative in preparation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2667898A1/en">
              <span itemprop="publicationNumber">EP2667898A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-01-26</td>
          <td itemprop="publicationDate">2013-12-04</td>
          <td><span itemprop="assigneeOriginal">Cenix Bioscience GmbH</span></td>
          <td itemprop="title">Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10363309B2/en">
              <span itemprop="publicationNumber">US10363309B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-02-04</td>
          <td itemprop="publicationDate">2019-07-30</td>
          <td><span itemprop="assigneeOriginal">Case Western Reserve University</span></td>
          <td itemprop="title">Targeted nanoparticle conjugates 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012116715A1/en">
              <span itemprop="publicationNumber">WO2012116715A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-03-02</td>
          <td itemprop="publicationDate">2012-09-07</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Vaccination in newborns and infants 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2827118A1/en">
              <span itemprop="publicationNumber">CA2827118A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-02-15</td>
          <td itemprop="publicationDate">2012-08-23</td>
          <td><span itemprop="assigneeOriginal">Merrimack Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivering nucleic acid to a cell 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012113413A1/en">
              <span itemprop="publicationNumber">WO2012113413A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-02-21</td>
          <td itemprop="publicationDate">2012-08-30</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012116714A1/en">
              <span itemprop="publicationNumber">WO2012116714A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-03-02</td>
          <td itemprop="publicationDate">2012-09-07</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Vaccination in elderly patients 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102204920B/en">
              <span itemprop="publicationNumber">CN102204920B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-03-18</td>
          <td itemprop="publicationDate">2013-03-20</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Solid preparation of sodium aspirin and sodium pravastatin medicinal composition 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2688590B1/en">
              <span itemprop="publicationNumber">EP2688590B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-03-24</td>
          <td itemprop="publicationDate">2020-02-12</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Adjuvant nanoemulsions with phospholipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012142132A1/en">
              <span itemprop="publicationNumber">WO2012142132A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-04-11</td>
          <td itemprop="publicationDate">2012-10-18</td>
          <td><span itemprop="assigneeOriginal">Life Technologies Corporation</span></td>
          <td itemprop="title">Polymer particles and methods of making and using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013158127A1/en">
              <span itemprop="publicationNumber">WO2013158127A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-16</td>
          <td itemprop="publicationDate">2013-10-24</td>
          <td><span itemprop="assigneeOriginal">Molecular Transfer, Inc.</span></td>
          <td itemprop="title">Agents for improved delivery of nucleic acids to eukaryotic cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2012149376A2/en">
              <span itemprop="publicationNumber">WO2012149376A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-04-28</td>
          <td itemprop="publicationDate">2012-11-01</td>
          <td><span itemprop="assigneeOriginal">Stc.Unm</span></td>
          <td itemprop="title">Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery and methods of using same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EA201790030A1/en">
              <span itemprop="publicationNumber">EA201790030A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-04-29</td>
          <td itemprop="publicationDate">2017-09-29</td>
          <td><span itemprop="assigneeOriginal"> , .</span></td>
          <td itemprop="title">
        NANOSEAGES CAUSING IMMUNE TOLERANCE TO REDUCE THE RESPONSE REACTION OF CYTOTOXIC T-LYMPHOCYTES
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2012254842A1/en">
              <span itemprop="publicationNumber">AU2012254842A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-05-12</td>
          <td itemprop="publicationDate">2013-05-02</td>
          <td><span itemprop="assigneeOriginal">Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.</span></td>
          <td itemprop="title">Liposomes comprising polymer-conjugated lipids and related uses 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8691750B2/en">
              <span itemprop="publicationNumber">US8691750B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-05-17</td>
          <td itemprop="publicationDate">2014-04-08</td>
          <td><span itemprop="assigneeOriginal">Axolabs Gmbh</span></td>
          <td itemprop="title">Lipids and compositions for intracellular delivery of biologically active compounds 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013052167A2/en">
              <span itemprop="publicationNumber">WO2013052167A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-02</td>
          <td itemprop="publicationDate">2013-04-11</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of California</span></td>
          <td itemprop="title">Membrane encapsulated nanoparticles and method of use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2987057T3/en">
              <span itemprop="publicationNumber">ES2987057T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-08</td>
          <td itemprop="publicationDate">2024-11-13</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">
        Cleavable lipids
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2740248T3/en">
              <span itemprop="publicationNumber">ES2740248T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-08</td>
          <td itemprop="publicationDate">2020-02-05</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">
        Lipid nanoparticle compositions and methods for mRNA administration
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN102813929B/en">
              <span itemprop="publicationNumber">CN102813929B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-09</td>
          <td itemprop="publicationDate">2014-04-09</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Low-concentration polyethylene glycol-lipid (PEG-lipid) derivative and application thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2840977A1/en">
              <span itemprop="publicationNumber">CA2840977A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2013-01-10</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Liposomes having useful n:p ratio for delivery of rna molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN103781470A/en">
              <span itemprop="publicationNumber">CN103781470A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2014-05-07</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Oil-in-water emulsions that contain nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3508219A1/en">
              <span itemprop="publicationNumber">EP3508219A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2019-07-10</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals S.A.</span></td>
          <td itemprop="title">Self-replicating rna prime - protein boost vaccines 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2729165B1/en">
              <span itemprop="publicationNumber">EP2729165B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2017-11-08</td>
          <td><span itemprop="assigneeOriginal">GlaxoSmithKline Biologicals SA</span></td>
          <td itemprop="title">Immunogenic combination compositions and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP6120839B2/en">
              <span itemprop="publicationNumber">JP6120839B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-07-06</td>
          <td itemprop="publicationDate">2017-04-26</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Cationic oil-in-water emulsion
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013016058A1/en">
              <span itemprop="publicationNumber">WO2013016058A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2011-07-22</td>
          <td itemprop="publicationDate">2013-01-31</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2014525461A/en">
              <span itemprop="publicationNumber">JP2014525461A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-08-31</td>
          <td itemprop="publicationDate">2014-09-29</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
        PEGylated liposomes for delivery of RNA encoding immunogens
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN103930135A/en">
              <span itemprop="publicationNumber">CN103930135A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-08-31</td>
          <td itemprop="publicationDate">2014-07-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Nanoparticle PEG modification with H-phosphonates 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9126966B2/en">
              <span itemprop="publicationNumber">US9126966B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-08-31</td>
          <td itemprop="publicationDate">2015-09-08</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Cationic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4245369A3/en">
              <span itemprop="publicationNumber">EP4245369A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-09-08</td>
          <td itemprop="publicationDate">2023-11-22</td>
          <td><span itemprop="assigneeOriginal">Sage Therapeutics, Inc.</span></td>
          <td itemprop="title">Neuroactive steroids, compositions, and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013072929A2/en">
              <span itemprop="publicationNumber">WO2013072929A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-09-23</td>
          <td itemprop="publicationDate">2013-05-23</td>
          <td><span itemprop="assigneeOriginal">Indian Institute Of Technology</span></td>
          <td itemprop="title">Nanop article based cosmetic composition 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9701623B2/en">
              <span itemprop="publicationNumber">US9701623B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-09-27</td>
          <td itemprop="publicationDate">2017-07-11</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Di-aliphatic substituted pegylated lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2852064A1/en">
              <span itemprop="publicationNumber">CA2852064A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-14</td>
          <td itemprop="publicationDate">2013-04-18</td>
          <td><span itemprop="assigneeOriginal">Stc.Unm</span></td>
          <td itemprop="title">Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN103987847B/en">
              <span itemprop="publicationNumber">CN103987847B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-18</td>
          <td itemprop="publicationDate">2017-06-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Amine cationic lipids and uses thereof
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013057715A1/en">
              <span itemprop="publicationNumber">WO2013057715A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-20</td>
          <td itemprop="publicationDate">2013-04-25</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">Adjuvanted influenza b virus vaccines for pediatric priming 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013059922A1/en">
              <span itemprop="publicationNumber">WO2013059922A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-25</td>
          <td itemprop="publicationDate">2013-05-02</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Limit size lipid nanoparticles and related methods 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/FR2981941B1/en">
              <span itemprop="publicationNumber">FR2981941B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-26</td>
          <td itemprop="publicationDate">2014-06-06</td>
          <td><span itemprop="assigneeOriginal">Commissariat Energie Atomique</span></td>
          <td itemprop="title">
        METHOD FOR DIRECTLY TREATING AND BONDING A LAYER OF MATERIAL
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN104023793B/en">
              <span itemprop="publicationNumber">CN104023793B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-31</td>
          <td itemprop="publicationDate">2017-11-24</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Joint liposome composition for treating cancer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9579338B2/en">
              <span itemprop="publicationNumber">US9579338B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2017-02-28</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corporation</span></td>
          <td itemprop="title">Method of producing lipid nanoparticles for drug delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9872870B2/en">
              <span itemprop="publicationNumber">US9872870B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2018-01-23</td>
          <td><span itemprop="assigneeOriginal">University Of Notre Dame Du Lac</span></td>
          <td itemprop="title">Multifunctional micellar nanoparticle-based drug and targeting agent system 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RS58562B1/en">
              <span itemprop="publicationNumber">RS58562B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2019-05-31</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corp</span></td>
          <td itemprop="title">Method for sterilely producing lipid-nucleic acid particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2776013B8/en">
              <span itemprop="publicationNumber">EP2776013B8</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-08</td>
          <td itemprop="publicationDate">2023-08-30</td>
          <td><span itemprop="assigneeOriginal">The Board of Trustees of the University of Arkansas</span></td>
          <td itemprop="title">Methods and compositions for x-ray induced release from ph sensitive liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2785333A4/en">
              <span itemprop="publicationNumber">EP2785333A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-02</td>
          <td itemprop="publicationDate">2015-04-01</td>
          <td><span itemprop="assigneeOriginal">Pegasus Lab Inc</span></td>
          <td itemprop="title">
        EXTENDED RELEASE COMPOSITIONS BASED ON AMPHIPATHIC LIPIDS
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20140308304A1/en">
              <span itemprop="publicationNumber">US20140308304A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-07</td>
          <td itemprop="publicationDate">2014-10-16</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Lipids for the delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2788316B1/en">
              <span itemprop="publicationNumber">EP2788316B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-07</td>
          <td itemprop="publicationDate">2019-04-24</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3165769A1/en">
              <span itemprop="publicationNumber">CA3165769A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-07</td>
          <td itemprop="publicationDate">2013-06-13</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Biodegradable lipids for the delivery of active agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013086526A1/en">
              <span itemprop="publicationNumber">WO2013086526A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-09</td>
          <td itemprop="publicationDate">2013-06-13</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of California</span></td>
          <td itemprop="title">Liposomal drug encapsulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2012353463B2/en">
              <span itemprop="publicationNumber">AU2012353463B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-12</td>
          <td itemprop="publicationDate">2017-08-24</td>
          <td><span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co., Ltd.</span></td>
          <td itemprop="title">Lipid nanoparticles containing combinations of cationic lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013089151A1/en">
              <span itemprop="publicationNumber">WO2013089151A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-12</td>
          <td itemprop="publicationDate">2013-06-20</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticles for drug delivery system containing cationic lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2604253A1/en">
              <span itemprop="publicationNumber">EP2604253A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-13</td>
          <td itemprop="publicationDate">2013-06-19</td>
          <td><span itemprop="assigneeOriginal">Otto Glatter</span></td>
          <td itemprop="title">Water-in-oil emulsions and methods for their preparation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9636414B2/en">
              <span itemprop="publicationNumber">US9636414B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-15</td>
          <td itemprop="publicationDate">2017-05-02</td>
          <td><span itemprop="assigneeOriginal">Biontech Ag</span></td>
          <td itemprop="title">Particles comprising single stranded RNA and double stranded RNA for immunomodulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HRP20220717T1/en">
              <span itemprop="publicationNumber">HRP20220717T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-16</td>
          <td itemprop="publicationDate">2022-07-22</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Modified mrna compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013103659A1/en">
              <span itemprop="publicationNumber">WO2013103659A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-01-04</td>
          <td itemprop="publicationDate">2013-07-11</td>
          <td><span itemprop="assigneeOriginal">Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College</span></td>
          <td itemprop="title">Stabilizing rna by incorporating chain-terminating nucleosides at the 3&#39;-terminus 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013113325A1/en">
              <span itemprop="publicationNumber">WO2013113325A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-01-31</td>
          <td itemprop="publicationDate">2013-08-08</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Negatively charged nucleic acid comprising complexes for immunostimulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013113326A1/en">
              <span itemprop="publicationNumber">WO2013113326A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-01-31</td>
          <td itemprop="publicationDate">2013-08-08</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2623121A1/en">
              <span itemprop="publicationNumber">EP2623121A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-01-31</td>
          <td itemprop="publicationDate">2013-08-07</td>
          <td><span itemprop="assigneeOriginal">Bayer Innovation GmbH</span></td>
          <td itemprop="title">Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2812360B1/en">
              <span itemprop="publicationNumber">EP2812360B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-09</td>
          <td itemprop="publicationDate">2022-08-31</td>
          <td><span itemprop="assigneeOriginal">Life Technologies Corporation</span></td>
          <td itemprop="title">Hydrophilic polymeric particles and methods for making same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013120499A1/en">
              <span itemprop="publicationNumber">WO2013120499A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-15</td>
          <td itemprop="publicationDate">2013-08-22</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013120498A1/en">
              <span itemprop="publicationNumber">WO2013120498A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-15</td>
          <td itemprop="publicationDate">2013-08-22</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013120500A1/en">
              <span itemprop="publicationNumber">WO2013120500A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-15</td>
          <td itemprop="publicationDate">2013-08-22</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013120497A1/en">
              <span itemprop="publicationNumber">WO2013120497A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-15</td>
          <td itemprop="publicationDate">2013-08-22</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HK1205751A1/en">
              <span itemprop="publicationNumber">HK1205751A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-22</td>
          <td itemprop="publicationDate">2015-12-24</td>
          <td><span itemprop="assigneeOriginal">Cerulean Pharma Inc.</span></td>
          <td itemprop="title">Conjugates, particles, compositions, and related methods 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20130243867A1/en">
              <span itemprop="publicationNumber">US20130243867A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-23</td>
          <td itemprop="publicationDate">2013-09-19</td>
          <td><span itemprop="assigneeOriginal">University Of South Florida (A Florida Non-Profit Corporation)</span></td>
          <td itemprop="title">Micelle compositions and methods for their use 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG11201405157PA/en">
              <span itemprop="publicationNumber">SG11201405157PA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-02-24</td>
          <td itemprop="publicationDate">2014-10-30</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc</span></td>
          <td itemprop="title">Trialkyl cationic lipids and methods of use thereof 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10322089B2/en">
              <span itemprop="publicationNumber">US10322089B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-14</td>
          <td itemprop="publicationDate">2019-06-18</td>
          <td><span itemprop="assigneeOriginal">The Board Of Trustees Of The Leland Stanford Junior University</span></td>
          <td itemprop="title">Nanoparticles, nanoparticle delivery methods, and systems of delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/NO2825156T3/en">
              <span itemprop="publicationNumber">NO2825156T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-16</td>
          <td itemprop="publicationDate">2017-12-23</td>
          <td></td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013143555A1/en">
              <span itemprop="publicationNumber">WO2013143555A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-26</td>
          <td itemprop="publicationDate">2013-10-03</td>
          <td><span itemprop="assigneeOriginal">Biontech Ag</span></td>
          <td itemprop="title">Rna formulation for immunotherapy 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2830991A1/en">
              <span itemprop="publicationNumber">EP2830991A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-26</td>
          <td itemprop="publicationDate">2015-02-04</td>
          <td><span itemprop="assigneeOriginal">President and Fellows of Harvard College</span></td>
          <td itemprop="title">Lipid-coated nucleic acid nanostructures of defined shape 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG10201710631RA/en">
              <span itemprop="publicationNumber">SG10201710631RA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-27</td>
          <td itemprop="publicationDate">2018-02-27</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Artificial nucleic acid molecules for improved protein or peptide expression 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20140139101A/en">
              <span itemprop="publicationNumber">KR20140139101A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-27</td>
          <td itemprop="publicationDate">2014-12-04</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Artificial nucleic acid molecules comprising a 5&#39;top utr 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR102186497B1/en">
              <span itemprop="publicationNumber">KR102186497B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-27</td>
          <td itemprop="publicationDate">2020-12-04</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Artificial nucleic acid molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2013240051B2/en">
              <span itemprop="publicationNumber">AU2013240051B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-27</td>
          <td itemprop="publicationDate">2017-11-30</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Diether based biodegradable cationic lipids for siRNA delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2868030C/en">
              <span itemprop="publicationNumber">CA2868030C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-29</td>
          <td itemprop="publicationDate">2021-05-25</td>
          <td><span itemprop="assigneeOriginal">Shire Human Genetic Therapies, Inc.</span></td>
          <td itemprop="title">Lipid-derived neutral nanoparticles 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20150064115A1/en">
              <span itemprop="publicationNumber">US20150064115A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-05</td>
          <td itemprop="publicationDate">2015-03-05</td>
          <td><span itemprop="assigneeOriginal">University Of Florida Research Foundation, Inc.</span></td>
          <td itemprop="title">Neurophilic nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL2836234T3/en">
              <span itemprop="publicationNumber">PL2836234T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-12</td>
          <td itemprop="publicationDate">2020-02-28</td>
          <td><span itemprop="assigneeOriginal">Yale University</span></td>
          <td itemprop="title">Vehicles for controlled delivery of different pharmaceutical agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013158579A1/en">
              <span itemprop="publicationNumber">WO2013158579A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-19</td>
          <td itemprop="publicationDate">2013-10-24</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013163234A1/en">
              <span itemprop="publicationNumber">WO2013163234A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-04-23</td>
          <td itemprop="publicationDate">2013-10-31</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Stable layer-by-layer coated particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/HK1208377A1/en">
              <span itemprop="publicationNumber">HK1208377A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-05-04</td>
          <td itemprop="publicationDate">2016-03-04</td>
          <td><span itemprop="assigneeOriginal">The Johns Hopkins University</span></td>
          <td itemprop="title">Lipid-based drug carriers for rapid penetration through mucus linings 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013173693A1/en">
              <span itemprop="publicationNumber">WO2013173693A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-05-18</td>
          <td itemprop="publicationDate">2013-11-21</td>
          <td><span itemprop="assigneeOriginal">The United States Of America, As Represented By The Secretary, Department Of Health And Human Services</span></td>
          <td itemprop="title">Nanoparticles with enhanced entry into cancer cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN104582691A/en">
              <span itemprop="publicationNumber">CN104582691A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-05-23</td>
          <td itemprop="publicationDate">2015-04-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3498267A1/en">
              <span itemprop="publicationNumber">EP3498267A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-05-25</td>
          <td itemprop="publicationDate">2019-06-19</td>
          <td><span itemprop="assigneeOriginal">CureVac AG</span></td>
          <td itemprop="title">Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN104519915A/en">
              <span itemprop="publicationNumber">CN104519915A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-06-08</td>
          <td itemprop="publicationDate">2015-04-15</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Pulmonary delivery of mRNA to non-lung target cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI2858974T1/en">
              <span itemprop="publicationNumber">SI2858974T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-06-08</td>
          <td itemprop="publicationDate">2019-01-31</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corporation</span></td>
          <td itemprop="title">Lipids for therapeutic agent delivery formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201408625A/en">
              <span itemprop="publicationNumber">TW201408625A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-07-06</td>
          <td itemprop="publicationDate">2014-03-01</td>
          <td><span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co Ltd</span></td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014008334A1/en">
              <span itemprop="publicationNumber">WO2014008334A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-07-06</td>
          <td itemprop="publicationDate">2014-01-09</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Stable non-aggregating nucleic acid lipid particle formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9956291B2/en">
              <span itemprop="publicationNumber">US9956291B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-07-10</td>
          <td itemprop="publicationDate">2018-05-01</td>
          <td><span itemprop="assigneeOriginal">Shaker A. Mousa</span></td>
          <td itemprop="title">Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014028487A1/en">
              <span itemprop="publicationNumber">WO2014028487A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-08-13</td>
          <td itemprop="publicationDate">2014-02-20</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Amine-containing lipidoids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2881605A1/en">
              <span itemprop="publicationNumber">CA2881605A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-08-14</td>
          <td itemprop="publicationDate">2014-02-20</td>
          <td><span itemprop="assigneeOriginal">Aaron FROESE</span></td>
          <td itemprop="title">Internal structured self assembling liposomes 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2013302526B2/en">
              <span itemprop="publicationNumber">AU2013302526B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-08-15</td>
          <td itemprop="publicationDate">2018-03-22</td>
          <td><span itemprop="assigneeOriginal">The University Of Chicago</span></td>
          <td itemprop="title">Exosome-based therapeutics against neurodegenerative disorders 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014047649A1/en">
              <span itemprop="publicationNumber">WO2014047649A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-09-24</td>
          <td itemprop="publicationDate">2014-03-27</td>
          <td><span itemprop="assigneeOriginal">The Regents Of The University Of California</span></td>
          <td itemprop="title">Methods for arranging and packing nucleic acids for unusual resistance to nucleases and targeted delivery for gene therapy 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2925687A1/en">
              <span itemprop="publicationNumber">CA2925687A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-09-27</td>
          <td itemprop="publicationDate">2014-04-03</td>
          <td><span itemprop="assigneeOriginal">The University Of North Carolina At Chapel Hill</span></td>
          <td itemprop="title">Lipid coated nanoparticles containing agents having low aqueous and lipid solubilities and methods thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014048969A1/en">
              <span itemprop="publicationNumber">WO2014048969A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-09-28</td>
          <td itemprop="publicationDate">2014-04-03</td>
          <td><span itemprop="assigneeOriginal">Ionovation Gmbh</span></td>
          <td itemprop="title">Reactive, lipophilic nucleoside building blocks for the synthesis of hydrophobic nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014054026A1/en">
              <span itemprop="publicationNumber">WO2014054026A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-10-04</td>
          <td itemprop="publicationDate">2014-04-10</td>
          <td><span itemprop="assigneeOriginal">University Of The Witwatersrand, Johannesburg</span></td>
          <td itemprop="title">Liposomal drug delivery system 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014071072A2/en">
              <span itemprop="publicationNumber">WO2014071072A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-11-02</td>
          <td itemprop="publicationDate">2014-05-08</td>
          <td><span itemprop="assigneeOriginal">Pungente Michael D</span></td>
          <td itemprop="title">Novel cationic carotenoid-based lipids for cellular nucleic acid uptake 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014072997A1/en">
              <span itemprop="publicationNumber">WO2014072997A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-11-07</td>
          <td itemprop="publicationDate">2014-05-15</td>
          <td><span itemprop="assigneeOriginal">Council Of Scientific &amp; Industrial Research</span></td>
          <td itemprop="title">Nanocomplex containing amphipathic peptide useful for efficient transfection of biomolecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2014089486A1/en">
              <span itemprop="publicationNumber">WO2014089486A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-12-07</td>
          <td itemprop="publicationDate">2014-06-12</td>
          <td><span itemprop="assigneeOriginal">Shire Human Genetic Therapies, Inc.</span></td>
          <td itemprop="title">Lipidic nanoparticles for mrna delivering 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG10201710472PA/en">
              <span itemprop="publicationNumber">SG10201710472PA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-02-22</td>
          <td itemprop="publicationDate">2018-02-27</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Combination of vaccination and inhibition of the pd-1 pathway 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20160032316A1/en">
              <span itemprop="publicationNumber">US20160032316A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-03-14</td>
          <td itemprop="publicationDate">2016-02-04</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2795249T3/en">
              <span itemprop="publicationNumber">ES2795249T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-03-15</td>
          <td itemprop="publicationDate">2020-11-23</td>
          <td><span itemprop="assigneeOriginal">Translate Bio Inc</span></td>
          <td itemprop="title">
  Synergistic enhancement of nucleic acid delivery through mixed formulations
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN105143456A/en">
              <span itemprop="publicationNumber">CN105143456A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-03-15</td>
          <td itemprop="publicationDate">2015-12-09</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticles for transfection and related methods 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10246708B2/en">
              <span itemprop="publicationNumber">US10246708B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-05-06</td>
          <td itemprop="publicationDate">2019-04-02</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Dosages and methods for delivering lipid formulated nucleic acid molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9895443B2/en">
              <span itemprop="publicationNumber">US9895443B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-06-26</td>
          <td itemprop="publicationDate">2018-02-20</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Multi-tailed lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2015002667A1/en">
              <span itemprop="publicationNumber">WO2015002667A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-07-01</td>
          <td itemprop="publicationDate">2015-01-08</td>
          <td><span itemprop="assigneeOriginal">Myq, Inc.</span></td>
          <td itemprop="title">A location regulated point-of-sale system and enhancements 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2919226C/en">
              <span itemprop="publicationNumber">CA2919226C</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-07-23</td>
          <td itemprop="publicationDate">2024-05-14</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivering messenger rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2014310935B2/en">
              <span itemprop="publicationNumber">AU2014310935B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2019-11-21</td>
          <td><span itemprop="assigneeOriginal">CureVac SE</span></td>
          <td itemprop="title">Combination vaccine 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN105517569A/en">
              <span itemprop="publicationNumber">CN105517569A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2016-04-20</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Rabies vaccine 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RU2733424C2/en">
              <span itemprop="publicationNumber">RU2733424C2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2020-10-01</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Method for increasing the expression of encoded rna proteins 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SG10201801433XA/en">
              <span itemprop="publicationNumber">SG10201801433XA</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2018-04-27</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Composition and vaccine for treating prostate cancer 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN105473158B/en">
              <span itemprop="publicationNumber">CN105473158B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2021-04-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Respiratory Syncytial Virus (RSV) vaccine 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2015024666A1/en">
              <span itemprop="publicationNumber">WO2015024666A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-08-21</td>
          <td itemprop="publicationDate">2015-02-26</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Composition and vaccine for treating lung cancer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2015062738A1/en">
              <span itemprop="publicationNumber">WO2015062738A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-11-01</td>
          <td itemprop="publicationDate">2015-05-07</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Modified rna with decreased immunostimulatory properties 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9365610B2/en">
              <span itemprop="publicationNumber">US9365610B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-11-18</td>
          <td itemprop="publicationDate">2016-06-14</td>
          <td><span itemprop="assigneeOriginal">Arcturus Therapeutics, Inc.</span></td>
          <td itemprop="title">Asymmetric ionizable cationic lipid for RNA delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2908827T3/en">
              <span itemprop="publicationNumber">ES2908827T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-19</td>
          <td itemprop="publicationDate">2022-05-04</td>
          <td><span itemprop="assigneeOriginal">Novartis Ag</span></td>
          <td itemprop="title">
  Lipids and lipid compositions for the delivery of active agents
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2015101416A1/en">
              <span itemprop="publicationNumber">WO2015101416A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-30</td>
          <td itemprop="publicationDate">2015-07-09</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Methods for rna analysis 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP6704850B2/en">
              <span itemprop="publicationNumber">JP6704850B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-30</td>
          <td itemprop="publicationDate">2020-06-03</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Artificial nucleic acid molecule
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2015101415A1/en">
              <span itemprop="publicationNumber">WO2015101415A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-12-30</td>
          <td itemprop="publicationDate">2015-07-09</td>
          <td><span itemprop="assigneeOriginal">Curevac Gmbh</span></td>
          <td itemprop="title">Artificial nucleic acid molecules 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3110401A4/en">
              <span itemprop="publicationNumber">EP3110401A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-02-25</td>
          <td itemprop="publicationDate">2017-10-25</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Lipid nanoparticle vaccine adjuvants and antigen delivery systems 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9833416B2/en">
              <span itemprop="publicationNumber">US9833416B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-04-04</td>
          <td itemprop="publicationDate">2017-12-05</td>
          <td><span itemprop="assigneeOriginal">Ohio State Innovation Foundation</span></td>
          <td itemprop="title">Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3766916T1/en">
              <span itemprop="publicationNumber">SI3766916T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-06-25</td>
          <td itemprop="publicationDate">2023-01-31</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9840479B2/en">
              <span itemprop="publicationNumber">US9840479B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-07-02</td>
          <td itemprop="publicationDate">2017-12-12</td>
          <td><span itemprop="assigneeOriginal">Massachusetts Institute Of Technology</span></td>
          <td itemprop="title">Polyamine-fatty acid derived lipidoids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114146063A/en">
              <span itemprop="publicationNumber">CN114146063A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-07-02</td>
          <td itemprop="publicationDate">2022-03-08</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Encapsulation of messenger RNA 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN104644555A/en">
              <span itemprop="publicationNumber">CN104644555A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-11-18</td>
          <td itemprop="publicationDate">2015-05-27</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Long-circulating liposome capable of avoiding accelerated blood clearance (ABC) phenomenon, and preparation method and application thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3247363A4/en">
              <span itemprop="publicationNumber">EP3247363A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-01-21</td>
          <td itemprop="publicationDate">2018-10-03</td>
          <td><span itemprop="assigneeOriginal">Moderna Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3247328B1/en">
              <span itemprop="publicationNumber">EP3247328B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-01-21</td>
          <td itemprop="publicationDate">2026-01-07</td>
          <td><span itemprop="assigneeOriginal">Genevant Sciences Gmbh</span></td>
          <td itemprop="title">Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016176330A1/en">
              <span itemprop="publicationNumber">WO2016176330A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-04-27</td>
          <td itemprop="publicationDate">2016-11-03</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Nucleoside-modified rna for inducing an adaptive immune response 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DK3313829T3/en">
              <span itemprop="publicationNumber">DK3313829T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-06-29</td>
          <td itemprop="publicationDate">2024-06-17</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc</span></td>
          <td itemprop="title">
  Lipids and lipid nanoparticle formulations for delivery of nucleic acids
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2018150239A/en">
              <span itemprop="publicationNumber">JP2018150239A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-07-15</td>
          <td itemprop="publicationDate">2018-09-27</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">2GPI GENE SILENCING RNAi PHARMACEUTICAL COMPOSITION 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017015630A2/en">
              <span itemprop="publicationNumber">WO2017015630A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-07-23</td>
          <td itemprop="publicationDate">2017-01-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017031232A1/en">
              <span itemprop="publicationNumber">WO2017031232A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-08-17</td>
          <td itemprop="publicationDate">2017-02-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Methods for preparing particles and related compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3350157B1/en">
              <span itemprop="publicationNumber">EP3350157B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="publicationDate">2022-01-05</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4086269A1/en">
              <span itemprop="publicationNumber">EP4086269A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-16</td>
          <td itemprop="publicationDate">2022-11-09</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Mrna cap analogs with modified phosphate linkage 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2018531290A/en">
              <span itemprop="publicationNumber">JP2018531290A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2018-10-25</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Sexually transmitted disease vaccine
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2922760T3/en">
              <span itemprop="publicationNumber">ES2922760T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-22</td>
          <td itemprop="publicationDate">2022-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        Respiratory virus vaccines
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3368507T1/en">
              <span itemprop="publicationNumber">SI3368507T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-10-28</td>
          <td itemprop="publicationDate">2023-04-28</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics Inc.</span></td>
          <td itemprop="title">
        Novel lipids and lipid nanoparticle formulations for nucleic acid delivery
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3386484T1/en">
              <span itemprop="publicationNumber">SI3386484T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-10</td>
          <td itemprop="publicationDate">2022-06-30</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017100744A1/en">
              <span itemprop="publicationNumber">WO2017100744A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-11</td>
          <td itemprop="publicationDate">2017-06-15</td>
          <td><span itemprop="assigneeOriginal">Preceres Inc.</span></td>
          <td itemprop="title">Aminolipidoids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7065036B2/en">
              <span itemprop="publicationNumber">JP7065036B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-17</td>
          <td itemprop="publicationDate">2022-05-11</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding methylmalonyl CoA mutase
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2913626T5/en">
              <span itemprop="publicationNumber">ES2913626T5</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-22</td>
          <td itemprop="publicationDate">2025-05-12</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017117528A1/en">
              <span itemprop="publicationNumber">WO2017117528A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-12-30</td>
          <td itemprop="publicationDate">2017-07-06</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3405579A1/en">
              <span itemprop="publicationNumber">EP3405579A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-01-22</td>
          <td itemprop="publicationDate">2018-11-28</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US10457631B2/en">
              <span itemprop="publicationNumber">US10457631B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-04-06</td>
          <td itemprop="publicationDate">2019-10-29</td>
          <td><span itemprop="assigneeOriginal">Ohio State Innovation Foundation</span></td>
          <td itemprop="title">Biodegradable amino-ester nanomaterials for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190167811A1/en">
              <span itemprop="publicationNumber">US20190167811A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-04-13</td>
          <td itemprop="publicationDate">2019-06-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Lipid compositions and their uses for intratumoral polynucleotide delivery 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017192470A1/en">
              <span itemprop="publicationNumber">WO2017192470A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-03</td>
          <td itemprop="publicationDate">2017-11-09</td>
          <td><span itemprop="assigneeOriginal">Merck Sharp &amp; Dohme Corp.</span></td>
          <td itemprop="title">Combination therapy of anti-il-10 antibody and compositions comprising lipid nanoparticles and tlr9 agonist cpg oligonucleotides 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017266948B2/en">
              <span itemprop="publicationNumber">AU2017266948B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2024-07-04</td>
          <td><span itemprop="assigneeOriginal">Fundacion Para La Investigacion Medica Aplicada</span></td>
          <td itemprop="title">Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7246930B2/en">
              <span itemprop="publicationNumber">JP7246930B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-03-28</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Polynucleotides encoding interleukin-12 (IL12) and uses thereof
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017201347A1/en">
              <span itemprop="publicationNumber">WO2017201347A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7210287B2/en">
              <span itemprop="publicationNumber">JP7210287B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-01-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotides encoding citrine for the treatment of type II citrullinemia
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3458107B1/en">
              <span itemprop="publicationNumber">EP3458107B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2024-03-13</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding jagged1 for the treatment of alagille syndrome 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017201333A1/en">
              <span itemprop="publicationNumber">WO2017201333A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding lipoprotein lipase for the treatment of hyperlipidemia 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017201325A1/en">
              <span itemprop="publicationNumber">WO2017201325A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Combinations of mrnas encoding immune modulating polypeptides and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN115837014A/en">
              <span itemprop="publicationNumber">CN115837014A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-03-24</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Polynucleotide encoding relaxin
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2973443T3/en">
              <span itemprop="publicationNumber">ES2973443T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2024-06-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
  Polynucleotides encoding galactose-1-phosphate uridylyltransferase for the treatment of galactosemia type 1
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3024509A1/en">
              <span itemprop="publicationNumber">CA3024509A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2017-11-23</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Mrna combination therapy for the treatment of cancer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2017266932B2/en">
              <span itemprop="publicationNumber">AU2017266932B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2023-04-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190298657A1/en">
              <span itemprop="publicationNumber">US20190298657A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2019-10-03</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190382774A1/en">
              <span itemprop="publicationNumber">US20190382774A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-05-18</td>
          <td itemprop="publicationDate">2019-12-19</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Polyribonucleotides containing reduced uracil content and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017218704A1/en">
              <span itemprop="publicationNumber">WO2017218704A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-06-14</td>
          <td itemprop="publicationDate">2017-12-21</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Stabilized formulations of lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/MX2019004913A/en">
              <span itemprop="publicationNumber">MX2019004913A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-26</td>
          <td itemprop="publicationDate">2019-09-16</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Lipid nanoparticle mrna vaccines. 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3532103B1/en">
              <span itemprop="publicationNumber">EP3532103B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-26</td>
          <td itemprop="publicationDate">2025-12-03</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190274968A1/en">
              <span itemprop="publicationNumber">US20190274968A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-27</td>
          <td itemprop="publicationDate">2019-09-12</td>
          <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
          <td itemprop="title">Nucleoside-modified rna for inducing an adaptive immune response 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3538067A1/en">
              <span itemprop="publicationNumber">EP3538067A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-11-08</td>
          <td itemprop="publicationDate">2019-09-18</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Stabilized formulations of lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20190110612A/en">
              <span itemprop="publicationNumber">KR20190110612A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-02-01</td>
          <td itemprop="publicationDate">2019-09-30</td>
          <td><span itemprop="assigneeOriginal">, .</span></td>
          <td itemprop="title">
        Immunomodulatory Therapeutic MRNA Compositions Encoding Activating Oncogene Mutant Peptides
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11464848B2/en">
              <span itemprop="publicationNumber">US11464848B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2022-10-11</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Respiratory syncytial virus vaccine 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018170270A1/en">
              <span itemprop="publicationNumber">WO2018170270A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2018-09-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Varicella zoster virus (vzv) vaccine 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/PL3596041T3/en">
              <span itemprop="publicationNumber">PL3596041T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2023-03-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compound and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3595727B1/en">
              <span itemprop="publicationNumber">EP3595727B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2024-11-27</td>
          <td><span itemprop="assigneeOriginal">ModernaTX, Inc.</span></td>
          <td itemprop="title">Lipid nanoparticle formulation 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7220154B2/en">
              <span itemprop="publicationNumber">JP7220154B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-03-15</td>
          <td itemprop="publicationDate">2023-02-09</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">
        Crystalline forms of amino lipids
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018191719A1/en">
              <span itemprop="publicationNumber">WO2018191719A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-04-13</td>
          <td itemprop="publicationDate">2018-10-18</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid delivery of therapeutic agents to adipose tissue 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3615510B1/en">
              <span itemprop="publicationNumber">EP3615510B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-04-28</td>
          <td itemprop="publicationDate">2024-03-27</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018225871A1/en">
              <span itemprop="publicationNumber">WO2018225871A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-09</td>
          <td itemprop="publicationDate">2018-12-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Compound serving as cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2018232120A1/en">
              <span itemprop="publicationNumber">WO2018232120A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-06-14</td>
          <td itemprop="publicationDate">2018-12-20</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US11639329B2/en">
              <span itemprop="publicationNumber">US11639329B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-16</td>
          <td itemprop="publicationDate">2023-05-02</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019036030A1/en">
              <span itemprop="publicationNumber">WO2019036030A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-17</td>
          <td itemprop="publicationDate">2019-02-21</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipids for use in lipid nanoparticle formulations 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN111315359A/en">
              <span itemprop="publicationNumber">CN111315359A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-08-31</td>
          <td itemprop="publicationDate">2020-06-19</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Methods of preparing lipid nanoparticles
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019089828A1/en">
              <span itemprop="publicationNumber">WO2019089828A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2017-10-31</td>
          <td itemprop="publicationDate">2019-05-09</td>
          <td><span itemprop="assigneeOriginal">Acuitas Therapeutics, Inc.</span></td>
          <td itemprop="title">Lamellar lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019152557A1/en">
              <span itemprop="publicationNumber">WO2019152557A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-01-30</td>
          <td itemprop="publicationDate">2019-08-08</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compositions and methods for delivery of agents to immune cells 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3773702A2/en">
              <span itemprop="publicationNumber">EP3773702A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-04-05</td>
          <td itemprop="publicationDate">2021-02-17</td>
          <td><span itemprop="assigneeOriginal">CureVac AG</span></td>
          <td itemprop="title">Novel yellow fever nucleic acid molecules for vaccination 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US20210170017A1/en">
              <span itemprop="publicationNumber">US20210170017A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-04-17</td>
          <td itemprop="publicationDate">2021-06-10</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Novel rsv rna molecules and compositions for vaccination 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2020002525A1/en">
              <span itemprop="publicationNumber">WO2020002525A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-06-27</td>
          <td itemprop="publicationDate">2020-01-02</td>
          <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
          <td itemprop="title">Novel lassa virus rna molecules and compositions for vaccination 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3113436A1/en">
              <span itemprop="publicationNumber">CA3113436A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-19</td>
          <td itemprop="publicationDate">2020-03-26</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN113271926A/en">
              <span itemprop="publicationNumber">CN113271926A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-09-20</td>
          <td itemprop="publicationDate">2021-08-17</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Preparation of lipid nanoparticles and methods of administration thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202039534A/en">
              <span itemprop="publicationNumber">TW202039534A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-12-14</td>
          <td itemprop="publicationDate">2020-11-01</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Kras variant mrna molecules 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2020351220A1/en">
              <span itemprop="publicationNumber">AU2020351220A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2022-04-07</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3154720A1/en">
              <span itemprop="publicationNumber">CA3154720A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2021-03-25</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20220101077A/en">
              <span itemprop="publicationNumber">KR20220101077A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2019-09-19</td>
          <td itemprop="publicationDate">2022-07-19</td>
          <td><span itemprop="assigneeOriginal">, .</span></td>
          <td itemprop="title">
        Branched tail lipid compounds and compositions for intracellular delivery of therapeutics
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN114206827B/en">
              <span itemprop="publicationNumber">CN114206827B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-04-09</td>
          <td itemprop="publicationDate">2023-05-23</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3214481A1/en">
              <span itemprop="publicationNumber">CA3214481A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-03-24</td>
          <td itemprop="publicationDate">2022-09-29</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AR127892A1/en">
              <span itemprop="publicationNumber">AR127892A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-12-10</td>
          <td itemprop="publicationDate">2024-03-06</td>
          <td><span itemprop="assigneeOriginal">Modernatx Inc</span></td>
          <td itemprop="title">
        COMPOUNDS AND COMPOSITIONS FOR THE ADMINISTRATION OF THERAPEUTIC AGENTS
       
     </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2016</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP16781895.4A</span>
            <a href="/patent/EP3350157B1/en"><span itemprop="documentId">patent/EP3350157B1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2016324310A</span>
            <a href="/patent/AU2016324310B2/en"><span itemprop="documentId">patent/AU2016324310B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">ES</span>
            <span itemprop="applicationNumber">ES20180006T</span>
            <a href="/patent/ES2969082T3/en"><span itemprop="documentId">patent/ES2969082T3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">CA</span>
            <span itemprop="applicationNumber">CA2998810A</span>
            <a href="/patent/CA2998810A1/en"><span itemprop="documentId">patent/CA2998810A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">PL</span>
            <span itemprop="applicationNumber">PL16781895T</span>
            <a href="/patent/PL3350157T3/en"><span itemprop="documentId">patent/PL3350157T3/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP20180006.7A</span>
            <a href="/patent/EP3736261B1/en"><span itemprop="documentId">patent/EP3736261B1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">SI</span>
            <span itemprop="applicationNumber">SI201631463T</span>
            <a href="/patent/SI3350157T1/en"><span itemprop="documentId">patent/SI3350157T1/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">RS</span>
            <span itemprop="applicationNumber">RS20220262A</span>
            <a href="/patent/RS63030B1/en"><span itemprop="documentId">patent/RS63030B1/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">LT</span>
            <span itemprop="applicationNumber">LTEPPCT/US2016/052352T</span>
            <a href="/patent/LT3350157T/en"><span itemprop="documentId">patent/LT3350157T/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2018514267A</span>
            <a href="/patent/JP6948313B6/en"><span itemprop="documentId">patent/JP6948313B6/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">HR</span>
            <span itemprop="applicationNumber">HRP20220156TT</span>
            <a href="/patent/HRP20220156T1/en"><span itemprop="documentId">patent/HRP20220156T1/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">DK</span>
            <span itemprop="applicationNumber">DK16781895.4T</span>
            <a href="/patent/DK3350157T3/en"><span itemprop="documentId">patent/DK3350157T3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP23202539.5A</span>
            <a href="/patent/EP4286012A3/en"><span itemprop="documentId">patent/EP4286012A3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">HU</span>
            <span itemprop="applicationNumber">HUE16781895A</span>
            <a href="/patent/HUE057613T2/en"><span itemprop="documentId">patent/HUE057613T2/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/US2016/052352</span>
            <a href="/patent/WO2017049245A2/en"><span itemprop="documentId">patent/WO2017049245A2/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">SM</span>
            <span itemprop="applicationNumber">SM20220178T</span>
            <a href="/patent/SMT202200178T1/en"><span itemprop="documentId">patent/SMT202200178T1/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">PT</span>
            <span itemprop="applicationNumber">PT167818954T</span>
            <a href="/patent/PT3350157T/en"><span itemprop="documentId">patent/PT3350157T/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-16</span>
            <span itemprop="countryCode">ES</span>
            <span itemprop="applicationNumber">ES16781895T</span>
            <a href="/patent/ES2910425T3/en"><span itemprop="documentId">patent/ES2910425T3/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-19</span>
            <span itemprop="countryCode">TW</span>
            <span itemprop="applicationNumber">TW105130231A</span>
            <a href="/patent/TWI757248B/en"><span itemprop="documentId">patent/TWI757248B/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus"></span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2016-09-19</span>
            <span itemprop="countryCode">TW</span>
            <span itemprop="applicationNumber">TW111107372A</span>
            <a href="/patent/TWI825602B/en"><span itemprop="documentId">patent/TWI825602B/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus"></span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2017</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-03-31</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US15/476,263</span>
            <a href="/patent/US9868692B2/en"><span itemprop="documentId">patent/US9868692B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-03-31</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US15/476,253</span>
            <a href="/patent/US9868691B2/en"><span itemprop="documentId">patent/US9868691B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-04-21</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US15/493,281</span>
            <a href="/patent/US9867888B2/en"><span itemprop="documentId">patent/US9867888B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-04-27</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US15/498,698</span>
            <a href="/patent/US9868693B2/en"><span itemprop="documentId">patent/US9868693B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2017-12-18</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US15/846,084</span>
            <a href="/patent/US10442756B2/en"><span itemprop="documentId">patent/US10442756B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2018</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-06-11</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/005,286</span>
            <a href="/patent/US10266485B2/en"><span itemprop="documentId">patent/US10266485B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-10-01</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/148,822</span>
            <a href="/patent/US10392341B2/en"><span itemprop="documentId">patent/US10392341B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2019</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2019-08-29</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/555,045</span>
            <a href="/patent/US11220476B2/en"><span itemprop="documentId">patent/US11220476B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2021</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2021-07-07</span>
            <span itemprop="countryCode">AU</span>
            <span itemprop="applicationNumber">AU2021204763A</span>
            <a href="/patent/AU2021204763B2/en"><span itemprop="documentId">patent/AU2021204763B2/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Expired - Fee Related</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2021-09-17</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2021151758A</span>
            <a href="/patent/JP7326395B2/en"><span itemprop="documentId">patent/JP7326395B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2021-11-30</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US17/538,217</span>
            <a href="/patent/US12404232B2/en"><span itemprop="documentId">patent/US12404232B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2022</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2022-03-15</span>
            <span itemprop="countryCode">CY</span>
            <span itemprop="applicationNumber">CY20221100215T</span>
            <a href="/patent/CY1125154T1/en"><span itemprop="documentId">patent/CY1125154T1/en</span></a>
            <span itemprop="legalStatusCat">unknown</span>
            <span itemprop="legalStatus"></span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2023</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2023-08-02</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2023125995A</span>
            <a href="/patent/JP7654724B2/en"><span itemprop="documentId">patent/JP7654724B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2023-09-14</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US18/467,190</span>
            <a href="/patent/US12151995B2/en"><span itemprop="documentId">patent/US12151995B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  

  

  <h2>Cited By (66)</h2>
  <table>
    <caption>* Cited by examiner,  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20180126005A1/en">
            <span itemprop="publicationNumber">US20180126005A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2007-09-04</td>
        <td itemprop="publicationDate">2018-05-10</td>
        <td><span itemprop="assigneeOriginal">Curevac Ag</span></td>
        <td itemprop="title">Complexes of rna and cationic peptides for transfection and for immunostimulation 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20190321464A1/en">
            <span itemprop="publicationNumber">US20190321464A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2015-10-22</td>
        <td itemprop="publicationDate">2019-10-24</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Human cytomegalovirus rna vaccines 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US10716846B2/en">
            <span itemprop="publicationNumber">US10716846B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2015-10-22</td>
        <td itemprop="publicationDate">2020-07-21</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Human cytomegalovirus RNA vaccines 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11484590B2/en">
            <span itemprop="publicationNumber">US11484590B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2015-10-22</td>
        <td itemprop="publicationDate">2022-11-01</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Human cytomegalovirus RNA vaccines 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11464848B2/en">
            <span itemprop="publicationNumber">US11464848B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2017-03-15</td>
        <td itemprop="publicationDate">2022-10-11</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Respiratory syncytial virus vaccine 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11497807B2/en">
            <span itemprop="publicationNumber">US11497807B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2017-03-17</td>
        <td itemprop="publicationDate">2022-11-15</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Zoonotic disease RNA vaccines 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11786607B2/en">
            <span itemprop="publicationNumber">US11786607B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2017-06-15</td>
        <td itemprop="publicationDate">2023-10-17</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">RNA formulations 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12357575B2/en">
            <span itemprop="publicationNumber">US12357575B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2017-08-31</td>
        <td itemprop="publicationDate">2025-07-15</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Methods of making lipid nanoparticles 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11744801B2/en">
            <span itemprop="publicationNumber">US11744801B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2017-08-31</td>
        <td itemprop="publicationDate">2023-09-05</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Methods of making lipid nanoparticles 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12090235B2/en">
            <span itemprop="publicationNumber">US12090235B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-09-20</td>
        <td itemprop="publicationDate">2024-09-17</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Preparation of lipid nanoparticles and methods of administration thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021113777A2/en">
            <span itemprop="publicationNumber">WO2021113777A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2019-12-04</td>
        <td itemprop="publicationDate">2021-06-10</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/EP4289951A2/en">
            <span itemprop="publicationNumber">EP4289951A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2019-12-04</td>
        <td itemprop="publicationDate">2023-12-13</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021189059A2/en">
            <span itemprop="publicationNumber">WO2021189059A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-03-20</td>
        <td itemprop="publicationDate">2021-09-23</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021195214A1/en">
            <span itemprop="publicationNumber">WO2021195214A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-03-24</td>
        <td itemprop="publicationDate">2021-09-30</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Non-viral dna vectors and uses thereof for expressing factor ix therapeutics 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021195218A1/en">
            <span itemprop="publicationNumber">WO2021195218A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-03-24</td>
        <td itemprop="publicationDate">2021-09-30</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Non-viral dna vectors and uses thereof for expressing gaucher therapeutics 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2021236855A1/en">
            <span itemprop="publicationNumber">WO2021236855A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-05-19</td>
        <td itemprop="publicationDate">2021-11-25</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11406703B2/en">
            <span itemprop="publicationNumber">US11406703B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-08-25</td>
        <td itemprop="publicationDate">2022-08-09</td>
        <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
        <td itemprop="title">Human cytomegalovirus vaccine 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12458604B2/en">
            <span itemprop="publicationNumber">US12458604B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2020-10-14</td>
        <td itemprop="publicationDate">2025-11-04</td>
        <td><span itemprop="assigneeOriginal">The Trustees Of The University Of Pennsylvania</span></td>
        <td itemprop="title">Methods of lipid nanoparticle manufacture and compositions derived therefrom 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022226396A1/en">
            <span itemprop="publicationNumber">WO2022226396A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-04-23</td>
        <td itemprop="publicationDate">2022-10-27</td>
        <td><span itemprop="assigneeOriginal">Ganna Bio, Inc.</span></td>
        <td itemprop="title">Glycan modified nucleic acids, methods of preparation, and therapeutic uses 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022232289A1/en">
            <span itemprop="publicationNumber">WO2022232289A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-04-27</td>
        <td itemprop="publicationDate">2022-11-03</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Non-viral dna vectors expressing therapeutic antibodies and uses thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022232286A1/en">
            <span itemprop="publicationNumber">WO2022232286A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-04-27</td>
        <td itemprop="publicationDate">2022-11-03</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2022261490A2/en">
            <span itemprop="publicationNumber">WO2022261490A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-06-10</td>
        <td itemprop="publicationDate">2022-12-15</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023279836A1/en">
            <span itemprop="publicationNumber">WO2023279836A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-07-07</td>
        <td itemprop="publicationDate">2023-01-12</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Ionizable lipid compound for nucleic acid delivery and lnp composition thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023023055A1/en">
            <span itemprop="publicationNumber">WO2023023055A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-08-16</td>
        <td itemprop="publicationDate">2023-02-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Compositions and methods for optimizing tropism of delivery systems for rna 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044333A1/en">
            <span itemprop="publicationNumber">WO2023044333A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023044343A1/en">
            <span itemprop="publicationNumber">WO2023044343A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-03-23</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Acyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023056033A1/en">
            <span itemprop="publicationNumber">WO2023056033A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-30</td>
        <td itemprop="publicationDate">2023-04-06</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023081756A1/en">
            <span itemprop="publicationNumber">WO2023081756A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-11-03</td>
        <td itemprop="publicationDate">2023-05-11</td>
        <td><span itemprop="assigneeOriginal">The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone</span></td>
        <td itemprop="title">Precise genome editing using retrons 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023081526A1/en">
            <span itemprop="publicationNumber">WO2023081526A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-11-08</td>
        <td itemprop="publicationDate">2023-05-11</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023122752A1/en">
            <span itemprop="publicationNumber">WO2023122752A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-12-23</td>
        <td itemprop="publicationDate">2023-06-29</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Constrained lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN117377651A/en">
            <span itemprop="publicationNumber">CN117377651A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-12-31</td>
        <td itemprop="publicationDate">2024-01-09</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">
        A cationic lipid with functional groups in its side chain and its application
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023141602A2/en">
            <span itemprop="publicationNumber">WO2023141602A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-01-21</td>
        <td itemprop="publicationDate">2023-07-27</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Engineered retrons and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023141586A1/en">
            <span itemprop="publicationNumber">WO2023141586A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-01-21</td>
        <td itemprop="publicationDate">2023-07-27</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Systemic administration of circular rna polynucleotides encoding muscle proteins or protein complexes 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023177655A1/en">
            <span itemprop="publicationNumber">WO2023177655A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-03-14</td>
        <td itemprop="publicationDate">2023-09-21</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Heterologous prime boost vaccine compositions and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023196931A1/en">
            <span itemprop="publicationNumber">WO2023196931A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-04-07</td>
        <td itemprop="publicationDate">2023-10-12</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023239756A1/en">
            <span itemprop="publicationNumber">WO2023239756A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-06-07</td>
        <td itemprop="publicationDate">2023-12-14</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Lipid nanoparticle compositions and uses thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024020346A2/en">
            <span itemprop="publicationNumber">WO2024020346A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-07-18</td>
        <td itemprop="publicationDate">2024-01-25</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Gene editing components, systems, and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024040222A1/en">
            <span itemprop="publicationNumber">WO2024040222A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-08-19</td>
        <td itemprop="publicationDate">2024-02-22</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Cleavable closed-ended dna (cedna) and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024044723A1/en">
            <span itemprop="publicationNumber">WO2024044723A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-08-25</td>
        <td itemprop="publicationDate">2024-02-29</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Engineered retrons and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024051825A1/en">
            <span itemprop="publicationNumber">WO2024051825A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-09-09</td>
        <td itemprop="publicationDate">2024-03-14</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Carbon nucleus cationic lipid 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024102677A1/en">
            <span itemprop="publicationNumber">WO2024102677A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-11-08</td>
        <td itemprop="publicationDate">2024-05-16</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024102730A1/en">
            <span itemprop="publicationNumber">WO2024102730A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-11-08</td>
        <td itemprop="publicationDate">2024-05-16</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipids and nanoparticle compositions for delivering polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024102762A1/en">
            <span itemprop="publicationNumber">WO2024102762A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-11-08</td>
        <td itemprop="publicationDate">2024-05-16</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipids and lipid nanoparticle compositions for delivering polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024119039A2/en">
            <span itemprop="publicationNumber">WO2024119039A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-12-01</td>
        <td itemprop="publicationDate">2024-06-06</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Stealth lipid nanoparticles and uses thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024119103A1/en">
            <span itemprop="publicationNumber">WO2024119103A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-12-01</td>
        <td itemprop="publicationDate">2024-06-06</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024119074A1/en">
            <span itemprop="publicationNumber">WO2024119074A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-12-01</td>
        <td itemprop="publicationDate">2024-06-06</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Stealth lipid nanoparticle compositions for cell targeting 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024119051A1/en">
            <span itemprop="publicationNumber">WO2024119051A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2022-12-01</td>
        <td itemprop="publicationDate">2024-06-06</td>
        <td><span itemprop="assigneeOriginal">Generation Bio Co.</span></td>
        <td itemprop="title">Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024192291A1/en">
            <span itemprop="publicationNumber">WO2024192291A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-03-15</td>
        <td itemprop="publicationDate">2024-09-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Delivery of gene editing systems and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024192277A2/en">
            <span itemprop="publicationNumber">WO2024192277A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-03-15</td>
        <td itemprop="publicationDate">2024-09-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024205657A2/en">
            <span itemprop="publicationNumber">WO2024205657A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-03-29</td>
        <td itemprop="publicationDate">2024-10-03</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipids and lipid nanoparticle compositions for delivering polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024233308A2/en">
            <span itemprop="publicationNumber">WO2024233308A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-05-05</td>
        <td itemprop="publicationDate">2024-11-14</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025007148A1/en">
            <span itemprop="publicationNumber">WO2025007148A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-06-30</td>
        <td itemprop="publicationDate">2025-01-02</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Polymer lipid nanoparticle compositions for delivering circular polynucleotides 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025049690A1/en">
            <span itemprop="publicationNumber">WO2025049690A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-08-29</td>
        <td itemprop="publicationDate">2025-03-06</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular polyethylene glycol lipids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025049959A2/en">
            <span itemprop="publicationNumber">WO2025049959A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-09-01</td>
        <td itemprop="publicationDate">2025-03-06</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Gene editing systems, compositions, and methods for treatment of vexas syndrome 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025052180A2/en">
            <span itemprop="publicationNumber">WO2025052180A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-09-07</td>
        <td itemprop="publicationDate">2025-03-13</td>
        <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
        <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025081042A1/en">
            <span itemprop="publicationNumber">WO2025081042A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-10-12</td>
        <td itemprop="publicationDate">2025-04-17</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Nickase-retron template-based precision editing system and methods of use 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025101501A1/en">
            <span itemprop="publicationNumber">WO2025101501A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-11-07</td>
        <td itemprop="publicationDate">2025-05-15</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025109173A1/en">
            <span itemprop="publicationNumber">WO2025109173A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-11-22</td>
        <td itemprop="publicationDate">2025-05-30</td>
        <td><span itemprop="assigneeOriginal">Advantage Therapeutics, Inc.</span></td>
        <td itemprop="title">Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/EP4566618A1/en">
            <span itemprop="publicationNumber">EP4566618A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-06</td>
        <td itemprop="publicationDate">2025-06-11</td>
        <td><span itemprop="assigneeOriginal">ADvantage Therapeutics, Inc.</span></td>
        <td itemprop="title">Nucleic acid encoding klotho for use in therapeutic and non-therapeutic methods for reducing body weight 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025128871A2/en">
            <span itemprop="publicationNumber">WO2025128871A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-13</td>
        <td itemprop="publicationDate">2025-06-19</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025144938A1/en">
            <span itemprop="publicationNumber">WO2025144938A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2023-12-26</td>
        <td itemprop="publicationDate">2025-07-03</td>
        <td><span itemprop="assigneeOriginal">Emmune, Inc.</span></td>
        <td itemprop="title">Systems for nucleic acid transfer 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025155753A2/en">
            <span itemprop="publicationNumber">WO2025155753A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-01-17</td>
        <td itemprop="publicationDate">2025-07-24</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Improved gene editing system, guides, and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025166238A1/en">
            <span itemprop="publicationNumber">WO2025166238A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-01-31</td>
        <td itemprop="publicationDate">2025-08-07</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Fast-shedding polyethylene glycol lipids 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025174765A1/en">
            <span itemprop="publicationNumber">WO2025174765A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-02-12</td>
        <td itemprop="publicationDate">2025-08-21</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025250751A1/en">
            <span itemprop="publicationNumber">WO2025250751A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-05-31</td>
        <td itemprop="publicationDate">2025-12-04</td>
        <td><span itemprop="assigneeOriginal">Orna Therapeutics, Inc.</span></td>
        <td itemprop="title">Circular rna compositions and methods 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2026003582A2/en">
            <span itemprop="publicationNumber">WO2026003582A2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2024-06-27</td>
        <td itemprop="publicationDate">2026-01-02</td>
        <td><span itemprop="assigneeOriginal">Axelyf ehf.</span></td>
        <td itemprop="title">Lipids and lipid nanoparticles 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017049245A2/en">
              <span itemprop="publicationNumber">WO2017049245A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-03-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US9868693B2/en">
              <span itemprop="publicationNumber">US9868693B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/RS63030B1/en">
              <span itemprop="publicationNumber">RS63030B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-04-29</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US9868691B2/en">
              <span itemprop="publicationNumber">US9868691B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/TWI825602B/en">
              <span itemprop="publicationNumber">TWI825602B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-12-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/TWI757248B/en">
              <span itemprop="publicationNumber">TWI757248B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-03-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2018532721A/en">
              <span itemprop="publicationNumber">JP2018532721A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-11-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20190016669A1/en">
              <span itemprop="publicationNumber">US20190016669A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-01-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20200123100A1/en">
              <span itemprop="publicationNumber">US20200123100A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-04-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7326395B2/en">
              <span itemprop="publicationNumber">JP7326395B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-08-15</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3350157B1/en">
              <span itemprop="publicationNumber">EP3350157B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-01-05</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US12404232B2/en">
              <span itemprop="publicationNumber">US12404232B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2025-09-02</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7654724B2/en">
              <span itemprop="publicationNumber">JP7654724B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2025-04-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2022008431A/en">
              <span itemprop="publicationNumber">JP2022008431A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-01-13</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US12151995B2/en">
              <span itemprop="publicationNumber">US12151995B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-11-26</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20170224844A1/en">
              <span itemprop="publicationNumber">US20170224844A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-08-10</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2021204763A1/en">
              <span itemprop="publicationNumber">AU2021204763A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-08-05</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/SI3350157T1/en">
              <span itemprop="publicationNumber">SI3350157T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-04-29</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2016324310A1/en">
              <span itemprop="publicationNumber">AU2016324310A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-04-12</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/LT3350157T/en">
              <span itemprop="publicationNumber">LT3350157T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-02-25</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3736261B1/en">
              <span itemprop="publicationNumber">EP3736261B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-10-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202241844A/en">
              <span itemprop="publicationNumber">TW202241844A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-11-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/HUE057613T2/en">
              <span itemprop="publicationNumber">HUE057613T2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-28</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3736261A1/en">
              <span itemprop="publicationNumber">EP3736261A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-11-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4286012A2/en">
              <span itemprop="publicationNumber">EP4286012A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-12-06</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2910425T3/en">
              <span itemprop="publicationNumber">ES2910425T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-12</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20240124388A1/en">
              <span itemprop="publicationNumber">US20240124388A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-04-18</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2016324310B2/en">
              <span itemprop="publicationNumber">AU2016324310B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-04-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US10442756B2/en">
              <span itemprop="publicationNumber">US10442756B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-10-15</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US9867888B2/en">
              <span itemprop="publicationNumber">US9867888B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201718017A/en">
              <span itemprop="publicationNumber">TW201718017A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-06-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20170233332A1/en">
              <span itemprop="publicationNumber">US20170233332A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-08-17</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20170210698A1/en">
              <span itemprop="publicationNumber">US20170210698A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-07-27</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2017049245A3/en">
              <span itemprop="publicationNumber">WO2017049245A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-05-18</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US10392341B2/en">
              <span itemprop="publicationNumber">US10392341B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-08-27</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US9868692B2/en">
              <span itemprop="publicationNumber">US9868692B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-01-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CY1125154T1/en">
              <span itemprop="publicationNumber">CY1125154T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-06-09</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3350157A2/en">
              <span itemprop="publicationNumber">EP3350157A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-07-25</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/HRP20220156T1/en">
              <span itemprop="publicationNumber">HRP20220156T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-04-15</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2998810A1/en">
              <span itemprop="publicationNumber">CA2998810A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2017-03-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20220380299A1/en">
              <span itemprop="publicationNumber">US20220380299A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-12-01</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/DK3350157T3/en">
              <span itemprop="publicationNumber">DK3350157T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-02-14</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20180273467A1/en">
              <span itemprop="publicationNumber">US20180273467A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-09-27</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/PT3350157T/en">
              <span itemprop="publicationNumber">PT3350157T</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-03-18</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US10266485B2/en">
              <span itemprop="publicationNumber">US10266485B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-04-23</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP6948313B2/en">
              <span itemprop="publicationNumber">JP6948313B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-10-13</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US11220476B2/en">
              <span itemprop="publicationNumber">US11220476B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-01-11</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/PL3350157T3/en">
              <span itemprop="publicationNumber">PL3350157T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2969082T3/en">
              <span itemprop="publicationNumber">ES2969082T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-05-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/SMT202200178T1/en">
              <span itemprop="publicationNumber">SMT202200178T1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-05-12</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2021204763B2/en">
              <span itemprop="publicationNumber">AU2021204763B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-11-16</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP6948313B6/en">
              <span itemprop="publicationNumber">JP6948313B6</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2022-01-14</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4286012A3/en">
              <span itemprop="publicationNumber">EP4286012A3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-05-29</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US20180201572A1/en">
              <span itemprop="publicationNumber">US20180201572A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2018-07-19</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2023164798A/en">
              <span itemprop="publicationNumber">JP2023164798A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-11-14</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US12151995B2/en">
                <span itemprop="publicationNumber">US12151995B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-11-26">2024-11-26</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20250228777A1/en">
                <span itemprop="publicationNumber">US20250228777A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-07-17">2025-07-17</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US12324859B2/en">
                <span itemprop="publicationNumber">US12324859B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-06-10">2025-06-10</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US12396961B2/en">
                <span itemprop="publicationNumber">US12396961B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2025-08-26">2025-08-26</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US12077501B2/en">
                <span itemprop="publicationNumber">US12077501B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2024-09-03">2024-09-03</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of agents 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/HK40039825A/en">
                <span itemprop="publicationNumber">HK40039825A</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2021-07-23">2021-07-23</time>
            
            
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2017-04-07">2017-04-07</time></td>
          <td itemprop="code">AS</td>
          <td itemprop="title">Assignment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Owner name</strong>:
              <span itemprop="value">MODERNATX, INC., MASSACHUSETTS</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BENENATO, KERRY E.;KUMARASINGHE, ELLALAHEWAGE SATHYAJITH;CORNEBISE, MARK;REEL/FRAME:041932/0317</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Effective date</strong>:
              <span itemprop="value">20170405</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2017-12-27">2017-12-27</time></td>
          <td itemprop="code">STCF</td>
          <td itemprop="title">Information on status: patent grant</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PATENTED CASE</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-06-30">2021-06-30</time></td>
          <td itemprop="code">MAFP</td>
          <td itemprop="title">Maintenance fee payment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Year of fee payment</strong>:
              <span itemprop="value">4</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2025-07-02">2025-07-02</time></td>
          <td itemprop="code">MAFP</td>
          <td itemprop="title">Maintenance fee payment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Year of fee payment</strong>:
              <span itemprop="value">8</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
